@CHEMICAL$ antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated @GENE$.	4
Androgen antagonistic effect of @CHEMICAL$ (EMP) metabolites on wild-type and mutated @GENE$.	4
Androgen antagonistic effect of estramustine phosphate (@CHEMICAL$) metabolites on wild-type and mutated @GENE$.	4
Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated @CHEM-GENE$.	0
We investigated, by displacement of @CHEMICAL$ in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of @CHEMICAL$ in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of @CHEMICAL$ in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of @CHEMICAL$ in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of @CHEMICAL$, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of @CHEMICAL$, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of @CHEMICAL$, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of @CHEMICAL$, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of @CHEMICAL$ and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of @CHEMICAL$ and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of @CHEMICAL$ and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of @CHEMICAL$ and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, @CHEMICAL$, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, @CHEMICAL$, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, @CHEMICAL$, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, @CHEMICAL$, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, @CHEMICAL$, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, @CHEMICAL$, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, @CHEMICAL$, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, @CHEMICAL$, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, @CHEMICAL$, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, @CHEMICAL$, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, @CHEMICAL$, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, @CHEMICAL$, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and @CHEMICAL$, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and @CHEMICAL$, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and @CHEMICAL$, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and @CHEMICAL$, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including @CHEMICAL$, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including @CHEMICAL$, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including @CHEMICAL$, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including @CHEMICAL$, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, @CHEMICAL$, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, @CHEMICAL$, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, @CHEMICAL$, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, @CHEMICAL$, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and @CHEMICAL$, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and @CHEMICAL$, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and @CHEMICAL$, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and @CHEMICAL$, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @CHEM-GENE$ (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @CHEMICAL$ receptor (m-@GENE$) in LNCaP cells and to the wild-type androgen receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @CHEMICAL$ receptor (m-AR) in LNCaP cells and to the wild-type @GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @CHEMICAL$ receptor (m-AR) in LNCaP cells and to the wild-type androgen receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated @GENE$ (m-AR) in LNCaP cells and to the wild-type @CHEMICAL$ receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-@GENE$) in LNCaP cells and to the wild-type @CHEMICAL$ receptor in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @CHEM-GENE$ in wild-type AR cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
We investigated, by displacement of [3H]methyltrienolone in the presence of 2.5 mM of triamcinolone acetonide, the binding of estramustine phosphate and its metabolites, estramustine, estromustine, estrone, and beta-estradiol, as well as other antiandrogen agents including alpha-estradiol, bicalutamide, and hydroxyflutamide, to the mutated androgen receptor (m-AR) in LNCaP cells and to the wild-type @CHEMICAL$ receptor in wild-type @GENE$ cDNA expression plasmid (w-pAR0) cDNA-transfected HeLa cells.	0
Analogous to the antiandrogens, @CHEMICAL$ and hydroxyflutamide, binding of estramustine phosphate metabolites to the @GENE$ was observed.	0
Analogous to the antiandrogens, bicalutamide and @CHEMICAL$, binding of estramustine phosphate metabolites to the @GENE$ was observed.	0
Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of @CHEMICAL$ metabolites to the @GENE$ was observed.	0
Analogous to the antiandrogens, bicalutamide and hydroxyflutamide, binding of estramustine phosphate metabolites to the @CHEM-GENE$ was observed.	0
Down-regulation of @GENE$ (PSA) expression, an AR-target gene, by @CHEMICAL$ and bicalutamide was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (@GENE$) expression, an AR-target gene, by @CHEMICAL$ and bicalutamide was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (PSA) expression, an @GENE$-target gene, by @CHEMICAL$ and bicalutamide was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by @CHEMICAL$ and bicalutamide was accompanied by the blockade of the mutated @GENE$.	2
Down-regulation of @GENE$ (PSA) expression, an AR-target gene, by estramustine and @CHEMICAL$ was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (@GENE$) expression, an AR-target gene, by estramustine and @CHEMICAL$ was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (PSA) expression, an @GENE$-target gene, by estramustine and @CHEMICAL$ was accompanied by the blockade of the mutated androgen receptor.	2
Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and @CHEMICAL$ was accompanied by the blockade of the mutated @GENE$.	2
Down-regulation of @GENE$ (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated @CHEMICAL$ receptor.	0
Down-regulation of prostate-specific antigen (@GENE$) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated @CHEMICAL$ receptor.	0
Down-regulation of prostate-specific antigen (PSA) expression, an @GENE$-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated @CHEMICAL$ receptor.	0
Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated @CHEM-GENE$.	0
Exposure of LNCaP cells to @CHEMICAL$ for 24 hr caused transcriptional inhibition of @GENE$ in a concentration-dependent manner.	2
The levels of @GENE$ mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of @CHEMICAL$, respectively (IC50 = 10.97 +/- 1.68 microM).	2
Binding of @CHEMICAL$ to m-@GENE$ in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.	0
Binding of @CHEMICAL$ to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of @GENE$ expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR.	1
Binding of @CHEMICAL$ to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-@GENE$.	0
Binding of hydroxyflutamide to m-@GENE$ in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that @CHEMICAL$ acted as an agonist of the m-AR.	0
Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of @GENE$ expression, suggesting that @CHEMICAL$ acted as an agonist of the m-AR.	0
Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that @CHEMICAL$ acted as an agonist of the m-@GENE$.	3
Our data indicate that @CHEMICAL$ metabolites perform as androgen antagonists of @GENE$, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.	4
Our data indicate that estramustine phosphate metabolites perform as @CHEMICAL$ antagonists of @GENE$, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.	4
Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of @GENE$, an additional mechanism involved in the therapeutic effect of @CHEMICAL$ in patients with prostate cancer.	0
In order to address one aspect of the feasibility of performing time-resolved studies on @GENE$, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor @CHEMICAL$, using a total X-ray exposure time of 24 ms. Electron-density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.	0
In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of @GENE$ soaked with the reversible inhibitor @CHEMICAL$, using a total X-ray exposure time of 24 ms. Electron-density maps obtained from the Laue data, which are of surprisingly good quality compared with similar maps from monochromatic data, show essentially the same features.	2
Selective inhibition of @GENE$ spares renal function and @CHEMICAL$ synthesis in cirrhotic rats with ascites.	5
The current study evaluates the effects of a selective @GENE$ inhibitor (@CHEMICAL$) on renal function in cirrhotic rats with ascites.	2
RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective @GENE$/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of @CHEMICAL$, and glomerular filtration rate and in a significant impairment in renal water metabolism.	5
RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/@GENE$ inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of @CHEMICAL$, and glomerular filtration rate and in a significant impairment in renal water metabolism.	5
RESULTS: Administration of @CHEMICAL$ to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective @GENE$/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.	0
RESULTS: Administration of @CHEMICAL$ to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/@GENE$ inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.	0
RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective @GENE$/COX-2 inhibitor, @CHEMICAL$, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.	2
RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/@GENE$ inhibitor, @CHEMICAL$, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.	2
Inhibition of @GENE$ translocation and @CHEMICAL$ secretion by fluticasone propionate in exogenously activated human eosinophils.	0
Inhibition of @GENE$ translocation and leukotriene C4 secretion by @CHEMICAL$ in exogenously activated human eosinophils.	2
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of @GENE$ (cPLA2), and (2) blockade of leukotriene C4 (@CHEMICAL$) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (@GENE$), and (2) blockade of leukotriene C4 (@CHEMICAL$) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, @CHEMICAL$ (FP), in causing (1) inhibition of nuclear translocation of @GENE$ (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, @CHEMICAL$ (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (@GENE$), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (@CHEMICAL$), in causing (1) inhibition of nuclear translocation of @GENE$ (cPLA2), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (@CHEMICAL$), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (@GENE$), and (2) blockade of leukotriene C4 (LTC4) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of @GENE$ (cPLA2), and (2) blockade of @CHEMICAL$ (LTC4) synthesis in isolated human eosinophils in vitro.	0
We examined the effect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition of nuclear translocation of cytosolic phospholipase A2 (@GENE$), and (2) blockade of @CHEMICAL$ (LTC4) synthesis in isolated human eosinophils in vitro.	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M @CHEMICAL$ in the presence of 10 pg/ml @GENE$ (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M @CHEMICAL$ in the presence of 10 pg/ml human recombinant interleukin-5 (@GENE$) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml @GENE$ (rhIL-5) and activated with @CHEMICAL$ (FMLP) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (@GENE$) and activated with @CHEMICAL$ (FMLP) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml @GENE$ (rhIL-5) and activated with formyl-met-leu-phe (@CHEMICAL$) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (@GENE$) and activated with formyl-met-leu-phe (@CHEMICAL$) + cytochalasin B (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml @GENE$ (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + @CHEMICAL$ (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (@GENE$) and activated with formyl-met-leu-phe (FMLP) + @CHEMICAL$ (CB).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml @GENE$ (rhIL-5) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (@CHEMICAL$).	0
Eosinophils were isolated from peripheral blood, treated with either buffer or 10(-)10 M to 10(-)6 M FP in the presence of 10 pg/ml human recombinant interleukin-5 (@GENE$) and activated with formyl-met-leu-phe (FMLP) + cytochalasin B (@CHEMICAL$).	0
@CHEMICAL$/CB-stimulated translocation of @GENE$ to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.	0
FMLP/@CHEMICAL$-stimulated translocation of @GENE$ to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP.	0
FMLP/CB-stimulated translocation of @GENE$ to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by @CHEMICAL$.	2
By contrast, membrane expression of @GENE$, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M @CHEMICAL$, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA).	0
By contrast, membrane expression of @GENE$, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of @CHEMICAL$ synthesis was reversed by exogenous arachidonic acid (AA).	0
By contrast, membrane expression of @GENE$, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous @CHEMICAL$ (AA).	0
By contrast, membrane expression of @GENE$, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (@CHEMICAL$).	0
We find that @CHEMICAL$ causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by @GENE$ (PLA2).	2
We find that @CHEMICAL$ causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (@GENE$).	0
We find that FP causes a decrease in stimulated eosinophil secretion of @CHEMICAL$ that is regulated by @GENE$ (PLA2).	5
We find that FP causes a decrease in stimulated eosinophil secretion of @CHEMICAL$ that is regulated by phospholipase A2 (@GENE$).	5
Inhibition of @CHEMICAL$ synthesis precedes the global cytotoxic effects of FP as indicated by the simultaneous upregulation of @GENE$ expression.	0
Inhibition of LTC4 synthesis precedes the global cytotoxic effects of @CHEMICAL$ as indicated by the simultaneous upregulation of @GENE$ expression.	1
@CHEMICAL$ treatment decreases 3H-nisoxetine binding and @GENE$ mRNA in SK-N-SHSY5Y cells.	2
Desipramine treatment decreases @CHEMICAL$ binding and @GENE$ mRNA in SK-N-SHSY5Y cells.	0
Desipramine treatment decreases 3H-nisoxetine binding and @CHEM-GENE$ mRNA in SK-N-SHSY5Y cells.	0
The antidepressant @CHEMICAL$ has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (@GENE$) in vivo and in vitro, on both an acute and a chronic basis.	2
The antidepressant @CHEMICAL$ has been shown to decrease synaptic membrane concentrations of the @GENE$ (NET) in vivo and in vitro, on both an acute and a chronic basis.	2
The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the @CHEMICAL$ re-uptake transporter (@GENE$) in vivo and in vitro, on both an acute and a chronic basis.	0
The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the @CHEM-GENE$ (NET) in vivo and in vitro, on both an acute and a chronic basis.	0
In this study, we treated SK-N-SHSY5Y cells with 100 nM @CHEMICAL$ for 24 or 72 h, and measured 3H-nisoxetine binding (as an estimate of @GENE$) and NET mRNA by quantitative reverse transcription polymerase chain reaction.	0
In this study, we treated SK-N-SHSY5Y cells with 100 nM @CHEMICAL$ for 24 or 72 h, and measured 3H-nisoxetine binding (as an estimate of NETs) and @GENE$ mRNA by quantitative reverse transcription polymerase chain reaction.	0
In this study, we treated SK-N-SHSY5Y cells with 100 nM desipramine for 24 or 72 h, and measured @CHEMICAL$ binding (as an estimate of @GENE$) and NET mRNA by quantitative reverse transcription polymerase chain reaction.	0
In this study, we treated SK-N-SHSY5Y cells with 100 nM desipramine for 24 or 72 h, and measured @CHEMICAL$ binding (as an estimate of NETs) and @GENE$ mRNA by quantitative reverse transcription polymerase chain reaction.	0
We conclude that decreased @GENE$ synthesis may contribute to the chronic, but not acute, effect of @CHEMICAL$ to downregulate the NET.	0
We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of @CHEMICAL$ to downregulate the @GENE$.	2
Inhibition of the @CHEM-GENE$ by cisapride: affinity for open and inactivated states.	0
Inhibition of the @CHEM-GENE$ by cisapride: affinity for open and inactivated states.	0
Inhibition of the @GENE$ by @CHEMICAL$: affinity for open and inactivated states.	2
2 In a chronic transfection model using CHO-K1 cells, @CHEMICAL$ inhibited @GENE$ tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16.	2
6 In conclusion, @GENE$ channel inhibition by @CHEMICAL$ exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.	2
6 In conclusion, @GENE$ channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external @CHEMICAL$ concentration.	0
Comparison of the novel antipsychotic @CHEMICAL$ with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of @GENE$ activation.	0
Comparison of the novel antipsychotic ziprasidone with @CHEMICAL$ and olanzapine: inhibition of dorsal raphe cell firing and the role of @GENE$ activation.	0
Comparison of the novel antipsychotic ziprasidone with clozapine and @CHEMICAL$: inhibition of dorsal raphe cell firing and the role of @GENE$ activation.	0
@CHEMICAL$ is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to @GENE$, 5-HT2, and D2 sites.	0
@CHEMICAL$ is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, @GENE$, and D2 sites.	0
@CHEMICAL$ is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and @GENE$ sites.	0
@CHEMICAL$ is a novel antipsychotic agent which binds with high affinity to @GENE$ (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites.	0
While it is an antagonist at these latter receptors, @CHEMICAL$ behaves as a @GENE$ agonist in vitro in adenylate cyclase measurements.	3
While it is an antagonist at these latter receptors, @CHEMICAL$ behaves as a 5-HT1A agonist in vitro in @GENE$ measurements.	0
While it is an antagonist at these latter receptors, ziprasidone behaves as a @GENE$ agonist in vitro in @CHEMICAL$ cyclase measurements.	0
While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in @CHEM-GENE$ measurements.	0
The goal of the present study was to examine the @GENE$ properties of @CHEMICAL$ in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus.	0
The goal of the present study was to examine the 5-HT1A properties of @CHEMICAL$ in vivo using as a marker of central @GENE$ activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus.	0
The goal of the present study was to examine the @GENE$ properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of @CHEMICAL$-containing neurons in the dorsal raphe nucleus.	0
The goal of the present study was to examine the 5-HT1A properties of ziprasidone in vivo using as a marker of central @GENE$ activity the inhibition of firing of @CHEMICAL$-containing neurons in the dorsal raphe nucleus.	0
Pretreatment with the @GENE$ antagonist @CHEMICAL$ (10 micrograms/kg i.v.)	4
Because all three agents also bind to @GENE$, antagonists of which inhibit @CHEMICAL$ neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	0
Because all three agents also bind to @GENE$, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with @CHEMICAL$ (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	0
Because all three agents also bind to @GENE$, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (@CHEMICAL$), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	0
Because all three agents also bind to @GENE$, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a @CHEMICAL$ re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity.	0
These profiles suggest a mechanism of action for each agent, @GENE$ agonism for @CHEMICAL$ and alpha 1 antagonism for clozapine and olanzapine.	3
These profiles suggest a mechanism of action for each agent, @GENE$ agonism for ziprasidone and alpha 1 antagonism for @CHEMICAL$ and olanzapine.	0
These profiles suggest a mechanism of action for each agent, @GENE$ agonism for ziprasidone and alpha 1 antagonism for clozapine and @CHEMICAL$.	0
The @GENE$ agonist activity reported here clearly distinguishes @CHEMICAL$ from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.	3
Reduction of oral @CHEMICAL$ self-administration in rats by @GENE$ inhibitors.	0
Reduction of oral ethanol self-administration in rats by @CHEM-GENE$ inhibitors.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of @CHEMICAL$ and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of @CHEMICAL$ and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and @CHEMICAL$ by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and @CHEMICAL$ by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of @CHEMICAL$ and serotonin in the control of ethanol intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of @CHEMICAL$ and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of @CHEMICAL$ dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of @CHEMICAL$ dependence.	0
Evidence for a role of dopamine and @CHEMICAL$ in the control of ethanol intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and @CHEMICAL$ in the control of ethanol intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of @CHEMICAL$ intake in animals suggests that @GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of @CHEMICAL$ intake in animals suggests that monoamine oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that @CHEM-GENE$ (MAO) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
Evidence for a role of dopamine and serotonin in the control of ethanol intake in animals suggests that @CHEMICAL$ oxidase (@GENE$) inhibitors, which increase the synaptic availability of serotonin and dopamine by blocking their metabolism, might have efficacy in the treatment of alcohol dependence.	0
The aim of the present study was, therefore, to evaluate several @GENE$ inhibitors for their capacity to affect @CHEMICAL$ self-administration in rats trained to self-administer ethanol (10% v/v) orally in a free-choice two-lever operant task.	0
The aim of the present study was, therefore, to evaluate several @GENE$ inhibitors for their capacity to affect ethanol self-administration in rats trained to self-administer @CHEMICAL$ (10% v/v) orally in a free-choice two-lever operant task.	0
The nonselective and irreversible @GENE$ inhibitors, @CHEMICAL$ (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.	2
The nonselective and irreversible @GENE$ inhibitors, phenelzine (3-10 mg/kg), @CHEMICAL$ (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.	2
The nonselective and irreversible @GENE$ inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and @CHEMICAL$ (30 mg/kg), decreased rates of responding maintained by ethanol reinforcement.	2
The nonselective and irreversible @GENE$ inhibitors, phenelzine (3-10 mg/kg), tranylcypromine (1-3 mg/kg), and nialamide (30 mg/kg), decreased rates of responding maintained by @CHEMICAL$ reinforcement.	0
The reversible @GENE$ inhibitor, @CHEMICAL$ (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.	2
The reversible MAO-A inhibitor, @CHEMICAL$ (0.3-3 mg/kg), and the irreversible @GENE$ inhibitor, clorgyline (10-30 mg/kg), also reduced ethanol self-administration.	0
The reversible @GENE$ inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, @CHEMICAL$ (10-30 mg/kg), also reduced ethanol self-administration.	0
The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible @GENE$ inhibitor, @CHEMICAL$ (10-30 mg/kg), also reduced ethanol self-administration.	2
The reversible @GENE$ inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg/kg), also reduced @CHEMICAL$ self-administration.	0
The reversible MAO-A inhibitor, befloxatone (0.3-3 mg/kg), and the irreversible @GENE$ inhibitor, clorgyline (10-30 mg/kg), also reduced @CHEMICAL$ self-administration.	0
The irreversible @GENE$ inhibitors, @CHEMICAL$ (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.	2
The irreversible @GENE$ inhibitors, pargyline (30 mg/kg) and @CHEMICAL$ (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.	2
The irreversible @GENE$ inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by @CHEMICAL$ reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice.	0
The irreversible @GENE$ inhibitors, pargyline (30 mg/kg) and l-deprenyl (3-10 mg/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased @CHEMICAL$ intake in mice.	0
In conclusion, the present results showing that several @GENE$ inhibitors decreased @CHEMICAL$ self-administration in rats are consistent with previous findings that synaptic levels of serotonin and dopamine play a critical role in the control of ethanol self-administration.	0
In conclusion, the present results showing that several @GENE$ inhibitors decreased ethanol self-administration in rats are consistent with previous findings that synaptic levels of @CHEMICAL$ and dopamine play a critical role in the control of ethanol self-administration.	0
In conclusion, the present results showing that several @GENE$ inhibitors decreased ethanol self-administration in rats are consistent with previous findings that synaptic levels of serotonin and @CHEMICAL$ play a critical role in the control of ethanol self-administration.	0
In conclusion, the present results showing that several @GENE$ inhibitors decreased ethanol self-administration in rats are consistent with previous findings that synaptic levels of serotonin and dopamine play a critical role in the control of @CHEMICAL$ self-administration.	0
@CHEMICAL$, a potent inhibitor of @GENE$, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.	2
Dicumarol, a potent inhibitor of @CHEM-GENE$, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.	0
Dicumarol, a potent inhibitor of @GENE$, at high concentration (500 microm ) caused only a 72% decrease in the utilization of @CHEMICAL$.	0
A novel mutation of the @GENE$ gene in a patient with non-inherited @CHEMICAL$-responsive sideroblastic anemia.	0
A novel mutation of the @CHEM-GENE$ gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia.	0
A novel missense mutation, @GENE$, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) was identified in a Japanese male with @CHEMICAL$-responsive sideroblastic anemia.	0
A novel missense mutation, G663A, in exon 5 of the @GENE$ gene (ALAS2) was identified in a Japanese male with @CHEMICAL$-responsive sideroblastic anemia.	0
A novel missense mutation, G663A, in exon 5 of the erythroid-specific delta-aminolevulinate synthase gene (@GENE$) was identified in a Japanese male with @CHEMICAL$-responsive sideroblastic anemia.	0
A novel missense mutation, @GENE$, in exon 5 of the erythroid-specific @CHEMICAL$ synthase gene (ALAS2) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia.	0
A novel missense mutation, G663A, in exon 5 of the @CHEM-GENE$ gene (ALAS2) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia.	0
A novel missense mutation, G663A, in exon 5 of the erythroid-specific @CHEMICAL$ synthase gene (@GENE$) was identified in a Japanese male with pyridoxine-responsive sideroblastic anemia.	0
Activity of the mutant @CHEM-GENE$ protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to pyridoxine treatment.	0
Activity of the mutant @GENE$ protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of @CHEMICAL$, consistent with the clinical response of the patient to pyridoxine treatment.	1
Activity of the mutant @GENE$ protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate, consistent with the clinical response of the patient to @CHEMICAL$ treatment.	0
Preferential cerebrospinal fluid @GENE$ inhibition by @CHEMICAL$ in humans.	2
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that @CHEMICAL$ (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits @GENE$ in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of @GENE$ (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that @CHEMICAL$ (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (@GENE$) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that @CHEMICAL$ (ENA-713; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (@CHEMICAL$; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits @GENE$ in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of @GENE$ (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (@CHEMICAL$; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (@GENE$) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (@CHEMICAL$; Exelon, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; @CHEMICAL$, Novartis Pharma AG, Basel, Switzerland) selectively inhibits @GENE$ in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of @GENE$ (AChE) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; @CHEMICAL$, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (@GENE$) activity in the cerebrospinal fluid (CSF) of volunteers and to test the hypothesis that rivastigmine (ENA-713; @CHEMICAL$, Novartis Pharma AG, Basel, Switzerland) selectively inhibits AChE in CSF in humans at a dose producing minimal inhibition of the peripheral enzyme.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for @CHEMICAL$ and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte @GENE$ activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for @CHEMICAL$ and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF @GENE$ activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for @CHEMICAL$ and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF @GENE$ (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for @CHEMICAL$ and its metabolite NAP 226-90 ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (@GENE$) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite @CHEMICAL$ ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte @GENE$ activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite @CHEMICAL$ ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF @GENE$ activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite @CHEMICAL$ ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF @GENE$ (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite @CHEMICAL$ ([-] [3-([1-dimethylaminolethyl)-phenol]), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (@GENE$) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 (@CHEMICAL$), erythrocyte @GENE$ activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 (@CHEMICAL$), erythrocyte AChE activity, CSF @GENE$ activity, and plasma and CSF butyrylcholinesterase (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 (@CHEMICAL$), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF @GENE$ (BuChE) activity.	0
CSF specimens and samples of blood cells and blood plasma were analyzed at intervals for rivastigmine and its metabolite NAP 226-90 (@CHEMICAL$), erythrocyte AChE activity, CSF AChE activity, and plasma and CSF butyrylcholinesterase (@GENE$) activity.	0
Inhibition of @GENE$ in the CSF after @CHEMICAL$ administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.	2
Plasma @GENE$ activity was significantly lower after @CHEMICAL$ than after placebo, but this was not clinically relevant.	2
@GENE$ activity in CSF was significantly lower after @CHEMICAL$ than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.	2
This study confirms the feasibility of using continuous measurement of @GENE$ activity in CSF over prolonged periods, that @CHEMICAL$ markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.	0
This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that @CHEMICAL$ markedly inhibits CSF @GENE$ after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.	2
This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that @CHEMICAL$ markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central @GENE$ is substantially greater than that of peripheral AChE or BuChE.	2
This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that @CHEMICAL$ markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral @GENE$ or BuChE.	2
This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that @CHEMICAL$ markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or @GENE$.	2
Identification of @CHEMICAL$ in the @GENE$ required for activation of factor IX.	0
Identification of @CHEMICAL$ in the factor XI apple 3 domain required for activation of @GENE$.	0
To identify key @CHEMICAL$ involved in @GENE$ activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	0
To identify key @CHEMICAL$ involved in factor IX activation, recombinant @GENE$ proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	0
To identify key amino acids involved in @GENE$ activation, recombinant factor XIa proteins containing @CHEMICAL$ substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	0
To identify key amino acids involved in factor IX activation, recombinant @GENE$ proteins containing @CHEMICAL$ substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.	0
Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the @CHEMICAL$ terminus and for Ser(258)-Ser(264) at the C terminus of the @GENE$ markedly decreased factor XI coagulant activity.	0
Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the @CHEMICAL$ terminus and for Ser(258)-Ser(264) at the C terminus of the A3 domain markedly decreased @GENE$ coagulant activity.	0
Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the @CHEMICAL$ terminus of the @GENE$ markedly decreased factor XI coagulant activity.	0
Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the @CHEMICAL$ terminus of the A3 domain markedly decreased @GENE$ coagulant activity.	0
@CHEMICAL$ between Ile(183) and Val(191) are necessary for proper @GENE$ activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, @CHEMICAL$ (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, @CHEMICAL$ @GENE$, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, @CHEMICAL$ (5-HT)(1A), @GENE$, 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, @CHEMICAL$ (5-HT)(1A), 5-HT(1B), @GENE$ and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, @CHEMICAL$ (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @GENE$.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at @GENE$ (AR)s, @CHEMICAL$ (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, serotonin (@CHEMICAL$)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin @CHEM-GENE$, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (@CHEMICAL$)(1A), @GENE$, 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (@CHEMICAL$)(1A), 5-HT(1B), @GENE$ and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (@CHEMICAL$)(1A), 5-HT(1B), 5-HT(1D) and @GENE$.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at @GENE$ (AR)s, serotonin (@CHEMICAL$)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, serotonin (5-HT)(1A), @CHEMICAL$(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin @GENE$, @CHEMICAL$(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @CHEM-GENE$, 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @CHEMICAL$(1B), @GENE$ and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @CHEMICAL$(1B), 5-HT(1D) and @GENE$.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at @GENE$ (AR)s, serotonin (5-HT)(1A), @CHEMICAL$(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, serotonin (5-HT)(1A), 5-HT(1B), @CHEMICAL$(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin @GENE$, 5-HT(1B), @CHEMICAL$(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @GENE$, @CHEMICAL$(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @CHEM-GENE$ and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @CHEMICAL$(1D) and @GENE$.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at @GENE$ (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @CHEMICAL$(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @CHEMICAL$ D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin @GENE$, 5-HT(1B), 5-HT(1D) and @CHEMICAL$ D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @GENE$, 5-HT(1D) and @CHEMICAL$ D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @GENE$ and @CHEMICAL$ D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @CHEM-GENE$.	0
Agonist and antagonist actions of yohimbine as compared to fluparoxan at @GENE$ (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @CHEMICAL$ D(2) and D(3) receptors.	0
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at alpha(2)-adrenergic receptors @GENE$, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin @GENE$, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @GENE$, 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @GENE$ and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @GENE$.	0
Agonist and antagonist actions of @CHEMICAL$ as compared to fluparoxan at @GENE$ (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at alpha(2)-adrenergic receptors @GENE$, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at alpha(2)-adrenergic receptors (AR)s, serotonin @GENE$, 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), @GENE$, 5-HT(1D) and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), @GENE$ and dopamine D(2) and D(3) receptors.	0
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and @GENE$.	0
Agonist and antagonist actions of yohimbine as compared to @CHEMICAL$ at @GENE$ (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors.	4
Herein, we evaluate the interaction of the alpha(2)-AR antagonist, @CHEMICAL$, as compared to fluparoxan, at multiple @GENE$ and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.	0
Herein, we evaluate the interaction of the @GENE$, @CHEMICAL$, as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.	4
Herein, we evaluate the interaction of the alpha(2)-AR antagonist, yohimbine, as compared to @CHEMICAL$, at multiple @GENE$ and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.	0
Herein, we evaluate the interaction of the @GENE$, yohimbine, as compared to @CHEMICAL$, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats.	4
@CHEMICAL$ displays marked affinity at @GENE$, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.	0
@CHEMICAL$ displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for @GENE$, h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.	0
@CHEMICAL$ displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), @GENE$, h5-HT(1D), and hD(2) receptors and weak affinity for hD(3) receptors.	0
@CHEMICAL$ displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), @GENE$, and hD(2) receptors and weak affinity for hD(3) receptors.	0
@CHEMICAL$ displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and @GENE$ and weak affinity for hD(3) receptors.	0
@CHEMICAL$ displays marked affinity at human (h)alpha(2A)-, halpha(2B)- and halpha(2C)-ARs, significant affinity for h5-HT(1A), h5-HT(1B), h5-HT(1D), and hD(2) receptors and weak affinity for @GENE$.	0
In [@CHEMICAL$]GTPgammaS binding protocols, yohimbine exerts antagonist actions at @GENE$, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	0
In [@CHEMICAL$]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, @GENE$, h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	0
In [@CHEMICAL$]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), @GENE$, and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	0
In [@CHEMICAL$]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and @GENE$ sites, yet partial agonist actions at h5-HT(1A) sites.	0
In [@CHEMICAL$]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at @GENE$ sites.	0
In [(35)S]GTPgammaS binding protocols, @CHEMICAL$ exerts antagonist actions at @GENE$, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	4
In [(35)S]GTPgammaS binding protocols, @CHEMICAL$ exerts antagonist actions at halpha(2A)-AR, @GENE$, h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	4
In [(35)S]GTPgammaS binding protocols, @CHEMICAL$ exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), @GENE$, and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites.	4
In [(35)S]GTPgammaS binding protocols, @CHEMICAL$ exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and @GENE$ sites, yet partial agonist actions at h5-HT(1A) sites.	4
In [(35)S]GTPgammaS binding protocols, @CHEMICAL$ exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at @GENE$ sites.	3
In vivo, agonist actions of @CHEMICAL$ at @GENE$ sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.	3
In vivo, agonist actions of yohimbine at @CHEM-GENE$ sites are revealed by WAY100,635-reversible induction of hypothermia in the rat.	0
In vivo, agonist actions of yohimbine at @GENE$ sites are revealed by @CHEMICAL$-reversible induction of hypothermia in the rat.	4
In guinea pigs, antagonist actions of @CHEMICAL$ at @GENE$ receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.	4
In guinea pigs, antagonist actions of @CHEMICAL$ at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the @GENE$ agonist, GR46,611.	0
In guinea pigs, antagonist actions of yohimbine at @CHEM-GENE$ receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611.	0
In guinea pigs, antagonist actions of yohimbine at @CHEMICAL$(1B) receptors are revealed by blockade of hypothermia evoked by the @GENE$ agonist, GR46,611.	0
In guinea pigs, antagonist actions of yohimbine at @GENE$ receptors are revealed by blockade of hypothermia evoked by the @CHEMICAL$(1B) agonist, GR46,611.	0
In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the @CHEM-GENE$ agonist, GR46,611.	0
In guinea pigs, antagonist actions of yohimbine at @GENE$ receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, @CHEMICAL$.	0
In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the @GENE$ agonist, @CHEMICAL$.	3
In distinction to @CHEMICAL$, fluparoxan shows only modest partial agonist actions at @GENE$ sites versus marked antagonist actions at halpha(2)-ARs.	3
In distinction to @CHEMICAL$, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at @GENE$.	4
In distinction to yohimbine, @CHEMICAL$ shows only modest partial agonist actions at @GENE$ sites versus marked antagonist actions at halpha(2)-ARs.	3
In distinction to yohimbine, @CHEMICAL$ shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at @GENE$.	4
In conclusion, the @GENE$ antagonist properties of @CHEMICAL$ increase DA and NAD levels both alone and in association with fluoxetine.	4
In conclusion, the @GENE$ antagonist properties of yohimbine increase @CHEMICAL$ and NAD levels both alone and in association with fluoxetine.	0
In conclusion, the @GENE$ antagonist properties of yohimbine increase DA and @CHEMICAL$ levels both alone and in association with fluoxetine.	0
However, in contrast to the selective @GENE$ antagonist, @CHEMICAL$, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	4
However, in contrast to the selective alpha(2)-AR antagonist, @CHEMICAL$, the @GENE$ agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective @GENE$ antagonist, fluparoxan, the @CHEMICAL$(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the @CHEM-GENE$ agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective @GENE$ antagonist, fluparoxan, the 5-HT(1A) agonist actions of @CHEMICAL$ suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the @GENE$ agonist actions of @CHEMICAL$ suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	3
However, in contrast to the selective @GENE$ antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress @CHEMICAL$ levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the @GENE$ agonist actions of yohimbine suppress @CHEMICAL$ levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.	0
However, in contrast to the selective @GENE$ antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of @CHEMICAL$ upon 5-HT levels.	0
However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the @GENE$ agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of @CHEMICAL$ upon 5-HT levels.	0
However, in contrast to the selective @GENE$ antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon @CHEMICAL$ levels.	0
However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the @GENE$ agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon @CHEMICAL$ levels.	0
In this study, the activity of the @GENE$ subtype-selective agonist, @CHEMICAL$, was investigated in a guinea pig model of citric acid-induced cough.	3
In this study, the activity of the @GENE$ subtype-selective agonist, SB 227122, was investigated in a guinea pig model of @CHEMICAL$-induced cough.	0
Parenteral administration of selective agonists of the @GENE$ (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (@CHEMICAL$) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), @GENE$ (codeine and hydrocodone), and kappa-opioid receptor (@CHEMICAL$) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and @GENE$ (@CHEMICAL$) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	3
Parenteral administration of selective agonists of the @GENE$ (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of @CHEMICAL$-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), @GENE$ (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of @CHEMICAL$-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and @GENE$ (BRL 52974) produced dose-related inhibition of @CHEMICAL$-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the @GENE$ (@CHEMICAL$), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	3
Parenteral administration of selective agonists of the delta-opioid receptor (@CHEMICAL$), @GENE$ (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (@CHEMICAL$), mu-opioid receptor (codeine and hydrocodone), and @GENE$ (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the @GENE$ (SB 227122), mu-opioid receptor (@CHEMICAL$ and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), @GENE$ (@CHEMICAL$ and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	3
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (@CHEMICAL$ and hydrocodone), and @GENE$ (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the @GENE$ (SB 227122), mu-opioid receptor (codeine and @CHEMICAL$), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), @GENE$ (codeine and @CHEMICAL$), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	3
Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and @CHEMICAL$), and @GENE$ (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.	0
The nonselective @GENE$ antagonist, @CHEMICAL$ (3 mg/kg, i.m.	4
), attenuated the antitussive effects of @CHEMICAL$ or SB 227122, indicating that the antitussive activity of both compounds is @GENE$-mediated.	3
), attenuated the antitussive effects of codeine or @CHEMICAL$, indicating that the antitussive activity of both compounds is @GENE$-mediated.	3
The @GENE$ antagonist, @CHEMICAL$ (10 mg/kg, i.p.	4
In contrast, combined pretreatment with @CHEMICAL$ (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of @GENE$ agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with @CHEMICAL$ (@GENE$ antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	4
In contrast, combined pretreatment with @CHEMICAL$ (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (@GENE$ antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and @CHEMICAL$ (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of @GENE$ agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with beta-funaltrexamine (@GENE$ antagonist; 20 mg/kg, s.c.) and @CHEMICAL$ (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and @CHEMICAL$ (@GENE$ antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).	4
In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of @GENE$ agonists, respectively, was without effect on the antitussive response of @CHEMICAL$ (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with beta-funaltrexamine (@GENE$ antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of @CHEMICAL$ (20 mg/kg, i.p.).	0
In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (@GENE$ antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of @CHEMICAL$ (20 mg/kg, i.p.).	0
The @GENE$ antagonist @CHEMICAL$ (3 mg/kg, i.p.)	4
These studies provide compelling evidence that the antitussive effects of @CHEMICAL$ in this guinea pig cough model are mediated by agonist activity at the @GENE$.	3
New modes of therapy have recently been introduced, and data on the @GENE$ (COX-2)-specific inhibitors @CHEMICAL$ and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	2
New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (@GENE$)-specific inhibitors @CHEMICAL$ and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	2
New modes of therapy have recently been introduced, and data on the @GENE$ (COX-2)-specific inhibitors celecoxib and @CHEMICAL$ suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	2
New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (@GENE$)-specific inhibitors celecoxib and @CHEMICAL$ suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.	2
Kinetics of inhibition of @GENE$ by atovaquone, lawsone derivatives, @CHEMICAL$ and polyporic acid.	2
Kinetics of inhibition of @GENE$ by atovaquone, lawsone derivatives, brequinar sodium and @CHEMICAL$.	2
Kinetics of inhibition of @CHEM-GENE$ by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.	0
Kinetics of inhibition of @GENE$ by @CHEMICAL$, lawsone derivatives, brequinar sodium and polyporic acid.	2
Kinetics of inhibition of @GENE$ by atovaquone, @CHEMICAL$ derivatives, brequinar sodium and polyporic acid.	2
Mitochondrially-bound @CHEM-GENE$ (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate.	0
Mitochondrially-bound @CHEMICAL$ dehydrogenase (@GENE$) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate.	0
Mitochondrially-bound @GENE$ (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of @CHEMICAL$.	5
Mitochondrially-bound dihydroorotate dehydrogenase (@GENE$) catalyzes the fourth sequential step in the de novo synthesis of @CHEMICAL$.	5
Despite this broad spectrum of biological and clinical relevance, there have been no comparative studies on drug-@CHEM-GENE$ interactions.	0
Here, we describe a study of the inhibition of the purified recombinant @CHEM-GENE$ by ten compounds.	0
With respect to the @CHEMICAL$ co-substrate of the @GENE$, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.	5
With respect to the @CHEMICAL$ co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of @GENE$.	0
With respect to the quinone co-substrate of the @CHEM-GENE$, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.	0
With respect to the quinone co-substrate of the @CHEMICAL$ dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of @GENE$.	0
With respect to the quinone co-substrate of the @GENE$, @CHEMICAL$ (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.	0
With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, @CHEMICAL$ (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of @GENE$.	2
With respect to the quinone co-substrate of the @GENE$, atovaquone (Kic = 2.7 microM) and @CHEMICAL$ (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.	0
With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and @CHEMICAL$ (Kic = 9.8 nM) were shown to be competitive inhibitors of @GENE$.	2
With respect to the quinone co-substrate of the @GENE$, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human @CHEMICAL$ dehydrogenase.	0
With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of @CHEM-GENE$.	0
@CHEMICAL$ was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for @GENE$.	2
Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for @CHEM-GENE$.	0
Another inhibitor, @CHEMICAL$ was previously reported to be a slow-binding inhibitor of the @GENE$ [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	2
Another inhibitor, @CHEMICAL$ was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of @GENE$ by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the @CHEM-GENE$ [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human @CHEMICAL$ dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of @GENE$ by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the @GENE$ [W. Knecht, M. Loffler, Species-related inhibition of human and rat @CHEMICAL$ dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of @CHEM-GENE$ by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the @GENE$ [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive @CHEMICAL$ and cinchoninic acid derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of @GENE$ by immunosuppressive @CHEMICAL$ and cinchoninic acid derivatives, Biochem.	2
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the @GENE$ [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and @CHEMICAL$ derivatives, Biochem.	0
Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of @GENE$ by immunosuppressive isoxazol and @CHEMICAL$ derivatives, Biochem.	2
With respect to the substrate @CHEMICAL$, atovaquone was an uncompetitive inhibitor of @GENE$ (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).	2
With respect to the substrate dihydroorotate, @CHEMICAL$ was an uncompetitive inhibitor of @GENE$ (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).	2
With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of @CHEM-GENE$ (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).	0
@CHEM-GENE$ blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.	0
BACKGROUND: A mutation in the @CHEM-GENE$ gene (SCN5A) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome).	0
BACKGROUND: A mutation in the cardiac @CHEMICAL$ channel gene (@GENE$) has been described in patients with the syndrome of right bundle branch block, ST-segment elevation in leads V1 to V3, and sudden death (Brugada syndrome).	0
The present study examined arrhythmic risk in patients with overt and concealed forms of the disease and the effectiveness of @CHEM-GENE$ blockers to unmask the syndrome and, thus, identify patients at risk.	0
METHODS AND RESULTS: The effect of intravenous @CHEMICAL$ (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a @GENE$ mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	0
METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), @CHEMICAL$ (10 mg/kg), or flecainide (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a @GENE$ mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	0
METHODS AND RESULTS: The effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or @CHEMICAL$ (2 mg/kg) on the ECG was studied in 34 patients with the syndrome and transient normalization of the ECG (group A), 11 members of 3 families in whom a @GENE$ mutation was associated with the syndrome and 8 members in whom it was not (group B), and 53 control subjects (group C).	0
CONCLUSIONS: The data demonstrated a similar incidence of potentially lethal arrhythmias in patients displaying transient versus persistent ST-segment elevation and right bundle branch block, as well as the effectiveness of @CHEM-GENE$ blockers to unmask the syndrome and, thus, identify patients at risk.	0
Determinants of voltage-dependent inactivation affect @CHEMICAL$ block of @GENE$.	2
Determinants of voltage-dependent inactivation affect Mibefradil block of @CHEM-GENE$.	0
The @CHEM-GENE$ family is a major target for a range of therapeutic drugs.	0
@CHEMICAL$ (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block @GENE$.	2
Mibefradil (@CHEMICAL$) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block @GENE$.	2
Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other @CHEMICAL$ antagonists by its ability to potently block @GENE$.	0
Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block @CHEM-GENE$.	0
However, this molecule has also been shown to inhibit other @CHEM-GENE$ subtypes.	0
To further analyze the mechanism governing the @GENE$-@CHEMICAL$ interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the Ca2+ channel-@CHEMICAL$ interaction, we examined the effect of Mibefradil on various recombinant @GENE$ expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the @GENE$-Mibefradil interaction, we examined the effect of @CHEMICAL$ on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of @CHEMICAL$ on various recombinant @GENE$ expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the @GENE$-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant @CHEMICAL$ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant @CHEM-GENE$ expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the @GENE$-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using @CHEMICAL$ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant @GENE$ expressed in mammalian cells from their cloned cDNAs, using @CHEMICAL$ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the @CHEM-GENE$-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
To further analyze the mechanism governing the @CHEMICAL$ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant @GENE$ expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.	0
@CHEMICAL$ blocked alpha1A and alpha1E with a Kd comparable to that reported for @GENE$, but had a lower affinity (approximately 30-fold) for alpha1C.	2
Therefore, we conclude that the tissue and sub-cellular localization of @CHEM-GENE$ subunits as well as their specific associations are essential parameters to understand the in vivo effects of Mibefradil.	0
Therefore, we conclude that the tissue and sub-cellular localization of @GENE$ subunits as well as their specific associations are essential parameters to understand the in vivo effects of @CHEMICAL$.	0
Postoperative concentrations of @GENE$ were decreased significantly in the @CHEMICAL$ group (P < 0.001).	2
Iontophoresis of @CHEMICAL$, whose serotonergic actions include antagonism and partial agonism at @GENE$ receptors, also increased serotonin and decreased firing (n=4).	4
Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at @GENE$ receptors, also increased @CHEMICAL$ and decreased firing (n=4).	0
@CHEMICAL$ (intravenous, 1 mg/kg), whose serotonergic actions include @GENE$ and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).	4
@CHEMICAL$ (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and @GENE$ antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).	4
Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include @GENE$ and 5-HT2 antagonism, typically raised @CHEMICAL$ levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).	0
Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and @GENE$ antagonism, typically raised @CHEMICAL$ levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).	0
Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include @GENE$ and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by @CHEMICAL$ (n = 3).	0
Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and @GENE$ antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by @CHEMICAL$ (n = 3).	0
The released @CHEMICAL$ could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory @GENE$ receptors and excitatory 5-HT2 receptors, respectively, have previously been shown to dominate their serotonergic responses.	0
The released @CHEMICAL$ could contribute to the inhibition of off(M) cells and excitation of on(M) cells by noxious stimulation, since inhibitory 5-HT1a receptors and excitatory @GENE$ receptors, respectively, have previously been shown to dominate their serotonergic responses.	0
The @GENE$-specific inhibitor @CHEMICAL$ selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.	2
The Hsp90-specific inhibitor @CHEMICAL$ selectively disrupts @GENE$-mediated signaling events of T-lymphocyte activation.	2
Improper function of these proteins can be induced by selective disruption of their complexes with @GENE$ using the @CHEMICAL$ geldanamycin.	2
Improper function of these proteins can be induced by selective disruption of their complexes with @GENE$ using the benzoquinonoid ansamycin @CHEMICAL$.	2
In this study, we demonstrate that @CHEMICAL$ treatment blocks @GENE$ secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.	2
In this study, we demonstrate that @CHEMICAL$ treatment blocks interleukin (IL)-2 secretion, @GENE$ expression, and proliferation of stimulated T-lymphocytes.	2
Moreover, @CHEMICAL$ decreases the amount and phosphorylation of @GENE$ and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.	2
Moreover, @CHEMICAL$ decreases the amount and phosphorylation of Lck and @GENE$ kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.	2
Moreover, @CHEMICAL$ decreases the amount and phosphorylation of Lck and Raf-1 @GENE$ and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.	2
Moreover, @CHEMICAL$ decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the @GENE$ kinase.	2
Moreover, @CHEMICAL$ decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 @GENE$.	2
@CHEMICAL$ also disrupts the @GENE$-mediated activation of nuclear factor of activated T-cells (NF-AT).	2
@CHEMICAL$ also disrupts the T-cell receptor-mediated activation of @GENE$ (NF-AT).	2
@CHEMICAL$ also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (@GENE$).	2
Treatment with @CHEMICAL$, however, does not affect the activation of lysophosphatide acyltransferase, which is a plasma membrane enzyme coupled to the @GENE$ after T-cell stimulation.	0
Treatment with @CHEMICAL$, however, does not affect the activation of @GENE$, which is a plasma membrane enzyme coupled to the T-cell receptor after T-cell stimulation.	0
Through demonstrating the selective inhibition of @GENE$-related T-lymphocyte responses by @CHEMICAL$, our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.	2
Through demonstrating the selective inhibition of kinase-related T-lymphocyte responses by @CHEMICAL$, our results emphasize the substantial role of @GENE$-kinase complexes in T-cell activation.	0
Through demonstrating the selective inhibition of kinase-related T-lymphocyte responses by @CHEMICAL$, our results emphasize the substantial role of Hsp90-@GENE$ complexes in T-cell activation.	0
Purification of @CHEM-GENE$ from rat liver.	0
@GENE$ catalyse the last step in @CHEMICAL$ biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.	5
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of @CHEMICAL$ from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.	5
@CHEM-GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.	0
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from @CHEMICAL$, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen.	5
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on @CHEMICAL$, alpha-ketoglutarate, ascorbate and oxygen.	0
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, @CHEMICAL$, ascorbate and oxygen.	0
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, @CHEMICAL$ and oxygen.	0
@GENE$ catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and @CHEMICAL$.	0
Initial attempts to purify the protein from rat liver showed that @CHEM-GENE$ is unstable.	0
We, therefore, determined the influence of various compounds on the stability of @CHEM-GENE$ at different storage temperatures.	0
@CHEMICAL$ and sodium salicylate inhibit endothelin @GENE$ by an allosteric type of mechanism.	0
Aspirin and @CHEMICAL$ inhibit endothelin @GENE$ by an allosteric type of mechanism.	0
This study shows that @CHEMICAL$ and sodium salicylate, its major blood metabolite, reverse contractile actions of @GENE$ (ET-1) in isolated rat aorta and human mammary arteries.	0
This study shows that @CHEMICAL$ and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 (@GENE$) in isolated rat aorta and human mammary arteries.	0
This study shows that aspirin and @CHEMICAL$, its major blood metabolite, reverse contractile actions of @GENE$ (ET-1) in isolated rat aorta and human mammary arteries.	0
This study shows that aspirin and @CHEMICAL$, its major blood metabolite, reverse contractile actions of endothelin-1 (@GENE$) in isolated rat aorta and human mammary arteries.	0
They also prevent the intracellular @CHEMICAL$ mobilizing action of @GENE$ in cultured endothelial cells but not those of neuromedin B or UTP.	0
They also prevent the intracellular @CHEMICAL$ mobilizing action of ET-1 in cultured endothelial cells but not those of @GENE$ or UTP.	0
Inhibition of the actions of @GENE$ by @CHEMICAL$ is apparently competitive.	2
@CHEMICAL$ inhibit (125)I-@GENE$ binding to recombinant rat ETA receptors.	0
@CHEMICAL$ inhibit (125)I-ET-1 binding to recombinant @GENE$.	0
Salicylates inhibit @CHEMICAL$-@GENE$ binding to recombinant rat ETA receptors.	0
Salicylates inhibit @CHEMICAL$-ET-1 binding to recombinant @GENE$.	0
@CHEMICAL$ promotes dissociation of (125)I-@GENE$ ETA receptor complexes both in the absence and the presence of unlabeled ET-1.	0
@CHEMICAL$ promotes dissociation of (125)I-ET-1 @GENE$ complexes both in the absence and the presence of unlabeled ET-1.	0
@CHEMICAL$ promotes dissociation of (125)I-ET-1 ETA receptor complexes both in the absence and the presence of unlabeled @GENE$.	0
Salicylic acid promotes dissociation of @CHEMICAL$-@GENE$ ETA receptor complexes both in the absence and the presence of unlabeled ET-1.	0
Salicylic acid promotes dissociation of @CHEMICAL$-ET-1 @GENE$ complexes both in the absence and the presence of unlabeled ET-1.	0
Salicylic acid promotes dissociation of @CHEMICAL$-ET-1 ETA receptor complexes both in the absence and the presence of unlabeled @GENE$.	0
It has no influence on the rate of association of @CHEMICAL$-@GENE$ to ETA receptors.	0
It has no influence on the rate of association of @CHEMICAL$-ET-1 to @GENE$.	0
@CHEMICAL$ do not promote dissociation of (125)I-@GENE$ ETB receptor complexes.	0
@CHEMICAL$ do not promote dissociation of (125)I-ET-1 @GENE$ complexes.	0
Salicylates do not promote dissociation of @CHEMICAL$-@GENE$ ETB receptor complexes.	0
Salicylates do not promote dissociation of @CHEMICAL$-ET-1 @GENE$ complexes.	0
It is concluded that @CHEMICAL$ are allosteric inhibitors of @GENE$.	0
The results also suggest that: 1) irreversible @GENE$ binding probably limits actions of receptor antagonists in vivo, and 2) an association of @CHEMICAL$ and ETA receptor antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.	0
The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of @CHEMICAL$ and @GENE$ antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.	0
The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of @CHEMICAL$ and ETA receptor antagonists should be used to evaluate the physiopathological role of @GENE$ and may be of therapeutic interest in the treatment of ischemic heart disease.	0
A unique cytosolic activity related but distinct from @GENE$ catalyses metabolic activation of @CHEMICAL$.	5
Among the various enzymes, dicoumarol inhibitable cytosolic @GENE$ (NQO1) was shown to catalyse bioreductive activation of @CHEMICAL$ leading to cross-linking of the DNA and cytotoxicity.	5
Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (@GENE$) was shown to catalyse bioreductive activation of @CHEMICAL$ leading to cross-linking of the DNA and cytotoxicity.	5
Among the various enzymes, @CHEMICAL$ inhibitable cytosolic @GENE$ (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	2
Among the various enzymes, @CHEMICAL$ inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (@GENE$) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	2
Among the various enzymes, dicoumarol inhibitable cytosolic @CHEM-GENE$ (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	0
Among the various enzymes, dicoumarol inhibitable cytosolic @CHEMICAL$:quinone oxidoreductase1 (@GENE$) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	0
Among the various enzymes, dicoumarol inhibitable cytosolic @CHEM-GENE$ (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	0
Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:@CHEMICAL$ oxidoreductase1 (@GENE$) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity.	0
However, the role of @GENE$ in metabolic activation of @CHEMICAL$ has been disputed.	5
In this report, we present cellular and animal models to demonstrate that @GENE$ may play only a minor role in metabolic activation of @CHEMICAL$.	5
We further demonstrate that bioreductive activation of @CHEMICAL$ is catalysed by a unique cytosolic activity which is related but distinct from @GENE$.	0
The cytosolic fractions from liver and colon tissues of @GENE$-/- mice showed similar amounts of DNA cross-linking upon exposure to @CHEMICAL$, as observed in NQO1+/+ mice.	0
The cytosolic fractions from liver and colon tissues of NQO1-/- mice showed similar amounts of DNA cross-linking upon exposure to @CHEMICAL$, as observed in @GENE$+/+ mice.	0
The unique cytosolic activity that activated @CHEMICAL$ in cytosolic fractions of liver and colon tissues of @GENE$-/- mice was designated as cytosolic MMC reductase.	0
The unique cytosolic activity that activated @CHEMICAL$ in cytosolic fractions of liver and colon tissues of NQO1-/- mice was designated as cytosolic @GENE$.	0
The unique cytosolic activity that activated MMC in cytosolic fractions of liver and colon tissues of @GENE$-/- mice was designated as cytosolic @CHEMICAL$ reductase.	0
The unique cytosolic activity that activated MMC in cytosolic fractions of liver and colon tissues of NQO1-/- mice was designated as cytosolic @CHEM-GENE$.	0
This activity, like @GENE$, was inhibited by @CHEMICAL$ and immunologically related to NQO1.	2
This activity, like NQO1, was inhibited by @CHEMICAL$ and immunologically related to @GENE$.	0
@CHEMICAL$ reduces @GENE$ expression and secretion in cultured human adipocytes.	2
In this study, we investigated the effect of @CHEMICAL$, a ligand of the @GENE$ peroxisome proliferator activated receptor-gamma, on PAI-1 expression and secretion in human adipocytes.	0
In this study, we investigated the effect of @CHEMICAL$, a ligand of the nuclear receptor @GENE$, on PAI-1 expression and secretion in human adipocytes.	0
In this study, we investigated the effect of @CHEMICAL$, a ligand of the nuclear receptor peroxisome proliferator activated receptor-gamma, on @GENE$ expression and secretion in human adipocytes.	0
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml @CHEMICAL$ for 72 h caused a reduction of both @GENE$ secretion (by 29 +/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +/- 3%; p < 0.05).	2
RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram/ml @CHEMICAL$ for 72 h caused a reduction of both PAI-1 secretion (by 29 +/- 5%; p < 0.01) and @GENE$ mRNA expression (by 26 +/- 3%; p < 0.05).	2
In cultures from severely obese subjects, @CHEMICAL$ induced a decrease of @GENE$ antigen secretion from newly differentiated omental adipocytes by 49 +/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +/- 7% (p < 0.05).	2
Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to @CHEMICAL$ induced a similar reduction of @GENE$ concentration in the culture medium (by 35 +/- 11%, p < 0.05, and 33 +/- 8%, p < 0.05 compared with control, respectively).	2
CONCLUSION/INTERPRETATION: This study provides evidence that @CHEMICAL$ reduces @GENE$ production in human adipocytes, probably at the transcriptional level.	2
We examined the effect of JTH-601 (3- inverted question mark@CHEMICAL$ ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new @GENE$ antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	4
We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom @CHEMICAL$ inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new @GENE$ antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	4
We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-@CHEMICAL$), a new @GENE$ antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	4
We examined the effect of @CHEMICAL$ (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new @GENE$ antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.	4
In these tissues, @CHEMICAL$, prazosin (a non-selective @GENE$ antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.	4
In these tissues, @CHEMICAL$, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an @GENE$ antagonist) competitively antagonized contraction in a concentration-dependent manner.	0
In these tissues, JTH-601, @CHEMICAL$ (a non-selective @GENE$ antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.	4
In these tissues, JTH-601, @CHEMICAL$ (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an @GENE$ antagonist) competitively antagonized contraction in a concentration-dependent manner.	0
In these tissues, JTH-601, prazosin (a non-selective @GENE$ antagonist), and @CHEMICAL$ (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.	0
In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and @CHEMICAL$ (an @GENE$ antagonist) competitively antagonized contraction in a concentration-dependent manner.	4
@CHEMICAL$ is expected to be an effective @GENE$ antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.	4
Severe impairment of salivation in @CHEM-GENE$ (NKCC1)-deficient mice.	0
Severe impairment of salivation in @CHEMICAL$/K+/2Cl- cotransporter (@GENE$)-deficient mice.	0
Severe impairment of salivation in @CHEM-GENE$ (NKCC1)-deficient mice.	0
Severe impairment of salivation in Na+/@CHEMICAL$/2Cl- cotransporter (@GENE$)-deficient mice.	0
Severe impairment of salivation in @CHEM-GENE$ (NKCC1)-deficient mice.	0
Severe impairment of salivation in Na+/K+/@CHEMICAL$ cotransporter (@GENE$)-deficient mice.	0
The salivary fluid secretory mechanism is thought to require @CHEM-GENE$-mediated Cl(-) uptake.	0
The salivary fluid secretory mechanism is thought to require @CHEM-GENE$-mediated Cl(-) uptake.	0
The salivary fluid secretory mechanism is thought to require @CHEM-GENE$-mediated Cl(-) uptake.	0
The salivary fluid secretory mechanism is thought to require @GENE$-mediated @CHEMICAL$ uptake.	5
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @CHEM-GENE$ (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @CHEMICAL$/K(+)/2Cl(-) cotransporter isoform 1 (@GENE$), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @CHEMICAL$/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @GENE$.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @CHEM-GENE$ (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/@CHEMICAL$/2Cl(-) cotransporter isoform 1 (@GENE$), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/@CHEMICAL$/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @GENE$.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @CHEM-GENE$ (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/@CHEMICAL$ cotransporter isoform 1 (@GENE$), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/@CHEMICAL$ cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @GENE$.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @GENE$ (Nkcc1), the gene encoding the salivary @CHEMICAL$/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (@GENE$), the gene encoding the salivary @CHEMICAL$/K(+)/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @CHEM-GENE$.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @GENE$ (Nkcc1), the gene encoding the salivary Na(+)/@CHEMICAL$/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (@GENE$), the gene encoding the salivary Na(+)/@CHEMICAL$/2Cl(-) cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @CHEM-GENE$.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of @GENE$ (Nkcc1), the gene encoding the salivary Na(+)/K(+)/@CHEMICAL$ cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (@GENE$), the gene encoding the salivary Na(+)/K(+)/@CHEMICAL$ cotransporter.	0
To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary @CHEM-GENE$.	0
Consistent with defective @CHEMICAL$ uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking @GENE$.	0
Consistent with defective Cl(-) uptake, a loss of @CHEMICAL$-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking @GENE$.	0
Consistent with defective Cl(-) uptake, a loss of bumetanide-sensitive @CHEMICAL$ influx was observed in parotid acinar cells from mice lacking @GENE$.	0
@CHEMICAL$/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking @GENE$ is associated with anion exchanger-dependent Cl(-) uptake.	0
@CHEM-GENE$ activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake.	0
Cl(-)/ @CHEMICAL$ exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking @GENE$ is associated with anion exchanger-dependent Cl(-) uptake.	0
@CHEM-GENE$ activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake.	0
Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking @GENE$ is associated with anion exchanger-dependent @CHEMICAL$ uptake.	0
@GENE$ activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent @CHEMICAL$ uptake.	0
Indeed, expression of the @CHEM-GENE$ AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the @CHEMICAL$/ HCO(3)(-) exchanger @GENE$ was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the @CHEMICAL$/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional @GENE$.	0
Indeed, expression of the @CHEM-GENE$ AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ @CHEMICAL$ exchanger @GENE$ was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ @CHEMICAL$ exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional @GENE$.	0
Indeed, expression of the @GENE$ AE2 was enhanced suggesting that this transporter compensates for the loss of functional @CHEMICAL$/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger @GENE$ was enhanced suggesting that this transporter compensates for the loss of functional @CHEMICAL$/K(+)/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional @CHEM-GENE$.	0
Indeed, expression of the @GENE$ AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/@CHEMICAL$/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger @GENE$ was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/@CHEMICAL$/2Cl(-) cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional @CHEM-GENE$.	0
Indeed, expression of the @GENE$ AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/@CHEMICAL$ cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger @GENE$ was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/@CHEMICAL$ cotransporter.	0
Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional @CHEM-GENE$.	0
Furthermore, the ability of the parotid gland to conserve @CHEMICAL$ was abolished in @GENE$-deficient mice.	0
These data directly demonstrate that @GENE$ is the major @CHEMICAL$ uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.	5
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (@CHEMICAL$) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (@CHEMICAL$) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent muscarinic @CHEMICAL$ (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent @CHEM-GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and @CHEMICAL$ (3H-QNB).	0
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and @CHEMICAL$ (3H-QNB).	0
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (@CHEMICAL$).	0
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (@CHEMICAL$).	0
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by @CHEMICAL$, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by @CHEMICAL$, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	4
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and @CHEMICAL$, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	4
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and @CHEMICAL$, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective @GENE$ antagonist, was estimated with competitive binding studies using two different radioligands: @CHEMICAL$ (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
UNLABELLED: Apparent @GENE$ occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: @CHEMICAL$ (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).	0
Both radioligands labeled @GENE$ in these brain regions, and the relative regional distributions of the specific binding of @CHEMICAL$ in vivo paralleled the distribution of mAch receptors.	0
Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of @CHEMICAL$ in vivo paralleled the distribution of @GENE$.	0
A similar discrepancy in sensitivity to competitors between @CHEMICAL$ and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the @GENE$ could not account for the observed differences in sensitivity to competition.	0
A similar discrepancy in sensitivity to competitors between 3H-NMPB and @CHEMICAL$ was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the @GENE$ could not account for the observed differences in sensitivity to competition.	0
A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when @CHEMICAL$ was used as a competitor, indicating that binding to different subtypes of the @GENE$ could not account for the observed differences in sensitivity to competition.	0
This finding, together with the more favorable accumulation of @CHEMICAL$ in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of @GENE$ occupancy by cholinergic drugs in the brain.	0
This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that @CHEMICAL$, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of @GENE$ occupancy by cholinergic drugs in the brain.	0
KEYWORDS: @GENE$, @CHEMICAL$, NMPB, in vivo, mouse.	0
KEYWORDS: @GENE$, QNB, @CHEMICAL$, in vivo, mouse.	0
Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and @CHEMICAL$ reverse lactation-induced downregulation of the @GENE$ gene.	1
Impaired expression of the @GENE$ gene in skeletal muscle during lactation: fibrates and @CHEMICAL$ reverse lactation-induced downregulation of the uncoupling protein-3 gene.	0
Changes in @GENE$ mRNA occur in parallel with modifications in the levels of free @CHEMICAL$, which are reduced in lactation and are upregulated due to weaning or fasting.	0
Conversely, when mice are fed a high-fat diet after parturition, the downregulation of @GENE$ mRNA and UCP-3 protein levels due to lactation is partially reversed, as is the reduction in serum free @CHEMICAL$ levels.	0
Conversely, when mice are fed a high-fat diet after parturition, the downregulation of UCP-3 mRNA and @GENE$ protein levels due to lactation is partially reversed, as is the reduction in serum free @CHEMICAL$ levels.	0
Treatment of lactating mice with a single injection of @CHEMICAL$, an activator of the @GENE$ (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.	1
Treatment of lactating mice with a single injection of @CHEMICAL$, an activator of the peroxisome proliferator-activated receptor (@GENE$), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice.	1
Treatment of lactating mice with a single injection of @CHEMICAL$, an activator of the peroxisome proliferator-activated receptor (PPAR), raises @GENE$ mRNA in skeletal muscle to levels similar to those in virgin mice.	1
@CHEMICAL$ (WY-14,643), a specific ligand of the @GENE$ subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
@CHEMICAL$ (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in @GENE$ mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	1
@CHEMICAL$ (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of @GENE$, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
@CHEMICAL$ (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases @GENE$ mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (@CHEMICAL$), a specific ligand of the @GENE$ subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (@CHEMICAL$), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in @GENE$ mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	1
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (@CHEMICAL$), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of @GENE$, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (@CHEMICAL$), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases @GENE$ mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the @GENE$ subtype, causes the most dramatic increase in UCP-3 mRNA, whereas @CHEMICAL$, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in @GENE$ mRNA, whereas @CHEMICAL$, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	0
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas @CHEMICAL$, a specific activator of @GENE$, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice.	1
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas @CHEMICAL$, a specific activator of PPAR-gamma, also significantly increases @GENE$ mRNA abundance in skeletal muscle of lactating mice.	1
However, in virgin mice, @CHEMICAL$ and WY-14,643 do not significantly affect @GENE$ mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams.	0
However, in virgin mice, bezafibrate and @CHEMICAL$ do not significantly affect @GENE$ mRNA expression, whereas troglitazone is at least as effective as it is in lactating dams.	0
However, in virgin mice, bezafibrate and WY-14,643 do not significantly affect @GENE$ mRNA expression, whereas @CHEMICAL$ is at least as effective as it is in lactating dams.	0
It is proposed that the @GENE$ gene is regulated in skeletal muscle during lactation in response to changes in circulating free @CHEMICAL$ by mechanisms involving activation of PPARs.	0
It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free @CHEMICAL$ by mechanisms involving activation of @GENE$.	1
The impaired expression of the @GENE$ gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of @CHEMICAL$ as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.	0
The impaired expression of the UCP-3 gene is consistent with the involvement of @GENE$ gene regulation in the reduction of the use of @CHEMICAL$ as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.	0
Various biochemical processes including oligomerization, @CHEMICAL$ ATP/dATP binding, and @GENE$ interaction play a role in regulating the ternary death complex.	0
Various biochemical processes including oligomerization, adenosine triphosphate @CHEMICAL$/dATP binding, and @GENE$ interaction play a role in regulating the ternary death complex.	0
@CHEMICAL$, a novel anti-convulsant, enhances activation of @GENE$ potassium channels.	0
@CHEMICAL$, a novel anti-convulsant, enhances activation of KCNQ2/Q3 @GENE$.	1
Retigabine, a novel anti-convulsant, enhances activation of @GENE$ @CHEMICAL$ channels.	0
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 @CHEM-GENE$.	0
In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and @GENE$ @CHEMICAL$ channels expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3).	0
In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3 @CHEM-GENE$ expressed in Chinese hamster ovary cells (CHO-KCNQ2/Q3).	0
In the present study, we sought to determine whether retigabine could enhance current through M-like currents in PC12 cells and KCNQ2/Q3 @CHEMICAL$ channels expressed in Chinese hamster ovary cells (CHO-@GENE$).	0
@CHEMICAL$ (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing @GENE$ cells but not in wild-type cells.	0
Retigabine (0.1 to 10 microM) induced a @CHEMICAL$ current and hyperpolarized CHO cells expressing @GENE$ cells but not in wild-type cells.	0
@CHEMICAL$-induced currents in CHO-@GENE$ cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	0
@CHEMICAL$-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the @GENE$ blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	0
Retigabine-induced currents in CHO-@GENE$ cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, @CHEMICAL$ (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	0
Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the @GENE$ blocker, @CHEMICAL$ (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	0
Retigabine-induced currents in CHO-@GENE$ cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by @CHEMICAL$ (10 mM).	0
Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the @GENE$ blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by @CHEMICAL$ (10 mM).	0
The mechanism by which @CHEMICAL$ enhanced @GENE$ currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine).	0
The mechanism by which retigabine enhanced @GENE$ currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM @CHEMICAL$).	0
Our findings identify @GENE$ channels as a molecular target for @CHEMICAL$ and suggest that activation of KCNQ2/Q3 channels may be responsible for at least some of the anticonvulsant activity of this agent.	0
Our findings identify KCNQ2/Q3 channels as a molecular target for @CHEMICAL$ and suggest that activation of @GENE$ channels may be responsible for at least some of the anticonvulsant activity of this agent.	0
@CHEM-GENE$ gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	0
@CHEMICAL$ transporter gene regulatory region polymorphism (@GENE$), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	0
@GENE$ gene regulatory region polymorphism (5-HTTLPR), @CHEMICAL$ binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	0
Serotonin transporter gene regulatory region polymorphism (@GENE$), @CHEMICAL$ binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity.	0
The aim of this study was to investigate @CHEMICAL$ binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region @GENE$ (5-HTT) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate @CHEMICAL$ binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (@GENE$) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate @CHEMICAL$ binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism (@GENE$).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in @CHEMICAL$-dependent and age-matched control subjects in relation to a 5'-promoter region @GENE$ (5-HTT) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in @CHEMICAL$-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (@GENE$) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in @CHEMICAL$-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism (@GENE$).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region @CHEM-GENE$ (5-HTT) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region @CHEMICAL$ transporter (@GENE$) polymorphism (5-HTTLPR).	0
The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region @CHEMICAL$ transporter (5-HTT) polymorphism (@GENE$).	0
@GENE$ S-genotype carriers in both @CHEMICAL$-dependent and control subjects were expected to show significantly fewer binding sites and a lower dissociation constant.	0
Blood samples were taken from both alcohol-dependent and control subjects to determine @GENE$ genotypes using PCR of lymphocyte DNA, and to perform platelet @CHEMICAL$ binding (binding capacity: B(max); and dissociation constant: K(D)).	0
Blood samples were taken from both @CHEMICAL$-dependent and control subjects to determine @GENE$ genotypes using PCR of lymphocyte DNA, and to perform platelet [3H]paroxetine binding (binding capacity: B(max); and dissociation constant: K(D)).	0
This was the first study to investigate platelet @CHEMICAL$ binding in alcohol-dependent and age-matched control subjects in relation to the @GENE$ genotype.	0
This was the first study to investigate platelet [3H]paroxetine binding in @CHEMICAL$-dependent and age-matched control subjects in relation to the @GENE$ genotype.	0
No differences concerning @GENE$-alleles were found in these groups Furthermore, no significant interaction between these parameters and impulsivity was shown in @CHEMICAL$-dependent subjects.	0
These results do not support previous results of altered @CHEMICAL$ binding sites in alcohol-dependent subjects or @GENE$ S-allele carriers.	0
Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the human @CHEMICAL$ synthase-2 (@GENE$).	0
Arachidonic acid and nonsteroidal anti-inflammatory drugs induce conformational changes in the @CHEM-GENE$ (cyclooxygenase-2).	0
@CHEMICAL$ and nonsteroidal anti-inflammatory drugs induce conformational changes in the human prostaglandin endoperoxide H2 synthase-2 (@GENE$).	0
@CHEMICAL$ and nonsteroidal anti-inflammatory drugs induce conformational changes in the @GENE$ (cyclooxygenase-2).	0
By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of @CHEMICAL$ and nonsteroidal anti-inflammatory drugs induces conformational changes in the @GENE$ (PGHS-2).	0
By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of @CHEMICAL$ and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (@GENE$).	0
By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the @CHEM-GENE$ (PGHS-2).	0
By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the human @CHEMICAL$ synthase enzyme (@GENE$).	0
Line shape broadening resulting from spin-spin coupling of @CHEMICAL$ pairs introduced into the membrane-binding helices of @GENE$ was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands.	0
However, inter-helical distances calculated and determined by EPR for @GENE$ complexed with @CHEMICAL$, flurbiprofen, and SC-58125 were in close agreement with those obtained from the cognate crystal structures.	0
However, inter-helical distances calculated and determined by EPR for @GENE$ complexed with arachidonic acid, @CHEMICAL$, and SC-58125 were in close agreement with those obtained from the cognate crystal structures.	0
However, inter-helical distances calculated and determined by EPR for @GENE$ complexed with arachidonic acid, flurbiprofen, and @CHEMICAL$ were in close agreement with those obtained from the cognate crystal structures.	0
Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-@CHEMICAL$ anti-inflammatory drugs alters the conformation of @GENE$, but the present experiments are the first to directly measure such changes.	0
The finding that @CHEMICAL$ can also induce a conformational change in @GENE$ was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.	0
The finding that @CHEMICAL$ can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the @GENE$ catalytic mechanism.	0
Suppression of @GENE$ activity by @CHEMICAL$ is mediated by direct inhibition of IkappaB kinases alpha and beta.	2
Suppression of NF-kappaB activity by @CHEMICAL$ is mediated by direct inhibition of @GENE$.	0
Various drugs used in the treatment of IBD, such as glucocorticoids, @CHEMICAL$, and sulfasalazine, interfere with @GENE$/Rel signaling.	0
Various drugs used in the treatment of IBD, such as glucocorticoids, @CHEMICAL$, and sulfasalazine, interfere with NF-kappaB/@GENE$ signaling.	0
Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and @CHEMICAL$, interfere with @GENE$/Rel signaling.	0
Various drugs used in the treatment of IBD, such as glucocorticoids, 5-aminosalicylic acid, and @CHEMICAL$, interfere with NF-kappaB/@GENE$ signaling.	0
The aim of this study was to define the molecular mechanism by which @CHEMICAL$ inhibits @GENE$ activation.	2
METHODS: The effects of @CHEMICAL$ and its moieties on @GENE$ signaling were evaluated using electromobility shift, transfection, and immune complex kinase assays.	0
The direct effect of @CHEMICAL$ on @GENE$ (IKK) activity was investigated using purified recombinant IKK-alpha and -beta proteins.	0
The direct effect of @CHEMICAL$ on IkappaB kinase (@GENE$) activity was investigated using purified recombinant IKK-alpha and -beta proteins.	0
The direct effect of @CHEMICAL$ on IkappaB kinase (IKK) activity was investigated using purified recombinant @GENE$ proteins.	0
RESULTS: @GENE$/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	1
RESULTS: NF-kappaB/@GENE$ activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	1
RESULTS: NF-kappaB/Rel activity induced by @GENE$, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of @GENE$, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, @GENE$, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, @GENE$, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active @GENE$ and IKK-beta mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, @CHEMICAL$, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and @GENE$ mutants was inhibited dose dependently by sulfasalazine.	0
RESULTS: @GENE$/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/@GENE$ activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/Rel activity induced by @GENE$, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	0
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of @GENE$, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, @GENE$, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, @GENE$, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active @GENE$ and IKK-beta mutants was inhibited dose dependently by @CHEMICAL$.	2
RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and @GENE$ mutants was inhibited dose dependently by @CHEMICAL$.	2
@CHEMICAL$ inhibited @GENE$-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.	2
@CHEMICAL$ inhibited tumor necrosis factor alpha-induced activation of endogenous @GENE$ in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.	2
@CHEMICAL$ inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified @GENE$ and IKK-beta in vitro.	2
@CHEMICAL$ inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and @GENE$ in vitro.	2
Activation of @GENE$, c-Jun-@CHEMICAL$-terminal kinase (JNK) 1, and p38 was unaffected by sulfasalazine.	0
Activation of extracellular signal-related kinase (ERK) 1 and 2, @CHEM-GENE$, and p38 was unaffected by sulfasalazine.	0
Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-@CHEMICAL$-terminal kinase (JNK) 1, and @GENE$ was unaffected by sulfasalazine.	0
Activation of @GENE$, c-Jun-N-terminal kinase (JNK) 1, and p38 was unaffected by @CHEMICAL$.	0
Activation of extracellular signal-related kinase (ERK) 1 and 2, @GENE$, and p38 was unaffected by @CHEMICAL$.	0
Activation of extracellular signal-related kinase (ERK) 1 and 2, c-Jun-N-terminal kinase (JNK) 1, and @GENE$ was unaffected by @CHEMICAL$.	0
The decrease in substrate phosphorylation by @GENE$ is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess @CHEMICAL$.	0
The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of @GENE$ and can be antagonized by excess @CHEMICAL$.	2
CONCLUSIONS: These data identify @CHEMICAL$ as a direct inhibitor of @GENE$ by antagonizing adenosine triphosphate binding.	0
CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of @GENE$ by antagonizing @CHEMICAL$ binding.	0
The suppression of @GENE$ activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of @CHEMICAL$.	2
The suppression of NF-kappaB activation by inhibition of the @GENE$ contributes to the well-known anti-inflammatory and immunosuppressive effects of @CHEMICAL$.	2
@GENE$ produces @CHEMICAL$ that inhibit apoptosis and stimulate angiogenesis and invasiveness.	5
Selective @GENE$ inhibitors reduce @CHEMICAL$ synthesis, restore apoptosis, and inhibit cancer cell proliferation.	0
In contrast, aspirin-like nonselective NSAIDs such as sulindac and @CHEMICAL$ inhibit not only the enzymatic action of the highly inducible, proinflammatory @GENE$ but the constitutively expressed, cytoprotective COX-1 as well.	2
In contrast, aspirin-like nonselective NSAIDs such as sulindac and @CHEMICAL$ inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective @GENE$ as well.	2
In contrast, @CHEMICAL$-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory @GENE$ but the constitutively expressed, cytoprotective COX-1 as well.	2
In contrast, @CHEMICAL$-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective @GENE$ as well.	2
In contrast, aspirin-like nonselective NSAIDs such as @CHEMICAL$ and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory @GENE$ but the constitutively expressed, cytoprotective COX-1 as well.	2
In contrast, aspirin-like nonselective NSAIDs such as @CHEMICAL$ and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective @GENE$ as well.	2
Selective COX-2 inhibitors, such as @CHEMICAL$, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit @GENE$ but not COX-1.	2
Selective COX-2 inhibitors, such as @CHEMICAL$, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not @GENE$.	0
Selective @GENE$ inhibitors, such as @CHEMICAL$, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, @CHEMICAL$ (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit @GENE$ but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, @CHEMICAL$ (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not @GENE$.	0
Selective @GENE$ inhibitors, such as meloxicam, @CHEMICAL$ (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (@CHEMICAL$), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit @GENE$ but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (@CHEMICAL$), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not @GENE$.	0
Selective @GENE$ inhibitors, such as meloxicam, celecoxib (@CHEMICAL$), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and @CHEMICAL$ (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit @GENE$ but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and @CHEMICAL$ (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not @GENE$.	0
Selective @GENE$ inhibitors, such as meloxicam, celecoxib (SC-58635), and @CHEMICAL$ (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (@CHEMICAL$), are NSAIDs that have been modified chemically to preferentially inhibit @GENE$ but not COX-1.	2
Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (@CHEMICAL$), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not @GENE$.	0
Selective @GENE$ inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (@CHEMICAL$), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.	2
For instance, @CHEMICAL$ inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express @GENE$ but has no effect on HCT-116 tumor cells that do not express COX-2.	2
For instance, @CHEMICAL$ inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express @GENE$.	0
@CHEMICAL$ induces apoptosis in @GENE$ expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S/KS cells that does not express COX-2.	0
@CHEMICAL$ induces apoptosis in COX-2 expressing LNCaP prostate cancer cells and, surprisingly, in colon cancer S/KS cells that does not express @GENE$.	0
This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of @GENE$, as has been demonstrated for some nonselective NSAIDs, for instance, @CHEMICAL$.	2
The @CHEM-GENE$ inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.	0
In studying kinetics of @CHEM-GENE$ and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
In studying kinetics of @CHEMICAL$ hydroxylase and @GENE$ (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
In studying kinetics of @CHEMICAL$ hydroxylase and aromatic-L-amino acid decarboxylase (@GENE$) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
In studying kinetics of @GENE$ and @CHEMICAL$ decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
In studying kinetics of tryptophan hydroxylase and @CHEM-GENE$ (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
In studying kinetics of tryptophan hydroxylase and @CHEMICAL$ decarboxylase (@GENE$) in human carcinoid hepatic metastases and adjacent normal liver (J.	0
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors @CHEMICAL$ (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors @CHEMICAL$ (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors carbidopa (@CHEMICAL$), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors carbidopa (@CHEMICAL$), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), @CHEMICAL$ (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors carbidopa (alpha-methyl-dopahydrazine), @CHEMICAL$ (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (@CHEMICAL$), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (@CHEMICAL$), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and @CHEMICAL$ (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and @CHEMICAL$ (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
To assess the feasibility of targeting these high @GENE$ levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (@CHEMICAL$) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	0
To assess the feasibility of targeting these high AAAD levels for chemotherapy, @GENE$ inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (@CHEMICAL$) were incubated (72 h) with NCI-H727 human lung carcinoid cells.	2
For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), @GENE$ activity was correlated with the potency of @CHEMICAL$-induced cytotoxicity.	0
However, carcinoid cell death was not solely attributable to complete inhibition of either @GENE$ activity or the @CHEMICAL$ synthetic pathway.	0
@CHEMICAL$ derivatives as @GENE$ inhibitors.	2
In a search for less flexible analogues of caproctamine (1), a diamine @CHEMICAL$ endowed with an interesting @GENE$ affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.	0
In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting @GENE$ affinity profile, we discovered compound 2, in which the terminal @CHEMICAL$ groups of 1 have been incorporated into a tricyclic system.	0
In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting @GENE$ affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a @CHEMICAL$ system.	0
In a search for less flexible analogues of @CHEMICAL$ (1), a diamine diamide endowed with an interesting @GENE$ affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.	0
In a search for less flexible analogues of caproctamine (1), a @CHEMICAL$ diamide endowed with an interesting @GENE$ affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.	0
Since this compound retains good @GENE$ inhibitory activity and its @CHEMICAL$ moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.	2
Since this compound retains good AChE inhibitory activity and its @CHEMICAL$ moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against @GENE$ and BChE.	0
Since this compound retains good AChE inhibitory activity and its @CHEMICAL$ moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and @GENE$.	0
Since this compound retains good @GENE$ inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the @CHEMICAL$ (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.	2
Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the @CHEMICAL$ (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against @GENE$ and BChE.	0
Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the @CHEMICAL$ (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and @GENE$.	0
Since this compound retains good @GENE$ inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized @CHEMICAL$ 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE.	0
Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized @CHEMICAL$ 4-6, and their biological evaluation has been assessed in vitro against @GENE$ and BChE.	0
Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized @CHEMICAL$ 4-6, and their biological evaluation has been assessed in vitro against human AChE and @GENE$.	0
Brugada syndrome without mutation of the @CHEM-GENE$ gene in a Taiwanese patient.	0
Molecular study did not reveal the same mutations in the @CHEM-GENE$ gene (SCN5A) as previously reported in Brugada syndrome.	0
Molecular study did not reveal the same mutations in the cardiac @CHEMICAL$ channel gene (@GENE$) as previously reported in Brugada syndrome.	0
In addition, @CHEMICAL$ levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding @GENE$) in CD4+ T cells were increased in these mice.	0
In addition, @CHEMICAL$ levels in splenic tissue or serum and @GENE$ mRNA expression (mRNA encoding cholesterol side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice.	0
In addition, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression (mRNA encoding @CHEM-GENE$) in CD4+ T cells were increased in these mice.	0
In addition, corticosterone levels in splenic tissue or serum and @GENE$ mRNA expression (mRNA encoding @CHEMICAL$ side-chain cleavage p450 enzyme) in CD4+ T cells were increased in these mice.	0
When the anti-corticosterone drug @CHEMICAL$ (@GENE$ inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.	2
When the anti-corticosterone drug @CHEMICAL$ (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and @GENE$ mRNA expression were decreased at 14 days after tumor inoculation.	2
When the anti-corticosterone drug aminoglutethimide (@GENE$ inhibitor) was administered to B16F10 mice, @CHEMICAL$ levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.	0
When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, @CHEMICAL$ levels in splenic tissue or serum and @GENE$ mRNA expression were decreased at 14 days after tumor inoculation.	0
Moreover, it was suggested that promotion of @GENE$ mRNA expression in Th2 cells was partially involved due to an increase in level of @CHEMICAL$ in splenic tissue and the breakdown of Th cell responses locally in the splenic tissue, which then affected the maintenance of Th2 cell functions in the microenvironment of tumor-bearing mice.	0
Phosphorylation of this subunit by @CHEM-GENE$ has previously been found to activate the complex.	0
Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive @CHEM-GENE$ activity of complex I, which was insensitive to cAMP stimulation.	0
Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive @CHEMICAL$-->UQ oxidoreductase activity of @GENE$, which was insensitive to cAMP stimulation.	0
Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive @GENE$ activity of complex I, which was insensitive to @CHEMICAL$ stimulation.	0
Fibroblast cultures from the patient exhibited severe reduction of the rotenone-sensitive NADH-->UQ oxidoreductase activity of @GENE$, which was insensitive to @CHEMICAL$ stimulation.	0
We report here that a human degradation-resistant @GENE$ analogue, h[@CHEMICAL$]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil.	0
We report here that a human degradation-resistant GLP-2 analogue, h[@CHEMICAL$]-@GENE$ significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil.	0
We report here that a human degradation-resistant GLP-2 analogue, h[@CHEMICAL$]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of @GENE$ inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil.	0
We report here that a human degradation-resistant @GENE$ analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor @CHEMICAL$ or the antimetabolite 5-fluorouracil.	0
We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-@GENE$ significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor @CHEMICAL$ or the antimetabolite 5-fluorouracil.	0
We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of @GENE$ inhibitor @CHEMICAL$ or the antimetabolite 5-fluorouracil.	2
We report here that a human degradation-resistant @GENE$ analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite @CHEMICAL$.	0
We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-@GENE$ significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite @CHEMICAL$.	0
We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of @GENE$ inhibitor irinotecan hydrochloride or the antimetabolite @CHEMICAL$.	0
h[@CHEMICAL$]-@GENE$ significantly improved survival and reduced weight loss but did not impair chemotherapy effectiveness in tumor-bearing mice treated with cyclical irinotecan.	0
Furthermore, h[@CHEMICAL$]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the @GENE$.	0
Furthermore, h[@CHEMICAL$]-@GENE$ reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor.	0
Furthermore, h[@CHEMICAL$]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of @GENE$, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor.	0
Furthermore, h[@CHEMICAL$]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited @GENE$ cleavage in heterologous cells transfected with the GLP-2 receptor.	2
Furthermore, h[Gly2]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(@CHEMICAL$) polymerase cleavage in heterologous cells transfected with the @GENE$.	0
Furthermore, h[Gly2]-@GENE$ reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(@CHEMICAL$) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor.	0
Furthermore, h[Gly2]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of @GENE$, and inhibited poly(@CHEMICAL$) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor.	0
Furthermore, h[Gly2]-GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited @CHEM-GENE$ cleavage in heterologous cells transfected with the GLP-2 receptor.	0
On the relationship between the @CHEM-GENE$ and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns.	0
OBJECTIVES: The hypothesis of the present study was that differences among @CHEM-GENE$ (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.	0
OBJECTIVES: The hypothesis of the present study was that differences among @CHEMICAL$ transporter (@GENE$) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors.	0
OBJECTIVES: The hypothesis of the present study was that differences among @GENE$ (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as @CHEMICAL$ uptake inhibitors.	5
OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (@GENE$) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as @CHEMICAL$ uptake inhibitors.	5
Accordingly, self-administration of a group of local anesthetics that are @GENE$ ligands was compared to their effects as @CHEMICAL$ uptake blockers in vitro in brain tissue.	5
Effects at @CHEM-GENE$ may limit the reinforcing effects of local anesthetics.	0
Contribution of the @CHEM-GENE$ NKCC1 to Cl- secretion in rat OMCD.	0
Contribution of the @CHEMICAL$-K+-2Cl- cotransporter @GENE$ to Cl- secretion in rat OMCD.	0
Contribution of the @CHEM-GENE$ NKCC1 to Cl- secretion in rat OMCD.	0
Contribution of the Na+-@CHEMICAL$-2Cl- cotransporter @GENE$ to Cl- secretion in rat OMCD.	0
Contribution of the @CHEM-GENE$ NKCC1 to Cl- secretion in rat OMCD.	0
Contribution of the Na+-K+-@CHEMICAL$ cotransporter @GENE$ to Cl- secretion in rat OMCD.	0
Contribution of the @GENE$ NKCC1 to @CHEMICAL$ secretion in rat OMCD.	5
Contribution of the Na+-K+-2Cl- cotransporter @GENE$ to @CHEMICAL$ secretion in rat OMCD.	5
In rat kidney the "secretory" isoform of the @CHEM-GENE$ (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell.	0
In rat kidney the "secretory" isoform of the @CHEMICAL$-K+-2Cl- cotransporter (@GENE$) localizes to the basolateral membrane of the alpha-intercalated cell.	0
In rat kidney the "secretory" isoform of the @CHEM-GENE$ (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell.	0
In rat kidney the "secretory" isoform of the Na+-@CHEMICAL$-2Cl- cotransporter (@GENE$) localizes to the basolateral membrane of the alpha-intercalated cell.	0
In rat kidney the "secretory" isoform of the @CHEM-GENE$ (NKCC1) localizes to the basolateral membrane of the alpha-intercalated cell.	0
In rat kidney the "secretory" isoform of the Na+-K+-@CHEMICAL$ cotransporter (@GENE$) localizes to the basolateral membrane of the alpha-intercalated cell.	0
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes @CHEMICAL$ and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by @GENE$ in series with Cl- efflux across the apical membrane.	0
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial @CHEMICAL$ transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by @GENE$ in series with Cl- efflux across the apical membrane.	0
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through @CHEMICAL$ uptake across the basolateral membrane mediated by @GENE$ in series with Cl- efflux across the apical membrane.	5
The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by @GENE$ in series with @CHEMICAL$ efflux across the apical membrane.	5
@CHEMICAL$-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of @GENE$-mediated Cl- transport.	0
Bumetanide-sensitive @CHEMICAL$ secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of @GENE$-mediated Cl- transport.	0
Bumetanide-sensitive Cl- secretion was dependent on extracellular @CHEMICAL$ and either K+ or NH, consistent with the ion dependency of @GENE$-mediated Cl- transport.	0
Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either @CHEMICAL$ or NH, consistent with the ion dependency of @GENE$-mediated Cl- transport.	0
Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or @CHEMICAL$, consistent with the ion dependency of @GENE$-mediated Cl- transport.	0
Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of @GENE$-mediated @CHEMICAL$ transport.	5
In conclusion, OMCD tubules from @CHEMICAL$-treated rats secrete Cl- into the luminal fluid through @GENE$-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.	0
In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete @CHEMICAL$ into the luminal fluid through @GENE$-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.	5
In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through @GENE$-mediated @CHEMICAL$ uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.	5
In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through @GENE$-mediated Cl- uptake across the basolateral membrane in series with @CHEMICAL$ efflux across the apical membrane.	5
The physiological role of @GENE$-mediated @CHEMICAL$ uptake remains to be determined.	5
There are 2 forms of PHA1: the autosomal recessive form with symptoms persisting into adulthood, caused by mutations in the @CHEM-GENE$, and the autosomal dominant or sporadic form, which shows milder symptoms that remit with age.	0
There are 2 forms of PHA1: the autosomal recessive form with symptoms persisting into adulthood, caused by mutations in the @CHEM-GENE$, and the autosomal dominant or sporadic form, which shows milder symptoms that remit with age.	0
This mutation is the first described in exon 9 and impairs the last 27 @CHEMICAL$ of the @GENE$.	0
The broad-spectrum anti-emetic activity of @CHEMICAL$, a novel @GENE$ and 5-HT3 receptors antagonist.	0
The broad-spectrum anti-emetic activity of @CHEMICAL$, a novel dopamine D2, D3 and @GENE$ antagonist.	4
The broad-spectrum anti-emetic activity of AS-8112, a novel @CHEM-GENE$ and 5-HT3 receptors antagonist.	0
The broad-spectrum anti-emetic activity of AS-8112, a novel @CHEMICAL$ D2, D3 and @GENE$ antagonist.	0
The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent @CHEM-GENE$ and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent @CHEMICAL$ D2, D3 and @GENE$ ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent @GENE$ and @CHEMICAL$-3 (5-HT3) receptors ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of AS-8112 ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and @CHEM-GENE$ ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of @CHEMICAL$ ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent @GENE$ and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of @CHEMICAL$ ((R)-5-bromo-N-(1-ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methy lamino-3-pyridinecarboxamide.2 fumarate), a novel and potent dopamine D2, D3 and @GENE$ ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of AS-8112 (@CHEMICAL$), a novel and potent @GENE$ and 5-hydroxytryptamine-3 (5-HT3) receptors ligand, was investigated in the present study.	0
The anti-emetic and pharmacological profile of AS-8112 (@CHEMICAL$), a novel and potent dopamine D2, D3 and @GENE$ ligand, was investigated in the present study.	0
In guinea-pig isolated colon, @CHEMICAL$ produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a @GENE$ agonist (pA2 value of 7.04).	4
In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of @CHEMICAL$, a @GENE$ agonist (pA2 value of 7.04).	3
Other @GENE$ antagonists also produced such a shift in the following antagonistic-potency order: @CHEMICAL$> ondansetron=AS-8112>>metoclopramide.	4
Other @GENE$ antagonists also produced such a shift in the following antagonistic-potency order: granisetron> @CHEMICAL$=AS-8112>>metoclopramide.	4
Other @GENE$ antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=@CHEMICAL$>>metoclopramide.	4
Other @GENE$ antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>>@CHEMICAL$.	4
In mice, @CHEMICAL$ (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the @GENE$ agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).	2
In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the @CHEM-GENE$ agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).	0
In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the @GENE$ agonist; @CHEMICAL$ (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.).	3
In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the @GENE$ agonist; R(+)-7-OH-DPAT (@CHEMICAL$) (0.3 mg kg(-1) s.c.).	3
@CHEMICAL$ and haloperidol, which have affinity for @GENE$, also inhibited R(+)-7-OH-DPAT-induced hypothermia.	0
Domperidone and @CHEMICAL$, which have affinity for @GENE$, also inhibited R(+)-7-OH-DPAT-induced hypothermia.	0
Domperidone and haloperidol, which have affinity for @CHEM-GENE$, also inhibited R(+)-7-OH-DPAT-induced hypothermia.	0
Domperidone and haloperidol, which have affinity for @GENE$, also inhibited @CHEMICAL$-induced hypothermia.	0
In conclusion, AS-8112 is a potent @CHEM-GENE$ and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.	0
In conclusion, AS-8112 is a potent @CHEMICAL$ D2, D3 and @GENE$ antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.	0
In conclusion, @CHEMICAL$ is a potent @GENE$ and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.	0
In conclusion, @CHEMICAL$ is a potent dopamine D2, D3 and @GENE$ antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity.	4
Recent studies have indicated that the basic residues Arg(93), Lys(96), @CHEMICAL$(125), Arg(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), @CHEMICAL$(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), @CHEMICAL$(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), @CHEMICAL$(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), @CHEMICAL$(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), @CHEMICAL$(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), @CHEMICAL$(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), @CHEMICAL$(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), @CHEMICAL$(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), @CHEMICAL$(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), @CHEMICAL$(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), @CHEMICAL$(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), @CHEMICAL$(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), @CHEMICAL$(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), @CHEMICAL$(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), @CHEMICAL$(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and @CHEMICAL$(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and @CHEMICAL$(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and @CHEMICAL$(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and @CHEMICAL$(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @CHEMICAL$-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic @CHEMICAL$-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @CHEM-GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @CHEMICAL$-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of @CHEMICAL$.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of @CHEMICAL$.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of @CHEMICAL$.	0
Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of @CHEMICAL$.	0
Recent studies have indicated that the basic residues @CHEMICAL$(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues @CHEMICAL$(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues @CHEMICAL$(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues @CHEMICAL$(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), @CHEMICAL$(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (@GENE$ numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), @CHEMICAL$(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of @GENE$ that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), @CHEMICAL$(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic @GENE$ of the proteinase was neutralized by physiological levels of calcium.	0
Recent studies have indicated that the basic residues Arg(93), @CHEMICAL$(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the @GENE$ was neutralized by physiological levels of calcium.	0
Binding of a full-length heparin chain to this site of @GENE$ in the presence of @CHEMICAL$ makes a significant contribution to acceleration of the proteinase inhibition by antithrombin through a ternary complex bridging or template mechanism.	0
Binding of a full-length heparin chain to this site of factor Xa in the presence of @CHEMICAL$ makes a significant contribution to acceleration of the @GENE$ inhibition by antithrombin through a ternary complex bridging or template mechanism.	0
Binding of a full-length heparin chain to this site of factor Xa in the presence of @CHEMICAL$ makes a significant contribution to acceleration of the proteinase inhibition by @GENE$ through a ternary complex bridging or template mechanism.	0
Moreover, certain basic residues of this site, particularly @CHEMICAL$(165) and Lys(169), play a key role in @GENE$ and/or prothrombin recognition by factor Xa in the prothrombinase complex.	0
Moreover, certain basic residues of this site, particularly @CHEMICAL$(165) and Lys(169), play a key role in factor Va and/or @GENE$ recognition by factor Xa in the prothrombinase complex.	0
Moreover, certain basic residues of this site, particularly @CHEMICAL$(165) and Lys(169), play a key role in factor Va and/or prothrombin recognition by @GENE$ in the prothrombinase complex.	0
Moreover, certain basic residues of this site, particularly Arg(165) and @CHEMICAL$(169), play a key role in @GENE$ and/or prothrombin recognition by factor Xa in the prothrombinase complex.	0
Moreover, certain basic residues of this site, particularly Arg(165) and @CHEMICAL$(169), play a key role in factor Va and/or @GENE$ recognition by factor Xa in the prothrombinase complex.	0
Moreover, certain basic residues of this site, particularly Arg(165) and @CHEMICAL$(169), play a key role in factor Va and/or prothrombin recognition by @GENE$ in the prothrombinase complex.	0
@CHEMICAL$ is a selective @GENE$ inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.	2
@CHEMICAL$ is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the @GENE$ isoenzyme at doses up to 1000 mg/day.	0
Rofecoxib has greater selectivity for @GENE$ than @CHEMICAL$, meloxicam, diclofenac and indomethacin.	0
Rofecoxib has greater selectivity for @GENE$ than celecoxib, @CHEMICAL$, diclofenac and indomethacin.	0
Rofecoxib has greater selectivity for @GENE$ than celecoxib, meloxicam, @CHEMICAL$ and indomethacin.	0
Rofecoxib has greater selectivity for @GENE$ than celecoxib, meloxicam, diclofenac and @CHEMICAL$.	0
@CHEMICAL$ has greater selectivity for @GENE$ than celecoxib, meloxicam, diclofenac and indomethacin.	2
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the @CHEM-GENE$ (NCCT).	0
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the @CHEMICAL$-sensitive NaCl co-transporter (@GENE$).	0
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the @CHEM-GENE$ (NCCT).	0
Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutation in the thiazide-sensitive @CHEMICAL$ co-transporter (@GENE$).	0
Different forms of therapy, @CHEMICAL$ and magnesium substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized @GENE$ levels in the three patients with short stature.	0
Different forms of therapy, potassium and @CHEMICAL$ substitution, spironolactone and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized @GENE$ levels in the three patients with short stature.	0
Different forms of therapy, potassium and magnesium substitution, @CHEMICAL$ and indomethacin failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized @GENE$ levels in the three patients with short stature.	0
Different forms of therapy, potassium and magnesium substitution, spironolactone and @CHEMICAL$ failed to fully correct hypokalemia and hypomagnesemia, but markedly improved growth velocity and normalized @GENE$ levels in the three patients with short stature.	0
@CHEMICAL$ bind to the @GENE$, and thiazolidinediones are ligands of PPAR-gamma.	0
@CHEMICAL$ bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and thiazolidinediones are ligands of @GENE$.	0
Fibrates bind to the @GENE$, and @CHEMICAL$ are ligands of PPAR-gamma.	0
Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and @CHEMICAL$ are ligands of @GENE$.	0
These intracellular receptors form heterodimers with @CHEM-GENE$ to modulate gene transcription.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a @GENE$-specific compound, @CHEMICAL$, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, @CHEMICAL$, a @GENE$-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, @CHEMICAL$, a PPAR-gamma-specific ligand, rosiglitazone, and a @GENE$ coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a @GENE$-specific compound, fenofibrate, a PPAR-gamma-specific ligand, @CHEMICAL$, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a @GENE$-specific ligand, @CHEMICAL$, and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, @CHEMICAL$, and a @GENE$ coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a @GENE$-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, @CHEMICAL$, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a @GENE$-specific ligand, rosiglitazone, and a PPAR-alpha/-gamma coagonist, @CHEMICAL$, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a PPAR-gamma-specific ligand, rosiglitazone, and a @GENE$ coagonist, @CHEMICAL$, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.	0
@CHEMICAL$ and GW2331 induced expression of @GENE$ and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	1
@CHEMICAL$ and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and @GENE$ and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	1
@CHEMICAL$ and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced @GENE$ and phosphoenolpyruvate carboxykinase mRNAs.	2
@CHEMICAL$ and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and @GENE$ mRNAs.	2
Fenofibrate and @CHEMICAL$ induced expression of @GENE$ and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	1
Fenofibrate and @CHEMICAL$ induced expression of acyl-coenzyme A (CoA) oxidase and @GENE$ and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	1
Fenofibrate and @CHEMICAL$ induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced @GENE$ and phosphoenolpyruvate carboxykinase mRNAs.	2
Fenofibrate and @CHEMICAL$ induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and @GENE$ mRNAs.	2
Fenofibrate and GW2331 induced expression of @CHEM-GENE$ and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of @CHEMICAL$ (CoA) oxidase and @GENE$ and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of @CHEMICAL$ (CoA) oxidase and enoyl-CoA hydratase and reduced @GENE$ and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of @CHEMICAL$ (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and @GENE$ mRNAs.	0
Fenofibrate and GW2331 induced expression of @CHEM-GENE$ and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (@CHEMICAL$) oxidase and @GENE$ and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (@CHEMICAL$) oxidase and enoyl-CoA hydratase and reduced @GENE$ and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (@CHEMICAL$) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and @GENE$ mRNAs.	0
Fenofibrate and GW2331 induced expression of @GENE$ and @CHEMICAL$ hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and @CHEM-GENE$ and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and @CHEMICAL$ hydratase and reduced @GENE$ and phosphoenolpyruvate carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and @CHEMICAL$ hydratase and reduced apolipoprotein C-III and @GENE$ mRNAs.	0
Fenofibrate and GW2331 induced expression of @GENE$ and enoyl-CoA hydratase and reduced apolipoprotein C-III and @CHEMICAL$ carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and @GENE$ and reduced apolipoprotein C-III and @CHEMICAL$ carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced @GENE$ and @CHEMICAL$ carboxykinase mRNAs.	0
Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and @CHEM-GENE$ mRNAs.	0
@CHEMICAL$ modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of @GENE$ and phosphoenolpyruvate carboxykinase in adipose tissue.	1
@CHEMICAL$ modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and @GENE$ in adipose tissue.	1
@CHEMICAL$ modestly increased @GENE$ mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.	1
Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of @CHEM-GENE$ and phosphoenolpyruvate carboxykinase in adipose tissue.	0
Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of @CHEMICAL$ transporter 4 and @GENE$ in adipose tissue.	0
Rosiglitazone modestly increased @GENE$ mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of @CHEMICAL$ transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.	0
Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of @GENE$ and @CHEMICAL$ carboxykinase in adipose tissue.	0
Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and @CHEM-GENE$ in adipose tissue.	0
Rosiglitazone modestly increased @GENE$ mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and @CHEMICAL$ carboxykinase in adipose tissue.	0
The results of these studies suggest that activation of @GENE$ as well as PPAR-gamma in therapy for type 2 diabetes will enhance @CHEMICAL$ and triglyceride control by combining actions in hepatic and peripheral tissues.	0
The results of these studies suggest that activation of PPAR-alpha as well as @GENE$ in therapy for type 2 diabetes will enhance @CHEMICAL$ and triglyceride control by combining actions in hepatic and peripheral tissues.	0
The results of these studies suggest that activation of @GENE$ as well as PPAR-gamma in therapy for type 2 diabetes will enhance glucose and @CHEMICAL$ control by combining actions in hepatic and peripheral tissues.	0
The results of these studies suggest that activation of PPAR-alpha as well as @GENE$ in therapy for type 2 diabetes will enhance glucose and @CHEMICAL$ control by combining actions in hepatic and peripheral tissues.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the @GENE$ receptor agonists eletriptan, zolmitriptan and @CHEMICAL$ in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, zolmitriptan and @CHEMICAL$ in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at @GENE$, 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, zolmitriptan and @CHEMICAL$ in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), @GENE$ and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, zolmitriptan and @CHEMICAL$ in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and @GENE$ receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the @GENE$ receptor agonists @CHEMICAL$, zolmitriptan and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists @CHEMICAL$, zolmitriptan and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at @GENE$, 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists @CHEMICAL$, zolmitriptan and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), @GENE$ and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists @CHEMICAL$, zolmitriptan and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and @GENE$ receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the @GENE$ receptor agonists eletriptan, @CHEMICAL$ and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, @CHEMICAL$ and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at @GENE$, 5-HT(1D) and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, @CHEMICAL$ and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), @GENE$ and 5-HT(1A) receptors.	0
In vivo microdialysis was used to assess the central serotonergic effects and extracellular brain levels of the 5-HT(1B/1D) receptor agonists eletriptan, @CHEMICAL$ and sumatriptan in rats after intravenous and intracerebral administration, while their binding affinities and functional potencies were determined at 5-HT(1B), 5-HT(1D) and @GENE$ receptors.	0
In vitro studies showed that all three @CHEMICAL$ are high affinity, full agonists at @GENE$ receptors, but that sumatriptan is functionally less potent as a 5-HT(1B/1D) agonist than zolmitriptan and eletriptan.	0
In vitro studies showed that all three @CHEMICAL$ are high affinity, full agonists at 5-HT(1B/1D) receptors, but that sumatriptan is functionally less potent as a @GENE$ agonist than zolmitriptan and eletriptan.	0
In vitro studies showed that all three triptans are high affinity, full agonists at @GENE$ receptors, but that @CHEMICAL$ is functionally less potent as a 5-HT(1B/1D) agonist than zolmitriptan and eletriptan.	0
In vitro studies showed that all three triptans are high affinity, full agonists at 5-HT(1B/1D) receptors, but that @CHEMICAL$ is functionally less potent as a @GENE$ agonist than zolmitriptan and eletriptan.	0
In vitro studies showed that all three triptans are high affinity, full agonists at @GENE$ receptors, but that sumatriptan is functionally less potent as a 5-HT(1B/1D) agonist than @CHEMICAL$ and eletriptan.	0
In vitro studies showed that all three triptans are high affinity, full agonists at 5-HT(1B/1D) receptors, but that sumatriptan is functionally less potent as a @GENE$ agonist than @CHEMICAL$ and eletriptan.	0
In vitro studies showed that all three triptans are high affinity, full agonists at @GENE$ receptors, but that sumatriptan is functionally less potent as a 5-HT(1B/1D) agonist than zolmitriptan and @CHEMICAL$.	0
In vitro studies showed that all three triptans are high affinity, full agonists at 5-HT(1B/1D) receptors, but that sumatriptan is functionally less potent as a @GENE$ agonist than zolmitriptan and @CHEMICAL$.	0
The observation that @CHEMICAL$ and zolmitriptan produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional @GENE$ receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg/kg i.v.	0
The observation that eletriptan and @CHEMICAL$ produce almost identical central serotonergic effects, after intracerebral as well as after systemic administration, is in agreement with their comparable functional @GENE$ receptor agonist potencies and their free levels in cortical dialysates after 3.2 mg/kg i.v.	0
@CHEMICAL$ is likely due to its weaker functional @GENE$ receptor agonist potency than eletriptan and zolmitriptan, rather than lower brain levels, consistent with sumatriptan's fivefold lower potency after intracerebral administration.	0
sumatriptan is likely due to its weaker functional @GENE$ receptor agonist potency than @CHEMICAL$ and zolmitriptan, rather than lower brain levels, consistent with sumatriptan's fivefold lower potency after intracerebral administration.	0
sumatriptan is likely due to its weaker functional @GENE$ receptor agonist potency than eletriptan and @CHEMICAL$, rather than lower brain levels, consistent with sumatriptan's fivefold lower potency after intracerebral administration.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent @GENE$.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the @GENE$ (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the hemofiltrate CC chemokine 1 (@GENE$), and characterized HCC-1[9-74] as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized @GENE$ as a strong agonist of CCR1, CCR5, and to a lower extent CCR3.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of @GENE$, CCR5, and to a lower extent CCR3.	0
We have previously isolated from human hemofiltrate an @CHEMICAL$-terminally truncated form of the hemofiltrate CC chemokine 1 (HCC-1), and characterized HCC-1[9-74] as a strong agonist of CCR1, @GENE$, and to a lower extent CCR3.	0
@CHEMICAL$ and long-chain alkanol sites on the @GENE$ and their allosteric interaction.	0
Cembranoid and @CHEMICAL$ sites on the @GENE$ and their allosteric interaction.	0
Cembranoid and long-chain alkanol sites on the @CHEM-GENE$ and their allosteric interaction.	0
@CHEMICAL$ are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral @GENE$ (AChR) by binding to one or more specific sites on the AChR.	2
@CHEMICAL$ are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (@GENE$) by binding to one or more specific sites on the AChR.	0
@CHEMICAL$ are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the @GENE$.	0
Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral @CHEM-GENE$ (AChR) by binding to one or more specific sites on the AChR.	0
Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic @CHEMICAL$ receptor (@GENE$) by binding to one or more specific sites on the AChR.	0
Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic @CHEMICAL$ receptor (AChR) by binding to one or more specific sites on the @GENE$.	0
@CHEMICAL$ are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal @GENE$, which have no demonstrable general anesthetic activity in vivo.	2
In this study, @CHEMICAL$ ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
In this study, [3H]tenocyclidine (@CHEMICAL$), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor @CHEMICAL$ (PCP), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (@CHEMICAL$), was used to characterize the cembranoid and long-chain alkanol sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the @CHEMICAL$ and long-chain alkanol sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
In this study, [3H]tenocyclidine ([3H]TCP), an analogue of the cationic noncompetitive inhibitor phencyclidine (PCP), was used to characterize the cembranoid and @CHEMICAL$ sites on the desensitized Torpedo californica @GENE$ and to investigate if these sites interact.	0
@CHEMICAL$, a potent suppressor of lymphoma growth by inhibition of the @GENE$: a new action for an old drug.	2
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the @CHEM-GENE$: a new action for an old drug.	0
Accordingly, we previously suggested that the @CHEM-GENE$ provided a target for lymphoid cancer therapy.	0
@CHEMICAL$ was fortuitously found to be a novel, potent inhibitor of the @GENE$.	2
It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of @GENE$--mediated @CHEMICAL$ uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.	5
It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of @GENE$--mediated cystine uptake, in contrast to its colonic metabolites, @CHEMICAL$ and 5-aminosalicylic acid.	2
It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of @GENE$--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and @CHEMICAL$.	2
The @CHEM-GENE$ represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.	0
The @GENE$ represents a novel target for @CHEMICAL$-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.	0
The @GENE$ represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular @CHEMICAL$.	5
Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with @CHEMICAL$, a @GENE$ inhibitor.	2
Advances in antihypertensive combination therapy: benefits of low-dose @CHEMICAL$ diuretics in conjunction with omapatrilat, a @GENE$ inhibitor.	0
The preferred initial agents for the treatment of high blood pressure are low-dose @CHEMICAL$ diuretics, beta blockers, calcium antagonists, and @GENE$ (ACE) inhibitors.	0
The preferred initial agents for the treatment of high blood pressure are low-dose @CHEMICAL$ diuretics, beta blockers, calcium antagonists, and angiotensin-converting enzyme (@GENE$) inhibitors.	0
The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, @CHEMICAL$ antagonists, and @GENE$ (ACE) inhibitors.	0
The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, @CHEMICAL$ antagonists, and angiotensin-converting enzyme (@GENE$) inhibitors.	0
The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, calcium antagonists, and @CHEM-GENE$ (ACE) inhibitors.	0
The preferred initial agents for the treatment of high blood pressure are low-dose thiazide diuretics, beta blockers, calcium antagonists, and @CHEMICAL$-converting enzyme (@GENE$) inhibitors.	0
@CHEMICAL$, the prototypical @GENE$ inhibitor, inhibits not only ACE but also neutral endopeptidase.	2
@CHEMICAL$, the prototypical vasopeptidase inhibitor, inhibits not only @GENE$ but also neutral endopeptidase.	2
@CHEMICAL$, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also @GENE$.	2
Like conventional @GENE$ inhibitors, @CHEMICAL$ causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.	2
Like conventional ACE inhibitors, @CHEMICAL$ causes extracellular volume reduction and vasodilatation; moreover, it increases levels of @GENE$ and bradykinin.	1
Like conventional ACE inhibitors, @CHEMICAL$ causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and @GENE$.	1
Like conventional @GENE$ inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and @CHEMICAL$.	0
Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of @GENE$ and @CHEMICAL$.	0
Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and @CHEM-GENE$.	0
The transport @CHEMICAL$-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (@GENE$ isoform).	0
The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to @CHEMICAL$-H+ exchange (@GENE$ isoform).	5
The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-@CHEMICAL$ exchange (@GENE$ isoform).	5
@CHEMICAL$ and salicylate bind to @GENE$ (BiP) and inhibit its ATPase activity in human fibroblasts.	0
@CHEMICAL$ and salicylate bind to immunoglobulin heavy chain binding protein (@GENE$) and inhibit its ATPase activity in human fibroblasts.	0
@CHEMICAL$ and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its @GENE$ activity in human fibroblasts.	2
Aspirin and @CHEMICAL$ bind to @GENE$ (BiP) and inhibit its ATPase activity in human fibroblasts.	0
Aspirin and @CHEMICAL$ bind to immunoglobulin heavy chain binding protein (@GENE$) and inhibit its ATPase activity in human fibroblasts.	0
Aspirin and @CHEMICAL$ bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its @GENE$ activity in human fibroblasts.	2
The Kd values of @CHEMICAL$ binding to crude extract and to recombinant @GENE$ were 45.2 and 54.6 microM, respectively.	0
@GENE$ is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an @CHEMICAL$ binding site.	0
BiP is a @GENE$ containing a polypeptide binding site recognizing specific heptapeptide sequence and an @CHEMICAL$ binding site.	0
BiP is a chaperone protein containing a polypeptide binding site recognizing specific @GENE$ and an @CHEMICAL$ binding site.	0
BiP is a chaperone protein containing a polypeptide binding site recognizing specific heptapeptide sequence and an @CHEM-GENE$.	0
@CHEMICAL$ inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce @GENE$ expression.	0
@CHEMICAL$ inhibited @GENE$ activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression.	2
Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block @CHEMICAL$ binding or induce @GENE$ expression.	0
Salicylates inhibited @GENE$ activity stimulated by this specific heptapeptide but did not block @CHEMICAL$ binding or induce BiP expression.	0
These results indicate that @CHEMICAL$ bind specifically to the polypeptide binding site of @GENE$ in human cells that may interfere with folding and transport of proteins important in inflammation.	0
The present study investigates enzyme activities of the urea cycle, @GENE$ and @CHEMICAL$-proline inter-conversion in the hypertrophied kidney after unilateral nephrectomy in mice.	0
The present study investigates enzyme activities of the urea cycle, @GENE$ and ornithine-@CHEMICAL$ inter-conversion in the hypertrophied kidney after unilateral nephrectomy in mice.	0
The specific activity of only @CHEM-GENE$ (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy.	0
The specific activity of only @CHEMICAL$ aminotransferase (@GENE$), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy.	0
The specific activity of only @GENE$ (OAT), the rate-limiting enzyme in the conversion of @CHEMICAL$ to proline, increased in 2 weeks of hypertrophy.	5
The specific activity of only ornithine aminotransferase (@GENE$), the rate-limiting enzyme in the conversion of @CHEMICAL$ to proline, increased in 2 weeks of hypertrophy.	5
The specific activity of only @GENE$ (OAT), the rate-limiting enzyme in the conversion of ornithine to @CHEMICAL$, increased in 2 weeks of hypertrophy.	5
The specific activity of only ornithine aminotransferase (@GENE$), the rate-limiting enzyme in the conversion of ornithine to @CHEMICAL$, increased in 2 weeks of hypertrophy.	5
A series of studies is reviewed that assesses the relationship between @GENE$ released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (@CHEMICAL$) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).	0
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective @GENE$ inhibitor (@CHEMICAL$) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).	2
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (@CHEMICAL$) in comparison to a dual @GENE$/COX-2 inhibitor (ketorolac).	0
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (@CHEMICAL$) in comparison to a dual COX-1/@GENE$ inhibitor (ketorolac).	0
A series of studies is reviewed that assesses the relationship between @GENE$ released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (@CHEMICAL$).	0
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective @GENE$ inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (@CHEMICAL$).	0
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual @GENE$/COX-2 inhibitor (@CHEMICAL$).	2
A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/@GENE$ inhibitor (@CHEMICAL$).	2
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of @CHEMICAL$ (PGE2; a product of both @GENE$ and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.	5
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of @CHEMICAL$ (PGE2; a product of both COX-1 and @GENE$) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.	5
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of @CHEMICAL$ (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for @GENE$ activity) with parallel assessments of pain.	0
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (@CHEMICAL$; a product of both @GENE$ and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.	5
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (@CHEMICAL$; a product of both COX-1 and @GENE$) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.	5
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (@CHEMICAL$; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for @GENE$ activity) with parallel assessments of pain.	0
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both @GENE$ and COX-2) and @CHEMICAL$ (as a biomarker for COX-1 activity) with parallel assessments of pain.	0
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and @GENE$) and @CHEMICAL$ (as a biomarker for COX-1 activity) with parallel assessments of pain.	0
Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and @CHEMICAL$ (as a biomarker for @GENE$ activity) with parallel assessments of pain.	0
The time course of @CHEMICAL$ production was consistent with early release due to @GENE$ activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.	5
The time course of @CHEMICAL$ production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with @GENE$ expression.	5
@CHEMICAL$ selectively suppressed PGE2 but not TxB2 at time points consistent with @GENE$ activity, while producing analgesia.	2
Celecoxib selectively suppressed @CHEMICAL$ but not TxB2 at time points consistent with @GENE$ activity, while producing analgesia.	5
Celecoxib selectively suppressed PGE2 but not @CHEMICAL$ at time points consistent with @GENE$ activity, while producing analgesia.	0
These studies demonstrate the ability to assess the time course and selective effects of @GENE$ inhibitors in vivo and suggest that suppression of COX-2 mediated @CHEMICAL$ is temporally related to NSAID analgesia.	0
These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of @GENE$ mediated @CHEMICAL$ is temporally related to NSAID analgesia.	5
@CHEMICAL$ binding to @GENE$ transfected membranes: a potential high throughput preclinical screen.	0
The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing @CHEM-GENE$.	0
The pharmacological characteristics of [3H]dofetilide binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing @CHEM-GENE$.	0
The pharmacological characteristics of @CHEMICAL$ binding were examined in membranes prepared from human embryonic kidney (HEK293) cells stably expressing @GENE$.	0
These data indicate that a @CHEMICAL$ binding assay using @GENE$ membranes may help identify compounds that prolong the QT interval.	0
Effects of the antidepressant/antipanic drug @CHEMICAL$ on alanine and @GENE$ in rat brain.	0
Effects of the antidepressant/antipanic drug phenelzine on @CHEMICAL$ and @GENE$ in rat brain.	0
Effects of the antidepressant/antipanic drug phenelzine on alanine and @CHEM-GENE$ in rat brain.	0
Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, @CHEM-GENE$ (GABA-T).	0
Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, @CHEMICAL$ transaminase (@GENE$).	0
Acute and chronic @CHEMICAL$ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, @GENE$ (GABA-T).	2
Acute and chronic @CHEMICAL$ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (@GENE$).	2
Acute and chronic PLZ administration increase brain @CHEMICAL$ levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, @GENE$ (GABA-T).	0
Acute and chronic PLZ administration increase brain @CHEMICAL$ levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (@GENE$).	0
Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the @CHEMICAL$ metabolizing enzyme, @GENE$ (GABA-T).	5
Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the @CHEMICAL$ metabolizing enzyme, GABA transaminase (@GENE$).	5
As with @CHEMICAL$, the metabolism of alanine involves a @GENE$.	0
As with GABA, the metabolism of @CHEMICAL$ involves a @GENE$.	5
As with GABA, the metabolism of alanine involves a @CHEM-GENE$.	0
In the study reported here, the effects of acute @CHEMICAL$ treatment on the levels of various amino acids, some of which are also metabolized by @GENE$ were compared in rat whole brain.	0
In the study reported here, the effects of acute PLZ treatment on the levels of various @CHEMICAL$, some of which are also metabolized by @GENE$ were compared in rat whole brain.	5
In the study reported here, the effects of acute PLZ treatment on the levels of various amino acids, some of which are also metabolized by @CHEM-GENE$ were compared in rat whole brain.	0
The elevation in brain @CHEMICAL$ levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on @GENE$ (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	5
The elevation in brain @CHEMICAL$ levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (@GENE$), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	5
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of @CHEMICAL$ on @GENE$ (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	2
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of @CHEMICAL$ on alanine transaminase (@GENE$), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	2
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on @CHEM-GENE$ (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	0
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on @CHEMICAL$ transaminase (@GENE$), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	0
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on @GENE$ (@CHEMICAL$-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	0
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (@CHEM-GENE$), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.	0
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on @GENE$ (ALA-T), although as with @CHEMICAL$ the increases are higher than expected from the degree of enzyme inhibition produced.	0
The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (@GENE$), although as with @CHEMICAL$ the increases are higher than expected from the degree of enzyme inhibition produced.	0
In addition, we also showed that the elevation in @CHEMICAL$ levels and the inhibition of @GENE$ in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.	5
In addition, we also showed that the elevation in alanine levels and the inhibition of @CHEM-GENE$ in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.	0
In addition, we also showed that the elevation in alanine levels and the inhibition of @GENE$ in the brain are retained after 14 days of @CHEMICAL$ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.	2
In addition, we also showed that the elevation in alanine levels and the inhibition of @GENE$ in the brain are retained after 14 days of PLZ treatment, and that @CHEMICAL$ produces a marked increase in extracellular levels of alanine.	0
In addition, we also showed that the elevation in alanine levels and the inhibition of @GENE$ in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of @CHEMICAL$.	0
@CHEMICAL$-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and @GENE$ metabolites.	0
Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive @CHEMICAL$ species and @GENE$ metabolites.	0
@CHEMICAL$ radical scavengers, @GENE$ and catalase, significantly attenuated the contraction.	0
@CHEMICAL$ radical scavengers, superoxide dismutase and @GENE$, significantly attenuated the contraction.	0
@GENE$ (COX-1) inhibitors (@CHEMICAL$, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (@GENE$) inhibitors (@CHEMICAL$, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (COX-1) inhibitors (@CHEMICAL$, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (@CHEMICAL$, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
@GENE$ (COX-1) inhibitors (flurbiprofen, @CHEMICAL$ and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (@GENE$) inhibitors (flurbiprofen, @CHEMICAL$ and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, @CHEMICAL$ and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, @CHEMICAL$ and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
@GENE$ (COX-1) inhibitors (flurbiprofen, ketoprofen and @CHEMICAL$) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (@GENE$) inhibitors (flurbiprofen, ketoprofen and @CHEMICAL$) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and @CHEMICAL$) attenuated the nicotine-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and @CHEMICAL$) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
@GENE$ (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the @CHEMICAL$-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (@GENE$) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the @CHEMICAL$-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the @CHEMICAL$-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the @CHEMICAL$-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction.	0
@GENE$ (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (@CHEMICAL$ and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (@GENE$) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (@CHEMICAL$ and NS-389) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (@CHEMICAL$ and NS-389) slightly attenuated the contraction.	2
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (@CHEMICAL$ and NS-389) slightly attenuated the contraction.	2
@GENE$ (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and @CHEMICAL$) slightly attenuated the contraction.	0
Cyclooxygenase-1 (@GENE$) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and @CHEMICAL$) slightly attenuated the contraction.	0
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and @GENE$ (COX-2) inhibitors at high concentrations (nimesulide and @CHEMICAL$) slightly attenuated the contraction.	2
Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (@GENE$) inhibitors at high concentrations (nimesulide and @CHEMICAL$) slightly attenuated the contraction.	2
A @CHEM-GENE$ inhibitor (OKY-046) attenuated the contraction to a small extent only at high concentrations.	0
A @GENE$ inhibitor (@CHEMICAL$) attenuated the contraction to a small extent only at high concentrations.	2
A @CHEM-GENE$ antagonist (S-1452) attenuated the contraction in a concentration-dependent manner.	0
A @GENE$ antagonist (@CHEMICAL$) attenuated the contraction in a concentration-dependent manner.	4
A @GENE$ antagonist (@CHEMICAL$) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction.	4
A nicotinic receptor antagonist (@CHEMICAL$) attenuated the contraction in part and an @GENE$ antagonist (prazosin) nearly abolished the contraction.	0
A @GENE$ antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (@CHEMICAL$) nearly abolished the contraction.	0
A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an @GENE$ antagonist (@CHEMICAL$) nearly abolished the contraction.	4
From these results, it was suggested that the contraction induced by nicotine in the rat coronary artery in the presence of L-NAME and arachidonic acid is endothelium dependent, and involves reactive oxygen species and endothelial @GENE$ metabolites of @CHEMICAL$.	0
From these results, it was suggested that the contraction induced by @CHEMICAL$ in the rat coronary artery in the presence of L-NAME and arachidonic acid is endothelium dependent, and involves reactive oxygen species and endothelial @GENE$ metabolites of arachidonic acid.	0
From these results, it was suggested that the contraction induced by nicotine in the rat coronary artery in the presence of @CHEMICAL$ and arachidonic acid is endothelium dependent, and involves reactive oxygen species and endothelial @GENE$ metabolites of arachidonic acid.	0
From these results, it was suggested that the contraction induced by nicotine in the rat coronary artery in the presence of L-NAME and @CHEMICAL$ is endothelium dependent, and involves reactive oxygen species and endothelial @GENE$ metabolites of arachidonic acid.	0
From these results, it was suggested that the contraction induced by nicotine in the rat coronary artery in the presence of L-NAME and arachidonic acid is endothelium dependent, and involves reactive @CHEMICAL$ species and endothelial @GENE$ metabolites of arachidonic acid.	0
Efficacy and safety of the factor VIII/@GENE$ concentrate, haemate-P/humate-P: @CHEMICAL$ cofactor unit dosing in patients with von Willebrand disease.	0
Efficacy and safety of the @GENE$/von Willebrand factor concentrate, haemate-P/humate-P: @CHEMICAL$ cofactor unit dosing in patients with von Willebrand disease.	0
The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic @GENE$/VWF complex [human] dried, pasteurized) dosed in @CHEMICAL$ cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada.	0
The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic FVIII/@GENE$ complex [human] dried, pasteurized) dosed in @CHEMICAL$ cofactor units (VWF:RCo) in the treatment of von Willebrand disease (VWD) patients in Canada.	0
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of @GENE$ (COX), the enzyme that mediates biosynthesis of @CHEMICAL$ and thromboxanes from arachidonic acid.	5
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (@GENE$), the enzyme that mediates biosynthesis of @CHEMICAL$ and thromboxanes from arachidonic acid.	5
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of @GENE$ (COX), the enzyme that mediates biosynthesis of prostaglandins and @CHEMICAL$ from arachidonic acid.	5
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (@GENE$), the enzyme that mediates biosynthesis of prostaglandins and @CHEMICAL$ from arachidonic acid.	5
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of @GENE$ (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from @CHEMICAL$.	5
Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (@GENE$), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from @CHEMICAL$.	5
Non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs) are competitive inhibitors of @GENE$ (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.	2
Non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (@GENE$), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, @CHEMICAL$, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, @CHEMICAL$, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, @CHEMICAL$ and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and @CHEMICAL$ were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: @CHEMICAL$, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, @CHEMICAL$, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, @CHEMICAL$, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
Accordingly, docking of different @GENE$ inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, @CHEMICAL$, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program.	2
ICI 182,780 (fulvestrant) (Faslodex) and @CHEMICAL$ are competitive inhibitors of estrogen by binding to the @GENE$ (ER).	0
ICI 182,780 (fulvestrant) (Faslodex) and @CHEMICAL$ are competitive inhibitors of estrogen by binding to the estrogen receptor (@GENE$).	0
ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of @CHEMICAL$ by binding to the @GENE$ (ER).	0
ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of @CHEMICAL$ by binding to the estrogen receptor (@GENE$).	0
ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the @CHEM-GENE$ (ER).	0
ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the @CHEMICAL$ receptor (@GENE$).	0
@CHEMICAL$ (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the @GENE$ (ER).	0
@CHEMICAL$ (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (@GENE$).	0
ICI 182,780 (@CHEMICAL$) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the @GENE$ (ER).	0
ICI 182,780 (@CHEMICAL$) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (@GENE$).	0
ICI 182,780 (fulvestrant) (@CHEMICAL$) and ICI 164,384 are competitive inhibitors of estrogen by binding to the @GENE$ (ER).	0
ICI 182,780 (fulvestrant) (@CHEMICAL$) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (@GENE$).	0
@CHEMICAL$ and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to @GENE$.	0
EM-800 and @CHEMICAL$ are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to @GENE$.	0
EM-800 and EM-652 are the most potent pure antiestrogens and @CHEMICAL$ has the highest affinity of all antiestrogens to @GENE$.	0
Of the antihypertensive agents, methyldopa is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the @CHEM-GENE$ and converting enzyme inhibitors are increasingly reported.	0
Of the antihypertensive agents, methyldopa is now rarely prescribed and adverse effects are reported infrequently, whereas cases of liver injury associated with the @CHEMICAL$ receptor and @GENE$ inhibitors are increasingly reported.	0
Of the antidiabetic agents, @CHEMICAL$, gliclazide, metformin, and @GENE$ have been implicated in causing liver injury.	0
Of the antidiabetic agents, acarbose, @CHEMICAL$, metformin, and @GENE$ have been implicated in causing liver injury.	0
Of the antidiabetic agents, acarbose, gliclazide, @CHEMICAL$, and @GENE$ have been implicated in causing liver injury.	0
Olopatadine hydrochloride (@CHEMICAL$, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/@GENE$ antagonistic drug that was synthesized and evaluated in our laboratories.	4
Olopatadine hydrochloride (olopatadine, @CHEMICAL$) is a novel antiallergic/@GENE$ antagonistic drug that was synthesized and evaluated in our laboratories.	4
@CHEMICAL$ (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/@GENE$ antagonistic drug that was synthesized and evaluated in our laboratories.	4
Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/@CHEM-GENE$ antagonistic drug that was synthesized and evaluated in our laboratories.	0
@CHEMICAL$ is a selective @GENE$ antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.	4
Olopatadine is a selective @CHEM-GENE$ antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.	0
Olopatadine is a selective @GENE$ antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as @CHEMICAL$ and thromboxane from human polymorphonuclear leukocytes and eosinophils.	0
Olopatadine is a selective @GENE$ antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and @CHEMICAL$ from human polymorphonuclear leukocytes and eosinophils.	0
@CHEMICAL$ exerted no significant effects on action potential duration in isolated guinea pig ventricular myocytes, myocardium and @GENE$.	0
@GENE$ polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American @CHEMICAL$-dependent individuals.	0
@CHEM-GENE$ polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals.	0
Considerable evidence indicates that serotonergic mechanisms, particularly the serotonin transporter (@GENE$), may mediate central effects of @CHEMICAL$ and may also be involved in impulsive and aggressive behavior.	0
Considerable evidence indicates that serotonergic mechanisms, particularly the @GENE$ (5HTT), may mediate central effects of @CHEMICAL$ and may also be involved in impulsive and aggressive behavior.	0
Considerable evidence indicates that serotonergic mechanisms, particularly the @CHEMICAL$ transporter (@GENE$), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior.	0
Considerable evidence indicates that serotonergic mechanisms, particularly the @CHEM-GENE$ (5HTT), may mediate central effects of cocaine and may also be involved in impulsive and aggressive behavior.	0
We investigated whether polymorphisms in the @GENE$ gene were related to traits of impulsivity, sensation seeking, and aggression among @CHEMICAL$ abusers.	0
Two polymorphisms of the @GENE$ gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among @CHEMICAL$ patients.	0
Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (@GENE$) region and a 17 base pair variable-number-tandem-repeat (VNTR) marker among @CHEMICAL$ patients.	0
Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair @GENE$ (VNTR) marker among @CHEMICAL$ patients.	0
Two polymorphisms of the 5HTT gene were examined involving the 5' promoter (5HTTLPR) region and a 17 base pair variable-number-tandem-repeat (@GENE$) marker among @CHEMICAL$ patients.	0
The findings do not seem to support an association between these polymorphisms in the @GENE$ gene and impulsive-aggressive traits among @CHEMICAL$-dependent African-American individuals.	0
A molecular mechanism of action of @CHEMICAL$: Induction of @GENE$ activity to decrease inflammatory gene expression.	1
@CHEMICAL$ act, at least in part, by recruitment of @GENE$ (HDACs) to the site of active inflammatory gene transcription.	0
@CHEMICAL$ act, at least in part, by recruitment of histone deacetylases (@GENE$) to the site of active inflammatory gene transcription.	0
We show both in vitro and in vivo that low-dose @CHEMICAL$ enhances @GENE$ activity in epithelial cells and macrophages.	1
This increased @GENE$ activity is then available for @CHEMICAL$ recruitment and predicts a cooperative interaction between corticosteroids and theophylline.	0
This increased @GENE$ activity is then available for corticosteroid recruitment and predicts a cooperative interaction between @CHEMICAL$ and theophylline.	0
This increased @GENE$ activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and @CHEMICAL$.	0
This mechanism occurs at therapeutic concentrations of @CHEMICAL$ and is dissociated from @GENE$ inhibition (the mechanism of bronchodilation) or the blockade of adenosine receptors, which are partially responsible for its side effects.	0
This mechanism occurs at therapeutic concentrations of @CHEMICAL$ and is dissociated from phosphodiesterase inhibition (the mechanism of bronchodilation) or the blockade of @GENE$, which are partially responsible for its side effects.	0
This mechanism occurs at therapeutic concentrations of theophylline and is dissociated from @GENE$ inhibition (the mechanism of bronchodilation) or the blockade of @CHEMICAL$ receptors, which are partially responsible for its side effects.	0
This mechanism occurs at therapeutic concentrations of theophylline and is dissociated from phosphodiesterase inhibition (the mechanism of bronchodilation) or the blockade of @CHEM-GENE$, which are partially responsible for its side effects.	0
Thus we have shown that low-dose @CHEMICAL$ exerts an anti-asthma effect through increasing activation of @GENE$ which is subsequently recruited by corticosteroids to suppress inflammatory genes.	1
Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of @GENE$ which is subsequently recruited by @CHEMICAL$ to suppress inflammatory genes.	0
In rats, @CHEMICAL$ and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the @GENE$ Oatp1 and Oatp2.	2
In rats, @CHEMICAL$ and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides @GENE$ and Oatp2.	2
In rats, @CHEMICAL$ and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and @GENE$.	2
In rats, rifamycin SV and @CHEMICAL$ were shown to interfere with hepatic organic anion uptake by inhibition of the @GENE$ Oatp1 and Oatp2.	2
In rats, rifamycin SV and @CHEMICAL$ were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides @GENE$ and Oatp2.	2
In rats, rifamycin SV and @CHEMICAL$ were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and @GENE$.	2
Therefore, we investigated the effects of @CHEMICAL$ and rifampicin on the @GENE$ of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers.	0
Therefore, we investigated the effects of rifamycin SV and @CHEMICAL$ on the @GENE$ of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers.	0
Therefore, we investigated the effects of rifamycin SV and rifampicin on the @GENE$ of human liver and determined whether @CHEMICAL$ is a substrate of 1 or several of these carriers.	0
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited @GENE$ (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (@GENE$) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (@GENE$), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), @GENE$ (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (@GENE$) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (@GENE$), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), @GENE$ (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (@GENE$) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (@GENE$), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and @GENE$ (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (@GENE$) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
In complementary RNA (cRNA)-injected Xenopus laevis oocytes, @CHEMICAL$ (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (@GENE$) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.	2
@CHEMICAL$ (10 micromol/L) inhibited @GENE$-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.	2
@CHEMICAL$ (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of @GENE$-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.	2
@CHEMICAL$ (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, @GENE$-, and OATP-A-mediated BSP transport was below 15%.	2
@CHEMICAL$ (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and @GENE$-mediated BSP transport was below 15%.	2
Rifampicin (10 micromol/L) inhibited @GENE$-mediated @CHEMICAL$ uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.	5
Rifampicin (10 micromol/L) inhibited OATP8-mediated @CHEMICAL$ uptake by 50%, whereas inhibition of @GENE$-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.	0
Rifampicin (10 micromol/L) inhibited OATP8-mediated @CHEMICAL$ uptake by 50%, whereas inhibition of OATP-C-, @GENE$-, and OATP-A-mediated BSP transport was below 15%.	0
Rifampicin (10 micromol/L) inhibited OATP8-mediated @CHEMICAL$ uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and @GENE$-mediated BSP transport was below 15%.	0
Rifampicin (10 micromol/L) inhibited @GENE$-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated @CHEMICAL$ transport was below 15%.	0
Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of @GENE$-, OATP-B-, and OATP-A-mediated @CHEMICAL$ transport was below 15%.	5
Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, @GENE$-, and OATP-A-mediated @CHEMICAL$ transport was below 15%.	5
Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and @GENE$-mediated @CHEMICAL$ transport was below 15%.	5
100 micromol/L @CHEMICAL$ inhibited @GENE$- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	2
100 micromol/L @CHEMICAL$ inhibited OATP-C- and @GENE$-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	2
100 micromol/L @CHEMICAL$ inhibited OATP-C- and OATP8-, @GENE$- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	2
100 micromol/L @CHEMICAL$ inhibited OATP-C- and OATP8-, OATP-B- and @GENE$-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.	2
100 micromol/L rifampicin inhibited @GENE$- and OATP8-, OATP-B- and OATP-A-mediated @CHEMICAL$ uptake by 66%, 96%, 25%, and 49%, respectively.	5
100 micromol/L rifampicin inhibited OATP-C- and @GENE$-, OATP-B- and OATP-A-mediated @CHEMICAL$ uptake by 66%, 96%, 25%, and 49%, respectively.	5
100 micromol/L rifampicin inhibited OATP-C- and OATP8-, @GENE$- and OATP-A-mediated @CHEMICAL$ uptake by 66%, 96%, 25%, and 49%, respectively.	5
100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and @GENE$-mediated @CHEMICAL$ uptake by 66%, 96%, 25%, and 49%, respectively.	5
Direct transport of @CHEMICAL$ could be shown for @GENE$ (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).	5
Direct transport of @CHEMICAL$ could be shown for OATP-C (apparent K(m) value 13 micromol/L) and @GENE$ (2.3 micromol/L).	5
In conclusion, these results show that @CHEMICAL$ and rifampicin interact with @GENE$-mediated substrate transport to different extents.	0
In conclusion, these results show that rifamycin SV and @CHEMICAL$ interact with @GENE$-mediated substrate transport to different extents.	0
Inhibition of @GENE$ can explain the previously observed effects of @CHEMICAL$ and rifampicin on hepatic organic anion elimination.	2
Inhibition of @GENE$ can explain the previously observed effects of rifamycin SV and @CHEMICAL$ on hepatic organic anion elimination.	2
@CHEMICAL$ increases @GENE$ activity in skeletal muscle of subjects with type 2 diabetes.	1
Metformin increases @CHEM-GENE$ activity in skeletal muscle of subjects with type 2 diabetes.	0
@CHEM-GENE$ (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	0
@CHEMICAL$-activated protein kinase (@GENE$) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	0
@GENE$ (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of @CHEMICAL$ uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	5
AMP-activated protein kinase (@GENE$) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of @CHEMICAL$ uptake into skeletal muscle and the inhibition of liver gluconeogenesis.	5
We recently reported that @GENE$ is activated by @CHEMICAL$ in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.	1
We recently reported that @GENE$ is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic @CHEMICAL$ production.	0
In the present study, we evaluated whether therapeutic doses of @CHEMICAL$ increase @GENE$ activity in vivo in subjects with type 2 diabetes.	1
@CHEMICAL$ treatment for 10 weeks significantly increased @GENE$ activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.	1
@CHEMICAL$ treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of @GENE$ on Thr172 and decreased acetyl-CoA carboxylase-2 activity.	1
@CHEMICAL$ treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased @GENE$ activity.	2
Metformin treatment for 10 weeks significantly increased @GENE$ activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased @CHEMICAL$ carboxylase-2 activity.	0
Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of @GENE$ on Thr172 and decreased @CHEMICAL$ carboxylase-2 activity.	0
Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased @CHEM-GENE$ activity.	0
The increase in @GENE$ activity was likely due to a change in muscle energy status because @CHEMICAL$ and phosphocreatine concentrations were lower after metformin treatment.	0
The increase in @GENE$ activity was likely due to a change in muscle energy status because ATP and @CHEMICAL$ concentrations were lower after metformin treatment.	0
The increase in @GENE$ activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after @CHEMICAL$ treatment.	1
@CHEMICAL$-induced increases in @GENE$ activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.	1
Metformin-induced increases in @GENE$ activity were associated with higher rates of @CHEMICAL$ disposal and muscle glycogen concentrations.	0
@CHEMICAL$ prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and @GENE$ production.	2
Thalidomide prevents @CHEMICAL$ liver injury in rats through suppression of Kupffer cell sensitization and @GENE$ production.	0
BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of @GENE$ are critical for progression of @CHEMICAL$ liver injury.	0
@CHEMICAL$ has been shown to suppress @GENE$ production from macrophages.	2
KCs were isolated after 4 weeks of @CHEMICAL$ treatment and intracellular Ca2+ ([Ca2+]i) was measured using fura-2, whereas @GENE$ was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay.	0
KCs were isolated after 4 weeks of ethanol treatment and intracellular @CHEMICAL$ ([Ca2+]i) was measured using fura-2, whereas @GENE$ was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay.	0
KCs were isolated after 4 weeks of ethanol treatment and intracellular Ca2+ ([@CHEMICAL$]i) was measured using fura-2, whereas @GENE$ was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay.	0
Furthermore, @CHEMICAL$ abolished the LPS-induced increase in @GENE$ expression and [Ca2+]i elevation in KCs.	2
Furthermore, thalidomide abolished the LPS-induced increase in @GENE$ expression and [@CHEMICAL$]i elevation in KCs.	0
Moreover, @CHEMICAL$ reduced the LPS-induced @GENE$ production by KCs by decreasing TNF-alpha messenger RNA.	2
Moreover, @CHEMICAL$ reduced the LPS-induced TNF-alpha production by KCs by decreasing @GENE$ messenger RNA.	2
CONCLUSIONS: These results collectively indicate that @CHEMICAL$ prevents alcoholic liver injury through suppression of @GENE$ production and abolishment of KC sensitization.	2
Identification and characterization of a novel @CHEMICAL$-containing @GENE$ of mammalian cell origin.	0
Identification and characterization of a novel flavin-containing @CHEM-GENE$ of mammalian cell origin.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce @CHEMICAL$ and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce @CHEMICAL$ and putrescine, respectively.	5
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce @CHEMICAL$ and putrescine, respectively.	5
During polyamine catabolism, spermine and spermidine are first acetylated by @GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce @CHEMICAL$ and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and @CHEMICAL$, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and @CHEMICAL$, respectively.	5
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and @CHEMICAL$, respectively.	5
During polyamine catabolism, spermine and spermidine are first acetylated by @GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and @CHEMICAL$, respectively.	0
During polyamine catabolism, @CHEMICAL$ and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During polyamine catabolism, @CHEMICAL$ and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, @CHEMICAL$ and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, @CHEMICAL$ and spermidine are first acetylated by @GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During polyamine catabolism, spermine and @CHEMICAL$ are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During polyamine catabolism, spermine and @CHEMICAL$ are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and @CHEMICAL$ are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and @CHEMICAL$ are first acetylated by @GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During @CHEMICAL$ catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During @CHEMICAL$ catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During @CHEMICAL$ catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During @CHEMICAL$ catabolism, spermine and spermidine are first acetylated by @GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	5
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEMICAL$/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEMICAL$/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEMICAL$/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEM-GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/@CHEMICAL$ N(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/@CHEMICAL$ N(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/@CHEMICAL$ N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEM-GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine @CHEMICAL$(1)-acetyltransferase (@GENE$) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine @CHEMICAL$(1)-acetyltransferase (SSAT) and subsequently oxidized by @GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine @CHEMICAL$(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @CHEM-GENE$ (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (@GENE$) and subsequently oxidized by @CHEMICAL$ oxidase (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @CHEM-GENE$ (PAO) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by @CHEMICAL$ oxidase (@GENE$) to produce spermidine and putrescine, respectively.	0
During polyamine catabolism, spermine and spermidine are first acetylated by @GENE$ (SSAT) and subsequently oxidized by @CHEMICAL$ oxidase (PAO) to produce spermidine and putrescine, respectively.	0
In attempting to clone the @GENE$ involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves @CHEMICAL$ in the absence of prior acetylation by SSAT.	0
In attempting to clone the PAO involved in this back-conversion pathway, we encountered an @GENE$ that preferentially cleaves @CHEMICAL$ in the absence of prior acetylation by SSAT.	0
In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves @CHEMICAL$ in the absence of prior acetylation by @GENE$.	5
A BLAST search using @GENE$ sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 @CHEMICAL$.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on @CHEMICAL$, spermidine or the preferred @GENE$ substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of @GENE$-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on @CHEMICAL$, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified @GENE$ strongly favoured spermine over N (1)-acetylspermine and that it failed to act on @CHEMICAL$, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured @CHEMICAL$ over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred @GENE$ substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of @GENE$-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured @CHEMICAL$ over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified @GENE$ strongly favoured @CHEMICAL$ over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	5
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over @CHEMICAL$ and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred @GENE$ substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of @GENE$-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over @CHEMICAL$ and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified @GENE$ strongly favoured spermine over @CHEMICAL$ and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	5
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, @CHEMICAL$ or the preferred @GENE$ substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of @GENE$-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, @CHEMICAL$ or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified @GENE$ strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, @CHEMICAL$ or the preferred PAO substrate, N (1), N (12)-diacetylspermine.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred @GENE$ substrate, @CHEMICAL$.	5
Substrate specificity using lysates of @GENE$-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, @CHEMICAL$.	0
Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified @GENE$ strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, @CHEMICAL$.	0
The @GENE$ inhibitor, @CHEMICAL$, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.	2
The PAO inhibitor, @CHEMICAL$, only partially blocked oxidation of spermine while a previously reported @GENE$ substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.	0
The @GENE$ inhibitor, MDL-72,527, only partially blocked oxidation of @CHEMICAL$ while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.	0
The PAO inhibitor, MDL-72,527, only partially blocked oxidation of @CHEMICAL$ while a previously reported @GENE$ substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.	0
The @GENE$ inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, @CHEMICAL$, potently inhibited the reaction.	0
The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported @GENE$ substrate, @CHEMICAL$, potently inhibited the reaction.	5
Overall, the data indicate that the enzyme represents a novel @GENE$ which, on the basis of substrate specificity, we have designated @CHEMICAL$ oxidase in order to distinguish it from the PAO involved in polyamine back-conversion.	0
Overall, the data indicate that the enzyme represents a novel mammalian oxidase which, on the basis of substrate specificity, we have designated @CHEM-GENE$ in order to distinguish it from the PAO involved in polyamine back-conversion.	0
Overall, the data indicate that the enzyme represents a novel mammalian oxidase which, on the basis of substrate specificity, we have designated @CHEMICAL$ oxidase in order to distinguish it from the @GENE$ involved in polyamine back-conversion.	0
Overall, the data indicate that the enzyme represents a novel @GENE$ which, on the basis of substrate specificity, we have designated spermine oxidase in order to distinguish it from the PAO involved in @CHEMICAL$ back-conversion.	0
Overall, the data indicate that the enzyme represents a novel mammalian oxidase which, on the basis of substrate specificity, we have designated @GENE$ in order to distinguish it from the PAO involved in @CHEMICAL$ back-conversion.	0
Overall, the data indicate that the enzyme represents a novel mammalian oxidase which, on the basis of substrate specificity, we have designated spermine oxidase in order to distinguish it from the @GENE$ involved in @CHEMICAL$ back-conversion.	0
The effects of abciximab (1-10 microg/ml), @CHEMICAL$ (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and ADP (3 microM)-induced @GENE$ externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	0
The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or @CHEMICAL$ (0.3-3 microg/ml) on basal and ADP (3 microM)-induced @GENE$ externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	0
The effects of abciximab (1-10 microg/ml), tirofiban (3-30 nM), or eptifibatide (0.3-3 microg/ml) on basal and @CHEMICAL$ (3 microM)-induced @GENE$ externalization were measured in n=62 healthy blood donors and n=177 patients with stable coronary artery disease.	0
Although a significant platelet hyperreactivity was observed in the patients, the @GENE$ genotype did not influence basal or @CHEMICAL$-induced CD62P expression.	0
Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or @CHEMICAL$-induced @GENE$ expression.	1
A moderate (twofold) stimulation of @GENE$ expression by abciximab but not by @CHEMICAL$ or eptifibatide was observed in one patient.	0
A moderate (twofold) stimulation of @GENE$ expression by abciximab but not by tirofiban or @CHEMICAL$ was observed in one patient.	0
In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of @GENE$ inhibitors on basal or @CHEMICAL$-stimulated CD62P expression.	0
In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or @CHEMICAL$-stimulated @GENE$ expression.	1
In no other subject any activation of platelets by @GENE$ inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or @CHEMICAL$-stimulated CD62P expression.	0
In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between @GENE$ genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or @CHEMICAL$-stimulated CD62P expression.	0
Most halogenated @CHEMICAL$ are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by @CHEMICAL$ @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	0
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to @CHEMICAL$, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, @CHEMICAL$, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an @CHEMICAL$ (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with @CHEMICAL$) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an @CHEMICAL$ (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with @CHEMICAL$) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	5
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate @CHEMICAL$ to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.	0
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a @CHEMICAL$, which reacts with epsilon-amino groups of lysine residues in proteins.	0
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with @CHEMICAL$ groups of lysine residues in proteins.	0
Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate @GENE$ to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of @CHEMICAL$ residues in proteins.	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze @CHEMICAL$ @GENE$ reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze @CHEMICAL$ beta-lyase reactions, including @GENE$ (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze @CHEMICAL$ beta-lyase reactions, including mitochondrial aspartate aminotransferase (@GENE$), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze @CHEMICAL$ beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and @GENE$ (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze @CHEMICAL$ beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (@GENE$).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate @GENE$ reactions, including mitochondrial @CHEMICAL$ aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including @CHEM-GENE$ (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial @CHEMICAL$ aminotransferase (@GENE$), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial @CHEMICAL$ aminotransferase (mitAspAT), and @GENE$ (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial @CHEMICAL$ aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (@GENE$).	0
Nine mammalian @CHEMICAL$ (PLP)-containing enzymes catalyze cysteine S-conjugate @GENE$ reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian @CHEMICAL$ (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including @GENE$ (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian @CHEMICAL$ (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (@GENE$), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian @CHEMICAL$ (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and @GENE$ (BCAT(m)).	0
Nine mammalian @CHEMICAL$ (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (@GENE$).	0
Nine mammalian pyridoxal 5'-phosphate (@CHEMICAL$)-containing enzymes catalyze cysteine S-conjugate @GENE$ reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (@CHEMICAL$)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including @GENE$ (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (@CHEMICAL$)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (@GENE$), and mitochondrial branched-chain amino acid aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (@CHEMICAL$)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and @GENE$ (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (@CHEMICAL$)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial branched-chain amino acid aminotransferase (@GENE$).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate @GENE$ reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial @CHEMICAL$ aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including @GENE$ (mitAspAT), and mitochondrial @CHEMICAL$ aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (@GENE$), and mitochondrial @CHEMICAL$ aminotransferase (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and @CHEM-GENE$ (BCAT(m)).	0
Nine mammalian pyridoxal 5'-phosphate (PLP)-containing enzymes catalyze cysteine S-conjugate beta-lyase reactions, including mitochondrial aspartate aminotransferase (mitAspAT), and mitochondrial @CHEMICAL$ aminotransferase (@GENE$).	0
Most of the @CHEMICAL$ @GENE$ are syncatalytically inactivated.	0
Interestingly, the @CHEM-GENE$ (KGDHC and BCDHC), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the @CHEMICAL$- and branched-chain alpha-keto acid dehydrogenase complexes (@GENE$ and BCDHC), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the @CHEMICAL$- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and @GENE$), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the @CHEMICAL$- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and BCDHC), but not the @GENE$ (PDHC), are susceptible to inactivation.	0
Interestingly, the @CHEMICAL$- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and BCDHC), but not the pyruvate dehydrogenase complex (@GENE$), are susceptible to inactivation.	0
Interestingly, the @CHEM-GENE$ (KGDHC and BCDHC), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and @CHEMICAL$ dehydrogenase complexes (@GENE$ and BCDHC), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and @CHEMICAL$ dehydrogenase complexes (KGDHC and @GENE$), but not the pyruvate dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and @CHEMICAL$ dehydrogenase complexes (KGDHC and BCDHC), but not the @GENE$ (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and @CHEMICAL$ dehydrogenase complexes (KGDHC and BCDHC), but not the pyruvate dehydrogenase complex (@GENE$), are susceptible to inactivation.	0
Interestingly, the @GENE$ (KGDHC and BCDHC), but not the @CHEMICAL$ dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes (@GENE$ and BCDHC), but not the @CHEMICAL$ dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and @GENE$), but not the @CHEMICAL$ dehydrogenase complex (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and BCDHC), but not the @CHEM-GENE$ (PDHC), are susceptible to inactivation.	0
Interestingly, the alpha-ketoglutarate- and branched-chain alpha-keto acid dehydrogenase complexes (KGDHC and BCDHC), but not the @CHEMICAL$ dehydrogenase complex (@GENE$), are susceptible to inactivation.	0
@GENE$ and BCAT(m) may form metabolons with KGDHC and BCDHC, respectively, but no @CHEMICAL$ enzyme is known to associate with PDHC.	0
mitAspAT and @GENE$ may form metabolons with KGDHC and BCDHC, respectively, but no @CHEMICAL$ enzyme is known to associate with PDHC.	0
mitAspAT and BCAT(m) may form metabolons with @GENE$ and BCDHC, respectively, but no @CHEMICAL$ enzyme is known to associate with PDHC.	0
mitAspAT and BCAT(m) may form metabolons with KGDHC and @GENE$, respectively, but no @CHEMICAL$ enzyme is known to associate with PDHC.	0
mitAspAT and BCAT(m) may form metabolons with KGDHC and BCDHC, respectively, but no @CHEM-GENE$ is known to associate with PDHC.	0
mitAspAT and BCAT(m) may form metabolons with KGDHC and BCDHC, respectively, but no @CHEMICAL$ enzyme is known to associate with @GENE$.	0
The juvenile visceral steatosis (jvs) mouse, having a mutation in the @CHEMICAL$ transporter gene @GENE$, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).	5
The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene @GENE$, is a model of primary systemic @CHEMICAL$ deficiency in humans (SCD, OMIM 212140).	0
Reuptake of extracellular @CHEMICAL$ (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the @GENE$ (NAT, uptake 1).	5
Reuptake of extracellular @CHEMICAL$ (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (@GENE$, uptake 1).	5
Reuptake of extracellular noradrenaline (@CHEMICAL$) into superior cervical ganglion (SCG) neurones is mediated by means of the @GENE$ (NAT, uptake 1).	5
Reuptake of extracellular noradrenaline (@CHEMICAL$) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (@GENE$, uptake 1).	5
Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the @CHEM-GENE$ (NAT, uptake 1).	0
Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the @CHEMICAL$ transporter (@GENE$, uptake 1).	0
Making use of the @GENE$ as a powerful, neurone-specific transporter system, we loaded@CHEMICAL$ ([3H]-MPP+) into cultured rat SCG neurones.	0
Making use of the @GENE$ as a powerful, neurone-specific transporter system, we loaded[3H]-N-methyl-4-phenylpyridinium (@CHEMICAL$) into cultured rat SCG neurones.	0
The ensuing radioactive outflow from these cultures was enhanced by @CHEMICAL$ and reserpine, but reduced (in the presence of desipramine) by the @GENE$ inhibitors cyanine 863, oestradiol and corticosterone.	0
The ensuing radioactive outflow from these cultures was enhanced by desipramine and @CHEMICAL$, but reduced (in the presence of desipramine) by the @GENE$ inhibitors cyanine 863, oestradiol and corticosterone.	0
The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of @CHEMICAL$) by the @GENE$ inhibitors cyanine 863, oestradiol and corticosterone.	0
The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the @GENE$ inhibitors cyanine 863, @CHEMICAL$ and corticosterone.	2
The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the @GENE$ inhibitors cyanine 863, oestradiol and @CHEMICAL$.	2
Two observations suggest that a depletion of storage vesicles by cyanine 863 accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with @CHEMICAL$ was the metabolite [3H]-DHPG; and second, inhibition of @GENE$ significantly reduced the radioactive outflow in response to cyanine 863.	0
Two observations suggest that a depletion of storage vesicles by cyanine 863 accounts for the latter phenomenon: first, the primary radioactive product isolated from supernatants of cultures loaded with [3H]-NA was the metabolite @CHEMICAL$; and second, inhibition of @GENE$ significantly reduced the radioactive outflow in response to cyanine 863.	0
The outflow of @CHEMICAL$ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for @GENE$-related transmembrane transporters.	5
The outflow of @CHEMICAL$ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related @GENE$.	5
The outflow of [3H]-MPP+ was significantly enhanced by @CHEMICAL$, guanidine, choline and amantadine as potential substrates for @GENE$-related transmembrane transporters.	5
The outflow of [3H]-MPP+ was significantly enhanced by @CHEMICAL$, guanidine, choline and amantadine as potential substrates for OCT-related @GENE$.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, @CHEMICAL$, choline and amantadine as potential substrates for @GENE$-related transmembrane transporters.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, @CHEMICAL$, choline and amantadine as potential substrates for OCT-related @GENE$.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, @CHEMICAL$ and amantadine as potential substrates for @GENE$-related transmembrane transporters.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, @CHEMICAL$ and amantadine as potential substrates for OCT-related @GENE$.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and @CHEMICAL$ as potential substrates for @GENE$-related transmembrane transporters.	5
The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and @CHEMICAL$ as potential substrates for OCT-related @GENE$.	5
However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of @CHEMICAL$, indicating the @GENE$ and not an OCT as their primary site of action.	5
However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of @CHEMICAL$, indicating the NAT and not an @GENE$ as their primary site of action.	0
However, @CHEMICAL$ at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the @GENE$ and not an OCT as their primary site of action.	0
However, @CHEMICAL$ at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an @GENE$ as their primary site of action.	0
No trans-stimulation of @CHEMICAL$ outflow was observed by the @GENE$ and OCTN2 substrate carnitine at 100 microM.	0
No trans-stimulation of @CHEMICAL$ outflow was observed by the OCTN1 and @GENE$ substrate carnitine at 100 microM.	0
Our observations indicate an @GENE$-mediated transmembrane transport of @CHEMICAL$.	5
Amongst the three @GENE$ expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of @CHEMICAL$ release.	5
Amongst the three OCTs expressed in the SCG, @GENE$ best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of @CHEMICAL$ release.	5
An inhibitor of @GENE$ (MAO-B), @CHEMICAL$ (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	2
An inhibitor of type B monoamine oxidase (@GENE$), @CHEMICAL$ (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	2
An inhibitor of @GENE$ (MAO-B), (-)deprenyl (@CHEMICAL$), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	2
An inhibitor of type B monoamine oxidase (@GENE$), (-)deprenyl (@CHEMICAL$), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	2
An inhibitor of @CHEM-GENE$ (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	0
An inhibitor of type B @CHEMICAL$ oxidase (@GENE$), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.	0
@CHEMICAL$ prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic @GENE$ and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).	1
@CHEMICAL$ prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a @GENE$, glial cell line-derived neurotrophic factor (GDNF).	1
@CHEMICAL$ prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, @GENE$ (GDNF).	1
@CHEMICAL$ prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (@GENE$).	1
Long-term administration of @CHEMICAL$ to rats increased the activities of antioxidative enzymes @GENE$ (SOD) and catalase in the brain regions containing dopamine neurons.	1
Long-term administration of @CHEMICAL$ to rats increased the activities of antioxidative enzymes superoxide dismutase (@GENE$) and catalase in the brain regions containing dopamine neurons.	1
Long-term administration of @CHEMICAL$ to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and @GENE$ in the brain regions containing dopamine neurons.	1
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes @CHEM-GENE$ (SOD) and catalase in the brain regions containing dopamine neurons.	0
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes @CHEMICAL$ dismutase (@GENE$) and catalase in the brain regions containing dopamine neurons.	0
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes @CHEMICAL$ dismutase (SOD) and @GENE$ in the brain regions containing dopamine neurons.	0
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes @GENE$ (SOD) and catalase in the brain regions containing @CHEMICAL$ neurons.	0
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (@GENE$) and catalase in the brain regions containing @CHEMICAL$ neurons.	0
Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and @GENE$ in the brain regions containing @CHEMICAL$ neurons.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate @CHEMICAL$ (PGE2), leukotriene B4 (LTB4) and @GENE$ concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate @CHEMICAL$ (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and @GENE$-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (@CHEMICAL$), leukotriene B4 (LTB4) and @GENE$ concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (@CHEMICAL$), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and @GENE$-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), @CHEMICAL$ (LTB4) and @GENE$ concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), @CHEMICAL$ (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and @GENE$-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (@CHEMICAL$) and @GENE$ concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (@CHEMICAL$) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (TxB2), and @GENE$-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and @GENE$ concentrations and exudate leucocyte numbers, serum @CHEMICAL$ (TxB2), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum @CHEMICAL$ (TxB2), and @GENE$-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and @GENE$ concentrations and exudate leucocyte numbers, serum thromboxane B2 (@CHEMICAL$), and bradykinin-induced skin swelling.	0
The higher concentrations in calves were insufficient to inhibit significantly exudate prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and beta-glucuronidase concentrations and exudate leucocyte numbers, serum thromboxane B2 (@CHEMICAL$), and @GENE$-induced skin swelling.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active @CHEMICAL$ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the @GENE$ (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active @CHEMICAL$ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (@GENE$) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active @CHEMICAL$ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, @GENE$ and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active @CHEMICAL$ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and @GENE$ or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, @CHEMICAL$; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the @GENE$ (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, @CHEMICAL$; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (@GENE$) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, @CHEMICAL$; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, @GENE$ and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, @CHEMICAL$; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and @GENE$ or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of @CHEMICAL$ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the @GENE$ (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of @CHEMICAL$ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (@GENE$) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of @CHEMICAL$ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, @GENE$ and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of @CHEMICAL$ to plasma protein in calves; (c) species differences in the sensitivity to PBZ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and @GENE$ or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to @CHEMICAL$ of the @GENE$ (COX) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to @CHEMICAL$ of the cyclo-oxygenase (@GENE$) isoenzymes, COX-1 and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to @CHEMICAL$ of the cyclo-oxygenase (COX) isoenzymes, @GENE$ and COX-2 or; (d) a combination of these factors.	0
These differences from the horse might be the result of: (a) the presence in equine biological fluids of higher concentrations than in calves of the active PBZ metabolite, OPBZ; (b) a greater degree of binding of PBZ to plasma protein in calves; (c) species differences in the sensitivity to @CHEMICAL$ of the cyclo-oxygenase (COX) isoenzymes, COX-1 and @GENE$ or; (d) a combination of these factors.	0
Practical asymmetric synthesis of @CHEMICAL$, a potent human @GENE$ antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.	4
A streamlined and high-yielding synthesis of @CHEMICAL$ (1), a potent @GENE$ antagonist, is described.	4
A streamlined and high-yielding synthesis of aprepitant (1), a potent @CHEM-GENE$ antagonist, is described.	0
A streamlined and high-yielding synthesis of aprepitant (1), a potent @CHEM-GENE$ antagonist, is described.	0
Redundancy and specificity in the regulation of @CHEM-GENE$ and other effectors.	0
Platelet agonists such as @CHEMICAL$ and epinephrine suppress PGI(2)-stimulated cAMP formation by activating receptors coupled to @GENE$ family members, four of which are present in platelets.	0
Platelet agonists such as ADP and epinephrine suppress @CHEMICAL$-stimulated cAMP formation by activating receptors coupled to @GENE$ family members, four of which are present in platelets.	0
Platelet agonists such as ADP and epinephrine suppress PGI(2)-stimulated @CHEMICAL$ formation by activating receptors coupled to @GENE$ family members, four of which are present in platelets.	0
To address questions about the specificity of receptor:@GENE$ coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of @GENE$-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of G(i)-mediated pathways that do not involve @GENE$, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed @GENE$ family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @GENE$, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of @CHEMICAL$ formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, @GENE$.	0
To address questions about the specificity of receptor:@GENE$ coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @CHEMICAL$ cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of @GENE$-mediated pathways that do not involve @CHEMICAL$ cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @CHEM-GENE$, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @CHEMICAL$ cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed @GENE$ family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @CHEMICAL$ cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @GENE$, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @CHEMICAL$ cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, @GENE$.	0
To address questions about the specificity of receptor:@GENE$ coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @CHEMICAL$ receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of @GENE$-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @CHEMICAL$ receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve @GENE$, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @CHEMICAL$ receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed @GENE$ family members and compared the results with platelets from mice that lacked the @CHEMICAL$ receptor, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @CHEM-GENE$, IP.	0
To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the alpha subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the @CHEMICAL$ receptor, @GENE$.	0
As reported previously, loss of @GENE$ or G(z)alpha inhibited aggregation in response to @CHEMICAL$ and epinephrine, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or @GENE$ inhibited aggregation in response to @CHEMICAL$ and epinephrine, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or G(z)alpha inhibited aggregation in response to @CHEMICAL$ and epinephrine, respectively, producing defects that could not be reversed by adding an @GENE$ inhibitor.	0
As reported previously, loss of @GENE$ or G(z)alpha inhibited aggregation in response to ADP and @CHEMICAL$, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or @GENE$ inhibited aggregation in response to ADP and @CHEMICAL$, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or G(z)alpha inhibited aggregation in response to ADP and @CHEMICAL$, respectively, producing defects that could not be reversed by adding an @GENE$ inhibitor.	0
As reported previously, loss of @GENE$ or G(z)alpha inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an @CHEMICAL$ cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or @GENE$ inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an @CHEMICAL$ cyclase inhibitor.	0
As reported previously, loss of G(i2)alpha or G(z)alpha inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an @CHEM-GENE$ inhibitor.	0
Loss of either @GENE$ or G(i2)alpha impaired the ability of @CHEMICAL$ and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or @GENE$ impaired the ability of @CHEMICAL$ and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of @CHEMICAL$ and epinephrine to inhibit PGI(2)-stimulated @GENE$ activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of @CHEMICAL$ and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of @GENE$ did not.	0
Loss of either @GENE$ or G(i2)alpha impaired the ability of ADP and @CHEMICAL$ to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or @GENE$ impaired the ability of ADP and @CHEMICAL$ to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and @CHEMICAL$ to inhibit PGI(2)-stimulated @GENE$ activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and @CHEMICAL$ to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of @GENE$ did not.	0
Loss of either @GENE$ or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit @CHEMICAL$-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or @GENE$ impaired the ability of ADP and epinephrine to inhibit @CHEMICAL$-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit @CHEMICAL$-stimulated @GENE$ activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit @CHEMICAL$-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of @GENE$ did not.	0
Loss of either @GENE$ or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated @CHEMICAL$ cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or @GENE$ impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated @CHEMICAL$ cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated @CHEM-GENE$ activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated @CHEMICAL$ cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of @GENE$ did not.	0
Loss of either @GENE$ or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal @CHEMICAL$ levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or @GENE$ impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal @CHEMICAL$ levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated @GENE$ activity and caused a 40%-50% rise in basal @CHEMICAL$ levels, whereas loss of G(i3)alpha did not.	0
Loss of either G(z)alpha or G(i2)alpha impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal @CHEMICAL$ levels, whereas loss of @GENE$ did not.	0
Conversely, deletion of @GENE$ abolished responses to @CHEMICAL$ and caused cAMP levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo.	0
Conversely, deletion of @GENE$ abolished responses to PGI(2) and caused @CHEMICAL$ levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo.	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through @GENE$, G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), @GENE$, and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and @GENE$, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not @GENE$; 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine @GENE$) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (@GENE$) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among @GENE$ family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) @CHEMICAL$ levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to @GENE$.	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through @GENE$, G(z), and IP, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), @GENE$, and IP, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and @GENE$, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not @GENE$; 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet @CHEMICAL$ @GENE$) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (@GENE$) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among @GENE$ family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet @CHEMICAL$ (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to @GENE$.	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through @GENE$, G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), @GENE$, and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and @GENE$, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not @GENE$; 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine @GENE$) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (@GENE$) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among @GENE$ family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3).	0
From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and @CHEMICAL$ (P2Y12) receptors display strong preferences among G(i) family members with little evidence of redundancy; and 3) these receptor preferences do not extend to @GENE$.	0
Finally, the failure of @CHEMICAL$ and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for @GENE$ signaling pathways that involve effectors other than adenylyl cyclase.	0
Finally, the failure of @CHEMICAL$ and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than @GENE$.	0
Finally, the failure of ADP and @CHEMICAL$ to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for @GENE$ signaling pathways that involve effectors other than adenylyl cyclase.	0
Finally, the failure of ADP and @CHEMICAL$ to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than @GENE$.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to @CHEMICAL$-stimulated, cAMP formation highlights the need during platelet activation for @GENE$ signaling pathways that involve effectors other than adenylyl cyclase.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to @CHEMICAL$-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than @GENE$.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, @CHEMICAL$ formation highlights the need during platelet activation for @GENE$ signaling pathways that involve effectors other than adenylyl cyclase.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, @CHEMICAL$ formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than @GENE$.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for @GENE$ signaling pathways that involve effectors other than @CHEMICAL$ cyclase.	0
Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than @CHEM-GENE$.	0
Pentosan polysulfate @CHEMICAL$ (PPS) has been shown to exert antitumor activity by antagonizing the binding of @GENE$ to cell surface receptors.	4
Localization of the @CHEM-GENE$ RhBG and RhCG in mouse kidney.	0
Localization of the @CHEMICAL$ transporter proteins @GENE$ and RhCG in mouse kidney.	0
Localization of the @CHEMICAL$ transporter proteins RhBG and @GENE$ in mouse kidney.	0
Recent studies have identified a family of putative @CHEM-GENE$; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and Rh C-glycoprotein (RhCG), is expressed in the kidney.	0
Recent studies have identified a family of putative @CHEMICAL$ transporters; mRNA for two members of this family, @GENE$ (RhBG) and Rh C-glycoprotein (RhCG), is expressed in the kidney.	0
Recent studies have identified a family of putative @CHEMICAL$ transporters; mRNA for two members of this family, Rh B-glycoprotein (@GENE$) and Rh C-glycoprotein (RhCG), is expressed in the kidney.	0
Recent studies have identified a family of putative @CHEMICAL$ transporters; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and @GENE$ (RhCG), is expressed in the kidney.	0
Recent studies have identified a family of putative @CHEMICAL$ transporters; mRNA for two members of this family, Rh B-glycoprotein (RhBG) and Rh C-glycoprotein (@GENE$), is expressed in the kidney.	0
Colocalization of RhBG with carbonic anhydrase II, the @CHEMICAL$-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated @GENE$ immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Colocalization of @GENE$ with carbonic anhydrase II, the @CHEMICAL$-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Colocalization of RhBG with @GENE$, the @CHEMICAL$-sensitive transporter, and the anion exchangers AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Colocalization of RhBG with carbonic anhydrase II, the @CHEMICAL$-sensitive transporter, and the @GENE$ AE1 and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Colocalization of RhBG with carbonic anhydrase II, the @CHEMICAL$-sensitive transporter, and the anion exchangers @GENE$ and pendrin demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Colocalization of RhBG with carbonic anhydrase II, the @CHEMICAL$-sensitive transporter, and the anion exchangers AE1 and @GENE$ demonstrated RhBG immunoreactivity in all CNT cells and all CCD and ICT principal cells.	0
Immunoreactivity for a second putative @CHEM-GENE$, RhCG, was present in the apical region of cells with almost the same distribution as RhBG.	0
Immunoreactivity for a second putative @CHEMICAL$ transporter, @GENE$, was present in the apical region of cells with almost the same distribution as RhBG.	0
Immunoreactivity for a second putative @CHEMICAL$ transporter, RhCG, was present in the apical region of cells with almost the same distribution as @GENE$.	0
These findings suggest that @GENE$ and RhCG may play important and cell-specific roles in @CHEMICAL$ transport and signaling in these regions of the kidney.	5
These findings suggest that RhBG and @GENE$ may play important and cell-specific roles in @CHEMICAL$ transport and signaling in these regions of the kidney.	5
Published literature on the @CHEMICAL$-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on @GENE$ inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.	0
Published literature on the @CHEMICAL$-cyclic guanosine monophosphate (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic @GENE$ inhibition are assessed.	0
Published literature on the nitric oxide-@CHEMICAL$ (cGMP) pathway for penile erection and on @GENE$ inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.	0
Published literature on the nitric oxide-@CHEMICAL$ (cGMP) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic @GENE$ inhibition are assessed.	0
Published literature on the nitric oxide-cyclic guanosine monophosphate (@CHEMICAL$) pathway for penile erection and on @GENE$ inhibition using sildenafil as the model for pharmacologic PDE5 inhibition are assessed.	0
Published literature on the nitric oxide-cyclic guanosine monophosphate (@CHEMICAL$) pathway for penile erection and on PDE5 inhibition using sildenafil as the model for pharmacologic @GENE$ inhibition are assessed.	0
@GENE$ is the predominant PDE in the corpus cavernosum, and @CHEMICAL$ is its primary substrate.	5
PDE5 is the predominant @GENE$ in the corpus cavernosum, and @CHEMICAL$ is its primary substrate.	5
Therefore, in men with ED, elevation of @CHEMICAL$ in corpus cavernosal tissue via selective inhibition of cGMP-specific @GENE$ is a means of improving erectile function at minimal risk of adverse events.	0
Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of @CHEMICAL$-specific @GENE$ is a means of improving erectile function at minimal risk of adverse events.	2
This approach is validated by the clinical efficacy and safety of @CHEMICAL$, the pioneering drug for selective @GENE$ inhibitor therapy for ED.	2
@CHEMICAL$ exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant @GENE$ in the phototransduction cascade in rods.	2
@CHEMICAL$ exhibits inhibitory potency against @GENE$ and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.	2
@CHEMICAL$ exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment @GENE$, the predominant PDE in the phototransduction cascade in rods.	2
As free @CHEMICAL$ plasma concentrations approach concentrations sufficient to inhibit retinal @GENE$, usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.	2
Selective inhibition of @GENE$ is a rational therapeutic approach in ED, as proved by the clinical success of @CHEMICAL$.	2
Study of the nematode putative @CHEM-GENE$ subunits: evidence for modulation by ivermectin.	0
Study of the nematode putative @GENE$ subunits: evidence for modulation by @CHEMICAL$.	0
Two alleles of the @GENE$ gene, which encodes a putative @CHEMICAL$ receptor alpha/gamma subunit, were isolated from Haemonchus contortus.	0
Two alleles of the HG1 gene, which encodes a putative @CHEM-GENE$ subunit, were isolated from Haemonchus contortus.	0
These two alleles were shown previously to be associated with @CHEMICAL$ susceptibility (@GENE$) and resistance (HG1E), respectively.	0
These two alleles were shown previously to be associated with @CHEMICAL$ susceptibility (HG1A) and resistance (@GENE$), respectively.	0
To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the @CHEM-GENE$, was isolated from Caenorhabditis elegans (gab-1, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the HG1 alleles.	0
To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the @CHEMICAL$ receptor, was isolated from Caenorhabditis elegans (@GENE$, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the HG1 alleles.	0
To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the @CHEMICAL$ receptor, was isolated from Caenorhabditis elegans (gab-1, corresponding to the @GENE$) and coexpressed in Xenopus oocytes with the HG1 alleles.	0
To explore the functional properties of the two alleles, a full-length cDNA encoding the beta subunit, a key functional component of the @CHEMICAL$ receptor, was isolated from Caenorhabditis elegans (gab-1, corresponding to the GenBank locus ZC482.1) and coexpressed in Xenopus oocytes with the @GENE$ alleles.	0
When @GENE$ was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, @CHEMICAL$ (GABA)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the @GENE$ allele or the HG1E allele in Xenopus oocytes, @CHEMICAL$ (GABA)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the HG1A allele or the @GENE$ allele in Xenopus oocytes, @CHEMICAL$ (GABA)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, @CHEM-GENE$ with different sensitivity to the agonist were formed.	0
When @GENE$ was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (@CHEMICAL$)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the @GENE$ allele or the HG1E allele in Xenopus oocytes, gamma-aminobutyric acid (@CHEMICAL$)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the HG1A allele or the @GENE$ allele in Xenopus oocytes, gamma-aminobutyric acid (@CHEMICAL$)-responsive channels with different sensitivity to the agonist were formed.	0
When gab-1 was coexpressed with either the HG1A allele or the HG1E allele in Xenopus oocytes, @CHEM-GENE$ with different sensitivity to the agonist were formed.	0
However, when coapplied with 10 micro m @CHEMICAL$, ivermectin potentiated the GABA-evoked current of the @GENE$/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m @CHEMICAL$, ivermectin potentiated the GABA-evoked current of the GAB-1/@GENE$ receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m @CHEMICAL$, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the @GENE$/HG1E receptor.	0
However, when coapplied with 10 micro m @CHEMICAL$, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/@GENE$ receptor.	0
However, when coapplied with 10 micro m GABA, @CHEMICAL$ potentiated the GABA-evoked current of the @GENE$/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	1
However, when coapplied with 10 micro m GABA, @CHEMICAL$ potentiated the GABA-evoked current of the GAB-1/@GENE$ receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	1
However, when coapplied with 10 micro m GABA, @CHEMICAL$ potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the @GENE$/HG1E receptor.	2
However, when coapplied with 10 micro m GABA, @CHEMICAL$ potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/@GENE$ receptor.	2
However, when coapplied with 10 micro m GABA, ivermectin potentiated the @CHEMICAL$-evoked current of the @GENE$/HG1A receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the @CHEMICAL$-evoked current of the GAB-1/@GENE$ receptor, but attenuated the GABA response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the @CHEMICAL$-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the @GENE$/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the @CHEMICAL$-evoked current of the GAB-1/HG1A receptor, but attenuated the GABA response of the GAB-1/@GENE$ receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the @GENE$/HG1A receptor, but attenuated the @CHEMICAL$ response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/@GENE$ receptor, but attenuated the @CHEMICAL$ response of the GAB-1/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the @CHEMICAL$ response of the @GENE$/HG1E receptor.	0
However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1/HG1A receptor, but attenuated the @CHEMICAL$ response of the GAB-1/@GENE$ receptor.	0
We demonstrated that the coexpressed @GENE$ and GAB-1 receptors are @CHEMICAL$-responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed HG1 and @GENE$ receptors are @CHEMICAL$-responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed HG1 and GAB-1 receptors are @CHEMICAL$-responsive, and provide evidence for the possible involvement of @GENE$ in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed @GENE$ and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of @CHEMICAL$ receptors in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed HG1 and @GENE$ receptors are GABA-responsive, and provide evidence for the possible involvement of @CHEMICAL$ receptors in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed HG1 and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of @CHEM-GENE$ in the mechanism of ivermectin resistance.	0
We demonstrated that the coexpressed @GENE$ and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of @CHEMICAL$ resistance.	0
We demonstrated that the coexpressed HG1 and @GENE$ receptors are GABA-responsive, and provide evidence for the possible involvement of GABA receptors in the mechanism of @CHEMICAL$ resistance.	0
We demonstrated that the coexpressed HG1 and GAB-1 receptors are GABA-responsive, and provide evidence for the possible involvement of @GENE$ in the mechanism of @CHEMICAL$ resistance.	0
@CHEMICAL$ dimers exhibiting selectivity for the @GENE$ subtype.	0
@CHEMICAL$ is a potent and selective @GENE$ antagonist.	4
Initial studies showed that @CHEMICAL$ was about 4- and 15-fold more selective for the @GENE$ in comparison with the alpha2A- and alpha2B-adrenoceptors, respectively.	0
Initial studies showed that @CHEMICAL$ was about 4- and 15-fold more selective for the human alpha2C-adrenoceptor in comparison with the @GENE$, respectively.	0
To improve on this @GENE$ subtype selectivity, a series of @CHEMICAL$ dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on human alpha2-adrenoceptor subtypes expressed in Chinese hamster ovary cells.	0
To improve on this alpha2-adrenoceptor subtype selectivity, a series of @CHEMICAL$ dimers (varying from n = 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on @GENE$ subtypes expressed in Chinese hamster ovary cells.	0
Each dimeric analog showed higher affinities for @GENE$ versus the alpha2B-adrenoceptor; and @CHEMICAL$ dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the alpha2C-adrenoceptor.	0
Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the @GENE$; and @CHEMICAL$ dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the alpha2C-adrenoceptor.	0
Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and @CHEMICAL$ dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the @GENE$.	0
respectively) for the @GENE$ in receptor binding and in functional studies (42- and 29-fold, respectively) measuring @CHEMICAL$ changes using a cell-based luciferase reporter gene assay.	0
These findings demonstrate that the addition of spacer linkages to bivalent @CHEMICAL$ molecules provides a successful approach to the development of ligands that are potent and highly selective for the @GENE$.	0
Plasmacytoid dendritic cells produce @GENE$ and mature in response to the TLR7 agonists, imiquimod and @CHEMICAL$.	0
Plasmacytoid dendritic cells produce cytokines and mature in response to the @GENE$ agonists, imiquimod and @CHEMICAL$.	3
Plasmacytoid dendritic cells produce @GENE$ and mature in response to the TLR7 agonists, @CHEMICAL$ and resiquimod.	0
Plasmacytoid dendritic cells produce cytokines and mature in response to the @GENE$ agonists, @CHEMICAL$ and resiquimod.	3
The immune response modifiers, @CHEMICAL$ and resiquimod, are @GENE$ agonists that induce type I interferon in numerous species, including humans.	3
The immune response modifiers, @CHEMICAL$ and resiquimod, are TLR7 agonists that induce @GENE$ in numerous species, including humans.	1
The immune response modifiers, imiquimod and @CHEMICAL$, are @GENE$ agonists that induce type I interferon in numerous species, including humans.	3
The immune response modifiers, imiquimod and @CHEMICAL$, are TLR7 agonists that induce @GENE$ in numerous species, including humans.	1
Here, we characterize the activation of human pDC with the @GENE$ agonists @CHEMICAL$ and resiquimod.	3
Here, we characterize the activation of human pDC with the @GENE$ agonists imiquimod and @CHEMICAL$.	3
Results indicate that @CHEMICAL$ and resiquimod induce @GENE$ and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.	1
Results indicate that @CHEMICAL$ and resiquimod induce IFN-alpha and @GENE$ from purified pDC, and pDC are the principle IFN-producing cells in the blood.	1
Results indicate that @CHEMICAL$ and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle @GENE$-producing cells in the blood.	0
Results indicate that imiquimod and @CHEMICAL$ induce @GENE$ and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.	0
Results indicate that imiquimod and @CHEMICAL$ induce IFN-alpha and @GENE$ from purified pDC, and pDC are the principle IFN-producing cells in the blood.	0
Results indicate that imiquimod and @CHEMICAL$ induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle @GENE$-producing cells in the blood.	0
@CHEMICAL$-stimulated pDC also produce a number of other @GENE$ including TNF-alpha and IP-10.	1
@CHEMICAL$-stimulated pDC also produce a number of other cytokines including @GENE$ and IP-10.	1
@CHEMICAL$-stimulated pDC also produce a number of other cytokines including TNF-alpha and @GENE$.	1
@CHEMICAL$ enhances co-stimulatory marker expression, @GENE$ expression, and pDC viability.	1
Resiquimod was compared throughout the study to the pDC survival factors, @GENE$ and IFN-alpha; @CHEMICAL$ more effectively matures pDC than either IL-3 or IFN-alpha alone.	0
Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and @GENE$; @CHEMICAL$ more effectively matures pDC than either IL-3 or IFN-alpha alone.	0
Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; @CHEMICAL$ more effectively matures pDC than either @GENE$ or IFN-alpha alone.	0
Resiquimod was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; @CHEMICAL$ more effectively matures pDC than either IL-3 or @GENE$ alone.	0
@CHEMICAL$ was compared throughout the study to the pDC survival factors, @GENE$ and IFN-alpha; resiquimod more effectively matures pDC than either IL-3 or IFN-alpha alone.	0
@CHEMICAL$ was compared throughout the study to the pDC survival factors, IL-3 and @GENE$; resiquimod more effectively matures pDC than either IL-3 or IFN-alpha alone.	0
@CHEMICAL$ was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; resiquimod more effectively matures pDC than either @GENE$ or IFN-alpha alone.	0
@CHEMICAL$ was compared throughout the study to the pDC survival factors, IL-3 and IFN-alpha; resiquimod more effectively matures pDC than either IL-3 or @GENE$ alone.	0
These results demonstrate that @CHEMICAL$ molecules directly induce pDC maturation as determined by @GENE$ induction, CCR7 and co-stimulatory marker expression and prolonging viability.	1
These results demonstrate that @CHEMICAL$ molecules directly induce pDC maturation as determined by cytokine induction, @GENE$ and co-stimulatory marker expression and prolonging viability.	0
Induction of @GENE$ (HSPs) by @CHEMICAL$ in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.	1
Induction of heat shock proteins (@GENE$) by @CHEMICAL$ in cultured astrocytes and reduction of hydrogen peroxide-induced cell death.	1
Induction of @GENE$ (HSPs) by sodium arsenite in cultured astrocytes and reduction of @CHEMICAL$-induced cell death.	0
Induction of heat shock proteins (@GENE$) by sodium arsenite in cultured astrocytes and reduction of @CHEMICAL$-induced cell death.	0
Arsenite triggered strong induction of @GENE$, which was prevented by 1 micro g/mL @CHEMICAL$ (CXH).	2
Arsenite triggered strong induction of @GENE$, which was prevented by 1 micro g/mL cycloheximide (@CHEMICAL$).	2
@CHEMICAL$ triggered strong induction of @GENE$, which was prevented by 1 micro g/mL cycloheximide (CXH).	1
Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (@GENE$) phosphorylation after @CHEMICAL$.	0
Pre-treatment with arsenite increased @GENE$ (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after @CHEMICAL$.	1
Pre-treatment with arsenite increased protein kinase B (@GENE$) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after @CHEMICAL$.	1
Pre-treatment with arsenite increased protein kinase B (Akt) and @GENE$ (ERK1/2) phosphorylation after @CHEMICAL$.	0
However, while @GENE$ phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by @CHEMICAL$.	2
However, while Akt phosphorylation was prevented by CHX, @GENE$ phosphorylation was further enhanced by @CHEMICAL$.	0
The results show that transient @CHEMICAL$ pre-treatment induces @GENE$, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.	1
The results show that transient @CHEMICAL$ pre-treatment induces Hsp72, @GENE$ and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.	1
The results show that transient @CHEMICAL$ pre-treatment induces Hsp72, HO-1 and, to a lesser extent, @GENE$; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.	1
The results show that transient @CHEMICAL$ pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of @GENE$ following H2O2.	1
The results show that transient arsenite pre-treatment induces @GENE$, HO-1 and, to a lesser extent, Hsp27; it reduces @CHEMICAL$-induced astrocyte death; and it causes selective activation of Akt following H2O2.	0
The results show that transient arsenite pre-treatment induces Hsp72, @GENE$ and, to a lesser extent, Hsp27; it reduces @CHEMICAL$-induced astrocyte death; and it causes selective activation of Akt following H2O2.	0
The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, @GENE$; it reduces @CHEMICAL$-induced astrocyte death; and it causes selective activation of Akt following H2O2.	0
The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces @CHEMICAL$-induced astrocyte death; and it causes selective activation of @GENE$ following H2O2.	0
The results show that transient arsenite pre-treatment induces @GENE$, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following @CHEMICAL$.	0
The results show that transient arsenite pre-treatment induces Hsp72, @GENE$ and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following @CHEMICAL$.	0
The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, @GENE$; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following @CHEMICAL$.	0
The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of @GENE$ following @CHEMICAL$.	1
It is suggested that @GENE$ expression at the time of @CHEMICAL$ exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival Akt.	0
It is suggested that HSP expression at the time of @CHEMICAL$ exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival @GENE$.	0
Investigation of @GENE$ metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors @CHEMICAL$ and omapatrilat.	0
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual @GENE$/NEP inhibitors @CHEMICAL$ and omapatrilat.	2
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/@GENE$ inhibitors @CHEMICAL$ and omapatrilat.	2
Investigation of @GENE$ metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and @CHEMICAL$.	0
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual @GENE$/NEP inhibitors GW660511X and @CHEMICAL$.	2
Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/@GENE$ inhibitors GW660511X and @CHEMICAL$.	2
Investigation of @CHEM-GENE$ metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.	0
Investigation of @CHEMICAL$ metabolism in human and rat plasma in the presence of the dual @GENE$/NEP inhibitors GW660511X and omapatrilat.	0
Investigation of @CHEMICAL$ metabolism in human and rat plasma in the presence of the dual ACE/@GENE$ inhibitors GW660511X and omapatrilat.	0
Several studies have suggested that the accumulation of @CHEMICAL$, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various @GENE$i.	0
Several studies have suggested that the accumulation of @CHEM-GENE$, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @CHEM-GENE$ (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @CHEMICAL$ (@GENE$) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @CHEMICAL$ (79/81 Br-Phe5) @GENE$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @CHEMICAL$ (79/81 Br-Phe5) BrBK in the presence of two new dual @GENE$/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @CHEMICAL$ (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/@GENE$ inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @GENE$ (79/81 @CHEMICAL$) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (@CHEM-GENE$) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 @CHEMICAL$) @GENE$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 @CHEMICAL$) BrBK in the presence of two new dual @GENE$/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 @CHEMICAL$) BrBK in the presence of two new dual ACE/@GENE$ inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @GENE$ (79/81 Br-Phe5) @CHEMICAL$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (@GENE$) @CHEMICAL$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) @CHEM-GENE$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) @CHEMICAL$ in the presence of two new dual @GENE$/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) @CHEMICAL$ in the presence of two new dual ACE/@GENE$ inhibitors (GW660511X and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @GENE$ (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (@CHEMICAL$ and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (@GENE$) BrBK in the presence of two new dual ACE/NEP inhibitors (@CHEMICAL$ and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) @GENE$ in the presence of two new dual ACE/NEP inhibitors (@CHEMICAL$ and omapatrilat) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual @GENE$/NEP inhibitors (@CHEMICAL$ and omapatrilat) currently under clinical trial.	2
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/@GENE$ inhibitors (@CHEMICAL$ and omapatrilat) currently under clinical trial.	2
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled @GENE$ (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and @CHEMICAL$) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (@GENE$) BrBK in the presence of two new dual ACE/NEP inhibitors (GW660511X and @CHEMICAL$) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) @GENE$ in the presence of two new dual ACE/NEP inhibitors (GW660511X and @CHEMICAL$) currently under clinical trial.	0
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual @GENE$/NEP inhibitors (GW660511X and @CHEMICAL$) currently under clinical trial.	2
In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/@GENE$ inhibitors (GW660511X and @CHEMICAL$) currently under clinical trial.	2
In human plasma the @CHEM-GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe.	0
In human plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or @CHEMICAL$ (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEM-GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEMICAL$ was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @CHEM-GENE$, BrBK1-7, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @CHEMICAL$, @GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, @GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, @CHEMICAL$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @CHEM-GENE$, BrBK1-5 and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, @GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, @CHEMICAL$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, @CHEMICAL$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEM-GENE$ and Br-Phe.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and @GENE$.	0
In human plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and @CHEMICAL$.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and @CHEMICAL$.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and @CHEMICAL$.	0
In human plasma the BrBK half-life values in the absence or in the presence of GW660511X (3.8 microM) or omapatrilat (32 nM) were 38.7 +/- 2.4, 51.2 +/- 4.7 and 114.7 +/- 9.3 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEM-GENE$.	0
Unlike @CHEMICAL$, omapatrilat abolished the production of @GENE$ and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike @CHEMICAL$, omapatrilat abolished the production of BrBK1-5 and @GENE$, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike @CHEMICAL$, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better @GENE$ inhibition effect over GW660511X as no NEP activity was found.	0
Unlike @CHEMICAL$, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no @GENE$ activity was found.	0
Unlike GW660511X, @CHEMICAL$ abolished the production of @GENE$ and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	2
Unlike GW660511X, @CHEMICAL$ abolished the production of BrBK1-5 and @GENE$, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	2
Unlike GW660511X, @CHEMICAL$ abolished the production of BrBK1-5 and BrBK1-7, suggesting a better @GENE$ inhibition effect over GW660511X as no NEP activity was found.	2
Unlike GW660511X, @CHEMICAL$ abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no @GENE$ activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @CHEM-GENE$ and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @CHEMICAL$ and @GENE$, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @CHEMICAL$ and BrBK1-7, suggesting a better @GENE$ inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @CHEMICAL$ and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no @GENE$ activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @GENE$ and @CHEMICAL$, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and @CHEM-GENE$, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and @CHEMICAL$, suggesting a better @GENE$ inhibition effect over GW660511X as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and @CHEMICAL$, suggesting a better ACE inhibition effect over GW660511X as no @GENE$ activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of @GENE$ and BrBK1-7, suggesting a better ACE inhibition effect over @CHEMICAL$ as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and @GENE$, suggesting a better ACE inhibition effect over @CHEMICAL$ as no NEP activity was found.	0
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better @GENE$ inhibition effect over @CHEMICAL$ as no NEP activity was found.	2
Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over @CHEMICAL$ as no @GENE$ activity was found.	0
In addition the production of @CHEM-GENE$ was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat.	0
In addition the production of @GENE$ was enhanced in the presence of these inhibitors with a greater accumulation being observed with @CHEMICAL$.	1
The production of @CHEM-GENE$ was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation.	0
The production of @GENE$ was reduced with @CHEMICAL$ while no significant change was observed with omapatrilat after 4 h of incubation.	2
The production of @GENE$ was reduced with GW660511X while no significant change was observed with @CHEMICAL$ after 4 h of incubation.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEM-GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @CHEMICAL$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEM-GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @CHEMICAL$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEM-GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @CHEMICAL$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEM-GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @CHEMICAL$ plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus @CHEMICAL$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEM-GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @CHEMICAL$, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, @CHEMICAL$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEM-GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @CHEMICAL$ and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and @CHEMICAL$ metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @CHEM-GENE$ metabolites not found in human plasma.	0
In rat plasma the @CHEM-GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the @CHEMICAL$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of @CHEMICAL$ (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or @CHEMICAL$ (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and BrBK was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
In rat plasma the @GENE$ half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEM-GENE$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into @GENE$, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, @GENE$, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, @GENE$ and Br-Phe5 plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and @GENE$ plus BrBK2-9, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus @GENE$, BrBK4-8 and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, @GENE$ and BrBK2-8 metabolites not found in human plasma.	0
In rat plasma the BrBK half-life values in the absence or in the presence of GW660511X (530 nM) or omapatrilat (50 nM) were 9.31 +/- 1.7, 22.06 +/- 3.1 and 25.3 +/- 1.7 min, respectively and @CHEMICAL$ was degraded into BrBK1-8, BrBK1-7, BrBK1-5 and Br-Phe5 plus BrBK2-9, BrBK4-8 and @GENE$ metabolites not found in human plasma.	0
@CHEMICAL$ and omapatrilat reduced the production of @GENE$ and BrBK1-7 with more effect being observed with omapatrilat.	2
@CHEMICAL$ and omapatrilat reduced the production of BrBK1-5 and @GENE$ with more effect being observed with omapatrilat.	2
GW660511X and @CHEMICAL$ reduced the production of @GENE$ and BrBK1-7 with more effect being observed with omapatrilat.	2
GW660511X and @CHEMICAL$ reduced the production of BrBK1-5 and @GENE$ with more effect being observed with omapatrilat.	2
GW660511X and omapatrilat reduced the production of @CHEM-GENE$ and BrBK1-7 with more effect being observed with omapatrilat.	0
GW660511X and omapatrilat reduced the production of @CHEMICAL$ and @GENE$ with more effect being observed with omapatrilat.	0
GW660511X and omapatrilat reduced the production of @GENE$ and @CHEMICAL$ with more effect being observed with omapatrilat.	0
GW660511X and omapatrilat reduced the production of BrBK1-5 and @CHEM-GENE$ with more effect being observed with omapatrilat.	0
GW660511X and omapatrilat reduced the production of @GENE$ and BrBK1-7 with more effect being observed with @CHEMICAL$.	2
GW660511X and omapatrilat reduced the production of BrBK1-5 and @GENE$ with more effect being observed with @CHEMICAL$.	2
@CHEMICAL$ and omapatrilat increased the production of both @GENE$ and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.	1
@CHEMICAL$ and omapatrilat increased the production of both BrBK1-8 and @GENE$ but not that of BrBK4-8 and BrBK2-8.	1
@CHEMICAL$ and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of @GENE$ and BrBK2-8.	0
@CHEMICAL$ and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and @GENE$.	0
GW660511X and @CHEMICAL$ increased the production of both @GENE$ and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.	1
GW660511X and @CHEMICAL$ increased the production of both BrBK1-8 and @GENE$ but not that of BrBK4-8 and BrBK2-8.	1
GW660511X and @CHEMICAL$ increased the production of both BrBK1-8 and Br-Phe5 but not that of @GENE$ and BrBK2-8.	0
GW660511X and @CHEMICAL$ increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and @GENE$.	0
GW660511X and omapatrilat increased the production of both @CHEM-GENE$ and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both @CHEMICAL$ and @GENE$ but not that of BrBK4-8 and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both @CHEMICAL$ and Br-Phe5 but not that of @GENE$ and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both @CHEMICAL$ and Br-Phe5 but not that of BrBK4-8 and @GENE$.	0
GW660511X and omapatrilat increased the production of both @GENE$ and @CHEMICAL$ but not that of BrBK4-8 and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and @CHEM-GENE$ but not that of BrBK4-8 and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and @CHEMICAL$ but not that of @GENE$ and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and @CHEMICAL$ but not that of BrBK4-8 and @GENE$.	0
GW660511X and omapatrilat increased the production of both @GENE$ and Br-Phe5 but not that of @CHEMICAL$ and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and @GENE$ but not that of @CHEMICAL$ and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of @CHEM-GENE$ and BrBK2-8.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of @CHEMICAL$ and @GENE$.	0
GW660511X and omapatrilat increased the production of both @GENE$ and Br-Phe5 but not that of BrBK4-8 and @CHEMICAL$.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and @GENE$ but not that of BrBK4-8 and @CHEMICAL$.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of @GENE$ and @CHEMICAL$.	0
GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and @CHEM-GENE$.	0
This study shows that the potency of @CHEMICAL$ in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of @GENE$/NEP inhibition in relation to effects in humans.	2
This study shows that the potency of @CHEMICAL$ in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/@GENE$ inhibition in relation to effects in humans.	2
This study shows that the potency of GW660511X in comparison with @CHEMICAL$ is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of @GENE$/NEP inhibition in relation to effects in humans.	0
This study shows that the potency of GW660511X in comparison with @CHEMICAL$ is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/@GENE$ inhibition in relation to effects in humans.	2
Efficacies and potencies of these ligands were determined relative to the endogenous ligand @GENE$ and the common mu agonist, @CHEMICAL$.	0
Acetylcholinesterase (@GENE$) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain @CHEMICAL$ (ACh) levels.	5
Acetylcholinesterase (AChE) predominates in the healthy brain, with @GENE$ (BuChE) considered to play a minor role in regulating brain @CHEMICAL$ (ACh) levels.	5
Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (@GENE$) considered to play a minor role in regulating brain @CHEMICAL$ (ACh) levels.	5
@GENE$ (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain @CHEMICAL$ (ACh) levels.	5
Acetylcholinesterase (@GENE$) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (@CHEMICAL$) levels.	5
Acetylcholinesterase (AChE) predominates in the healthy brain, with @GENE$ (BuChE) considered to play a minor role in regulating brain acetylcholine (@CHEMICAL$) levels.	5
Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (@GENE$) considered to play a minor role in regulating brain acetylcholine (@CHEMICAL$) levels.	5
@GENE$ (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (@CHEMICAL$) levels.	5
Experimental evidence from the use of agents with enhanced selectivity for @GENE$ (@CHEMICAL$ analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (@CHEMICAL$ analogues, MF-8622) and the dual inhibitor of both @GENE$ and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (@CHEMICAL$ analogues, MF-8622) and the dual inhibitor of both AChE and @GENE$, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (@CHEMICAL$ analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both @GENE$ and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (@CHEMICAL$ analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and @GENE$ in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for @GENE$ (cymserine analogues, @CHEMICAL$) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, @CHEMICAL$) and the dual inhibitor of both @GENE$ and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, @CHEMICAL$) and the dual inhibitor of both AChE and @GENE$, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, @CHEMICAL$) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both @GENE$ and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, @CHEMICAL$) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and @GENE$ in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for @GENE$ (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, @CHEMICAL$, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	0
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both @GENE$ and BuChE, @CHEMICAL$, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	2
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and @GENE$, @CHEMICAL$, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.	2
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, @CHEMICAL$, indicates potential therapeutic benefits of inhibiting both @GENE$ and BuChE in AD and related dementias.	2
Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, @CHEMICAL$, indicates potential therapeutic benefits of inhibiting both AChE and @GENE$ in AD and related dementias.	2
The development of specific @GENE$ inhibitors and further experience with the dual enzyme inhibitor @CHEMICAL$ will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.	2
A low toxicity maintenance regime, using @CHEMICAL$ and readily available drugs, for mantle cell lymphoma and other malignancies with excess @GENE$ levels.	0
Agents which have recently been shown to block @GENE$ translation by regulating calcium levels are the @CHEMICAL$, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.	2
Agents which have recently been shown to block @GENE$ translation by regulating calcium levels are the unsaturated essential fatty acid, @CHEMICAL$ (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.	2
Agents which have recently been shown to block @GENE$ translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (@CHEMICAL$), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.	2
Agents which have recently been shown to block @GENE$ translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic @CHEMICAL$, and the antifungal agent, clotrimazole.	2
Agents which have recently been shown to block @GENE$ translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, @CHEMICAL$.	2
Two types of agent which have been shown to inhibit angiogenesis are the teratogen, @CHEMICAL$, and the selective inhibitors of @GENE$ (COX-2).	0
Two types of agent which have been shown to inhibit angiogenesis are the teratogen, @CHEMICAL$, and the selective inhibitors of cyclo-oxygenase 2 (@GENE$).	0
@CHEM-GENE$ antagonist losartan and the defence reaction in the anaesthetised rat.	0
@GENE$ antagonist @CHEMICAL$ and the defence reaction in the anaesthetised rat.	4
@CHEM-GENE$ acting on angiotensin AT1 receptors at the central nervous system appears to have an important role in these modulatory processes.	0
@CHEMICAL$ acting on @GENE$ at the central nervous system appears to have an important role in these modulatory processes.	0
@GENE$ acting on @CHEMICAL$ AT1 receptors at the central nervous system appears to have an important role in these modulatory processes.	0
Angiotensin II acting on @CHEM-GENE$ at the central nervous system appears to have an important role in these modulatory processes.	0
The hypothalamic defence area (HDA) is a potential source of descending fibres containing @CHEM-GENE$ that innervate the NTS.	0
We investigated the effect of @GENE$ blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent @CHEMICAL$.	2
Defective processing of the @GENE$ in @CHEMICAL$-induced mouse colon tumors.	0
To determine the expression and activation status of @GENE$ in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either @CHEMICAL$ (AOM) (10 mg/kg body weight, once a week for 6 wk) or normal saline solution, and colon tumors were isolated 24 wk following the last injection.	0
To determine the expression and activation status of @GENE$ in chemically induced tumors, 6-wk-old A/J mice were injected intraperitoneally with either azoxymethane (@CHEMICAL$) (10 mg/kg body weight, once a week for 6 wk) or normal saline solution, and colon tumors were isolated 24 wk following the last injection.	0
With a fluorogenic peptide substrate for @CHEM-GENE$, a deficiency in plasmin activity was found in the tumors.	0
With a fluorogenic peptide substrate for @CHEMICAL$ proteases, a deficiency in @GENE$ activity was found in the tumors.	0
To gain further insight into the functionality of the @GENE$ pathway, cDNA microarrays were performed and the expression levels of a panel of 21 TGF-beta1-specific target genes were determined in @CHEMICAL$-induced tumors that overexpress the ligand.	0
To gain further insight into the functionality of the TGF-beta1 pathway, cDNA microarrays were performed and the expression levels of a panel of 21 @GENE$-specific target genes were determined in @CHEMICAL$-induced tumors that overexpress the ligand.	0
Binding and @CHEMICAL$ autoradiographic analysis of preproorphanin precursor peptide products at the @GENE$ and opioid receptors.	0
Binding and @CHEMICAL$ autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and @GENE$.	0
Binding and @CHEMICAL$ autoradiographic analysis of @GENE$ products at the ORL1 and opioid receptors.	0
Utilizing agonist-stimulated GTPgammaS autoradiography, we analyzed the ability of @GENE$ to stimulate @CHEMICAL$ binding in adult rat brain.	0
Utilizing agonist-stimulated @CHEMICAL$ autoradiography, we analyzed the ability of @GENE$ to stimulate [35S]-GTPgammaS binding in adult rat brain.	0
@GENE$ (OFQ) stimulated @CHEMICAL$ binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (@GENE$) stimulated @CHEMICAL$ binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (OFQ) stimulated @CHEMICAL$ binding in a pattern similar to that described for [125I]-@GENE$ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (OFQ) stimulated @CHEMICAL$ binding in a pattern similar to that described for [125I]-OFQ at the endogenous @GENE$.	0
@GENE$ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [@CHEMICAL$]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (@GENE$) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [@CHEMICAL$]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [@CHEMICAL$]-@GENE$ at the endogenous opioid receptor-like (ORL1) receptor.	0
Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [@CHEMICAL$]-OFQ at the endogenous @GENE$.	0
Unlike @GENE$, high concentrations of its @CHEMICAL$-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.	0
Unlike OFQ II(1-17), high concentrations of its @CHEMICAL$-terminal extension, @GENE$, stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.	0
Unlike OFQ II(1-17), high concentrations of its @CHEMICAL$-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a @GENE$-like distribution and the effect was blocked by naloxone.	0
Unlike @GENE$, high concentrations of its C-terminal extension, OFQ II(1-28), stimulated @CHEMICAL$ binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.	0
Unlike OFQ II(1-17), high concentrations of its C-terminal extension, @GENE$, stimulated @CHEMICAL$ binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.	0
Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated @CHEMICAL$ binding in a @GENE$-like distribution and the effect was blocked by naloxone.	0
Unlike @GENE$, high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by @CHEMICAL$.	0
Unlike OFQ II(1-17), high concentrations of its C-terminal extension, @GENE$, stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by @CHEMICAL$.	0
Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a @GENE$-like distribution and the effect was blocked by @CHEMICAL$.	0
Taken together, these findings support the view that (1) @GENE$ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate @CHEMICAL$ binding in cells expressing the mu opioid receptor.	0
Taken together, these findings support the view that (1) OFQ is the only @GENE$ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate @CHEMICAL$ binding in cells expressing the mu opioid receptor.	0
Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the @GENE$ receptor and (2) OFQ II(1-28) does not bind or stimulate @CHEMICAL$ binding in cells expressing the mu opioid receptor.	0
Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) @GENE$ does not bind or stimulate @CHEMICAL$ binding in cells expressing the mu opioid receptor.	0
Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate @CHEMICAL$ binding in cells expressing the @GENE$.	0
Tethered dimers as @CHEM-GENE$ inhibitors with antibacterial activity.	0
The solution-phase parallel synthesis of tethered dimers was employed to identify lead inhibitors of @CHEM-GENE$.	0
Effective inhibitors of @CHEM-GENE$ also inhibited the growth of Gram-positive (but not Gram-negative) bacteria, including antibiotic-resistant strains.	0
These results are consistent with the premise that @CHEMICAL$ synthetase inhibition is responsible for the antibacterial actions and support further studies on @GENE$ as a new target for antibacterial agents.	0
These results are consistent with the premise that @CHEM-GENE$ inhibition is responsible for the antibacterial actions and support further studies on NAD synthetase as a new target for antibacterial agents.	0
These results are consistent with the premise that NAD synthetase inhibition is responsible for the antibacterial actions and support further studies on @CHEM-GENE$ as a new target for antibacterial agents.	0
These results are consistent with the premise that @GENE$ inhibition is responsible for the antibacterial actions and support further studies on @CHEMICAL$ synthetase as a new target for antibacterial agents.	0
Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and @CHEM-GENE$ inhibition in human eosinophils.	0
Blockade of LTC4 synthesis caused by additive inhibition of @GENE$ phosphorylation: Effect of salmeterol and @CHEMICAL$ inhibition in human eosinophils.	0
Blockade of @CHEMICAL$ synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and @GENE$ inhibition in human eosinophils.	0
Blockade of @CHEMICAL$ synthesis caused by additive inhibition of @GENE$ phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.	5
Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of @CHEMICAL$ and @GENE$ inhibition in human eosinophils.	0
Blockade of LTC4 synthesis caused by additive inhibition of @GENE$ phosphorylation: Effect of @CHEMICAL$ and PDE4 inhibition in human eosinophils.	0
However, recent reports indicate that @CHEM-GENE$ activity in eosinophils is 10-fold that of other inflammatory cells.	0
However, recent reports indicate that @CHEM-GENE$ activity in eosinophils is 10-fold that of other inflammatory cells.	0
We postulated that selective blockade of @CHEM-GENE$ in eosinophils would unmask the inhibitory effect of beta(2)-adrenoceptor stimulation and that this inhibition would result from decreased phosphor-ylation of cytosolic group IV-PLA(2) (gIV-PLA(2)).	0
We postulated that selective blockade of @CHEMICAL$ in eosinophils would unmask the inhibitory effect of @GENE$ stimulation and that this inhibition would result from decreased phosphor-ylation of cytosolic group IV-PLA(2) (gIV-PLA(2)).	0
We postulated that selective blockade of @CHEMICAL$ in eosinophils would unmask the inhibitory effect of beta(2)-adrenoceptor stimulation and that this inhibition would result from decreased phosphor-ylation of @GENE$ (gIV-PLA(2)).	0
We postulated that selective blockade of @CHEMICAL$ in eosinophils would unmask the inhibitory effect of beta(2)-adrenoceptor stimulation and that this inhibition would result from decreased phosphor-ylation of cytosolic group IV-PLA(2) (@GENE$).	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous @CHEMICAL$ concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous @CHEMICAL$ concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous @CHEMICAL$ concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @CHEM-GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @CHEMICAL$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @CHEMICAL$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with @CHEMICAL$ blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	2
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with @CHEMICAL$ blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with @CHEMICAL$ blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of @CHEMICAL$ (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of @CHEMICAL$ (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of @CHEMICAL$ (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (@CHEMICAL$) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (@CHEMICAL$) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (@CHEMICAL$) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and @CHEMICAL$ (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and @CHEMICAL$ (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and @CHEMICAL$ (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (@CHEMICAL$) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (@CHEMICAL$) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (@CHEMICAL$) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of @CHEMICAL$ and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of @CHEMICAL$ and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of @CHEMICAL$ and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with @CHEMICAL$ plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with @CHEMICAL$ plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with @CHEMICAL$ plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus @CHEMICAL$ (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus @CHEMICAL$ (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus @CHEMICAL$ (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @CHEMICAL$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @CHEM-GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @CHEMICAL$ inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and @CHEMICAL$ synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and @CHEMICAL$ synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and @CHEMICAL$ synthesis is regulated by cAMP.	0
OBJECTIVE: To determine (a) whether @GENE$ inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by @CHEMICAL$.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if @GENE$ inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by @CHEMICAL$.	0
OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus @GENE$ agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by @CHEMICAL$.	0
Release of @CHEMICAL$ and LTC(4), intracellular cAMP concentration, and phosphorylation and activation of @GENE$ were determined.	0
Release of AA and @CHEMICAL$, intracellular cAMP concentration, and phosphorylation and activation of @GENE$ were determined.	0
Release of AA and LTC(4), intracellular @CHEMICAL$ concentration, and phosphorylation and activation of @GENE$ were determined.	0
RESULTS: @CHEMICAL$ unmasked the inhibitory effect of @GENE$ stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4).	0
RESULTS: Rolipram unmasked the inhibitory effect of @GENE$ stimulation with @CHEMICAL$ and significantly attenuated the stimulated release of AA and subsequent LTC(4).	1
RESULTS: Rolipram unmasked the inhibitory effect of @GENE$ stimulation with salmeterol and significantly attenuated the stimulated release of @CHEMICAL$ and subsequent LTC(4).	0
RESULTS: Rolipram unmasked the inhibitory effect of @GENE$ stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent @CHEMICAL$.	0
Inhibition corresponded to increased @CHEMICAL$ production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of @GENE$ in FMLP/B-activated eosinophils.	0
Inhibition corresponded to increased cAMP production caused by @CHEMICAL$ alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of @GENE$ in FMLP/B-activated eosinophils.	0
Inhibition corresponded to increased cAMP production caused by rolipram alone or @CHEMICAL$ plus salmeterol and blocked proportionately the phosphorylation and activation of @GENE$ in FMLP/B-activated eosinophils.	2
Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus @CHEMICAL$ and blocked proportionately the phosphorylation and activation of @GENE$ in FMLP/B-activated eosinophils.	2
CONCLUSIONS: Inhibition of @CHEM-GENE$ by rolipram unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.	0
CONCLUSIONS: Inhibition of @CHEMICAL$ by rolipram unmasks @GENE$ blockade of LTC(4) synthesis caused by FMLP/B.	0
CONCLUSIONS: Inhibition of @GENE$ by @CHEMICAL$ unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.	2
CONCLUSIONS: Inhibition of PDE4 by @CHEMICAL$ unmasks @GENE$ blockade of LTC(4) synthesis caused by FMLP/B.	0
CONCLUSIONS: Inhibition of @GENE$ by rolipram unmasks beta(2)-adrenergic blockade of @CHEMICAL$ synthesis caused by FMLP/B.	0
CONCLUSIONS: Inhibition of PDE4 by rolipram unmasks @GENE$ blockade of @CHEMICAL$ synthesis caused by FMLP/B.	0
Tazarotene is an acetylenic retinoid which is metabolised to @CHEMICAL$ and which binds selectively to the @GENE$ RARbeta and RARgamma.	0
Tazarotene is an acetylenic retinoid which is metabolised to @CHEMICAL$ and which binds selectively to the retinoid receptors @GENE$ and RARgamma.	0
Tazarotene is an acetylenic retinoid which is metabolised to @CHEMICAL$ and which binds selectively to the retinoid receptors RARbeta and @GENE$.	0
@CHEMICAL$ is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the @GENE$ RARbeta and RARgamma.	0
@CHEMICAL$ is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors @GENE$ and RARgamma.	0
@CHEMICAL$ is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and @GENE$.	0
Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the @CHEM-GENE$ RARbeta and RARgamma.	0
Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the @CHEMICAL$ receptors @GENE$ and RARgamma.	0
Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the @CHEMICAL$ receptors RARbeta and @GENE$.	0
Tazarotene is an @CHEMICAL$ which is metabolised to tazarotenic acid and which binds selectively to the @GENE$ RARbeta and RARgamma.	0
Tazarotene is an @CHEMICAL$ which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors @GENE$ and RARgamma.	0
Tazarotene is an @CHEMICAL$ which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and @GENE$.	0
Anabolic effects of @CHEMICAL$ on skeletal muscle are mediated by @GENE$ activation.	1
The potent anabolic effects of the beta 2-adrenoceptor agonist @CHEMICAL$ on skeletal muscle have been reported to be independent of actions on @GENE$.	0
The potent anabolic effects of the @GENE$ agonist @CHEMICAL$ on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.	3
These effects were not mimicked by oral administration of the @GENE$ agonist @CHEMICAL$ even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).	3
These effects were not mimicked by oral administration of the @GENE$ agonist salbutamol even at high dose (52 mg/kg diet), and the effects of @CHEMICAL$ were not inhibited by addition of DL-propranolol (200 mg/kg diet).	3
These effects were not mimicked by oral administration of the @GENE$ agonist salbutamol even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of @CHEMICAL$ (200 mg/kg diet).	0
These results indicate that the anabolic effects of @CHEMICAL$ are dependent on interaction with the @GENE$.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, @CHEMICAL$, was abolished by the @GENE$ antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, @CHEMICAL$, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent @GENE$ antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, @CHEMICAL$, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential @GENE$ antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the @GENE$ agonist, @CHEMICAL$, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	3
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the @GENE$ antagonist, @CHEMICAL$, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	4
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, @CHEMICAL$, the potent @GENE$ antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, @CHEMICAL$, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential @GENE$ antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the @GENE$ agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, @CHEMICAL$, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the @GENE$ antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, @CHEMICAL$ and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent @GENE$ antagonist, @CHEMICAL$ and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	4
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, @CHEMICAL$ and the preferential @GENE$ antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the @GENE$ agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, @CHEMICAL$ and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the @GENE$ antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, @CHEMICAL$.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent @GENE$ antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, @CHEMICAL$.	0
In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential @GENE$ antagonist, @CHEMICAL$.	4
In the hot-plate test in mice, the antinociceptive action of the @GENE$ agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, @CHEMICAL$.	0
In contrast, the preferential @GENE$ ligands ('antagonists'), @CHEMICAL$, BRL 41992 and prazosin were inactive.	0
In contrast, the preferential @GENE$ ligands ('antagonists'), ARC-239, @CHEMICAL$ and prazosin were inactive.	0
In contrast, the preferential @GENE$ ligands ('antagonists'), ARC-239, BRL 41992 and @CHEMICAL$ were inactive.	0
The preferential @GENE$ partial agonist, @CHEMICAL$, partially inhibited UK 14,304-induced antinociception.	3
The preferential @GENE$ partial agonist, guanfacine, partially inhibited @CHEMICAL$-induced antinociception.	3
Crystal structure of @CHEM-GENE$ from rat liver.	0
@GENE$ (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of @CHEMICAL$ to yield pyruvate and ammonia.	5
SDH (L-serine dehydratase, @GENE$) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of @CHEMICAL$ to yield pyruvate and ammonia.	5
SDH @GENE$, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of @CHEMICAL$ to yield pyruvate and ammonia.	5
@GENE$ (@CHEMICAL$ dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH (@CHEMICAL$ dehydratase, @GENE$) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH @CHEM-GENE$, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
@GENE$ (L-serine dehydratase, EC 4.3.1.17) catalyzes the @CHEMICAL$ (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH (L-serine dehydratase, @GENE$) catalyzes the @CHEMICAL$ (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH @GENE$, EC 4.3.1.17) catalyzes the @CHEMICAL$ (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
@GENE$ (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield @CHEMICAL$ and ammonia.	5
SDH (L-serine dehydratase, @GENE$) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield @CHEMICAL$ and ammonia.	5
SDH @GENE$, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield @CHEMICAL$ and ammonia.	5
@GENE$ (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (@CHEMICAL$)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH (L-serine dehydratase, @GENE$) catalyzes the pyridoxal 5'-phosphate (@CHEMICAL$)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
SDH @GENE$, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (@CHEMICAL$)-dependent dehydration of L-serine to yield pyruvate and ammonia.	0
@GENE$ (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and @CHEMICAL$.	5
SDH (L-serine dehydratase, @GENE$) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and @CHEMICAL$.	5
SDH @GENE$, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and @CHEMICAL$.	5
Formation of @CHEMICAL$ by @GENE$ is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.	5
Formation of pyruvate by @GENE$ is a two-step reaction in which the @CHEMICAL$ group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.	0
Formation of pyruvate by @GENE$ is a two-step reaction in which the hydroxyl group of @CHEMICAL$ is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.	0
Formation of pyruvate by @GENE$ is a two-step reaction in which the hydroxyl group of serine is cleaved to produce @CHEMICAL$, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate.	5
Formation of pyruvate by @GENE$ is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the @CHEMICAL$ is deaminated by nonenzymatic hydrolysis to produce pyruvate.	0
Formation of pyruvate by @GENE$ is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce @CHEMICAL$.	5
The @GENE$ crystallized with @CHEMICAL$ (OMS) was also determined at 2.6 A resolution by molecular replacement.	0
The @GENE$ crystallized with O-methylserine (@CHEMICAL$) was also determined at 2.6 A resolution by molecular replacement.	0
The @GENE$ contained PLP-OMS @CHEMICAL$ in the active site, indicating that OMS can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.	0
The @GENE$ contained PLP-OMS aldimine in the active site, indicating that @CHEMICAL$ can form the Schiff base linkage with PLP, but the subsequent dehydration did not occur.	0
The @GENE$ contained PLP-OMS aldimine in the active site, indicating that OMS can form the @CHEMICAL$ linkage with PLP, but the subsequent dehydration did not occur.	0
The @GENE$ contained PLP-OMS aldimine in the active site, indicating that OMS can form the Schiff base linkage with @CHEMICAL$, but the subsequent dehydration did not occur.	0
The phosphate group of @CHEMICAL$ is surrounded by a characteristic @GENE$ ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of @CHEMICAL$ is surrounded by a characteristic G-rich sequence ((168)@GENE$(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic @GENE$ ((168)@CHEMICAL$(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)@CHEM-GENE$(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic @GENE$ ((168)GGGGL(172)) and forms @CHEMICAL$ bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)@GENE$(172)) and forms @CHEMICAL$ bonds with the amide groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic @GENE$ ((168)GGGGL(172)) and forms hydrogen bonds with the @CHEMICAL$ groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)@GENE$(172)) and forms hydrogen bonds with the @CHEMICAL$ groups of those amino acid residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic @GENE$ ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those @CHEMICAL$ residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)@GENE$(172)) and forms hydrogen bonds with the amide groups of those @CHEMICAL$ residues, suggesting that the phosphate group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic @GENE$ ((168)GGGGL(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the @CHEMICAL$ group can be protonated.	0
The phosphate group of PLP is surrounded by a characteristic G-rich sequence ((168)@GENE$(172)) and forms hydrogen bonds with the amide groups of those amino acid residues, suggesting that the @CHEMICAL$ group can be protonated.	0
These characteristics of the bound @CHEMICAL$ suggest that @GENE$ catalysis is not facilitated by forming the resonance-stabilized structure of the PLP-Ser aldimine as seen in aminotransferases.	0
These characteristics of the bound @CHEMICAL$ suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the PLP-Ser aldimine as seen in @GENE$.	0
These characteristics of the bound PLP suggest that @GENE$ catalysis is not facilitated by forming the resonance-stabilized structure of the @CHEMICAL$ as seen in aminotransferases.	0
These characteristics of the bound PLP suggest that SDH catalysis is not facilitated by forming the resonance-stabilized structure of the @CHEMICAL$ as seen in @GENE$.	0
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that @GENE$-dependent signaling pathways involved in radioresistance include those mediated by @CHEMICAL$ 3'-kinase (PI3-K) and Raf.	0
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by @CHEM-GENE$ (PI3-K) and Raf.	0
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by @CHEMICAL$ 3'-kinase (@GENE$) and Raf.	0
Although not all of the signaling pathways for radioresistance are well defined, it is now clear that Ras-dependent signaling pathways involved in radioresistance include those mediated by @CHEMICAL$ 3'-kinase (PI3-K) and @GENE$.	0
Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) @CHEMICAL$ decreased the postradiation survival of irradiated @GENE$-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	2
Blocking @GENE$ signaling with the EGFR/HER-2 kinase inhibitor (KI) @CHEMICAL$ decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	2
Blocking EGFR signaling with the @GENE$/HER-2 kinase inhibitor (KI) @CHEMICAL$ decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	2
Blocking EGFR signaling with the EGFR/@GENE$ kinase inhibitor (KI) @CHEMICAL$ decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.	2
@GENE$-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by @CHEMICAL$.	0
Ras-CM and @GENE$ also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by @CHEMICAL$.	0
Ras-CM and TGF-alpha also increase @GENE$ activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by @CHEMICAL$.	2
Ras-CM and TGF-alpha also increase PI3-K activity downstream of the @GENE$ and increase postradiation survival, both of which are abrogated by @CHEMICAL$.	2
Thus, @GENE$ utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI @CHEMICAL$ acts as a radiosensitizer.	2
Thus, Ras utilizes autocrine signaling through @GENE$ to increase radioresistance, and the EGFR KI @CHEMICAL$ acts as a radiosensitizer.	0
Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the @GENE$ KI @CHEMICAL$ acts as a radiosensitizer.	2
The observation that @GENE$-transformed cells can be sensitized to killing by ionizing radiation with @CHEMICAL$ demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.	2
The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with @CHEMICAL$ demonstrates that @GENE$ KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.	2
The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with @CHEMICAL$ demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on @GENE$-driven autocrine signaling through EGFR.	0
The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with @CHEMICAL$ demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through @GENE$.	0
@CHEMICAL$ and a nonconventional @GENE$ agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.	0
(-)-Isoprenaline and a nonconventional @GENE$ agonist, @CHEMICAL$ ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.	3
(-)-Isoprenaline and a nonconventional @GENE$ agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride (@CHEMICAL$), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.	3
(-)-Isoprenaline and a nonconventional @GENE$ agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of @CHEMICAL$ (0.3 microM) preconstricted spiral preparations.	0
Pretreatment with a combination of @CHEMICAL$ (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of @CHEMICAL$ (CGP20712A, a selective @GENE$ antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	4
Pretreatment with a combination of @CHEMICAL$ (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (@CHEMICAL$, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (@CHEMICAL$, a selective @GENE$ antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	4
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (@CHEMICAL$, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and @CHEMICAL$ (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective @GENE$ antagonist) and @CHEMICAL$ (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and @CHEMICAL$ (ICI-118,5511, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	4
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (@CHEMICAL$, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective @GENE$ antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (@CHEMICAL$, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (@CHEMICAL$, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	4
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for @CHEMICAL$; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective @GENE$ antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for @CHEMICAL$; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for @CHEMICAL$; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to @CHEMICAL$ was unaffected by the blockade of @GENE$.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective @GENE$ antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to @CHEMICAL$ was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective @GENE$ antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to @CHEMICAL$ was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.	0
In the presence of @CHEMICAL$ and ICI-118,551 (0.1 microM for each), the concentration-response curves for (-)-isoprenaline and (+/-)-CGP12177A were shifted to the right by a nonselective @GENE$ antagonist, (+/-)-bupranolol (3 and 10 microM).	0
In the presence of CGP20712A and @CHEMICAL$ (0.1 microM for each), the concentration-response curves for (-)-isoprenaline and (+/-)-CGP12177A were shifted to the right by a nonselective @GENE$ antagonist, (+/-)-bupranolol (3 and 10 microM).	0
In the presence of CGP20712A and ICI-118,551 (0.1 microM for each), the concentration-response curves for @CHEMICAL$ and (+/-)-CGP12177A were shifted to the right by a nonselective @GENE$ antagonist, (+/-)-bupranolol (3 and 10 microM).	0
In the presence of CGP20712A and ICI-118,551 (0.1 microM for each), the concentration-response curves for (-)-isoprenaline and @CHEMICAL$ were shifted to the right by a nonselective @GENE$ antagonist, (+/-)-bupranolol (3 and 10 microM).	0
In the presence of CGP20712A and ICI-118,551 (0.1 microM for each), the concentration-response curves for (-)-isoprenaline and (+/-)-CGP12177A were shifted to the right by a nonselective @GENE$ antagonist, @CHEMICAL$ (3 and 10 microM).	0
Use of the @CHEM-GENE$ as a reporter gene for non-invasive imaging of genetically modified cells.	0
BACKGROUND: The @CHEM-GENE$ (NET) is a high-affinity transporter for catecholamines.	0
BACKGROUND: The @CHEMICAL$ transporter (@GENE$) is a high-affinity transporter for catecholamines.	0
BACKGROUND: The @GENE$ (NET) is a high-affinity transporter for @CHEMICAL$.	0
BACKGROUND: The norepinephrine transporter (@GENE$) is a high-affinity transporter for @CHEMICAL$.	0
The specificity of tracer uptake was determined by adding the @GENE$ inhibitor @CHEMICAL$.	2
Parental and A431@GENE$ cells were xenotransplanted into nude mice and tumor uptake of @CHEMICAL$ in vivo was determined after tracer administration.	0
@CHEMICAL$ uptake in PC12 cells, which express the @GENE$ endogenously, was 20- to 28-fold lower than in transduced cells.	5
In vivo, A431@GENE$ tumors demonstrated a 33-fold higher @CHEMICAL$ uptake than parental tumors.	5
CONCLUSIONS: Transduction of tumor cells with @GENE$ cDNA causes highly specific uptake and significant retention of @CHEMICAL$ analogs in vitro and in vivo.	0
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, @CHEMICAL$, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, @CHEMICAL$) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (@CHEMICAL$, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, @CHEMICAL$, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, @CHEMICAL$, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, @CHEMICAL$, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, @CHEMICAL$, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, @CHEMICAL$, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, @CHEMICAL$, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, @CHEMICAL$, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, @CHEMICAL$, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, @CHEMICAL$, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, @CHEMICAL$, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, @CHEMICAL$) at all three subtypes of @GENE$ in an identical cellular background.	4
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (@CHEMICAL$, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, @CHEMICAL$, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, @CHEMICAL$, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, @CHEMICAL$, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, @CHEMICAL$, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, @CHEMICAL$, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, @CHEMICAL$, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of @GENE$ in an identical cellular background.	3
Furthermore, we analyzed the @GENE$-mediated @CHEMICAL$ cyclase activity in isolated membranes from these cell lines.	0
Furthermore, we analyzed the beta-receptor-mediated @CHEM-GENE$ activity in isolated membranes from these cell lines.	0
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at @GENE$ and other @CHEMICAL$ receptors in cultured cells.	0
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other @CHEM-GENE$ in cultured cells.	0
Ocular hypotensive FP prostaglandin (PG) analogs: @GENE$ subtype binding affinities and selectivities, and agonist potencies at FP and other @CHEMICAL$ receptors in cultured cells.	0
Ocular hypotensive FP @CHEMICAL$ (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at @GENE$ and other PG receptors in cultured cells.	0
Ocular hypotensive FP @CHEMICAL$ (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other @GENE$ in cultured cells.	0
Ocular hypotensive FP @CHEMICAL$ (PG) analogs: @GENE$ subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.	0
Ocular hypotensive FP prostaglandin (@CHEMICAL$) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at @GENE$ and other PG receptors in cultured cells.	0
Ocular hypotensive FP prostaglandin (@CHEMICAL$) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other @GENE$ in cultured cells.	0
Ocular hypotensive FP prostaglandin (@CHEMICAL$) analogs: @GENE$ subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.	0
Ocular hypotensive FP prostaglandin (PG) analogs: @CHEMICAL$ receptor subtype binding affinities and selectivities, and agonist potencies at @GENE$ and other PG receptors in cultured cells.	0
Ocular hypotensive FP prostaglandin (PG) analogs: @CHEMICAL$ receptor subtype binding affinities and selectivities, and agonist potencies at FP and other @GENE$ in cultured cells.	0
Ocular hypotensive FP prostaglandin (PG) analogs: @CHEM-GENE$ subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.	0
@CHEMICAL$ ([+]-fluprostenol) was the most @GENE$-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the @GENE$, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for @GENE$ (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), @GENE$ (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), @GENE$ (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), @GENE$ (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), @GENE$ (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and @GENE$ (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most @GENE$-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the @GENE$, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for @GENE$ (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), @GENE$ (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), @GENE$ (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), @GENE$ (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), @GENE$ (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors.	0
Travoprost acid (@CHEMICAL$) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and @GENE$ (Ki = 121,000 nM) receptors.	0
@CHEMICAL$ was the most potent PG analog tested in @GENE$ functional phosphoinositide turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	0
Travoprost acid was the most potent @CHEMICAL$ analog tested in @GENE$ functional phosphoinositide turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	0
Travoprost acid was the most potent PG analog tested in @GENE$ functional @CHEMICAL$ turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM).	0
Although @CHEMICAL$ exhibited a relatively high affinity for the @GENE$ (Ki = 98 nM), it had significant functional activity at FP (EC50 = 32-124 nM) and EP1 (EC50 = 119 nM) receptors.	0
Although @CHEMICAL$ exhibited a relatively high affinity for the FP receptor (Ki = 98 nM), it had significant functional activity at @GENE$ (EC50 = 32-124 nM) and EP1 (EC50 = 119 nM) receptors.	0
Although @CHEMICAL$ exhibited a relatively high affinity for the FP receptor (Ki = 98 nM), it had significant functional activity at FP (EC50 = 32-124 nM) and @GENE$ (EC50 = 119 nM) receptors.	0
@CHEMICAL$ was less selective, exhibiting a relatively high affinity for the @GENE$ (Ki = 83 nM), EP1 (Ki = 95 nM), and EP3 (Ki = 387 nM) receptors.	0
@CHEMICAL$ was less selective, exhibiting a relatively high affinity for the FP (Ki = 83 nM), @GENE$ (Ki = 95 nM), and EP3 (Ki = 387 nM) receptors.	0
@CHEMICAL$ was less selective, exhibiting a relatively high affinity for the FP (Ki = 83 nM), EP1 (Ki = 95 nM), and @GENE$ (Ki = 387 nM) receptors.	0
@CHEMICAL$ exhibited functional activity at the @GENE$ (EC50 = 2.7 nM) and FP (EC50 = 2.8-3.8 nM in most cells) receptors.	0
@CHEMICAL$ exhibited functional activity at the EP1 (EC50 = 2.7 nM) and @GENE$ (EC50 = 2.8-3.8 nM in most cells) receptors.	0
@CHEMICAL$ (nonhydrolyzed amide) also behaved as an @GENE$ agonist at the cloned human FP receptor (EC50 = 681 nM), in h-TM (EC50 = 3245 nM) and other cell types.	0
@CHEMICAL$ (nonhydrolyzed amide) also behaved as an FP agonist at the cloned @GENE$ (EC50 = 681 nM), in h-TM (EC50 = 3245 nM) and other cell types.	0
@CHEMICAL$ and S-1033 bound with low affinity (Ki = 5.9 microM to > 22 microM) to the @GENE$, were not selective, but activated the FP receptor.	0
@CHEMICAL$ and S-1033 bound with low affinity (Ki = 5.9 microM to > 22 microM) to the FP receptor, were not selective, but activated the @GENE$.	0
Unoprostone and @CHEMICAL$ bound with low affinity (Ki = 5.9 microM to > 22 microM) to the @GENE$, were not selective, but activated the FP receptor.	0
Unoprostone and @CHEMICAL$ bound with low affinity (Ki = 5.9 microM to > 22 microM) to the FP receptor, were not selective, but activated the @GENE$.	0
In conclusion, @CHEMICAL$ has the highest affinity, the highest @GENE$-selectivity, and the highest potency at the FP receptor as compared to the other ocular hypotensive PG analogs known so far, including free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester.	0
In conclusion, @CHEMICAL$ has the highest affinity, the highest FP-receptor-selectivity, and the highest potency at the @GENE$ as compared to the other ocular hypotensive PG analogs known so far, including free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester.	0
In conclusion, travoprost acid has the highest affinity, the highest @GENE$-selectivity, and the highest potency at the FP receptor as compared to the other ocular hypotensive PG analogs known so far, including @CHEMICAL$.	0
In conclusion, travoprost acid has the highest affinity, the highest FP-receptor-selectivity, and the highest potency at the @GENE$ as compared to the other ocular hypotensive PG analogs known so far, including @CHEMICAL$.	0
Loss of beta-adrenoceptor response in myocytes overexpressing the @CHEM-GENE$.	0
Loss of @GENE$ response in myocytes overexpressing the @CHEMICAL$/Ca(2+)-exchanger.	0
Loss of beta-adrenoceptor response in myocytes overexpressing the @CHEM-GENE$.	0
Loss of @GENE$ response in myocytes overexpressing the Na+/@CHEMICAL$-exchanger.	0
Increased @CHEMICAL$/Ca(2+)-exchanger (@GENE$) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart.	0
Increased @CHEMICAL$/Ca(2+)-exchanger (NCX) and altered @GENE$ (betaAR) responses are observed in failing human heart.	0
Increased @CHEMICAL$/Ca(2+)-exchanger (NCX) and altered beta-adrenoceptor (@GENE$) responses are observed in failing human heart.	0
Increased @CHEM-GENE$ (NCX) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart.	0
Increased Na+/@CHEMICAL$-exchanger (@GENE$) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart.	0
Increased Na+/@CHEMICAL$-exchanger (NCX) and altered @GENE$ (betaAR) responses are observed in failing human heart.	0
Increased Na+/@CHEMICAL$-exchanger (NCX) and altered beta-adrenoceptor (@GENE$) responses are observed in failing human heart.	0
Increased @CHEM-GENE$ (NCX) and altered beta-adrenoceptor (betaAR) responses are observed in failing human heart.	0
Responses to @CHEMICAL$ were largely mediated through the @GENE$ in control myocytes.	0
Adenovirally-mediated overexpression of @GENE$, at levels, which did not alter basal contraction of myocytes, markedly depressed the @CHEMICAL$ concentration-response curve.	0
Responses to @CHEMICAL$ could be restored to normal by @GENE$ blockade, suggesting a beta2AR-mediated inhibition of beta1AR signalling.	0
Responses to @CHEMICAL$ could be restored to normal by beta2AR blockade, suggesting a @GENE$-mediated inhibition of beta1AR signalling.	0
Responses to @CHEMICAL$ could be restored to normal by beta2AR blockade, suggesting a beta2AR-mediated inhibition of @GENE$ signalling.	0
@GENE$ normalised @CHEMICAL$ responses in NCX cells, indicating that beta2AR effects were mediated by Gi.	0
Pertussis toxin normalised @CHEMICAL$ responses in @GENE$ cells, indicating that beta2AR effects were mediated by Gi.	0
Pertussis toxin normalised @CHEMICAL$ responses in NCX cells, indicating that @GENE$ effects were mediated by Gi.	0
Pertussis toxin normalised @CHEMICAL$ responses in NCX cells, indicating that beta2AR effects were mediated by @GENE$.	0
Manipulation of kinetic profiles in @CHEMICAL$ @GENE$ inhibitors.	2
The nonsteroidal anti-inflammatory drugs @CHEMICAL$ and ibuprofen were modified in an attempt to alter the kinetics of inhibitor binding by @GENE$.	0
The nonsteroidal anti-inflammatory drugs flurbiprofen and @CHEMICAL$ were modified in an attempt to alter the kinetics of inhibitor binding by @GENE$.	0
Effects of the @GENE$/HER2 kinase inhibitor @CHEMICAL$ on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	2
Effects of the EGFR/@GENE$ kinase inhibitor @CHEMICAL$ on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	2
Effects of the EGFR/HER2 @GENE$ inhibitor @CHEMICAL$ on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	2
Effects of the EGFR/HER2 kinase inhibitor @CHEMICAL$ on @GENE$- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	0
Effects of the EGFR/HER2 kinase inhibitor @CHEMICAL$ on EGFR- and @GENE$-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.	0
To gauge the potential clinical utility of targeting both @GENE$ and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, @CHEMICAL$, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.	0
To gauge the potential clinical utility of targeting both EGFR and @GENE$ to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, @CHEMICAL$, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.	0
To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual @GENE$/HER2 inhibitor, @CHEMICAL$, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.	2
To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/@GENE$ inhibitor, @CHEMICAL$, on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.	2
To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, @CHEMICAL$, on the proliferation and radiation response of either @GENE$- or HER2-overexpressing human breast cancer cell lines.	0
To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/HER2 inhibitor, @CHEMICAL$, on the proliferation and radiation response of either EGFR- or @GENE$-overexpressing human breast cancer cell lines.	0
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress @GENE$ or HER2 and luminal mammary epithelial H16N2 cells stably transfected with HER2 were evaluated for the effect of @CHEMICAL$ on inhibition of ligand-induced or constitutive receptor phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	0
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress EGFR or @GENE$ and luminal mammary epithelial H16N2 cells stably transfected with HER2 were evaluated for the effect of @CHEMICAL$ on inhibition of ligand-induced or constitutive receptor phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	0
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress EGFR or HER2 and luminal mammary epithelial H16N2 cells stably transfected with @GENE$ were evaluated for the effect of @CHEMICAL$ on inhibition of ligand-induced or constitutive receptor phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	0
METHODS AND MATERIALS: Primary human breast cancer cell lines that endogenously overexpress EGFR or HER2 and luminal mammary epithelial H16N2 cells stably transfected with HER2 were evaluated for the effect of @CHEMICAL$ on inhibition of ligand-induced or @GENE$ phosphorylation, proliferation, radiosensitization, and inhibition of downstream signaling.	0
RESULTS: GW572016 inhibited constitutive and/or ligand-induced @GENE$ or HER2 @CHEMICAL$ phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	0
RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or @GENE$ @CHEMICAL$ phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	0
RESULTS: @CHEMICAL$ inhibited constitutive and/or ligand-induced @GENE$ or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	2
RESULTS: @CHEMICAL$ inhibited constitutive and/or ligand-induced EGFR or @GENE$ tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.	2
@CHEMICAL$ radiosensitized @GENE$-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization.	0
@CHEMICAL$ radiosensitized EGFR-overexpressing cell lines, but @GENE$-overexpressing cells were unable to form colonies after brief exposure to GW572016 even in the absence of radiation, and thus could not be evaluated for radiosensitization.	0
GW572016 radiosensitized @GENE$-overexpressing cell lines, but HER2-overexpressing cells were unable to form colonies after brief exposure to @CHEMICAL$ even in the absence of radiation, and thus could not be evaluated for radiosensitization.	0
GW572016 radiosensitized EGFR-overexpressing cell lines, but @GENE$-overexpressing cells were unable to form colonies after brief exposure to @CHEMICAL$ even in the absence of radiation, and thus could not be evaluated for radiosensitization.	0
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of @CHEMICAL$ to inhibit downstream @GENE$ and Akt activation, despite inhibition of HER2 phosphorylation.	0
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of @CHEMICAL$ to inhibit downstream ERK and @GENE$ activation, despite inhibition of HER2 phosphorylation.	0
Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of @CHEMICAL$ to inhibit downstream ERK and Akt activation, despite inhibition of @GENE$ phosphorylation.	2
CONCLUSION: @CHEMICAL$ potently inhibits receptor phosphorylation in either @GENE$- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	2
CONCLUSION: @CHEMICAL$ potently inhibits receptor phosphorylation in either EGFR- or @GENE$-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.	2
Resistance to @CHEMICAL$ was not due to a lack of receptor inhibition, but rather with a lack of inhibition of @GENE$ and Akt, suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.	0
Resistance to @CHEMICAL$ was not due to a lack of receptor inhibition, but rather with a lack of inhibition of ERK and @GENE$, suggesting that measurement of inhibition of crucial signaling pathways may better predict response than inhibition of receptor phosphorylation.	0
CSF production in wildtype mice was (in microl/min) 0.37 +/- 0.04 microl/min (control), 0.16 +/- 0.03 microl/min (@CHEMICAL$-treated) and 1.14 +/- 0.15 microl/min (forskolin-treated), and reduced by up to 25% in @GENE$ null mice.	0
CSF production in wildtype mice was (in microl/min) 0.37 +/- 0.04 microl/min (control), 0.16 +/- 0.03 microl/min (acetazolamide-treated) and 1.14 +/- 0.15 microl/min (@CHEMICAL$-treated), and reduced by up to 25% in @GENE$ null mice.	0
@CHEMICAL$, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated @GENE$ secretion.	0
@CHEMICAL$, but not leptin, regulates @GENE$ in pancreatic islets: impact on glucose-stimulated insulin secretion.	0
Metformin, but not leptin, regulates @CHEMICAL$-activated protein kinase in pancreatic islets: impact on glucose-stimulated @GENE$ secretion.	0
Metformin, but not leptin, regulates @CHEM-GENE$ in pancreatic islets: impact on glucose-stimulated insulin secretion.	0
Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on @CHEMICAL$-stimulated @GENE$ secretion.	1
Metformin, but not leptin, regulates @GENE$ in pancreatic islets: impact on @CHEMICAL$-stimulated insulin secretion.	0
@CHEMICAL$, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of @GENE$ (AMPK).	1
@CHEMICAL$, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (@GENE$).	1
Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of @CHEM-GENE$ (AMPK).	0
Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of @CHEMICAL$-activated protein kinase (@GENE$).	0
Whether @CHEMICAL$ or the satiety factor leptin, which also stimulates @GENE$ in muscle, regulates this enzyme in pancreatic islets is unknown.	1
Here, we explore whether 1) @CHEMICAL$, metformin, or leptin regulates @GENE$ activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets.	0
Here, we explore whether 1) @CHEMICAL$, metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in @GENE$ activity modulate insulin secretion from human islets.	0
Here, we explore whether 1) @CHEMICAL$, metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate @GENE$ secretion from human islets.	0
Here, we explore whether 1) glucose, @CHEMICAL$, or leptin regulates @GENE$ activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets.	0
Here, we explore whether 1) glucose, @CHEMICAL$, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in @GENE$ activity modulate insulin secretion from human islets.	0
Here, we explore whether 1) glucose, @CHEMICAL$, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate @GENE$ secretion from human islets.	0
Increases in @CHEMICAL$ concentration from 0 to 3 and from 3 to 17 mM inhibited @GENE$ activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.	2
Incubation with @CHEMICAL$ (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of @GENE$ secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.	2
Incubation with @CHEMICAL$ (0.2-1 mM) activated @GENE$ in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.	1
These studies demonstrate that @GENE$ activity is subject to regulation by both @CHEMICAL$ and metformin in pancreatic islets and clonal beta-cells.	0
These studies demonstrate that @GENE$ activity is subject to regulation by both glucose and @CHEMICAL$ in pancreatic islets and clonal beta-cells.	0
The inhibitory effects of @CHEMICAL$ on @GENE$ secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.	2
A novel retinoic acid-responsive element regulates @CHEMICAL$-induced @GENE$ expression.	1
A novel @GENE$ regulates @CHEMICAL$-induced BLR1 expression.	0
A novel @CHEMICAL$-responsive element regulates retinoic acid-induced @GENE$ expression.	0
A novel @CHEM-GENE$ regulates retinoic acid-induced BLR1 expression.	0
RA is known to induce expression of the @GENE$ (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by @CHEMICAL$.	0
RA is known to induce expression of the Burkitt's lymphoma receptor 1 (@GENE$) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by @CHEMICAL$.	0
RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of @GENE$ expression by @CHEMICAL$.	1
@CHEMICAL$ is known to induce expression of the @GENE$ (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.	1
@CHEMICAL$ is known to induce expression of the Burkitt's lymphoma receptor 1 (@GENE$) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.	1
@CHEMICAL$ is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of @GENE$ expression by RA.	0
RA is known to induce expression of the @GENE$ (BLR1) gene which propels @CHEMICAL$-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.	0
RA is known to induce expression of the Burkitt's lymphoma receptor 1 (@GENE$) gene which propels @CHEMICAL$-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.	0
RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels @CHEMICAL$-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of @GENE$ expression by RA.	0
The @CHEMICAL$-treated HL-60 cells used here expressed all @GENE$ (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The @CHEMICAL$-treated HL-60 cells used here expressed all RA receptor (@GENE$) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The @CHEMICAL$-treated HL-60 cells used here expressed all RA receptor (RAR) and @GENE$ (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The @CHEMICAL$-treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (@GENE$) subtypes (as detected by Northern analysis) except RXRgamma.	0
The @CHEMICAL$-treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except @GENE$.	0
The RA-treated HL-60 cells used here expressed all @CHEM-GENE$ (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all @CHEMICAL$ receptor (@GENE$) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all @CHEMICAL$ receptor (RAR) and @GENE$ (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all @CHEMICAL$ receptor (RAR) and retinoid X receptor (@GENE$) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all @CHEMICAL$ receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except @GENE$.	0
The RA-treated HL-60 cells used here expressed all @GENE$ (RAR) and @CHEMICAL$ X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all RA receptor (@GENE$) and @CHEMICAL$ X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and @CHEM-GENE$ (RXR) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and @CHEMICAL$ X receptor (@GENE$) subtypes (as detected by Northern analysis) except RXRgamma.	0
The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and @CHEMICAL$ X receptor (RXR) subtypes (as detected by Northern analysis) except @GENE$.	0
A 5'-flanking region capable of supporting @CHEMICAL$-induced @GENE$ activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.	1
A 5'-flanking region capable of supporting RA-induced @GENE$ activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by @CHEMICAL$.	0
Within this sequence DNase I footprinting revealed that @CHEMICAL$ induced binding of a nuclear protein complex to an element containing two @GENE$.	0
Within this sequence @GENE$ footprinting revealed that @CHEMICAL$ induced binding of a nuclear protein complex to an element containing two GT boxes.	0
Within this sequence DNase I footprinting revealed that @CHEMICAL$ induced binding of a @GENE$ to an element containing two GT boxes.	0
Both @GENE$ were needed for binding the complex, and mutation of either GT box caused the loss of transcriptional activation by @CHEMICAL$.	0
Both GT boxes were needed for binding the complex, and mutation of either @GENE$ caused the loss of transcriptional activation by @CHEMICAL$.	0
The ability of this cis-acting @GENE$ to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an @GENE$ (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (@GENE$) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a @GENE$ (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	2
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (@GENE$) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @GENE$ (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (@GENE$) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to @CHEMICAL$ also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the @GENE$ gene, were necessary.	0
The ability of this cis-acting @GENE$ to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an @GENE$ (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (@GENE$) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a @GENE$ (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (@GENE$) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEM-GENE$ (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (@GENE$) site between the transcriptional start and first exon of the blr1 gene, were necessary.	0
The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a @CHEMICAL$ response element binding factor (CREB) site between the transcriptional start and first exon of the @GENE$ gene, were necessary.	0
A transcription factor-transcription factor binding array analysis of nuclear lysate from @CHEMICAL$-treated cells indicated several prominent @GENE$ binding partners; among these, Oct1, NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	0
A transcription factor-transcription factor binding array analysis of nuclear lysate from @CHEMICAL$-treated cells indicated several prominent RARalpha binding partners; among these, @GENE$, NFATc3, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	0
A transcription factor-transcription factor binding array analysis of nuclear lysate from @CHEMICAL$-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, @GENE$, and CREB2 were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	0
A transcription factor-transcription factor binding array analysis of nuclear lysate from @CHEMICAL$-treated cells indicated several prominent RARalpha binding partners; among these, Oct1, NFATc3, and @GENE$ were identified by competition EMSA and supershift and chromatin immunoprecipitation assays as components of the complex.	0
In sum the results of the present study indicate that RA-induced expression of @GENE$ expression depends on a novel @CHEMICAL$ response element.	0
In sum the results of the present study indicate that RA-induced expression of blr1 expression depends on a novel @CHEM-GENE$.	0
In sum the results of the present study indicate that @CHEMICAL$-induced expression of @GENE$ expression depends on a novel RA response element.	1
In sum the results of the present study indicate that @CHEMICAL$-induced expression of blr1 expression depends on a novel @GENE$.	0
The persistent membrane retention of @CHEMICAL$ causes lasting inhibition of @GENE$ function.	2
The persistent membrane retention of desipramine causes lasting inhibition of @CHEM-GENE$ function.	0
The present study examined the potential membrane retention of desipramine (@CHEMICAL$) following exposures of 293-@GENE$ cells to DMI, and its effect on [3H]NE uptake.	0
The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-@GENE$ cells to @CHEMICAL$, and its effect on [3H]NE uptake.	0
The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-@GENE$ cells to DMI, and its effect on @CHEMICAL$ uptake.	0
The present study examined the potential membrane retention of @CHEMICAL$ (DMI) following exposures of 293-@GENE$ cells to DMI, and its effect on [3H]NE uptake.	0
[3H]DMI trapped in membranes was displaceable by the structurally unrelated @GENE$ inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained @CHEMICAL$ with the NET.	0
[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained @CHEMICAL$ with the @GENE$.	0
@CHEMICAL$ trapped in membranes was displaceable by the structurally unrelated @GENE$ inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.	0
@CHEMICAL$ trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the @GENE$.	0
[3H]DMI trapped in membranes was displaceable by the structurally unrelated @GENE$ inhibitor, @CHEMICAL$, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.	2
[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, @CHEMICAL$, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the @GENE$.	0
The results demonstrate that @CHEMICAL$ and nisoxetine are persistently retained in cell membranes, at least partly in association with the @GENE$.	0
The results demonstrate that DMI and @CHEMICAL$ are persistently retained in cell membranes, at least partly in association with the @GENE$.	0
The retention and slow diffusion of @CHEMICAL$ and nisoxetine from membranes may contribute to their pharmacological and modulatory action on @GENE$.	0
The retention and slow diffusion of DMI and @CHEMICAL$ from membranes may contribute to their pharmacological and modulatory action on @GENE$.	0
@GENE$-receptor antagonism in hypertension: what has been learned with @CHEMICAL$?	0
@CHEMICAL$ is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (@GENE$-receptor).	0
@CHEMICAL$ is a long-acting @GENE$ antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).	4
Irbesartan is a long-acting @CHEMICAL$ antagonist acting specifically at the level of the Type 1-receptor subtype (@GENE$-receptor).	0
Irbesartan is a long-acting @CHEM-GENE$ antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).	0
@CHEMICAL$ may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this @GENE$-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II.	2
@CHEMICAL$ may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of @GENE$.	2
Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this @GENE$-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of @CHEMICAL$.	0
Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of @CHEM-GENE$.	0
Binding of @CHEMICAL$ at two sites in recombinant @GENE$ and interaction with beta-blockers.	0
To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, @GENE$, expressed in CHO cells, were labelled with @CHEMICAL$.	0
To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two @GENE$ sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with @CHEMICAL$.	0
To verify the hypothesis that the non-conventional partial agonist @CHEMICAL$ binds at two beta(1)-adrenoceptor sites, @GENE$, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.	3
To verify the hypothesis that the non-conventional partial agonist @CHEMICAL$ binds at two @GENE$ sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.	3
@CHEMICAL$ dissociated from the @GENE$ with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site.	0
We conclude that @CHEMICAL$ binds at two sites in the recombinant @GENE$.	0
@CHEMICAL$, a @GENE$ agonist, induces perforin in cytotoxic T lymphocytes in vitro.	3
@CHEMICAL$, a Toll-like receptor-7 agonist, induces @GENE$ in cytotoxic T lymphocytes in vitro.	1
@CHEMICAL$ (IMQ), an activator of @GENE$ (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	1
@CHEMICAL$ (IMQ), an activator of Toll-like receptor-7 (@GENE$), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	1
Imiquimod (@CHEMICAL$), an activator of @GENE$ (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	1
Imiquimod (@CHEMICAL$), an activator of Toll-like receptor-7 (@GENE$), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	1
This functional synergism prompted our current experiments addressing the question whether @CHEMICAL$ may influence @GENE$-release and/or induce perforin in CTLs in vitro.	0
This functional synergism prompted our current experiments addressing the question whether @CHEMICAL$ may influence perforin-release and/or induce @GENE$ in CTLs in vitro.	0
In peripheral lymphocytes of healthy and diseased subjects, @CHEMICAL$ induced a significant increase of @GENE$(+) CTLs within 12h in all experiments performed.	1
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal @GENE$ expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] @CHEMICAL$.	0
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to @GENE$(+) CTLs detected at time point zero (100%), up to 270% of perforin(+) CTLs were induced by 2.5 microg/ml [corrected] @CHEMICAL$.	0
This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of @GENE$(+) CTLs were induced by 2.5 microg/ml [corrected] @CHEMICAL$.	1
@GENE$ release from peripheral blood CTLs after PMA/ionomycin-stimulation was not influenced significantly by @CHEMICAL$.	0
Thus, the biological activity of @CHEMICAL$ appears to exceed its previously known functions, inasmuch as it boosts up significantly the @GENE$-granule system.	1
@CHEM-GENE$ are expressed in the basal ganglia, a group of structures involved in various aspects of motor control.	0
These cells express high levels of @CHEM-GENE$, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and cyclic AMP-regulated 32-kDa phosphoprotein DARPP-32.	0
These cells express high levels of @CHEMICAL$ A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the @GENE$ DARPP-32.	0
These cells express high levels of @CHEMICAL$ A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and cyclic AMP-regulated 32-kDa phosphoprotein @GENE$.	0
These cells express high levels of @GENE$, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the @CHEMICAL$- and cyclic AMP-regulated 32-kDa phosphoprotein DARPP-32.	0
These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the @CHEM-GENE$ DARPP-32.	0
These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the @CHEMICAL$- and cyclic AMP-regulated 32-kDa phosphoprotein @GENE$.	0
These cells express high levels of @GENE$, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and @CHEMICAL$-regulated 32-kDa phosphoprotein DARPP-32.	0
These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the @CHEM-GENE$ DARPP-32.	0
These cells express high levels of adenosine A(2A) receptors, which are involved in various intracellular processes, including the expression of immediate early genes and regulation of the dopamine- and @CHEMICAL$-regulated 32-kDa phosphoprotein @GENE$.	0
AIM: To investigate the remodeling of mesenteric artery and the expression of @GENE$, c-Jun in mesenteric artery and effects of @CHEMICAL$ and irbesartan on the remodeling in spontaneously hypertensive rats (SHR).	0
AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, @GENE$ in mesenteric artery and effects of @CHEMICAL$ and irbesartan on the remodeling in spontaneously hypertensive rats (SHR).	0
AIM: To investigate the remodeling of mesenteric artery and the expression of @GENE$, c-Jun in mesenteric artery and effects of imidapril and @CHEMICAL$ on the remodeling in spontaneously hypertensive rats (SHR).	0
AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, @GENE$ in mesenteric artery and effects of imidapril and @CHEMICAL$ on the remodeling in spontaneously hypertensive rats (SHR).	0
@CHEM-GENE$ (Ang II) level in plasma and mesenteric arteries was measured by radioimmunoassay.	0
@CHEMICAL$ (@GENE$) level in plasma and mesenteric arteries was measured by radioimmunoassay.	0
@GENE$ (@CHEMICAL$) level in plasma and mesenteric arteries was measured by radioimmunoassay.	0
Angiotensin II (@CHEM-GENE$) level in plasma and mesenteric arteries was measured by radioimmunoassay.	0
@CHEM-GENE$ level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group.	0
@GENE$ level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in @CHEMICAL$ group and lower in imidapril group.	1
@GENE$ level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in @CHEMICAL$ group.	2
The ratio of @GENE$ absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, @CHEMICAL$ group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).	1
The ratio of TGF-beta1 absorbed light value to @GENE$ absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, @CHEMICAL$ group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).	1
The ratio of @GENE$ absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and @CHEMICAL$ group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).	1
The ratio of TGF-beta1 absorbed light value to @GENE$ absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and @CHEMICAL$ group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).	1
@CHEM-GENE$ level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05).	0
@GENE$ level in plasma and mesenteric arteries in @CHEMICAL$ group was significantly lower than that in irbesartan group (P<0.05).	2
@GENE$ level in plasma and mesenteric arteries in imidapril group was significantly lower than that in @CHEMICAL$ group (P<0.05).	1
The @GENE$ absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, @CHEMICAL$, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).	1
The c-Jun absorbed light value/@GENE$ absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, @CHEMICAL$, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).	1
The @GENE$ absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and @CHEMICAL$ groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).	1
The c-Jun absorbed light value/@GENE$ absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and @CHEMICAL$ groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).	1
The @GENE$ absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in @CHEMICAL$ group than in irbesartan group (P<0.05).	0
The c-Jun absorbed light value/@GENE$ absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in @CHEMICAL$ group than in irbesartan group (P<0.05).	0
The @GENE$ absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in @CHEMICAL$ group (P<0.05).	0
The c-Jun absorbed light value/@GENE$ absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in @CHEMICAL$ group (P<0.05).	0
CONCLUSION: @CHEMICAL$ and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of @GENE$, c-Jun in SHR.	2
CONCLUSION: @CHEMICAL$ and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, @GENE$ in SHR.	2
CONCLUSION: Imidapril and @CHEMICAL$ can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of @GENE$, c-Jun in SHR.	2
CONCLUSION: Imidapril and @CHEMICAL$ can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, @GENE$ in SHR.	2
Clinical assessment of @CHEM-GENE$ blockade through biochemical and pharmacological profiles.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @CHEM-GENE$ (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (@CHEMICAL$) transporter (@GENE$) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (@CHEMICAL$) transporter (NET) function, we chronically antagonized @GENE$ by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @GENE$ (NET) function, we chronically antagonized NET by a range of doses of @CHEMICAL$ [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (@GENE$) function, we chronically antagonized NET by a range of doses of @CHEMICAL$ [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized @GENE$ by a range of doses of @CHEMICAL$ [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	4
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @GENE$ (NET) function, we chronically antagonized NET by a range of doses of duloxetine [@CHEMICAL$], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (@GENE$) function, we chronically antagonized NET by a range of doses of duloxetine [@CHEMICAL$], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized @GENE$ by a range of doses of duloxetine [@CHEMICAL$], which blocks the NE reuptake process.	4
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @GENE$ (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the @CHEMICAL$ reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (@GENE$) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the @CHEMICAL$ reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized @GENE$ by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the @CHEMICAL$ reuptake process.	5
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @CHEM-GENE$ (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @CHEMICAL$ (NE) transporter (@GENE$) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral @CHEMICAL$ (NE) transporter (NET) function, we chronically antagonized @GENE$ by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.	0
Plasma from @CHEMICAL$-treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to @GENE$ (maximum inhibition was 60%) (P=0.02).	0
CONCLUSIONS: These findings suggest that the degree of @GENE$ blockade can be assessed with the plasma or urine @CHEMICAL$/NE ratio and the pressor effect of tyramine.	0
CONCLUSIONS: These findings suggest that the degree of @GENE$ blockade can be assessed with the plasma or urine DHPG/@CHEMICAL$ ratio and the pressor effect of tyramine.	0
Also, the @CHEMICAL$/NE ratio is more sensitive at the lower end of @GENE$ inhibition, whereas tyramine exhibits a linear relation, with NET inhibition commencing at a higher dose.	0
Also, the @CHEMICAL$/NE ratio is more sensitive at the lower end of NET inhibition, whereas tyramine exhibits a linear relation, with @GENE$ inhibition commencing at a higher dose.	0
Also, the DHPG/@CHEMICAL$ ratio is more sensitive at the lower end of @GENE$ inhibition, whereas tyramine exhibits a linear relation, with NET inhibition commencing at a higher dose.	0
Also, the DHPG/@CHEMICAL$ ratio is more sensitive at the lower end of NET inhibition, whereas tyramine exhibits a linear relation, with @GENE$ inhibition commencing at a higher dose.	0
@CHEMICAL$, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and @GENE$.	2
@CHEMICAL$, an antirheumatic gold compound, is an inhibitor of @GENE$, such as thioredoxin reductase and glutathione peroxidase.	2
@CHEMICAL$, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as @GENE$ and glutathione peroxidase.	2
Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and @CHEM-GENE$.	0
Auranofin, an antirheumatic gold compound, is an inhibitor of @GENE$, such as thioredoxin reductase and @CHEMICAL$ peroxidase.	0
Auranofin, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as @GENE$ and @CHEMICAL$ peroxidase.	0
Auranofin, an antirheumatic gold compound, is an inhibitor of @CHEMICAL$ enzymes, such as thioredoxin reductase and @GENE$.	0
Auranofin, an antirheumatic gold compound, is an inhibitor of @CHEM-GENE$, such as thioredoxin reductase and glutathione peroxidase.	0
Auranofin, an antirheumatic gold compound, is an inhibitor of @CHEMICAL$ enzymes, such as @GENE$ and glutathione peroxidase.	0
The activity of @GENE$ and @CHEMICAL$ peroxidase was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia-reperfusion.	0
The activity of thioredoxin reductase and @CHEM-GENE$ was determined in liver and heart tissues in an attempt to correlate enzymatic activity with heart recovery after ischaemia-reperfusion.	0
There was significantly less @GENE$ activity in rat liver extracts, whereas the level of @CHEMICAL$ activity remained unchanged, demonstrating that the dose of auranofin used was able to selectively inhibit one of these enzyme systems.	0
There was significantly less @GENE$ activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of @CHEMICAL$ used was able to selectively inhibit one of these enzyme systems.	2
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that @CHEMICAL$ behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with @GENE$ and transferrin receptor-mediated endocytosis.	0
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that @CHEMICAL$ behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and @GENE$-mediated endocytosis.	0
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an @CHEMICAL$ analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with @GENE$ and transferrin receptor-mediated endocytosis.	0
Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an @CHEMICAL$ analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and @GENE$-mediated endocytosis.	0
Furthermore, @CHEMICAL$ also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on @GENE$.	2
Furthermore, gallium also seems to affect intracellular availability of @CHEMICAL$ already taken up via this pathway, probably due to its inhibitory activity on @GENE$.	0
Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on @CHEM-GENE$.	0
Apart from the consequences of @CHEMICAL$ deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme @GENE$, resulting in reduced dNTP pools and inhibition of DNA synthesis.	0
Apart from the consequences of iron deprivation, @CHEMICAL$ exerts cytotoxic effects by direct interaction with the iron-dependent enzyme @GENE$, resulting in reduced dNTP pools and inhibition of DNA synthesis.	0
Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the @CHEMICAL$-dependent enzyme @GENE$, resulting in reduced dNTP pools and inhibition of DNA synthesis.	0
Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme @CHEM-GENE$, resulting in reduced dNTP pools and inhibition of DNA synthesis.	0
Both the abundance of @GENE$ and upregulation of @CHEMICAL$ reductase render tumors susceptible to gallium-induced cytotoxicity.	0
Both the abundance of transferrin receptors and upregulation of @CHEM-GENE$ render tumors susceptible to gallium-induced cytotoxicity.	0
Both the abundance of @GENE$ and upregulation of ribonucleotide reductase render tumors susceptible to @CHEMICAL$-induced cytotoxicity.	0
Both the abundance of transferrin receptors and upregulation of @GENE$ render tumors susceptible to @CHEMICAL$-induced cytotoxicity.	0
However, some experimental findings raise the question whether these effects resulting from the @CHEMICAL$-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting @GENE$ polymerization.	2
However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of @CHEMICAL$ are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting @GENE$ polymerization.	2
The @GENE$ is the binding site for the antiepileptic drug @CHEMICAL$.	0
Here, we show that the @GENE$ is the brain binding site of @CHEMICAL$ (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.	0
Here, we show that the @GENE$ is the brain binding site of levetiracetam (@CHEMICAL$), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.	0
Brain membranes and purified synaptic vesicles from mice lacking @GENE$ do not bind a tritiated @CHEMICAL$ derivative, indicating that SV2A is necessary for LEV binding.	0
Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated @CHEMICAL$ derivative, indicating that @GENE$ is necessary for LEV binding.	0
Brain membranes and purified synaptic vesicles from mice lacking @GENE$ do not bind a tritiated LEV derivative, indicating that SV2A is necessary for @CHEMICAL$ binding.	0
Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that @GENE$ is necessary for @CHEMICAL$ binding.	0
@CHEMICAL$ and related compounds bind to @GENE$ expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding.	0
@CHEMICAL$ and related compounds bind to SV2A expressed in fibroblasts, indicating that @GENE$ is sufficient for LEV binding.	0
LEV and related compounds bind to @GENE$ expressed in fibroblasts, indicating that SV2A is sufficient for @CHEMICAL$ binding.	0
LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that @GENE$ is sufficient for @CHEMICAL$ binding.	0
Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to @GENE$ in fibroblasts and to the @CHEMICAL$-binding site in brain.	0
Furthermore, there is a high degree of correlation between binding affinities of a series of @CHEMICAL$ derivatives to @GENE$ in fibroblasts and to the LEV-binding site in brain.	0
These experimental results suggest that @GENE$ is the binding site of @CHEMICAL$ in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
These experimental results suggest that SV2A is the binding site of @CHEMICAL$ in the brain and that LEV acts by modulating the function of @GENE$, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
These experimental results suggest that @GENE$ is the binding site of LEV in the brain and that @CHEMICAL$ acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
These experimental results suggest that SV2A is the binding site of LEV in the brain and that @CHEMICAL$ acts by modulating the function of @GENE$, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
These experimental results suggest that @GENE$ is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that @CHEMICAL$ possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of @GENE$, supporting previous indications that @CHEMICAL$ possesses a mechanism of action distinct from that of other antiepileptic drugs.	0
@CHEMICAL$-evoked currents were completely and reversibly blocked by the competitive @GENE$ antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.	0
@CHEMICAL$-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of @GENE$ but not GABAC receptors.	0
@CHEMICAL$-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not @GENE$.	0
GABA-evoked currents were completely and reversibly blocked by the competitive @GENE$ antagonist @CHEMICAL$ (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.	4
GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist @CHEMICAL$ (IC50 = 1.7 microM), indicating expression of @GENE$ but not GABAC receptors.	0
GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist @CHEMICAL$ (IC50 = 1.7 microM), indicating expression of GABAA but not @GENE$.	0
Their affinity for @CHEMICAL$ was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two @GENE$.	0
Their affinity for GABA was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two @CHEM-GENE$.	0
Furthermore, @CHEM-GENE$ of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, @CHEMICAL$ receptors of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS @GENE$.	0
Furthermore, @GENE$ of horizontal cells were modulated by extracellular application of @CHEMICAL$, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of @CHEMICAL$, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS @GENE$.	0
Furthermore, @GENE$ of horizontal cells were modulated by extracellular application of diazepam, @CHEMICAL$, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of diazepam, @CHEMICAL$, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS @GENE$.	0
Furthermore, @GENE$ of horizontal cells were modulated by extracellular application of diazepam, zolpidem, @CHEMICAL$, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of diazepam, zolpidem, @CHEMICAL$, pentobarbital, and alphaxalone, thus showing typical pharmacological properties of CNS @GENE$.	0
Furthermore, @GENE$ of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, @CHEMICAL$, and alphaxalone, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, @CHEMICAL$, and alphaxalone, thus showing typical pharmacological properties of CNS @GENE$.	0
Furthermore, @GENE$ of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and @CHEMICAL$, thus showing typical pharmacological properties of CNS GABAA receptors.	0
Furthermore, GABA receptors of horizontal cells were modulated by extracellular application of diazepam, zolpidem, methyl 6,7-dimethoxy-4-ethyl-beta-carboxylate, pentobarbital, and @CHEMICAL$, thus showing typical pharmacological properties of CNS @GENE$.	0
Decreased @CHEM-GENE$ binding in the brain of depressed patients.	0
Cerebral @CHEM-GENE$ (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [(11)C]-doxepin.	0
Cerebral @CHEMICAL$ H1 receptor (@GENE$) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [(11)C]-doxepin.	0
Cerebral @GENE$ (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and @CHEMICAL$.	0
Cerebral histamine H1 receptor (@GENE$) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and @CHEMICAL$.	0
Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain @CHEM-GENE$ occupancy using 11C-doxepin positron emission tomography.	0
Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain @GENE$ occupancy using @CHEMICAL$ positron emission tomography.	0
Central effects of @CHEMICAL$ and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain @GENE$ occupancy using 11C-doxepin positron emission tomography.	0
Central effects of fexofenadine and @CHEMICAL$: measurement of psychomotor performance, subjective sleepiness, and brain @GENE$ occupancy using 11C-doxepin positron emission tomography.	0
@GENE$ (H1R) antagonists, or @CHEMICAL$, often induce sedative side effects when used for the treatment of allergic disorders.	4
Histamine H1-receptor (@GENE$) antagonists, or @CHEMICAL$, often induce sedative side effects when used for the treatment of allergic disorders.	4
@CHEM-GENE$ (H1R) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders.	0
@CHEMICAL$ H1-receptor (@GENE$) antagonists, or antihistamines, often induce sedative side effects when used for the treatment of allergic disorders.	0
This study compared the sedative profiles of the second-generation @CHEMICAL$, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of @GENE$ occupancy (H1RO) in the brain.	0
This study compared the sedative profiles of the second-generation antihistamines, @CHEMICAL$ and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of @GENE$ occupancy (H1RO) in the brain.	0
This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and @CHEMICAL$, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of @GENE$ occupancy (H1RO) in the brain.	0
This study compared the sedative profiles of the second-generation antihistamines, fexofenadine and cetirizine, using 3 different criteria: subjective sleepiness evaluated by the Stanford Sleepiness Scale, objective psychomotor tests (simple and choice reaction time tests and visual discrimination tests at 4 different exposure durations), and measurement of @CHEM-GENE$ occupancy (H1RO) in the brain.	0
A novel membrane sensor for @CHEM-GENE$ antagonist "fexofenadine".	0
A novel membrane sensor for @GENE$ antagonist "@CHEMICAL$".	4
@CHEM-GENE$: a critical target in cancer therapy?	0
@CHEM-GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@CHEMICAL$ synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for @CHEMICAL$ (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for @CHEMICAL$ (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (@CHEMICAL$) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (@CHEMICAL$) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, @CHEMICAL$/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, @CHEMICAL$/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/@CHEMICAL$ (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/@CHEMICAL$ (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (@CHEMICAL$), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (@CHEMICAL$), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), @CHEMICAL$ (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), @CHEMICAL$ (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (@CHEMICAL$), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (@CHEMICAL$), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and @CHEMICAL$, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and @CHEMICAL$, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate, a precursor for DNA synthesis.	0
@GENE$ (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of @CHEMICAL$, a precursor for DNA synthesis.	5
Thymidylate synthase (@GENE$) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of @CHEMICAL$, a precursor for DNA synthesis.	5
While @CHEMICAL$ antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent @GENE$ inhibitors.	0
While fluoropyrimidine antimetabolites have other sites of action, antifolates @CHEMICAL$ (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent @GENE$ inhibitors.	2
While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (@CHEMICAL$, Tomudex) and AG337 (Thymitag) are more specific and potent @GENE$ inhibitors.	2
While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, @CHEMICAL$) and AG337 (Thymitag) are more specific and potent @GENE$ inhibitors.	2
While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and @CHEMICAL$ (Thymitag) are more specific and potent @GENE$ inhibitors.	2
While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (@CHEMICAL$) are more specific and potent @GENE$ inhibitors.	2
The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that @CHEM-GENE$, the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts.	0
The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that @GENE$, the activating enzyme for @CHEMICAL$, is expressed at a higher level in tumor tissue compared with normal tissue counterparts.	5
The availability of the @CHEMICAL$ prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that @GENE$, the activating enzyme for 5-FU, is expressed at a higher level in tumor tissue compared with normal tissue counterparts.	0
@CHEMICAL$ is an inhibitor of @GENE$ which is able to block the absorption of 30% of ingested fat.	2
Troglitazone, bosentan and glibenclamide inhibit the @GENE$ (Bsep) which transports @CHEMICAL$ into bile.	5
Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (@GENE$) which transports @CHEMICAL$ into bile.	5
@CHEMICAL$, bosentan and glibenclamide inhibit the @GENE$ (Bsep) which transports taurocholate into bile.	2
@CHEMICAL$, bosentan and glibenclamide inhibit the bile salt export pump (@GENE$) which transports taurocholate into bile.	2
Troglitazone, @CHEMICAL$ and glibenclamide inhibit the @GENE$ (Bsep) which transports taurocholate into bile.	2
Troglitazone, @CHEMICAL$ and glibenclamide inhibit the bile salt export pump (@GENE$) which transports taurocholate into bile.	2
Troglitazone, bosentan and @CHEMICAL$ inhibit the @GENE$ (Bsep) which transports taurocholate into bile.	2
Troglitazone, bosentan and @CHEMICAL$ inhibit the bile salt export pump (@GENE$) which transports taurocholate into bile.	2
Sandwich-cultured rat hepatocytes maintain functional @CHEM-GENE$ and Bsep transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL).	0
Sandwich-cultured rat hepatocytes maintain functional @CHEMICAL$ co-transporting polypeptide and @GENE$ transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL).	0
The purpose of this study was to compare viability assessments determined with the neutral red, @CHEM-GENE$ (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @CHEMICAL$ dehydrogenase (@GENE$), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @CHEMICAL$ dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit @GENE$, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @GENE$ (LDH), @CHEMICAL$, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (@GENE$), @CHEMICAL$, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), @CHEMICAL$, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit @GENE$, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @GENE$ (LDH), alamar blue, @CHEMICAL$ (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (@GENE$), alamar blue, @CHEMICAL$ (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, @CHEMICAL$ (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit @GENE$, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @GENE$ (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (@CHEMICAL$) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (@GENE$), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (@CHEMICAL$) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (@CHEMICAL$) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit @GENE$, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, @GENE$ (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and @CHEMICAL$ assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (@GENE$), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and @CHEMICAL$ assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.	0
The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and @CHEMICAL$ assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit @GENE$, and to define the LOAEL for these xenobiotics in this system.	0
@CHEMICAL$ also decreased viability as measured by the @GENE$, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.	0
Bosentan also decreased viability as measured by the @GENE$, @CHEMICAL$ and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.	0
Bosentan also decreased viability as measured by the @GENE$, MTT and @CHEMICAL$ assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.	0
Bosentan also decreased viability as measured by the @GENE$, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the @CHEMICAL$ assay.	0
Based on the results of this study, the @GENE$ or @CHEMICAL$ assays would be the methods of choice to assess viability in sandwich-cultured rat hepatocytes after xenobiotic exposure.	0
@CHEMICAL$: assessment of @GENE$ potency and selectivity.	0
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit @GENE$ in humans while sparing @CHEMICAL$ formation from COX-1.	0
The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing @CHEMICAL$ formation from @GENE$.	5
The discovery of a @GENE$ (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing @CHEMICAL$ formation from COX-1.	0
The discovery of a second isoform of cyclooxygenase (@GENE$) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing @CHEMICAL$ formation from COX-1.	0
We report here the pharmacological properties of a third selective @GENE$ inhibitor, @CHEMICAL$, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied.	2
We report here the pharmacological properties of a third selective COX-2 inhibitor, @CHEMICAL$, which is the most potent and in vitro selective of the marketed @GENE$ inhibitors that we have studied.	2
@CHEMICAL$ potently inhibits recombinant @GENE$, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.	2
Valdecoxib potently inhibits recombinant @GENE$, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for @CHEMICAL$, 0.5 microM for rofecoxib, and 5 microM for etoricoxib.	2
Valdecoxib potently inhibits recombinant @GENE$, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for @CHEMICAL$, and 5 microM for etoricoxib.	2
Valdecoxib potently inhibits recombinant @GENE$, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for @CHEMICAL$.	2
Unique binding interactions of valdecoxib with @GENE$ translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for @CHEMICAL$ and 80 M/s for etoricoxib).	0
Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of @GENE$ (110,000 M/s compared with 7000 M/s for @CHEMICAL$ and 80 M/s for etoricoxib).	0
Unique binding interactions of @CHEMICAL$ with @GENE$ translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).	0
Unique binding interactions of @CHEMICAL$ with COX-2 translate into a fast rate of inactivation of @GENE$ (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib).	2
Unique binding interactions of valdecoxib with @GENE$ translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for @CHEMICAL$).	0
Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of @GENE$ (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for @CHEMICAL$).	0
The overall saturation binding affinity for @GENE$ of @CHEMICAL$ is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).	0
The overall saturation binding affinity for @GENE$ of valdecoxib is 2.6 nM (compared with 1.6 nM for @CHEMICAL$, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).	0
The overall saturation binding affinity for @GENE$ of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for @CHEMICAL$, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min).	0
The overall saturation binding affinity for @GENE$ of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for @CHEMICAL$), with a slow off-rate (t(1/2) approximately 98 min).	0
@CHEMICAL$ inhibits @GENE$ in a competitive fashion only at very high concentrations (IC(50) = 150 microM).	2
Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of @CHEMICAL$ for @GENE$.	0
@CHEMICAL$ showed similar activity in the @GENE$ assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).	2
@CHEMICAL$ showed similar activity in the human whole-blood COX assay (@GENE$ IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM).	2
@CHEMICAL$ showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; @GENE$ IC(50) = 21.9 microM).	2
An @GENE$ antagonist, @CHEMICAL$ augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.	4
An angiotensin II AT1 receptor antagonist, @CHEMICAL$ augments glucose uptake and @GENE$ protein expression in 3T3-L1 adipocytes.	1
An @GENE$ antagonist, telmisartan augments @CHEMICAL$ uptake and GLUT4 protein expression in 3T3-L1 adipocytes.	0
An angiotensin II AT1 receptor antagonist, telmisartan augments @CHEMICAL$ uptake and @GENE$ protein expression in 3T3-L1 adipocytes.	5
An @CHEM-GENE$ antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.	0
An @CHEMICAL$ AT1 receptor antagonist, telmisartan augments glucose uptake and @GENE$ protein expression in 3T3-L1 adipocytes.	0
Evidence has accumulated that some of the @CHEM-GENE$ antagonists have insulin-sensitizing property.	0
Evidence has accumulated that some of the @CHEMICAL$ AT1 receptor antagonists have @GENE$-sensitizing property.	0
We thus examined the effect of @CHEMICAL$ on @GENE$ action using 3T3-L1 adipocytes.	0
Treatment of both differentiating adipocytes and fully differentiated adipocytes with @CHEMICAL$ caused a dose-dependent increase in mRNA levels for @GENE$ target genes such as aP2 and adiponectin.	1
Treatment of both differentiating adipocytes and fully differentiated adipocytes with @CHEMICAL$ caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as @GENE$ and adiponectin.	1
Treatment of both differentiating adipocytes and fully differentiated adipocytes with @CHEMICAL$ caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and @GENE$.	1
By contrast, @CHEMICAL$ attenuated @GENE$ mRNA level in differentiated adipocytes.	1
By contrast, telmisartan attenuated @CHEM-GENE$ mRNA level in differentiated adipocytes.	0
Of note, we demonstrated for the first time that @CHEMICAL$ augmented @GENE$ protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.	1
Of note, we demonstrated for the first time that @CHEMICAL$ augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and @GENE$-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.	0
Of note, we demonstrated for the first time that @CHEMICAL$ augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its @GENE$-sensitizing ability.	0
Of note, we demonstrated for the first time that telmisartan augmented @GENE$ protein expression and @CHEMICAL$ uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.	5
Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and @CHEMICAL$ uptake both in basal and @GENE$-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.	0
Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and @CHEMICAL$ uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its @GENE$-sensitizing ability.	0
Genetic variants at the @GENE$ (beta(2)AR) may modify asthma severity and @CHEMICAL$ responsiveness.	0
Genetic variants at the beta(2)-adrenergic receptor (@GENE$) may modify asthma severity and @CHEMICAL$ responsiveness.	0
We tested the association of @GENE$ genotypes with asthma severity and bronchodilator response to @CHEMICAL$ in Puerto Ricans and Mexicans with asthma.	0
METHODS: We used both family-based and cross-sectional tests of association with 8 @GENE$ single @CHEMICAL$ polymorphisms in 684 Puerto Rican and Mexican families.	0
We found a strong interaction of baseline FEV(1) with the @GENE$ (@CHEMICAL$) polymorphism in predicting bronchodilator response.	0
Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme @GENE$, as compared to the standard tyrosinase inhibitors @CHEMICAL$ (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.	2
Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme @GENE$, as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and @CHEMICAL$ (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.	2
In vivo activity of the potent @CHEM-GENE$ antagonist on uterine activity in the rat.	0
@CHEM-GENE$ antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.	0
@CHEMICAL$ antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or @GENE$-induced uterine contractions in primates.	0
@GENE$ antagonist (OTA), @CHEMICAL$, was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates.	4
Oxytocin antagonist (OTA), @CHEMICAL$, was developed by our group and shown to inhibit either spontaneous or @GENE$-induced uterine contractions in primates.	2
@GENE$ antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or @CHEMICAL$-induced uterine contractions in primates.	0
Oxytocin antagonist (OTA), TT-235, was developed by our group and shown to inhibit either spontaneous or @CHEM-GENE$-induced uterine contractions in primates.	0
The purpose of the present study was to confirm the duration of @CHEMICAL$ to block @GENE$-induced uterine contractions in estrous rats.	2
The purpose of the present study was to confirm the duration of TT-235 to block @CHEM-GENE$-induced uterine contractions in estrous rats.	0
Each OTA was administered as a single bolus injection of 5 microg, followed by 100 mU of @CHEM-GENE$ 5 minutes later, also done as a single bolus.	0
@CHEM-GENE$ injection of the same dosage was repeated every hour for 5 hours.	0
Experiment 2 determined the effect of the three OTAs on uterine @CHEM-GENE$ number (Rn) and binding affinity (Kd).	0
In Experiment 1, @CHEMICAL$, Antag II and TT-235 inhibited the integrated uterine response to @GENE$ at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	2
In Experiment 1, Antag I, @CHEMICAL$ and TT-235 inhibited the integrated uterine response to @GENE$ at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	2
In Experiment 1, Antag I, Antag II and @CHEMICAL$ inhibited the integrated uterine response to @GENE$ at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	2
In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to @CHEM-GENE$ at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05).	0
In Experiment 2, @CHEMICAL$ induced a significant decrease (p<0.05) in @GENE$ number and binding affinity at both 0.5 and 4 hours compared with controls.	2
In Experiment 2, TT-235 induced a significant decrease (p<0.05) in @CHEM-GENE$ number and binding affinity at both 0.5 and 4 hours compared with controls.	0
@CHEMICAL$ and Antag II did not alter @GENE$ number or binding affinity significantly at each time point studied compared with controls.	0
Antag I and @CHEMICAL$ did not alter @GENE$ number or binding affinity significantly at each time point studied compared with controls.	0
Antag I and Antag II did not alter @CHEM-GENE$ number or binding affinity significantly at each time point studied compared with controls.	0
In conclusion, @CHEMICAL$ may inhibit the uterine response to @GENE$ by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	2
In conclusion, @CHEMICAL$ may inhibit the uterine response to oxytocin by decreasing @GENE$ numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	2
In conclusion, @CHEMICAL$ may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and @GENE$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, @CHEMICAL$ may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged @GENE$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @CHEM-GENE$ by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @CHEMICAL$ by decreasing @GENE$ numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @CHEMICAL$ by decreasing oxytocin receptor numbers and @GENE$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @CHEMICAL$ by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged @GENE$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @GENE$ by decreasing @CHEMICAL$ receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @CHEM-GENE$ numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @CHEMICAL$ receptor numbers and @GENE$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @CHEMICAL$ receptor numbers and oxytocin binding affinity, which might explain the prolonged @GENE$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @GENE$ by decreasing oxytocin receptor numbers and @CHEMICAL$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @GENE$ numbers and @CHEMICAL$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and @CHEM-GENE$ binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and @CHEMICAL$ binding affinity, which might explain the prolonged @GENE$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @GENE$ by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged @CHEMICAL$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @GENE$ numbers and oxytocin binding affinity, which might explain the prolonged @CHEMICAL$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and @GENE$ binding affinity, which might explain the prolonged @CHEMICAL$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged @CHEM-GENE$ antagonist activity of TT-235.	0
In conclusion, TT-235 may inhibit the uterine response to @GENE$ by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of @CHEMICAL$.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing @GENE$ numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of @CHEMICAL$.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and @GENE$ binding affinity, which might explain the prolonged oxytocin antagonist activity of @CHEMICAL$.	0
In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged @GENE$ antagonist activity of @CHEMICAL$.	4
Preclinical pharmacology of @CHEMICAL$: a novel selective inhibitor of @GENE$.	2
This manuscript presents the preclinical profile of @CHEMICAL$, a novel @GENE$ (COX-2) selective inhibitor.	2
This manuscript presents the preclinical profile of @CHEMICAL$, a novel cyclooxygenase-2 (@GENE$) selective inhibitor.	2
@CHEMICAL$ inhibited purified @GENE$ and COX-2 with K(i) values of 3 and 0.06 microM, respectively.	2
@CHEMICAL$ inhibited purified COX-1 and @GENE$ with K(i) values of 3 and 0.06 microM, respectively.	2
In cellular assays, @CHEMICAL$ had an IC(50) of 0.14 microM in @GENE$-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).	2
In cellular assays, @CHEMICAL$ had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of @GENE$ at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).	0
In cellular assays, @CHEMICAL$ had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with @GENE$).	0
In a human whole blood assay, IC(50) values for @CHEMICAL$ were 0.13 microM for @GENE$ and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).	2
In a human whole blood assay, IC(50) values for @CHEMICAL$ were 0.13 microM for COX-2 and 67 microM for @GENE$ (COX-1/COX-2 selectivity ratio 515).	2
In a human whole blood assay, IC(50) values for @CHEMICAL$ were 0.13 microM for COX-2 and 67 microM for COX-1 (@GENE$/COX-2 selectivity ratio 515).	2
In a human whole blood assay, IC(50) values for @CHEMICAL$ were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/@GENE$ selectivity ratio 515).	2
Ex vivo, @CHEMICAL$ inhibited @GENE$-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	2
Ex vivo, @CHEMICAL$ inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas @GENE$-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	0
Ex vivo, lumiracoxib inhibited @GENE$-derived @CHEMICAL$ (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	5
Ex vivo, lumiracoxib inhibited COX-1-derived @CHEMICAL$ (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas @GENE$-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	0
Ex vivo, lumiracoxib inhibited @GENE$-derived thromboxane B(2) (@CHEMICAL$) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	5
Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (@CHEMICAL$) generation with an ID(50) of 33 mg kg(-1), whereas @GENE$-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	0
Ex vivo, lumiracoxib inhibited @GENE$-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of @CHEMICAL$ (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	0
Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas @GENE$-derived production of @CHEMICAL$ (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	5
Ex vivo, lumiracoxib inhibited @GENE$-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (@CHEMICAL$) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	0
Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas @GENE$-derived production of prostaglandin E(2) (@CHEMICAL$) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).	5
However, consistent with its low @GENE$ inhibitory activity, @CHEMICAL$ at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).	2
However, consistent with its low @GENE$ inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than @CHEMICAL$ (P<0.05).	2
@CHEMICAL$ is a highly selective @GENE$ inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.	2
Lumiracoxib is a highly selective @GENE$ inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with @CHEMICAL$, the reference NSAID, but with much improved gastrointestinal safety.	2
Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/@CHEM-GENE$ (hTPK).	0
Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (PP20)/human @CHEMICAL$ pyrophosphokinase (@GENE$).	0
Cloning, sequencing, structural and molecular biological characterization of @GENE$ (PP20)/human @CHEMICAL$ pyrophosphokinase (hTPK).	0
Cloning, sequencing, structural and molecular biological characterization of placental protein 20 (@GENE$)/human @CHEMICAL$ pyrophosphokinase (hTPK).	0
Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to @CHEM-GENE$ (hTPK) as confirmed by protein sequence analysis.	0
Full-length cDNAs of placental protein 20 (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human @CHEMICAL$ pyrophosphokinase (@GENE$) as confirmed by protein sequence analysis.	0
Full-length cDNAs of @GENE$ (PP20) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human @CHEMICAL$ pyrophosphokinase (hTPK) as confirmed by protein sequence analysis.	0
Full-length cDNAs of placental protein 20 (@GENE$) were cloned by screening a human placental cDNA library, which encode a 243 amino acid protein, identical to human @CHEMICAL$ pyrophosphokinase (hTPK) as confirmed by protein sequence analysis.	0
As @CHEMICAL$ metabolism deficiencies have been seen in placental infarcts previously, these indicate that @GENE$/hTPK may have a role in placental diseases.	5
As @CHEMICAL$ metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/@GENE$ may have a role in placental diseases.	5
Safety and tolerability of @CHEMICAL$ inhalation solution, a novel @GENE$ agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.	3
@CHEMICAL$ (INS37217) is a selective @GENE$ agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	3
Denufosol tetrasodium (INS37217) is a selective @GENE$ agonist that stimulates ciliary beat frequency and @CHEMICAL$ secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	0
Denufosol tetrasodium (@CHEMICAL$) is a selective @GENE$ agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.	3
The @CHEMICAL$ secretory response is mediated via a non-@GENE$ pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.	5
The @CHEMICAL$ secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of @GENE$ activation to also inhibit epithelial Na(+) transport.	0
The Cl(-) secretory response is mediated via a non-@GENE$ pathway, and the driving force for @CHEMICAL$ secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.	0
The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for @CHEMICAL$ secretion is enhanced by the effect of @GENE$ activation to also inhibit epithelial Na(+) transport.	0
The Cl(-) secretory response is mediated via a non-@GENE$ pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial @CHEMICAL$ transport.	0
The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of @GENE$ activation to also inhibit epithelial @CHEMICAL$ transport.	0
@CHEMICAL$ is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated @GENE$ agonists.	3
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via @GENE$ activation: comparison with the effects of @CHEMICAL$.	0
The dextromethorphan analog @CHEMICAL$ attenuates kainate-induced seizures via @GENE$ activation: comparison with the effects of dextromethorphan.	1
The @CHEMICAL$ analog dimemorfan attenuates kainate-induced seizures via @GENE$ activation: comparison with the effects of dextromethorphan.	1
@CHEMICAL$ and dimemorfan are high-affinity ligands at @GENE$.	0
Dextromethorphan and @CHEMICAL$ are high-affinity ligands at @GENE$.	0
@CHEMICAL$ pre-treatment also attenuated the KA-induced increases in @GENE$/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	2
@CHEMICAL$ pre-treatment also attenuated the KA-induced increases in c-fos/@GENE$ expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	2
@CHEMICAL$ pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, @GENE$ DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	2
Dimemorfan pre-treatment also attenuated the @CHEMICAL$-induced increases in @GENE$/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	1
Dimemorfan pre-treatment also attenuated the @CHEMICAL$-induced increases in c-fos/@GENE$ expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	1
Dimemorfan pre-treatment also attenuated the @CHEMICAL$-induced increases in c-fos/c-jun expression, @GENE$ DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.	1
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist @CHEMICAL$, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to @GENE$-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist @CHEMICAL$, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of @GENE$ transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective @GENE$ antagonist @CHEMICAL$, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	4
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of @CHEMICAL$ or dimemorfan is, at least in part, related to @GENE$-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of @CHEMICAL$ or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of @GENE$ transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective @GENE$ antagonist BD 1047, suggesting that the anticonvulsant action of @CHEMICAL$ or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of @CHEMICAL$ or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to @GENE$-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of @CHEMICAL$ or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of @GENE$ transcription factors.	0
The anticonvulsant action of @CHEMICAL$ or dimemorfan was significantly counteracted by a selective @GENE$ antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or @CHEMICAL$ was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to @GENE$-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or @CHEMICAL$ was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of @GENE$ transcription factors.	0
The anticonvulsant action of dextromethorphan or @CHEMICAL$ was significantly counteracted by a selective @GENE$ antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or @CHEMICAL$ is, at least in part, related to @GENE$-activated modulation of AP-1 transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or @CHEMICAL$ is, at least in part, related to sigma1 receptor-activated modulation of @GENE$ transcription factors.	0
The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective @GENE$ antagonist BD 1047, suggesting that the anticonvulsant action of dextromethorphan or @CHEMICAL$ is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.	0
Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists @CHEM-GENE$ and carbetocin.	0
Binding domains of the @GENE$ for the selective oxytocin receptor antagonist barusiban in comparison to the agonists @CHEMICAL$ and carbetocin.	0
Binding domains of the oxytocin receptor for the selective @GENE$ antagonist barusiban in comparison to the agonists @CHEMICAL$ and carbetocin.	3
Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists @GENE$ and @CHEMICAL$.	0
Binding domains of the @GENE$ for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and @CHEMICAL$.	0
Binding domains of the oxytocin receptor for the selective @GENE$ antagonist barusiban in comparison to the agonists oxytocin and @CHEMICAL$.	3
Binding domains of the @CHEMICAL$ receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists @GENE$ and carbetocin.	0
Binding domains of the @CHEM-GENE$ for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.	0
Binding domains of the @CHEMICAL$ receptor for the selective @GENE$ antagonist barusiban in comparison to the agonists oxytocin and carbetocin.	0
Binding domains of the oxytocin receptor for the selective @CHEMICAL$ receptor antagonist barusiban in comparison to the agonists @GENE$ and carbetocin.	0
Binding domains of the @GENE$ for the selective @CHEMICAL$ receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.	0
Binding domains of the oxytocin receptor for the selective @CHEM-GENE$ antagonist barusiban in comparison to the agonists oxytocin and carbetocin.	0
Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist @CHEMICAL$ in comparison to the agonists @GENE$ and carbetocin.	0
Binding domains of the @GENE$ for the selective oxytocin receptor antagonist @CHEMICAL$ in comparison to the agonists oxytocin and carbetocin.	0
Binding domains of the oxytocin receptor for the selective @GENE$ antagonist @CHEMICAL$ in comparison to the agonists oxytocin and carbetocin.	4
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @CHEM-GENE$ antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @CHEMICAL$ V1A/oxytocin receptor antagonist atosiban and the agonists @GENE$ and carbetocin.	0
We have analyzed binding domains of the @GENE$ for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @CHEMICAL$ V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @GENE$ antagonist, in comparison to the combined @CHEMICAL$ V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @GENE$ antagonist @CHEMICAL$ and the agonists oxytocin and carbetocin.	4
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist @CHEMICAL$ and the agonists @GENE$ and carbetocin.	0
We have analyzed binding domains of the @GENE$ for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist @CHEMICAL$ and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist @CHEMICAL$ and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @GENE$ antagonist atosiban and the agonists @CHEMICAL$ and carbetocin.	3
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @CHEM-GENE$ and carbetocin.	0
We have analyzed binding domains of the @GENE$ for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @CHEMICAL$ and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @CHEMICAL$ and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @GENE$ antagonist atosiban and the agonists oxytocin and @CHEMICAL$.	3
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @GENE$ and @CHEMICAL$.	0
We have analyzed binding domains of the @GENE$ for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and @CHEMICAL$.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and @CHEMICAL$.	0
We have analyzed binding domains of the @CHEMICAL$ receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined @GENE$ antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the @CHEMICAL$ receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @GENE$ and carbetocin.	0
We have analyzed binding domains of the @CHEM-GENE$ for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the @CHEMICAL$ receptor for barusiban, a highly selective @GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for @CHEMICAL$, a highly selective oxytocin receptor antagonist, in comparison to the combined @GENE$ antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for @CHEMICAL$, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @GENE$ and carbetocin.	0
We have analyzed binding domains of the @GENE$ for @CHEMICAL$, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for @CHEMICAL$, a highly selective @GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	4
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @CHEMICAL$ receptor antagonist, in comparison to the combined @GENE$ antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @CHEMICAL$ receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists @GENE$ and carbetocin.	0
We have analyzed binding domains of the @GENE$ for barusiban, a highly selective @CHEMICAL$ receptor antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective @CHEM-GENE$ antagonist, in comparison to the combined vasopressin V1A/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin.	0
For this purpose, chimeric 'gain-in function' @CHEM-GENE$ were expressed in COS-7 cells.	0
For this purpose, chimeric 'gain-in function' @CHEM-GENE$ were expressed in COS-7 cells.	0
These recombinant receptors have been produced by transfer of domains from the @CHEM-GENE$ into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the @CHEMICAL$ receptor into the related @GENE$ and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the @CHEMICAL$ receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the @GENE$ (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the @GENE$ into the related @CHEMICAL$ V2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related @CHEM-GENE$ and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related @CHEMICAL$ V2 receptor and have already been successfully employed for the identification of ligand binding domains at the @GENE$ (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the @GENE$ into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the @CHEMICAL$ receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related @GENE$ and have already been successfully employed for the identification of ligand binding domains at the @CHEMICAL$ receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the @CHEM-GENE$ (Postina, R., Kojro, E., Fahrenholz, F., 1996.	0
Separate agonist and peptide antagonist binding sites of the @CHEM-GENE$ defined by their transfer into the V2 vasopressin receptor.	0
Separate agonist and peptide antagonist binding sites of the @CHEMICAL$ receptor defined by their transfer into the @GENE$.	0
Separate agonist and peptide antagonist binding sites of the @GENE$ defined by their transfer into the V2 @CHEMICAL$ receptor.	0
Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the @CHEM-GENE$.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]@GENE$, @CHEMICAL$, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands @GENE$, [Arg8]vasopressin, @CHEMICAL$, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]@GENE$, carbetocin, and @CHEMICAL$.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands @GENE$, [Arg8]vasopressin, carbetocin, and @CHEMICAL$.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of @CHEMICAL$ was compared with the binding profiles of the ligands oxytocin, [Arg8]@GENE$, carbetocin, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of @CHEMICAL$ was compared with the binding profiles of the ligands @GENE$, [Arg8]vasopressin, carbetocin, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands @CHEMICAL$, [Arg8]@GENE$, carbetocin, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands @CHEM-GENE$, [Arg8]vasopressin, carbetocin, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, @CHEM-GENE$, carbetocin, and atosiban.	0
In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands @GENE$, @CHEMICAL$, carbetocin, and atosiban.	0
The binding profiles for the agonists @CHEM-GENE$ and carbetocin were found to be similar.	0
The binding profiles for the agonists @GENE$ and @CHEMICAL$ were found to be similar.	0
For both agonists, important binding domains were the extracellular @CHEMICAL$-terminus (=E1) and the extracellular loops E2 and E3 from the @GENE$.	0
For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the @CHEM-GENE$.	0
For the @GENE$ antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting @CHEMICAL$ V2 receptor.	0
For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting @CHEM-GENE$.	0
For the @CHEM-GENE$ antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.	0
For the @CHEMICAL$ V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting @GENE$.	0
For the @CHEM-GENE$ antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.	0
For the vasopressin V1A/@CHEMICAL$ receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting @GENE$.	0
For the @GENE$ antagonist @CHEMICAL$, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.	4
For the vasopressin V1A/oxytocin receptor antagonist @CHEMICAL$, none of the receptor constructs were able to provide a binding with higher affinity than the starting @GENE$.	0
In contrast, the binding of @CHEMICAL$ was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the @GENE$.	0
In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the @CHEMICAL$ receptor to the @GENE$.	0
In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the @CHEM-GENE$.	0
The binding domain of @CHEMICAL$ differs from the binding domain of the agonists and the nonselective @GENE$ antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies.	0
The binding domain of @CHEMICAL$ differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]@GENE$ that has been used in previous studies.	0
The binding domain of barusiban differs from the binding domain of the agonists and the nonselective @CHEM-GENE$ antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies.	0
The binding domain of barusiban differs from the binding domain of the agonists and the nonselective @CHEMICAL$ receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]@GENE$ that has been used in previous studies.	0
The binding domain of barusiban differs from the binding domain of the agonists and the nonselective @GENE$ antagonist @CHEMICAL$ that has been used in previous studies.	4
The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist @CHEM-GENE$ that has been used in previous studies.	0
Overall, the data supported the concept of a central pocket site within the @CHEM-GENE$.	0
Neonatal epileptic encephalopathy caused by mutations in the @GENE$ gene encoding @CHEMICAL$ oxidase.	0
Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding @CHEM-GENE$.	0
Cerebrospinal fluid and urine analyses indicated reduced activity of @CHEM-GENE$ and other PLP-dependent enzymes.	0
Cerebrospinal fluid and urine analyses indicated reduced activity of @GENE$ and other @CHEMICAL$-dependent enzymes.	0
Seizures ceased with the administration of @CHEMICAL$, having been resistant to treatment with pyridoxine, suggesting a defect of @GENE$ (PNPO).	0
Seizures ceased with the administration of @CHEMICAL$, having been resistant to treatment with pyridoxine, suggesting a defect of pyridox(am)ine 5'-phosphate oxidase (@GENE$).	0
Seizures ceased with the administration of PLP, having been resistant to treatment with pyridoxine, suggesting a defect of @CHEM-GENE$ (PNPO).	0
Seizures ceased with the administration of PLP, having been resistant to treatment with pyridoxine, suggesting a defect of @CHEMICAL$ oxidase (@GENE$).	0
Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3-1@GENE$) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation (R229W) markedly reduced @CHEMICAL$ oxidase activity.	0
Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3-1g>a) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation (@GENE$) markedly reduced @CHEMICAL$ oxidase activity.	0
Expression studies in Chinese hamster ovary cells showed that the splice site (IVS3-1g>a) and stop codon (X262Q) mutations were null activity mutations and that the missense mutation (R229W) markedly reduced @CHEM-GENE$ activity.	0
Effect of 5-azacytidine and @CHEMICAL$ on @GENE$ expression in Jurkat T cells.	0
Effect of @CHEMICAL$ and procainamide on @GENE$ expression in Jurkat T cells.	0
The compounds @CHEMICAL$ (AZC) and procainamide (PCA) belong to inhibitors of @GENE$, whose low activity correlates with increase in transcription of various genes.	2
The compounds 5'-azacytidine (@CHEMICAL$) and procainamide (PCA) belong to inhibitors of @GENE$, whose low activity correlates with increase in transcription of various genes.	2
The compounds 5'-azacytidine (AZC) and @CHEMICAL$ (PCA) belong to inhibitors of @GENE$, whose low activity correlates with increase in transcription of various genes.	2
The compounds 5'-azacytidine (AZC) and procainamide (@CHEMICAL$) belong to inhibitors of @GENE$, whose low activity correlates with increase in transcription of various genes.	2
Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that @CHEMICAL$ and PCA did not profoundly affect on @GENE$ transcription in Jurkat T leukemia cells clone E6-1.	0
Using the reverse-transcription and real-time quantitative PCR (RQ-PCR) analysis, we indicated that AZC and @CHEMICAL$ did not profoundly affect on @GENE$ transcription in Jurkat T leukemia cells clone E6-1.	0
However, the flowcytometric analysis revealed that @CHEMICAL$ and PCA decreased intracellular contents of @GENE$ in these cells in dose dependent manner.	2
However, the flowcytometric analysis revealed that AZC and @CHEMICAL$ decreased intracellular contents of @GENE$ in these cells in dose dependent manner.	2
Changes in gene expression associated with loss of function of the @GENE$ @CHEMICAL$ dehydrogenase in mouse embryonic fibroblasts.	0
Changes in gene expression associated with loss of function of the NSDHL @CHEM-GENE$ in mouse embryonic fibroblasts.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene @CHEM-GENE$ (NSDHL) encoding a sterol dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene @CHEMICAL$ sterol dehydrogenase-like (@GENE$) encoding a sterol dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene @CHEMICAL$ sterol dehydrogenase-like (NSDHL) encoding a @GENE$.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene @CHEM-GENE$ (NSDHL) encoding a sterol dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene NADH @CHEMICAL$ dehydrogenase-like (@GENE$) encoding a sterol dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene NADH @CHEMICAL$ dehydrogenase-like (NSDHL) encoding a @GENE$.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene @GENE$ (NSDHL) encoding a @CHEMICAL$ dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene NADH sterol dehydrogenase-like (@GENE$) encoding a @CHEMICAL$ dehydrogenase.	0
One of these, congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) syndrome, results from mutations in the X-linked gene NADH sterol dehydrogenase-like (NSDHL) encoding a @CHEM-GENE$.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in @CHEMICAL$ biosynthesis, 7 are involved in fatty acid synthesis, 3 (@GENE$, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in @CHEMICAL$ biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, @GENE$, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in @CHEMICAL$ biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and @GENE$) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in @CHEMICAL$ biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (@GENE$ and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in @CHEMICAL$ biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and @GENE$) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in @CHEMICAL$ synthesis, 3 (@GENE$, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in @CHEMICAL$ synthesis, 3 (Srebp2, @GENE$, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in @CHEMICAL$ synthesis, 3 (Srebp2, Insig1, and @GENE$) encode sterol-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in @CHEMICAL$ synthesis, 3 (Srebp2, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (@GENE$ and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in @CHEMICAL$ synthesis, 3 (Srebp2, Insig1, and Orf11) encode sterol-regulatory proteins, and 2 (Ldlr and @GENE$) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (@GENE$, Insig1, and Orf11) encode @CHEMICAL$-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, @GENE$, and Orf11) encode @CHEMICAL$-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and @GENE$) encode @CHEMICAL$-regulatory proteins, and 2 (Ldlr and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and Orf11) encode @CHEMICAL$-regulatory proteins, and 2 (@GENE$ and StarD4) are lipid transporters.	0
Among 44 genes that showed higher expression in the Bpa(1H) versus wt cells grown in LDS, 11 function in cholesterol biosynthesis, 7 are involved in fatty acid synthesis, 3 (Srebp2, Insig1, and Orf11) encode @CHEMICAL$-regulatory proteins, and 2 (Ldlr and @GENE$) are lipid transporters.	0
Clinical studies in cancer patients treated with the new @CHEMICAL$ analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of @GENE$ (TS).	2
Clinical studies in cancer patients treated with the new @CHEMICAL$ analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (@GENE$).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue @CHEMICAL$ (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of @GENE$ (TS).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue @CHEMICAL$ (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (@GENE$).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (@CHEMICAL$) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of @GENE$ (TS).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (@CHEMICAL$) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (@GENE$).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma @CHEMICAL$ was significantly elevated after 1 week of treatment, consistent with inhibition of @GENE$ (TS).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma @CHEMICAL$ was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (@GENE$).	2
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of @CHEM-GENE$ (TS).	0
Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of @CHEMICAL$ synthase (@GENE$).	0
These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to @GENE$ inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (@CHEMICAL$).	2
These findings suggest that the mechanism of antiproliferative toxicity of @CHEMICAL$ is at least partly due to @GENE$ inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP).	2
These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to @GENE$ inhibitory activity of its active metabolite @CHEMICAL$ (FdUMP).	2
Monitoring of plasma @CHEMICAL$ concentrations have the potential to help clinicians to guide scheduling of capecitabine or other @GENE$ inhibitors in clinical trials.	0
Monitoring of plasma UdR concentrations have the potential to help clinicians to guide scheduling of @CHEMICAL$ or other @GENE$ inhibitors in clinical trials.	0
Induction of @GENE$ and activation of EGF receptor in @CHEMICAL$-treated squamous carcinoma cells.	0
Induction of heparin-binding EGF-like growth factor and activation of @GENE$ in @CHEMICAL$-treated squamous carcinoma cells.	1
@CHEMICAL$ is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (@GENE$), and c-kit kinases.	2
@CHEMICAL$ is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and @GENE$ kinases.	2
@CHEMICAL$ is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit @GENE$.	2
@CHEMICAL$ is a @GENE$ inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.	2
@CHEMICAL$ is a tyrosine kinase inhibitor of the @GENE$, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.	2
@CHEMICAL$ is a tyrosine kinase inhibitor of the ABL, @GENE$ (PDGFR), and c-kit kinases.	2
Imatinib mesylate is a @CHEMICAL$ kinase inhibitor of the ABL, platelet-derived growth factor receptor (@GENE$), and c-kit kinases.	0
Imatinib mesylate is a @CHEMICAL$ kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and @GENE$ kinases.	0
Imatinib mesylate is a @CHEMICAL$ kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit @GENE$.	0
Imatinib mesylate is a @CHEM-GENE$ inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.	0
Imatinib mesylate is a @CHEMICAL$ kinase inhibitor of the @GENE$, platelet-derived growth factor receptor (PDGFR), and c-kit kinases.	0
Imatinib mesylate is a @CHEMICAL$ kinase inhibitor of the ABL, @GENE$ (PDGFR), and c-kit kinases.	0
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of @CHEMICAL$-induced changes in cell morphology and growth similar to changes associated with @GENE$ (EGFR) activation.	1
Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of @CHEMICAL$-induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (@GENE$) activation.	1
@CHEMICAL$-induced changes were blocked with the @GENE$ antagonist cetuximab, which suggested direct involvement of EGFR in this process.	0
@CHEMICAL$-induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of @GENE$ in this process.	1
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of @GENE$ and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/ErbB2.	1
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of @GENE$ (MEK1) and EGFR, but not Her2/ErbB2.	0
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (@GENE$) and EGFR, but not Her2/ErbB2.	0
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and @GENE$, but not Her2/ErbB2.	0
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not @GENE$/ErbB2.	0
Western blot analysis of cells incubated with @CHEMICAL$ demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2/@GENE$.	0
An in vitro kinase assay showed that @CHEMICAL$ did not directly affect EGFR @GENE$ activity, suggesting involvement of EGFR-activating molecules.	0
An in vitro kinase assay showed that @CHEMICAL$ did not directly affect EGFR kinase activity, suggesting involvement of @GENE$-activating molecules.	0
An in vitro @GENE$ assay showed that @CHEMICAL$ did not directly affect EGFR kinase activity, suggesting involvement of EGFR-activating molecules.	0
An in vitro kinase assay showed that @CHEMICAL$ did not directly affect @GENE$ kinase activity, suggesting involvement of EGFR-activating molecules.	0
Inhibitors and neutralizing antibodies against @GENE$ (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced @CHEMICAL$-mediated mitogen activated protein kinase (MAPK) activation.	0
Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (@GENE$), and to a lesser extent transforming growth factor-alpha, reduced @CHEMICAL$-mediated mitogen activated protein kinase (MAPK) activation.	0
Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent @GENE$, reduced @CHEMICAL$-mediated mitogen activated protein kinase (MAPK) activation.	0
Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced @CHEMICAL$-mediated @GENE$ (MAPK) activation.	1
Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced @CHEMICAL$-mediated mitogen activated protein kinase (@GENE$) activation.	1
@CHEMICAL$ stimulated the rapid release of soluble @GENE$ and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation.	1
@CHEMICAL$ stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound @GENE$, which correlated with biphasic MAPK activation.	1
@CHEMICAL$ stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic @GENE$ activation.	1
Together, these results suggested that @CHEMICAL$ affects @GENE$ activation and signaling pathways through rapid release and increased expression of endogenous EGFR-activating ligands.	0
Together, these results suggested that @CHEMICAL$ affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous @GENE$-activating ligands.	1
Although, @CHEMICAL$ primarily inhibits @GENE$, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.	2
Although, @CHEMICAL$ primarily inhibits tyrosine kinases, it also stimulates the activity of @GENE$ tyrosine kinase in head and neck squamous tumors.	1
Although, @CHEMICAL$ primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR @GENE$ in head and neck squamous tumors.	1
Although, imatinib primarily inhibits @GENE$, it also stimulates the activity of EGFR @CHEMICAL$ kinase in head and neck squamous tumors.	0
Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of @GENE$ @CHEMICAL$ kinase in head and neck squamous tumors.	0
Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR @CHEM-GENE$ in head and neck squamous tumors.	0
@CHEMICAL$ (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both @GENE$ and c-kit oncoproteins.	0
@CHEMICAL$ (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and @GENE$ oncoproteins.	0
STI 571 (@CHEMICAL$ [Gleevec]) might be an effective therapy in this case, since Gleevec targets both @GENE$ and c-kit oncoproteins.	0
STI 571 (@CHEMICAL$ [Gleevec]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and @GENE$ oncoproteins.	0
STI 571 (imatinib mesylate [@CHEMICAL$]) might be an effective therapy in this case, since Gleevec targets both @GENE$ and c-kit oncoproteins.	0
STI 571 (imatinib mesylate [@CHEMICAL$]) might be an effective therapy in this case, since Gleevec targets both PDGFRA and @GENE$ oncoproteins.	0
STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since @CHEMICAL$ targets both @GENE$ and c-kit oncoproteins.	0
STI 571 (imatinib mesylate [Gleevec]) might be an effective therapy in this case, since @CHEMICAL$ targets both PDGFRA and @GENE$ oncoproteins.	0
Genetic polymorphism and activities of @GENE$: implications for @CHEMICAL$ metabolism and cytotoxicity.	0
Genetic polymorphism and activities of @CHEM-GENE$: implications for ethanol metabolism and cytotoxicity.	0
Genetic polymorphism and activities of @CHEM-GENE$: implications for ethanol metabolism and cytotoxicity.	0
@CHEM-GENE$ (ADH) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity.	0
@CHEMICAL$ dehydrogenase (@GENE$) and aldehyde dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity.	0
@CHEMICAL$ dehydrogenase (ADH) and @GENE$ (ALDH) exhibit genetic polymorphism and tissue specificity.	0
@CHEMICAL$ dehydrogenase (ADH) and aldehyde dehydrogenase (@GENE$) exhibit genetic polymorphism and tissue specificity.	0
@GENE$ (ADH) and @CHEMICAL$ dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity.	0
Alcohol dehydrogenase (@GENE$) and @CHEMICAL$ dehydrogenase (ALDH) exhibit genetic polymorphism and tissue specificity.	0
Alcohol dehydrogenase (ADH) and @CHEM-GENE$ (ALDH) exhibit genetic polymorphism and tissue specificity.	0
Alcohol dehydrogenase (ADH) and @CHEMICAL$ dehydrogenase (@GENE$) exhibit genetic polymorphism and tissue specificity.	0
The identity of the lung @GENE$ was further demonstrated by their characteristic pH-activity profiles for @CHEMICAL$ oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.	5
The identity of the lung @GENE$ was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and @CHEMICAL$, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.	5
The identity of the lung @GENE$ was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by @CHEMICAL$ or 1,10-phenanthroline.	2
The identity of the lung @GENE$ was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or @CHEMICAL$.	2
These findings indicate that human pulmonary @CHEMICAL$-metabolizing activities differ significantly with respect to genetic polymorphism at both the @GENE$ and the ALDH2 loci.	5
These findings indicate that human pulmonary @CHEMICAL$-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the @GENE$ loci.	5
The results suggest that individuals with high Vmax @GENE$ and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with @CHEMICAL$ accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	5
The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial @GENE$, accounting for approximately 45% of the Chinese population, may end up with @CHEMICAL$ accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	5
The results suggest that individuals with high Vmax @GENE$ and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during @CHEMICAL$ consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	5
The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial @GENE$, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during @CHEMICAL$ consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.	5
@CHEMICAL$ induces @GENE$ production in human peripheral blood mononuclear cells.	1
The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A (@CHEMICAL$) reductase and @GENE$, which is a ligand of intercellular adhesion molecule (ICAM)-1.	0
The effects of statins on immune response depend on the inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A (@CHEMICAL$) reductase and leukocyte function-associated antigen (LFA)-1, which is a ligand of @GENE$.	0
The effects of statins on immune response depend on the inhibition of @CHEM-GENE$ and leukocyte function-associated antigen (LFA)-1, which is a ligand of intercellular adhesion molecule (ICAM)-1.	0
The effects of statins on immune response depend on the inhibition of @CHEMICAL$ (HMG-CoA) reductase and @GENE$, which is a ligand of intercellular adhesion molecule (ICAM)-1.	0
The effects of statins on immune response depend on the inhibition of @CHEMICAL$ (HMG-CoA) reductase and leukocyte function-associated antigen (LFA)-1, which is a ligand of @GENE$.	0
The effects of statins on immune response depend on the inhibition of @CHEM-GENE$ and leukocyte function-associated antigen (LFA)-1, which is a ligand of intercellular adhesion molecule (ICAM)-1.	0
@CHEMICAL$, an @GENE$ inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	2
@CHEMICAL$, an HMG-CoA reductase inhibitor with mild inhibition of @GENE$, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	2
@CHEMICAL$, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of @GENE$, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	1
@CHEMICAL$, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, @GENE$ and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	1
@CHEMICAL$, an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and @GENE$ in human peripheral blood mononuclear cells (PBMC).	1
Simvastatin, an @CHEM-GENE$ inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	0
Simvastatin, an @CHEMICAL$ reductase inhibitor with mild inhibition of @GENE$, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	0
Simvastatin, an @CHEMICAL$ reductase inhibitor with mild inhibition of LFA-1, induced the production of @GENE$, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	0
Simvastatin, an @CHEMICAL$ reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, @GENE$ and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC).	0
Simvastatin, an @CHEMICAL$ reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and @GENE$ in human peripheral blood mononuclear cells (PBMC).	0
The @GENE$ production is located upstream of the cytokine cascade activated by @CHEMICAL$.	1
The IL-18 production is located upstream of the @GENE$ cascade activated by @CHEMICAL$.	1
Moreover, @CHEMICAL$ concentration-dependently inhibited the expression of @GENE$ and induced the expression of CD40 on monocytes.	2
Moreover, @CHEMICAL$ concentration-dependently inhibited the expression of ICAM-1 and induced the expression of @GENE$ on monocytes.	1
In the presence of @GENE$, @CHEMICAL$ suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.	0
In the presence of IL-18, @CHEMICAL$ suppressed the expression of @GENE$ and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.	2
In the presence of IL-18, @CHEMICAL$ suppressed the expression of ICAM-1 and @GENE$ as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.	2
In the presence of IL-18, @CHEMICAL$ suppressed the expression of ICAM-1 and CD40 as well as the production of @GENE$, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.	1
In the presence of IL-18, @CHEMICAL$ suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, @GENE$ and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin.	1
In the presence of IL-18, @CHEMICAL$ suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and @GENE$ in PBMC, contributing to the anti-inflammatory effect of simvastatin.	1
In the presence of @GENE$, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
In the presence of IL-18, simvastatin suppressed the expression of @GENE$ and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and @GENE$ as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of @GENE$, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, @GENE$ and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and @GENE$ in PBMC, contributing to the anti-inflammatory effect of @CHEMICAL$.	0
The effects of @CHEMICAL$ were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of @GENE$ in the action of simvastatin.	0
The effects of @CHEMICAL$ were abolished by the addition of the product of the @GENE$, mevalonate, indicating the involvement of HMG-CoA reductase in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the @CHEMICAL$ reductase, mevalonate, indicating the involvement of @GENE$ in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the @CHEM-GENE$, mevalonate, indicating the involvement of HMG-CoA reductase in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, @CHEMICAL$, indicating the involvement of @GENE$ in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the @GENE$, @CHEMICAL$, indicating the involvement of HMG-CoA reductase in the action of simvastatin.	5
The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of @CHEM-GENE$ in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the @GENE$, mevalonate, indicating the involvement of @CHEMICAL$ reductase in the action of simvastatin.	0
The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase, mevalonate, indicating the involvement of @GENE$ in the action of @CHEMICAL$.	0
The effects of simvastatin were abolished by the addition of the product of the @GENE$, mevalonate, indicating the involvement of HMG-CoA reductase in the action of @CHEMICAL$.	0
@GENE$ and COX-2 inhibition in horse blood by @CHEMICAL$, flunixin, carprofen and meloxicam: an in vitro analysis.	2
COX-1 and @GENE$ inhibition in horse blood by @CHEMICAL$, flunixin, carprofen and meloxicam: an in vitro analysis.	2
@GENE$ and COX-2 inhibition in horse blood by phenylbutazone, @CHEMICAL$, carprofen and meloxicam: an in vitro analysis.	2
COX-1 and @GENE$ inhibition in horse blood by phenylbutazone, @CHEMICAL$, carprofen and meloxicam: an in vitro analysis.	2
@GENE$ and COX-2 inhibition in horse blood by phenylbutazone, flunixin, @CHEMICAL$ and meloxicam: an in vitro analysis.	2
COX-1 and @GENE$ inhibition in horse blood by phenylbutazone, flunixin, @CHEMICAL$ and meloxicam: an in vitro analysis.	2
@GENE$ and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and @CHEMICAL$: an in vitro analysis.	2
COX-1 and @GENE$ inhibition in horse blood by phenylbutazone, flunixin, carprofen and @CHEMICAL$: an in vitro analysis.	2
We report on the inhibitory activity of the NSAIDs meloxicam, @CHEMICAL$, phenylbutazone and flunixin, on blood @GENE$ in the horse using in vitro enzyme-linked assays.	2
We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, @CHEMICAL$ and flunixin, on blood @GENE$ in the horse using in vitro enzyme-linked assays.	2
We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and @CHEMICAL$, on blood @GENE$ in the horse using in vitro enzyme-linked assays.	2
We report on the inhibitory activity of the NSAIDs @CHEMICAL$, carprofen, phenylbutazone and flunixin, on blood @GENE$ in the horse using in vitro enzyme-linked assays.	2
As expected, comparison of IC50 indicated that @CHEMICAL$ and carprofen are more selective inhibitors of @GENE$ than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.	2
As expected, comparison of IC50 indicated that meloxicam and @CHEMICAL$ are more selective inhibitors of @GENE$ than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.	2
As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of @GENE$ than @CHEMICAL$ and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.	2
As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of @GENE$ than phenylbutazone and @CHEMICAL$; meloxicam was the most advantageous for horses of four NSAIDs examined.	2
As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of @GENE$ than phenylbutazone and flunixin; @CHEMICAL$ was the most advantageous for horses of four NSAIDs examined.	0
However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater @GENE$ selectivity than at IC50, and meloxicam (-41.2%) and @CHEMICAL$ (-12.9%) had lower COX-2 selectivity than at IC50.	0
However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and @CHEMICAL$ (-12.9%) had lower @GENE$ selectivity than at IC50.	2
However at IC80, @CHEMICAL$ (+134.4%) and flunixin (+29.7%) had greater @GENE$ selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	2
However at IC80, @CHEMICAL$ (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower @GENE$ selectivity than at IC50.	0
However at IC80, phenylbutazone (+134.4%) and @CHEMICAL$ (+29.7%) had greater @GENE$ selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	2
However at IC80, phenylbutazone (+134.4%) and @CHEMICAL$ (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower @GENE$ selectivity than at IC50.	0
However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater @GENE$ selectivity than at IC50, and @CHEMICAL$ (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	0
However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and @CHEMICAL$ (-41.2%) and carprofen (-12.9%) had lower @GENE$ selectivity than at IC50.	2
@CHEMICAL$ prevents cardiac hypertrophy and overexpression of @GENE$ and vascular endothelial growth factor in pressure-overloaded rat heart.	2
@CHEMICAL$ prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and @GENE$ in pressure-overloaded rat heart.	2
To evaluate the effect of @CHEMICAL$ on both myocardial @GENE$ expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy.	0
Treatment with @CHEMICAL$, doxazosin, or N-acetylcysteine did not significantly affect @GENE$ and VEGF proteins expression in the banding groups.	0
Treatment with @CHEMICAL$, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and @GENE$ proteins expression in the banding groups.	0
Treatment with valsartan, @CHEMICAL$, or N-acetylcysteine did not significantly affect @GENE$ and VEGF proteins expression in the banding groups.	0
Treatment with valsartan, @CHEMICAL$, or N-acetylcysteine did not significantly affect HIF-1alpha and @GENE$ proteins expression in the banding groups.	0
Treatment with valsartan, doxazosin, or @CHEMICAL$ did not significantly affect @GENE$ and VEGF proteins expression in the banding groups.	0
Treatment with valsartan, doxazosin, or @CHEMICAL$ did not significantly affect HIF-1alpha and @GENE$ proteins expression in the banding groups.	0
Treatment with @CHEMICAL$ reversed both protein and mRNA of @GENE$, VEGF, BNP, and NGF-beta to the baseline values.	2
Treatment with @CHEMICAL$ reversed both protein and mRNA of HIF-1alpha, @GENE$, BNP, and NGF-beta to the baseline values.	2
Treatment with @CHEMICAL$ reversed both protein and mRNA of HIF-1alpha, VEGF, @GENE$, and NGF-beta to the baseline values.	2
Treatment with @CHEMICAL$ reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and @GENE$ to the baseline values.	1
Increased immunohistochemical labeling of @GENE$, VEGF, and BNP in the ventricular myocardium was observed in the banding group and @CHEMICAL$ again normalized the labeling.	2
Increased immunohistochemical labeling of HIF-1alpha, @GENE$, and BNP in the ventricular myocardium was observed in the banding group and @CHEMICAL$ again normalized the labeling.	2
Increased immunohistochemical labeling of HIF-1alpha, VEGF, and @GENE$ in the ventricular myocardium was observed in the banding group and @CHEMICAL$ again normalized the labeling.	2
Treatment with @CHEMICAL$ is associated with a reversal of abnormal regulation of @GENE$, VEGF, BNP, and NGF-beta in the hypertrophic myocardium.	2
Treatment with @CHEMICAL$ is associated with a reversal of abnormal regulation of HIF-1alpha, @GENE$, BNP, and NGF-beta in the hypertrophic myocardium.	2
Treatment with @CHEMICAL$ is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, @GENE$, and NGF-beta in the hypertrophic myocardium.	2
Treatment with @CHEMICAL$ is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and @GENE$ in the hypertrophic myocardium.	0
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of @GENE$, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, @GENE$, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, @GENE$-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-@GENE$, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, @GENE$, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
@CHEMICAL$ (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and @GENE$ represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of @GENE$, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, @GENE$, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, @GENE$-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-@GENE$, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, @GENE$, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (@CHEMICAL$, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and @GENE$ represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of @GENE$, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, @GENE$, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, @GENE$-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-@GENE$, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, @GENE$, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, @CHEMICAL$, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and @GENE$ represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of @GENE$, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, @GENE$, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, @GENE$-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-@GENE$, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, @GENE$, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
Imatinib (STI571, Gleevec, @CHEMICAL$; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and @GENE$ represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.	2
The reported mechanism of @CHEMICAL$ resistance in GISTs involves missense mutation in the @GENE$ of KIT, including Thr670Ile, Tyr823Asp, and Val654Ala.	0
The reported mechanism of @CHEMICAL$ resistance in GISTs involves missense mutation in the kinase domain of @GENE$ including Thr670Ile, Tyr823Asp, and Val654Ala.	0
The reported mechanism of @CHEMICAL$ resistance in GISTs involves missense mutation in the kinase domain of KIT, including @GENE$, Tyr823Asp, and Val654Ala.	0
The reported mechanism of @CHEMICAL$ resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, @GENE$, and Val654Ala.	0
The reported mechanism of @CHEMICAL$ resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670Ile, Tyr823Asp, and @GENE$.	0
Evaluation of @GENE$ ligands at the human histamine H4 receptor: identification of @CHEMICAL$ as the first potent and selective H4 receptor agonist.	0
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of @CHEMICAL$ as the first potent and selective @GENE$ agonist.	3
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the @GENE$: identification of @CHEMICAL$ as the first potent and selective H4 receptor agonist.	0
Evaluation of @CHEM-GENE$ ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.	0
Evaluation of @CHEMICAL$ H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective @GENE$ agonist.	0
Evaluation of @CHEMICAL$ H1-, H2-, and H3-receptor ligands at the @GENE$: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.	0
Evaluation of @GENE$ ligands at the human @CHEMICAL$ H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.	0
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human @CHEMICAL$ H4 receptor: identification of 4-methylhistamine as the first potent and selective @GENE$ agonist.	0
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the @CHEM-GENE$: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.	0
The @CHEMICAL$ H(4) receptor (@GENE$) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy.	0
The @CHEM-GENE$ (H(4)R) is involved in the chemotaxis of leukocytes and mast cells to sites of inflammation and is suggested to be a potential drug target for asthma and allergy.	0
Almost all of the tested @GENE$ and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific @CHEMICAL$ binding to the hH(4)R at concentrations up to 10 microM.	0
Almost all of the tested H(1)R and @GENE$ antagonists, including several important therapeutics, displaced less than 30% of specific @CHEMICAL$ binding to the hH(4)R at concentrations up to 10 microM.	0
Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific @CHEMICAL$ binding to the @GENE$ at concentrations up to 10 microM.	0
Most of the tested @GENE$ agonists and @CHEMICAL$-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.	0
Most of the tested H(2)R agonists and @CHEMICAL$-based @GENE$ ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.	0
Most of the tested H(2)R agonists and @CHEMICAL$-based H(3)R ligands show micromolar-to-nanomolar range @GENE$ affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.	0
Most of the tested H(2)R agonists and @CHEMICAL$-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic @GENE$ activities, ranging from full agonists to inverse agonists.	3
Interestingly, we identified @CHEMICAL$ as a high-affinity @GENE$ ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.	0
Interestingly, we identified @CHEMICAL$ as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the @GENE$ over the other histamine receptor subtypes.	0
Interestingly, we identified @CHEMICAL$ as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other @GENE$ subtypes.	0
Interestingly, we identified 4-methylhistamine as a high-affinity @GENE$ ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other @CHEMICAL$ receptor subtypes.	0
Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the @GENE$ over the other @CHEMICAL$ receptor subtypes.	0
Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other @CHEM-GENE$ subtypes.	0
Moreover, @CHEMICAL$ potently activated the @GENE$ (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).	1
Moreover, @CHEMICAL$ potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective @GENE$ antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).	0
Moreover, 4-methylhistamine potently activated the @GENE$ (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist @CHEMICAL$ [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).	0
Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective @GENE$ antagonist @CHEMICAL$ [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).	4
Moreover, 4-methylhistamine potently activated the @GENE$ (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [@CHEMICAL$] (pA(2) = 7.8).	0
Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective @GENE$ antagonist JNJ 7777120 [@CHEMICAL$] (pA(2) = 7.8).	4
The identification of @CHEMICAL$ as a potent @GENE$ agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.	3
The identification of @CHEMICAL$ as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the @GENE$.	0
Irinotecan (CPT-11, @CHEMICAL$) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting @GENE$ (Topo I).	2
Irinotecan (CPT-11, @CHEMICAL$) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (@GENE$).	2
@CHEMICAL$ (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting @GENE$ (Topo I).	2
@CHEMICAL$ (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (@GENE$).	2
Irinotecan (@CHEMICAL$, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting @GENE$ (Topo I).	2
Irinotecan (@CHEMICAL$, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (@GENE$).	2
Early-onset diarrhea is observed immediately after @CHEMICAL$ infusion and probably due to the inhibition of @GENE$ activity, which can be eliminated by administration of atropine.	2
Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of @GENE$ activity, which can be eliminated by administration of @CHEMICAL$.	1
Late-onset diarrhea appears to be associated with intestinal exposure to @CHEMICAL$ (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to @GENE$ and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	0
Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (@CHEMICAL$), the major active metabolite of CPT-11, which may bind to @GENE$ and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	0
Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of @CHEMICAL$, which may bind to @GENE$ and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa.	0
@CHEMICAL$ and SN-38 may also stimulate the production of pro-inflammatory @GENE$ and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).	1
CPT-11 and @CHEMICAL$ may also stimulate the production of pro-inflammatory @GENE$ and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-).	1
CPT-11 and SN-38 may also stimulate the production of pro-inflammatory @GENE$ and @CHEMICAL$ (PGs), thus inducing the secretion of Na(+) and Cl(-).	0
CPT-11 and SN-38 may also stimulate the production of pro-inflammatory @GENE$ and prostaglandins (@CHEMICAL$), thus inducing the secretion of Na(+) and Cl(-).	0
CPT-11 and SN-38 may also stimulate the production of pro-inflammatory @GENE$ and prostaglandins (PGs), thus inducing the secretion of @CHEMICAL$ and Cl(-).	0
CPT-11 and SN-38 may also stimulate the production of pro-inflammatory @GENE$ and prostaglandins (PGs), thus inducing the secretion of Na(+) and @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, @GENE$ (PgP) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (@GENE$) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, @GENE$ (COX-2) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, cyclooxygenase-2 (@GENE$) inhibitors, tumor necrosis factor-alpha (TNF-alpha) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, @GENE$ (TNF-alpha) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
These include intestinal alkalizing agents, oral antibiotics, enzyme inducers, P-glycoprotein (PgP) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, tumor necrosis factor-alpha (@GENE$) inhibitors, or blockers of biliary excretion of @CHEMICAL$.	0
Crystal structure of @CHEM-GENE$ in complex with roscovitine and derivatives.	0
Crystal structure of @GENE$ in complex with @CHEMICAL$ and derivatives.	0
@GENE$ (PDXK) catalyzes the phosphorylation of @CHEMICAL$, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.	5
Pyridoxal kinase (@GENE$) catalyzes the phosphorylation of @CHEMICAL$, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.	5
@GENE$ (PDXK) catalyzes the phosphorylation of pyridoxal, @CHEMICAL$, and pyridoxine in the presence of ATP and Zn2+.	5
Pyridoxal kinase (@GENE$) catalyzes the phosphorylation of pyridoxal, @CHEMICAL$, and pyridoxine in the presence of ATP and Zn2+.	5
@CHEM-GENE$ (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.	0
@CHEMICAL$ kinase (@GENE$) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.	0
@GENE$ (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and @CHEMICAL$ in the presence of ATP and Zn2+.	5
Pyridoxal kinase (@GENE$) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and @CHEMICAL$ in the presence of ATP and Zn2+.	5
@GENE$ (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of @CHEMICAL$ and Zn2+.	0
Pyridoxal kinase (@GENE$) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of @CHEMICAL$ and Zn2+.	0
@GENE$ (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and @CHEMICAL$.	0
Pyridoxal kinase (@GENE$) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and @CHEMICAL$.	0
@CHEMICAL$ (CYC202, Seliciclib) is a relatively selective inhibitor of @GENE$ (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
@CHEMICAL$ (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (@GENE$), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
(R)-Roscovitine (@CHEMICAL$, Seliciclib) is a relatively selective inhibitor of @GENE$ (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
(R)-Roscovitine (@CHEMICAL$, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (@GENE$), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
(R)-Roscovitine (CYC202, @CHEMICAL$) is a relatively selective inhibitor of @GENE$ (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
(R)-Roscovitine (CYC202, @CHEMICAL$) is a relatively selective inhibitor of cyclin-dependent kinases (@GENE$), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.	2
Affinity chromatography investigations have shown that @CHEMICAL$ also interacts with @GENE$.	0
To understand this interaction, we determined the crystal structure of @GENE$ in complex with @CHEMICAL$, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with @CHEMICAL$, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to @GENE$ but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with @CHEMICAL$, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to @GENE$.	0
To understand this interaction, we determined the crystal structure of @GENE$ in complex with (R)-roscovitine, @CHEMICAL$, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, @CHEMICAL$, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to @GENE$ but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, @CHEMICAL$, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to @GENE$.	0
To understand this interaction, we determined the crystal structure of @GENE$ in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and @CHEMICAL$, the two latter derivatives being designed to bind to PDXK but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and @CHEMICAL$, the two latter derivatives being designed to bind to @GENE$ but not to CDKs.	0
To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and @CHEMICAL$, the two latter derivatives being designed to bind to PDXK but not to @GENE$.	0
Structural analysis revealed that these three @CHEMICAL$ bind similarly in the pyridoxal-binding site of @GENE$ rather than in the anticipated ATP-binding site.	0
Structural analysis revealed that these three roscovitines bind similarly in the @CHEMICAL$-binding site of @GENE$ rather than in the anticipated ATP-binding site.	0
Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of @GENE$ rather than in the anticipated @CHEMICAL$-binding site.	0
This work provides detailed structural information on the interactions between @GENE$ and @CHEMICAL$ and analogs.	0
It could also aid in the design of @CHEMICAL$ derivatives displaying strict selectivity for either @GENE$ or CDKs.	0
It could also aid in the design of @CHEMICAL$ derivatives displaying strict selectivity for either PDXK or @GENE$.	0
In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (@GENE$) activation into functional cellular pathways requires the involvement of receptor @CHEMICAL$ kinase.	0
In many systems, the integration of converging regulatory signals that relay on G protein-coupled receptor (GPCR) activation into functional cellular pathways requires the involvement of @CHEM-GENE$.	0
In many systems, the integration of converging regulatory signals that relay on @GENE$ (GPCR) activation into functional cellular pathways requires the involvement of receptor @CHEMICAL$ kinase.	0
Using @CHEMICAL$-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on @GENE$ secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	0
Using @CHEMICAL$-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by @GENE$ kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	0
Using @CHEMICAL$-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR @GENE$ inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.	0
Using @CHEMICAL$-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of @GENE$.	0
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on @GENE$ secretion was inhibited by EGFR kinase inhibitor, @CHEMICAL$, as well as wortmannin, a specific inhibitor of PI3K.	2
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by @GENE$ kinase inhibitor, @CHEMICAL$, as well as wortmannin, a specific inhibitor of PI3K.	2
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR @GENE$ inhibitor, @CHEMICAL$, as well as wortmannin, a specific inhibitor of PI3K.	2
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, @CHEMICAL$, as well as wortmannin, a specific inhibitor of @GENE$.	0
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on @GENE$ secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as @CHEMICAL$, a specific inhibitor of PI3K.	2
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by @GENE$ kinase inhibitor, PD153035, as well as @CHEMICAL$, a specific inhibitor of PI3K.	0
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR @GENE$ inhibitor, PD153035, as well as @CHEMICAL$, a specific inhibitor of PI3K.	0
Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as @CHEMICAL$, a specific inhibitor of @GENE$.	2
Both inhibitors, moreover, blunted the @GENE$ secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, @CHEMICAL$.	2
Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as @GENE$ activator, @CHEMICAL$.	1
Both inhibitors, moreover, blunted the @GENE$ secretory responses to beta-adrenergic agonist-generated second messenger, @CHEMICAL$ as well as adenylate cyclase activator, forskolin.	0
Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, @CHEMICAL$ as well as @GENE$ activator, forskolin.	5
Both inhibitors, moreover, blunted the @GENE$ secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as @CHEMICAL$ cyclase activator, forskolin.	0
Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as @CHEM-GENE$ activator, forskolin.	0
The gastric mucin secretory responses to @CHEMICAL$, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent @GENE$ autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to @CHEMICAL$, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by @GENE$ inhibitor, PD98059.	0
The @GENE$ secretory responses to @CHEMICAL$, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to @CHEMICAL$, furthermore, were inhibited by PP2, a selective inhibitor of @GENE$ Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to @CHEMICAL$, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase @GENE$ responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by @CHEMICAL$, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent @GENE$ autophosphorylation, but not by ERK inhibitor, PD98059.	1
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by @CHEMICAL$, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by @GENE$ inhibitor, PD98059.	0
The @GENE$ secretory responses to isoproterenol, furthermore, were inhibited by @CHEMICAL$, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	2
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by @CHEMICAL$, a selective inhibitor of @GENE$ Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	2
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by @CHEMICAL$, a selective inhibitor of tyrosine kinase @GENE$ responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	2
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @CHEMICAL$ kinase Src responsible for ligand-independent @GENE$ autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @CHEMICAL$ kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by @GENE$ inhibitor, PD98059.	0
The @GENE$ secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @CHEMICAL$ kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @CHEM-GENE$ Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @CHEMICAL$ kinase @GENE$ responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent @GENE$ autophosphorylation, but not by ERK inhibitor, @CHEMICAL$.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by @GENE$ inhibitor, @CHEMICAL$.	2
The @GENE$ secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, @CHEMICAL$.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of @GENE$ Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, @CHEMICAL$.	0
The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase @GENE$ responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, @CHEMICAL$.	0
The inhibition of @GENE$, moreover, did not cause attenuation in mucin secretion in response to @CHEMICAL$ and forskolin.	2
The inhibition of ERK, moreover, did not cause attenuation in @GENE$ secretion in response to @CHEMICAL$ and forskolin.	0
The inhibition of @GENE$, moreover, did not cause attenuation in mucin secretion in response to cAMP and @CHEMICAL$.	2
The inhibition of ERK, moreover, did not cause attenuation in @GENE$ secretion in response to cAMP and @CHEMICAL$.	0
@CHEMICAL$: a selective @GENE$ antagonist for the treatment of heart failure.	4
Losartan: a selective @CHEM-GENE$ antagonist for the treatment of heart failure.	0
Losartan (COZAAR) is the prototype of a new class of potent and selective @CHEM-GENE$ antagonists with the largest published preclinical and clinical data base.	0
Losartan (COZAAR) is the prototype of a new class of potent and selective @CHEM-GENE$ antagonists with the largest published preclinical and clinical data base.	0
@CHEMICAL$ (COZAAR) is the prototype of a new class of potent and selective @GENE$ antagonists with the largest published preclinical and clinical data base.	4
Losartan (@CHEMICAL$) is the prototype of a new class of potent and selective @GENE$ antagonists with the largest published preclinical and clinical data base.	4
Since all of the @CHEM-GENE$ antagonists are selective for the AT(1) receptor, these drugs should exhibit similar cardiovascular effects.	0
Since all of the @CHEMICAL$ antagonists are selective for the @GENE$, these drugs should exhibit similar cardiovascular effects.	0
@CHEMICAL$ (parent compound), has moderate affinity for the @GENE$ (competitive inhibition).	0
@CHEMICAL$ is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the @GENE$ (non-competitive inhibition).	2
Clinical experience in heart failure is growing, and recent data suggest an improved survival with @CHEMICAL$ versus captopril, a drug from the @GENE$ inhibitor class with proven benefit in this population.	2
Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus @CHEMICAL$, a drug from the @GENE$ inhibitor class with proven benefit in this population.	2
Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the @CHEM-GENE$ inhibitor class with proven benefit in this population.	0
The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The @CHEMICAL$ Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.	0
The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The @CHEMICAL$ Renal Protection Study - RENAAL.	0
The current comprehensive @CHEMICAL$ clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.	0
The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with @CHEMICAL$ compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.	2
The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with losartan compared to standard therapy: 1) The @CHEMICAL$ Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.	0
The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the @GENE$ with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The @CHEMICAL$ Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.	0
Effect of @CHEMICAL$ on @GENE$ production in endotoxic shock.	0
We now demonstrate that @CHEMICAL$, a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced @GENE$ production at concentrations readily achieved in vivo.	2
Combined application of @CHEMICAL$ and amrinone caused additive inhibition of @GENE$ biosynthesis in vitro.	2
Combined application of dexamethasone and @CHEMICAL$ caused additive inhibition of @GENE$ biosynthesis in vitro.	2
Abrupt removal of @CHEMICAL$ or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented @GENE$ production.	1
Abrupt removal of amrinone or @CHEMICAL$ from the culture medium prior to LPS stimulation, however, caused significantly augmented @GENE$ production.	1
Therefore, @CHEMICAL$ and other @GENE$ inhibitors may also enhance sensitivity to LPS during a period of time following discontinuation of therapy.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (@GENE$) and @CHEMICAL$ oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and @CHEM-GENE$ (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and @CHEMICAL$ oxidase (@GENE$), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, @GENE$ (PLK) and @CHEMICAL$ oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of @CHEMICAL$ (PLP) synthesizing enzymes, pyridoxal kinase (@GENE$) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of @CHEMICAL$ (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and @GENE$ (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of @CHEMICAL$ (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (@GENE$), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of @CHEMICAL$ (PLP) synthesizing enzymes, @GENE$ (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of pyridoxal 5'-phosphate (@CHEMICAL$) synthesizing enzymes, pyridoxal kinase (@GENE$) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of pyridoxal 5'-phosphate (@CHEMICAL$) synthesizing enzymes, pyridoxal kinase (PLK) and @GENE$ (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of pyridoxal 5'-phosphate (@CHEMICAL$) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (@GENE$), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of pyridoxal 5'-phosphate (@CHEMICAL$) synthesizing enzymes, @GENE$ (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	5
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, @CHEMICAL$ kinase (@GENE$) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, @CHEMICAL$ kinase (PLK) and @GENE$ (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, @CHEMICAL$ kinase (PLK) and pyridoxine 5'-phosphate oxidase (@GENE$), their protein contents and activities were examined in the gerbil hippocampus proper.	0
In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, @CHEM-GENE$ (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.	0
Therefore, decreases of @GENE$ and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with @CHEMICAL$ (GABA) function.	2
Therefore, decreases of PLK and @GENE$ in the hippocampal CA1 region of aged brains may be involved in aging processes related with @CHEMICAL$ (GABA) function.	2
Therefore, decreases of @GENE$ and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (@CHEMICAL$) function.	2
Therefore, decreases of PLK and @GENE$ in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (@CHEMICAL$) function.	2
This process was reduced by a protonophore, @CHEMICAL$, and a typical @GENE$ (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, @CHEMICAL$, and a typical monocarboxylate transporter (@GENE$) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, @CHEMICAL$, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @GENE$.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @CHEM-GENE$ (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @CHEMICAL$ transporter (@GENE$) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @CHEMICAL$ transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @GENE$.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @GENE$ (MCT) inhibitor, @CHEMICAL$, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	2
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (@GENE$) inhibitor, @CHEMICAL$, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	2
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, @CHEMICAL$, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @GENE$.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @GENE$ (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that @CHEMICAL$ uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (@GENE$) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that @CHEMICAL$ uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that @CHEMICAL$ uptake by rat astrocytes is mediated by H(+)-coupled @GENE$.	5
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @GENE$ (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by @CHEMICAL$-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (@GENE$) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by @CHEMICAL$-coupled monocarboxylate transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by @CHEMICAL$-coupled @GENE$.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical @GENE$ (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @CHEMICAL$ transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (@GENE$) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @CHEMICAL$ transport system.	0
This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled @CHEM-GENE$.	0
Because @CHEMICAL$ reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by @GENE$ and/or MCT2.	0
Because @CHEMICAL$ reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or @GENE$.	0
Because l-lactate reduced to 67% of the @CHEMICAL$ uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by @GENE$ and/or MCT2.	0
Because l-lactate reduced to 67% of the @CHEMICAL$ uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or @GENE$.	0
Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that @CHEMICAL$ uptake in rat astrocytes is mediated by @GENE$ and/or MCT2.	5
Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that @CHEMICAL$ uptake in rat astrocytes is mediated by MCT1 and/or @GENE$.	5
These results provide biochemical evidence of a @CHEMICAL$-coupled and saturable transport system, presumed to be a @GENE$ MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a @CHEMICAL$-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter @GENE$ or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a @CHEMICAL$-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown @GENE$, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a @CHEM-GENE$ MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity @CHEMICAL$ transporter @GENE$ or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity @CHEMICAL$ transporter MCT4 or other unknown @GENE$, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a @GENE$ MCT4 or other unknown @CHEMICAL$-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter @GENE$ or other unknown @CHEMICAL$-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown @CHEM-GENE$, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a @GENE$ MCT4 or other unknown H(+)-coupled @CHEMICAL$ transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter @GENE$ or other unknown H(+)-coupled @CHEMICAL$ transport system, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown @CHEM-GENE$, for nicotinate in rat cerebrocortical astrocytes.	0
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a @GENE$ MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for @CHEMICAL$ in rat cerebrocortical astrocytes.	5
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter @GENE$ or other unknown H(+)-coupled monocarboxylate transport system, for @CHEMICAL$ in rat cerebrocortical astrocytes.	5
These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown @GENE$, for @CHEMICAL$ in rat cerebrocortical astrocytes.	5
A review of the structural and functional features of @CHEMICAL$, an @GENE$ blocker.	2
The @CHEM-GENE$-mediated effects of A-II play a key role in the pathophysiology of hypertension.	0
The angiotensin II (@CHEMICAL$) type 1 (AT1) receptor-mediated effects of @GENE$ play a key role in the pathophysiology of hypertension.	0
The @CHEM-GENE$-mediated effects of A-II play a key role in the pathophysiology of hypertension.	0
The @CHEMICAL$ (A-II) type 1 (AT1) receptor-mediated effects of @GENE$ play a key role in the pathophysiology of hypertension.	0
The @GENE$-mediated effects of @CHEMICAL$ play a key role in the pathophysiology of hypertension.	0
The angiotensin II (A-II) type 1 (AT1) receptor-mediated effects of @CHEM-GENE$ play a key role in the pathophysiology of hypertension.	0
Effective inhibition of @CHEM-GENE$ is provided by the latest class of antihypertensive medications, the AT1 receptor blockers (ARBs).	0
Effective inhibition of @CHEMICAL$ is provided by the latest class of antihypertensive medications, the @GENE$ receptor blockers (ARBs).	0
The marked antihypertensive efficacy of @CHEMICAL$ may result from a unique pharmacological interaction of the drug with the @GENE$ receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II.	0
The marked antihypertensive efficacy of @CHEMICAL$ may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of @GENE$.	2
The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the @GENE$ receptor, resulting in a potent, long-lasting, dose-dependent blockade of @CHEMICAL$.	0
The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of @CHEM-GENE$.	0
Effects of @GENE$ (G-CSF) and neutrophil elastase inhibitor (@CHEMICAL$) on acid-induced lung injury in rats.	2
Effects of granulocyte colony-stimulating factor (@GENE$) and neutrophil elastase inhibitor (@CHEMICAL$) on acid-induced lung injury in rats.	2
Effects of granulocyte colony-stimulating factor (G-CSF) and @GENE$ inhibitor (@CHEMICAL$) on acid-induced lung injury in rats.	2
We examined the effects of the high dose of @GENE$ (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (@CHEMICAL$) on acid lung injury in rats.	0
We examined the effects of the high dose of granulocyte-colony stimulating factor (@GENE$), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (@CHEMICAL$) on acid lung injury in rats.	0
We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific @GENE$ inhibitor (@CHEMICAL$) on acid lung injury in rats.	2
Thirty minutes before @CHEMICAL$ instillation, @GENE$ (150 microg kg(-1)) was injected subcutaneously or ONO-5046 (10 mg kg(-1) h(-1)) was infused continuously into the right jugular vein.	0
Thirty minutes before HCl instillation, @GENE$ (150 microg kg(-1)) was injected subcutaneously or @CHEMICAL$ (10 mg kg(-1) h(-1)) was infused continuously into the right jugular vein.	0
Both @CHEMICAL$ and @GENE$ attenuated the parameters increased by acid-induced lung injury in rats.	0
@CHEMICAL$, an imino sugar that reversibly inhibits @GENE$ and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.	2
Miglustat, an @CHEMICAL$ that reversibly inhibits @GENE$ and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.	2
@GENE$ potentiator drugs, huprine X and @CHEMICAL$, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.	0
Nicotinic-receptor potentiator drugs, huprine X and @CHEMICAL$, increase ACh release by blocking AChE activity but not acting on @GENE$.	0
Nicotinic-receptor potentiator drugs, huprine X and @CHEMICAL$, increase ACh release by blocking @GENE$ activity but not acting on nicotinic receptors.	2
@GENE$ potentiator drugs, huprine X and galantamine, increase @CHEMICAL$ release by blocking AChE activity but not acting on nicotinic receptors.	0
Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase @CHEMICAL$ release by blocking AChE activity but not acting on @GENE$.	0
Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase @CHEMICAL$ release by blocking @GENE$ activity but not acting on nicotinic receptors.	0
The main goal of the present study was to analyse the effects of (+/-)-huprine X ((+/-)-HX) and galantamine (GAL), with potentiating action on @GENE$, and huperzine A (HPA), devoid of nicotinic activity, on @CHEMICAL$ ([3H]-ACh) release in striatal slices of rat brain.	0
The main goal of the present study was to analyse the effects of (+/-)-huprine X ((+/-)-HX) and galantamine (GAL), with potentiating action on @GENE$, and huperzine A (HPA), devoid of nicotinic activity, on [3H]-acetylcholine (@CHEMICAL$) release in striatal slices of rat brain.	0
This effect was reverted in the presence of @CHEMICAL$ (ATR; 0.1 microM), which blocks the pre-synaptic @GENE$.	2
This effect was reverted in the presence of atropine (@CHEMICAL$; 0.1 microM), which blocks the pre-synaptic @GENE$.	2
After that, a wide range of concentrations of drugs, concomitantly with @CHEMICAL$ (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a @GENE$ antagonist.	0
After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of @CHEMICAL$ (HAL; 0.01 microM), a @GENE$ antagonist.	4
After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (@CHEMICAL$; 0.01 microM), a @GENE$ antagonist.	4
After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a @CHEM-GENE$ antagonist.	0
To test the role of @GENE$ in the drugs' effects on @CHEMICAL$ release, mecamylamine (MEC) 100 microM was used to block such receptors.	0
To test the role of @GENE$ in the drugs' effects on [3H]-ACh release, @CHEMICAL$ (MEC) 100 microM was used to block such receptors.	2
To test the role of @GENE$ in the drugs' effects on [3H]-ACh release, mecamylamine (@CHEMICAL$) 100 microM was used to block such receptors.	2
Many stimuli cause HSC to activate, lose their @CHEMICAL$ and produce @GENE$.	0
We also determine if @CHEMICAL$: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC @GENE$ (RAR) in HSC that are becoming activated or are chronically activated.	0
We also determine if @CHEMICAL$: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for retinoic acid (@GENE$) in HSC that are becoming activated or are chronically activated.	0
We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular @CHEMICAL$ levels; (3) maintain expression of HSC @GENE$ (RAR) in HSC that are becoming activated or are chronically activated.	0
We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular @CHEMICAL$ levels; (3) maintain expression of HSC nuclear receptors for retinoic acid (@GENE$) in HSC that are becoming activated or are chronically activated.	0
We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC @CHEM-GENE$ (RAR) in HSC that are becoming activated or are chronically activated.	0
We also determine if retinoids: (1) reverse HSC activation; (2) maintain/restore HSC intracellular retinoid levels; (3) maintain expression of HSC nuclear receptors for @CHEMICAL$ (@GENE$) in HSC that are becoming activated or are chronically activated.	0
mRNA levels for @GENE$, RAR-beta and RAR-gamma, the nuclear receptors for @CHEMICAL$, decreased during activation of freshly isolated HSC even with retinoid supplementation.	0
mRNA levels for RAR-alpha, @GENE$ and RAR-gamma, the nuclear receptors for @CHEMICAL$, decreased during activation of freshly isolated HSC even with retinoid supplementation.	0
mRNA levels for RAR-alpha, RAR-beta and @GENE$, the nuclear receptors for @CHEMICAL$, decreased during activation of freshly isolated HSC even with retinoid supplementation.	0
mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the @GENE$ for @CHEMICAL$, decreased during activation of freshly isolated HSC even with retinoid supplementation.	0
mRNA levels for @GENE$, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with @CHEMICAL$ supplementation.	2
mRNA levels for RAR-alpha, @GENE$ and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with @CHEMICAL$ supplementation.	2
mRNA levels for RAR-alpha, RAR-beta and @GENE$, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with @CHEMICAL$ supplementation.	2
mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the @GENE$ for retinoic acid, decreased during activation of freshly isolated HSC even with @CHEMICAL$ supplementation.	2
RAR-alpha, RAR-beta and @GENE$ mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after @CHEMICAL$ supplementation.	0
RAR-alpha, RAR-beta and RAR-gamma mRNA and @GENE$ protein was undetectable in chronically activated HSC and remained absent after @CHEMICAL$ supplementation.	0
@GENE$, RAR-beta and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after @CHEMICAL$ supplementation.	0
RAR-alpha, @GENE$ and RAR-gamma mRNA and RAR-beta protein was undetectable in chronically activated HSC and remained absent after @CHEMICAL$ supplementation.	0
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of @CHEMICAL$ decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the @GENE$.	2
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased @CHEMICAL$-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the @GENE$.	3
Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of @CHEMICAL$-contracted preparations in a concentration dependent fashion, indicating desensitization of the @GENE$.	0
Preincubation with 1 microM of the @GENE$ (PKC) activator phorbol 12-myristate 13-acetate (@CHEMICAL$) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (@GENE$) activator phorbol 12-myristate 13-acetate (@CHEMICAL$) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (@CHEMICAL$) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated @GENE$-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (@CHEMICAL$) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous @GENE$ desensitization.	2
Preincubation with 1 microM of the @GENE$ (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in @CHEMICAL$-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	0
Preincubation with 1 microM of the protein kinase C (@GENE$) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in @CHEMICAL$-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	0
Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in @CHEMICAL$-induced E(max), indicating activated @GENE$-mediated heterologous beta(2)-adrenoceptor desensitization.	0
Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in @CHEMICAL$-induced E(max), indicating activated PKC-mediated heterologous @GENE$ desensitization.	3
Preincubation with 1 microM of the @GENE$ (PKC) activator @CHEMICAL$ (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (@GENE$) activator @CHEMICAL$ (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (PKC) activator @CHEMICAL$ (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated @GENE$-mediated heterologous beta(2)-adrenoceptor desensitization.	1
Preincubation with 1 microM of the protein kinase C (PKC) activator @CHEMICAL$ (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous @GENE$ desensitization.	2
To investigate the capacity of activated @GENE$ to regulate homologous desensitization, we incubated the smooth muscle strips with the combination of both 1 microM PMA and 1 microM @CHEMICAL$.	0
Moreover, the specific @GENE$-inhibitor @CHEMICAL$ (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.	2
Moreover, the specific @GENE$-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (@CHEMICAL$) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.	2
Moreover, the specific @GENE$-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of @CHEMICAL$ for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.	0
Moreover, the specific @GENE$-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of @CHEMICAL$ and fenoterol were completely prevented.	0
Moreover, the specific @GENE$-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and @CHEMICAL$ were completely prevented.	0
@CHEM-GENE$ inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
@CHEMICAL$ kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @GENE$ of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
@CHEMICAL$ kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including @GENE$, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
@CHEMICAL$ kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, @GENE$, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
@CHEMICAL$ kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and @GENE$, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
@CHEMICAL$ kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of @GENE$ signaling.	0
@GENE$ inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	2
Tyrosine kinase inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular @GENE$ of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	2
Tyrosine kinase inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including @GENE$, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	2
Tyrosine kinase inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, @GENE$, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	2
Tyrosine kinase inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and @GENE$, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	2
Tyrosine kinase inhibitors are @CHEMICAL$-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of @GENE$ signaling.	2
@GENE$ inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEMICAL$ kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEM-GENE$ of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEMICAL$ kinase domain of several receptors, including @GENE$, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEMICAL$ kinase domain of several receptors, including EGFR, @GENE$, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEMICAL$ kinase domain of several receptors, including EGFR, Erb2, and @GENE$, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.	0
Tyrosine kinase inhibitors are quinazoline-derived, low molecular weight synthetic molecules that can block the intracellular @CHEMICAL$ kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of @GENE$ signaling.	0
Isolation and function of the @CHEMICAL$ transporter PAT1 (slc36a1) from rabbit and discrimination between transport via @GENE$ and system IMINO in renal brush-border membrane vesicles.	0
Isolation and function of the @CHEMICAL$ transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and @GENE$ in renal brush-border membrane vesicles.	0
Isolation and function of the @CHEM-GENE$ (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles.	0
Isolation and function of the @CHEMICAL$ transporter PAT1 (@GENE$) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles.	0
The purpose of this investigation was to determine whether this pH-dependent uptake represents H(+)/@CHEMICAL$ cotransport via a @GENE$-like transport system.	0
The purpose of this investigation was to determine whether this pH-dependent uptake represents @CHEMICAL$/amino acid cotransport via a @GENE$-like transport system.	0
The @GENE$ cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 @CHEMICAL$ (92% identity to human PAT1).	0
The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and @GENE$ and the open reading frame codes for a protein of 475 @CHEMICAL$ (92% identity to human PAT1).	0
The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the @GENE$ codes for a protein of 475 @CHEMICAL$ (92% identity to human PAT1).	0
The rabbit PAT1 cDNA was isolated (2296bp including both 5' and 3' untranslated regions and poly(A) tail) and the open reading frame codes for a protein of 475 @CHEMICAL$ (92% identity to @GENE$).	0
When expressed heterologously in a mammalian cell line, @GENE$ mediates pH-dependent, @CHEMICAL$-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid.	0
When expressed heterologously in a mammalian cell line, @GENE$ mediates pH-dependent, Na(+)-independent uptake of @CHEMICAL$, glycine, l-alanine and alpha-(methylamino)isobutyric acid.	5
When expressed heterologously in a mammalian cell line, @GENE$ mediates pH-dependent, Na(+)-independent uptake of proline, @CHEMICAL$, l-alanine and alpha-(methylamino)isobutyric acid.	5
When expressed heterologously in a mammalian cell line, @GENE$ mediates pH-dependent, Na(+)-independent uptake of proline, glycine, @CHEMICAL$ and alpha-(methylamino)isobutyric acid.	5
When expressed heterologously in a mammalian cell line, @GENE$ mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and @CHEMICAL$.	5
In the presence of @CHEMICAL$ and under conditions in which @GENE$ transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.	0
In the presence of @CHEMICAL$ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the @GENE$.	0
In the presence of Na+ and under conditions in which @GENE$ transport function was suppressed, a second @CHEMICAL$ uptake system was detected that exhibited functional characteristics similar to those of the IMINO system.	5
In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second @CHEMICAL$ uptake system was detected that exhibited functional characteristics similar to those of the @GENE$.	0
The functional characteristics of @GENE$ in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of @CHEMICAL$, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.	0
The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that @GENE$ is the low-affinity transporter of @CHEMICAL$, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.	5
The functional characteristics of @GENE$ in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, @CHEMICAL$ and hydroxyproline believed to be defective in patients with iminoglycinuria.	0
The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that @GENE$ is the low-affinity transporter of proline, @CHEMICAL$ and hydroxyproline believed to be defective in patients with iminoglycinuria.	5
The functional characteristics of @GENE$ in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and @CHEMICAL$ believed to be defective in patients with iminoglycinuria.	0
The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that @GENE$ is the low-affinity transporter of proline, glycine and @CHEMICAL$ believed to be defective in patients with iminoglycinuria.	5
Antidepressants suppress production of the Th1 @GENE$ interferon-gamma, independent of @CHEMICAL$ transporter blockade.	0
Antidepressants suppress production of the Th1 cytokine @GENE$, independent of @CHEMICAL$ transporter blockade.	0
Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of @CHEM-GENE$ blockade.	0
In this study, antidepressants with selectivity for the @CHEMICAL$ transporter (reboxetine and desipramine), or the @GENE$ (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the @CHEMICAL$ transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @CHEM-GENE$ (reboxetine and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (@CHEMICAL$ and desipramine), or the @GENE$ (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (@CHEMICAL$ and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @GENE$ (@CHEMICAL$ and desipramine), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and @CHEMICAL$), or the @GENE$ (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and @CHEMICAL$), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @GENE$ (reboxetine and @CHEMICAL$), or the serotonin transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the @CHEM-GENE$ (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the @CHEMICAL$ transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @GENE$ (reboxetine and desipramine), or the @CHEMICAL$ transporter (fluoxetine and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the @GENE$ (@CHEMICAL$ and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (@CHEMICAL$ and clomipramine) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @GENE$ (reboxetine and desipramine), or the serotonin transporter (@CHEMICAL$ and clomipramine) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the @GENE$ (fluoxetine and @CHEMICAL$) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In this study, antidepressants with selectivity for the noradrenaline transporter (reboxetine and desipramine), or the serotonin transporter (fluoxetine and @CHEMICAL$) were examined in terms of their ability to promote an anti-inflammatory @GENE$ phenotype in human blood.	0
In this study, antidepressants with selectivity for the @GENE$ (reboxetine and desipramine), or the serotonin transporter (fluoxetine and @CHEMICAL$) were examined in terms of their ability to promote an anti-inflammatory cytokine phenotype in human blood.	0
In addition, we examined the ability of trimipramine; a @CHEMICAL$ antidepressant that is devoid of monoamine reuptake inhibitory properties on @GENE$ production.	0
In addition, we examined the ability of trimipramine; a tricyclic antidepressant that is devoid of @CHEMICAL$ reuptake inhibitory properties on @GENE$ production.	0
In addition, we examined the ability of @CHEMICAL$; a tricyclic antidepressant that is devoid of monoamine reuptake inhibitory properties on @GENE$ production.	0
All of the antidepressants suppressed @GENE$ production in the 10-50 microM concentration range, irrespective of their preference for @CHEMICAL$ or noradrenaline transporters.	0
All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for @CHEM-GENE$.	0
All of the antidepressants suppressed @GENE$ production in the 10-50 microM concentration range, irrespective of their preference for serotonin or @CHEMICAL$ transporters.	0
All of the antidepressants suppressed IFN-gamma production in the 10-50 microM concentration range, irrespective of their preference for @CHEM-GENE$.	0
The fact that @CHEMICAL$ also suppressed @GENE$ production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake.	2
The fact that trimipramine also suppressed @GENE$ production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of @CHEMICAL$ reuptake.	0
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived @GENE$ production, with significant effects elicited by the @CHEMICAL$ reuptake inhibitors reboxetine and desipramine.	0
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived @GENE$ production, with significant effects elicited by the noradrenaline reuptake inhibitors @CHEMICAL$ and desipramine.	0
Interestingly, exposure to a lower concentration (1 microM) of the antidepressants tended to increase T-cell-derived @GENE$ production, with significant effects elicited by the noradrenaline reuptake inhibitors reboxetine and @CHEMICAL$.	0
Effect of @CHEMICAL$ on serum @GENE$ levels.	0
@GENE$ is a 167 @CHEMICAL$ protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.	0
@CHEMICAL$ is a piperidine antihistamine that increases appetite through its antiserotonergic effect on @GENE$ receptors in the brain.	0
Cyproheptadine is a @CHEMICAL$ antihistamine that increases appetite through its antiserotonergic effect on @GENE$ receptors in the brain.	0
Cyproheptadine is a piperidine @CHEMICAL$ that increases appetite through its antiserotonergic effect on @GENE$ receptors in the brain.	0
Although both @GENE$ and @CHEMICAL$ are effective in controlling appetite, their interaction has not been addressed in clinical studies.	0
The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean @GENE$ level after 1 week of treatment with @CHEMICAL$ (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).	1
This increase may suggest that both @GENE$ and @CHEMICAL$ may affect appetite via similar receptors and that cyproheptadine does not impair leptin activity through these receptors.	0
This increase may suggest that both @GENE$ and cyproheptadine may affect appetite via similar receptors and that @CHEMICAL$ does not impair leptin activity through these receptors.	0
Comparison of @CHEMICAL$ and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with @GENE$ inhibitors in high dieted methionine mice.	2
Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with @GENE$ inhibitors in high dieted @CHEMICAL$ mice.	0
Comparison of captopril and @CHEMICAL$ to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with @GENE$ inhibitors in high dieted methionine mice.	2
Comparison of captopril and enalapril to study the role of the @CHEMICAL$-group in improvement of endothelial dysfunction with @GENE$ inhibitors in high dieted methionine mice.	2
To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (@GENE$) inhibitors in experimental high dose of @CHEMICAL$ dieted rats.	0
To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with @GENE$ (ACE) inhibitors in experimental high dose of @CHEMICAL$ dieted rats.	0
To examine the role of @CHEMICAL$ (-SH) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (@GENE$) inhibitors in experimental high dose of methionine dieted rats.	0
To examine the role of @CHEMICAL$ (-SH) group in improvement of endothelial dysfunction with @GENE$ (ACE) inhibitors in experimental high dose of methionine dieted rats.	0
To examine the role of sulfhydryl (-@CHEMICAL$) group in improvement of endothelial dysfunction with angiotensin-converting enzyme (@GENE$) inhibitors in experimental high dose of methionine dieted rats.	0
To examine the role of sulfhydryl (-@CHEMICAL$) group in improvement of endothelial dysfunction with @GENE$ (ACE) inhibitors in experimental high dose of methionine dieted rats.	0
To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with @CHEMICAL$-converting enzyme (@GENE$) inhibitors in experimental high dose of methionine dieted rats.	0
To examine the role of sulfhydryl (-SH) group in improvement of endothelial dysfunction with @CHEM-GENE$ (ACE) inhibitors in experimental high dose of methionine dieted rats.	0
We compared the effects of @CHEMICAL$ (an @GENE$ inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	2
We compared the effects of @CHEMICAL$ (an ACE inhibitor with -SH group), enalapril (an @GENE$-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of @CHEMICAL$ (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -@CHEMICAL$ group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	2
We compared the effects of Captopril (an ACE inhibitor with -@CHEMICAL$ group), enalapril (an @GENE$-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -@CHEMICAL$ group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -SH group), @CHEMICAL$ (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), @CHEMICAL$ (an @GENE$-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	2
We compared the effects of Captopril (an ACE inhibitor with -SH group), @CHEMICAL$ (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -SH group), enalapril (an ACE-inhibitor without -@CHEMICAL$ group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an @GENE$-inhibitor without -@CHEMICAL$ group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -@CHEMICAL$ group), N-acetylcysteine (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), @CHEMICAL$ (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an @GENE$-inhibitor without -SH group), @CHEMICAL$ (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), @CHEMICAL$ (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -@CHEMICAL$ group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an @GENE$-inhibitor without -SH group), N-acetylcysteine (only -@CHEMICAL$ group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -@CHEMICAL$ group not @GENE$ inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an @GENE$ inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by @CHEMICAL$-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an @GENE$-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by @CHEMICAL$-induced hyperhomocysteinemia (HHcy) in rats.	0
We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not @GENE$ inhibitor) on endothelial dysfunction injured by @CHEMICAL$-induced hyperhomocysteinemia (HHcy) in rats.	0
@GENE$ (PON1) and ACE activity, @CHEMICAL$ (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (@GENE$) and ACE activity, @CHEMICAL$ (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and @GENE$ activity, @CHEMICAL$ (MDA), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, @CHEMICAL$ (MDA), nitric oxide (NO), @GENE$ (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, @CHEMICAL$ (MDA), nitric oxide (NO), superoxide dismutase (@GENE$) in serum were analyzed.	0
@GENE$ (PON1) and ACE activity, malondialdehyde (@CHEMICAL$), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (@GENE$) and ACE activity, malondialdehyde (@CHEMICAL$), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and @GENE$ activity, malondialdehyde (@CHEMICAL$), nitric oxide (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (@CHEMICAL$), nitric oxide (NO), @GENE$ (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (@CHEMICAL$), nitric oxide (NO), superoxide dismutase (@GENE$) in serum were analyzed.	0
@GENE$ (PON1) and ACE activity, malondialdehyde (MDA), @CHEMICAL$ (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (@GENE$) and ACE activity, malondialdehyde (MDA), @CHEMICAL$ (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and @GENE$ activity, malondialdehyde (MDA), @CHEMICAL$ (NO), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), @CHEMICAL$ (NO), @GENE$ (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), @CHEMICAL$ (NO), superoxide dismutase (@GENE$) in serum were analyzed.	0
@GENE$ (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (@CHEMICAL$), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (@GENE$) and ACE activity, malondialdehyde (MDA), nitric oxide (@CHEMICAL$), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and @GENE$ activity, malondialdehyde (MDA), nitric oxide (@CHEMICAL$), superoxide dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (@CHEMICAL$), @GENE$ (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (@CHEMICAL$), superoxide dismutase (@GENE$) in serum were analyzed.	0
@GENE$ (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), @CHEMICAL$ dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (@GENE$) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), @CHEMICAL$ dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and @GENE$ activity, malondialdehyde (MDA), nitric oxide (NO), @CHEMICAL$ dismutase (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), @CHEM-GENE$ (SOD) in serum were analyzed.	0
Paraoxonase1 (PON1) and ACE activity, malondialdehyde (MDA), nitric oxide (NO), @CHEMICAL$ dismutase (@GENE$) in serum were analyzed.	0
It was found that a single intragastric gavage by @CHEMICAL$ resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of @GENE$ and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	2
It was found that a single intragastric gavage by @CHEMICAL$ resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and @GENE$, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	2
It was found that a single intragastric gavage by @CHEMICAL$ resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and @GENE$ activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of @CHEMICAL$ and decreased the activity of @GENE$ and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of @CHEMICAL$ and decreased the activity of PON1 and @GENE$, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of @CHEMICAL$ and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and @GENE$ activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of @GENE$ and SOD, similarly decreased the level of @CHEMICAL$ in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and @GENE$, similarly decreased the level of @CHEMICAL$ in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of @CHEMICAL$ in the serum; but had no effects on endothelium-independent relaxation and @GENE$ activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of @GENE$ and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and @CHEMICAL$-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and @GENE$, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and @CHEMICAL$-converting enzyme activity compared with the control group.	0
It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and @CHEM-GENE$ activity compared with the control group.	0
Given the treatment with three doses of @CHEMICAL$ (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of @GENE$ and SOD in serum by single intragastric gavaged L-methionine.	1
Given the treatment with three doses of @CHEMICAL$ (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and @GENE$ in serum by single intragastric gavaged L-methionine.	1
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to @CHEMICAL$, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of @GENE$ and SOD in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to @CHEMICAL$, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and @GENE$ in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of @CHEMICAL$, the decreased level of NO, activity of @GENE$ and SOD in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of @CHEMICAL$, the decreased level of NO, activity of PON1 and @GENE$ in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of @CHEMICAL$, activity of @GENE$ and SOD in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of @CHEMICAL$, activity of PON1 and @GENE$ in serum by single intragastric gavaged L-methionine.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of @GENE$ and SOD in serum by single intragastric gavaged @CHEMICAL$.	0
Given the treatment with three doses of Captopril (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and @GENE$ in serum by single intragastric gavaged @CHEMICAL$.	0
However, there were some significant differences among @CHEMICAL$ (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of @GENE$ and ACE.	0
However, there were some significant differences among @CHEMICAL$ (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and @GENE$.	0
However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), @CHEMICAL$ (20 mg/kg), and N-acetylcysteine particular in the activity of @GENE$ and ACE.	0
However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), @CHEMICAL$ (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and @GENE$.	0
However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and @CHEMICAL$ particular in the activity of @GENE$ and ACE.	0
However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and @CHEMICAL$ particular in the activity of PON1 and @GENE$.	0
These results suggested that @CHEMICAL$ can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in @GENE$ activity and NO levels.	0
These results suggested that Captopril can protect the vascular endothelium against the damages induced by @CHEMICAL$ in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in @GENE$ activity and NO levels.	2
These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of @CHEMICAL$ may be related to attenuating the decrease in @GENE$ activity and NO levels.	1
These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in @GENE$ activity and @CHEMICAL$ levels.	0
@CHEMICAL$, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of @GENE$ and its favorable kinase selectivity profile.	2
@CHEMICAL$, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable @GENE$ selectivity profile.	2
Sorafenib, which belongs chemically to a class that can be described as @CHEMICAL$, was selected for further pharmacologic characterization based on potent inhibition of @GENE$ and its favorable kinase selectivity profile.	2
Sorafenib, which belongs chemically to a class that can be described as @CHEMICAL$, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable @GENE$ selectivity profile.	2
Further characterization showed that @CHEMICAL$ suppresses both wild-type and @GENE$ mutant B-Raf activity in vitro.	2
Further characterization showed that @CHEMICAL$ suppresses both wild-type and V599E mutant @GENE$ activity in vitro.	2
In addition, @CHEMICAL$ demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, @GENE$, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	1
In addition, @CHEMICAL$ demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, @GENE$ Flt-3, and c-KIT.	1
In addition, @CHEMICAL$ demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta @GENE$, and c-KIT.	1
In addition, @CHEMICAL$ demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and @GENE$.	1
In addition, @CHEMICAL$ demonstrated significant activity against several @GENE$ involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	1
In addition, @CHEMICAL$ demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including @GENE$, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	1
In addition, sorafenib demonstrated significant activity against several receptor @CHEMICAL$ kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, @GENE$, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	0
In addition, sorafenib demonstrated significant activity against several receptor @CHEMICAL$ kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, @GENE$ Flt-3, and c-KIT.	0
In addition, sorafenib demonstrated significant activity against several receptor @CHEMICAL$ kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta @GENE$, and c-KIT.	0
In addition, sorafenib demonstrated significant activity against several receptor @CHEMICAL$ kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and @GENE$.	0
In addition, sorafenib demonstrated significant activity against several @CHEM-GENE$ involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	0
In addition, sorafenib demonstrated significant activity against several receptor @CHEMICAL$ kinases involved in neovascularization and tumor progression, including @GENE$, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT.	0
A selective @CHEM-GENE$ agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.	0
A selective @GENE$ agonist @CHEMICAL$ (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.	3
A selective @GENE$ agonist bexarotene (@CHEMICAL$, targretin) inhibits angiogenesis and metastasis in solid tumours.	3
A selective @GENE$ agonist bexarotene (LGD1069, @CHEMICAL$) inhibits angiogenesis and metastasis in solid tumours.	3
The present study determined the influence of a @CHEM-GENE$ agonist bexarotene on angiogenesis and metastasis in solid tumours.	0
The present study determined the influence of a @GENE$ agonist @CHEMICAL$ on angiogenesis and metastasis in solid tumours.	3
In vivo angiogenesis assay utilising gelfoam sponges, @CHEMICAL$ reduced angiogenesis in sponges containing @GENE$, epidermal growth factor and basic fibroblast growth factor to various extent.	0
In vivo angiogenesis assay utilising gelfoam sponges, @CHEMICAL$ reduced angiogenesis in sponges containing vascular endothelial growth factor, @GENE$ and basic fibroblast growth factor to various extent.	0
In vivo angiogenesis assay utilising gelfoam sponges, @CHEMICAL$ reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic @GENE$ to various extent.	0
Analysis of tumour-conditioned medium indicated that @CHEMICAL$ decreased the secretion of angiogenic factors and @GENE$ and increased the tissue inhibitor of matrix metalloproteinases.	2
Analysis of tumour-conditioned medium indicated that @CHEMICAL$ decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of @GENE$.	1
The ability of @CHEMICAL$ to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner @GENE$.	1
OBJECTIVE: All antipsychotics act on the @CHEM-GENE$.	0
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two @GENE$ region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either @CHEMICAL$ or olanzapine.	0
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (@GENE$ and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either @CHEMICAL$ or olanzapine.	0
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two @GENE$ region polymorphisms (A-241G and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or @CHEMICAL$.	0
METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (@GENE$ and -141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or @CHEMICAL$.	0
Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and @CHEM-GENE$-induced dysmenorrhea.	0
Intrauterine pressure, ischemia markers, and experienced pain during administration of a @GENE$ antagonist in spontaneous and @CHEMICAL$-induced dysmenorrhea.	0
Intrauterine pressure, ischemia markers, and experienced pain during administration of a @CHEMICAL$ V1a receptor antagonist in spontaneous and @GENE$-induced dysmenorrhea.	0
Intrauterine pressure, ischemia markers, and experienced pain during administration of a @CHEM-GENE$ antagonist in spontaneous and vasopressin-induced dysmenorrhea.	0
BACKGROUND: A model to study the effect of @CHEM-GENE$ antagonist in dysmenorrhea.	0
At each menstruation a bolus injection of 10 pmol/kg of @GENE$ was administered before and during infusion of either 300 microg/min of @CHEMICAL$ or placebo.	0
At each menstruation a bolus injection of 10 pmol/kg of @CHEM-GENE$ was administered before and during infusion of either 300 microg/min of atosiban or placebo.	0
Ischemia markers in plasma and pain recorded by a visual analog scale were measured before and after each @CHEM-GENE$ injection as well as before and after the start of either atosiban or placebo infusion.	0
Ischemia markers in plasma and pain recorded by a visual analog scale were measured before and after each @GENE$ injection as well as before and after the start of either @CHEMICAL$ or placebo infusion.	0
RESULTS: @CHEM-GENE$ injections elevated area under the curve in both healthy volunteers and dysmenorrhea subjects.	0
In subjects with dysmenorrhea the increase in pain following the administration of @CHEM-GENE$ was significantly lower during atosiban than during placebo infusion.	0
In subjects with dysmenorrhea the increase in pain following the administration of @GENE$ was significantly lower during @CHEMICAL$ than during placebo infusion.	2
Healthy volunteers experienced only slight discomfort after the @CHEM-GENE$ injections.	0
CONCLUSIONS: @CHEMICAL$ reduces @GENE$-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.	2
CONCLUSIONS: Atosiban reduces @CHEM-GENE$-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.	0
The dysmenorrhea pain evoked by @CHEM-GENE$ correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one V1a-like receptor.	0
The dysmenorrhea pain evoked by @CHEMICAL$ correlated poorly with area under the curve, which may suggest that the effect is mediated by more than one @GENE$.	0
@CHEM-GENE$ expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?	0
BACKGROUND AND AIMS: @GENE$ (TS) is an important enzyme for DNA synthesis and the target for @CHEMICAL$ (5-FU).	0
BACKGROUND AND AIMS: Thymidylate synthase (@GENE$) is an important enzyme for DNA synthesis and the target for @CHEMICAL$ (5-FU).	0
BACKGROUND AND AIMS: @GENE$ (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (@CHEMICAL$).	0
BACKGROUND AND AIMS: Thymidylate synthase (@GENE$) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (@CHEMICAL$).	0
BACKGROUND AND AIMS: @CHEM-GENE$ (TS) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU).	0
BACKGROUND AND AIMS: @CHEMICAL$ synthase (@GENE$) is an important enzyme for DNA synthesis and the target for 5-fluorouracil (5-FU).	0
Enzymatic and biochemical properties of a novel @CHEM-GENE$ isoform.	0
A cDNA clone similar to @CHEM-GENE$ (SDH) is deposited in the GenBank/EMBL databases, but its structural and functional bases remain unknown.	0
A cDNA clone similar to human @CHEMICAL$ dehydratase (@GENE$) is deposited in the GenBank/EMBL databases, but its structural and functional bases remain unknown.	0
The purified protein showed @CHEM-GENE$ activity, demonstrating to be an isoform of SDH.	0
The purified protein showed @CHEMICAL$ and l-threonine dehydratase activity, demonstrating to be an isoform of @GENE$.	0
The purified protein showed @CHEM-GENE$ activity, demonstrating to be an isoform of SDH.	0
The purified protein showed l-serine and @CHEMICAL$ dehydratase activity, demonstrating to be an isoform of @GENE$.	0
Removal of Pro128 from the hepatic @GENE$ consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for @CHEMICAL$, whereas addition of a proline residue to the isoform was without effect.	0
Removal of Pro128 from the hepatic @GENE$ consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for pyridoxal 5'-phosphate, whereas addition of a @CHEMICAL$ residue to the isoform was without effect.	0
Multiple enzyme inhibitions by @CHEM-GENE$ antagonists as potential procognitive agents.	0
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, @CHEM-GENE$, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	0
Novel highly affine @GENE$ ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, @CHEMICAL$-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	0
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, @CHEMICAL$-methyltransferase, chemically show structural elements of the @GENE$ inhibitor tacrine.	0
Novel highly affine @CHEMICAL$ H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, @GENE$, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	0
Novel highly affine @CHEM-GENE$ ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	0
Novel highly affine @CHEMICAL$ H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the @GENE$ inhibitor tacrine.	0
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, @GENE$, chemically show structural elements of the acetylcholinesterase inhibitor @CHEMICAL$.	0
Novel highly affine @GENE$ ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor @CHEMICAL$.	0
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the @GENE$ inhibitor @CHEMICAL$.	2
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main @CHEMICAL$ metabolizing enzyme in the brain, @GENE$, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	5
Novel highly affine @GENE$ ligands with additional inhibitory effects on the main @CHEMICAL$ metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine.	0
Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main @CHEMICAL$ metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the @GENE$ inhibitor tacrine.	0
@GENE$ antagonism, inhibition of metabolisation of neuronal @CHEMICAL$ as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease.	0
@GENE$ antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of @CHEMICAL$ are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease.	0
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of @GENE$ and of butyrylcholinesterase which is another catalytic enzyme hydrolysing @CHEMICAL$.	5
Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of @GENE$ which is another catalytic enzyme hydrolysing @CHEMICAL$.	5
Some compounds with (sub)nanomolar activities on the @CHEMICAL$-related targets are also active in the nanomolar concentration range on both @GENE$ targets being 5- to 40-times more potent than tacrine.	0
Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both @GENE$ targets being 5- to 40-times more potent than @CHEMICAL$.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for @GENE$, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	2
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, @GENE$ inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, farnesyltransferase inhibitors for @GENE$, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for @GENE$/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/@GENE$, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for @GENE$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including @CHEMICAL$ for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either @GENE$ or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for @GENE$, farnesyltransferase inhibitors for NRAS, @CHEMICAL$ for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, @GENE$ inhibitors for NRAS, @CHEMICAL$ for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for @GENE$, @CHEMICAL$ for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, @CHEMICAL$ for @GENE$/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	2
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, @CHEMICAL$ for mitogen-activated protein kinase/@GENE$, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	2
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, @CHEMICAL$ for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for @GENE$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, @CHEMICAL$ for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either @GENE$ or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for @GENE$, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, @GENE$ inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for @GENE$, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for @GENE$/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/@GENE$, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for @GENE$, and agents that inhibit either vascular endothelial growth factor or its receptors.	2
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, @CHEMICAL$ analogues for mammalian target of rapamycin, and agents that inhibit either @GENE$ or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for @GENE$, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, @GENE$ inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for @GENE$, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for @GENE$/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/@GENE$, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for @CHEM-GENE$, and agents that inhibit either vascular endothelial growth factor or its receptors.	0
For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of @CHEMICAL$, and agents that inhibit either @GENE$ or its receptors.	0
This aminophospholipid "@GENE$" selectively transports @CHEMICAL$ to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.	5
This aminophospholipid "@GENE$" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to @CHEMICAL$, Ca(2+), and modification by sulfhydryl reagents.	0
This aminophospholipid "@GENE$" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, @CHEMICAL$, and modification by sulfhydryl reagents.	0
This aminophospholipid "@GENE$" selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by @CHEMICAL$ reagents.	0
A candidate @CHEM-GENE$ (ATPase II), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the yeast protein Drs2, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry.	0
A candidate @CHEMICAL$ flippase ATP8A1 (@GENE$), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the yeast protein Drs2, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry.	0
A candidate @CHEMICAL$ flippase ATP8A1 (ATPase II), originally isolated from bovine secretory vesicles, is a member of this subfamily based on sequence homology to the founding member of the subfamily, the @GENE$, which has been linked to ribosomal assembly, the formation of Golgi-coated vesicles, and the maintenance of PS asymmetry.	0
To determine if @GENE$ has biochemical characteristics consistent with a @CHEMICAL$ flippase, a murine homologue of this enzyme was expressed in insect cells and purified.	0
To determine if ATP8A1 has biochemical characteristics consistent with a @CHEM-GENE$, a murine homologue of this enzyme was expressed in insect cells and purified.	0
The purified @GENE$ is inactive in detergent micelles or in micelles containing @CHEMICAL$, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.	0
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, @CHEMICAL$, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.	0
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or @CHEMICAL$, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS.	0
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by @CHEMICAL$ or phosphatidylethanolamine (PE), and is maximally activated by PS.	1
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or @CHEMICAL$ (PE), and is maximally activated by PS.	1
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (@CHEMICAL$), and is maximally activated by PS.	1
The purified @GENE$ is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by @CHEMICAL$.	1
Similar to the @GENE$, Atp8a1 is activated only by the naturally occurring @CHEMICAL$ isomer of PS and not the sn-2,3-glycerol stereoisomer.	1
Similar to the plasma membrane PS transporter, @GENE$ is activated only by the naturally occurring @CHEMICAL$ isomer of PS and not the sn-2,3-glycerol stereoisomer.	1
Similar to the @GENE$, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the @CHEMICAL$ stereoisomer.	0
Similar to the plasma membrane PS transporter, @GENE$ is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the @CHEMICAL$ stereoisomer.	0
Similar to the @CHEM-GENE$, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer.	0
Similar to the plasma membrane @CHEMICAL$ transporter, @GENE$ is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer.	0
Most modifications of the @CHEMICAL$ headgroup structure decrease recognition by the plasma membrane @GENE$.	0
Most modifications of the PS headgroup structure decrease recognition by the plasma membrane @CHEM-GENE$.	0
Activation of @GENE$ is also reduced by these modifications; @CHEMICAL$, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.	2
Activation of Atp8a1 is also reduced by these modifications; @CHEMICAL$, lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate @GENE$.	0
Activation of @GENE$ is also reduced by these modifications; phosphatidylserine-O-methyl ester, @CHEMICAL$, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.	2
Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, @CHEMICAL$, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate @GENE$.	0
Activation of @GENE$ is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, @CHEMICAL$, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1.	2
Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, @CHEMICAL$, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate @GENE$.	0
Activation of @GENE$ is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and @CHEMICAL$, which are not transported by the plasma membrane flippase, do not activate Atp8a1.	2
Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and @CHEMICAL$, which are not transported by the plasma membrane flippase, do not activate @GENE$.	0
Weakly translocated lipids (@CHEMICAL$, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak @GENE$ activators.	1
Weakly translocated lipids (PE, @CHEMICAL$, and phosphatidylhomoserine) are also weak @GENE$ activators.	1
Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and @CHEMICAL$) are also weak @GENE$ activators.	1
However, @CHEMICAL$, which is transported by the plasma membrane @GENE$ at a rate equivalent to PS, is incapable of activating Atp8a1 activity.	5
However, @CHEMICAL$, which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating @GENE$ activity.	0
However, N-methyl-phosphatidylserine, which is transported by the plasma membrane @GENE$ at a rate equivalent to @CHEMICAL$, is incapable of activating Atp8a1 activity.	0
However, N-methyl-phosphatidylserine, which is transported by the plasma membrane flippase at a rate equivalent to @CHEMICAL$, is incapable of activating @GENE$ activity.	0
These results indicate that the @GENE$ activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (@CHEMICAL$ selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	1
These results indicate that the ATPase activity of the secretory granule @GENE$ is activated by phospholipids binding to a specific site whose properties (@CHEMICAL$ selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	1
These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (@CHEMICAL$ selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane @GENE$.	0
These results indicate that the @GENE$ activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon @CHEMICAL$ but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	0
These results indicate that the ATPase activity of the secretory granule @GENE$ is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon @CHEMICAL$ but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	0
These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon @CHEMICAL$ but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane @GENE$.	0
These results indicate that the @GENE$ activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not @CHEMICAL$, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	0
These results indicate that the ATPase activity of the secretory granule @GENE$ is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not @CHEMICAL$, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.	0
These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not @CHEMICAL$, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane @GENE$.	0
High-mannose-type glycan modifications of @CHEM-GENE$ using glycan-methotrexate conjugates.	0
High-@CHEMICAL$-type glycan modifications of @GENE$ using glycan-methotrexate conjugates.	0
High-mannose-type glycan modifications of @GENE$ using glycan-@CHEMICAL$ conjugates.	0
Various high-@CHEMICAL$-type glycan modifications of dihydrofolate reductase (DHFR) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for @GENE$.	0
Various high-@CHEMICAL$-type glycan modifications of @GENE$ (DHFR) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-@CHEMICAL$-type glycan modifications of dihydrofolate reductase (@GENE$) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of dihydrofolate reductase (DHFR) were achieved by ligand-based approach using glycan-@CHEMICAL$ (MTX) conjugates as tight binding glycan bearing ligands for @GENE$.	0
Various high-mannose-type glycan modifications of @GENE$ (DHFR) were achieved by ligand-based approach using glycan-@CHEMICAL$ (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of dihydrofolate reductase (@GENE$) were achieved by ligand-based approach using glycan-@CHEMICAL$ (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of dihydrofolate reductase (DHFR) were achieved by ligand-based approach using glycan-methotrexate (@CHEMICAL$) conjugates as tight binding glycan bearing ligands for @GENE$.	0
Various high-mannose-type glycan modifications of @GENE$ (DHFR) were achieved by ligand-based approach using glycan-methotrexate (@CHEMICAL$) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of dihydrofolate reductase (@GENE$) were achieved by ligand-based approach using glycan-methotrexate (@CHEMICAL$) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of @CHEMICAL$ reductase (DHFR) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for @GENE$.	0
Various high-mannose-type glycan modifications of @CHEM-GENE$ (DHFR) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
Various high-mannose-type glycan modifications of @CHEMICAL$ reductase (@GENE$) were achieved by ligand-based approach using glycan-methotrexate (MTX) conjugates as tight binding glycan bearing ligands for DHFR.	0
The resulting glycan-@CHEMICAL$ conjugates and the corresponding artificial glycoproteins could be useful as oligosaccharide- and glycoprotein-probes to perform quantitative analysis of @GENE$ such as lectins, glycosyltransferases or glycosidases.	0
The resulting glycan-@CHEMICAL$ conjugates and the corresponding artificial glycoproteins could be useful as oligosaccharide- and glycoprotein-probes to perform quantitative analysis of glycan recognizing protein such as @GENE$, glycosyltransferases or glycosidases.	0
The resulting glycan-@CHEMICAL$ conjugates and the corresponding artificial glycoproteins could be useful as oligosaccharide- and glycoprotein-probes to perform quantitative analysis of glycan recognizing protein such as lectins, @GENE$ or glycosidases.	0
The resulting glycan-@CHEMICAL$ conjugates and the corresponding artificial glycoproteins could be useful as oligosaccharide- and glycoprotein-probes to perform quantitative analysis of glycan recognizing protein such as lectins, glycosyltransferases or @GENE$.	0
@CHEM-GENE$ are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
@CHEMICAL$ receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and @GENE$ leads to disease-specific nuances of glutamate-signalling.	0
@CHEMICAL$ receptors are not alone: dynamic regulation of @GENE$ structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
@CHEMICAL$ receptors are not alone: dynamic regulation of NMDA receptor structure and function by @GENE$ and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
@GENE$ are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient @CHEMICAL$-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and @CHEM-GENE$ leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of @GENE$ structure and function by neuregulins and transient @CHEMICAL$-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by @GENE$ and transient @CHEMICAL$-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
@GENE$ are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of @CHEMICAL$-signalling.	0
NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and @GENE$ leads to disease-specific nuances of @CHEMICAL$-signalling.	0
NMDA receptors are not alone: dynamic regulation of @GENE$ structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of @CHEMICAL$-signalling.	0
NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by @GENE$ and transient cholesterol-rich membrane domains leads to disease-specific nuances of @CHEMICAL$-signalling.	0
@GENE$ are not alone: dynamic regulation of @CHEMICAL$ receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of @CHEMICAL$ receptor structure and function by neuregulins and @GENE$ leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of @CHEM-GENE$ structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
NMDA receptors are not alone: dynamic regulation of @CHEMICAL$ receptor structure and function by @GENE$ and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	0
@GENE$ of the N-methyl-D-asparate (@CHEMICAL$-) subtype are tetrameric allosteric and ligand-gated calcium channels.	0
Glutamate receptors of the N-methyl-D-asparate (@CHEMICAL$-) subtype are tetrameric allosteric and @GENE$.	0
@CHEM-GENE$ of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels.	0
@CHEMICAL$ receptors of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and @GENE$.	0
@GENE$ of the @CHEMICAL$ (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels.	0
Glutamate receptors of the @CHEMICAL$ (NMDA-) subtype are tetrameric allosteric and @GENE$.	0
On the structural level @CHEM-GENE$ have an enormous flexibility due to seven genes (NR1, NR2A-D and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	0
On the structural level @CHEMICAL$ receptors have an enormous flexibility due to seven genes (@GENE$, NR2A-D and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	0
On the structural level @CHEMICAL$ receptors have an enormous flexibility due to seven genes (NR1, @GENE$ and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	0
On the structural level @CHEMICAL$ receptors have an enormous flexibility due to seven genes (NR1, NR2A-D and @GENE$), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation.	0
@CHEM-GENE$ are thought to be responsible for excitotoxicity and subsequent downstream events like neuroinflammation and apoptosis and thus have been implicated in many important human pathologies, ranging from amyotrophic lateral sclerosis, Alzheimer's and Parkinson' disease, depression, epilepsy, trauma and stroke to schizophrenia.	0
This fundamental significance of @CHEM-GENE$-related excitotoxicity is discussed in the context of the developing clinical success of Memantine, but moreover set into relation to various proteomic and genetic markers of said diseases.	0
This fundamental significance of @GENE$-related excitotoxicity is discussed in the context of the developing clinical success of @CHEMICAL$, but moreover set into relation to various proteomic and genetic markers of said diseases.	0
The very complex localisational and functional regulation of @CHEM-GENE$ appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of @CHEMICAL$ receptors appears to be dependent on @GENE$ and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of @CHEMICAL$ receptors appears to be dependent on neuregulins and @GENE$ in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of @CHEMICAL$ receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like @GENE$ (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of @CHEMICAL$ receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (@GENE$).	0
The very complex localisational and functional regulation of @GENE$ appears to be dependent on neuregulins and receptor @CHEMICAL$ kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on @GENE$ and receptor @CHEMICAL$ kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and @CHEM-GENE$ in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor @CHEMICAL$ kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like @GENE$ (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor @CHEMICAL$ kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (@GENE$).	0
The very complex localisational and functional regulation of @GENE$ appears to be dependent on neuregulins and receptor tyrosine kinases in @CHEMICAL$-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on @GENE$ and receptor tyrosine kinases in @CHEMICAL$-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and @GENE$ in @CHEMICAL$-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in @CHEMICAL$-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like @GENE$ (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in @CHEMICAL$-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (@GENE$).	0
The very complex localisational and functional regulation of @GENE$ appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), @CHEMICAL$-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on @GENE$ and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), @CHEMICAL$-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and @GENE$ in cholesterol-rich membrane domains (lipid rafts), @CHEMICAL$-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), @CHEMICAL$-related mitochondrial feedback-loops and subsynaptic structural elements like @GENE$ (post-synaptic density protein of 95 kD).	0
The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), @CHEMICAL$-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (@GENE$).	0
@CHEMICAL$: recent update on activity as a single agent and in combination with @GENE$ in patients with advanced-stage renal cell carcinoma.	0
@CHEMICAL$ (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of @GENE$ that are known to be involved in tumor cell proliferation and tumor angiogenesis.	2
Sorafenib (@CHEMICAL$) is a small-molecule inhibitor that has been shown to target members of multiple classes of @GENE$ that are known to be involved in tumor cell proliferation and tumor angiogenesis.	2
Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of @CHEM-GENE$ that are known to be involved in tumor cell proliferation and tumor angiogenesis.	0
@CHEMICAL$ inhibits nitric oxide production and @GENE$ via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	2
@CHEMICAL$ inhibits nitric oxide production and nuclear factor-kappaB via @GENE$ expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	0
Hydrogen sulfide inhibits @CHEMICAL$ production and @GENE$ via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	0
Hydrogen sulfide inhibits @CHEMICAL$ production and nuclear factor-kappaB via @GENE$ expression in RAW264.7 macrophages stimulated with lipopolysaccharide.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from @CHEMICAL$ (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from @CHEMICAL$ (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from @CHEMICAL$ (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from @CHEMICAL$ (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (@CHEMICAL$) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (@CHEMICAL$) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (@CHEMICAL$) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (@CHEMICAL$) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (@CHEMICAL$), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (@CHEMICAL$), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (@CHEMICAL$), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (@CHEMICAL$), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
@CHEMICAL$ (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
@CHEMICAL$ (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
@CHEMICAL$ (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
@CHEMICAL$ (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	5
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in @CHEMICAL$ (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in @CHEMICAL$ (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in @CHEMICAL$ (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in @CHEMICAL$ (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (@CHEMICAL$) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (@CHEMICAL$) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (@CHEMICAL$) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (@CHEMICAL$) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @CHEMICAL$ gamma-lyase (@GENE$) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @CHEMICAL$ gamma-lyase (CSE) and/or @GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @CHEMICAL$ gamma-lyase (CSE) and/or cystathionine beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @CHEM-GENE$ (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (@GENE$) and/or @CHEMICAL$ beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @CHEM-GENE$ (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or @CHEMICAL$ beta-synthase (@GENE$) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by @GENE$ (CSE) and/or @CHEMICAL$ beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.	0
Here, we show that at noncytotoxic concentrations, @CHEMICAL$ was able to inhibit NO production and @GENE$ (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	2
Here, we show that at noncytotoxic concentrations, @CHEMICAL$ was able to inhibit NO production and inducible NO synthase (@GENE$) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	2
Here, we show that at noncytotoxic concentrations, @CHEMICAL$ was able to inhibit NO production and inducible NO synthase (iNOS) expression via @GENE$ (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, @CHEMICAL$ was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (@GENE$) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit @CHEMICAL$ production and @GENE$ (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	5
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit @CHEMICAL$ production and inducible NO synthase (@GENE$) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	5
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit @CHEMICAL$ production and inducible NO synthase (iNOS) expression via @GENE$ (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit @CHEMICAL$ production and inducible NO synthase (iNOS) expression via heme oxygenase (@GENE$) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and @CHEM-GENE$ (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible @CHEMICAL$ synthase (@GENE$) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible @CHEMICAL$ synthase (iNOS) expression via @GENE$ (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible @CHEMICAL$ synthase (iNOS) expression via heme oxygenase (@GENE$) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).	0
Both @CHEMICAL$ solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced @GENE$ expression through the activation of the extracellular signal-regulated kinase (ERK).	1
Both @CHEMICAL$ solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the @GENE$ (ERK).	1
Both @CHEMICAL$ solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (@GENE$).	1
Both H(2)S solution prepared by bubbling pure @CHEMICAL$ gas and NaSH, a H(2)S donor, dose dependently induced @GENE$ expression through the activation of the extracellular signal-regulated kinase (ERK).	0
Both H(2)S solution prepared by bubbling pure @CHEMICAL$ gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the @GENE$ (ERK).	0
Both H(2)S solution prepared by bubbling pure @CHEMICAL$ gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (@GENE$).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and @CHEMICAL$, a H(2)S donor, dose dependently induced @GENE$ expression through the activation of the extracellular signal-regulated kinase (ERK).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and @CHEMICAL$, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the @GENE$ (ERK).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and @CHEMICAL$, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (@GENE$).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a @CHEMICAL$ donor, dose dependently induced @GENE$ expression through the activation of the extracellular signal-regulated kinase (ERK).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a @CHEMICAL$ donor, dose dependently induced HO-1 expression through the activation of the @GENE$ (ERK).	0
Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a @CHEMICAL$ donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (@GENE$).	0
Pretreatment with @CHEMICAL$ or NaHS significantly inhibited LPS-induced @GENE$ expression and NO production.	2
Pretreatment with H(2)S or @CHEMICAL$ significantly inhibited LPS-induced @GENE$ expression and NO production.	2
Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced @GENE$ expression and @CHEMICAL$ production.	5
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective @GENE$ inhibitor @CHEMICAL$ but not by the CBS inhibitor aminooxyacetic acid.	2
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor @CHEMICAL$ but not by the @GENE$ inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing @GENE$ mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor @CHEMICAL$ but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, @CHEMICAL$ production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective @GENE$ inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, @CHEMICAL$ production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the @GENE$ inhibitor aminooxyacetic acid.	0
Moreover, @CHEMICAL$ production in LPS-stimulated macrophages that are expressing @GENE$ mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of @CHEMICAL$, a substrate for H(2)S, but enhanced by the selective @GENE$ inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of @CHEMICAL$, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the @GENE$ inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing @GENE$ mRNA was significantly reduced by the addition of @CHEMICAL$, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	5
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for @CHEMICAL$, but enhanced by the selective @GENE$ inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for @CHEMICAL$, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the @GENE$ inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing @GENE$ mRNA was significantly reduced by the addition of L-Cys, a substrate for @CHEMICAL$, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective @GENE$ inhibitor beta-cyano-L-alanine but not by the CBS inhibitor @CHEMICAL$.	0
Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the @GENE$ inhibitor @CHEMICAL$.	2
Moreover, NO production in LPS-stimulated macrophages that are expressing @GENE$ mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor @CHEMICAL$.	0
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with @CHEMICAL$ (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with @CHEMICAL$ (CO), an end product of @GENE$.	5
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (@CHEMICAL$), an end product of @GENE$.	5
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	2
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of @CHEMICAL$ on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of @GENE$.	0
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	5
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and @CHEMICAL$ production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of @GENE$.	0
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of @CHEMICAL$. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of @GENE$.	0
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	2
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with @CHEMICAL$. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of @GENE$.	0
While either blockage of @GENE$ activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the @GENE$ inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of @GENE$ expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by @GENE$ small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on @GENE$ expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, @GENE$ overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor @GENE$ activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on @GENE$ activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	2
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with @GENE$ siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either @GENE$ gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.	0
While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of @CHEMICAL$ on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of @GENE$.	0
@CHEMICAL$ treatment also inhibited LPS-induced NO production and @GENE$ expression via its inactivation of NF-kappaB.	2
@CHEMICAL$ treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of @GENE$.	2
CO treatment also inhibited LPS-induced @CHEMICAL$ production and @GENE$ expression via its inactivation of NF-kappaB.	5
CO treatment also inhibited LPS-induced @CHEMICAL$ production and iNOS expression via its inactivation of @GENE$.	0
Collectively, our results suggest that @CHEMICAL$ can inhibit NO production and @GENE$ activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.	2
Collectively, our results suggest that @CHEMICAL$ can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of @GENE$/CO.	0
Collectively, our results suggest that H(2)S can inhibit @CHEMICAL$ production and @GENE$ activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.	0
Collectively, our results suggest that H(2)S can inhibit @CHEMICAL$ production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of @GENE$/CO.	0
Collectively, our results suggest that H(2)S can inhibit NO production and @GENE$ activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/@CHEMICAL$.	0
Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of @GENE$/@CHEMICAL$.	5
Effect of chronic renal failure on @GENE$ and @CHEMICAL$ synthetase expression.	0
Effect of chronic renal failure on arginase and @CHEM-GENE$ expression.	0
Sources of L-arg include dietary proteins and endogenous synthesis by @GENE$ and @CHEMICAL$ lyase.	0
Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and @CHEM-GENE$.	0
Sources of @CHEMICAL$ include dietary proteins and endogenous synthesis by @GENE$ and argininosuccinate lyase.	5
Sources of @CHEMICAL$ include dietary proteins and endogenous synthesis by argininosuccinate synthetase and @GENE$.	5
Sources of L-arg include dietary proteins and endogenous synthesis by @CHEM-GENE$ and argininosuccinate lyase.	0
Sources of L-arg include dietary proteins and endogenous synthesis by @CHEMICAL$ synthetase and @GENE$.	0
@CHEMICAL$ is converted to urea by @GENE$ in the liver and arginase II in the kidney.	5
@CHEMICAL$ is converted to urea by arginase I in the liver and @GENE$ in the kidney.	5
L-arg is converted to @CHEMICAL$ by @GENE$ in the liver and arginase II in the kidney.	5
L-arg is converted to @CHEMICAL$ by arginase I in the liver and @GENE$ in the kidney.	5
We hypothesized that preservation of plasma @CHEMICAL$ in CRF may be, partly, due to downregulation/inhibition of @GENE$.	5
METHODS: @CHEM-GENE$, arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation.	0
METHODS: @CHEMICAL$ synthetase, @GENE$ protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation.	0
In addition, @GENE$ activity was measured in the presence of different @CHEMICAL$ concentrations to simulate azotemia in vitro.	0
However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of @GENE$ activity by @CHEMICAL$ in the tissue lysates.	2
CRF had no significant effect on @CHEM-GENE$ abundance in the kidney, liver, spleen or intestine.	0
CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of @GENE$, the inherent rise in @CHEMICAL$ concentration inhibits its enzymatic activity.	2
@CHEM-GENE$ antagonists as aquaretic agents for the treatment of hyponatremia.	0
It is a state of relative water excess due to stimulated @GENE$ (@CHEMICAL$) and fluid intake greater than obligatory losses.	0
It is a state of relative water excess due to stimulated arginine vasopressin (@CHEM-GENE$) and fluid intake greater than obligatory losses.	0
It is a state of relative water excess due to stimulated @CHEM-GENE$ (AVP) and fluid intake greater than obligatory losses.	0
It is a state of relative water excess due to stimulated @CHEMICAL$ (@GENE$) and fluid intake greater than obligatory losses.	0
In this respect, pharmacologic research has yielded a number of compounds exhibiting antagonistic qualities at the @CHEM-GENE$.	0
Among these agents, peptidic derivatives of @CHEM-GENE$ turned out to have intrinsic antidiuretic properties in vivo when given over days or weeks.	0
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are @CHEMICAL$ (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (@CHEMICAL$), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (lixivaptan), @CHEMICAL$ (conivaptan), OPC-41061 (tolvaptan), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (@CHEMICAL$), OPC-41061 (tolvaptan), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), @CHEMICAL$ (tolvaptan), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (@CHEMICAL$), and SR-121463.	4
However, several promising nonpeptide, @GENE$ antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and @CHEMICAL$.	4
Sedation and @GENE$ antagonism: studies in man with the enantiomers of chlorpheniramine and @CHEMICAL$.	4
Sedation and @CHEM-GENE$ antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene.	0
Sedation and @GENE$ antagonism: studies in man with the enantiomers of @CHEMICAL$ and dimethindene.	4
In the present study, changes in measures of drowsiness and performance were limited to the enantiomers with high affinity for the @CHEM-GENE$.	0
BG also showed a protective effect in the presence of a @GENE$ inhibitor (@CHEMICAL$, Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.	2
BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (@CHEMICAL$, Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving @GENE$.	0
BG also showed a protective effect in the presence of a @GENE$ inhibitor (cytosine arabinoside-3-phosphate, @CHEMICAL$), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.	2
BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (cytosine arabinoside-3-phosphate, @CHEMICAL$), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving @GENE$.	0
Association of @GENE$ polymorphisms and @CHEMICAL$-induced extrapyramidal syndrome in Chinese schizophrenic patients.	0
In this study, we evaluate the role @GENE$ plays in @CHEMICAL$-induced EPS in schizophrenic patients.	0
METHODS: We identified seven SNP(single @CHEMICAL$ polymorphism) (-141Cins>del, TaqIB, TaqID, @GENE$, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.	0
METHODS: We identified seven SNP(single @CHEMICAL$ polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the @GENE$ gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.	0
METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, @GENE$, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with @CHEMICAL$ after 8 weeks.	0
METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the @GENE$ gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with @CHEMICAL$ after 8 weeks.	0
CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the @GENE$ gene plays a major role in the individually variable adverse effect induced by @CHEMICAL$, at least in Chinese patients with schizophrenia.	0
Activity-dependent cleavage of brain @CHEM-GENE$ by calpain.	0
Activity-dependent cleavage of brain @CHEMICAL$ decarboxylase 65 by @GENE$.	0
Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks @CHEMICAL$ 1-69 from the N-terminus, @GENE$.	0
Previously, we reported that @GENE$ (GAD65) could be cleaved in vitro to release a stable truncated form which lacks @CHEMICAL$ 1-69 from the N-terminus, GAD65(Delta1-69).	0
Previously, we reported that l-glutamic acid decarboxylase isoform 65 (@GENE$) could be cleaved in vitro to release a stable truncated form which lacks @CHEMICAL$ 1-69 from the N-terminus, GAD65(Delta1-69).	0
Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the @CHEMICAL$-terminus, @GENE$.	0
Previously, we reported that @GENE$ (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the @CHEMICAL$-terminus, GAD65(Delta1-69).	0
Previously, we reported that l-glutamic acid decarboxylase isoform 65 (@GENE$) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the @CHEMICAL$-terminus, GAD65(Delta1-69).	0
Previously, we reported that @CHEMICAL$ decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, @GENE$.	0
Previously, we reported that @CHEM-GENE$ (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69).	0
Previously, we reported that @CHEMICAL$ decarboxylase isoform 65 (@GENE$) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69).	0
@CHEMICAL$-chelating reagents such as EDTA and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of @GENE$.	0
Calcium-chelating reagents such as @CHEMICAL$ and 1,2-bis-(o-aminphenoxy)-ethane-N,N,N',N'-tetra-acetic acid tetra-acetoxy-methyl ester prevented the cleavage of @GENE$.	0
Calcium-chelating reagents such as EDTA and @CHEMICAL$ prevented the cleavage of @GENE$.	0
In addition, our data suggested that calpain, a @CHEMICAL$-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated @GENE$ in the brain.	0
In addition, our data suggested that @GENE$, a @CHEMICAL$-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain.	0
In addition, our data suggested that calpain, a @CHEM-GENE$, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain.	0
In addition, our data suggested that calpain, a @CHEMICAL$-dependent cysteine protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length @GENE$ to truncated GAD65 in the brain.	0
In addition, our data suggested that calpain, a calcium-dependent @CHEMICAL$ protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated @GENE$ in the brain.	0
In addition, our data suggested that @GENE$, a calcium-dependent @CHEMICAL$ protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain.	0
In addition, our data suggested that calpain, a @CHEM-GENE$, is activated upon neuronal stimulation and could be responsible for the conversion of full-length GAD65 to truncated GAD65 in the brain.	0
In addition, our data suggested that calpain, a calcium-dependent @CHEMICAL$ protease, is activated upon neuronal stimulation and could be responsible for the conversion of full-length @GENE$ to truncated GAD65 in the brain.	0
Agents that specifically target BRAF, such as @CHEMICAL$, as well as new molecules that function both upstream and downstream of @GENE$, are being actively investigated.	0
Agents that specifically target @GENE$, such as @CHEMICAL$, as well as new molecules that function both upstream and downstream of BRAF, are being actively investigated.	0
Reduction of cerebral infarct size by the @GENE$-receptor blocker candesartan, the HMG-CoA reductase inhibitor @CHEMICAL$ and their combination.	0
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the @GENE$ inhibitor @CHEMICAL$ and their combination.	2
Reduction of cerebral infarct size by the @GENE$-receptor blocker @CHEMICAL$, the HMG-CoA reductase inhibitor rosuvastatin and their combination.	2
Reduction of cerebral infarct size by the AT1-receptor blocker @CHEMICAL$, the @GENE$ inhibitor rosuvastatin and their combination.	0
Reduction of cerebral infarct size by the @GENE$-receptor blocker candesartan, the @CHEMICAL$ reductase inhibitor rosuvastatin and their combination.	0
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the @CHEM-GENE$ inhibitor rosuvastatin and their combination.	0
Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker @CHEMICAL$ and the @GENE$ inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.	0
Our purpose was to test the impact of single and/or combined treatment with the @GENE$-receptor blocker @CHEMICAL$ and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.	2
Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the @CHEM-GENE$ inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.	0
Our purpose was to test the impact of single and/or combined treatment with the @GENE$-receptor blocker candesartan and the @CHEMICAL$ reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.	0
Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the @GENE$ inhibitor @CHEMICAL$ on infarct size and neuroscore in transient cerebral ischemia in rats.	2
Our purpose was to test the impact of single and/or combined treatment with the @GENE$-receptor blocker candesartan and the HMG-CoA reductase inhibitor @CHEMICAL$ on infarct size and neuroscore in transient cerebral ischemia in rats.	0
@CHEMICAL$ was used to test whether any potential effect was due to activation of @GENE$ (eNOS).	0
@CHEMICAL$ was used to test whether any potential effect was due to activation of endothelial nitric oxide synthase (@GENE$).	0
L-NAME was used to test whether any potential effect was due to activation of @CHEM-GENE$ (eNOS).	0
L-NAME was used to test whether any potential effect was due to activation of endothelial @CHEMICAL$ synthase (@GENE$).	0
Previously, we and others have shown that mutations in the @GENE$ gene encoding an @CHEMICAL$-binding cassette (ABC) transporter underlie the skin disease HI.	0
Previously, we and others have shown that mutations in the ABCA12 gene encoding an @CHEM-GENE$ underlie the skin disease HI.	0
Phosphorylation and up-regulation of @CHEM-GENE$ via its interaction with protein kinase C gamma.	0
Phosphorylation and up-regulation of @CHEMICAL$ kinase gamma via its interaction with @GENE$.	0
Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to @CHEMICAL$ by @GENE$ (DGK).	5
Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to @CHEMICAL$ by DAG kinase (@GENE$).	5
Diacylglycerol (DAG) acts as an allosteric activator of @GENE$ (PKC) and is converted to @CHEMICAL$ by DAG kinase (DGK).	0
Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (@GENE$) and is converted to @CHEMICAL$ by DAG kinase (DGK).	0
@CHEMICAL$ (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by @GENE$ (DGK).	5
@CHEMICAL$ (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (@GENE$).	5
@CHEMICAL$ (DAG) acts as an allosteric activator of @GENE$ (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).	0
@CHEMICAL$ (DAG) acts as an allosteric activator of protein kinase C (@GENE$) and is converted to phosphatidic acid by DAG kinase (DGK).	0
Diacylglycerol (@CHEMICAL$) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by @GENE$ (DGK).	5
Diacylglycerol (@CHEMICAL$) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (@GENE$).	5
Diacylglycerol (@CHEMICAL$) acts as an allosteric activator of @GENE$ (PKC) and is converted to phosphatidic acid by DAG kinase (DGK).	0
Diacylglycerol (@CHEMICAL$) acts as an allosteric activator of protein kinase C (@GENE$) and is converted to phosphatidic acid by DAG kinase (DGK).	0
@GENE$ directly associated with DGKgamma through its accessory domain (AD), depending on @CHEMICAL$ as well as phosphatidylserine/diolein in vitro.	0
gammaPKC directly associated with @GENE$ through its accessory domain (AD), depending on @CHEMICAL$ as well as phosphatidylserine/diolein in vitro.	0
@GENE$ directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as @CHEMICAL$/diolein in vitro.	0
gammaPKC directly associated with @GENE$ through its accessory domain (AD), depending on Ca2+ as well as @CHEMICAL$/diolein in vitro.	0
@GENE$ directly associated with DGKgamma through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/@CHEMICAL$ in vitro.	0
gammaPKC directly associated with @GENE$ through its accessory domain (AD), depending on Ca2+ as well as phosphatidylserine/@CHEMICAL$ in vitro.	0
Mass spectrometric analysis and mutation studies revealed that @GENE$ @CHEMICAL$-776 and Ser-779 in the AD of DGKgamma.	0
Mass spectrometric analysis and mutation studies revealed that gammaPKC @CHEMICAL$-776 and Ser-779 in the AD of @GENE$.	0
Mass spectrometric analysis and mutation studies revealed that @GENE$ phosphorylated Ser-776 and @CHEMICAL$-779 in the AD of DGKgamma.	0
Mass spectrometric analysis and mutation studies revealed that gammaPKC phosphorylated Ser-776 and @CHEMICAL$-779 in the AD of @GENE$.	0
The phosphorylation by @GENE$ resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with @CHEMICAL$ to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of @GENE$ because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with @CHEMICAL$ to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a @GENE$ mutant in which Ser-776 and Ser-779 were substituted with @CHEMICAL$ to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with @CHEMICAL$ to mimic phosphorylation exhibited significantly higher activity compared with wild type @GENE$ and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with @CHEMICAL$ to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable @GENE$ mutant.	0
The phosphorylation by @GENE$ resulted in activation of DGKgamma because a DGKgamma mutant in which @CHEMICAL$-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of @GENE$ because a DGKgamma mutant in which @CHEMICAL$-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a @GENE$ mutant in which @CHEMICAL$-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which @CHEMICAL$-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type @GENE$ and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which @CHEMICAL$-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable @GENE$ mutant.	0
The phosphorylation by @GENE$ resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and @CHEMICAL$-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of @GENE$ because a DGKgamma mutant in which Ser-776 and @CHEMICAL$-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a @GENE$ mutant in which Ser-776 and @CHEMICAL$-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and @CHEMICAL$-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type @GENE$ and an unphosphorylatable DGKgamma mutant.	0
The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and @CHEMICAL$-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable @GENE$ mutant.	0
Monoclonal antibody 25B1 generated against @CHEMICAL$ inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its @GENE$ properties.	0
Monoclonal antibody 25B1 generated against @CHEMICAL$ inhibited fetal @GENE$ has been extensively characterized with respect to its anticholinesterase properties.	2
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of @GENE$ against denaturation by heat or @CHEMICAL$ following phosphorylation by organophosphorus anticholinesterase compounds.	2
Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of acetylcholinesterase against denaturation by heat or @CHEMICAL$ following phosphorylation by organophosphorus @GENE$ compounds.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged @CHEMICAL$ attached to the P atom, CH3P(O)(O-)-@GENE$, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged @CHEMICAL$ attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of @GENE$.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the @CHEMICAL$ atom, CH3P(O)(O-)-@GENE$, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the @CHEMICAL$ atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of @GENE$.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, @CHEMICAL$-@GENE$, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, @CHEMICAL$-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of @GENE$.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-@GENE$, conferred the greatest protection to the active site of aged or nonaged @CHEMICAL$ conjugates of acetylcholinesterase.	0
Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged @CHEMICAL$ conjugates of @GENE$.	0
Among all the @CHEMICAL$ tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-@GENE$, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.	0
Among all the @CHEMICAL$ tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of @GENE$.	0
Effects of @CHEMICAL$ deficiency and @GENE$ C677T polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes.	0
Effects of @CHEMICAL$ deficiency and MTHFR @GENE$ polymorphism on spontaneous and radiation-induced micronuclei in human lymphocytes.	0
The @GENE$ polymorphism of the @CHEMICAL$ reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.	0
The C677T polymorphism of the @CHEM-GENE$ (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.	0
The C677T polymorphism of the @CHEMICAL$ reductase (@GENE$) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on folate status.	0
The @GENE$ polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on @CHEMICAL$ status.	0
The C677T polymorphism of the @GENE$ (MTHFR) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on @CHEMICAL$ status.	0
The C677T polymorphism of the methylene-tetrahydrofolate reductase (@GENE$) gene is associated with a reduction of catalytic activity and is suggested to modify cancer risk differently depending on @CHEMICAL$ status.	0
In this work the effect of @CHEMICAL$ deficiency on genome stability and radiosensitivity has been investigated in cultured lymphocytes of 12 subjects with different @GENE$ genotype (four for each genotype).	0
The results obtained indicate that @CHEMICAL$ deficiency induces to a comparable extent chromosome loss and breakage, irrespective of the @GENE$ genotype.	0
Also nucleoplasmic bridges and buds were significantly increased under low @CHEMICAL$ supply; the increase in bridges was mainly observed in TT cells, highlighting a significant effect of the @GENE$ genotype (P = 0.006) on this biomarker.	0
@CHEMICAL$ concentration significantly affected radiation-induced micronuclei (P < 0.001): the increased incidence of radiation-induced micronuclei with low folic acid was mainly accounted for by carriers of the variant @GENE$ allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance.	0
Folic acid concentration significantly affected radiation-induced micronuclei (P < 0.001): the increased incidence of radiation-induced micronuclei with low @CHEMICAL$ was mainly accounted for by carriers of the variant @GENE$ allele (both homozygotes and heterozygotes), but the overall effect of genotype did not attain statistical significance.	0
The effect of @CHEMICAL$ level on this end-point was modulated by the @GENE$ genotype (P for interaction = 0.02), with TT cells grown at low folic acid concentration apparently resistant to the induction of radiation-induced bridges.	0
The effect of folic acid level on this end-point was modulated by the @GENE$ genotype (P for interaction = 0.02), with TT cells grown at low @CHEMICAL$ concentration apparently resistant to the induction of radiation-induced bridges.	0
The main molecular target of @CHEMICAL$ antifungals is the @GENE$ protein Erg11p/Cyp51p.	0
The main molecular target of @CHEMICAL$ antifungals is the cytochrome P-450 protein @GENE$/Cyp51p.	0
The main molecular target of @CHEMICAL$ antifungals is the cytochrome P-450 protein Erg11p/@GENE$.	0
The @CHEMICAL$, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: @GENE$ (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).	0
The @CHEMICAL$, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (@GENE$) and Erg2p (delta 8-delta 7 isomerase).	0
The @CHEMICAL$, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and @GENE$ (delta 8-delta 7 isomerase).	0
The @CHEMICAL$, of which amorolfine is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (@GENE$).	0
The phenylmorpholines, of which @CHEMICAL$ is the sole representative in human therapy, affect two targets in the ergosterol pathway: @GENE$ (delta 14 reductase) and Erg2p (delta 8-delta 7 isomerase).	0
The phenylmorpholines, of which @CHEMICAL$ is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (@GENE$) and Erg2p (delta 8-delta 7 isomerase).	0
The phenylmorpholines, of which @CHEMICAL$ is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and @GENE$ (delta 8-delta 7 isomerase).	0
The phenylmorpholines, of which @CHEMICAL$ is the sole representative in human therapy, affect two targets in the ergosterol pathway: Erg24p (delta 14 reductase) and Erg2p (@GENE$).	0
The @CHEMICAL$ group are protein synthesis inhibitors that work by blocking the function of @GENE$.	2
@CHEMICAL$ as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor @GENE$ activation.	0
D-myo-inositol 1-phosphate as a surrogate of @CHEMICAL$ to monitor @GENE$ activation.	0
@GENE$ (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring @CHEMICAL$ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring @CHEMICAL$ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a @GENE$ hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (@GENE$)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring @CHEMICAL$ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled @GENE$ (GPCR) activities traditionally are assessed by measuring @CHEMICAL$ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (@GENE$) activities traditionally are assessed by measuring @CHEMICAL$ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
@GENE$ (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by @CHEMICAL$ (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by @CHEMICAL$ (IP3), a @GENE$ hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	5
Phospholipase C beta (@GENE$)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by @CHEMICAL$ (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled @GENE$ (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by @CHEMICAL$ (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (@GENE$) activities traditionally are assessed by measuring Ca2+ triggered by @CHEMICAL$ (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
@GENE$ (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (@CHEMICAL$), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (@CHEMICAL$), a @GENE$ hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	5
Phospholipase C beta (@GENE$)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (@CHEMICAL$), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled @GENE$ (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (@CHEMICAL$), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (@GENE$) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (@CHEMICAL$), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.	0
@GENE$ (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of @CHEMICAL$ using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a @GENE$ hydrolysis product, or by measuring the production of @CHEMICAL$ using cumbersome radioactive assays.	5
Phospholipase C beta (@GENE$)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of @CHEMICAL$ using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled @GENE$ (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of @CHEMICAL$ using cumbersome radioactive assays.	0
Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (@GENE$) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of @CHEMICAL$ using cumbersome radioactive assays.	0
The short lifetime of @CHEMICAL$ makes this detection very challenging in measuring @GENE$ responses.	0
It has been known for decades that @CHEMICAL$ (LiCl) leads to D-myo-inositol 1-phosphate accumulation on @GENE$ activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.	1
It has been known for decades that @CHEMICAL$ (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting @GENE$, the final enzyme of the IP3 metabolic cascade.	2
It has been known for decades that lithium chloride (@CHEMICAL$) leads to D-myo-inositol 1-phosphate accumulation on @GENE$ activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.	1
It has been known for decades that lithium chloride (@CHEMICAL$) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting @GENE$, the final enzyme of the IP3 metabolic cascade.	2
It has been known for decades that lithium chloride (LiCl) leads to @CHEMICAL$ accumulation on @GENE$ activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.	0
It has been known for decades that lithium chloride (LiCl) leads to @CHEMICAL$ accumulation on GPCR activation by inhibiting @GENE$, the final enzyme of the IP3 metabolic cascade.	5
It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on @GENE$ activation by inhibiting inositol monophosphatase, the final enzyme of the @CHEMICAL$ metabolic cascade.	0
It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting @GENE$, the final enzyme of the @CHEMICAL$ metabolic cascade.	5
We show here that @CHEMICAL$ can be used as a surrogate of IP3 to monitor @GENE$ activation.	0
We show here that IP1 can be used as a surrogate of @CHEMICAL$ to monitor @GENE$ activation.	0
It has the advantage over the traditional @CHEMICAL$ assay of allowing the measurement of inverse agonist activity as well as the analysis of @GENE$ activity in any nontransfected primary cultures.	0
Once formed, the molecule can be converted to @CHEMICAL$ by @GENE$ (AGAT).	5
Once formed, the molecule can be converted to @CHEMICAL$ by alanine-glyoxylate aminotransferase (@GENE$).	5
Once formed, the molecule can be converted to glycine by @CHEM-GENE$ (AGAT).	0
Once formed, the molecule can be converted to glycine by @CHEMICAL$-glyoxylate aminotransferase (@GENE$).	0
Once formed, the molecule can be converted to glycine by @CHEM-GENE$ (AGAT).	0
Once formed, the molecule can be converted to glycine by alanine-@CHEMICAL$ aminotransferase (@GENE$).	0
In defects of @GENE$, glyoxylate is transformed to @CHEMICAL$, resulting in high levels of oxalate in the body.	0
In defects of @GENE$, glyoxylate is transformed to oxalate, resulting in high levels of @CHEMICAL$ in the body.	0
In defects of @GENE$, @CHEMICAL$ is transformed to oxalate, resulting in high levels of oxalate in the body.	0
At a pre-receptor level, glucocorticoid action is modulated by @CHEM-GENE$ (11beta-HSDs).	0
At a pre-receptor level, glucocorticoid action is modulated by @CHEMICAL$ dehydrogenases (@GENE$).	0
@GENE$ activates @CHEMICAL$ to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.	5
11Beta-HSD1 activates @CHEMICAL$ to cortisol to facilitate @GENE$ (GR)-mediated action.	0
11Beta-HSD1 activates @CHEMICAL$ to cortisol to facilitate glucocorticoid receptor (@GENE$)-mediated action.	0
@GENE$ activates cortisone to @CHEMICAL$ to facilitate glucocorticoid receptor (GR)-mediated action.	5
11Beta-HSD1 activates cortisone to @CHEMICAL$ to facilitate @GENE$ (GR)-mediated action.	0
11Beta-HSD1 activates cortisone to @CHEMICAL$ to facilitate glucocorticoid receptor (@GENE$)-mediated action.	0
By contrast, @GENE$ plays a pivotal role in @CHEMICAL$ target tissues where it catalyses the opposite reaction (i.e.	0
inactivation of @CHEMICAL$ to cortisone) to prevent activation of the @GENE$ (MR) by cortisol.	0
inactivation of @CHEMICAL$ to cortisone) to prevent activation of the mineralocorticoid receptor (@GENE$) by cortisol.	0
inactivation of cortisol to @CHEMICAL$) to prevent activation of the @GENE$ (MR) by cortisol.	0
inactivation of cortisol to @CHEMICAL$) to prevent activation of the mineralocorticoid receptor (@GENE$) by cortisol.	0
inactivation of cortisol to cortisone) to prevent activation of the @GENE$ (MR) by @CHEMICAL$.	1
inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (@GENE$) by @CHEMICAL$.	1
Mutations in the @GENE$ gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which @CHEMICAL$ activates the MR resulting in severe hypertension and hypokalemia.	0
Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which @CHEMICAL$ activates the @GENE$ resulting in severe hypertension and hypokalemia.	1
Ingestion of competitive inhibitors of @GENE$ such as liquorice and @CHEMICAL$ result in a similar but milder clinical phenotype.	2
@GENE$ controls CD1d expression by turning on @CHEMICAL$ synthesis in developing human dendritic cells.	0
PPARgamma controls @GENE$ expression by turning on @CHEMICAL$ synthesis in developing human dendritic cells.	0
Here we demonstrate that @GENE$, turns on @CHEMICAL$ synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on @CHEMICAL$ synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @GENE$ and retinaldehyde dehydrogenase type 2 (RALDH2).	5
Here we demonstrate that PPARgamma, turns on @CHEMICAL$ synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and @GENE$ (RALDH2).	5
Here we demonstrate that PPARgamma, turns on @CHEMICAL$ synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (@GENE$).	5
Here we demonstrate that @GENE$, turns on retinoic acid synthesis by inducing the expression of @CHEMICAL$ and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of @CHEMICAL$ and retinal metabolizing enzymes such as @GENE$ and retinaldehyde dehydrogenase type 2 (RALDH2).	5
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of @CHEMICAL$ and retinal metabolizing enzymes such as retinol dehydrogenase 10 and @GENE$ (RALDH2).	5
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of @CHEMICAL$ and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (@GENE$).	5
Here we demonstrate that @GENE$, turns on retinoic acid synthesis by inducing the expression of retinol and @CHEMICAL$ metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and @CHEMICAL$ metabolizing enzymes such as @GENE$ and retinaldehyde dehydrogenase type 2 (RALDH2).	5
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and @CHEMICAL$ metabolizing enzymes such as retinol dehydrogenase 10 and @GENE$ (RALDH2).	5
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and @CHEMICAL$ metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (@GENE$).	5
Here we demonstrate that @GENE$, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @CHEMICAL$ dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @CHEM-GENE$ and retinaldehyde dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @CHEMICAL$ dehydrogenase 10 and @GENE$ (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @CHEMICAL$ dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (@GENE$).	0
Here we demonstrate that @GENE$, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and @CHEMICAL$ dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as @GENE$ and @CHEMICAL$ dehydrogenase type 2 (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and @CHEM-GENE$ (RALDH2).	0
Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and @CHEMICAL$ dehydrogenase type 2 (@GENE$).	0
@GENE$-regulated expression of these enzymes leads to an increase in the intracellular generation of all-trans retinoic acid (ATRA) from @CHEMICAL$.	0
@GENE$-regulated expression of these enzymes leads to an increase in the intracellular generation of @CHEMICAL$ (ATRA) from retinol.	0
@GENE$-regulated expression of these enzymes leads to an increase in the intracellular generation of all-trans retinoic acid (@CHEMICAL$) from retinol.	0
@CHEMICAL$ regulates gene expression via the activation of the @GENE$ in human DCs, and RARalpha acutely regulates CD1d expression.	1
@CHEMICAL$ regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and @GENE$ acutely regulates CD1d expression.	1
@CHEMICAL$ regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates @GENE$ expression.	1
ATRA regulates gene expression via the activation of the @CHEM-GENE$ in human DCs, and RARalpha acutely regulates CD1d expression.	0
ATRA regulates gene expression via the activation of the @CHEMICAL$ receptor (RAR)alpha in human DCs, and @GENE$ acutely regulates CD1d expression.	0
ATRA regulates gene expression via the activation of the @CHEMICAL$ receptor (RAR)alpha in human DCs, and RARalpha acutely regulates @GENE$ expression.	0
The @CHEMICAL$-induced elevated expression of @GENE$ is coupled to enhanced iNKT cell activation.	1
Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit @CHEMICAL$ signaling leading to @GENE$ up-regulation.	1
These data show that regulation of @CHEMICAL$ metabolism and signaling is part of the @GENE$-controlled transcriptional events in DCs.	0
CONTEXT: @CHEMICAL$ is a novel @GENE$ and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.	3
CONTEXT: @CHEMICAL$ is a novel MT1 and @GENE$ selective agonist recently approved for insomnia treatment.	3
Inhibition of cardiac @CHEM-GENE$ by grape polyphenols.	0
Inhibition of cardiac @CHEM-GENE$ (VGSCs) is antiarrhythmic and cardioprotective.	0
Inhibition of cardiac voltage-gated @CHEMICAL$ channels (@GENE$) is antiarrhythmic and cardioprotective.	0
Late INa induced by the @GENE$ long QT mutant R1623Q was reduced by @CHEMICAL$ and quercetin.	2
Late INa induced by the VGSC long QT mutant @GENE$ was reduced by @CHEMICAL$ and quercetin.	2
Late INa induced by the @GENE$ long QT mutant R1623Q was reduced by resveratrol and @CHEMICAL$.	2
Late INa induced by the VGSC long QT mutant @GENE$ was reduced by resveratrol and @CHEMICAL$.	2
Enhancement of radiosensitivity by @GENE$ inhibitor, @CHEMICAL$ and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.	2
Enhancement of radiosensitivity by @GENE$ inhibitor, amrubicin and @CHEMICAL$, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.	2
Similar to @CHEMICAL$ and AMROH, adriamycin and etoposide (VP-16) are @GENE$ inhibitors.	2
Similar to AMR and @CHEMICAL$, adriamycin and etoposide (VP-16) are @GENE$ inhibitors.	2
Similar to AMR and AMROH, @CHEMICAL$ and etoposide (VP-16) are @GENE$ inhibitors.	2
Similar to AMR and AMROH, adriamycin and @CHEMICAL$ (VP-16) are @GENE$ inhibitors.	2
Similar to AMR and AMROH, adriamycin and etoposide (@CHEMICAL$) are @GENE$ inhibitors.	2
Accumulated evidence in humans and animals shows that both @CHEMICAL$ and H. pylori upregulate the expression of @GENE$ both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.	1
Accumulated evidence in humans and animals shows that both @CHEMICAL$ and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of @GENE$.	0
It was, therefore, proposed that H. pylori may in fact, antagonize, @CHEMICAL$-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as @GENE$ and VEGF.	1
It was, therefore, proposed that H. pylori may in fact, antagonize, @CHEMICAL$-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and @GENE$.	1
It was, therefore, proposed that H. pylori may in fact, antagonize, @CHEMICAL$-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from @GENE$ expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.	1
It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in @CHEMICAL$ possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as @GENE$ and VEGF.	0
It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in @CHEMICAL$ possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and @GENE$.	0
It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in @CHEMICAL$ possibly derived from @GENE$ expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.	5
The effect of a novel transition state inhibitor of @CHEM-GENE$ on pemetrexed activity.	0
The effect of a novel transition state inhibitor of @GENE$ on @CHEMICAL$ activity.	0
Pemetrexed is a new-generation antifolate inhibitor of @CHEMICAL$ synthase (TS) and a weaker inhibitor of @GENE$ (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of @CHEMICAL$ synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (@GENE$) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of @CHEM-GENE$ (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of @CHEMICAL$ synthase (@GENE$) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of @CHEM-GENE$ (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of @CHEMICAL$ transformylase (@GENE$) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of @GENE$ (TS) and a weaker inhibitor of @CHEMICAL$ transformylase (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (@GENE$) and a weaker inhibitor of @CHEMICAL$ transformylase (GARFT) required for de novo purine synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of @GENE$ (GARFT) required for de novo @CHEMICAL$ synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (@GENE$) required for de novo @CHEMICAL$ synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of @GENE$ (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo @CHEMICAL$ synthesis.	0
Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (@GENE$) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo @CHEMICAL$ synthesis.	0
@GENE$ (MTAP) salvages @CHEMICAL$ by releasing adenine from methylthioadenosine and is often deleted in mesothelioma.	0
Methylthioadenosine phosphorylase (@GENE$) salvages @CHEMICAL$ by releasing adenine from methylthioadenosine and is often deleted in mesothelioma.	0
@GENE$ (MTAP) salvages purines by releasing @CHEMICAL$ from methylthioadenosine and is often deleted in mesothelioma.	5
Methylthioadenosine phosphorylase (@GENE$) salvages purines by releasing @CHEMICAL$ from methylthioadenosine and is often deleted in mesothelioma.	5
@GENE$ (MTAP) salvages purines by releasing adenine from @CHEMICAL$ and is often deleted in mesothelioma.	5
Methylthioadenosine phosphorylase (@GENE$) salvages purines by releasing adenine from @CHEMICAL$ and is often deleted in mesothelioma.	5
@CHEM-GENE$ (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma.	0
@CHEMICAL$ phosphorylase (@GENE$) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma.	0
The current study addresses the effect of @GENE$ on @CHEMICAL$ activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines.	0
The current study addresses the effect of MTAP on @CHEMICAL$ activity using a highly potent transition state inhibitor of @GENE$, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines.	0
The current study addresses the effect of MTAP on @CHEMICAL$ activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the @GENE$(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines.	0
The current study addresses the effect of MTAP on @CHEMICAL$ activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and @GENE$(-) NCI-H2052 mesothelioma cell lines.	0
Based on selective nucleoside protection, @GENE$ was found to be the primary @CHEMICAL$ target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations.	0
Based on selective nucleoside protection, TS was found to be the primary @CHEMICAL$ target in both cell lines with @GENE$ inhibition requiring 20- to 30-fold higher pemetrexed concentrations.	0
Based on selective nucleoside protection, @GENE$ was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher @CHEMICAL$ concentrations.	0
Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with @GENE$ inhibition requiring 20- to 30-fold higher @CHEMICAL$ concentrations.	2
ImmA had no effect on @CHEMICAL$ activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in @GENE$(+) H28 cells with no effect in MTAP(-) H2052 cells.	0
ImmA had no effect on @CHEMICAL$ activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in @GENE$(-) H2052 cells.	0
ImmA had no effect on pemetrexed activity but, when @CHEMICAL$ was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in @GENE$(+) H28 cells with no effect in MTAP(-) H2052 cells.	0
ImmA had no effect on pemetrexed activity but, when @CHEMICAL$ was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in @GENE$(-) H2052 cells.	0
ImmA had no effect on pemetrexed activity but, when thymidine was added, the @CHEMICAL$ IC(50) decreased by a factor of approximately 3 in @GENE$(+) H28 cells with no effect in MTAP(-) H2052 cells.	0
ImmA had no effect on pemetrexed activity but, when thymidine was added, the @CHEMICAL$ IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in @GENE$(-) H2052 cells.	0
Conversely, the transfection of @GENE$ into H2052 cells increased the @CHEMICAL$ IC(50) by nearly 3-fold but only in the presence of thymidine; this was reversed by ImmA.	0
Conversely, the transfection of @GENE$ into H2052 cells increased the pemetrexed IC(50) by nearly 3-fold but only in the presence of @CHEMICAL$; this was reversed by ImmA.	0
An @GENE$-specific short interfering RNA produced a 2-fold decrease in @CHEMICAL$ IC(50) in MTAP(+) HeLa cells in the presence of thymidine.	0
An MTAP-specific short interfering RNA produced a 2-fold decrease in @CHEMICAL$ IC(50) in @GENE$(+) HeLa cells in the presence of thymidine.	0
An @GENE$-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC(50) in MTAP(+) HeLa cells in the presence of @CHEMICAL$.	0
An MTAP-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC(50) in @GENE$(+) HeLa cells in the presence of @CHEMICAL$.	0
These data indicate that suppression of constitutive @GENE$ has no effect on @CHEMICAL$ activity when the primary target is TS.	0
These data indicate that suppression of constitutive MTAP has no effect on @CHEMICAL$ activity when the primary target is @GENE$.	0
There is a modest salutary effect when the @CHEMICAL$ target is @GENE$ alone.	0
@CHEMICAL$ and glinides exhibit @GENE$ activity: a combined virtual screening and biological assay approach.	0
Sulfonylureas and @CHEMICAL$ exhibit @GENE$ activity: a combined virtual screening and biological assay approach.	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @CHEMICAL$ receptor stimulating @GENE$ release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @CHEMICAL$ receptor stimulating insulin release (sulfonylureas, glinides), or target the @GENE$ (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @CHEMICAL$ receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (@GENE$) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @CHEMICAL$ receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving @GENE$ resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @CHEM-GENE$ stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating @GENE$ release (@CHEMICAL$, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	1
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (@CHEMICAL$, glinides), or target the @GENE$ (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (@CHEMICAL$, glinides), or target the peroxisome proliferator-activated receptor (@GENE$) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (@CHEMICAL$, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving @GENE$ resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @GENE$ stimulating insulin release (@CHEMICAL$, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating @GENE$ release (sulfonylureas, @CHEMICAL$), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	1
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, @CHEMICAL$), or target the @GENE$ (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, @CHEMICAL$), or target the peroxisome proliferator-activated receptor (@GENE$) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, @CHEMICAL$), or target the peroxisome proliferator-activated receptor (PPARgamma) improving @GENE$ resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @GENE$ stimulating insulin release (sulfonylureas, @CHEMICAL$), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating @GENE$ release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (@CHEMICAL$).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the @GENE$ (PPARgamma) improving insulin resistance (@CHEMICAL$).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (@GENE$) improving insulin resistance (@CHEMICAL$).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving @GENE$ resistance (@CHEMICAL$).	0
Most drugs currently employed in the treatment of type 2 diabetes either target the @GENE$ stimulating insulin release (sulfonylureas, glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (@CHEMICAL$).	0
Our work shows that @CHEMICAL$ and glinides additionally bind to @GENE$ and exhibit PPARgamma agonistic activity.	0
Our work shows that @CHEMICAL$ and glinides additionally bind to PPARgamma and exhibit @GENE$ agonistic activity.	3
Our work shows that sulfonylureas and @CHEMICAL$ additionally bind to @GENE$ and exhibit PPARgamma agonistic activity.	0
Our work shows that sulfonylureas and @CHEMICAL$ additionally bind to PPARgamma and exhibit @GENE$ agonistic activity.	3
Among the measured compounds, @CHEMICAL$ and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit @GENE$ agonistic activity at concentrations comparable with those reached under pharmacological treatment.	3
Among the measured compounds, gliquidone and @CHEMICAL$ (two sulfonylureas), as well as nateglinide (a glinide), exhibit @GENE$ agonistic activity at concentrations comparable with those reached under pharmacological treatment.	3
Among the measured compounds, gliquidone and glipizide (two @CHEMICAL$), as well as nateglinide (a glinide), exhibit @GENE$ agonistic activity at concentrations comparable with those reached under pharmacological treatment.	3
Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as @CHEMICAL$ (a glinide), exhibit @GENE$ agonistic activity at concentrations comparable with those reached under pharmacological treatment.	3
Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a @CHEMICAL$), exhibit @GENE$ agonistic activity at concentrations comparable with those reached under pharmacological treatment.	3
The most active of these compounds, @CHEMICAL$, is shown to be as potent as pioglitazone at inducing @GENE$ target gene expression.	1
The most active of these compounds, gliquidone, is shown to be as potent as @CHEMICAL$ at inducing @GENE$ target gene expression.	1
This dual mode of action of @CHEMICAL$ and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the @GENE$ and PPARgamma.	0
This dual mode of action of @CHEMICAL$ and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and @GENE$.	0
This dual mode of action of sulfonylureas and @CHEMICAL$ may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the @GENE$ and PPARgamma.	0
This dual mode of action of sulfonylureas and @CHEMICAL$ may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the sulfonylurea receptor and @GENE$.	0
This dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the @CHEM-GENE$ and PPARgamma.	0
This dual mode of action of sulfonylureas and glinides may open new perspectives for the molecular pharmacology of antidiabetic drugs, because it provides evidence that drugs can be designed that target both the @CHEMICAL$ receptor and @GENE$.	0
@CHEMICAL$, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new @GENE$ agonists.	3
Glinides, @CHEMICAL$, and other acidified sulfonamides may be promising leads in the development of new @GENE$ agonists.	3
Glinides, sulfonylureas, and other @CHEMICAL$ may be promising leads in the development of new @GENE$ agonists.	3
There is a growing appreciation that the @CHEMICAL$ (cAMP)-@GENE$ (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.	0
There is a growing appreciation that the @CHEMICAL$ (cAMP)-protein kinase A (@GENE$) signaling pathway is organized to form transduction units that function to deliver specific messages.	0
There is a growing appreciation that the cyclic adenosine monophosphate (@CHEMICAL$)-@GENE$ (PKA) signaling pathway is organized to form transduction units that function to deliver specific messages.	0
There is a growing appreciation that the cyclic adenosine monophosphate (@CHEMICAL$)-protein kinase A (@GENE$) signaling pathway is organized to form transduction units that function to deliver specific messages.	0
Such organization results in the local activation of @GENE$ subsets through the generation of confined intracellular gradients of @CHEMICAL$, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.	1
Such organization results in the local activation of @GENE$ subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of @CHEMICAL$ largely remain to be clarified.	0
By using pharmacological and genetic manipulation of @GENE$ (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of @CHEMICAL$ in individual subcellular compartments.	0
By using pharmacological and genetic manipulation of phosphodiesterases (@GENE$), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of @CHEMICAL$ in individual subcellular compartments.	0
By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized @GENE$ and PDE4D are responsible for selectively modulating the concentration of @CHEMICAL$ in individual subcellular compartments.	5
By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and @GENE$ are responsible for selectively modulating the concentration of @CHEMICAL$ in individual subcellular compartments.	5
We propose a model whereby compartmentalized @GENE$, rather than representing an enzymatic barrier to @CHEMICAL$ diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis.	0
We propose a model whereby compartmentalized @GENE$, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different @CHEMICAL$ concentrations irrespective of their distance from the site of cAMP synthesis.	5
We propose a model whereby compartmentalized @GENE$, rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of @CHEMICAL$ synthesis.	5
@GENE$ (TOP2A) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.	0
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving @GENE$, Her-2/neu and TOP2A genes.	0
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, @GENE$/neu and TOP2A genes.	0
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/@GENE$ and TOP2A genes.	0
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and @GENE$ genes.	0
DNA topoisomerase IIalpha (@GENE$) inhibitors up-regulate @CHEMICAL$ synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.	0
DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate @CHEM-GENE$ gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.	0
@CHEM-GENE$ (FAS), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas.	0
@CHEMICAL$ synthase (@GENE$), the key metabolic multi-enzyme that is responsible for the terminal catalytic step in the de novo fatty acid biosynthesis, plays an active role in the development, maintenance, and enhancement of the malignant phenotype in a subset of breast carcinomas.	0
SK-Br3 cells cultured in the presence of @GENE$ (TOP2A) inhibitors @CHEMICAL$ and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (@GENE$) inhibitors @CHEMICAL$ and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors @CHEMICAL$ and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in @GENE$ activity when compared with control cells growing in drug-free culture conditions.	1
SK-Br3 cells cultured in the presence of @GENE$ (TOP2A) inhibitors doxorubicin and @CHEMICAL$ (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (@GENE$) inhibitors doxorubicin and @CHEMICAL$ (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and @CHEMICAL$ (VP-16) demonstrated a 2- to 3-fold increase in @GENE$ activity when compared with control cells growing in drug-free culture conditions.	1
SK-Br3 cells cultured in the presence of @GENE$ (TOP2A) inhibitors doxorubicin and etopoxide (@CHEMICAL$) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (@GENE$) inhibitors doxorubicin and etopoxide (@CHEMICAL$) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.	2
SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (@CHEMICAL$) demonstrated a 2- to 3-fold increase in @GENE$ activity when compared with control cells growing in drug-free culture conditions.	1
We failed to observe any significant activation of @GENE$ following exposure to the anti-metabolite @CHEMICAL$, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and vincristine.	0
We failed to observe any significant activation of @GENE$ following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug @CHEMICAL$, or the microtubule interfering-agents paclitaxel and vincristine.	0
We failed to observe any significant activation of @GENE$ following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents @CHEMICAL$ and vincristine.	0
We failed to observe any significant activation of @GENE$ following exposure to the anti-metabolite 5-fluorouracil, the alkylating drug cisplatin, or the microtubule interfering-agents paclitaxel and @CHEMICAL$.	0
@CHEMICAL$ alters expression of endometrial @GENE$ and their cofactors in new users of medroxyprogesterone acetate.	0
Mifepristone alters expression of endometrial @GENE$ and their cofactors in new users of @CHEMICAL$.	0
Mifepristone alters expression of endometrial @CHEM-GENE$ and their cofactors in new users of medroxyprogesterone acetate.	0
OBJECTIVE: To evaluate the effect of mifepristone on the expression of endometrial @GENE$ and their co-factors in depot @CHEMICAL$ (DMPA) users.	0
OBJECTIVE: To evaluate the effect of mifepristone on the expression of endometrial @CHEM-GENE$ and their co-factors in depot medroxyprogesterone acetate (DMPA) users.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEM-GENE$ (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (@GENE$ and ERbeta), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (ERalpha and @GENE$), progesterone receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (ERalpha and ERbeta), @GENE$ (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (@GENE$ and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and @GENE$), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @CHEMICAL$ receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and @GENE$ messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @GENE$ (ERalpha and ERbeta), @CHEMICAL$ receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (@GENE$ and ERbeta), @CHEMICAL$ receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and @GENE$), @CHEMICAL$ receptors A and B (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), @CHEM-GENE$ (PRAB and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), @CHEMICAL$ receptors A and B (@GENE$ and PRB), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), @CHEMICAL$ receptors A and B (PRAB and @GENE$), and androgen receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), @CHEMICAL$ receptors A and B (PRAB and PRB), and @GENE$ messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of @GENE$ (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (@GENE$ and ERbeta), progesterone receptors A and B (PRAB and PRB), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and @GENE$), progesterone receptors A and B (PRAB and PRB), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), @GENE$ (PRAB and PRB), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (@GENE$ and PRB), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and @GENE$), and @CHEMICAL$ receptor messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
MAIN OUTCOME MEASURE(S): The expression of estrogen receptor subtypes alpha and beta (ERalpha and ERbeta), progesterone receptors A and B (PRAB and PRB), and @CHEM-GENE$ messenger RNA and protein was detected by real-time polymerase chain reaction and immunohistochemistry, respectively.	0
@CHEM-GENE$ (SRC-1), silencing mediator for retinoid and thyroid-hormone receptors, and cell proliferation were evaluated by immunohistochemistry.	0
@CHEMICAL$ receptor coactivator 1 (@GENE$), silencing mediator for retinoid and thyroid-hormone receptors, and cell proliferation were evaluated by immunohistochemistry.	0
@CHEMICAL$ receptor coactivator 1 (SRC-1), silencing mediator for @GENE$, and cell proliferation were evaluated by immunohistochemistry.	0
@GENE$ (SRC-1), silencing mediator for @CHEMICAL$ and thyroid-hormone receptors, and cell proliferation were evaluated by immunohistochemistry.	0
Steroid receptor coactivator 1 (@GENE$), silencing mediator for @CHEMICAL$ and thyroid-hormone receptors, and cell proliferation were evaluated by immunohistochemistry.	0
Steroid receptor coactivator 1 (SRC-1), silencing mediator for @CHEM-GENE$, and cell proliferation were evaluated by immunohistochemistry.	0
@GENE$ (SRC-1), silencing mediator for retinoid and @CHEMICAL$ receptors, and cell proliferation were evaluated by immunohistochemistry.	0
Steroid receptor coactivator 1 (@GENE$), silencing mediator for retinoid and @CHEMICAL$ receptors, and cell proliferation were evaluated by immunohistochemistry.	0
Steroid receptor coactivator 1 (SRC-1), silencing mediator for @CHEM-GENE$, and cell proliferation were evaluated by immunohistochemistry.	0
RESULT(S): The expression of endometrial @GENE$, PRAB, PRB, and SRC-1 was increased significantly after 1 week of @CHEMICAL$, but the increase was no longer seen after 10 weeks.	1
RESULT(S): The expression of endometrial ERalpha, @GENE$, PRB, and SRC-1 was increased significantly after 1 week of @CHEMICAL$, but the increase was no longer seen after 10 weeks.	1
RESULT(S): The expression of endometrial ERalpha, PRAB, @GENE$, and SRC-1 was increased significantly after 1 week of @CHEMICAL$, but the increase was no longer seen after 10 weeks.	1
RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and @GENE$ was increased significantly after 1 week of @CHEMICAL$, but the increase was no longer seen after 10 weeks.	1
CONCLUSION(S): Short-term exposure of @CHEMICAL$ in new starters of DMPA increases the expression of endometrial @GENE$, PRAB, PRB, and SRC-1 and promotes cell proliferation.	1
CONCLUSION(S): Short-term exposure of @CHEMICAL$ in new starters of DMPA increases the expression of endometrial ERalpha, @GENE$, PRB, and SRC-1 and promotes cell proliferation.	1
CONCLUSION(S): Short-term exposure of @CHEMICAL$ in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, @GENE$, and SRC-1 and promotes cell proliferation.	1
CONCLUSION(S): Short-term exposure of @CHEMICAL$ in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and @GENE$ and promotes cell proliferation.	1
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of @CHEMICAL$ (GalN), we focused on the role of @GENE$ (PTB) in islet insulin synthesis.	0
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of @CHEMICAL$ (GalN), we focused on the role of polyprimidine tract-binding protein (@GENE$) in islet insulin synthesis.	0
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of @CHEMICAL$ (GalN), we focused on the role of polyprimidine tract-binding protein (PTB) in islet @GENE$ synthesis.	0
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine (@CHEMICAL$), we focused on the role of @GENE$ (PTB) in islet insulin synthesis.	0
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine (@CHEMICAL$), we focused on the role of polyprimidine tract-binding protein (@GENE$) in islet insulin synthesis.	0
To investigate the mechanism of hyperinsulinaemia in rats with acute liver failure induced by the administration of d-galactosamine (@CHEMICAL$), we focused on the role of polyprimidine tract-binding protein (PTB) in islet @GENE$ synthesis.	0
In the present study, @CHEMICAL$-stimulated @GENE$ secretion was significantly increased in GalN-treated rats compared to controls.	1
In the present study, glucose-stimulated @GENE$ secretion was significantly increased in @CHEMICAL$-treated rats compared to controls.	1
Levels of mRNA encoding @GENE$, ICA512, and PC1/3 were increased in the pancreatic islets of @CHEMICAL$-treated rats.	1
Levels of mRNA encoding insulin 1, @GENE$, and PC1/3 were increased in the pancreatic islets of @CHEMICAL$-treated rats.	1
Levels of mRNA encoding insulin 1, ICA512, and @GENE$ were increased in the pancreatic islets of @CHEMICAL$-treated rats.	0
This mRNA level elevation was not prevented by pretreatment with @CHEMICAL$. When the @GENE$ in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats.	0
This mRNA level elevation was not prevented by pretreatment with @CHEMICAL$. When the PTB-binding site in @GENE$ mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN-treated rats compared to the level in control rats.	0
This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the @GENE$ in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from @CHEMICAL$-treated rats compared to the level in control rats.	1
This mRNA level elevation was not prevented by pretreatment with actinomycin D. When the PTB-binding site in @GENE$ mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from @CHEMICAL$-treated rats compared to the level in control rats.	1
The cytosolic fraction obtained from pancreatic islets obtained from @CHEMICAL$-treated rats had an increased @GENE$ level compared to the levels obtained from the pancreatic islets of control rats.	1
@CHEM-GENE$ is involved in N-methyl-D-aspartate-mediated neuronal injury in mice.	0
@GENE$ is involved in @CHEMICAL$-mediated neuronal injury in mice.	0
AIM: To determine whether @GENE$ (CysLT1 receptor) is involved in @CHEMICAL$ (NMDA)-induced excitotoxic injury in the mouse brain.	0
AIM: To determine whether cysteinyl leukotriene receptor 1 (@GENE$) is involved in @CHEMICAL$ (NMDA)-induced excitotoxic injury in the mouse brain.	0
AIM: To determine whether @GENE$ (CysLT1 receptor) is involved in N-methyl-D-aspartate (@CHEMICAL$)-induced excitotoxic injury in the mouse brain.	0
AIM: To determine whether cysteinyl leukotriene receptor 1 (@GENE$) is involved in N-methyl-D-aspartate (@CHEMICAL$)-induced excitotoxic injury in the mouse brain.	0
AIM: To determine whether @CHEM-GENE$ (CysLT1 receptor) is involved in N-methyl-D-aspartate (NMDA)-induced excitotoxic injury in the mouse brain.	0
AIM: To determine whether @CHEMICAL$ receptor 1 (@GENE$) is involved in N-methyl-D-aspartate (NMDA)-induced excitotoxic injury in the mouse brain.	0
The changes in @GENE$ expression 24 h after @CHEMICAL$ injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after @CHEMICAL$ injection and the effects of a @GENE$ antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after @CHEMICAL$ injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an @GENE$ antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in @GENE$ expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, @CHEMICAL$ (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a @GENE$ antagonist, @CHEMICAL$ (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	4
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, @CHEMICAL$ (0.01 and 0.1 mg/kg), an @GENE$ antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in @GENE$ expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an @CHEMICAL$ receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a @GENE$ antagonist, pranlukast (0.01 and 0.1 mg/kg), an @CHEMICAL$ receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an @CHEM-GENE$ antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in @GENE$ expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, @CHEMICAL$ (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a @GENE$ antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, @CHEMICAL$ (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an @GENE$ antagonist, @CHEMICAL$ (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.	4
The changes in @GENE$ expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, @CHEMICAL$ (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a @GENE$ antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, @CHEMICAL$ (9 mg/kg) were observed.	0
The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an @GENE$ antagonist, ketamine (30 mg/kg), and an antioxidant, @CHEMICAL$ (9 mg/kg) were observed.	0
RESULTS: In the @CHEMICAL$-injured brain, the @GENE$ mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.	1
@CHEMICAL$, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the @GENE$.	0
Pranlukast, @CHEMICAL$ and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the @GENE$.	0
Pranlukast, ketamine and @CHEMICAL$ decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the @GENE$.	0
Pranlukast, ketamine and edaravone decreased @CHEMICAL$-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the @GENE$.	0
Pranlukast, ketamine and edaravone decreased NMDA-induced injury; @CHEMICAL$ (0.1 mg/kg) and ketamine inhibited the upregulated expression of the @GENE$.	2
Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and @CHEMICAL$ inhibited the upregulated expression of the @GENE$.	2
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after @CHEMICAL$ injection, and NMDA-induced responses are inhibited by @GENE$ antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.	0
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after @CHEMICAL$ injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased @GENE$ is involved in NMDA excitotoxicity.	0
CONCLUSION: @GENE$ expression in neurons is upregulated after @CHEMICAL$ injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.	1
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and @CHEMICAL$-induced responses are inhibited by @GENE$ antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.	0
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and @CHEMICAL$-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased @GENE$ is involved in NMDA excitotoxicity.	0
CONCLUSION: @GENE$ expression in neurons is upregulated after NMDA injection, and @CHEMICAL$-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.	0
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by @GENE$ antagonists, indicating that the increased CysLT1 receptor is involved in @CHEMICAL$ excitotoxicity.	0
CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased @GENE$ is involved in @CHEMICAL$ excitotoxicity.	1
CONCLUSION: @GENE$ expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in @CHEMICAL$ excitotoxicity.	0
We have previously demonstrated that phosphorylation of @GENE$ (FADD) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (@GENE$) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 @CHEMICAL$ through @GENE$ (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (@GENE$) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that @GENE$ phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of @GENE$/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 @CHEMICAL$ through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/@GENE$ plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of @GENE$ (FADD) at 194 serine through c-jun @CHEMICAL$-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (@GENE$) at 194 serine through c-jun @CHEMICAL$-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through @CHEM-GENE$ (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun @CHEMICAL$-terminal kinase (@GENE$) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun @CHEMICAL$-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that @GENE$ phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun @CHEMICAL$-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of @GENE$/FADD plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun @CHEMICAL$-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/@GENE$ plays an important role in cell growth suppression by paclitaxel.	0
We have previously demonstrated that phosphorylation of @GENE$ (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by @CHEMICAL$.	1
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (@GENE$) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by @CHEMICAL$.	1
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through @GENE$ (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by @CHEMICAL$.	1
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (@GENE$) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by @CHEMICAL$.	1
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that @GENE$ phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by @CHEMICAL$.	0
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of @GENE$/FADD plays an important role in cell growth suppression by @CHEMICAL$.	1
We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/@GENE$ plays an important role in cell growth suppression by @CHEMICAL$.	1
In this study, the clinicopathological association of @GENE$ (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (@GENE$) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEM-GENE$, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, @GENE$ expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and @GENE$/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/@GENE$ (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (@GENE$/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEMICAL$, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/@GENE$) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of @GENE$ (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (@GENE$) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with @CHEM-GENE$, p53 expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, @GENE$ expressions and phosphorylated FADD/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and @GENE$/JNK (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/@GENE$ (P-FADD/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (@GENE$/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, @CHEMICAL$, c-erbB-2 receptors, p53 expressions and phosphorylated FADD/JNK (P-FADD/@GENE$) was analyzed immunohistochemically using 107 human breast cancer specimens.	0
The mechanism(s) responsible for arterial vasodilation observed following acute administration of @CHEMICAL$, a novel vasodilator/@GENE$ antagonist, has been investigated in rats.	4
@CHEMICAL$ (0.3 mg/kg, iv) produced a significant inhibition of the @GENE$ mediated positive chronotropic response to isoproterenol.	2
Carvedilol (0.3 mg/kg, iv) produced a significant inhibition of the @GENE$ mediated positive chronotropic response to @CHEMICAL$.	1
This same dose of @CHEMICAL$ also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of @GENE$.	0
This same dose of @CHEMICAL$ also inhibited, but to a lesser degree, the @GENE$ mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.	2
This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to @CHEMICAL$ in pithed rats whose blood pressure was elevated by a constant intravenous infusion of @GENE$.	0
This same dose of carvedilol also inhibited, but to a lesser degree, the @GENE$ mediated vasodepressor response to @CHEMICAL$ in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II.	0
Thus, @CHEMICAL$ blocks both @GENE$ at antihypertensive doses, with modest selectivity being observed for the beta 1 adrenoceptor subtype.	0
Thus, @CHEMICAL$ blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the @GENE$ subtype.	2
@CHEMICAL$ produced significant inhibition of the @GENE$ mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	2
@CHEMICAL$ produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the @GENE$ mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
@CHEMICAL$ produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an @GENE$ antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the @GENE$ mediated pressor response to @CHEMICAL$ in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to @CHEMICAL$ in the pithed rat, but had no effect on the @GENE$ mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to @CHEMICAL$ in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an @GENE$ antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the @GENE$ mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to @CHEMICAL$, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the @GENE$ mediated pressor response to @CHEMICAL$, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to @CHEMICAL$, suggesting that carvedilol is also an @GENE$ antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the @GENE$ mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that @CHEMICAL$ is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the @GENE$ mediated pressor response to B-HT 933, suggesting that @CHEMICAL$ is also an alpha 1 adrenoceptor antagonist at antihypertensive doses.	0
Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that @CHEMICAL$ is also an @GENE$ antagonist at antihypertensive doses.	4
@CHEMICAL$ had no effect on the pressor response elicited by @GENE$, indicating a lack of nonspecific vasodilator activity.	0
The vasopressor response to the @GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular @CHEMICAL$, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular @CHEMICAL$, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	5
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular @CHEMICAL$, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @GENE$ antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by @CHEMICAL$ (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by @CHEMICAL$ (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	2
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by @CHEMICAL$ (1 mg/kg, iv), suggesting that carvedilol is also a @GENE$ antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that @CHEMICAL$ is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that @CHEMICAL$ is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that @CHEMICAL$ is also a @GENE$ antagonist, consistent with our previous in vitro studies.	4
The vasopressor response to the @GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @CHEMICAL$ channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @CHEMICAL$ channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @CHEM-GENE$ antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @CHEM-GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @CHEMICAL$ channel activator, BAY-K-8644, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @CHEMICAL$ channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @GENE$ antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @GENE$ activator, @CHEMICAL$, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	1
The vasopressor response to the calcium channel activator, @CHEMICAL$, which is mediated through the opening of @GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	1
The vasopressor response to the calcium channel activator, @CHEMICAL$, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @GENE$ antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the @GENE$ activator, BAY-K-8644, which is mediated through the opening of voltage dependent @CHEMICAL$ channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of @CHEM-GENE$ and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies.	0
The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent @CHEMICAL$ channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg/kg, iv), suggesting that carvedilol is also a @GENE$ antagonist, consistent with our previous in vitro studies.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of @CHEMICAL$ was nearly abolished by combined pretreatment of the rats with high doses of the @GENE$ antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of @CHEMICAL$ was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective @GENE$ antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of @CHEMICAL$ was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of @GENE$.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the @GENE$ antagonist, @CHEMICAL$ (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	4
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, @CHEMICAL$ (1 mg/kg, iv), and the nonselective @GENE$ antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, @CHEMICAL$ (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of @GENE$.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the @GENE$ antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, @CHEMICAL$ (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective @GENE$ antagonist, @CHEMICAL$ (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors.	4
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, @CHEMICAL$ (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of @GENE$.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the @GENE$ antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by @CHEMICAL$ may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective @GENE$ antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by @CHEMICAL$ may be accounted for by blockade of beta and alpha 1 adrenoceptors.	0
In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg/kg, iv), suggesting that the majority of the antihypertensive response produced by @CHEMICAL$ may be accounted for by blockade of @GENE$.	0
We therefore conclude that @CHEMICAL$, at antihypertensive doses, is an antagonist of @GENE$, and also of calcium channels in vascular smooth muscle.	0
We therefore conclude that @CHEMICAL$, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of @GENE$ in vascular smooth muscle.	4
We therefore conclude that carvedilol, at antihypertensive doses, is an antagonist of @GENE$, and also of @CHEMICAL$ channels in vascular smooth muscle.	0
We therefore conclude that carvedilol, at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of @CHEM-GENE$ in vascular smooth muscle.	0
Results of renal biopsy prompted us to undertake a biochemical and molecular biological evaluation of the patient for suspected @CHEM-GENE$ (APRT) deficiency.	0
Results of renal biopsy prompted us to undertake a biochemical and molecular biological evaluation of the patient for suspected @CHEMICAL$ phosphoribosyltransferase (@GENE$) deficiency.	0
Analysis of the patient family showed that heterozygotes for this @GENE$ gene mutation, in spite of a 69% lower APRT enzymatic activity than that of healthy subjects, had no detectable @CHEMICAL$ concentrations in both serum and urine.	0
Analysis of the patient family showed that heterozygotes for this APRT gene mutation, in spite of a 69% lower @GENE$ enzymatic activity than that of healthy subjects, had no detectable @CHEMICAL$ concentrations in both serum and urine.	0
@GENE$ negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein @CHEMICAL$ phosphatase-1B.	0
Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with @GENE$ and protein @CHEMICAL$ phosphatase-1B.	0
Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and @CHEM-GENE$.	0
Phospholipase Cgamma1 negatively regulates @GENE$ signalling by forming a ternary complex with Jak2 and protein @CHEMICAL$ phosphatase-1B.	0
Here, we demonstrate that @GENE$ (PLCgamma1) modulates the action of growth hormone-mediated signalling by interacting with @CHEMICAL$ kinase Jak2 (janus kinase 2) in a growth hormone-dependent manner.	0
Here, we demonstrate that phospholipase Cgamma1 (@GENE$) modulates the action of growth hormone-mediated signalling by interacting with @CHEMICAL$ kinase Jak2 (janus kinase 2) in a growth hormone-dependent manner.	0
Here, we demonstrate that phospholipase Cgamma1 (PLCgamma1) modulates the action of @GENE$-mediated signalling by interacting with @CHEMICAL$ kinase Jak2 (janus kinase 2) in a growth hormone-dependent manner.	0
Here, we demonstrate that phospholipase Cgamma1 (PLCgamma1) modulates the action of growth hormone-mediated signalling by interacting with @CHEM-GENE$ (janus kinase 2) in a growth hormone-dependent manner.	0
Here, we demonstrate that phospholipase Cgamma1 (PLCgamma1) modulates the action of growth hormone-mediated signalling by interacting with @CHEMICAL$ kinase Jak2 (@GENE$) in a growth hormone-dependent manner.	0
Here, we demonstrate that phospholipase Cgamma1 (PLCgamma1) modulates the action of growth hormone-mediated signalling by interacting with @CHEMICAL$ kinase Jak2 (janus kinase 2) in a @GENE$-dependent manner.	0
Interestingly, @GENE$ physically linked Jak2 and protein @CHEMICAL$ phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2.	0
Interestingly, PLCgamma1 physically linked @GENE$ and protein @CHEMICAL$ phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2.	0
Interestingly, PLCgamma1 physically linked Jak2 and @CHEM-GENE$ (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2.	0
Interestingly, PLCgamma1 physically linked Jak2 and protein @CHEMICAL$ phosphatase-1B (@GENE$) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2.	0
Interestingly, PLCgamma1 physically linked Jak2 and protein @CHEMICAL$ phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of @GENE$ signalling through Jak2.	0
Interestingly, PLCgamma1 physically linked Jak2 and protein @CHEMICAL$ phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through @GENE$.	0
@GENE$ antagonism with @CHEMICAL$ reduced responses to 5-HT in controls but not during inflammation.	4
@GENE$ antagonism with alosetron reduced responses to @CHEMICAL$ in controls but not during inflammation.	0
Responses to the mast cell degranulator 48/80 mimicked those to @CHEMICAL$ in inflamed tissue but not in controls, and more 5-HT-containing mast cells were seen close to @GENE$-containing fibres in inflamed serosa.	0
Responses to the mast cell degranulator 48/80 mimicked those to 5-HT in inflamed tissue but not in controls, and more @CHEMICAL$-containing mast cells were seen close to @GENE$-containing fibres in inflamed serosa.	0
The role of extranuclear signaling actions of @CHEM-GENE$ in mediating progesterone regulation of gene expression and the cell cycle.	0
The role of extranuclear signaling actions of @GENE$ in mediating @CHEMICAL$ regulation of gene expression and the cell cycle.	0
@CHEM-GENE$ (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of @GENE$ and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream @GENE$ (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (PR) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (@GENE$) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (@GENE$) contains a motif that interacts with the SH3 domain of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (PR) contains a motif that interacts with the @GENE$ of Src and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
Human @CHEMICAL$ receptor (PR) contains a motif that interacts with the SH3 domain of @GENE$ and mediates rapid activation of Src and downstream MAPK (Erk-1/-2) without relying on the transcriptional activity of the receptor.	0
@CHEMICAL$ activation of @GENE$/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.	1
@CHEMICAL$ activation of Src/@GENE$ occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.	1
@CHEMICAL$ activation of Src/MAPK occurred outside the nucleus with the @GENE$ that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.	0
@CHEMICAL$ activation of Src/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with @GENE$ that was predominantly nuclear.	0
Breast cancer cells stably expressing wild-type @GENE$ or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of @CHEMICAL$ on endogenous target gene expression and cell proliferation.	0
Breast cancer cells stably expressing wild-type PR-B or @GENE$ with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of @CHEMICAL$ on endogenous target gene expression and cell proliferation.	0
Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the @GENE$ (PR-BDeltaSH3) that do not affect the transcriptional activity of PR, were compared for effects of @CHEMICAL$ on endogenous target gene expression and cell proliferation.	0
Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (@GENE$) that do not affect the transcriptional activity of PR, were compared for effects of @CHEMICAL$ on endogenous target gene expression and cell proliferation.	0
Breast cancer cells stably expressing wild-type PR-B or PR-B with disrupting point mutations in the SH3 domain binding motif (PR-BDeltaSH3) that do not affect the transcriptional activity of @GENE$, were compared for effects of @CHEMICAL$ on endogenous target gene expression and cell proliferation.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEM-GENE$ was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with @GENE$ activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of @GENE$.	0
Progestin induction of the @GENE$ gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @GENE$, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on @GENE$ activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the @GENE$/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/@GENE$ pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the @GENE$ (serum and glucocorticoid regulated kinase) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (@GENE$) gene that contains a functional @CHEMICAL$ response element was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @GENE$ was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with @GENE$ activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of @GENE$.	0
@CHEMICAL$ induction of the @GENE$ gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a @GENE$, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on @GENE$ activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	1
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the @GENE$/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	1
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/@GENE$ pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	1
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the @GENE$ (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (@GENE$) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional @GENE$ was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with @GENE$ activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of @GENE$.	0
Progestin induction of the @GENE$ gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEM-GENE$, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on @GENE$ activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the @GENE$/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/@GENE$ pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the @GENE$ (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
Progestin induction of the cyclin D1 gene, which lacks a @CHEMICAL$ response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (@GENE$) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.	0
@CHEMICAL$ induction of cell cycle progression was also abrogated in cells expressing @GENE$, and no effect of progestin on cyclin D1 expression and cell cycle was observed in the presence of PR-A.	0
@CHEMICAL$ induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of progestin on @GENE$ expression and cell cycle was observed in the presence of PR-A.	0
@CHEMICAL$ induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of progestin on cyclin D1 expression and cell cycle was observed in the presence of @GENE$.	0
Progestin induction of cell cycle progression was also abrogated in cells expressing @GENE$, and no effect of @CHEMICAL$ on cyclin D1 expression and cell cycle was observed in the presence of PR-A.	0
Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of @CHEMICAL$ on @GENE$ expression and cell cycle was observed in the presence of PR-A.	0
Progestin induction of cell cycle progression was also abrogated in cells expressing PR-BDeltaSH3, and no effect of @CHEMICAL$ on cyclin D1 expression and cell cycle was observed in the presence of @GENE$.	0
These results highlight the importance of @GENE$ activation of the Src/MAPK signaling pathway for @CHEMICAL$-induced transcription of select target genes and cell cycle progression.	1
These results highlight the importance of PR activation of the @GENE$/MAPK signaling pathway for @CHEMICAL$-induced transcription of select target genes and cell cycle progression.	1
These results highlight the importance of PR activation of the Src/@GENE$ signaling pathway for @CHEMICAL$-induced transcription of select target genes and cell cycle progression.	1
injection of a subthreshold dose of @CHEMICAL$, a use-dependent @GENE$ antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.	4
injection of a subthreshold dose of picrotoxin, a use-dependent @CHEM-GENE$ antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.	0
Molecular recognition of @CHEMICAL$ tRNA by @GENE$ from hyperthermophilic archaeon, Aeropyrum pernix K1.	0
To investigate the recognition sites of histidine tRNA for histidyl-tRNA synthetase from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed @CHEM-GENE$ and various histidine tRNA transcripts that were prepared by in vitro transcription system.	0
To investigate the recognition sites of histidine tRNA for @GENE$ from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed @CHEMICAL$-tRNA synthetase and various histidine tRNA transcripts that were prepared by in vitro transcription system.	0
To investigate the recognition sites of histidine tRNA for histidyl-tRNA synthetase from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed @GENE$ and various @CHEMICAL$ tRNA transcripts that were prepared by in vitro transcription system.	0
To investigate the recognition sites of histidine tRNA for @GENE$ from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed histidyl-tRNA synthetase and various @CHEMICAL$ tRNA transcripts that were prepared by in vitro transcription system.	0
To investigate the recognition sites of @CHEMICAL$ tRNA for histidyl-tRNA synthetase from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed @GENE$ and various histidine tRNA transcripts that were prepared by in vitro transcription system.	0
To investigate the recognition sites of @CHEMICAL$ tRNA for @GENE$ from an extreme hyperthermophilic archaeon, Aeropyrum pernix K1, we examined histidylation activities by using overexpressed histidyl-tRNA synthetase and various histidine tRNA transcripts that were prepared by in vitro transcription system.	0
Results indicated that anticodon was not recognized by the @CHEM-GENE$ similar to that of Escherichia coli histidine tRNA recognition system.	0
Results indicated that anticodon was not recognized by the @GENE$ similar to that of Escherichia coli @CHEMICAL$ tRNA recognition system.	0
Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the @CHEM-GENE$ with positron emission tomography.	0
Synthesis, radiosynthesis, and biological evaluation of @CHEMICAL$: candidate radioligands for in vivo imaging of the @GENE$ with positron emission tomography.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and @CHEMICAL$ (mZBrENT, 2) were synthesized and evaluated for binding to the @GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and @CHEMICAL$ (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and @CHEMICAL$ (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and @CHEMICAL$ (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
@CHEMICAL$ (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the @GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
@CHEMICAL$ (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
@CHEMICAL$ (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
@CHEMICAL$ (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (@CHEMICAL$, 2) were synthesized and evaluated for binding to the @GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (@CHEMICAL$, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (@CHEMICAL$, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (@CHEMICAL$, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the @CHEM-GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human @CHEMICAL$, dopamine, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human @CHEMICAL$, dopamine, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human @CHEMICAL$, dopamine, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the @CHEM-GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, @CHEMICAL$, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, @CHEMICAL$, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, @CHEMICAL$, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the @CHEM-GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and @CHEMICAL$ transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and @CHEMICAL$ transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and @CHEMICAL$ transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (@CHEMICAL$, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the @GENE$ (SERT, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (@CHEMICAL$, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (@GENE$, DAT, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (@CHEMICAL$, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, @GENE$, and NET, respectively) using transfected cells.	0
2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (@CHEMICAL$, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and @GENE$, respectively) using transfected cells.	0
Compound 2 has a significantly higher affinity for the @GENE$ than 1, and this may be a result of the different size and electronegativity of the @CHEMICAL$ atoms.	0
MicroPET imaging in nonhuman primates with [@CHEMICAL$]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the @GENE$-rich brain regions and peak uptake being achieved in about 55 min postinjection.	5
MicroPET imaging in nonhuman primates with [11C]1 and [@CHEMICAL$]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the @GENE$-rich brain regions and peak uptake being achieved in about 55 min postinjection.	5
Chase studies with @CHEMICAL$ and methylphenidate demonstrated that this uptake is the result of preferential binding to the @GENE$.	0
Chase studies with citalopram and @CHEMICAL$ demonstrated that this uptake is the result of preferential binding to the @GENE$.	0
BACKGROUND: Hypertension treatment guidelines recommend combination therapy with diuretics and other antihypertensive agents, including @CHEM-GENE$ antagonists.	0
This trial investigated the possibility of pharmacokinetic interactions between the @GENE$ antagonist @CHEMICAL$ and the thiazide diuretic hydrochlorothiazide in healthy subjects.	4
This trial investigated the possibility of pharmacokinetic interactions between the @GENE$ antagonist olmesartan medoxomil and the @CHEMICAL$ diuretic hydrochlorothiazide in healthy subjects.	0
This trial investigated the possibility of pharmacokinetic interactions between the @GENE$ antagonist olmesartan medoxomil and the thiazide diuretic @CHEMICAL$ in healthy subjects.	0
In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous @GENE$ (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of @CHEMICAL$ (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).	0
In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous @GENE$ (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: @CHEMICAL$, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: gemcitabine, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).	0
In vivo, cromolyn inhibited tumor growth in mice bearing tumor with endogenous @GENE$ (BxPC-3: control, mean = 1.6 x 10(9) photons/s, versus cromolyn, mean = 4.4 x 10(8) photons/s, difference = 1.2 x 10(9) photons/s; 95% CI = 6.2 x 10(8) to 1.6 x 10(9) photons/s; P<.001, n = 5; MPanc-96: control, mean = 1.1 x 10(10) photons/s, versus cromolyn, mean = 4.8 x 10(9) photons/s, difference = 6.2 x 10(9) photons/s; 95% CI = 1.9 x 10(9) to 1.0 x 10(10) photons/s; P = .009, n = 5) and increased the effectiveness of gemcitabine (BxPC-3: gemcitabine, mean = 9.2 x 10(8) photons/s, versus combination, mean = 1.8 x 10(8) photons/s, difference = 7.4 x 10(8) photons/s; 95% CI = 4.5 x 10(8) to 1.0 x 10(9) photons/s; P<.001; MPanc-96: @CHEMICAL$, mean = 4.1 x 10(9) photons/s, versus combination, mean = 2.0 x 10(9) photons/s, difference = 2.1 x 10(9) photons/s; 95% CI = 4.4 x 10(8) to 3.8 x 10(9) photons/s; P<.001).	0
CONCLUSION: Cromolyn binds @GENE$, prevents activation of RAGE, inhibits tumor growth, and increases the effectiveness of @CHEMICAL$ in experimental models.	0
@CHEMICAL$ (Sec) is cotranslationally inserted into protein in response to @GENE$ codons and is the 21st amino acid in the genetic code.	0
Selenocysteine (Sec) is cotranslationally inserted into protein in response to @GENE$ codons and is the 21st @CHEMICAL$ in the genetic code.	0
Selenocysteine (@CHEMICAL$) is cotranslationally inserted into protein in response to @GENE$ codons and is the 21st amino acid in the genetic code.	0
Herein, comparative genomics and experimental analyses revealed that the @CHEM-GENE$ (SecS) is the previously identified pyridoxal phosphate-containing protein known as the soluble liver antigen.	0
Herein, comparative genomics and experimental analyses revealed that the mammalian @CHEMICAL$ synthase (@GENE$) is the previously identified pyridoxal phosphate-containing protein known as the soluble liver antigen.	0
Herein, comparative genomics and experimental analyses revealed that the mammalian @CHEMICAL$ synthase (SecS) is the previously identified pyridoxal phosphate-containing protein known as the @GENE$.	0
Herein, comparative genomics and experimental analyses revealed that the @GENE$ (SecS) is the previously identified @CHEMICAL$-containing protein known as the soluble liver antigen.	0
Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (@GENE$) is the previously identified @CHEMICAL$-containing protein known as the soluble liver antigen.	0
Herein, comparative genomics and experimental analyses revealed that the mammalian Sec synthase (SecS) is the previously identified @CHEMICAL$-containing protein known as the @GENE$.	0
@GENE$ required selenophosphate and @CHEMICAL$-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).	5
@GENE$ required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate @CHEMICAL$-tRNA([Ser]Sec).	5
@GENE$ required @CHEMICAL$ and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec).	5
Moreover, it was found that @CHEM-GENE$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that @CHEMICAL$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that @CHEMICAL$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that @CHEMICAL$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that @CHEMICAL$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from @CHEMICAL$, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from @CHEMICAL$, ATP, and serine using tRNA([Ser]Sec), @GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from @CHEMICAL$, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from @CHEMICAL$, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from @CHEMICAL$, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from selenide, @CHEMICAL$, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, @CHEMICAL$, and serine using tRNA([Ser]Sec), @GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, @CHEMICAL$, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, @CHEMICAL$, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, @CHEMICAL$, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from selenide, ATP, and @CHEMICAL$ using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and @CHEMICAL$ using tRNA([Ser]Sec), @GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and @CHEMICAL$ using tRNA([Ser]Sec), seryl-tRNA synthetase, @GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and @CHEMICAL$ using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and @CHEMICAL$ using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @CHEMICAL$-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @CHEM-GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @CHEMICAL$-tRNA synthetase, @GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @CHEMICAL$-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @CHEMICAL$-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @CHEMICAL$-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @GENE$, @CHEMICAL$-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @CHEM-GENE$, selenophosphate synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @CHEMICAL$-tRNA([Ser]Sec) kinase, @GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @CHEMICAL$-tRNA([Ser]Sec) kinase, selenophosphate synthetase, and @GENE$.	0
Moreover, it was found that @GENE$ was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @CHEMICAL$ synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), @GENE$, O-phosphoseryl-tRNA([Ser]Sec) kinase, @CHEMICAL$ synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, @GENE$, @CHEMICAL$ synthetase, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @CHEM-GENE$, and SecS.	0
Moreover, it was found that Sec was synthesized on the tRNA scaffold from selenide, ATP, and serine using tRNA([Ser]Sec), seryl-tRNA synthetase, O-phosphoseryl-tRNA([Ser]Sec) kinase, @CHEMICAL$ synthetase, and @GENE$.	0
By identifying the pathway of @CHEMICAL$ biosynthesis in mammals, this study not only functionally characterized @GENE$ but also assigned the function of the O-phosphoseryl-tRNA([Ser]Sec) kinase.	0
By identifying the pathway of @CHEMICAL$ biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the @GENE$.	0
By identifying the pathway of Sec biosynthesis in mammals, this study not only functionally characterized @GENE$ but also assigned the function of the @CHEMICAL$-tRNA([Ser]Sec) kinase.	0
By identifying the pathway of Sec biosynthesis in mammals, this study not only functionally characterized SecS but also assigned the function of the @CHEM-GENE$.	0
In addition, we found that @CHEMICAL$ synthetase 2 could synthesize monoselenophosphate in vitro but @GENE$ could not.	0
In addition, we found that @CHEM-GENE$ could synthesize monoselenophosphate in vitro but selenophosphate synthetase 1 could not.	0
In addition, we found that selenophosphate synthetase 2 could synthesize @CHEMICAL$ in vitro but @GENE$ could not.	0
In addition, we found that @GENE$ could synthesize @CHEMICAL$ in vitro but selenophosphate synthetase 1 could not.	5
In addition, we found that selenophosphate synthetase 2 could synthesize monoselenophosphate in vitro but @CHEM-GENE$ could not.	0
In addition, we found that @GENE$ could synthesize monoselenophosphate in vitro but @CHEMICAL$ synthetase 1 could not.	0
@CHEMICAL$, a selective @GENE$, and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia.	0
Triflusal, a selective @GENE$, and its active metabolite @CHEMICAL$ may inhibit apoptosis and inflammation after cerebral ischemia.	0
@CHEMICAL$ (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of @GENE$ or Hsp27 immunostaining.	0
@CHEMICAL$ (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or @GENE$ immunostaining.	0
Triflusal (30 mg/kg) or @CHEMICAL$ treatment (30 mg/kg) did not reduce the levels of @GENE$ or Hsp27 immunostaining.	0
Triflusal (30 mg/kg) or @CHEMICAL$ treatment (30 mg/kg) did not reduce the levels of GFAP or @GENE$ immunostaining.	0
@CHEMICAL$ (30 mg/kg) also significantly decreased the protein levels of @GENE$ but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.	2
@CHEMICAL$ (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not @GENE$ or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.	0
@CHEMICAL$ (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or @GENE$ in the cortex ipsilateral to the middle cerebral artery occlusion.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (@CHEMICAL$ terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) @CHEMICAL$.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) @CHEMICAL$.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal @CHEMICAL$ (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (@CHEMICAL$); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal @CHEMICAL$ (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal @CHEMICAL$ with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (@CHEMICAL$); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for @CHEMICAL$ (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (@CHEMICAL$); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for @CHEMICAL$ (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (@CHEMICAL$); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for @CHEMICAL$ (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (@CHEMICAL$); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for @CHEMICAL$ (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (@CHEMICAL$); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without @CHEMICAL$ (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (@CHEMICAL$ wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo @CHEMICAL$); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal @CHEMICAL$ without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without @CHEMICAL$ (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal @CHEMICAL$ without SA); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); @GENE$ (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (@GENE$) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without @CHEMICAL$); Griffonia simplicifolia lectin II (GSL II) for terminal alpha/beta N-acetylglucosamine (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); @GENE$ (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (@GENE$) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and @GENE$ (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (@GENE$) alpha-fucose.	0
The expression of glycans was examined by @GENE$-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using @GENE$ (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (@GENE$) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); @GENE$ (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (@GENE$) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); @GENE$ (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (@GENE$) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); @GENE$ (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (@GENE$) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); @GENE$ (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (@GENE$) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); @GENE$ (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (@GENE$) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); @GENE$ (WGA) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
The expression of glycans was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta N-acetylgalactosamine (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal mannose alpha-1,3 (Man alpha-1,3); Peanut agglutinin (PNA) for galactose beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc); Erythrina cristagalli lectin (ECL) for galactose beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc); Sambucus nigra lectin (SNA) for sialic acid alpha-2.6 galactose (SA alpha-2,6 Gal); Maackia amurensis lectin II (MAL II) for sialic acid alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (@GENE$) for terminal N-acetylglucosamine with/ without sialic acid (GlcNAc wo SA); succynilated WGA (sWGA) for terminal N-acetylglucosamine without sialic acid (terminal GlcNAc without SA); Griffonia simplicifolia lectin II (GSL II) for terminal @CHEMICAL$ (alpha/beta GlcNAc terminal); and Lotus tetragonolobus lectin (LTL) alpha-fucose.	0
@CHEMICAL$ stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of @GENE$.	0
@CHEMICAL$ stimulates @GENE$ degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.	2
@CHEMICAL$ stimulates glutamate receptor interacting protein 1 degradation by @GENE$-proteasome system to regulate surface expression of GluR2.	0
@CHEMICAL$ stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-@GENE$ system to regulate surface expression of GluR2.	0
Glutamate stimulates @CHEMICAL$ receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of @GENE$.	0
Glutamate stimulates @CHEM-GENE$ degradation by ubiquitin-proteasome system to regulate surface expression of GluR2.	0
Glutamate stimulates @CHEMICAL$ receptor interacting protein 1 degradation by @GENE$-proteasome system to regulate surface expression of GluR2.	0
Glutamate stimulates @CHEMICAL$ receptor interacting protein 1 degradation by ubiquitin-@GENE$ system to regulate surface expression of GluR2.	0
The glutamate receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering @CHEM-GENE$ to other signaling proteins.	0
The @GENE$ (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering @CHEMICAL$ receptors to other signaling proteins.	0
The glutamate receptor interacting protein 1 (@GENE$) is a scaffolding protein in postsynaptic density (PSD), tethering @CHEMICAL$ receptors to other signaling proteins.	0
The @CHEMICAL$ receptor interacting protein 1 (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering @GENE$ to other signaling proteins.	0
The @CHEM-GENE$ (GRIP1) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.	0
The @CHEMICAL$ receptor interacting protein 1 (@GENE$) is a scaffolding protein in postsynaptic density (PSD), tethering AMPA receptors to other signaling proteins.	0
Here we report that @CHEMICAL$ stimulation caused a rapid reduction in protein levels of @GENE$, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	2
Here we report that @CHEMICAL$ stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor @GENE$, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	0
Here we report that @CHEMICAL$ stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, @GENE$ and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	0
Here we report that @CHEMICAL$ stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and @GENE$ (PICK1) in rat primary cortical neuron cultures.	0
Here we report that @CHEMICAL$ stimulation caused a rapid reduction in protein levels of GRIP1, but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (@GENE$) in rat primary cortical neuron cultures.	0
Here we report that glutamate stimulation caused a rapid reduction in protein levels of @GENE$, but not that of @CHEMICAL$ receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	0
Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of @CHEMICAL$ receptor @GENE$, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	0
Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of @CHEMICAL$ receptor (GluR) 1, @GENE$ and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures.	0
Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of @CHEMICAL$ receptor (GluR) 1, GluR2 and @GENE$ (PICK1) in rat primary cortical neuron cultures.	0
Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1, but not that of @CHEMICAL$ receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (@GENE$) in rat primary cortical neuron cultures.	0
Down-regulation of @GENE$ by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (@CHEMICAL$), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (@CHEMICAL$), a @GENE$ inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	2
Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (@CHEMICAL$), a proteasome inhibitor and by expression of @GENE$-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (@CHEMICAL$), a proteasome inhibitor and by expression of K48R-@GENE$, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (@CHEMICAL$), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of @GENE$.	0
Down-regulation of @GENE$ by @CHEMICAL$ was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	2
Down-regulation of GRIP1 by @CHEMICAL$ was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a @GENE$ inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by @CHEMICAL$ was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of @GENE$-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by @CHEMICAL$ was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-@GENE$, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by @CHEMICAL$ was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of @GENE$.	0
Down-regulation of @GENE$ by glutamate was blocked by @CHEMICAL$ (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by @CHEMICAL$ (MG132), a @GENE$ inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin.	2
Down-regulation of GRIP1 by glutamate was blocked by @CHEMICAL$ (MG132), a proteasome inhibitor and by expression of @GENE$-ubiquitin, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by @CHEMICAL$ (MG132), a proteasome inhibitor and by expression of K48R-@GENE$, a dominant negative form of ubiquitin.	0
Down-regulation of GRIP1 by glutamate was blocked by @CHEMICAL$ (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of @GENE$.	0
The @GENE$ reduction was inhibited by @CHEMICAL$, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	1
The GRIP1 reduction was inhibited by @CHEMICAL$, an @GENE$ antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	4
The GRIP1 reduction was inhibited by @CHEMICAL$, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @GENE$ antagonist.	0
The @GENE$ reduction was inhibited by MK-801, an @CHEMICAL$ (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @CHEM-GENE$ antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @CHEMICAL$ (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @GENE$ antagonist.	0
The @GENE$ reduction was inhibited by MK-801, an N-methyl-d-aspartate (@CHEMICAL$) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @CHEM-GENE$ antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (@CHEMICAL$) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @GENE$ antagonist.	0
The @GENE$ reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by @CHEMICAL$ (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @GENE$ antagonist, but not by @CHEMICAL$ (CNQX), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by @CHEMICAL$ (CNQX), an @GENE$ antagonist.	4
The @GENE$ reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (@CHEMICAL$), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @GENE$ antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (@CHEMICAL$), an AMPA receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (@CHEMICAL$), an @GENE$ antagonist.	4
The @GENE$ reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @CHEMICAL$ receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an @GENE$ antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @CHEMICAL$ receptor antagonist.	0
The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an @CHEM-GENE$ antagonist.	0
@CHEMICAL$ and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an @GENE$ blocker, prevented GRIP1 degradation.	0
@CHEMICAL$ and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented @GENE$ degradation.	1
EGTA and @CHEMICAL$ (BAPTA), two Ca2+ chelators, but not nifedipine, an @GENE$ blocker, prevented GRIP1 degradation.	0
EGTA and @CHEMICAL$ (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented @GENE$ degradation.	1
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (@CHEMICAL$), two Ca2+ chelators, but not nifedipine, an @GENE$ blocker, prevented GRIP1 degradation.	0
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (@CHEMICAL$), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented @GENE$ degradation.	1
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two @CHEMICAL$ chelators, but not nifedipine, an @GENE$ blocker, prevented GRIP1 degradation.	0
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two @CHEMICAL$ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented @GENE$ degradation.	0
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not @CHEMICAL$, an @GENE$ blocker, prevented GRIP1 degradation.	2
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not @CHEMICAL$, an L-type Ca2+ channel blocker, prevented @GENE$ degradation.	0
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an @CHEM-GENE$ blocker, prevented GRIP1 degradation.	0
EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type @CHEMICAL$ channel blocker, prevented @GENE$ degradation.	0
Furthermore, @CHEMICAL$ prevented glutamate-stimulated reduction in surface amount of @GENE$, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.	0
Furthermore, @CHEMICAL$ prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of @GENE$ by RNAi against GRIP1 reduced surface GluR2 in neurons.	0
Furthermore, @CHEMICAL$ prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against @GENE$ reduced surface GluR2 in neurons.	0
Furthermore, @CHEMICAL$ prevented glutamate-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface @GENE$ in neurons.	0
Furthermore, MG132 prevented @CHEMICAL$-stimulated reduction in surface amount of @GENE$, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons.	2
Furthermore, MG132 prevented @CHEMICAL$-stimulated reduction in surface amount of GluR2, and knockdown of @GENE$ by RNAi against GRIP1 reduced surface GluR2 in neurons.	0
Furthermore, MG132 prevented @CHEMICAL$-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against @GENE$ reduced surface GluR2 in neurons.	0
Furthermore, MG132 prevented @CHEMICAL$-stimulated reduction in surface amount of GluR2, and knockdown of GRIP1 by RNAi against GRIP1 reduced surface @GENE$ in neurons.	0
Our results suggest that @CHEMICAL$ induces @GENE$ degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	2
Our results suggest that @CHEMICAL$ induces GRIP1 degradation by @GENE$ through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that @CHEMICAL$ induces GRIP1 degradation by proteasome through an @GENE$-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that @CHEMICAL$ induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that @GENE$ degradation may play an important role in regulating GluR2 surface expression.	2
Our results suggest that @CHEMICAL$ induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating @GENE$ surface expression.	0
Our results suggest that glutamate induces @GENE$ degradation by proteasome through an @CHEMICAL$ receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by @GENE$ through an @CHEMICAL$ receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an @CHEM-GENE$-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an @CHEMICAL$ receptor-Ca2+ pathway and that @GENE$ degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an @CHEMICAL$ receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating @GENE$ surface expression.	0
Our results suggest that glutamate induces @GENE$ degradation by proteasome through an NMDA receptor-@CHEMICAL$ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by @GENE$ through an NMDA receptor-@CHEMICAL$ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an @GENE$-@CHEMICAL$ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-@CHEMICAL$ pathway and that @GENE$ degradation may play an important role in regulating GluR2 surface expression.	0
Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-@CHEMICAL$ pathway and that GRIP1 degradation may play an important role in regulating @GENE$ surface expression.	0
Transgenic expression of the @CHEM-GENE$ (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption.	0
Transgenic expression of the human @CHEMICAL$ receptor (@GENE$) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption.	0
Transgenic expression of the human @CHEMICAL$ receptor (hVDR) in the duodenum of @GENE$-null mice attenuates the age-dependent decline in calcium absorption.	0
Transgenic expression of the @GENE$ (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in @CHEMICAL$ absorption.	0
Transgenic expression of the human Vitamin D receptor (@GENE$) in the duodenum of VDR-null mice attenuates the age-dependent decline in @CHEMICAL$ absorption.	0
Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of @GENE$-null mice attenuates the age-dependent decline in @CHEMICAL$ absorption.	0
To determine if @GENE$'s actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the adenosine deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing @GENE$ exclusively in the duodenum of mVDR-null mice by using the adenosine deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of @GENE$-null mice by using the adenosine deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the @GENE$ (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the adenosine deaminase enhancer (@GENE$+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore @CHEMICAL$ homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the adenosine deaminase enhancer (hVDR+/@GENE$-null).	0
To determine if @GENE$'s actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the @CHEMICAL$ deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing @GENE$ exclusively in the duodenum of mVDR-null mice by using the @CHEMICAL$ deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of @GENE$-null mice by using the @CHEMICAL$ deaminase enhancer (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the @CHEM-GENE$ (hVDR+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the @CHEMICAL$ deaminase enhancer (@GENE$+/mVDR-null).	0
To determine if VDR's actions in the proximal small intestine can sufficiently restore calcium homeostasis, we generated transgenic mice expressing hVDR exclusively in the duodenum of mVDR-null mice by using the @CHEMICAL$ deaminase enhancer (hVDR+/@GENE$-null).	0
However, when 90-day-old rachitic mice were fed a rescue diet, serum @CHEMICAL$ improved in @GENE$+/mVDR-null mice, but not in mVDR-null mice.	0
However, when 90-day-old rachitic mice were fed a rescue diet, serum @CHEMICAL$ improved in hVDR+/@GENE$-null mice, but not in mVDR-null mice.	0
However, when 90-day-old rachitic mice were fed a rescue diet, serum @CHEMICAL$ improved in hVDR+/mVDR-null mice, but not in @GENE$-null mice.	0
In conclusion, transgenic hVDR in the proximal small intestine of @GENE$+/mVDR-null mice was transcriptionally active and regulated @CHEMICAL$ absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate calcium homeostasis.	0
In conclusion, transgenic hVDR in the proximal small intestine of hVDR+/@GENE$-null mice was transcriptionally active and regulated @CHEMICAL$ absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate calcium homeostasis.	0
In conclusion, transgenic hVDR in the proximal small intestine of hVDR+/mVDR-null mice was transcriptionally active and regulated @CHEMICAL$ absorption, but @GENE$ actions elsewhere in the intestine are probably necessary to support adequate calcium homeostasis.	0
In conclusion, transgenic @GENE$ in the proximal small intestine of hVDR+/mVDR-null mice was transcriptionally active and regulated @CHEMICAL$ absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate calcium homeostasis.	0
In conclusion, transgenic hVDR in the proximal small intestine of @GENE$+/mVDR-null mice was transcriptionally active and regulated calcium absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate @CHEMICAL$ homeostasis.	0
In conclusion, transgenic hVDR in the proximal small intestine of hVDR+/@GENE$-null mice was transcriptionally active and regulated calcium absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate @CHEMICAL$ homeostasis.	0
In conclusion, transgenic hVDR in the proximal small intestine of hVDR+/mVDR-null mice was transcriptionally active and regulated calcium absorption, but @GENE$ actions elsewhere in the intestine are probably necessary to support adequate @CHEMICAL$ homeostasis.	0
In conclusion, transgenic @GENE$ in the proximal small intestine of hVDR+/mVDR-null mice was transcriptionally active and regulated calcium absorption, but VDR actions elsewhere in the intestine are probably necessary to support adequate @CHEMICAL$ homeostasis.	0
In addition, @GENE$+/mVDR-null mice responded better to the late rescue diet suggesting that expression of VDR in the proximal small intestine protected the @CHEMICAL$ absorbing machinery from age-dependent decline.	0
In addition, hVDR+/@GENE$-null mice responded better to the late rescue diet suggesting that expression of VDR in the proximal small intestine protected the @CHEMICAL$ absorbing machinery from age-dependent decline.	0
In addition, hVDR+/mVDR-null mice responded better to the late rescue diet suggesting that expression of @GENE$ in the proximal small intestine protected the @CHEMICAL$ absorbing machinery from age-dependent decline.	0
The inhibitory effect of the @CHEMICAL$ receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and @GENE$ secretion in human airway epithelial cells.	0
The inhibitory effect of the @CHEM-GENE$ antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.	0
The inhibitory effect of the @CHEMICAL$ receptor antagonist on leukotriene D4-induced @GENE$ gene expression and mucin secretion in human airway epithelial cells.	0
The inhibitory effect of the leukotriene receptor antagonist on @CHEMICAL$-induced MUC2/5AC gene expression and @GENE$ secretion in human airway epithelial cells.	1
The inhibitory effect of the @GENE$ antagonist on @CHEMICAL$-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells.	0
The inhibitory effect of the leukotriene receptor antagonist on @CHEMICAL$-induced @GENE$ gene expression and mucin secretion in human airway epithelial cells.	1
@GENE$, lipopolysaccharides and other inflammatory mediators such as @CHEMICAL$ and leukotriene are related to the secretion and production of mucin.	0
Cytokines, lipopolysaccharides and other inflammatory mediators such as @CHEMICAL$ and leukotriene are related to the secretion and production of @GENE$.	0
@GENE$, lipopolysaccharides and other inflammatory mediators such as prostaglandin and @CHEMICAL$ are related to the secretion and production of mucin.	0
Cytokines, lipopolysaccharides and other inflammatory mediators such as prostaglandin and @CHEMICAL$ are related to the secretion and production of @GENE$.	0
However, the relationship of @CHEMICAL$ with @GENE$ genes expression is not clear.	0
The aim of this study is to evaluate @GENE$ gene expression and mucin secretion by the @CHEMICAL$ receptor in human airway epithelial cells.	0
The aim of this study is to evaluate MUC2/5AC gene expression and @GENE$ secretion by the @CHEMICAL$ receptor in human airway epithelial cells.	0
The aim of this study is to evaluate MUC2/5AC gene expression and mucin secretion by the @CHEM-GENE$ in human airway epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the @CHEM-GENE$ antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the @CHEMICAL$ receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of @GENE$ gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the @CHEMICAL$ receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and @GENE$ secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the @GENE$ antagonist, @CHEMICAL$ (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	4
METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, @CHEMICAL$ (ONO-1078) on the regulation of @GENE$ gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, @CHEMICAL$ (ONO-1078) on the regulation of MUC2/5AC gene expression and @GENE$ secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the @GENE$ antagonist, pranlukast hydrate (@CHEMICAL$) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	4
METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (@CHEMICAL$) on the regulation of @GENE$ gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (@CHEMICAL$) on the regulation of MUC2/5AC gene expression and @GENE$ secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of @CHEMICAL$ and the @GENE$ antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of @CHEMICAL$ and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of @GENE$ gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells.	0
METHODS: The effect of @CHEMICAL$ and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2/5AC gene expression and @GENE$ secretion were observed in human airway NCI-H292 epithelial cells.	0
RESULTS: @CHEMICAL$ upregulated @GENE$ gene expression and mucin secretion in a dose dependent pattern.	1
RESULTS: @CHEMICAL$ upregulated MUC2/5AC gene expression and @GENE$ secretion in a dose dependent pattern.	1
@CHEMICAL$ (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced @GENE$ gene expression and mucin secretion.	2
@CHEMICAL$ (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and @GENE$ secretion.	2
Pranlukast hydrate (@CHEMICAL$, 100 microM) downregulated the leukotriene D(4)-induced @GENE$ gene expression and mucin secretion.	2
Pranlukast hydrate (@CHEMICAL$, 100 microM) downregulated the leukotriene D(4)-induced MUC2/5AC gene expression and @GENE$ secretion.	2
Pranlukast hydrate (ONO-1078, 100 microM) downregulated the @CHEMICAL$-induced @GENE$ gene expression and mucin secretion.	1
Pranlukast hydrate (ONO-1078, 100 microM) downregulated the @CHEMICAL$-induced MUC2/5AC gene expression and @GENE$ secretion.	1
CONCLUSION: These results suggest that the @CHEM-GENE$ system is one of the mechanisms related to MUC2/5AC gene expression and mucin secretion in the human airway epithelium.	0
CONCLUSION: These results suggest that the @CHEMICAL$ receptor system is one of the mechanisms related to @GENE$ gene expression and mucin secretion in the human airway epithelium.	0
CONCLUSION: These results suggest that the @CHEMICAL$ receptor system is one of the mechanisms related to MUC2/5AC gene expression and @GENE$ secretion in the human airway epithelium.	0
Effect of isolated @CHEMICAL$ supplementation on @GENE$-dependent cholesterol efflux potential in postmenopausal women.	0
Effect of isolated isoflavone supplementation on @GENE$-dependent @CHEMICAL$ efflux potential in postmenopausal women.	0
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse @CHEMICAL$ transport as evaluated by @GENE$- (ABCA1), dependent cholesterol efflux from macrophages.	0
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse @CHEMICAL$ transport as evaluated by adenosine triphosphate-binding cassette A1- (@GENE$), dependent cholesterol efflux from macrophages.	0
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by @CHEM-GENE$- (ABCA1), dependent cholesterol efflux from macrophages.	0
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by @CHEMICAL$-binding cassette A1- (@GENE$), dependent cholesterol efflux from macrophages.	0
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by @GENE$- (ABCA1), dependent @CHEMICAL$ efflux from macrophages.	5
We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (@GENE$), dependent @CHEMICAL$ efflux from macrophages.	5
We studied in a clinical trial whether isolated @CHEMICAL$ treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by @GENE$- (ABCA1), dependent cholesterol efflux from macrophages.	0
We studied in a clinical trial whether isolated @CHEMICAL$ treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (@GENE$), dependent cholesterol efflux from macrophages.	0
@CHEMICAL$-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1-dependent cholesterol efflux and serum lipid and @GENE$ levels were assessed.	0
@CHEMICAL$-labeled J774 macrophage cells, with and without @GENE$ up-regulation, were incubated with the samples, and ABCA1-dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed.	0
@CHEMICAL$-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and @GENE$-dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed.	0
[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1-dependent @CHEMICAL$ efflux and serum lipid and @GENE$ levels were assessed.	0
[H]-Cholesterol-labeled J774 macrophage cells, with and without @GENE$ up-regulation, were incubated with the samples, and ABCA1-dependent @CHEMICAL$ efflux and serum lipid and lipoprotein levels were assessed.	0
[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and @GENE$-dependent @CHEMICAL$ efflux and serum lipid and lipoprotein levels were assessed.	5
Thus, @CHEMICAL$ supplementation did not affect @GENE$-dependent cholesterol efflux to serum.	0
Thus, isoflavone supplementation did not affect @GENE$-dependent @CHEMICAL$ efflux to serum.	5
However, as a novel finding, @CHEMICAL$ treatment increased a subclass of @GENE$, the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.	1
However, as a novel finding, @CHEMICAL$ treatment increased a subclass of high-density lipoprotein, the @GENE$ levels by 18% without affecting any other serum lipid concentrations.	1
@GENE$-facilitated cholesterol efflux and lipid parameters did not differ between equol-producing and non-@CHEMICAL$-producing women.	0
@GENE$-facilitated @CHEMICAL$ efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.	5
@GENE$-facilitated cholesterol efflux and lipid parameters did not differ between @CHEMICAL$-producing and non-equol-producing women.	0
CONCLUSION: In postmenopausal women, isolated @CHEMICAL$ treatment does not affect @GENE$-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.	0
CONCLUSION: In postmenopausal women, isolated @CHEMICAL$ treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating @GENE$ level, which could provide beneficial vascular effects.	1
CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect @GENE$-dependent @CHEMICAL$ efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.	5
CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1-dependent @CHEMICAL$ efflux potential from macrophages but increases circulating @GENE$ level, which could provide beneficial vascular effects.	0
The ability of @CHEMICAL$ to inhibit oncogenic @GENE$ and FLT3 mutants and overcome resistance to other small molecule inhibitors.	2
The ability of @CHEMICAL$ to inhibit oncogenic PDGFRbeta and @GENE$ mutants and overcome resistance to other small molecule inhibitors.	2
BACKGROUND AND OBJECTIVES: Activated @CHEM-GENE$ are implicated in the pathogenesis of chronic and acute leukemia, and represent attractive targets for therapy.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule @GENE$ inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor @CHEMICAL$ kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against @CHEM-GENE$ from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor @CHEMICAL$ kinases from the @GENE$ (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor @CHEMICAL$ kinases from the platelet-derived growth factor receptor (@GENE$) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor @CHEMICAL$ kinases from the platelet-derived growth factor receptor (PDGFR) and @GENE$ (VEGFR) families.	0
Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor @CHEMICAL$ kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (@GENE$) families.	0
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule @GENE$ inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	2
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against @GENE$ from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the @GENE$ (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (@GENE$) and vascular endothelial growth factor receptor (VEGFR) families.	0
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and @GENE$ (VEGFR) families.	0
@CHEMICAL$ (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (@GENE$) families.	0
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule @GENE$ inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	2
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against @GENE$ from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the @GENE$ (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (@GENE$) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and @GENE$ (VEGFR) families.	0
Sorafenib (@CHEMICAL$, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (@GENE$) families.	0
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule @GENE$ inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	2
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against @GENE$ from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the @GENE$ (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (@GENE$) and vascular endothelial growth factor receptor (VEGFR) families.	0
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and @GENE$ (VEGFR) families.	0
Sorafenib (BAY43-9006, @CHEMICAL$) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (@GENE$) families.	0
We investigated the efficacy of @CHEMICAL$ at inhibiting mutants of the @GENE$ PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	2
We investigated the efficacy of @CHEMICAL$ at inhibiting mutants of the receptor tyrosine kinases @GENE$, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	2
We investigated the efficacy of @CHEMICAL$ at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, @GENE$, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	2
We investigated the efficacy of @CHEMICAL$ at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and @GENE$, which are implicated in the pathogenesis of myeloid malignancies.	2
We investigated the efficacy of sorafenib at inhibiting mutants of the @CHEM-GENE$ PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	0
We investigated the efficacy of sorafenib at inhibiting mutants of the receptor @CHEMICAL$ kinases @GENE$, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	0
We investigated the efficacy of sorafenib at inhibiting mutants of the receptor @CHEMICAL$ kinases PDGFRbeta, @GENE$, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.	0
We investigated the efficacy of sorafenib at inhibiting mutants of the receptor @CHEMICAL$ kinases PDGFRbeta, KIT, and @GENE$, which are implicated in the pathogenesis of myeloid malignancies.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by @GENE$-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by ETV6-@GENE$, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, @GENE$ with an internal tandem duplication or D835Y point mutation, and the KIT(D816V) mutant.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or @GENE$ point mutation, and the KIT(D816V) mutant.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the @GENE$(D816V) mutant.	0
DESIGN AND METHODS: We tested the effect of @CHEMICAL$ on the proliferation of hematopoietic cells transformed by ETV6-PDGFRbeta, FLT3 with an internal tandem duplication or D835Y point mutation, and the KIT(@GENE$) mutant.	0
The direct effect of @CHEMICAL$ on the activity of these @GENE$ and their downstream signaling was tested using phospho-specific antibodies.	0
The direct effect of sorafenib on the activity of these @GENE$ and their downstream signaling was tested using @CHEMICAL$-specific antibodies.	0
RESULTS: We show that @CHEMICAL$ is a potent inhibitor of @GENE$-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.	2
RESULTS: We show that @CHEMICAL$ is a potent inhibitor of ETV6-@GENE$ and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.	2
RESULTS: We show that @CHEMICAL$ is a potent inhibitor of ETV6-PDGFRbeta and @GENE$ mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.	2
RESULTS: We show that @CHEMICAL$ is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other @GENE$ inhibitors.	2
@CHEMICAL$ induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing @GENE$ with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.	2
The @CHEMICAL$-resistant @GENE$(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.	0
The @CHEMICAL$-resistant KIT(@GENE$) mutant, associated with systemic mastocytosis, was found to be resistant to sorafenib.	0
The imatinib-resistant @GENE$(D816V) mutant, associated with systemic mastocytosis, was found to be resistant to @CHEMICAL$.	0
The imatinib-resistant KIT(@GENE$) mutant, associated with systemic mastocytosis, was found to be resistant to @CHEMICAL$.	0
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of @CHEMICAL$ for the treatment of myeloid malignancies expressing activated forms of @GENE$ and FLT3.	2
INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of @CHEMICAL$ for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and @GENE$.	2
We hypothesized that corticosteroid exposure modulates @CHEM-GENE$ (ENaC) expression and/or activity in bovine mammary epithelial cells.	0
We hypothesized that corticosteroid exposure modulates epithelial @CHEMICAL$ channel (@GENE$) expression and/or activity in bovine mammary epithelial cells.	0
Exposure to @CHEMICAL$ (a @GENE$ antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	4
Exposure to @CHEMICAL$ (a glucocorticoid receptor antagonist), but not spironolactone (a @GENE$ antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	0
Exposure to @CHEMICAL$ (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in @GENE$ mRNA.	0
Exposure to mifepristone (a @GENE$ antagonist), but not @CHEMICAL$ (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	0
Exposure to mifepristone (a glucocorticoid receptor antagonist), but not @CHEMICAL$ (a @GENE$ antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	4
Exposure to mifepristone (a glucocorticoid receptor antagonist), but not @CHEMICAL$ (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in @GENE$ mRNA.	0
Exposure to mifepristone (a @GENE$ antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in @CHEMICAL$-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	0
Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a @GENE$ antagonist), precluded both the corticosteroid-induced elevation in @CHEMICAL$-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA.	0
Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in @CHEMICAL$-sensitive I(sc) and the induced changes in @GENE$ mRNA.	0
We conclude that @CHEMICAL$ movement across mammary epithelia is modulated by corticosteroids via a @GENE$-mediated mechanism that regulates the expression of the beta- and gamma-subunits of ENaC.	0
We conclude that @CHEMICAL$ movement across mammary epithelia is modulated by corticosteroids via a glucocorticoid receptor-mediated mechanism that regulates the expression of the @GENE$.	0
@GENE$ expression and activity could account for the low @CHEMICAL$ concentration that is typical of milk.	0
Oral @CHEMICAL$ (as a representative of the salicylate family) inhibited diabetes-induced increase in @GENE$ DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.	2
Oral aspirin (as a representative of the @CHEMICAL$ family) inhibited diabetes-induced increase in @GENE$ DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.	2
All three @CHEMICAL$ inhibited the diabetes-induced translocation of @GENE$ (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.	2
All three @CHEMICAL$ inhibited the diabetes-induced translocation of p50 (a subunit of @GENE$) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.	2
All three @CHEMICAL$ inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of @GENE$ and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.	2
All three @CHEMICAL$ inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and @GENE$ into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections.	2
@CHEMICAL$ (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by @GENE$, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.	2
@CHEMICAL$ (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, @GENE$, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.	2
@CHEMICAL$ (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, @GENE$, and cyclooxygenase-2 in whole-retinal lysate.	2
@CHEMICAL$ (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and @GENE$ in whole-retinal lysate.	2
Sulfasalazine (also as a representative of the @CHEMICAL$) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by @GENE$, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.	2
Sulfasalazine (also as a representative of the @CHEMICAL$) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, @GENE$, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the @CHEMICAL$) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, @GENE$, and cyclooxygenase-2 in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the @CHEMICAL$) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and @GENE$ in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by @GENE$, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible @CHEMICAL$ synthase, and cyclooxygenase-2 in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, @GENE$, inducible @CHEMICAL$ synthase, and cyclooxygenase-2 in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, @CHEM-GENE$, and cyclooxygenase-2 in whole-retinal lysate.	0
Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible @CHEMICAL$ synthase, and @GENE$ in whole-retinal lysate.	0
@CHEMICAL$, in doses administrated in our experiments, inhibited @GENE$B and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.	2
Localization of an @CHEM-GENE$ activity to the distal nephron.	0
An @CHEM-GENE$ (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction.	0
An @CHEMICAL$ dehydrogenase (@GENE$) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction.	0
An @GENE$ (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links @CHEMICAL$ metabolism with the production of a color reaction.	0
An 11 beta hydroxysteroid dehydrogenase (@GENE$) activity has been localized in the rat kidney by a histochemical technique which links @CHEMICAL$ metabolism with the production of a color reaction.	0
These results demonstrate the presence of a @GENE$ activity separate from the @CHEMICAL$ (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver.	0
These results demonstrate the presence of a dehydrogenase activity separate from the @CHEMICAL$ (NADP)-dependent @GENE$ recently purified and cloned from rat liver.	0
These results demonstrate the presence of a @GENE$ activity separate from the nicotinamide-adenine dinucleotide phosphate (@CHEMICAL$)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver.	0
These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (@CHEMICAL$)-dependent @GENE$ recently purified and cloned from rat liver.	0
These results demonstrate the presence of a @GENE$ activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent @CHEMICAL$ dehydrogenase recently purified and cloned from rat liver.	0
These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent @CHEM-GENE$ recently purified and cloned from rat liver.	0
We have named this activity @GENE$ to distinguish it from the @CHEMICAL$-dependent 11 beta HSD.	0
We have named this activity 11 beta HSD2 to distinguish it from the @CHEMICAL$-dependent @GENE$.	0
These results support the crucial role played by an @CHEM-GENE$ in the local protection of type I receptors in mineralocorticoid selective tissues.	0
Effect of long-term @CHEMICAL$ treatment on the @GENE$ in Caco-2 cells.	0
Effect of long-term fluoxetine treatment on the @CHEM-GENE$ in Caco-2 cells.	0
The chronic effect of SSRIs on the activity of the @CHEM-GENE$ (SERT) has been less studied and the results have been contradictory.	0
The chronic effect of SSRIs on the activity of the @CHEMICAL$ transporter (@GENE$) has been less studied and the results have been contradictory.	0
The aim of this study was to determine the specific effect of long-term @CHEMICAL$ treatment on @GENE$ (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2.	0
The aim of this study was to determine the specific effect of long-term @CHEMICAL$ treatment on human serotonin transporter (@GENE$) in vitro, by using the human enterocyte-like cell line Caco-2.	0
The aim of this study was to determine the specific effect of long-term fluoxetine treatment on @CHEM-GENE$ (hSERT) in vitro, by using the human enterocyte-like cell line Caco-2.	0
The aim of this study was to determine the specific effect of long-term fluoxetine treatment on human @CHEMICAL$ transporter (@GENE$) in vitro, by using the human enterocyte-like cell line Caco-2.	0
@CHEMICAL$ affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total @GENE$ protein content or the hSERT mRNA level.	0
@CHEMICAL$ affected mainly the hSERT transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the @GENE$ mRNA level.	0
@CHEMICAL$ affected mainly the @GENE$ transport rate by reducing the availability of the transporter in the membrane with no significant alteration of either the total hSERT protein content or the hSERT mRNA level.	0
These results suggest that the effect of @CHEMICAL$ on the expression of @GENE$ is post-translational and has shown itself to be independent of PKC and PKA activity.	0
These results suggest that the effect of @CHEMICAL$ on the expression of hSERT is post-translational and has shown itself to be independent of @GENE$ and PKA activity.	0
These results suggest that the effect of @CHEMICAL$ on the expression of hSERT is post-translational and has shown itself to be independent of PKC and @GENE$ activity.	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (@CHEMICAL$); @GENE$ (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	5
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (@CHEMICAL$); choline acetyltransferase (@GENE$), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	5
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (@CHEMICAL$); choline acetyltransferase (ChAT), its synthesizing enzyme; and both @GENE$ (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (@CHEMICAL$); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (@GENE$ and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (@CHEMICAL$); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and @GENE$, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @CHEM-GENE$ (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @CHEMICAL$ acetyltransferase (@GENE$), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @CHEMICAL$ acetyltransferase (ChAT), its synthesizing enzyme; and both @GENE$ (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @CHEMICAL$ acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (@GENE$ and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @CHEMICAL$ acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and @GENE$, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); @GENE$ (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic @CHEMICAL$ receptors (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (@GENE$), its synthesizing enzyme; and both muscarinic and nicotinic @CHEMICAL$ receptors (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both @CHEM-GENE$ (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic @CHEMICAL$ receptors (@GENE$ and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic @CHEMICAL$ receptors (mAChRs and @GENE$, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including @CHEMICAL$ (ACh); @GENE$ (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	5
Lymphocytes possess the essential components of a cholinergic system, including @CHEMICAL$ (ACh); choline acetyltransferase (@GENE$), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively).	5
Lymphocytes possess the essential components of a cholinergic system, including @CHEMICAL$ (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both @GENE$ (mAChRs and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including @CHEMICAL$ (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (@GENE$ and nAChRs, respectively).	0
Lymphocytes possess the essential components of a cholinergic system, including @CHEMICAL$ (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and @GENE$, respectively).	0
Stimulation of lymphocytes with @GENE$, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of @CHEMICAL$ and up-regulates expression of ChAT and M(5) mAChR mRNAs.	0
Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the @GENE$/CD3 complex, enhances the synthesis and release of @CHEMICAL$ and up-regulates expression of ChAT and M(5) mAChR mRNAs.	0
Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/@GENE$ complex, enhances the synthesis and release of @CHEMICAL$ and up-regulates expression of ChAT and M(5) mAChR mRNAs.	0
Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of @CHEMICAL$ and up-regulates expression of @GENE$ and M(5) mAChR mRNAs.	0
Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of @CHEMICAL$ and up-regulates expression of ChAT and @GENE$ mRNAs.	0
In addition, activation of @GENE$ and increases in intracellular @CHEMICAL$ also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.	0
In addition, activation of protein kinase C and increases in intracellular @CHEMICAL$ also enhance cholinergic activity in T cells, and @GENE$ (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.	1
In addition, activation of protein kinase C and increases in intracellular @CHEMICAL$ also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (@GENE$; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.	1
In addition, activation of protein kinase C and increases in intracellular @CHEMICAL$ also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; @GENE$/CD18) is an important mediator of leukocyte migration and T cell activation.	1
In addition, activation of protein kinase C and increases in intracellular @CHEMICAL$ also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/@GENE$) is an important mediator of leukocyte migration and T cell activation.	1
Anti-@GENE$ monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte @GENE$ containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against @GENE$, CD7 and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, @GENE$ and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and @GENE$ all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase @GENE$ activity, @CHEMICAL$ synthesis and release, and expression of ChAT and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of @GENE$ and M(5) mAChR mRNAs in T cells.	0
Anti-CD11a monoclonal antibody (mAb) as well as antithymocyte globulin containing antibodies against CD2, CD7 and CD11a all increase ChAT activity, @CHEMICAL$ synthesis and release, and expression of ChAT and @GENE$ mRNAs in T cells.	0
The @CHEMICAL$-lowering drug simvastatin inhibits @GENE$ signaling by binding to an allosteric site on CD11a (LFA-1 alpha chain), which leads to immunomodulation.	0
The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on @GENE$ (LFA-1 alpha chain), which leads to immunomodulation.	0
The @CHEMICAL$-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (@GENE$ chain), which leads to immunomodulation.	0
We found that @CHEMICAL$ abolishes anti-@GENE$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.	2
We found that simvastatin abolishes anti-@GENE$ mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its @CHEMICAL$-lowering activity.	0
Collectively then, these results indicate that @GENE$ contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways and suggest that @CHEMICAL$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	0
Collectively then, these results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via @GENE$-mediated pathways and suggest that @CHEMICAL$ exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	0
Association of @CHEM-GENE$ and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	0
Association of @CHEMICAL$ receptor-alpha and @GENE$ A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	0
Association of @GENE$ and @CHEMICAL$ receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	0
Association of estrogen receptor-alpha and @CHEM-GENE$ A expression with hormonal mammary carcinogenesis: role of the host microenvironment.	0
INTRODUCTION: Medroxyprogesterone acetate (@CHEMICAL$) induces estrogen receptor (ER)-positive and progesterone receptor (@GENE$)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: Medroxyprogesterone acetate (@CHEMICAL$) induces @GENE$ (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: Medroxyprogesterone acetate (@CHEMICAL$) induces estrogen receptor (@GENE$)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: Medroxyprogesterone acetate (@CHEMICAL$) induces estrogen receptor (ER)-positive and @GENE$ (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces @CHEMICAL$ receptor (ER)-positive and progesterone receptor (@GENE$)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces @CHEM-GENE$ (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces @CHEMICAL$ receptor (@GENE$)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces @CHEMICAL$ receptor (ER)-positive and @GENE$ (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and @CHEMICAL$ receptor (@GENE$)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces @GENE$ (ER)-positive and @CHEMICAL$ receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (@GENE$)-positive and @CHEMICAL$ receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and @CHEM-GENE$ (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	0
INTRODUCTION: @CHEMICAL$ (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (@GENE$)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: @CHEMICAL$ (MPA) induces @GENE$ (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: @CHEMICAL$ (MPA) induces estrogen receptor (@GENE$)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
INTRODUCTION: @CHEMICAL$ (MPA) induces estrogen receptor (ER)-positive and @GENE$ (PR)-positive ductal invasive mammary carcinomas in BALB/c mice.	1
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by @CHEMICAL$ and progesterone, and the levels of @GENE$ and PR expression in MPA-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by @CHEMICAL$ and progesterone, and the levels of ER and @GENE$ expression in MPA-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and @CHEMICAL$, and the levels of @GENE$ and PR expression in MPA-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and @CHEMICAL$, and the levels of ER and @GENE$ expression in MPA-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of @GENE$ and PR expression in @CHEMICAL$-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and @GENE$ expression in @CHEMICAL$-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of @GENE$ and PR expression in MPA-treated and @CHEMICAL$-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of MPA, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and @GENE$ expression in MPA-treated and @CHEMICAL$-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of @CHEMICAL$, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of @GENE$ and PR expression in MPA-treated and progesterone-treated mammary glands.	0
Within this experimental setting, we studied the carcinogenic effects of @CHEMICAL$, the morphologic changes in mammary glands that are induced by MPA and progesterone, and the levels of ER and @GENE$ expression in MPA-treated and progesterone-treated mammary glands.	0
In addition, BALB/c and C57BL/6 females were treated with @CHEMICAL$ or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of @GENE$ and PR.	0
In addition, BALB/c and C57BL/6 females were treated with @CHEMICAL$ or MPA for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and @GENE$.	0
In addition, BALB/c and C57BL/6 females were treated with progesterone or @CHEMICAL$ for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of @GENE$ and PR.	0
In addition, BALB/c and C57BL/6 females were treated with progesterone or @CHEMICAL$ for 1 or 2 months, and mammary glands were excised for histologic studies and for immunohistochemical and Western blot evaluation of ER and @GENE$.	0
The expression of @GENE$ and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in @CHEMICAL$-treated BALB/c mice (P < 0.05).	2
The expression of ER-alpha and @GENE$ in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in @CHEMICAL$-treated BALB/c mice (P < 0.05).	2
@GENE$ levels were low in virgin control mice and increased after @CHEMICAL$ treatment in both strains.	1
Various genes controlled by @CHEMICAL$, including @GENE$, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.	1
Various genes controlled by @CHEMICAL$, including X-inactive-specific transcript, @GENE$, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.	1
Various genes controlled by @CHEMICAL$, including X-inactive-specific transcript, anterior gradient-2, @GENE$, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.	1
Various genes controlled by @CHEMICAL$, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, @GENE$, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.	1
Various genes controlled by @CHEMICAL$, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, @GENE$, and small proline-rich protein-2A, were dramatically over-expressed.	1
Various genes controlled by @CHEMICAL$, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and @GENE$, were dramatically over-expressed.	1
Various genes controlled by estrogen, including @GENE$, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small @CHEMICAL$-rich protein-2A, were dramatically over-expressed.	0
Various genes controlled by estrogen, including X-inactive-specific transcript, @GENE$, trefoil factor-1, CRP-ductin, ghrelin, and small @CHEMICAL$-rich protein-2A, were dramatically over-expressed.	0
Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, @GENE$, CRP-ductin, ghrelin, and small @CHEMICAL$-rich protein-2A, were dramatically over-expressed.	0
Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, @GENE$, ghrelin, and small @CHEMICAL$-rich protein-2A, were dramatically over-expressed.	0
Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, @GENE$, and small @CHEMICAL$-rich protein-2A, were dramatically over-expressed.	0
Various genes controlled by estrogen, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and @CHEM-GENE$, were dramatically over-expressed.	0
@CHEMICAL$-regulated genes including cytokeratin 1-19 and @GENE$ were over-expressed, although Cyp3a25 was suppressed.	1
@CHEMICAL$-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although @GENE$ was suppressed.	2
@CHEMICAL$-regulated genes including @GENE$ and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed.	1
Several genes involved with @CHEMICAL$ metabolism also showed remarkable expression changes, including increased expression of @GENE$ (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).	0
Several genes involved with @CHEMICAL$ metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (@GENE$; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).	0
Several genes involved with @CHEMICAL$ metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of @GENE$ (involved in testosterone production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of @CHEM-GENE$ (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of @CHEMICAL$ dehydrogenase-7 (@GENE$; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of @CHEMICAL$ dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of @GENE$ (involved in testosterone production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of @GENE$ (HSD17beta7; involved in @CHEMICAL$ production) and decreased expression of HSD17beta5 (involved in testosterone production).	5
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (@GENE$; involved in @CHEMICAL$ production) and decreased expression of HSD17beta5 (involved in testosterone production).	5
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in @CHEMICAL$ production) and decreased expression of @GENE$ (involved in testosterone production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of @GENE$ (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in @CHEMICAL$ production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (@GENE$; involved in estradiol production) and decreased expression of HSD17beta5 (involved in @CHEMICAL$ production).	0
Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of @GENE$ (involved in @CHEMICAL$ production).	5
The expression of key genes important in methionine metabolism, such as @GENE$, betaine-homocysteine methyltransferase and @CHEMICAL$ S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, @GENE$ and @CHEMICAL$ S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and @CHEM-GENE$, were suppressed.	0
The expression of key genes important in methionine metabolism, such as @GENE$, betaine-homocysteine methyltransferase and thioether @CHEMICAL$-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, @GENE$ and thioether @CHEMICAL$-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and @CHEM-GENE$, were suppressed.	0
The expression of key genes important in @CHEMICAL$ metabolism, such as @GENE$, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.	5
The expression of key genes important in @CHEMICAL$ metabolism, such as methionine adenosyltransferase-1a, @GENE$ and thioether S-methyltransferase, were suppressed.	5
The expression of key genes important in @CHEMICAL$ metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and @GENE$, were suppressed.	5
The expression of key genes important in methionine metabolism, such as @CHEM-GENE$, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as @CHEMICAL$ adenosyltransferase-1a, @GENE$ and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as @CHEMICAL$ adenosyltransferase-1a, betaine-homocysteine methyltransferase and @GENE$, were suppressed.	0
The expression of key genes important in methionine metabolism, such as @GENE$, @CHEMICAL$-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, @CHEM-GENE$ and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, @CHEMICAL$-homocysteine methyltransferase and @GENE$, were suppressed.	0
The expression of key genes important in methionine metabolism, such as @GENE$, betaine-@CHEMICAL$ methyltransferase and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, @CHEM-GENE$ and thioether S-methyltransferase, were suppressed.	0
The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-@CHEMICAL$ methyltransferase and @GENE$, were suppressed.	0
@CHEMICAL$ crystals stimulate monocytes and macrophages to release IL-1beta through the @GENE$ component of the inflammasome.	0
@CHEMICAL$ crystals stimulate monocytes and macrophages to release @GENE$ through the NALP3 component of the inflammasome.	1
The effectiveness of @GENE$ inhibition was first evaluated in a mouse model of @CHEMICAL$ crystal-induced inflammation.	0
Structural basis of inhibition of the @CHEM-GENE$ by suramin.	0
Structural basis of inhibition of the @GENE$ by @CHEMICAL$.	2
We identified @CHEMICAL$ as a compound that binds to @GENE$ and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.	0
We identified @CHEMICAL$ as a compound that binds to human SIRT5 and showed that it inhibits @GENE$ activity with an IC(50) value of 22 microM.	2
We identified suramin as a compound that binds to @GENE$ and showed that it inhibits SIRT5 @CHEMICAL$-dependent deacetylase activity with an IC(50) value of 22 microM.	0
We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits @CHEM-GENE$ activity with an IC(50) value of 22 microM.	0
To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of @GENE$, one in complex with @CHEMICAL$-ribose, the other bound to suramin.	0
To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of @GENE$, one in complex with ADP-ribose, the other bound to @CHEMICAL$.	0
Our structural studies provide a view of a synthetic inhibitory compound in a @GENE$ active site revealing that @CHEMICAL$ binds into the NAD(+), the product, and the substrate-binding site.	0
Our structural studies provide a view of a synthetic inhibitory compound in a @GENE$ active site revealing that suramin binds into the @CHEMICAL$, the product, and the substrate-binding site.	0
Metabolic derangement of @CHEMICAL$ and folate metabolism in mice deficient in @GENE$.	0
Metabolic derangement of methionine and @CHEMICAL$ metabolism in mice deficient in @GENE$.	0
Metabolic derangement of methionine and folate metabolism in mice deficient in @CHEM-GENE$.	0
In humans, @CHEM-GENE$ deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis.	0
In humans, @GENE$ deficiency results in the accumulation of @CHEMICAL$ at the expense of folate derivatives required for purine and thymidylate biosynthesis.	5
In humans, @GENE$ deficiency results in the accumulation of methyltetrahydrofolate at the expense of @CHEMICAL$ derivatives required for purine and thymidylate biosynthesis.	0
In humans, @GENE$ deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for @CHEMICAL$ and thymidylate biosynthesis.	0
In humans, @GENE$ deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and @CHEMICAL$ biosynthesis.	0
Complete ablation of @CHEM-GENE$ activity in mice results in embryonic lethality.	0
We have constructed a mouse model with a gene trap insertion in the @GENE$ gene specifying @CHEMICAL$ synthase reductase, an enzyme essential for the activity of methionine synthase.	0
We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying @CHEM-GENE$, an enzyme essential for the activity of methionine synthase.	0
We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying @CHEMICAL$ synthase reductase, an enzyme essential for the activity of @GENE$.	0
We have constructed a mouse model with a gene trap insertion in the @GENE$ gene specifying methionine synthase reductase, an enzyme essential for the activity of @CHEMICAL$ synthase.	0
We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying @GENE$, an enzyme essential for the activity of @CHEMICAL$ synthase.	0
We have constructed a mouse model with a gene trap insertion in the Mtrr gene specifying methionine synthase reductase, an enzyme essential for the activity of @CHEM-GENE$.	0
This model is a hypomorph, with reduced methionine synthase reductase activity, thus avoiding the lethality associated with the absence of @CHEM-GENE$ activity.	0
This model is a hypomorph, with reduced @GENE$ activity, thus avoiding the lethality associated with the absence of @CHEMICAL$ synthase activity.	0
This model is a hypomorph, with reduced @CHEMICAL$ synthase reductase activity, thus avoiding the lethality associated with the absence of @GENE$ activity.	0
This model is a hypomorph, with reduced @CHEM-GENE$ activity, thus avoiding the lethality associated with the absence of methionine synthase activity.	0
@GENE$(gt/gt) mice have increased plasma @CHEMICAL$, decreased plasma methionine, and increased tissue methyltetrahydrofolate.	0
@GENE$(gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma @CHEMICAL$, and increased tissue methyltetrahydrofolate.	0
@GENE$(gt/gt) mice have increased plasma homocyst(e)ine, decreased plasma methionine, and increased tissue @CHEMICAL$.	0
Unexpectedly, @GENE$(gt/gt) mice do not show decreases in the @CHEMICAL$/AdoHcy ratio in most tissues.	0
Unexpectedly, @GENE$(gt/gt) mice do not show decreases in the AdoMet/@CHEMICAL$ ratio in most tissues.	0
@CHEMICAL$ and phenformin activate @GENE$ in the heart by increasing cytosolic AMP concentration.	1
Metformin and phenformin activate @GENE$ in the heart by increasing cytosolic @CHEMICAL$ concentration.	0
Metformin and @CHEMICAL$ activate @GENE$ in the heart by increasing cytosolic AMP concentration.	1
Metformin and phenformin activate @CHEM-GENE$ in the heart by increasing cytosolic AMP concentration.	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the @CHEMICAL$-to-ATP ratio (AMP/ATP).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the @CHEMICAL$-to-ATP ratio (AMP/ATP).	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-@CHEMICAL$ ratio (AMP/ATP).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-@CHEMICAL$ ratio (AMP/ATP).	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (@CHEMICAL$/ATP).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (@CHEMICAL$/ATP).	0
@CHEM-GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).	0
@CHEMICAL$-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/@CHEMICAL$).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([AMP]) or the AMP-to-ATP ratio (AMP/@CHEMICAL$).	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in @CHEMICAL$ concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in @CHEMICAL$ concentration ([AMP]) or the AMP-to-ATP ratio (AMP/ATP).	0
@GENE$ (AMPK) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([@CHEMICAL$]) or the AMP-to-ATP ratio (AMP/ATP).	0
AMP-activated protein kinase (@GENE$) acts as a cellular energy sensor: it responds to an increase in AMP concentration ([@CHEMICAL$]) or the AMP-to-ATP ratio (AMP/ATP).	0
@CHEMICAL$ and phenformin, which are biguanides, have been reported to increase @GENE$ activity without increasing AMP/ATP.	1
Metformin and @CHEMICAL$, which are biguanides, have been reported to increase @GENE$ activity without increasing AMP/ATP.	1
Metformin and phenformin, which are @CHEMICAL$, have been reported to increase @GENE$ activity without increasing AMP/ATP.	1
Metformin and phenformin, which are biguanides, have been reported to increase @GENE$ activity without increasing @CHEMICAL$/ATP.	0
Metformin and phenformin, which are biguanides, have been reported to increase @GENE$ activity without increasing AMP/@CHEMICAL$.	0
This study tests the hypothesis that these @CHEMICAL$ increase @GENE$ activity in the heart by increasing cytosolic [AMP].	0
This study tests the hypothesis that these biguanides increase @GENE$ activity in the heart by increasing cytosolic [@CHEMICAL$].	0
At various times, hearts were freeze-clamped and assayed for @GENE$ activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on @CHEMICAL$ carboxylase, an AMPK target.	0
At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on @GENE$, and phosphorylation of Ser(79) on @CHEMICAL$ carboxylase, an AMPK target.	0
At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on @CHEM-GENE$, an AMPK target.	0
At various times, hearts were freeze-clamped and assayed for AMPK activity, phosphorylation of Thr(172) on AMPK-alpha, and phosphorylation of Ser(79) on @CHEMICAL$ carboxylase, an @GENE$ target.	0
In hearts treated with @CHEMICAL$ for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and @GENE$ activity was elevated at 36 min.	1
In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [@CHEMICAL$] began to increase at 26 min and @GENE$ activity was elevated at 36 min.	0
In hearts treated with @CHEMICAL$, [AMP] was increased at 50 min and @GENE$ activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.	1
In hearts treated with @CHEMICAL$, [AMP] was increased at 50 min and AMPK activity, phosphorylated @GENE$, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.	1
In hearts treated with @CHEMICAL$, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and @GENE$ were elevated at 61 min.	1
In hearts treated with metformin, [@CHEMICAL$] was increased at 50 min and @GENE$ activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.	0
In hearts treated with metformin, [@CHEMICAL$] was increased at 50 min and AMPK activity, phosphorylated @GENE$, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.	0
In hearts treated with metformin, [@CHEMICAL$] was increased at 50 min and AMPK activity, phosphorylated AMPK, and @GENE$ were elevated at 61 min.	0
In hearts treated with metformin, [AMP] was increased at 50 min and @GENE$ activity, phosphorylated AMPK, and phosphorylated @CHEMICAL$ carboxylase were elevated at 61 min.	0
In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated @GENE$, and phosphorylated @CHEMICAL$ carboxylase were elevated at 61 min.	0
In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and @CHEM-GENE$ were elevated at 61 min.	0
In summary, @CHEMICAL$ and metformin increase @GENE$ activity and phosphorylation in the isolated heart.	1
In summary, phenformin and @CHEMICAL$ increase @GENE$ activity and phosphorylation in the isolated heart.	1
The increase in @GENE$ activity was always preceded by and correlated with increased cytosolic [@CHEMICAL$].	0
Cytosolic [@CHEMICAL$] reported metabolically active AMP, which triggered increased @GENE$ activity, but measures of total AMP did not.	0
Cytosolic [AMP] reported metabolically active @CHEMICAL$, which triggered increased @GENE$ activity, but measures of total AMP did not.	1
Cytosolic [AMP] reported metabolically active AMP, which triggered increased @GENE$ activity, but measures of total @CHEMICAL$ did not.	0
The role of @CHEM-GENE$ in individual susceptibility to bladder cancer in a Tunisian population.	0
AIM: This study seeks to determine the role of the @CHEM-GENE$ null genotypes (GSTM1*0 and GSTT1*0) in individual susceptibility to bladder cancer in a Tunisian population.	0
AIM: This study seeks to determine the role of the @CHEMICAL$ transferases M1 and T1 null genotypes (@GENE$*0 and GSTT1*0) in individual susceptibility to bladder cancer in a Tunisian population.	0
AIM: This study seeks to determine the role of the @CHEMICAL$ transferases M1 and T1 null genotypes (GSTM1*0 and @GENE$*0) in individual susceptibility to bladder cancer in a Tunisian population.	0
Characterization of @GENE$ receptors in rat spinal cord via [125I]iodocyanopindolol binding and inhibition of @CHEMICAL$ release.	0
Characterization of @GENE$ receptors in rat spinal cord via @CHEMICAL$ binding and inhibition of [3H]-5-hydroxytryptamine release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @GENE$ defined by @CHEMICAL$ [( 125I] ICYP) binding and the 5-HT autoreceptor defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by @CHEMICAL$ [( 125I] ICYP) binding and the @GENE$ defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @GENE$ defined by [125I]iodocyanopindolol @CHEMICAL$ binding and the 5-HT autoreceptor defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by [125I]iodocyanopindolol @CHEMICAL$ binding and the @GENE$ defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @GENE$ defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the @CHEMICAL$ autoreceptor defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the @CHEM-GENE$ defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @CHEM-GENE$ defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the 5-HT autoreceptor defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @CHEMICAL$ (5-HT)1B receptor defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the @GENE$ defined by inhibition of [3H]-5-HT release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the @GENE$ defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the 5-HT autoreceptor defined by inhibition of @CHEMICAL$ release.	0
The aim of the present study in rat spinal cord synaptosomes was to compare the pharmacological characteristics of the serotonin (5-HT)1B receptor defined by [125I]iodocyanopindolol [( 125I] ICYP) binding and the @GENE$ defined by inhibition of @CHEMICAL$ release.	0
@CHEMICAL$ binding was not altered by compounds with activity at @GENE$, 5-HT1C, 5-HT2, 5-HT3 or alpha-2 receptor sites.	0
@CHEMICAL$ binding was not altered by compounds with activity at 5-HT1A, @GENE$, 5-HT2, 5-HT3 or alpha-2 receptor sites.	0
@CHEMICAL$ binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, @GENE$, 5-HT3 or alpha-2 receptor sites.	0
@CHEMICAL$ binding was not altered by compounds with activity at 5-HT1A, 5-HT1C, 5-HT2, @GENE$ or alpha-2 receptor sites.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than @CHEMICAL$.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by @CHEMICAL$, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM @CHEMICAL$-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of @CHEMICAL$ were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were @CHEMICAL$ = 5-carboxyamidotryptamine HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = @CHEMICAL$ HCl = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine @CHEMICAL$ = CGS 12066B greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = @CHEMICAL$ greater than 5-methoxytryptamine greater than 5-HT.	0
Similar to the pharmacological characteristics of the @GENE$ site defined by [125I]ICYP, compounds most active at inhibiting 15 mM K(+)-stimulated release of [3H]-5-HT were RU24969 = 5-carboxyamidotryptamine HCl = CGS 12066B greater than @CHEMICAL$ greater than 5-HT.	0
A correlation analysis of selective @GENE$ compounds comparing the pKD for displacement of @CHEMICAL$ vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of @CHEMICAL$ vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @GENE$ and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of @CHEMICAL$ vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the @GENE$ site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective @GENE$ compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of @CHEMICAL$ release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of @CHEMICAL$ release demonstrated the pharmacological similarity of the presynaptic inhibitory @GENE$ and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of @CHEMICAL$ release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the @GENE$ site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective @GENE$ compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @CHEMICAL$ autoreceptor and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @CHEM-GENE$ and the 5-HT receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @CHEMICAL$ autoreceptor and the @GENE$ site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective @GENE$ compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the @CHEMICAL$ receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @GENE$ and the @CHEMICAL$ receptor site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the @CHEM-GENE$ site defined by [125I]ICYP binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective @GENE$ compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the 5-HT receptor site defined by @CHEMICAL$ binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory @GENE$ and the 5-HT receptor site defined by @CHEMICAL$ binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
A correlation analysis of selective 5-HT1B compounds comparing the pKD for displacement of [125I]ICYP vs. the IC50 for inhibition of [3H]-5-HT release demonstrated the pharmacological similarity of the presynaptic inhibitory 5-HT autoreceptor and the @GENE$ site defined by @CHEMICAL$ binding in spinal cord synaptosomes (r = 0.791, P = .0193).	0
These results point out that @CHEMICAL$ identifies the @GENE$ receptor, and affinity of compounds for this site predicts action at the 5-HT1B autoreceptor.	0
These results point out that @CHEMICAL$ identifies the 5-HT1B receptor, and affinity of compounds for this site predicts action at the @GENE$ autoreceptor.	0
@CHEM-GENE$ involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine.	0
@GENE$ involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of @CHEMICAL$.	0
@CHEM-GENE$ blockade is one of the more prominent actions of the multi-receptor acting antipsychotic clozapine.	0
@GENE$ blockade is one of the more prominent actions of the multi-receptor acting antipsychotic @CHEMICAL$.	2
It is currently not known how much this @GENE$ antagonism of @CHEMICAL$ contributes to the therapeutic or adverse side effects of clozapine.	4
It is currently not known how much this @GENE$ antagonism of clozapine contributes to the therapeutic or adverse side effects of @CHEMICAL$.	0
The current studies with Sprague-Dawley rats were conducted to determine the participation of @GENE$ subtype in sensorimotor plasticity and memory function affected by @CHEMICAL$ using tests of prepulse inhibition (PPI) and radial-arm maze choice accuracy.	0
In the current project, we found that the selective @GENE$ antagonist @CHEMICAL$ also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.	4
In the current project, we found that the selective @GENE$ antagonist pyrilamine also reversed the @CHEMICAL$-induced impairment in PPI of tactile startle with an auditory prepulse.	1
In summary, the therapeutic effect of @CHEMICAL$ in reversing PPI impairment was mimicked by the @GENE$ antagonist pyrilamine, while pyrilamine had a mixed effect on cognition.	2
In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the @GENE$ antagonist @CHEMICAL$, while pyrilamine had a mixed effect on cognition.	4
In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the @GENE$ antagonist pyrilamine, while @CHEMICAL$ had a mixed effect on cognition.	4
Thus, @GENE$ antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as @CHEMICAL$.	4
The mRNA expression of @GENE$ (PSS1) and PtdSer synthase 2 (PSS2) was not reduced by @CHEMICAL$.	0
The mRNA expression of PtdSer synthase 1 (@GENE$) and PtdSer synthase 2 (PSS2) was not reduced by @CHEMICAL$.	0
The mRNA expression of PtdSer synthase 1 (PSS1) and @GENE$ (PSS2) was not reduced by @CHEMICAL$.	0
The mRNA expression of PtdSer synthase 1 (PSS1) and PtdSer synthase 2 (@GENE$) was not reduced by @CHEMICAL$.	0
Similarly, the @GENE$ enzyme level did not change after @CHEMICAL$ exposure but PSS2 could not be probed with the antibody available currently.	0
Similarly, the PSS1 enzyme level did not change after @CHEMICAL$ exposure but @GENE$ could not be probed with the antibody available currently.	0
We provide evidence that defective @CHEMICAL$ catabolism promotes the development of fasting hypoglycemia in @GENE$-/- mice by limiting gluconeogenic substrate availability.	0
@GENE$-/- liver and skeletal muscle show markedly reduced mRNA expression of @CHEMICAL$-degrading enzymes.	0
Furthermore, the enzymatic activity of @CHEM-GENE$ (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	0
Furthermore, the enzymatic activity of @CHEMICAL$ aminotransferase (@GENE$), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	0
Furthermore, the enzymatic activity of @CHEMICAL$ aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in @GENE$-/- hepatocytes.	0
Furthermore, the enzymatic activity of @GENE$ (ALT), which converts the critical gluconeogenic @CHEMICAL$ alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (@GENE$), which converts the critical gluconeogenic @CHEMICAL$ alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic @CHEMICAL$ alanine into pyruvate, is decreased (approximately 50%) in @GENE$-/- hepatocytes.	0
Furthermore, the enzymatic activity of @GENE$ (ALT), which converts the critical gluconeogenic amino acid @CHEMICAL$ into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (@GENE$), which converts the critical gluconeogenic amino acid @CHEMICAL$ into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid @CHEMICAL$ into pyruvate, is decreased (approximately 50%) in @GENE$-/- hepatocytes.	0
Furthermore, the enzymatic activity of @GENE$ (ALT), which converts the critical gluconeogenic amino acid alanine into @CHEMICAL$, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (@GENE$), which converts the critical gluconeogenic amino acid alanine into @CHEMICAL$, is decreased (approximately 50%) in KLF15-/- hepatocytes.	5
Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into @CHEMICAL$, is decreased (approximately 50%) in @GENE$-/- hepatocytes.	0
Consistent with this observation, intraperitoneal injection of @CHEMICAL$, but not alanine, rescues fasting hypoglycemia in @GENE$-/- mice.	0
Consistent with this observation, intraperitoneal injection of pyruvate, but not @CHEMICAL$, rescues fasting hypoglycemia in @GENE$-/- mice.	0
@CHEMICAL$ stimulation of L-arginine transport and nitric oxide synthesis results from activation of @GENE$ and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	0
@CHEMICAL$ stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and @GENE$ requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	1
@CHEMICAL$ stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional @GENE$ in human umbilical vein endothelium.	0
D-glucose stimulation of @CHEMICAL$ transport and nitric oxide synthesis results from activation of @GENE$ and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	0
D-glucose stimulation of @CHEMICAL$ transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and @GENE$ requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	0
D-glucose stimulation of @CHEMICAL$ transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional @GENE$ in human umbilical vein endothelium.	0
D-glucose stimulation of L-arginine transport and @CHEMICAL$ synthesis results from activation of @GENE$ and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	0
D-glucose stimulation of L-arginine transport and @CHEMICAL$ synthesis results from activation of mitogen-activated protein kinases p42/44 and @GENE$ requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	0
D-glucose stimulation of L-arginine transport and @CHEMICAL$ synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional @GENE$ in human umbilical vein endothelium.	0
Elevated extracellular @CHEMICAL$ increases @GENE$ (TGF-beta1) release from human umbilical vein endothelium (HUVEC).	1
Elevated extracellular @CHEMICAL$ increases transforming growth factor beta1 (@GENE$) release from human umbilical vein endothelium (HUVEC).	1
We studied whether @CHEMICAL$-stimulation of L-arginine transport and nitric oxide synthesis involves @GENE$ in primary cultures of HUVEC.	0
We studied whether D-glucose-stimulation of @CHEMICAL$ transport and nitric oxide synthesis involves @GENE$ in primary cultures of HUVEC.	0
We studied whether D-glucose-stimulation of L-arginine transport and @CHEMICAL$ synthesis involves @GENE$ in primary cultures of HUVEC.	0
@GENE$ release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) @CHEMICAL$.	1
@GENE$ increases @CHEMICAL$ transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport.	0
@GENE$ increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal @CHEMICAL$, but did not alter high D-glucose-increased L-arginine transport.	0
@GENE$ increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high @CHEMICAL$-increased L-arginine transport.	0
@GENE$ increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased @CHEMICAL$ transport.	0
@GENE$ and high @CHEMICAL$ increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high @CHEMICAL$ increased @GENE$ mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	1
TGF-beta1 and high @CHEMICAL$ increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and @GENE$ (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high @CHEMICAL$ increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (@GENE$) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high @CHEMICAL$ increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter @GENE$ phosphorylation.	0
@GENE$ and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), @CHEMICAL$ formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased @GENE$ mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), @CHEMICAL$ formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), @CHEMICAL$ formation from L-[(3)H]arginine (index of NO synthesis) and @GENE$ (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), @CHEMICAL$ formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (@GENE$) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), @CHEMICAL$ formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter @GENE$ phosphorylation.	0
@GENE$ and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from @CHEMICAL$ (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased @GENE$ mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from @CHEMICAL$ (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from @CHEMICAL$ (index of NO synthesis) and @GENE$ (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from @CHEMICAL$ (index of NO synthesis) and endothelial NO synthase (@GENE$) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from @CHEMICAL$ (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter @GENE$ phosphorylation.	0
@GENE$ and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of @CHEMICAL$ synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased @GENE$ mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of @CHEMICAL$ synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of @CHEMICAL$ synthesis) and @GENE$ (eNOS) protein abundance, but did not alter eNOS phosphorylation.	5
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of @CHEMICAL$ synthesis) and endothelial NO synthase (@GENE$) protein abundance, but did not alter eNOS phosphorylation.	5
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of @CHEMICAL$ synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter @GENE$ phosphorylation.	0
@GENE$ and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial @CHEMICAL$ synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased @GENE$ mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial @CHEMICAL$ synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and @CHEM-GENE$ (eNOS) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial @CHEMICAL$ synthase (@GENE$) protein abundance, but did not alter eNOS phosphorylation.	0
TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial @CHEMICAL$ synthase (eNOS) protein abundance, but did not alter @GENE$ phosphorylation.	0
@GENE$ and high @CHEMICAL$ increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).	0
TGF-beta1 and high @CHEMICAL$ increased @GENE$(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).	0
TGF-beta1 and high @CHEMICAL$ increased p42/44(@GENE$) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).	0
TGF-beta1 and high @CHEMICAL$ increased p42/44(mapk) and @GENE$ phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).	1
TGF-beta1 and high @CHEMICAL$ increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (@GENE$ inhibitor).	0
@GENE$ and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by @CHEMICAL$ (MEK1/2 inhibitor).	0
TGF-beta1 and high D-glucose increased @GENE$(mapk) and Smad2 phosphorylation, an effect blocked by @CHEMICAL$ (MEK1/2 inhibitor).	0
TGF-beta1 and high D-glucose increased p42/44(@GENE$) and Smad2 phosphorylation, an effect blocked by @CHEMICAL$ (MEK1/2 inhibitor).	0
TGF-beta1 and high D-glucose increased p42/44(mapk) and @GENE$ phosphorylation, an effect blocked by @CHEMICAL$ (MEK1/2 inhibitor).	2
TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by @CHEMICAL$ (@GENE$ inhibitor).	0
However, @GENE$ and high @CHEMICAL$ were ineffective in cells expressing a truncated, negative dominant TbetaRII.	0
However, TGF-beta1 and high @CHEMICAL$ were ineffective in cells expressing a truncated, negative dominant @GENE$.	0
High @CHEMICAL$ increases L-arginine transport and @GENE$ expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.	1
High @CHEMICAL$ increases L-arginine transport and eNOS expression following @GENE$ activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.	1
High @CHEMICAL$ increases L-arginine transport and eNOS expression following TbetaRII activation by @GENE$ involving p42/44(mapk) and Smad2 in HUVEC.	0
High @CHEMICAL$ increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving @GENE$(mapk) and Smad2 in HUVEC.	0
High @CHEMICAL$ increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(@GENE$) and Smad2 in HUVEC.	0
High @CHEMICAL$ increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and @GENE$ in HUVEC.	1
High D-glucose increases @CHEMICAL$ transport and @GENE$ expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.	0
High D-glucose increases @CHEMICAL$ transport and eNOS expression following @GENE$ activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.	0
High D-glucose increases @CHEMICAL$ transport and eNOS expression following TbetaRII activation by @GENE$ involving p42/44(mapk) and Smad2 in HUVEC.	0
High D-glucose increases @CHEMICAL$ transport and eNOS expression following TbetaRII activation by TGF-beta1 involving @GENE$(mapk) and Smad2 in HUVEC.	0
High D-glucose increases @CHEMICAL$ transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(@GENE$) and Smad2 in HUVEC.	0
High D-glucose increases @CHEMICAL$ transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and @GENE$ in HUVEC.	0
@CHEMICAL$ induce the expression of @GENE$ via PPARgamma activation in human keratinocyte HaCaT cells.	1
@CHEMICAL$ induce the expression of COX-2 via @GENE$ activation in human keratinocyte HaCaT cells.	1
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (@CHEMICAL$) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (@CHEMICAL$) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a @CHEMICAL$, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a @CHEMICAL$, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and @CHEMICAL$ a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and @CHEMICAL$ a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a @CHEMICAL$, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a @CHEMICAL$, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether @CHEMICAL$ (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether @CHEMICAL$ (EPA) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (@CHEMICAL$) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (@CHEMICAL$) a n-3 PUFA, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a @CHEMICAL$, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a @CHEMICAL$, gamma-linoleic acid (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, @CHEMICAL$ (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of @GENE$ (COX-2), an enzyme pivotal to skin inflammation and reparation.	0
We examined in HaCaT keratinocyte cell line whether eicosapentaenoic acid (EPA) a n-3 PUFA, @CHEMICAL$ (GLA) a n-6 PUFA, and arachidic acid a saturated fatty acid, modulate expression of cyclooxygenase-2 (@GENE$), an enzyme pivotal to skin inflammation and reparation.	0
We demonstrate that only treatment of HaCaT with @CHEMICAL$ and EPA or a @GENE$ ligand (roziglitazone), induced COX-2 expression (protein and mRNA).	0
We demonstrate that only treatment of HaCaT with @CHEMICAL$ and EPA or a PPARgamma ligand (roziglitazone), induced @GENE$ expression (protein and mRNA).	1
We demonstrate that only treatment of HaCaT with GLA and @CHEMICAL$ or a @GENE$ ligand (roziglitazone), induced COX-2 expression (protein and mRNA).	0
We demonstrate that only treatment of HaCaT with GLA and @CHEMICAL$ or a PPARgamma ligand (roziglitazone), induced @GENE$ expression (protein and mRNA).	1
We demonstrate that only treatment of HaCaT with GLA and EPA or a @GENE$ ligand (@CHEMICAL$), induced COX-2 expression (protein and mRNA).	0
We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (@CHEMICAL$), induced @GENE$ expression (protein and mRNA).	1
Moreover stimulation of @GENE$ activity was increased by those @CHEMICAL$ or rosiglitazone.	1
Moreover stimulation of @GENE$ activity was increased by those PUFAs or @CHEMICAL$.	1
The inhibitory effects of @CHEMICAL$ and T0070907 (@GENE$ antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	4
The inhibitory effects of @CHEMICAL$ and T0070907 (PPARgamma antagonists), on @GENE$ expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of @CHEMICAL$ and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of @GENE$ activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of @CHEMICAL$ and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that @GENE$ is implicated in COX-2 induction.	0
The inhibitory effects of @CHEMICAL$ and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in @GENE$ induction.	0
The inhibitory effects of GW9662 and @CHEMICAL$ (@GENE$ antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	4
The inhibitory effects of GW9662 and @CHEMICAL$ (PPARgamma antagonists), on @GENE$ expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and @CHEMICAL$ (PPARgamma antagonists), on COX-2 expression and on stimulation of @GENE$ activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and @CHEMICAL$ (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that @GENE$ is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and @CHEMICAL$ (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in @GENE$ induction.	0
The inhibitory effects of GW9662 and T0070907 (@GENE$ antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by @CHEMICAL$ and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on @GENE$ expression and on stimulation of COX-2 promoter activity by @CHEMICAL$ and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of @GENE$ activity by @CHEMICAL$ and GLA suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by @CHEMICAL$ and GLA suggest that @GENE$ is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by @CHEMICAL$ and GLA suggest that PPARgamma is implicated in @GENE$ induction.	0
The inhibitory effects of GW9662 and T0070907 (@GENE$ antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and @CHEMICAL$ suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on @GENE$ expression and on stimulation of COX-2 promoter activity by EPA and @CHEMICAL$ suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of @GENE$ activity by EPA and @CHEMICAL$ suggest that PPARgamma is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and @CHEMICAL$ suggest that @GENE$ is implicated in COX-2 induction.	0
The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and @CHEMICAL$ suggest that PPARgamma is implicated in @GENE$ induction.	0
Finally, PLA2 inhibitor methyl @CHEMICAL$ blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in @GENE$ activation.	0
Finally, @GENE$ inhibitor methyl @CHEMICAL$ blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.	2
Finally, PLA2 inhibitor methyl @CHEMICAL$ blocked the PUFA effects on @GENE$ induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.	2
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the @CHEMICAL$ effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in @GENE$ activation.	0
Finally, @GENE$ inhibitor methyl arachidonyl fluorophosphonate blocked the @CHEMICAL$ effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.	0
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the @CHEMICAL$ effects on @GENE$ induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.	0
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and @CHEMICAL$ mobilization suggesting involvement of AA metabolites in @GENE$ activation.	0
Finally, @GENE$ inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and @CHEMICAL$ mobilization suggesting involvement of AA metabolites in PPAR activation.	0
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on @GENE$ induction, promoter activity and @CHEMICAL$ mobilization suggesting involvement of AA metabolites in PPAR activation.	0
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of @CHEMICAL$ metabolites in @GENE$ activation.	1
Finally, @GENE$ inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of @CHEMICAL$ metabolites in PPAR activation.	0
Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on @GENE$ induction, promoter activity and arachidonic acid mobilization suggesting involvement of @CHEMICAL$ metabolites in PPAR activation.	0
These findings demonstrate that @CHEMICAL$ increased @GENE$ activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.	1
These findings demonstrate that @CHEMICAL$ increased PPARgamma activity is necessary for the @GENE$ induction in HaCaT human keratinocyte cells.	1
Given the anti-inflammatory properties of @CHEMICAL$, we suggest that induction of @GENE$ in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of PUFAs n-3 or n-6.	0
Given the anti-inflammatory properties of EPA, we suggest that induction of @GENE$ in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of @CHEMICAL$ or n-6.	1
MATERIALS AND METHODS: Methylation of @CHEMICAL$ sulfotransferase pi (@GENE$) and Ras associated family 1A (RASSF1A) genes was studied using methylation sensitive PCR (MS-PCR).	0
MATERIALS AND METHODS: Methylation of @CHEMICAL$ sulfotransferase pi (GSTP1) and @GENE$ (RASSF1A) genes was studied using methylation sensitive PCR (MS-PCR).	0
MATERIALS AND METHODS: Methylation of @CHEMICAL$ sulfotransferase pi (GSTP1) and Ras associated family 1A (@GENE$) genes was studied using methylation sensitive PCR (MS-PCR).	0
MATERIALS AND METHODS: Methylation of @CHEM-GENE$ (GSTP1) and Ras associated family 1A (RASSF1A) genes was studied using methylation sensitive PCR (MS-PCR).	0
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting @GENE$ agonist that is the @CHEMICAL$) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).	3
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting @GENE$ agonist that is the [R,R] isomer of formoterol) and @CHEMICAL$ versus placebo in patients with chronic obstructive pulmonary disease (COPD).	0
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized @CHEMICAL$ (a selective, long-acting @GENE$ agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).	3
Discovery of @GENE$ inhibitors: comparison of a fluorescence intensity-based @CHEMICAL$ assay and a fluorescence polarization-based ADP Assay for high-throughput screening.	0
Discovery of @CHEM-GENE$ inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based ADP Assay for high-throughput screening.	0
Discovery of @GENE$ inhibitors: comparison of a fluorescence intensity-based phosphate assay and a fluorescence polarization-based @CHEMICAL$ Assay for high-throughput screening.	0
@CHEM-GENE$ (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation.	0
@CHEMICAL$ carboxylase (@GENE$) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation.	0
@CHEMICAL$ carboxylase (ACC) enzymes exist as two isoforms, @GENE$ and ACC2, which play critical roles in fatty acid biosynthesis and oxidation.	0
@CHEMICAL$ carboxylase (ACC) enzymes exist as two isoforms, ACC1 and @GENE$, which play critical roles in fatty acid biosynthesis and oxidation.	0
@GENE$ (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in @CHEMICAL$ biosynthesis and oxidation.	5
Acetyl-coenzyme A carboxylase (@GENE$) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in @CHEMICAL$ biosynthesis and oxidation.	5
Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, @GENE$ and ACC2, which play critical roles in @CHEMICAL$ biosynthesis and oxidation.	5
Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and @GENE$, which play critical roles in @CHEMICAL$ biosynthesis and oxidation.	5
The cytosolic @GENE$ is expressed primarily in liver and adipose tissue, and uses @CHEMICAL$ as a key building block in fatty acid biosynthesis.	0
The cytosolic @GENE$ is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in @CHEMICAL$ biosynthesis.	5
The mitochondrial @GENE$ is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of @CHEMICAL$ oxidation.	5
@CHEM-GENE$ inhibitors were identified by these high-throughput screening methods and were confirmed in a radiometric high performance liquid chromatography assay of malonyl-coenzyme A production.	0
@GENE$ inhibitors were identified by these high-throughput screening methods and were confirmed in a radiometric high performance liquid chromatography assay of @CHEMICAL$ production.	0
In contrast, the @CHEMICAL$ catabolising enzymes @GENE$ and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye.	5
In contrast, the @CHEMICAL$ catabolising enzymes Cyp26A1 and @GENE$ which are known to be RA-responsive were not expressed at all in the developing eye.	5
In contrast, the RA catabolising enzymes @GENE$ and Cyp26B1 which are known to be @CHEMICAL$-responsive were not expressed at all in the developing eye.	0
In contrast, the RA catabolising enzymes Cyp26A1 and @GENE$ which are known to be @CHEMICAL$-responsive were not expressed at all in the developing eye.	0
As expected, mutations of @CHEMICAL$ kinase genes (FLT3, KIT, and @GENE$) were common in de novo AML, with a cumulative frequency of 30%.	0
As expected, mutations of @CHEM-GENE$ genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.	0
As expected, mutations of @CHEMICAL$ kinase genes (@GENE$, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.	0
As expected, mutations of @CHEMICAL$ kinase genes (FLT3, @GENE$, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.	0
These data support the hypothesis that mutations of @GENE$ may provide the "activated @CHEMICAL$ kinase signal" that is thought to be important for leukemogenesis.	0
These data support the hypothesis that mutations of CSF3R may provide the "activated @CHEM-GENE$ signal" that is thought to be important for leukemogenesis.	0
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the @GENE$ peptides @CHEMICAL$-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).	0
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides @CHEM-GENE$ (GIP) and glucagon-like peptide-1 (GLP-1).	0
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides @CHEMICAL$-dependent insulinotropic polypeptide (@GENE$) and glucagon-like peptide-1 (GLP-1).	0
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides @CHEMICAL$-dependent insulinotropic polypeptide (GIP) and @GENE$ (GLP-1).	0
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides @CHEMICAL$-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (@GENE$).	0
@GENE$ activation leads to @CHEMICAL$-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.	0
Incretin-receptor activation leads to @CHEMICAL$-dependent @GENE$ secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis.	1
In contrast, @GENE$ exerts glucoregulatory actions via slowing of gastric emptying and @CHEMICAL$-dependent inhibition of glucagon secretion.	0
In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and @CHEMICAL$-dependent inhibition of @GENE$ secretion.	0
Aripiprazole acts as a selective @CHEM-GENE$ partial agonist.	0
It has been claimed that partial agonism of the @CHEM-GENE$ and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the @CHEMICAL$ D(2) and 5-HT(1A) receptors and antagonism of the @GENE$ receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the @GENE$ and antagonism of the 5-HT(2) receptor contribute to the clinical profile of @CHEMICAL$, a so-called dopamine- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the @GENE$ receptor contribute to the clinical profile of @CHEMICAL$, a so-called dopamine- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the @GENE$ and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called @CHEMICAL$- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the @GENE$ receptor contribute to the clinical profile of aripiprazole, a so-called @CHEMICAL$- and 5-HT stabiliser.	0
It has been claimed that partial agonism of the @GENE$ and antagonism of the 5-HT(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and @CHEMICAL$ stabiliser.	0
It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism of the @GENE$ receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and @CHEMICAL$ stabiliser.	0
This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the @GENE$ and does not affect @CHEMICAL$ receptors at therapeutic doses.	0
This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect @CHEM-GENE$ at therapeutic doses.	0
This report reviews published and unpublished data that suggest that @CHEMICAL$ acts as a selective partial agonist at the @GENE$ and does not affect 5-HT receptors at therapeutic doses.	3
This report reviews published and unpublished data that suggest that @CHEMICAL$ acts as a selective partial agonist at the dopamine D(2) receptor and does not affect @GENE$ at therapeutic doses.	0
This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the @CHEM-GENE$ and does not affect 5-HT receptors at therapeutic doses.	0
This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the @CHEMICAL$ D(2) receptor and does not affect @GENE$ at therapeutic doses.	0
They include @CHEMICAL$ antagonists, dopaminergic agonists, valproic acid, reserpine, @GENE$ analogs and thiazolidinediones.	0
They include serotonin antagonists, dopaminergic agonists, @CHEMICAL$, reserpine, @GENE$ analogs and thiazolidinediones.	0
They include serotonin antagonists, dopaminergic agonists, valproic acid, @CHEMICAL$, @GENE$ analogs and thiazolidinediones.	0
They include serotonin antagonists, dopaminergic agonists, valproic acid, reserpine, @GENE$ analogs and @CHEMICAL$.	0
@CHEMICAL$ blocks @GENE$ activation without modifying cortisol synthesis.	2
Mifepriston'e blocks @GENE$ activation without modifying @CHEMICAL$ synthesis.	0
@CHEM-GENE$ in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies.	0
[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (@CHEMICAL$), a selective @GENE$ antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.	4
[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A), a selective @CHEM-GENE$ antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.	0
[@CHEMICAL$] (SR 141716A), a selective @GENE$ antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.	4
Double immunofluorescence studies with selective antibodies against @GENE$, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @GENE$ (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (@CHEM-GENE$ (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (@GENE$ and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and @GENE$), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), @GENE$ (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (@GENE$) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @GENE$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular @CHEMICAL$ transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that @GENE$ in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against @GENE$, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @GENE$ (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (@GENE$ (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (@GENE$ and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and @GENE$), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEM-GENE$ (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (@GENE$) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and @GENE$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @CHEMICAL$ decarboxylase-67 (GAD67) and oxytocin itself, have shown that @GENE$ in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against @GENE$, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @GENE$ (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (@GENE$ (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (@GENE$ and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and @GENE$), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @GENE$ (GAD67) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (@GENE$) and @CHEMICAL$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEM-GENE$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, glutamic acid transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @CHEMICAL$ itself, have shown that @GENE$ in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against @GENE$, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEM-GENE$ (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (@GENE$ (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (@GENE$ and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and @GENE$), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), @GENE$ (GAD67) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (@GENE$) and oxytocin itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and @GENE$ itself, have shown that CB1 receptors in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
Double immunofluorescence studies with selective antibodies against CB1 receptors, @CHEMICAL$ transporters (vesicular glutamate transporters 1 and 2 (VGlut1 and VGlut2), glutamic acid decarboxylase-67 (GAD67) and oxytocin itself, have shown that @GENE$ in the PVN are located mainly in GABAergic terminals and fibers surrounding oxytocinergic cell bodies.	0
As GABAergic synapses in the PVN impinge directly on oxytocinergic neurons or on excitatory glutamatergic synapses, which also impinge on oxytocinergic neurons, these results suggest that the blockade of @GENE$ decreases @CHEMICAL$ release in the PVN, increasing in turn glutamatergic neurotransmission to activate oxytocinergic neurons mediating penile erection.	0
The present findings confirm that PVN @GENE$, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by @CHEMICAL$ increases the density of these receptors in the PVN.	0
The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of @GENE$ by @CHEMICAL$ increases the density of these receptors in the PVN.	2
@GENE$-induced platelet aggregation was independent of @CHEMICAL$ formation and ADP secretion but enhanced by feedback stimulation through these pathways.	0
@GENE$-induced platelet aggregation was independent of thromboxane A2 formation and @CHEMICAL$ secretion but enhanced by feedback stimulation through these pathways.	0
Treatments that raised @CHEMICAL$ (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented @GENE$-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition.	0
Treatments that raised @CHEMICAL$ (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, @GENE$ [tPA]) induced almost complete inhibition.	0
Treatments that raised @CHEMICAL$ (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [@GENE$]) induced almost complete inhibition.	0
Treatments that raised cAMP (@CHEMICAL$), sequestered Ca2+ (BAPTA-AM) or prevented @GENE$-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (@CHEMICAL$), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, @GENE$ [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (@CHEMICAL$), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [@GENE$]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered @CHEMICAL$ (BAPTA-AM) or prevented @GENE$-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered @CHEMICAL$ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, @GENE$ [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered @CHEMICAL$ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [@GENE$]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered Ca2+ (@CHEMICAL$) or prevented @GENE$-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered Ca2+ (@CHEMICAL$) or prevented amyloid-platelet interaction (sRAGE, @GENE$ [tPA]) induced almost complete inhibition.	0
Treatments that raised cAMP (iloprost), sequestered Ca2+ (@CHEMICAL$) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [@GENE$]) induced almost complete inhibition.	0
Modulation of the function of @GENE$ (CD36-/- mice), p38(MAPK) (@CHEMICAL$), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), @GENE$(MAPK) (@CHEMICAL$), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	2
Modulation of the function of CD36 (CD36-/- mice), p38(@GENE$) (@CHEMICAL$), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	2
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (@CHEMICAL$), @GENE$ (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (@CHEMICAL$), COX-1 (indomethacin), and @GENE$ (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (@CHEMICAL$), COX-1 (indomethacin), and glycoprotein Ib alpha (@GENE$, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of @GENE$ (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (@CHEMICAL$), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), @GENE$(MAPK) (SB203580), COX-1 (@CHEMICAL$), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), p38(@GENE$) (SB203580), COX-1 (@CHEMICAL$), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), @GENE$ (@CHEMICAL$), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	2
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (@CHEMICAL$), and @GENE$ (Nk-protease, 6D1 antibody) induced approximately 50% inhibition.	0
Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (@CHEMICAL$), and glycoprotein Ib alpha (@GENE$, 6D1 antibody) induced approximately 50% inhibition.	0
@GENE$ activates platelets through 2 pathways: one is through CD36, p38(MAPK), @CHEMICAL$-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination.	0
Amyloid activates platelets through 2 pathways: one is through @GENE$, p38(MAPK), @CHEMICAL$-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination.	0
Amyloid activates platelets through 2 pathways: one is through CD36, @GENE$(MAPK), @CHEMICAL$-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination.	0
Amyloid activates platelets through 2 pathways: one is through CD36, p38(@GENE$), @CHEMICAL$-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination.	0
Amyloid activates platelets through 2 pathways: one is through CD36, p38(MAPK), @CHEMICAL$-mediated induction of aggregation; the other is through @GENE$-mediated aggregation and agglutination.	0
@GENE$, a @CHEMICAL$ dehydrogenase causing Leber's congenital amaurosis, is also involved in steroid metabolism.	0
RDH12, a @CHEM-GENE$ causing Leber's congenital amaurosis, is also involved in steroid metabolism.	0
Three @CHEM-GENE$ (RDHs) were tested for steroid converting abilities: human and murine RDH 12 and human RDH13.	0
Three @CHEMICAL$ dehydrogenases (RDHs) were tested for steroid converting abilities: @GENE$ and human RDH13.	0
Three @CHEMICAL$ dehydrogenases (RDHs) were tested for steroid converting abilities: human and murine RDH 12 and @GENE$.	0
Three @CHEMICAL$ dehydrogenases (@GENE$) were tested for steroid converting abilities: human and murine RDH 12 and human RDH13.	0
We show that @GENE$ and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to @CHEMICAL$, and is thus also involved in steroid metabolism.	0
We show that murine Rdh12 and @GENE$ do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to @CHEMICAL$, and is thus also involved in steroid metabolism.	0
We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that @GENE$ reduces dihydrotestosterone to @CHEMICAL$, and is thus also involved in steroid metabolism.	5
The influence of candidate gene polymorphisms involved in @CHEMICAL$ and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in @CHEMICAL$ and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in @CHEMICAL$ and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in @CHEMICAL$ and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and @CHEMICAL$ or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and @CHEMICAL$ or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and @CHEMICAL$ or receptor function (phenylethanolamine N-methyltransferase, @GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and @CHEMICAL$ or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (@CHEMICAL$ N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (@CHEMICAL$ N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (@CHEMICAL$ N-methyltransferase, @GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (@CHEMICAL$ N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine @CHEMICAL$-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine @CHEMICAL$-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine @CHEMICAL$-methyltransferase, @GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine @CHEMICAL$-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @CHEMICAL$ binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @CHEMICAL$ binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @CHEM-GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @CHEMICAL$ binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and @CHEM-GENE$ [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, @CHEMICAL$] member 4 [homo sapiens] [@GENE$]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, @GENE$, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, @CHEMICAL$] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, @GENE$, and solute carrier family 6 [neurotransmitter transporter, @CHEMICAL$] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.	0
The @CHEMICAL$ group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial @GENE$ compared with the placebo group.	1
The LS/SS genotype of the promoter for @GENE$ was associated with enhanced weight loss with @CHEMICAL$.	0
CONCLUSIONS: Weight reduction with @CHEMICAL$ is associated with altered gastric functions and increased @GENE$ and is significantly associated with SLC6A4 genotype.	1
CONCLUSIONS: Weight reduction with @CHEMICAL$ is associated with altered gastric functions and increased peptide YY and is significantly associated with @GENE$ genotype.	0
The role of genetic variation in @GENE$ on weight loss in response to @CHEMICAL$ deserves further study.	0
Multiple @GENE$ forms are produced by distinct starting points and alternative splicing of the @CHEMICAL$-terminal exons.	0
It was concluded that the presence of the @GENE$ in these isoforms is not relevant for the formation of the calpain/calpastatin complex in the absence of @CHEMICAL$, that is the interaction of calpastatin with inactive calpain.	0
It was concluded that the presence of the XL-domain in these isoforms is not relevant for the formation of the @GENE$/calpastatin complex in the absence of @CHEMICAL$, that is the interaction of calpastatin with inactive calpain.	0
It was concluded that the presence of the XL-domain in these isoforms is not relevant for the formation of the calpain/@GENE$ complex in the absence of @CHEMICAL$, that is the interaction of calpastatin with inactive calpain.	0
It was concluded that the presence of the XL-domain in these isoforms is not relevant for the formation of the calpain/calpastatin complex in the absence of @CHEMICAL$, that is the interaction of @GENE$ with inactive calpain.	0
It was concluded that the presence of the XL-domain in these isoforms is not relevant for the formation of the calpain/calpastatin complex in the absence of @CHEMICAL$, that is the interaction of calpastatin with inactive @GENE$.	0
An investigation of the absolute configuration of the potent @CHEM-GENE$ antagonist GT-2331 using vibrational circular dichroism.	0
An investigation of the absolute configuration of the potent @GENE$ antagonist @CHEMICAL$ using vibrational circular dichroism.	4
@CHEMICAL$ [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the @GENE$, and as such, is an important biomarker for pharmaceutical companies conducting research in this field.	0
GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of @CHEMICAL$ by the @GENE$, and as such, is an important biomarker for pharmaceutical companies conducting research in this field.	0
GT-2331 [(+)-1] is one of the most potent members of a class of chiral drug substances used to regulate the synthesis and release of histamine by the @CHEM-GENE$, and as such, is an important biomarker for pharmaceutical companies conducting research in this field.	0
Allosteric interaction of the neuromuscular blockers @CHEMICAL$ and pancuronium with recombinant @GENE$.	0
Allosteric interaction of the neuromuscular blockers vecuronium and @CHEMICAL$ with recombinant @GENE$.	0
Neuromuscular blocking drugs produce muscle weakness by interaction with @CHEM-GENE$.	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; @CHEMICAL$(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), @CHEMICAL$ 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug @CHEMICAL$ and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	2
In this study the neuromuscular blocking drug vecuronium and the controls @CHEMICAL$ and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	2
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and @CHEMICAL$ slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	2
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of @CHEMICAL$ induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced @CHEMICAL$ dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); @CHEMICAL$ (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), @CHEMICAL$ 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; @CHEMICAL$ (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant @GENE$ K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), @CHEMICAL$ 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01).	0
These data indicate that @CHEMICAL$, gallamine and pancuronium interact with an allosteric site on the @GENE$ (located on the heart) and this may explain some of their cardiac side effects.	0
These data indicate that vecuronium, @CHEMICAL$ and pancuronium interact with an allosteric site on the @GENE$ (located on the heart) and this may explain some of their cardiac side effects.	0
These data indicate that vecuronium, gallamine and @CHEMICAL$ interact with an allosteric site on the @GENE$ (located on the heart) and this may explain some of their cardiac side effects.	0
@CHEMICAL$-mediated oxidative stress disrupts calcium binding on @GENE$: more evidence for oxidative stress in vitiligo.	0
Hydrogen peroxide-mediated oxidative stress disrupts @CHEMICAL$ binding on @GENE$: more evidence for oxidative stress in vitiligo.	0
Patients with acute vitiligo have low epidermal @GENE$ expression/activities and accumulate 10(-3) M @CHEMICAL$.	5
Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined @CHEMICAL$ binding to @GENE$ in the presence and absence of H(2)O(2) utilising (45)calcium.	0
Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to @GENE$ in the presence and absence of @CHEMICAL$ utilising (45)calcium.	0
Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to @GENE$ in the presence and absence of H(2)O(2) utilising (45)@CHEMICAL$.	0
Since 10(-3)M @CHEMICAL$ oxidises methionine and tryptophan residues in proteins, we examined calcium binding to @GENE$ in the presence and absence of H(2)O(2) utilising (45)calcium.	0
Since 10(-3)M H(2)O(2) oxidises @CHEMICAL$ and tryptophan residues in proteins, we examined calcium binding to @GENE$ in the presence and absence of H(2)O(2) utilising (45)calcium.	0
Since 10(-3)M H(2)O(2) oxidises methionine and @CHEMICAL$ residues in proteins, we examined calcium binding to @GENE$ in the presence and absence of H(2)O(2) utilising (45)calcium.	0
The results showed that all four @CHEMICAL$ atoms exchanged per molecule of @GENE$.	0
Since oxidised @GENE$ looses its ability to activate @CHEMICAL$ ATPase, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6).	0
Since oxidised calmodulin looses its ability to activate @CHEM-GENE$, enzyme activities were followed in full skin biopsies from lesional skin of patients with acute vitiligo (n=6) and healthy controls (n=6).	0
Computer simulation of native and oxidised @GENE$ confirmed the loss of all four @CHEMICAL$ ions from their specific EF-hand domains.	0
Computer simulation of native and oxidised calmodulin confirmed the loss of all four @CHEMICAL$ ions from their specific @GENE$.	0
Taken together @CHEMICAL$-mediated oxidation affects calcium binding in @GENE$ leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.	0
Taken together H(2)O(2)-mediated oxidation affects @CHEMICAL$ binding in @GENE$ leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.	0
Taken together H(2)O(2)-mediated oxidation affects calcium binding in @GENE$ leading to perturbed @CHEMICAL$ homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.	0
Taken together H(2)O(2)-mediated oxidation affects calcium binding in @GENE$ leading to perturbed calcium homeostasis and perturbed @CHEMICAL$-uptake in the epidermis of acute vitiligo.	0
Characterization of the @CHEMICAL$ adduct of substrate-bound @GENE$ by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.	0
Characterization of the nitrosyl adduct of substrate-bound @CHEM-GENE$ by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.	0
@CHEM-GENE$ (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.	0
Mammalian @CHEMICAL$ dioxygenase (@GENE$) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.	0
@GENE$ (CDO) is a non-heme @CHEMICAL$ metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.	0
Mammalian cysteine dioxygenase (@GENE$) is a non-heme @CHEMICAL$ metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.	0
@GENE$ (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative @CHEMICAL$ catabolism.	5
Mammalian cysteine dioxygenase (@GENE$) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative @CHEMICAL$ catabolism.	5
The active site coordination of @GENE$ comprises a mononuclear @CHEMICAL$ ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.	0
The active site coordination of CDO comprises a mononuclear @CHEMICAL$ ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the @GENE$.	0
The active site coordination of @GENE$ comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived @CHEMICAL$, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.	0
The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived @CHEMICAL$, thus representing a new variant on the @GENE$.	0
The active site coordination of @GENE$ comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the @CHEMICAL$ (2H1C) facial triad motif.	0
The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the @CHEM-GENE$.	0
The active site coordination of @GENE$ comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (@CHEMICAL$) facial triad motif.	0
The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the @CHEM-GENE$.	0
In these experiments, @GENE$ exhibits an ordered binding of @CHEMICAL$ prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.	0
In these experiments, CDO exhibits an ordered binding of @CHEMICAL$ prior to NO (and presumably O2) similar to that observed for the @GENE$.	0
In these experiments, @GENE$ exhibits an ordered binding of l-cysteine prior to @CHEMICAL$ (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.	0
In these experiments, CDO exhibits an ordered binding of l-cysteine prior to @CHEMICAL$ (and presumably O2) similar to that observed for the @GENE$.	0
In these experiments, @GENE$ exhibits an ordered binding of l-cysteine prior to NO (and presumably @CHEMICAL$) similar to that observed for the 2H1C class of non-heme iron enzymes.	0
In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably @CHEMICAL$) similar to that observed for the @GENE$.	0
In these experiments, @GENE$ exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the @CHEMICAL$ class of non-heme iron enzymes.	0
In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the @CHEM-GENE$.	0
In these experiments, @GENE$ exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme @CHEMICAL$ enzymes.	0
In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the @CHEM-GENE$.	0
Moreover, the @GENE$ active site is essentially unreactive toward @CHEMICAL$ in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to NO.	0
Moreover, the @GENE$ active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of @CHEMICAL$ prior to NO.	0
Moreover, the @GENE$ active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to @CHEMICAL$.	0
However, upon addition of @CHEMICAL$ to @GENE$ in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.	0
However, upon addition of NO to @GENE$ in the presence of substrate @CHEMICAL$, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.	5
However, upon addition of NO to @GENE$ in the presence of substrate l-cysteine, a low-spin {@CHEMICAL$}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.	0
However, upon addition of NO to @GENE$ in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the @CHEMICAL$ within the enzyme develops.	0
The unusual {@CHEMICAL$}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl @GENE$ (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site.	0
The unusual {@CHEMICAL$}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound @GENE$ active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound @CHEMICAL$ @GENE$ (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound @CHEMICAL$ CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound @GENE$ active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl @GENE$ (termed {ES-@CHEMICAL$}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-@CHEMICAL$}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound @GENE$ active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl @GENE$ (termed {ES-NO}7) is a result of the @CHEMICAL$ coordination of l-cysteine in the NO-bound CDO active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the @CHEMICAL$ coordination of l-cysteine in the NO-bound @GENE$ active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl @GENE$ (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of @CHEMICAL$ in the NO-bound CDO active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of @CHEMICAL$ in the NO-bound @GENE$ active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl @GENE$ (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the @CHEMICAL$-bound CDO active site.	0
The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the @CHEMICAL$-bound @GENE$ active site.	0
The DFT-predicted geometric parameters for {ES-@CHEMICAL$}7 are in good agreement with the crystallographically determined substrate-bound active site configuration of @GENE$ and are consistent with known iron-nitrosyl model complexes.	0
The DFT-predicted geometric parameters for {ES-NO}7 are in good agreement with the crystallographically determined substrate-bound active site configuration of @GENE$ and are consistent with known @CHEMICAL$ model complexes.	0
Moreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this @GENE$ species and those obtained from comparable synthetic {@CHEMICAL$}7 (S = 1/2) iron-nitrosyl complexes.	0
Moreover, the computed EPR parameters (g and A values) are in excellent agreement with experimental results for this @GENE$ species and those obtained from comparable synthetic {FeNO}7 (S = 1/2) @CHEMICAL$ complexes.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (@GENE$), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), @GENE$, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, @GENE$, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, @GENE$, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and @GENE$, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
Structural and functional properties were investigated for four peroxisome proliferator-activated receptors (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEM-GENE$.	0
Structural and functional properties were investigated for four @GENE$ (PPARs), PPARalpha1, PPARalpha2, PPARbeta, and PPARgamma, from torafugu pufferfish Takifugu rubripes and determined for their transcriptional activity by the reporter assay using reporter plasmids containing three copies of the @CHEMICAL$ oxidase PPAR response element.	0
@GENE$ showed a high similarity in the primary structure to other vertebrate counterparts, torafugu PPARalpha2 and gamma contained additional sequences of 21 and 28 @CHEMICAL$, respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts.	0
Although torafugu PPARs showed a high similarity in the primary structure to other vertebrate counterparts, @GENE$ contained additional sequences of 21 and 28 @CHEMICAL$, respectively, as in the case of other teleost fish species when compared with African clawed frog counterparts.	0
The transcriptional activity of torafugu @GENE$ was enhanced 4.5- and 11.5-fold by @CHEMICAL$ and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by @CHEMICAL$ and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of @GENE$, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The transcriptional activity of torafugu @GENE$ was enhanced 4.5- and 11.5-fold by Wy-14643 and @CHEMICAL$ (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and @CHEMICAL$ (ETYA) each at 10 microM, respectively, whereas that of @GENE$, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The transcriptional activity of torafugu @GENE$ was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (@CHEMICAL$) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (@CHEMICAL$) each at 10 microM, respectively, whereas that of @GENE$, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.	1
The activities of torafugu @GENE$ were also enhanced 5.6- and 6.3-fold by @CHEMICAL$ at 1 microM, respectively, but not by Wy-14643 at this concentration.	0
The activities of torafugu @GENE$ were also enhanced 5.6- and 6.3-fold by ETYA at 1 microM, respectively, but not by @CHEMICAL$ at this concentration.	0
Furthermore, the activities of the two @GENE$ were enhanced 4.3- and 7.6-fold by @CHEMICAL$, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.	1
Furthermore, the activities of the two @GENE$ were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by @CHEMICAL$, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.	1
Furthermore, the activities of the two @GENE$ were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by @CHEMICAL$ each at 50 microM, respectively.	1
On the other hand, the activities of @GENE$ were not changed by @CHEMICAL$, ETYA, rosiglitazone, nor PUFAs.	0
On the other hand, the activities of @GENE$ were not changed by Wy-14643, @CHEMICAL$, rosiglitazone, nor PUFAs.	0
On the other hand, the activities of @GENE$ were not changed by Wy-14643, ETYA, @CHEMICAL$, nor PUFAs.	0
Combination chemotherapy with a @CHEM-GENE$ antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis.	0
Combination chemotherapy with a @GENE$ antagonist (@CHEMICAL$) and melarsoprol in a mouse model of human African trypanosomiasis.	4
Combination chemotherapy with a @GENE$ antagonist (aprepitant) and @CHEMICAL$ in a mouse model of human African trypanosomiasis.	4
There is evidence in a mouse model of HAT that @CHEM-GENE$ antagonism reduces the neuroinflammatory reaction to CNS trypanosome infection.	0
There is evidence in a mouse model of HAT that @CHEM-GENE$ antagonism reduces the neuroinflammatory reaction to CNS trypanosome infection.	0
In this study we investigated the effects of combination chemotherapy with @CHEMICAL$ and a @GENE$ antagonist aprepitant (EMEND) in this mouse model.	0
In this study we investigated the effects of combination chemotherapy with melarsoprol and a @CHEM-GENE$ antagonist aprepitant (EMEND) in this mouse model.	0
In this study we investigated the effects of combination chemotherapy with melarsoprol and a @GENE$ antagonist @CHEMICAL$ (EMEND) in this mouse model.	4
In this study we investigated the effects of combination chemotherapy with melarsoprol and a @GENE$ antagonist aprepitant (@CHEMICAL$) in this mouse model.	4
PURPOSE: Cellular retinaldehyde-binding protein (@GENE$), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 @CHEMICAL$ found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the @GENE$ gene, is a 36-kDa water-soluble protein with 316 @CHEMICAL$ found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: @GENE$ (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 @CHEMICAL$ found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a @GENE$ with 316 @CHEMICAL$ found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (@GENE$), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the @CHEMICAL$ pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the @GENE$ gene, is a 36-kDa water-soluble protein with 316 amino acids found in the @CHEMICAL$ pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: @GENE$ (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the @CHEMICAL$ pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a @GENE$ with 316 amino acids found in the @CHEMICAL$ pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular @CHEMICAL$-binding protein (@GENE$), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular @CHEMICAL$-binding protein (CRALBP), transcribed from the @GENE$ gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: @CHEM-GENE$ (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular @CHEMICAL$-binding protein (CRALBP), transcribed from the RLBP1 gene, is a @GENE$ with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (@GENE$), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in @CHEMICAL$ Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the @GENE$ gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in @CHEMICAL$ Muller cells.	0
PURPOSE: @GENE$ (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in @CHEMICAL$ Muller cells.	0
PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a @GENE$ with 316 amino acids found in the retinal pigment epithelium (RPE) and in @CHEMICAL$ Muller cells.	0
It is thought to play a critical role in the visual cycle by functioning as an acceptor of @CHEMICAL$ from the @GENE$ reaction.	5
Determination of @CHEM-GENE$ activity in the kidney.	0
@GENE$ (DDAH) metabolizes asymmetric dimethylarginine to generate @CHEMICAL$ and is present in large quantities in the kidney.	5
Dimethylarginine dimethylaminohydrolase (@GENE$) metabolizes asymmetric dimethylarginine to generate @CHEMICAL$ and is present in large quantities in the kidney.	5
@CHEM-GENE$ (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney.	0
@CHEMICAL$ dimethylaminohydrolase (@GENE$) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney.	0
@GENE$ (DDAH) metabolizes asymmetric @CHEMICAL$ to generate L-citrulline and is present in large quantities in the kidney.	5
Dimethylarginine dimethylaminohydrolase (@GENE$) metabolizes asymmetric @CHEMICAL$ to generate L-citrulline and is present in large quantities in the kidney.	5
We present a new study that optimizes the Prescott-Jones colorimetric assay to measure @GENE$-dependent @CHEMICAL$ generation in kidney homogenates.	5
We found that the removal of @CHEMICAL$ with @GENE$ is necessary since urea also produces a positive reaction.	5
We found that the removal of urea with @GENE$ is necessary since @CHEMICAL$ also produces a positive reaction.	0
Deproteinization with @CHEMICAL$ was found to be optimal and that @GENE$ inhibitors were not necessary.	0
@GENE$ or @CHEMICAL$ synthase isoenzymes were not found to influence L-citrulline production.	0
Arginase or @CHEM-GENE$ isoenzymes were not found to influence L-citrulline production.	0
@GENE$ or nitric oxide synthase isoenzymes were not found to influence @CHEMICAL$ production.	0
Arginase or @GENE$ isoenzymes were not found to influence @CHEMICAL$ production.	0
Our optimized @CHEMICAL$ production assay to measure @GENE$ activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption.	5
Our optimized L-citrulline production assay to measure @GENE$ activity correlated closely with the direct measure of the rate of asymmetric @CHEMICAL$ consumption.	5
Using this assay, we found that both @CHEMICAL$ and nitric oxide inhibit renal cortical @GENE$ activity in vitro.	2
Using this assay, we found that both superoxide and @CHEMICAL$ inhibit renal cortical @GENE$ activity in vitro.	2
A humanized antibody to @GENE$/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including @CHEMICAL$, cyclophosphamide, and paclitaxel.	0
A humanized antibody to HER2/@GENE$, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including @CHEMICAL$, cyclophosphamide, and paclitaxel.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, @GENE$/neu overexpressing breast cancer sequenced with chemotherapy including @CHEMICAL$, cyclophosphamide, and paclitaxel.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/@GENE$ overexpressing breast cancer sequenced with chemotherapy including @CHEMICAL$, cyclophosphamide, and paclitaxel.	0
A humanized antibody to @GENE$/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, @CHEMICAL$, and paclitaxel.	0
A humanized antibody to HER2/@GENE$, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, @CHEMICAL$, and paclitaxel.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, @GENE$/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, @CHEMICAL$, and paclitaxel.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/@GENE$ overexpressing breast cancer sequenced with chemotherapy including doxorubicin, @CHEMICAL$, and paclitaxel.	0
A humanized antibody to @GENE$/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and @CHEMICAL$.	0
A humanized antibody to HER2/@GENE$, trastuzumab, is now FDA approved for the treatment of early stage, HER2/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and @CHEMICAL$.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, @GENE$/neu overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and @CHEMICAL$.	0
A humanized antibody to HER2/neu, trastuzumab, is now FDA approved for the treatment of early stage, HER2/@GENE$ overexpressing breast cancer sequenced with chemotherapy including doxorubicin, cyclophosphamide, and @CHEMICAL$.	0
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral @CHEMICAL$ kinase inhibitor targeting @GENE$/neu as well as the epidermal growth factor receptor (EGFR), lapatinib.	0
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral @CHEMICAL$ kinase inhibitor targeting HER2/@GENE$ as well as the epidermal growth factor receptor (EGFR), lapatinib.	0
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral @CHEMICAL$ kinase inhibitor targeting HER2/neu as well as the @GENE$ (EGFR), lapatinib.	0
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral @CHEMICAL$ kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (@GENE$), lapatinib.	0
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting @GENE$/neu as well as the epidermal growth factor receptor (EGFR), @CHEMICAL$.	2
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/@GENE$ as well as the epidermal growth factor receptor (EGFR), @CHEMICAL$.	2
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the @GENE$ (EGFR), @CHEMICAL$.	2
The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (@GENE$), @CHEMICAL$.	2
Stimulation of @CHEM-GENE$ modulates Jurkat T cell growth and adhesion to fibronectin.	0
Stimulation of @CHEMICAL$ receptors modulates Jurkat T cell growth and adhesion to @GENE$.	0
The aims of this study were to investigate the expression and the functional roles of @CHEM-GENE$ in leukemic Jurkat T cells.	0
The aims of this study were to investigate the expression and the functional roles of @CHEM-GENE$ in leukemic Jurkat T cells.	0
RT-PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the @GENE$ and NR2B subunits of the @CHEMICAL$ receptors.	0
RT-PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and @GENE$ subunits of the @CHEMICAL$ receptors.	0
RT-PCR and immunofluorescence/confocal microscopy analysis showed that Jurkat T cells express the NR1 and NR2B subunits of the @CHEM-GENE$.	0
Exposure of Jurkat cells to either @CHEMICAL$ [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	4
Exposure of Jurkat cells to either @CHEMICAL$ [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [@CHEMICAL$] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	4
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [@CHEMICAL$] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or @CHEMICAL$ (D-AP5), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	4
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or @CHEMICAL$ (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (@CHEMICAL$), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	4
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (@CHEMICAL$), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @CHEM-GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @CHEMICAL$ receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas @CHEMICAL$ (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas @CHEMICAL$ (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective @GENE$ antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and @CHEMICAL$ (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.	0
Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and @CHEMICAL$ (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to @GENE$.	0
In conclusion, our results demonstrate that Jurkat T cells express @CHEM-GENE$ functionally active in controlling cell growth and adhesion to fibronectin.	0
In conclusion, our results demonstrate that Jurkat T cells express @CHEMICAL$ receptors functionally active in controlling cell growth and adhesion to @GENE$.	0
@CHEMICAL$ identifies novel antagonist binding determinants in the @GENE$.	4
Desvenlafaxine succinate identifies novel antagonist binding determinants in the @CHEM-GENE$.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human @CHEMICAL$ and serotonin transporters (@GENE$ and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human @CHEMICAL$ and serotonin transporters (hNET and @GENE$, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the @CHEM-GENE$ (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
@CHEMICAL$ (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (@GENE$ and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	4
@CHEMICAL$ (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and @GENE$, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	4
@CHEMICAL$ (DVS) is a recently introduced antagonist of the @GENE$ (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and @CHEMICAL$ transporters (@GENE$ and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and @CHEMICAL$ transporters (hNET and @GENE$, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the @CHEM-GENE$ (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Desvenlafaxine succinate (@CHEMICAL$) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (@GENE$ and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	4
Desvenlafaxine succinate (@CHEMICAL$) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and @GENE$, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	4
Desvenlafaxine succinate (@CHEMICAL$) is a recently introduced antagonist of the @GENE$ (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.	0
Initial evaluation of the pharmacological properties of @CHEMICAL$ (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the @GENE$ expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (NIS) binding.	0
Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the @GENE$ expressed in membranes compared with whole cells when competing for @CHEMICAL$ (NIS) binding.	0
Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the @GENE$ expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (@CHEMICAL$) binding.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the @CHEMICAL$ analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the @CHEMICAL$ analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog @CHEMICAL$ (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog @CHEMICAL$ (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (@CHEMICAL$), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (@CHEMICAL$), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), @CHEMICAL$, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), @CHEMICAL$, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the @CHEMICAL$ analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the @CHEMICAL$ analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog @CHEMICAL$ (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog @CHEMICAL$ (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (@CHEMICAL$) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (@CHEMICAL$) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as @CHEMICAL$, mazindol, tricyclic antidepressants, and cocaine.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as @CHEMICAL$, mazindol, tricyclic antidepressants, and cocaine.	4
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, @CHEMICAL$, tricyclic antidepressants, and cocaine.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, @CHEMICAL$, tricyclic antidepressants, and cocaine.	4
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, @CHEMICAL$ antidepressants, and cocaine.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, @CHEMICAL$ antidepressants, and cocaine.	4
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and @CHEMICAL$.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and @CHEMICAL$.	4
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for @CHEMICAL$ at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for @CHEMICAL$ at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by @CHEMICAL$ was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by @CHEMICAL$ was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
Using @GENE$ in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish @CHEMICAL$, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	4
Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish @CHEMICAL$, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other @GENE$ antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.	0
In an initial search for molecular features that differentially define antagonist binding determinants, we document that Val148 in @GENE$ selectively disrupts @CHEMICAL$ binding but not that of DVS.	0
The key difference in structure of @GENE$ and plasminogen is replacement of @CHEMICAL$ with Ser at position 560.	0
The key difference in structure of Lp(a) and @GENE$ is replacement of @CHEMICAL$ with Ser at position 560.	0
The key difference in structure of @GENE$ and plasminogen is replacement of Arg with @CHEMICAL$ at position 560.	0
The key difference in structure of Lp(a) and @GENE$ is replacement of Arg with @CHEMICAL$ at position 560.	0
@CHEMICAL$, sorafenib and @GENE$ inhibitors in renal cancer.	0
Sunitinib, @CHEMICAL$ and @GENE$ inhibitors in renal cancer.	0
Overexpression of @GENE$ (HIF) is also caused by the mammalian target of @CHEMICAL$ (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation.	0
Overexpression of hypoxia inducible factor (@GENE$) is also caused by the mammalian target of @CHEMICAL$ (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation.	0
Overexpression of hypoxia inducible factor (HIF) is also caused by the @CHEM-GENE$ (mTOR), a key component of signaling pathways inside the cell, involved in cell proliferation.	0
Overexpression of hypoxia inducible factor (HIF) is also caused by the mammalian target of @CHEMICAL$ (@GENE$), a key component of signaling pathways inside the cell, involved in cell proliferation.	0
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit @GENE$ (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	0
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (@GENE$, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, @GENE$) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and @GENE$ (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (@GENE$), while temsirolimus is an mTOR inhibitor.	2
@CHEMICAL$ and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an @GENE$ inhibitor.	0
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit @GENE$ (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	0
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (@GENE$, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, @GENE$) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and @GENE$ (PDGFR-beta), while temsirolimus is an mTOR inhibitor.	2
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (@GENE$), while temsirolimus is an mTOR inhibitor.	2
Sorafenib and @CHEMICAL$ are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an @GENE$ inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit @GENE$ (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while @CHEMICAL$ is an mTOR inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (@GENE$, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while @CHEMICAL$ is an mTOR inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, @GENE$) and platelet-derived growth factor receptor beta (PDGFR-beta), while @CHEMICAL$ is an mTOR inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and @GENE$ (PDGFR-beta), while @CHEMICAL$ is an mTOR inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (@GENE$), while @CHEMICAL$ is an mTOR inhibitor.	0
Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while @CHEMICAL$ is an @GENE$ inhibitor.	2
One is that the binding of @CHEMICAL$ to nuclear @GENE$ (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of @CHEMICAL$ to nuclear retinoic acid receptors (@GENE$) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of @CHEMICAL$ to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, @GENE$, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of @CHEMICAL$ to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates @GENE$ in preference to RAR-alpha.	0
One is that the binding of @CHEMICAL$ to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to @GENE$.	0
One is that the binding of retinoids to nuclear @CHEM-GENE$ (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear @CHEMICAL$ receptors (@GENE$) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear @CHEMICAL$ receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, @GENE$, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear @CHEMICAL$ receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates @GENE$ in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear @CHEMICAL$ receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to @GENE$.	0
One is that the binding of retinoids to nuclear @GENE$ (RARs) does not match their therapeutic efficacy: @CHEMICAL$ activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (@GENE$) does not match their therapeutic efficacy: @CHEMICAL$ activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: @CHEMICAL$ activates the three receptor subtypes, @GENE$, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: @CHEMICAL$ activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates @GENE$ in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: @CHEMICAL$ activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to @GENE$.	0
One is that the binding of retinoids to nuclear @GENE$ (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas @CHEMICAL$ preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (@GENE$) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas @CHEMICAL$ preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, @GENE$, without measurable receptor binding, whereas @CHEMICAL$ preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas @CHEMICAL$ preferentially binds to and activates @GENE$ in preference to RAR-alpha.	0
One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas @CHEMICAL$ preferentially binds to and activates RAR-beta and -gamma in preference to @GENE$.	1
Comprehensive review of @CHEMICAL$, a second-generation @GENE$ inhibitor, for the treatment of Parkinson's disease.	2
Comprehensive review of rasagiline, a second-generation @CHEM-GENE$ inhibitor, for the treatment of Parkinson's disease.	0
BACKGROUND: Inhibitors of @CHEM-GENE$ (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine.	0
BACKGROUND: Inhibitors of @CHEMICAL$ oxidase (@GENE$) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine.	0
BACKGROUND: Inhibitors of @CHEMICAL$ oxidase (MAO) with selectivity and specificity for @GENE$ (MAO-B) prolong the duration of action of both endogenously and exogenously derived dopamine.	0
BACKGROUND: Inhibitors of @CHEMICAL$ oxidase (MAO) with selectivity and specificity for MAO type B (@GENE$) prolong the duration of action of both endogenously and exogenously derived dopamine.	0
BACKGROUND: Inhibitors of @GENE$ (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived @CHEMICAL$.	0
BACKGROUND: Inhibitors of monoamine oxidase (@GENE$) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both endogenously and exogenously derived @CHEMICAL$.	0
BACKGROUND: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for @GENE$ (MAO-B) prolong the duration of action of both endogenously and exogenously derived @CHEMICAL$.	0
BACKGROUND: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (@GENE$) prolong the duration of action of both endogenously and exogenously derived @CHEMICAL$.	0
Rasagiline [@CHEMICAL$] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain @GENE$ and is specifically designed for the treatment of Parkinson's disease (PD).	2
Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation @CHEMICAL$ pharmacophore that selectively and irreversibly inhibits brain @GENE$ and is specifically designed for the treatment of Parkinson's disease (PD).	2
@CHEMICAL$ [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain @GENE$ and is specifically designed for the treatment of Parkinson's disease (PD).	2
The search terms were @CHEM-GENE$, neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline.	0
The search terms were @GENE$, neuroprotection, Parkinson disease, @CHEMICAL$, rasagiline, and selegiline.	0
The search terms were @GENE$, neuroprotection, Parkinson disease, propargylamine, @CHEMICAL$, and selegiline.	0
The search terms were @GENE$, neuroprotection, Parkinson disease, propargylamine, rasagiline, and @CHEMICAL$.	0
Based on the results from those studies, we concluded that @CHEMICAL$ PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited @GENE$.	2
In experimental models, @CHEMICAL$ has been found to have neuroprotective properties that may be independent of @GENE$ inhibition.	0
Mutation of Gly721 alters @GENE$ active site architecture and sensitivity to @CHEMICAL$.	0
@GENE$ is the cellular target of the anti-cancer drug @CHEMICAL$ (CPT), which reversibly stabilizes a covalent enzyme-DNA intermediate.	0
@GENE$ is the cellular target of the anti-cancer drug camptothecin (@CHEMICAL$), which reversibly stabilizes a covalent enzyme-DNA intermediate.	0
@GENE$ clamps around duplex DNA, wherein the core and @CHEMICAL$-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and @CHEMICAL$-terminal domains are connected by extended @GENE$ (linker domain), which position the active site Tyr of the C-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and @CHEMICAL$-terminal domains are connected by extended alpha-helices (@GENE$), which position the active site Tyr of the C-terminal domain within the catalytic pocket.	0
@GENE$ clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site @CHEMICAL$ of the C-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended @GENE$ (linker domain), which position the active site @CHEMICAL$ of the C-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (@GENE$), which position the active site @CHEMICAL$ of the C-terminal domain within the catalytic pocket.	0
@GENE$ clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (linker domain), which position the active site Tyr of the @CHEMICAL$-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended @GENE$ (linker domain), which position the active site Tyr of the @CHEMICAL$-terminal domain within the catalytic pocket.	0
Top1p clamps around duplex DNA, wherein the core and C-terminal domains are connected by extended alpha-helices (@GENE$), which position the active site Tyr of the @CHEMICAL$-terminal domain within the catalytic pocket.	0
The physical connection of the linker with the @GENE$ clamp as well as linker flexibility affect enzyme sensitivity to @CHEMICAL$.	0
Crystallographic data reveal that a conserved @CHEMICAL$ residue (located at the juncture between the linker and C-terminal domains) is at one end of a short @GENE$, which extends to the active site Tyr covalently linked to the DNA.	0
Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and @CHEMICAL$-terminal domains) is at one end of a short @GENE$, which extends to the active site Tyr covalently linked to the DNA.	0
Crystallographic data reveal that a conserved Gly residue (located at the juncture between the linker and C-terminal domains) is at one end of a short @GENE$, which extends to the active site @CHEMICAL$ covalently linked to the DNA.	0
In the presence of drug, the linker is rigid and this @GENE$ extends to include @CHEMICAL$ and the preceding Leu.	0
In the presence of drug, the linker is rigid and this @GENE$ extends to include Gly and the preceding @CHEMICAL$.	0
We report that mutation of this conserved @CHEMICAL$ in @GENE$ alters enzyme sensitivity to CPT.	0
We report that mutation of this conserved Gly in @GENE$ alters enzyme sensitivity to @CHEMICAL$.	0
We postulate that this conserved @CHEMICAL$ residue provides a flexible hinge within the @GENE$ catalytic pocket to facilitate linker dynamics and the structural alterations that accompany drug binding of the covalent enzyme-DNA intermediate.	0
Characterization of the substrate mimic bound to engineered @GENE$ in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of @CHEMICAL$.	0
Characterization of the substrate mimic bound to engineered @CHEM-GENE$ in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (@CHEMICAL$) to the engineered @GENE$ (PGIS) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (@CHEMICAL$) to the engineered prostacyclin (PGI2) synthase (@GENE$) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (@CHEMICAL$) mimic (U46619) to the engineered @GENE$ (PGIS) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (@CHEMICAL$) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (@GENE$) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered @CHEM-GENE$ (PGIS) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered @CHEMICAL$ (PGI2) synthase (@GENE$) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered @CHEM-GENE$ (PGIS) in solution.	0
High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered prostacyclin (@CHEMICAL$) synthase (@GENE$) in solution.	0
The binding of @CHEMICAL$ to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of @CHEMICAL$ to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered @GENE$ in a concentration-dependent manner.	0
The binding of U46619 to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at @CHEMICAL$, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at @CHEMICAL$, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered @GENE$ in a concentration-dependent manner.	0
The binding of U46619 to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, @CHEMICAL$, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, @CHEMICAL$, and H20 of U46619 were observed upon U46619 binding to the engineered @GENE$ in a concentration-dependent manner.	0
The binding of U46619 to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and @CHEMICAL$ of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and @CHEMICAL$ of U46619 were observed upon U46619 binding to the engineered @GENE$ in a concentration-dependent manner.	0
The binding of U46619 to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of @CHEMICAL$ were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of @CHEMICAL$ were observed upon U46619 binding to the engineered @GENE$ in a concentration-dependent manner.	0
The binding of U46619 to the @GENE$ protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon @CHEMICAL$ binding to the engineered PGIS in a concentration-dependent manner.	0
The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon @CHEMICAL$ binding to the engineered @GENE$ in a concentration-dependent manner.	0
The detailed conformational change and 3D structure of the @GENE$-bound @CHEMICAL$ were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique.	0
The detailed conformational change and 3D structure of the @GENE$-bound U46619 were further demonstrated by 2D @CHEMICAL$ NMR experiments using the transferred NOE technique.	0
The distances between the protons @CHEMICAL$ and H2, H18 and H2, and H18 and H4 are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The distances between the protons H20 and @CHEMICAL$, H18 and H2, and H18 and H4 are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The distances between the protons H20 and H2, @CHEMICAL$ and H2, and H18 and H4 are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The distances between the protons H20 and H2, H18 and @CHEMICAL$, and H18 and H4 are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The distances between the protons H20 and H2, H18 and H2, and @CHEMICAL$ and H4 are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The distances between the protons H20 and H2, H18 and H2, and H18 and @CHEMICAL$ are shorter following their binding to the @GENE$ in solution-down to within 5 A.	0
The bound conformation of @CHEMICAL$ fits the crystal structure of the @GENE$ substrate binding pocket considerably better than that of the unbound U46619.	0
The bound conformation of U46619 fits the crystal structure of the @GENE$ substrate binding pocket considerably better than that of the unbound @CHEMICAL$.	0
For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the @GENE$-bound form of @CHEMICAL$ and the PGIS crystal structure.	0
For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the PGIS-bound form of @CHEMICAL$ and the @GENE$ crystal structure.	0
The noted conformational changes where the C-6 position is closer to the C-9 position of U46619 provided the first experimental data for understanding the molecular mechanism of the catalytic function of @GENE$ in the isomerization of PGH2 to @CHEMICAL$.	0
The noted conformational changes where the @CHEMICAL$ position is closer to the C-9 position of U46619 provided the first experimental data for understanding the molecular mechanism of the catalytic function of @GENE$ in the isomerization of PGH2 to prostacyclin.	0
The noted conformational changes where the C-6 position is closer to the @CHEMICAL$ position of U46619 provided the first experimental data for understanding the molecular mechanism of the catalytic function of @GENE$ in the isomerization of PGH2 to prostacyclin.	0
The noted conformational changes where the C-6 position is closer to the C-9 position of @CHEMICAL$ provided the first experimental data for understanding the molecular mechanism of the catalytic function of @GENE$ in the isomerization of PGH2 to prostacyclin.	0
The noted conformational changes where the C-6 position is closer to the C-9 position of U46619 provided the first experimental data for understanding the molecular mechanism of the catalytic function of @GENE$ in the isomerization of @CHEMICAL$ to prostacyclin.	0
@CHEMICAL$, biguanides, @GENE$, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
@CHEMICAL$, biguanides, alpha-glucosidase, meglitinides, @GENE$ inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, @CHEMICAL$, @GENE$, meglitinides, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, @CHEMICAL$, alpha-glucosidase, meglitinides, @GENE$ inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, @GENE$, @CHEMICAL$, DPP-4 inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, alpha-glucosidase, @CHEMICAL$, @GENE$ inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, @GENE$, meglitinides, @CHEMICAL$ inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, alpha-glucosidase, meglitinides, @CHEM-GENE$ inhibitors and thiazolidinediones are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, @GENE$, meglitinides, DPP-4 inhibitors and @CHEMICAL$ are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
Sulfonylureas, biguanides, alpha-glucosidase, meglitinides, @GENE$ inhibitors and @CHEMICAL$ are among the classes of oral hypoglycemic drugs available to treat Type II diabetes, but concerns exist regarding safety and efficacy of these drugs.	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], @GENE$ [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], @GENE$ [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], @GENE$ [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], @GENE$ [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], @GENE$ [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and @GENE$ [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), @GENE$ [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], @GENE$ [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], @GENE$ [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and @GENE$ [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @GENE$ [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], @GENE$ [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], @GENE$ [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and @GENE$ [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @GENE$ [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and @GENE$ [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEM-GENE$ (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (@GENE$ [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @CHEMICAL$ receptors (5-HT1A [8.6], @GENE$ [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], @GENE$ [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], @GENE$ [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], @GENE$ [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], @GENE$ [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], @GENE$ [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and @GENE$ [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), @GENE$ [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], @GENE$ [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], @GENE$ [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and @GENE$ [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEM-GENE$ [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], @GENE$ [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], @GENE$ [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and @GENE$ [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @GENE$ [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and @GENE$ [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @GENE$ (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (@GENE$ [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], @GENE$ [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @CHEMICAL$ receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], @GENE$ [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], @GENE$ [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], @GENE$ [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], @GENE$ [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], @GENE$ [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and @GENE$ [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), @GENE$ [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], @GENE$ [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], @GENE$ [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and @GENE$ [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), @GENE$ [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], @GENE$ [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], @GENE$ [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and @GENE$ [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEM-GENE$ [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and @GENE$ [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for @GENE$ (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (@GENE$ [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], @GENE$ [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and @CHEMICAL$ receptors (H1 [9.0] and H2 [8.2]).	0
Indirect systemic and direct oral factor Xa and direct oral @GENE$ inhibitors with improved pharmacologic profiles compared with heparins and @CHEMICAL$ antagonists are currently in clinical development.	0
This overview focuses on the indirect antithrombin dependent @CHEMICAL$ derivatives of idraparinux and on the most advanced oral direct inhibitors to @GENE$ (rivaroxaban and apixaban) and IIa (dabigatran).	0
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of @CHEMICAL$ and on the most advanced oral direct inhibitors to @GENE$ (rivaroxaban and apixaban) and IIa (dabigatran).	0
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to @GENE$ (@CHEMICAL$ and apixaban) and IIa (dabigatran).	2
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to @GENE$ (rivaroxaban and @CHEMICAL$) and IIa (dabigatran).	2
This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to @GENE$ (rivaroxaban and apixaban) and IIa (@CHEMICAL$).	0
Triple pharmacological blockade of the @GENE$-angiotensin-@CHEMICAL$ system in nondiabetic CKD: an open-label crossover randomized controlled trial.	0
Triple pharmacological blockade of the renin-@GENE$-@CHEMICAL$ system in nondiabetic CKD: an open-label crossover randomized controlled trial.	0
BACKGROUND: Agents inhibiting the @GENE$-angiotensin-@CHEMICAL$ (RAAS) system have an important role in slowing the progression of chronic kidney disease.	0
BACKGROUND: Agents inhibiting the renin-@GENE$-@CHEMICAL$ (RAAS) system have an important role in slowing the progression of chronic kidney disease.	0
We evaluated the hypothesis that the addition of an @CHEM-GENE$ antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an @CHEMICAL$ receptor antagonist to an @GENE$ (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an @CHEMICAL$ receptor antagonist to an angiotensin-converting enzyme (@GENE$) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an @CHEMICAL$ receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and @GENE$ blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an @CHEMICAL$ receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an @GENE$ inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an @GENE$ antagonist to an angiotensin-converting enzyme (ACE) inhibitor and @CHEMICAL$ type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an @GENE$ (ACE) inhibitor and @CHEMICAL$ type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (@GENE$) inhibitor and @CHEMICAL$ type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and @CHEM-GENE$ blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an ACE inhibitor and ARB (double RAAS blockade).	0
We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and @CHEMICAL$ type 1 (AT-1) receptor blocker (ARB) (triple RAAS blockade) may provide an additional benefit compared with an @GENE$ inhibitor and ARB (double RAAS blockade).	0
INTERVENTIONS: In the 8-week run-in period, all participants received the @GENE$ inhibitor @CHEMICAL$ (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.	2
INTERVENTIONS: In the 8-week run-in period, all participants received the @GENE$ inhibitor cilazapril (5 mg), the ARB @CHEMICAL$n (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.	0
INTERVENTIONS: In the 8-week run-in period, all participants received the @GENE$ inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic @CHEMICAL$ (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.	0
CONCLUSIONS: Administration of an @CHEM-GENE$ antagonist in addition to double RAAS blockade with an ACE inhibitor and ARB may slow the progression of chronic kidney disease.	0
CONCLUSIONS: Administration of an @CHEMICAL$ receptor antagonist in addition to double RAAS blockade with an @GENE$ inhibitor and ARB may slow the progression of chronic kidney disease.	0
Porcine TLR8 and @GENE$ are both activated by a selective TLR7 ligand, @CHEMICAL$.	1
Porcine TLR8 and TLR7 are both activated by a selective @GENE$ ligand, @CHEMICAL$.	0
Porcine @GENE$ and TLR7 are both activated by a selective TLR7 ligand, @CHEMICAL$.	1
Both @GENE$ and TLR8 proteins were expressed in cell lines and were @CHEMICAL$-glycosylated.	0
Both porcine TLR7 and @GENE$ proteins were expressed in cell lines and were @CHEMICAL$-glycosylated.	0
Two @CHEMICAL$ molecules, imiquimod and gardiquimod, markedly activated both @GENE$ and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two @CHEMICAL$ molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and @GENE$ whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two @CHEMICAL$ molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only @GENE$, but not TLR8, was activated by the ligands.	1
Two @CHEMICAL$ molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not @GENE$, was activated by the ligands.	0
Two imidazoquinoline molecules, @CHEMICAL$ and gardiquimod, markedly activated both @GENE$ and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, @CHEMICAL$ and gardiquimod, markedly activated both porcine TLR7 and @GENE$ whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, @CHEMICAL$ and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only @GENE$, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, @CHEMICAL$ and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not @GENE$, was activated by the ligands.	0
Two imidazoquinoline molecules, imiquimod and @CHEMICAL$, markedly activated both @GENE$ and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, imiquimod and @CHEMICAL$, markedly activated both porcine TLR7 and @GENE$ whereas only human TLR7, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, imiquimod and @CHEMICAL$, markedly activated both porcine TLR7 and TLR8 whereas only @GENE$, but not TLR8, was activated by the ligands.	1
Two imidazoquinoline molecules, imiquimod and @CHEMICAL$, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not @GENE$, was activated by the ligands.	0
Moreover, activation of transfected cells and porcine PBMC by @GENE$ ligands was inhibited by @CHEMICAL$ indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.	2
High-affinity blockade of @CHEM-GENE$ by halogenated propofol analogues.	0
High-affinity blockade of @GENE$ by @CHEMICAL$ analogues.	2
BACKGROUND AND PURPOSE: @CHEM-GENE$ constitute major target sites for local anaesthetic-like action.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of @CHEMICAL$ on @GENE$ (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of @CHEMICAL$ on voltage-operated human skeletal muscle sodium channels (@GENE$) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of @CHEMICAL$ on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on @GENE$ (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of @CHEMICAL$ on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (@GENE$) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on @CHEM-GENE$ (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle @CHEMICAL$ channels (@GENE$) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle @CHEMICAL$ channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on @GENE$ (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle @CHEMICAL$ channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal sodium channels (@GENE$) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on @GENE$ (Na(V)1.4) and the effect of one compound (@CHEMICAL$) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (@GENE$) and the effect of one compound (@CHEMICAL$) on neuronal sodium channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (@CHEMICAL$) on @GENE$ (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (@CHEMICAL$) on neuronal sodium channels (@GENE$) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on @GENE$ (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal @CHEMICAL$ channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (@GENE$) and the effect of one compound (4-chloropropofol) on neuronal @CHEMICAL$ channels (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on @CHEM-GENE$ (Na(V)1.2) heterologously expressed in human embryonic kidney cell line 293.	0
EXPERIMENTAL APPROACH: We have investigated the effects of three halogenated structural analogues of propofol on voltage-operated human skeletal muscle sodium channels (Na(V)1.4) and the effect of one compound (4-chloropropofol) on neuronal @CHEMICAL$ channels (@GENE$) heterologously expressed in human embryonic kidney cell line 293.	0
The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in @GENE$, respectively, and 29.2 microM for @CHEMICAL$ in Na(V)1.2.	0
The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for @CHEMICAL$ in @GENE$.	2
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for @CHEMICAL$, 4-bromopropofol and 4-chloropropofol in @GENE$, and 450 nM for 4-chloropropofol in Na(V)1.2.	2
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for @CHEMICAL$, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in @GENE$.	0
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, @CHEMICAL$ and 4-chloropropofol in @GENE$, and 450 nM for 4-chloropropofol in Na(V)1.2.	2
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, @CHEMICAL$ and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in @GENE$.	0
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and @CHEMICAL$ in @GENE$, and 450 nM for 4-chloropropofol in Na(V)1.2.	2
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and @CHEMICAL$ in Na(V)1.4, and 450 nM for 4-chloropropofol in @GENE$.	0
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in @GENE$, and 450 nM for @CHEMICAL$ in Na(V)1.2.	0
Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for @CHEMICAL$ in @GENE$.	2
CONCLUSIONS AND IMPLICATIONS: @CHEMICAL$ analogues constitute a novel class of @GENE$-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.	2
CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of @CHEM-GENE$-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine.	0
CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of @GENE$-blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug @CHEMICAL$.	0
@CHEMICAL$ (Aprovel, Avapro, Irbetan, Karvea), an @GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	4
Irbesartan (@CHEMICAL$, Avapro, Irbetan, Karvea), an @GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	4
Irbesartan (Aprovel, @CHEMICAL$, Irbetan, Karvea), an @GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	4
Irbesartan (Aprovel, Avapro, @CHEMICAL$, Karvea), an @GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	4
Irbesartan (Aprovel, Avapro, Irbetan, @CHEMICAL$), an @GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	4
Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an @CHEM-GENE$ antagonist, is approved in many countries worldwide for the treatment of hypertension.	0
DNA damage is accepted as a consequence of @CHEMICAL$ deprivation induced by chemotherapeutic inhibitors of @GENE$ (TS), but the types of damage and signaling responses remain incompletely understood.	5
DNA damage is accepted as a consequence of @CHEMICAL$ deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (@GENE$), but the types of damage and signaling responses remain incompletely understood.	5
DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of @CHEM-GENE$ (TS), but the types of damage and signaling responses remain incompletely understood.	0
DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of @CHEMICAL$ synthase (@GENE$), but the types of damage and signaling responses remain incompletely understood.	0
When @GENE$, which is a central component of HR, was depleted by siRNA cells were sensitized to @CHEMICAL$ (RTX), which specifically inhibits TS.	0
When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to @CHEMICAL$ (RTX), which specifically inhibits @GENE$.	0
When @GENE$, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (@CHEMICAL$), which specifically inhibits TS.	0
When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (@CHEMICAL$), which specifically inhibits @GENE$.	2
To our knowledge, this is the first demonstration in mammalian cells that depletion of @GENE$ causes sensitivity to @CHEMICAL$ deprivation.	0
Phosphorylation of @GENE$ (RPA2 subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of @CHEMICAL$.	0
Phosphorylation of replication protein A (@GENE$ subunit) and formation of damage-induced foci were strikingly evident following IC(50) doses of @CHEMICAL$.	0
@CHEMICAL$ treatment also induced foci of @GENE$, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.	1
@CHEMICAL$ treatment also induced foci of RAD51, @GENE$, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.	1
@CHEMICAL$ treatment also induced foci of RAD51, gamma-H2AX, @GENE$, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.	1
@CHEMICAL$ treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and @GENE$, although the extent of co-localization with RPA2 foci varied.	1
@CHEMICAL$ treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with @GENE$ foci varied.	0
@CHEMICAL$ and @GENE$ for septic shock.	0
This article summarizes the current knowledge on the benefit/risk profile from the use of low-dose @CHEMICAL$ and @GENE$ in treating septic shock.	0
Physicians should consider using low-dose @CHEMICAL$ and @GENE$ activated in the treatment of patients who have vasopressor-dependent septic shock with persistent signs of hypoperfusion, organ dysfunction, or hypotension.	0
Adipose tissue as a source of @CHEM-GENE$ and homocysteine.	0
Adipose tissue as a source of @CHEM-GENE$ and homocysteine.	0
Adipose tissue as a source of @GENE$ and @CHEMICAL$.	0
@GENE$ (NNMT) catalyses the conversion of nicotinamide to @CHEMICAL$ and plays an important role in hepatic detoxification reactions.	5
Nicotinamide N-methyltransferase (@GENE$) catalyses the conversion of nicotinamide to @CHEMICAL$ and plays an important role in hepatic detoxification reactions.	5
@CHEM-GENE$ (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	0
@CHEMICAL$ N-methyltransferase (@GENE$) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	0
@CHEM-GENE$ (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	0
Nicotinamide @CHEMICAL$-methyltransferase (@GENE$) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	0
@GENE$ (NNMT) catalyses the conversion of @CHEMICAL$ to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	5
Nicotinamide N-methyltransferase (@GENE$) catalyses the conversion of @CHEMICAL$ to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.	5
@CHEMICAL$, the atherogenic product of the @GENE$-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.	5
@CHEMICAL$ release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the @GENE$ inhibitor 1-methylnicotinamide.	0
Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the @GENE$ inhibitor @CHEMICAL$.	2
Nicotinic acid (@CHEMICAL$), a widely used drug to lower elevated plasma lipid levels, induced @GENE$ enzyme activity in white adipose tissue of mice.	1
@CHEMICAL$ (NA), a widely used drug to lower elevated plasma lipid levels, induced @GENE$ enzyme activity in white adipose tissue of mice.	1
These data support the concept that adipose tissue @GENE$ contributes to the increased plasma @CHEMICAL$ levels in patients treated with NA.	5
These data support the concept that adipose tissue @GENE$ contributes to the increased plasma homocysteine levels in patients treated with @CHEMICAL$.	0
Expression and 1,4-dihydropyridine-binding properties of brain @CHEM-GENE$ isoforms.	0
Expression and @CHEMICAL$-binding properties of brain @GENE$ isoforms.	0
The L-type calcium channel (@GENE$) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (@CHEMICAL$) binding properties and are both expressed in mammalian brain.	0
The @GENE$ (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (@CHEMICAL$) binding properties and are both expressed in mammalian brain.	0
The L-type calcium channel (LTCC) isoforms @GENE$ and Ca(v)1.3 display similar 1,4-dihydropyridine (@CHEMICAL$) binding properties and are both expressed in mammalian brain.	0
The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and @GENE$ display similar 1,4-dihydropyridine (@CHEMICAL$) binding properties and are both expressed in mammalian brain.	0
The L-type @CHEMICAL$ channel (@GENE$) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain.	0
The @CHEM-GENE$ (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain.	0
The L-type @CHEMICAL$ channel (LTCC) isoforms @GENE$ and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain.	0
The L-type @CHEMICAL$ channel (LTCC) isoforms Ca(v)1.2 and @GENE$ display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain.	0
The L-type calcium channel (@GENE$) isoforms Ca(v)1.2 and Ca(v)1.3 display similar @CHEMICAL$ (DHP) binding properties and are both expressed in mammalian brain.	0
The @GENE$ (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar @CHEMICAL$ (DHP) binding properties and are both expressed in mammalian brain.	0
The L-type calcium channel (LTCC) isoforms @GENE$ and Ca(v)1.3 display similar @CHEMICAL$ (DHP) binding properties and are both expressed in mammalian brain.	0
The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and @GENE$ display similar @CHEMICAL$ (DHP) binding properties and are both expressed in mammalian brain.	0
It is also unknown to what extent @GENE$ and Ca(v)1.4 contribute to L-type-specific @CHEMICAL$ binding activity in brain.	0
It is also unknown to what extent Ca(v)1.1 and @GENE$ contribute to L-type-specific @CHEMICAL$ binding activity in brain.	0
@CHEMICAL$ binding to @GENE$DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs.	0
@CHEMICAL$ binding to Ca(v)1.2DHP(-/-) and @GENE$-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs.	0
@CHEMICAL$ binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that @GENE$ accounts for 10.7% of brain LTCCs.	0
@CHEMICAL$ binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain @GENE$.	0
Inhibition of @CHEMICAL$ binding to @GENE$DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of @CHEMICAL$ binding to Ca(v)1.2DHP(-/-) (predominantly @GENE$) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of @CHEMICAL$ binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly @GENE$) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of @CHEMICAL$ binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the @GENE$ binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to @GENE$DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of @CHEMICAL$ and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly @GENE$) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of @CHEMICAL$ and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly @GENE$) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of @CHEMICAL$ and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of @CHEMICAL$ and nifedipine for the @GENE$ binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to @GENE$DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and @CHEMICAL$ for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly @GENE$) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and @CHEMICAL$ for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly @GENE$) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and @CHEMICAL$ for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.	0
Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and @CHEMICAL$ for the @GENE$ binding pocket, a finding further confirmed with heterologously expressed channels.	0
Global target profile of the @GENE$ inhibitor @CHEMICAL$ in primary chronic myeloid leukemia cells.	2
Here, we characterized the target profile of the dual @GENE$/ABL inhibitor @CHEMICAL$ employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.	2
Here, we characterized the target profile of the dual SRC/@GENE$ inhibitor @CHEMICAL$ employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.	2
Here, we characterized the target profile of the dual SRC/ABL inhibitor @CHEMICAL$ employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro @GENE$ assays against a large recombinant kinase panel.	0
Here, we characterized the target profile of the dual SRC/ABL inhibitor @CHEMICAL$ employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant @GENE$ panel.	0
The combined strategy resulted in a global survey of @CHEMICAL$ targets comprised of over 45 novel @GENE$.	0
The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel @CHEM-GENE$.	0
The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel @CHEM-GENE$.	0
The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel @CHEM-GENE$.	0
A comparison of bosutinib with @CHEMICAL$ across the whole @GENE$ panel revealed overlapping, but distinct, inhibition profiles.	2
A comparison of @CHEMICAL$ with dasatinib across the whole @GENE$ panel revealed overlapping, but distinct, inhibition profiles.	2
@CHEMICAL$ did not inhibit @GENE$ or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.	0
@CHEMICAL$ did not inhibit KIT or @GENE$, but prominently targeted the apoptosis-linked STE20 kinases.	0
@CHEMICAL$ did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked @GENE$.	0
Although in vivo @CHEMICAL$ is inactive against @GENE$ T315I, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range.	0
Although in vivo @CHEMICAL$ is inactive against ABL @GENE$, we found this clinically important mutant to be enzymatically inhibited in the mid-nanomolar range.	0
Finally, @CHEMICAL$ is the first @GENE$ inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.	2
Finally, @CHEMICAL$ is the first kinase inhibitor shown to target @GENE$, recently implicated in myeloid leukemia cell proliferation.	2
The negatively charged @CHEMICAL$ has been found previously to be a @GENE$ (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].	0
The negatively charged @CHEMICAL$ has been found previously to be a microtubule-associated protein (@GENE$)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].	0
In the present study the binding of @CHEMICAL$ to @GENE$ and tau was investigated.	0
In the present study the binding of @CHEMICAL$ to MAP2 and @GENE$ was investigated.	0
Both these @GENE$ were found to have two to three binding sites for @CHEMICAL$ which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.	0
Both these MAPs were found to have two to three binding sites for @CHEMICAL$ which is compatible with the reported number of basic amino acid repeats of these @GENE$, considered to be the ultimate tubulin binding domains.	0
Both these MAPs were found to have two to three binding sites for @CHEMICAL$ which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate @GENE$ binding domains.	0
Both these @GENE$ were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic @CHEMICAL$ repeats of these MAPs, considered to be the ultimate tubulin binding domains.	0
Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic @CHEMICAL$ repeats of these @GENE$, considered to be the ultimate tubulin binding domains.	0
Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic @CHEMICAL$ repeats of these MAPs, considered to be the ultimate @GENE$ binding domains.	0
The Kd for the binding of @CHEMICAL$ to @GENE$ was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM.	0
Two new negatively charged @CHEMICAL$ derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar @GENE$-dependent microtubule inhibitors.	0
Two new negatively charged estramustine derivatives, @CHEMICAL$ and estramustine glucuronide, were found to be similar @GENE$-dependent microtubule inhibitors.	0
Two new negatively charged estramustine derivatives, estramustine sulphate and @CHEMICAL$, were found to be similar @GENE$-dependent microtubule inhibitors.	0
A positively charged derivative, @CHEMICAL$, did not inhibit microtubule assembly or alter the composition of the coassembled @GENE$.	0
The uncharged @CHEMICAL$ bound to both @GENE$ and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology.	0
The uncharged @CHEMICAL$ bound to both tubulin and @GENE$, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology.	0
The uncharged @CHEMICAL$ bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled @GENE$ or the microtubule morphology.	0
Our results suggest that only negatively charged @CHEMICAL$ derivatives have a @GENE$-dependent microtubule inhibitory effect.	0
Analysis of coenzyme binding by @GENE$ and steroid 5----4-ene-isomerase using @CHEMICAL$, an affinity labeling cofactor analog.	0
Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and @GENE$ using @CHEMICAL$, an affinity labeling cofactor analog.	0
Analysis of coenzyme binding by @CHEM-GENE$ and steroid 5----4-ene-isomerase using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.	0
Analysis of coenzyme binding by human placental @CHEMICAL$ dehydrogenase and @GENE$ using 5'-[p-(fluorosulfonyl)benzoyl]adenosine, an affinity labeling cofactor analog.	0
@CHEM-GENE$ and steroid 5----4-ene-isomerase copurify as a single, homogeneous protein from human placental microsomes.	0
@CHEMICAL$ dehydrogenase and @GENE$ copurify as a single, homogeneous protein from human placental microsomes.	0
Affinity alkylation with 2 @CHEMICAL$ suggests that the @GENE$ and isomerase substrate steroids bind at different sites on the same protein.	0
Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the @GENE$ and isomerase substrate @CHEMICAL$ bind at different sites on the same protein.	5
Unlike bacterial @CHEM-GENE$, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, NAD+).	0
Unlike bacterial @GENE$, the human isomerase reaction is stimulated by @CHEMICAL$ (NADH, NAD+).	0
Unlike bacterial @GENE$, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (@CHEMICAL$, NAD+).	0
Unlike bacterial @GENE$, the human isomerase reaction is stimulated by diphosphopyridine nucleotides (NADH, @CHEMICAL$).	0
The affinity labeling @CHEMICAL$ analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the @GENE$ and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).	2
The affinity labeling nucleotide analog, @CHEMICAL$ (FSA), inactivates the @GENE$ and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).	2
The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (@CHEMICAL$), inactivates the @GENE$ and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).	2
FSA is a cofactor site-directed reagent that binds with similar affinity as a competitive inhibitor of @CHEMICAL$ reduction by @GENE$ (Ki = 162 microM) or as a stimulator of isomerase (Km = 153 microM).	0
The @CHEMICAL$ substrate, pregnenolone, protects isomerase as well as @GENE$ from inactivation by FSA.	0
The 3 beta-hydroxysteroid substrate, @CHEMICAL$, protects isomerase as well as @GENE$ from inactivation by FSA.	0
The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as @GENE$ from inactivation by @CHEMICAL$.	2
@CHEM-GENE$ blockers: new hope for successful cancer therapy.	0
@CHEM-GENE$ (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth.	0
@CHEMICAL$ kinases (@GENE$) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth.	0
During the last few years, thorough analysis of the mechanism underlying @CHEM-GENE$'s activity led to novel cancer therapy using TKs blockers.	0
During the last few years, thorough analysis of the mechanism underlying @CHEMICAL$ kinase's activity led to novel cancer therapy using @GENE$ blockers.	0
The most successful example of @GENE$ blockers is @CHEMICAL$ (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is @CHEMICAL$ (Imatinib mesylate, Gleevec, STI571), the inhibitor of @GENE$/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is @CHEMICAL$ (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/@GENE$ oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of @GENE$ blockers is Imatinib (@CHEMICAL$, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (@CHEMICAL$, Gleevec, STI571), the inhibitor of @GENE$/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (@CHEMICAL$, Gleevec, STI571), the inhibitor of Bcr/@GENE$ oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of @GENE$ blockers is Imatinib (Imatinib mesylate, @CHEMICAL$, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (Imatinib mesylate, @CHEMICAL$, STI571), the inhibitor of @GENE$/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (Imatinib mesylate, @CHEMICAL$, STI571), the inhibitor of Bcr/@GENE$ oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of @GENE$ blockers is Imatinib (Imatinib mesylate, Gleevec, @CHEMICAL$), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, @CHEMICAL$), the inhibitor of @GENE$/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, @CHEMICAL$), the inhibitor of Bcr/@GENE$ oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (@CHEMICAL$, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (@CHEMICAL$, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (@CHEMICAL$, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (@CHEMICAL$, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (@CHEMICAL$, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, @CHEMICAL$) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, @CHEMICAL$) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, @CHEMICAL$) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, @CHEMICAL$) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, @CHEMICAL$) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, @CHEMICAL$ (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, @CHEMICAL$ (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, @CHEMICAL$ (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, @CHEMICAL$ (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, @CHEMICAL$ (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (@CHEMICAL$) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (@CHEMICAL$) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (@CHEMICAL$) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (@CHEMICAL$) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (@CHEMICAL$) and INNO-406 (NS-187) specific for @GENE$ kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and @CHEMICAL$ (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and @CHEMICAL$ (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and @CHEMICAL$ (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and @CHEMICAL$ (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and @CHEMICAL$ (NS-187) specific for @GENE$ kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (@CHEMICAL$) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (@CHEMICAL$) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (@CHEMICAL$) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (@CHEMICAL$) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (@CHEMICAL$) specific for @GENE$ kinase.	2
Others kinase inhibitors used recently in cancer therapy include @CHEMICAL$ (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include @CHEMICAL$ (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include @CHEMICAL$ (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include @CHEMICAL$ (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include @CHEMICAL$ (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (@CHEMICAL$) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (@CHEMICAL$) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (@CHEMICAL$) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (@CHEMICAL$) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (@CHEMICAL$) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, @CHEMICAL$ (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, @CHEMICAL$ (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, @CHEMICAL$ (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, @CHEMICAL$ (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, @CHEMICAL$ (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (@CHEMICAL$), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (@CHEMICAL$), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (@CHEMICAL$), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (@CHEMICAL$), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (@CHEMICAL$), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), @CHEMICAL$ (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), @CHEMICAL$ (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), @CHEMICAL$ (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), @CHEMICAL$ (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), @CHEMICAL$ (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (@CHEMICAL$, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (@CHEMICAL$, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (@CHEMICAL$, Tarceva) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (@CHEMICAL$, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (@CHEMICAL$, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, @CHEMICAL$) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, @CHEMICAL$) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, @CHEMICAL$) and Sunitinib (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, @CHEMICAL$) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, @CHEMICAL$) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for @GENE$ non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and @CHEMICAL$ (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL @GENE$, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and @CHEMICAL$ (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	0
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and @CHEMICAL$ (SU 11248, Sutent) specific for @GENE$ kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and @CHEMICAL$ (SU 11248, Sutent) specific for VEGF receptor @GENE$, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.	2
Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and @CHEMICAL$ (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for @GENE$ kinase.	0
The following @GENE$ blockers for treatment of various human tumors are in clinical development: @CHEMICAL$ (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (@CHEMICAL$, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, @CHEMICAL$, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, @CHEMICAL$), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), @CHEMICAL$ (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (@CHEMICAL$), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), @CHEMICAL$ (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (@CHEMICAL$), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), @CHEMICAL$ (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (@CHEMICAL$/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/@CHEMICAL$), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), @CHEMICAL$ (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (@CHEMICAL$, Nexavar), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, @CHEMICAL$), and Leflunomide (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and @CHEMICAL$ (SU101, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (@CHEMICAL$, Arava).	2
The following @GENE$ blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, @CHEMICAL$).	2
Herein, we discuss the chemistry, biological activity and clinical potential of new drugs with @CHEM-GENE$ blockers for cancer treatment.	0
Non-selective inhibition of @CHEM-GENE$ (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects.	0
Non-selective inhibition of @CHEMICAL$ oxidase (@GENE$) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects.	0
Currently, the use of orally administered @GENE$ inhibitor antidepressants (eg, @CHEMICAL$, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine.	2
Currently, the use of orally administered @GENE$ inhibitor antidepressants (eg, phenelzine, @CHEMICAL$) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine.	2
Currently, the use of orally administered @GENE$ inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of @CHEMICAL$-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary tyramine.	0
Currently, the use of orally administered @GENE$ inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the "cheese reaction") when combined with dietary @CHEMICAL$.	0
Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic @GENE$ activity (ie, reduced risk of @CHEMICAL$-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect.	0
Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic @GENE$ activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of @CHEMICAL$ in the brain to produce an antidepressant effect.	0
@CHEMICAL$ has a high affinity and selectivity for @GENE$, but little or no affinity for various neurotransmitter receptors.	0
@CHEMICAL$ has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various @GENE$.	0
Atomoxetine has a high affinity and selectivity for @CHEM-GENE$, but little or no affinity for various neurotransmitter receptors.	0
Atomoxetine has a high affinity and selectivity for @CHEMICAL$ transporters, but little or no affinity for various @GENE$.	0
It undergoes extensive biotransformation, which is affected by poor metabolism by @GENE$ in a small percentage of the population; these patients have greater exposure to and slower elimination of @CHEMICAL$ than extensive metabolizers.	5
@GENE$ inhibitors, such as @CHEMICAL$, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.	2
CYP2D6 inhibitors, such as @CHEMICAL$, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor @GENE$ metabolizers.	0
@GENE$ inhibitors, such as paroxetine, are associated with changes in @CHEMICAL$ pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.	0
CYP2D6 inhibitors, such as paroxetine, are associated with changes in @CHEMICAL$ pharmacokinetics similar to those observed among poor @GENE$ metabolizers.	5
@CHEMICAL$ appeared better tolerated among extensive @GENE$ metabolizers than among poor metabolizers.	5
Novel inhibitors complexed with @CHEM-GENE$: allosteric regulation by control of protein dynamics.	0
@CHEM-GENE$ (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme.	0
Mammalian @CHEMICAL$ dehydrogenase (@GENE$) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme.	0
@GENE$ (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of @CHEMICAL$ to 2-oxoglutarate using NAD(P)(+) as coenzyme.	5
Mammalian glutamate dehydrogenase (@GENE$) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of @CHEMICAL$ to 2-oxoglutarate using NAD(P)(+) as coenzyme.	5
@GENE$ (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to @CHEMICAL$ using NAD(P)(+) as coenzyme.	5
Mammalian glutamate dehydrogenase (@GENE$) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to @CHEMICAL$ using NAD(P)(+) as coenzyme.	5
@GENE$ (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using @CHEMICAL$ as coenzyme.	0
Mammalian glutamate dehydrogenase (@GENE$) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using @CHEMICAL$ as coenzyme.	0
The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of @GENE$ by @CHEMICAL$ causes excessive secretion of insulin.	0
The recently discovered hyperinsulinism/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by @CHEMICAL$ causes excessive secretion of @GENE$.	1
Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of @GENE$ are inhibited by the green tea polyphenols, @CHEMICAL$ and epicatechin gallate.	2
Subsequent studies demonstrated that wild-type and hyperinsulinemia/hyperammonemia forms of @GENE$ are inhibited by the green tea polyphenols, epigallocatechin gallate and @CHEMICAL$.	2
@CHEMICAL$ forms a ring around the internal cavity in @GENE$ through aromatic stacking interactions between the drug and GDH as well as between the drug molecules themselves.	0
@CHEMICAL$ forms a ring around the internal cavity in GDH through aromatic stacking interactions between the drug and @GENE$ as well as between the drug molecules themselves.	0
The effect of a peripheral block on inflammation-induced @CHEMICAL$ and @GENE$ expression in rats.	0
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord @GENE$ (cyclooxygenase-2), with a subsequent increase in central @CHEMICAL$ (PGE2) levels associated with the development of hyperalgesia.	5
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (@GENE$), with a subsequent increase in central @CHEMICAL$ (PGE2) levels associated with the development of hyperalgesia.	5
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord @GENE$ (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (@CHEMICAL$) levels associated with the development of hyperalgesia.	5
BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (@GENE$), with a subsequent increase in central prostaglandin E2 (@CHEMICAL$) levels associated with the development of hyperalgesia.	5
In this study, we evaluated the effect of @CHEMICAL$ administered via a nerve block or via a systemic route on the spinal expression of PGE2 and @GENE$ in a model of peripheral inflammation in rats.	0
In this study, we evaluated the effect of bupivacaine administered via a nerve block or via a systemic route on the spinal expression of @CHEMICAL$ and @GENE$ in a model of peripheral inflammation in rats.	0
Local edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid @CHEMICAL$ concentration and @GENE$ and COX-2 expression in the spinal cord in dorsal root ganglions were measured.	0
Local edema, thermal, and mechanical hyperalgesia as well as cerebrospinal fluid @CHEMICAL$ concentration and COX-1 and @GENE$ expression in the spinal cord in dorsal root ganglions were measured.	0
Systemic @CHEMICAL$ did not modify either the hyperalgesia and local inflammation or @GENE$ expression.	0
Two pharmacologically distinct @GENE$ subtypes in the contraction of rabbit aorta: each subtype couples with a different @CHEMICAL$ signalling mechanism and plays a different physiological role.	0
Using the @GENE$ subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and @CHEMICAL$, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.	4
Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and @CHEMICAL$, we have examined the possible heterogeneity in the @GENE$ populations in rabbit aorta.	0
Using the @GENE$ subtype-selective antagonists @CHEMICAL$ (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.	4
Using the alpha 1-adrenoceptor subtype-selective antagonists @CHEMICAL$ (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the @GENE$ populations in rabbit aorta.	0
Using the @GENE$ subtype-selective antagonists chlorethylclonidine (@CHEMICAL$), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.	4
Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (@CHEMICAL$), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the @GENE$ populations in rabbit aorta.	0
Using the @GENE$ subtype-selective antagonists chlorethylclonidine (CEC), @CHEMICAL$, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.	4
Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), @CHEMICAL$, and 5-methyl-urapidil, we have examined the possible heterogeneity in the @GENE$ populations in rabbit aorta.	0
The @GENE$ alkylating agent CEC selectively inhibited the phasic component of the @CHEMICAL$-induced contractile response, with little effect on the tonic component.	0
The @GENE$ occupancy-response relationship defined by the @CHEMICAL$ inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses.	0
Radioligand binding studies with the nonselective @GENE$ antagonist radioligand @CHEMICAL$ showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).	4
Radioligand binding studies with the nonselective @GENE$ antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are @CHEMICAL$ sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).	0
Radioligand binding studies with the nonselective @GENE$ antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for @CHEMICAL$ (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).	0
Radioligand binding studies with the nonselective @GENE$ antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for @CHEMICAL$ (pKd = 7.1).	0
Moreover, alpha 1-adrenoceptor-mediated @CHEMICAL$ (PI) hydrolysis was CEC sensitive, and fractional inactivation of @GENE$ with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, @GENE$-mediated @CHEMICAL$ (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (@CHEMICAL$) hydrolysis was CEC sensitive, and fractional inactivation of @GENE$ with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, @GENE$-mediated phosphatidylinositol (@CHEMICAL$) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was @CHEMICAL$ sensitive, and fractional inactivation of @GENE$ with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, @GENE$-mediated phosphatidylinositol (PI) hydrolysis was @CHEMICAL$ sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of @GENE$ with @CHEMICAL$ showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, @GENE$-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with @CHEMICAL$ showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of @GENE$ with CEC showed equivalent increments in the reduction of @CHEMICAL$ hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, @GENE$-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of @CHEMICAL$ hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites.	0
Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of @GENE$ with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the @CHEMICAL$-sensitive receptor sites.	0
Moreover, @GENE$-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the @CHEMICAL$-sensitive receptor sites.	0
The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against @GENE$-selective agonist @CHEMICAL$-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.	3
The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against @GENE$-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for @CHEMICAL$ and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.	4
The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against @GENE$-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for @CHEMICAL$.	4
The Schild plots for the competitive antagonists @CHEMICAL$ and 5-methyl-urapidil against @GENE$-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.	4
The Schild plots for the competitive antagonists WB4101 and @CHEMICAL$ against @GENE$-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.	4
Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that @GENE$ populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for @CHEMICAL$ and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.	4
Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that @GENE$ populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for @CHEMICAL$) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.	4
Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that @GENE$ populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both @CHEMICAL$ and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.	0
Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that @GENE$ populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and @CHEMICAL$), which was in good agreement with radioligand binding studies.	0
@CHEMICAL$ is an @GENE$ antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH).	4
@GENE$ mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces @CHEMICAL$ synthesis and acts to clear ET from the circulation.	0
ET(A) mediates the vasoconstrictor effect of @GENE$ on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces @CHEMICAL$ synthesis and acts to clear ET from the circulation.	0
ET(A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas @GENE$ is expressed primarily on vascular endothelial cells where it induces @CHEMICAL$ synthesis and acts to clear ET from the circulation.	0
ET(A) mediates the vasoconstrictor effect of ET on vascular smooth muscle, whereas ET(B) is expressed primarily on vascular endothelial cells where it induces @CHEMICAL$ synthesis and acts to clear @GENE$ from the circulation.	0
@CHEMICAL$ is the first @GENE$ selective ERA approved for use in the US.	4
A series of 4,5-diaryloxazole analogs were designed and the interaction between @CHEMICAL$ and @GENE$ studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin.	0
A series of @CHEMICAL$ analogs were designed and the interaction between oxaprozin and @GENE$ studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of oxaprozin.	0
A series of 4,5-diaryloxazole analogs were designed and the interaction between oxaprozin and @GENE$ studied by the docking method to improve the biological activity and reduce the gastrointestinal side effects of @CHEMICAL$.	0
These include @GENE$, aromatase, @CHEMICAL$-dehydrogenases, sulfotransferases, hydroxylases and glucuronidases.	0
These include sulfatases, @GENE$, @CHEMICAL$-dehydrogenases, sulfotransferases, hydroxylases and glucuronidases.	0
These include sulfatases, aromatase, @CHEM-GENE$, sulfotransferases, hydroxylases and glucuronidases.	0
These include sulfatases, aromatase, @CHEMICAL$-dehydrogenases, @GENE$, hydroxylases and glucuronidases.	0
These include sulfatases, aromatase, @CHEMICAL$-dehydrogenases, sulfotransferases, @GENE$ and glucuronidases.	0
These include sulfatases, aromatase, @CHEMICAL$-dehydrogenases, sulfotransferases, hydroxylases and @GENE$.	0
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, @CHEMICAL$, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, @CHEMICAL$, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, @CHEMICAL$ and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, @CHEMICAL$ and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and @CHEMICAL$ can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and @CHEMICAL$ can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of @CHEMICAL$ in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	5
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of @CHEMICAL$ in breast cancer by blocking sulfatase and @GENE$ activities.	5
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and @CHEMICAL$-dehydrogenase type 1 activities.	0
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @CHEM-GENE$ activities.	0
As discussed in this review, various @CHEMICAL$ including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various @CHEMICAL$ including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
As discussed in this review, various progestogens including @CHEMICAL$ and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various progestogens including @CHEMICAL$ and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, @CHEMICAL$, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking @GENE$ and 17beta-hydroxysteroid-dehydrogenase type 1 activities.	2
As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, @CHEMICAL$, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and @GENE$ activities.	2
A possible correlation has been postulated between breast cell proliferation and @CHEM-GENE$ activity.	0
In conclusion, treatment with anti-aromatases combined with anti-@GENE$ or @CHEMICAL$-dehydrogenase type 1 could provide new therapeutic possibilities in the treatment of patients with hormone-dependent breast cancer.	0
In conclusion, treatment with anti-aromatases combined with anti-sulfatase or @CHEM-GENE$ could provide new therapeutic possibilities in the treatment of patients with hormone-dependent breast cancer.	0
OBJECTIVE: The purpose of this study was to delineate the role of structural abnormalities and @CHEM-GENE$ dysfunction in the Brugada sign.	0
METHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss-of-function mutation in @GENE$ (G752R) and dilated cardiomyopathy were determined after induction of right-sided ST-segment elevation by @CHEMICAL$.	0
METHODS: Activation and repolarization characteristics of the explanted heart of a patient with a loss-of-function mutation in SCN5A (@GENE$) and dilated cardiomyopathy were determined after induction of right-sided ST-segment elevation by @CHEMICAL$.	0
In addition, right ventricular structural discontinuities and @CHEM-GENE$ dysfunction were simulated in a computer model encompassing the heart and thorax.	0
In computer simulations entailing right ventricular structural discontinuities, reduction of @CHEM-GENE$ conductance or size of the gaps between introduced barriers resulted in subepicardial excitation failure or delayed activation by current-to-load mismatch and in the Brugada sign on the ECG.	0
OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic @CHEM-GENE$ ligand, exhibits hypoglycemic action unlike other sulfonylureas.	0
OBJECTIVE: @CHEMICAL$, a rapid- and short-acting insulinotropic @GENE$ ligand, exhibits hypoglycemic action unlike other sulfonylureas.	0
OBJECTIVE: Mitiglinide, a rapid- and short-acting insulinotropic @GENE$ ligand, exhibits hypoglycemic action unlike other @CHEMICAL$.	0
The efficacy of the combination of @CHEMICAL$ and @GENE$ inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of mitiglinide in these patients.	0
The efficacy of the combination of mitiglinide and @GENE$ inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the efficacy and safety of @CHEMICAL$ in these patients.	0
The efficacy of the treatment was determined by monitoring plasma @CHEMICAL$, hemoglobin A1c (Hb(A1c)), and glycated albumin (GA) levels and using homeostasis model assessment of @GENE$ resistance (HOMA-IR).	0
The efficacy of the treatment was determined by monitoring plasma @CHEMICAL$, @GENE$ (Hb(A1c)), and glycated albumin (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR).	0
The efficacy of the treatment was determined by monitoring plasma @CHEMICAL$, hemoglobin A1c (@GENE$), and glycated albumin (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR).	0
The efficacy of the treatment was determined by monitoring plasma @CHEMICAL$, hemoglobin A1c (Hb(A1c)), and @GENE$ (GA) levels and using homeostasis model assessment of insulin resistance (HOMA-IR).	0
The efficacy of the treatment was determined by monitoring plasma @CHEMICAL$, hemoglobin A1c (Hb(A1c)), and glycated albumin (@GENE$) levels and using homeostasis model assessment of insulin resistance (HOMA-IR).	0
@CHEMICAL$ reduced fasting plasma glucose and @GENE$ levels after 4 weeks and Hb(A1c) levels after 8 weeks.	2
@CHEMICAL$ reduced fasting plasma glucose and GA levels after 4 weeks and @GENE$ levels after 8 weeks.	2
Mitiglinide reduced fasting plasma @CHEMICAL$ and @GENE$ levels after 4 weeks and Hb(A1c) levels after 8 weeks.	0
Mitiglinide reduced fasting plasma @CHEMICAL$ and GA levels after 4 weeks and @GENE$ levels after 8 weeks.	0
Cyan fluorescent protein was fused to the @CHEMICAL$ terminus of the @GENE$, and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.	0
Cyan fluorescent protein was fused to the C terminus of the @GENE$, and a specific binding sequence for the small fluorescent compound @CHEMICAL$ arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.	0
Because these speeds are significantly faster than the responses to antagonists, these data indicate that @CHEMICAL$ and dimethyl-W84 are allosteric ligands and actively induce a conformation of the @GENE$ with a reduced affinity for its agonists.	0
Because these speeds are significantly faster than the responses to antagonists, these data indicate that gallamine and @CHEMICAL$ are allosteric ligands and actively induce a conformation of the @GENE$ with a reduced affinity for its agonists.	0
A molecular mechanism for @CHEMICAL$-mediated @GENE$ inhibition in neurons.	2
@CHEMICAL$ is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of @GENE$.	2
Recently, we have demonstrated that @CHEMICAL$ inhibits intracellular signaling of @GENE$ and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents.	2
In addition, another study suggests that @CHEMICAL$ reduces generation of @GENE$ peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.	2
In addition, another study suggests that @CHEMICAL$ reduces generation of amyloid-beta42 peptide via inactivation of @GENE$ signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex.	2
In addition, another study suggests that @CHEMICAL$ reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate @GENE$ formation by direct inhibition of the gamma-secretase complex.	1
In addition, another study suggests that @CHEMICAL$ reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the @GENE$.	2
The molecular mechanisms by which @CHEMICAL$ inhibits the @GENE$ signal in neurons, however, remain unclear.	2
Here, we report that the transcription factor @GENE$ (PPARgamma) is essential for coupling @CHEMICAL$ to RhoA inhibition and subsequent neurite growth promotion in neurons.	0
Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (@GENE$) is essential for coupling @CHEMICAL$ to RhoA inhibition and subsequent neurite growth promotion in neurons.	0
Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling @CHEMICAL$ to @GENE$ inhibition and subsequent neurite growth promotion in neurons.	2
@CHEMICAL$ activates @GENE$ in neuron-like PC12 and B104 cells.	1
Activation of PPARgamma with traditional agonists mimics the @GENE$-inhibiting properties of @CHEMICAL$ in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	2
Activation of @GENE$ with traditional agonists mimics the RhoA-inhibiting properties of @CHEMICAL$ in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	0
Activation of PPARgamma with traditional agonists mimics the @GENE$-inhibiting properties of ibuprofen in PC12 cells and, like @CHEMICAL$, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	0
Activation of @GENE$ with traditional agonists mimics the RhoA-inhibiting properties of ibuprofen in PC12 cells and, like @CHEMICAL$, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors.	0
Moreover, the effect of @CHEMICAL$ on @GENE$ activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition.	0
Moreover, the effect of @CHEMICAL$ on RhoA activity and neurite growth in neuronal cultures is prevented by selective @GENE$ inhibition.	0
These findings support that @GENE$ plays an essential role in mediating the RhoA-inhibiting effect of @CHEMICAL$.	0
These findings support that PPARgamma plays an essential role in mediating the @GENE$-inhibiting effect of @CHEMICAL$.	2
Elucidation of the novel molecular mechanisms linking @CHEMICAL$ to @GENE$ inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.	2
Elucidation of the novel molecular mechanisms linking @CHEMICAL$ to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by @GENE$ activation, including spinal cord injuries and Alzheimer's disease.	0
Recent developments include the identification of non-peptidic small-molecules that selectively inhibit certain @CHEM-GENE$ within the coagulation cascade.	0
Of these, the @GENE$ inhibitor @CHEMICAL$ and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	2
Of these, the thrombin inhibitor @CHEMICAL$ and @GENE$ inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	0
Of these, the @GENE$ inhibitor dabigatran and factor Xa inhibitor @CHEMICAL$ have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	0
Of these, the thrombin inhibitor dabigatran and @GENE$ inhibitor @CHEMICAL$ have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.	2
In addition, the @GENE$ inhibitor @CHEMICAL$ is in late-stage clinical development.	2
However, alterations of @CHEMICAL$ and apixaban pharmacokinetics upon interactions with inhibitors and inducers of @GENE$ or P-glycoprotein may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	0
However, alterations of @CHEMICAL$ and apixaban pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or @GENE$ may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	0
However, alterations of rivaroxaban and @CHEMICAL$ pharmacokinetics upon interactions with inhibitors and inducers of @GENE$ or P-glycoprotein may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	0
However, alterations of rivaroxaban and @CHEMICAL$ pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or @GENE$ may complicate the use of these compounds in daily practice, whereas dabigatran elimination largely depends on renal function.	0
However, alterations of rivaroxaban and apixaban pharmacokinetics upon interactions with inhibitors and inducers of @GENE$ or P-glycoprotein may complicate the use of these compounds in daily practice, whereas @CHEMICAL$ elimination largely depends on renal function.	0
However, alterations of rivaroxaban and apixaban pharmacokinetics upon interactions with inhibitors and inducers of CYP3A4 or @GENE$ may complicate the use of these compounds in daily practice, whereas @CHEMICAL$ elimination largely depends on renal function.	0
@CHEMICAL$ directly inhibits @GENE$ activity in continuous ambulatory peritoneal dialysis therapy.	2
We determined whether an @CHEM-GENE$ (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	0
We determined whether an @CHEMICAL$-converting enzyme (@GENE$) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	0
We determined whether an @CHEMICAL$-converting enzyme (ACE) inhibitor, captopril, inhibits @GENE$ activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	0
We determined whether an @CHEMICAL$-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the @GENE$-captopril complex.	0
We determined whether an @GENE$ (ACE) inhibitor, @CHEMICAL$, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	2
We determined whether an angiotensin-converting enzyme (@GENE$) inhibitor, @CHEMICAL$, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	2
We determined whether an angiotensin-converting enzyme (ACE) inhibitor, @CHEMICAL$, inhibits @GENE$ activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.	0
We determined whether an angiotensin-converting enzyme (ACE) inhibitor, @CHEMICAL$, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the @GENE$-captopril complex.	0
We determined whether an @GENE$ (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-@CHEMICAL$ complex.	0
We determined whether an angiotensin-converting enzyme (@GENE$) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-@CHEMICAL$ complex.	0
We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits @GENE$ activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-@CHEMICAL$ complex.	0
We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the @GENE$-@CHEMICAL$ complex.	0
METHODS: The inhibitory effect of @CHEMICAL$ on @GENE$ activity was measured in peritoneal effluents from 17 patients on CAPD.	2
Molecular models of the @GENE$-@CHEMICAL$ complex were simulated by 1000 iterations of random docking and energy minimization.	0
RESULTS: @CHEMICAL$ directly inhibited @GENE$ activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.	2
RESULTS: @CHEMICAL$ directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the @GENE$ active site could be formed in each complex model without molecular distortion.	0
RESULTS: Captopril directly inhibited @GENE$ activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that @CHEMICAL$ binding to the MMP-2 active site could be formed in each complex model without molecular distortion.	0
RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that @CHEMICAL$ binding to the @GENE$ active site could be formed in each complex model without molecular distortion.	0
CONCLUSION: ACE inhibitors, such as @CHEMICAL$, may be applied as important compounds for @GENE$ inhibition in inflammation caused by CAPD.	2
CONCLUSION: @GENE$ inhibitors, such as @CHEMICAL$, may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.	2
@CHEMICAL$ has a direct inhibitory effect on the @GENE$.	2
Phenformin has a direct inhibitory effect on the @CHEM-GENE$.	0
Phenformin has a direct inhibitory effect on the @CHEM-GENE$.	0
The biguanides, phenformin and @CHEMICAL$, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating @GENE$ activity.	0
The @CHEMICAL$, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating @GENE$ activity.	0
The biguanides, @CHEMICAL$ and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating @GENE$ activity.	0
We used the patch-clamp technique and @CHEMICAL$ flux assays to determine the role of these drugs in @GENE$ (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and @CHEMICAL$ flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@GENE$) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and @CHEMICAL$ flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of @GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @CHEM-GENE$ (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @CHEMICAL$-sensitive K+ channel (@GENE$) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @CHEMICAL$-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of @GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @CHEM-GENE$ (K(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive @CHEMICAL$ channel (@GENE$) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive @CHEMICAL$ channel (K(ATP)) regulation in cell lines expressing the cloned components of @GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @GENE$ (@CHEMICAL$(ATP)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@CHEM-GENE$) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@CHEMICAL$(ATP)) regulation in cell lines expressing the cloned components of @GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @GENE$ (K(@CHEMICAL$)) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@CHEM-GENE$) regulation in cell lines expressing the cloned components of K(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(@CHEMICAL$)) regulation in cell lines expressing the cloned components of @GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @GENE$ (K(ATP)) regulation in cell lines expressing the cloned components of @CHEMICAL$(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@GENE$) regulation in cell lines expressing the cloned components of @CHEMICAL$(ATP) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of @CHEM-GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in @GENE$ (K(ATP)) regulation in cell lines expressing the cloned components of K(@CHEMICAL$) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (@GENE$) regulation in cell lines expressing the cloned components of K(@CHEMICAL$) and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
We used the patch-clamp technique and rubidium flux assays to determine the role of these drugs in ATP-sensitive K+ channel (K(ATP)) regulation in cell lines expressing the cloned components of @CHEM-GENE$ and the current natively expressed in vascular smooth muscle cells (VSMCs).	0
@CHEMICAL$ but not metformin inhibits a number of variants of @GENE$ including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (@GENE$/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/@GENE$ and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and @GENE$/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/@GENE$) and pancreatic beta-cells (Kir6.2/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (@GENE$/SUR1).	2
@CHEMICAL$ but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/@GENE$).	2
Phenformin but not @CHEMICAL$ inhibits a number of variants of @GENE$ including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (@GENE$/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/@GENE$ and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and @GENE$/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/@GENE$) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (@GENE$/SUR1).	0
Phenformin but not @CHEMICAL$ inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/@GENE$).	0
Phenformin but not metformin inhibits a number of variants of @CHEM-GENE$ including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (@GENE$/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/@GENE$ and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and @GENE$/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/@GENE$) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (@GENE$/SUR1).	0
Phenformin but not metformin inhibits a number of variants of @CHEMICAL$(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/@GENE$).	0
Phenformin but not metformin inhibits a number of variants of @CHEM-GENE$ including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (@GENE$/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/@GENE$ and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and @GENE$/SUR2B) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/@GENE$) and pancreatic beta-cells (Kir6.2/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (@GENE$/SUR1).	0
Phenformin but not metformin inhibits a number of variants of K(@CHEMICAL$) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1/SUR2B and Kir6.2/SUR2B) and pancreatic beta-cells (Kir6.2/@GENE$).	0
The extent and rate of inhibition are similar to that seen with the known @CHEM-GENE$ blocker PNU 37883A.	0
The extent and rate of inhibition are similar to that seen with the known @CHEM-GENE$ blocker PNU 37883A.	0
The extent and rate of inhibition are similar to that seen with the known @GENE$ blocker @CHEMICAL$.	2
Additionally, @CHEMICAL$ inhibited the current elicited through the @GENE$ (functional without SUR) channel with an IC50 of 1.78 mM.	2
Additionally, @CHEMICAL$ inhibited the current elicited through the Kir6.2DeltaC26 (functional without @GENE$) channel with an IC50 of 1.78 mM.	0
@CHEMICAL$ reduced the open probability of @GENE$/SUR2B channels by approximately 90% in inside-out patches.	2
@CHEMICAL$ reduced the open probability of Kir6.1/@GENE$ channels by approximately 90% in inside-out patches.	2
These findings suggest that @CHEMICAL$ interacts directly with the pore-forming @GENE$ subunit however the sulphonylurea receptor is able to significantly modulate the affinity.	0
These findings suggest that @CHEMICAL$ interacts directly with the pore-forming Kir6.0 subunit however the @GENE$ is able to significantly modulate the affinity.	0
These findings suggest that phenformin interacts directly with the pore-forming @GENE$ subunit however the @CHEMICAL$ receptor is able to significantly modulate the affinity.	0
These findings suggest that phenformin interacts directly with the pore-forming Kir6.0 subunit however the @CHEM-GENE$ is able to significantly modulate the affinity.	0
@CHEM-GENE$ agonists (VDRAs) directly suppress parathyroid hormone (PTH) mRNA expression.	0
@CHEMICAL$ receptor agonists (VDRAs) directly suppress @GENE$ (PTH) mRNA expression.	0
@CHEMICAL$ receptor agonists (VDRAs) directly suppress parathyroid hormone (@GENE$) mRNA expression.	0
Different VDRAs are known to have differential effects on serum @CHEMICAL$ (Ca), which may also affect serum @GENE$ levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum @CHEMICAL$ (Ca), which may also affect serum PTH levels since serum Ca regulates @GENE$ secretion mediated by the Ca-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum @CHEMICAL$ (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the @GENE$ (CaSR).	0
Different VDRAs are known to have differential effects on serum @CHEMICAL$ (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (@GENE$).	0
Different VDRAs are known to have differential effects on serum calcium (@CHEMICAL$), which may also affect serum @GENE$ levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (@CHEMICAL$), which may also affect serum PTH levels since serum Ca regulates @GENE$ secretion mediated by the Ca-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (@CHEMICAL$), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the @GENE$ (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (@CHEMICAL$), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (@GENE$).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum @GENE$ levels since serum @CHEMICAL$ regulates PTH secretion mediated by the Ca-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum @CHEMICAL$ regulates @GENE$ secretion mediated by the Ca-sensing receptor (CaSR).	1
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum @CHEMICAL$ regulates PTH secretion mediated by the @GENE$ (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum @CHEMICAL$ regulates PTH secretion mediated by the Ca-sensing receptor (@GENE$).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum @GENE$ levels since serum Ca regulates PTH secretion mediated by the @CHEMICAL$-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates @GENE$ secretion mediated by the @CHEMICAL$-sensing receptor (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the @CHEM-GENE$ (CaSR).	0
Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the @CHEMICAL$-sensing receptor (@GENE$).	0
In this study, we compared the effects of paricalcitol and @CHEMICAL$ on regulating serum Ca and @GENE$, and also the expression of PTH, VDR, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and @CHEMICAL$ on regulating serum Ca and PTH, and also the expression of @GENE$, VDR, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and @CHEMICAL$ on regulating serum Ca and PTH, and also the expression of PTH, @GENE$, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and @CHEMICAL$ on regulating serum Ca and PTH, and also the expression of PTH, VDR, and @GENE$ mRNA.	0
In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum @CHEMICAL$ and @GENE$, and also the expression of PTH, VDR, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum @CHEMICAL$ and PTH, and also the expression of @GENE$, VDR, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum @CHEMICAL$ and PTH, and also the expression of PTH, @GENE$, and CaSR mRNA.	0
In this study, we compared the effects of paricalcitol and doxercalciferol on regulating serum @CHEMICAL$ and PTH, and also the expression of PTH, VDR, and @GENE$ mRNA.	0
In this study, we compared the effects of @CHEMICAL$ and doxercalciferol on regulating serum Ca and @GENE$, and also the expression of PTH, VDR, and CaSR mRNA.	0
In this study, we compared the effects of @CHEMICAL$ and doxercalciferol on regulating serum Ca and PTH, and also the expression of @GENE$, VDR, and CaSR mRNA.	0
In this study, we compared the effects of @CHEMICAL$ and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, @GENE$, and CaSR mRNA.	0
In this study, we compared the effects of @CHEMICAL$ and doxercalciferol on regulating serum Ca and PTH, and also the expression of PTH, VDR, and @GENE$ mRNA.	0
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed @GENE$ mRNA expression and serum PTH effectively in the 5/6 NX rats, but @CHEMICAL$ was less potent in raising serum Ca than doxercalciferol.	2
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum @GENE$ effectively in the 5/6 NX rats, but @CHEMICAL$ was less potent in raising serum Ca than doxercalciferol.	2
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed @GENE$ mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum @CHEMICAL$ than doxercalciferol.	0
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum @GENE$ effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum @CHEMICAL$ than doxercalciferol.	0
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed @GENE$ mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than @CHEMICAL$.	2
Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum @GENE$ effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than @CHEMICAL$.	2
In pig parathyroid cells, @CHEMICAL$ and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of @GENE$ mRNA more effectively.	0
In pig parathyroid cells, @CHEMICAL$ and the active form of doxercalciferol induced @GENE$ translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.	0
In pig parathyroid cells, @CHEMICAL$ and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed @GENE$ mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.	2
In pig parathyroid cells, paricalcitol and the active form of @CHEMICAL$ induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of @GENE$ mRNA more effectively.	0
In pig parathyroid cells, paricalcitol and the active form of @CHEMICAL$ induced @GENE$ translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.	0
In pig parathyroid cells, paricalcitol and the active form of @CHEMICAL$ induced VDR translocation from the cytoplasm into the nucleus, suppressed @GENE$ mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.	2
In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although @CHEMICAL$ induced the expression of @GENE$ mRNA more effectively.	1
In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced @GENE$ translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although @CHEMICAL$ induced the expression of CaSR mRNA more effectively.	0
In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed @GENE$ mRNA expression and inhibited cell proliferation in a similar manner, although @CHEMICAL$ induced the expression of CaSR mRNA more effectively.	0
The multiple effects of VDRAs on modulating serum @CHEMICAL$, parathyroid cell proliferation, and the expression of @GENE$ and PTH mRNA reflect the complex involvement of the vitamin D axis in regulating the mineral homeostasis system.	0
The multiple effects of VDRAs on modulating serum @CHEMICAL$, parathyroid cell proliferation, and the expression of CaSR and @GENE$ mRNA reflect the complex involvement of the vitamin D axis in regulating the mineral homeostasis system.	0
The multiple effects of VDRAs on modulating serum Ca, parathyroid cell proliferation, and the expression of @GENE$ and PTH mRNA reflect the complex involvement of the @CHEMICAL$ axis in regulating the mineral homeostasis system.	0
The multiple effects of VDRAs on modulating serum Ca, parathyroid cell proliferation, and the expression of CaSR and @GENE$ mRNA reflect the complex involvement of the @CHEMICAL$ axis in regulating the mineral homeostasis system.	0
Here, we identified cereblon (CRBN) as a @CHEM-GENE$.	0
Here, we identified @GENE$ (CRBN) as a @CHEMICAL$-binding protein.	0
Here, we identified cereblon (@GENE$) as a @CHEMICAL$-binding protein.	0
@CHEMICAL$ initiates its teratogenic effects by binding to @GENE$ and inhibiting the associated ubiquitin ligase activity.	0
@CHEMICAL$ initiates its teratogenic effects by binding to CRBN and inhibiting the associated @GENE$ activity.	2
In this study we explore the mechanisms by which a double mutation (@GENE$/D75Y) in cardiac troponin C (CTnC) associated with dilated cardiomyopathy reduces the @CHEMICAL$-activated maximal tension of cardiac muscle.	0
In this study we explore the mechanisms by which a double mutation (E59D/@GENE$) in cardiac troponin C (CTnC) associated with dilated cardiomyopathy reduces the @CHEMICAL$-activated maximal tension of cardiac muscle.	0
In this study we explore the mechanisms by which a double mutation (E59D/D75Y) in @GENE$ (CTnC) associated with dilated cardiomyopathy reduces the @CHEMICAL$-activated maximal tension of cardiac muscle.	0
In this study we explore the mechanisms by which a double mutation (E59D/D75Y) in cardiac troponin C (@GENE$) associated with dilated cardiomyopathy reduces the @CHEMICAL$-activated maximal tension of cardiac muscle.	0
@GENE$ or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or @GENE$) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that @GENE$, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not @GENE$, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of @GENE$ in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in @GENE$ complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, @GENE$ (RTF), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (@GENE$), and the @CHEMICAL$ sensitivity of contraction and ATPase in cardiac muscle preparations.	0
E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the @CHEMICAL$ sensitivity of contraction and @GENE$ in cardiac muscle preparations.	0
RATIONALE: The @CHEM-GENE$ (5-HT1(B/D)) receptor has shown potential as a target for decreasing aggression.	0
RATIONALE: The @CHEMICAL$ 1(B/D) (@GENE$) receptor has shown potential as a target for decreasing aggression.	0
The @GENE$ agonist zolmitriptan's ability to reduce aggressive behavior in humans and its interaction with the well-known aggression-enhancing drug @CHEMICAL$ were examined.	0
Blockade of the @GENE$-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by @CHEMICAL$ throughout the cardiovascular and renal continua.	0
Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by @CHEM-GENE$ throughout the cardiovascular and renal continua.	0
Blockade of the renin-@GENE$ system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by @CHEMICAL$ throughout the cardiovascular and renal continua.	0
Blockade of the @GENE$-@CHEMICAL$ system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua.	0
Blockade of the renin-@CHEMICAL$ system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by @GENE$ throughout the cardiovascular and renal continua.	0
Blockade of the renin-@CHEM-GENE$ system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua.	0
@CHEMICAL$ is an @GENE$ blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.	2
Telmisartan is an @CHEM-GENE$ blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.	0
Jostling for position: optimizing linker location in the design of @CHEM-GENE$-targeting PROTACs.	0
@CHEM-GENE$ (ER) antagonists have been widely used for breast cancer therapy.	0
@CHEMICAL$ receptor-alpha (@GENE$) antagonists have been widely used for breast cancer therapy.	0
Recent studies indicate that @CHEMICAL$ initially acts as an antagonist, but later functions as an @GENE$ agonist, promoting tumor growth.	4
The @GENE$-targeting PROTACs are composed of an @CHEMICAL$ on one end and a hypoxia-inducing factor 1alpha (HIF-1alpha)-derived synthetic pentapeptide on the other.	0
The ER-targeting PROTACs are composed of an @CHEMICAL$ on one end and a @GENE$ (HIF-1alpha)-derived synthetic pentapeptide on the other.	0
The ER-targeting PROTACs are composed of an @CHEMICAL$ on one end and a hypoxia-inducing factor 1alpha (@GENE$)-derived synthetic pentapeptide on the other.	0
With the pentapeptide linked through the C7alpha position of @CHEMICAL$, the resulting PROTAC shows the most effective @GENE$ degradation and highest affinity for the estrogen receptor.	2
With the pentapeptide linked through the C7alpha position of @CHEMICAL$, the resulting PROTAC shows the most effective ER degradation and highest affinity for the @GENE$.	0
With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective @GENE$ degradation and highest affinity for the @CHEMICAL$ receptor.	0
With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the @CHEM-GENE$.	0
This result provides an opportunity to develop a novel type of @GENE$ antagonist that may overcome the resistance of breast tumors to conventional drugs such as @CHEMICAL$ and fulvestrant (Faslodex).	0
This result provides an opportunity to develop a novel type of @GENE$ antagonist that may overcome the resistance of breast tumors to conventional drugs such as tamoxifen and @CHEMICAL$ (Faslodex).	0
This result provides an opportunity to develop a novel type of @GENE$ antagonist that may overcome the resistance of breast tumors to conventional drugs such as tamoxifen and fulvestrant (@CHEMICAL$).	0
@GENE$ polymorphism of the methylenetetrahydrofolate reductase gene does not affect folic acid, vitamin B12, and @CHEMICAL$ serum levels in Turkish children with neural tube defects.	0
C677T polymorphism of the @GENE$ gene does not affect folic acid, vitamin B12, and @CHEMICAL$ serum levels in Turkish children with neural tube defects.	0
@GENE$ polymorphism of the @CHEMICAL$ reductase gene does not affect folic acid, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.	0
C677T polymorphism of the @CHEM-GENE$ gene does not affect folic acid, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.	0
@GENE$ polymorphism of the methylenetetrahydrofolate reductase gene does not affect @CHEMICAL$, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.	0
C677T polymorphism of the @GENE$ gene does not affect @CHEMICAL$, vitamin B12, and homocysteine serum levels in Turkish children with neural tube defects.	0
@GENE$ polymorphism of the methylenetetrahydrofolate reductase gene does not affect folic acid, @CHEMICAL$, and homocysteine serum levels in Turkish children with neural tube defects.	0
C677T polymorphism of the @GENE$ gene does not affect folic acid, @CHEMICAL$, and homocysteine serum levels in Turkish children with neural tube defects.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the @CHEMICAL$ reductase (@GENE$) gene was suspected, because the MTHFR gene codes for a key enzyme in folate metabolism.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the @CHEMICAL$ reductase (MTHFR) gene was suspected, because the @GENE$ gene codes for a key enzyme in folate metabolism.	0
Association between neural tube defects (NTDs) and @GENE$ polymorphism of the @CHEMICAL$ reductase (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in folate metabolism.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the @CHEM-GENE$ (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in folate metabolism.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the methylenetetrahydrofolate reductase (@GENE$) gene was suspected, because the MTHFR gene codes for a key enzyme in @CHEMICAL$ metabolism.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene was suspected, because the @GENE$ gene codes for a key enzyme in @CHEMICAL$ metabolism.	0
Association between neural tube defects (NTDs) and @GENE$ polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in @CHEMICAL$ metabolism.	0
Association between neural tube defects (NTDs) and C677T polymorphism of the @GENE$ (MTHFR) gene was suspected, because the MTHFR gene codes for a key enzyme in @CHEMICAL$ metabolism.	0
We examined @CHEMICAL$, vitamin B(12) and homocysteine serum concentrations and polymorphism of the @GENE$ MTHFR gene in Turkish children with neural tube defects.	0
We examined @CHEMICAL$, vitamin B(12) and homocysteine serum concentrations and polymorphism of the C677T @GENE$ gene in Turkish children with neural tube defects.	0
We examined folate, @CHEMICAL$ and homocysteine serum concentrations and polymorphism of the @GENE$ MTHFR gene in Turkish children with neural tube defects.	0
We examined folate, @CHEMICAL$ and homocysteine serum concentrations and polymorphism of the C677T @GENE$ gene in Turkish children with neural tube defects.	0
We examined folate, vitamin B(12) and @CHEMICAL$ serum concentrations and polymorphism of the @GENE$ MTHFR gene in Turkish children with neural tube defects.	0
We examined folate, vitamin B(12) and @CHEMICAL$ serum concentrations and polymorphism of the C677T @GENE$ gene in Turkish children with neural tube defects.	0
The levels of @CHEMICAL$, vitamin B(12) and homocysteine serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the @GENE$ gene.	0
The levels of folate, @CHEMICAL$ and homocysteine serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the @GENE$ gene.	0
The levels of folate, vitamin B(12) and @CHEMICAL$ serum concentrations in NTDs were evaluated and compared, along with information concerning alleles of the @GENE$ gene.	0
We concluded that @GENE$ MTHFR gene polymorphism does not affect @CHEMICAL$, vitamin B(12) and homocysteine metabolism in Turkish children with NTDs.	0
We concluded that C677T @GENE$ gene polymorphism does not affect @CHEMICAL$, vitamin B(12) and homocysteine metabolism in Turkish children with NTDs.	0
We concluded that @GENE$ MTHFR gene polymorphism does not affect folic acid, @CHEMICAL$ and homocysteine metabolism in Turkish children with NTDs.	0
We concluded that C677T @GENE$ gene polymorphism does not affect folic acid, @CHEMICAL$ and homocysteine metabolism in Turkish children with NTDs.	0
We concluded that @GENE$ MTHFR gene polymorphism does not affect folic acid, vitamin B(12) and @CHEMICAL$ metabolism in Turkish children with NTDs.	0
We concluded that C677T @GENE$ gene polymorphism does not affect folic acid, vitamin B(12) and @CHEMICAL$ metabolism in Turkish children with NTDs.	0
EXPERIMENTAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the @GENE$, were used, and whole-cell @CHEMICAL$ radioligand binding and [(3)H]-cAMP accumulation were measured.	0
EXPERIMENTAL APPROACH: Stable clonal CHO-K1 cell lines, transfected with either the @GENE$, were used, and whole-cell [(3)H]-CGP 12177 radioligand binding and @CHEMICAL$ accumulation were measured.	0
@CHEMICAL$ and formoterol, for the @GENE$ over the beta(1) or beta(3)), while others (e.g.	3
@CHEMICAL$ and formoterol, for the beta(2)-adrenoceptor over the @GENE$ or beta(3)), while others (e.g.	3
@CHEMICAL$ and formoterol, for the beta(2)-adrenoceptor over the beta(1) or @GENE$), while others (e.g.	0
salmeterol and @CHEMICAL$, for the @GENE$ over the beta(1) or beta(3)), while others (e.g.	3
salmeterol and @CHEMICAL$, for the beta(2)-adrenoceptor over the @GENE$ or beta(3)), while others (e.g.	0
salmeterol and @CHEMICAL$, for the beta(2)-adrenoceptor over the beta(1) or @GENE$), while others (e.g.	3
denopamine for @GENE$; clenbuterol, AZ 40140d, @CHEMICAL$ for beta(2)) were found to have subtype-selective intrinsic efficacy.	0
denopamine for beta(1); clenbuterol, AZ 40140d, @CHEMICAL$ for @GENE$) were found to have subtype-selective intrinsic efficacy.	0
@CHEMICAL$ for @GENE$; clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.	0
@CHEMICAL$ for beta(1); clenbuterol, AZ 40140d, salbutamol for @GENE$) were found to have subtype-selective intrinsic efficacy.	0
denopamine for @GENE$; @CHEMICAL$, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.	0
denopamine for beta(1); @CHEMICAL$, AZ 40140d, salbutamol for @GENE$) were found to have subtype-selective intrinsic efficacy.	0
denopamine for @GENE$; clenbuterol, @CHEMICAL$, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.	0
denopamine for beta(1); clenbuterol, @CHEMICAL$, salbutamol for @GENE$) were found to have subtype-selective intrinsic efficacy.	0
@CHEMICAL$: a novel anti-Parkinsonian @GENE$ inhibitor with neuroprotective activity.	2
Rasagiline: a novel anti-Parkinsonian @CHEM-GENE$ inhibitor with neuroprotective activity.	0
Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible @CHEM-GENE$ inhibitor, anti-Parkinsonian drug.	0
@CHEMICAL$ (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible @GENE$ inhibitor, anti-Parkinsonian drug.	2
Rasagiline (@CHEMICAL$) is a novel, highly potent irreversible @GENE$ inhibitor, anti-Parkinsonian drug.	2
Its S-isomer, @CHEMICAL$ is thousand times less potent as an @GENE$ inhibitor.	2
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of @CHEMICAL$ does not depend on inhibition of @GENE$, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.	2
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of @CHEMICAL$ does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating @GENE$ family proteins.	0
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of @GENE$, but rather is associated with the @CHEMICAL$ moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.	0
However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the @CHEMICAL$ moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating @GENE$ family proteins.	1
As the RTH mutant, @GENE$, was new, the optimum dose of @CHEMICAL$ was unclear.	0
SUMMARY: The patient was a newborn female having severe hypothyroidism with a free @CHEMICAL$ level of 0.36 ng/dL and a serum @GENE$ level of 177 microU/mL.	0
Supplementation with @CHEMICAL$ at a dose of >350 microg/day did not normalize the serum @GENE$ level; however, the patient showed normal growth and intelligence at 14 years of age.	0
Consistent with the results of a computer analysis, the binding of @GENE$ to triiodothyronine (@CHEMICAL$) was significantly decreased to 38% that of the wild type.	0
Consistent with the results of a computer analysis, the binding of @GENE$ to @CHEMICAL$ (T3) was significantly decreased to 38% that of the wild type.	0
However, a @CHEMICAL$-S-transferase pull-down assay showed reduced binding of @GENE$ with NCoR in the absence of T3 and impaired release in the presence of T3.	0
However, a @CHEMICAL$-S-transferase pull-down assay showed reduced binding of R316C with @GENE$ in the absence of T3 and impaired release in the presence of T3.	0
However, a glutathione-@CHEMICAL$-transferase pull-down assay showed reduced binding of @GENE$ with NCoR in the absence of T3 and impaired release in the presence of T3.	0
However, a glutathione-@CHEMICAL$-transferase pull-down assay showed reduced binding of R316C with @GENE$ in the absence of T3 and impaired release in the presence of T3.	0
However, a glutathione-S-transferase pull-down assay showed reduced binding of @GENE$ with NCoR in the absence of @CHEMICAL$ and impaired release in the presence of T3.	0
However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with @GENE$ in the absence of @CHEMICAL$ and impaired release in the presence of T3.	0
However, a glutathione-S-transferase pull-down assay showed reduced binding of @GENE$ with NCoR in the absence of T3 and impaired release in the presence of @CHEMICAL$.	0
However, a glutathione-S-transferase pull-down assay showed reduced binding of R316C with @GENE$ in the absence of T3 and impaired release in the presence of @CHEMICAL$.	0
Our findings suggest that @GENE$ causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of @CHEMICAL$ might be optimum for normal growth.	0
Our findings suggest that R316C causes reduced association with and impaired release of @GENE$, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of @CHEMICAL$ might be optimum for normal growth.	0
Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum @GENE$ level with high dose of @CHEMICAL$ might be optimum for normal growth.	1
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEM-GENE$ modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (@GENE$-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-@GENE$) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (@GENE$-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-@GENE$) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (@GENE$-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-@GENE$), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of @GENE$ (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (@GENE$, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, @GENE$) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (@GENE$-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-@GENE$) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @CHEMICAL$(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or @GENE$ agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @GENE$ modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (@GENE$-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-@GENE$) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (@GENE$-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-@GENE$) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (@GENE$-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-@GENE$), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of @GENE$ (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (@GENE$, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, @GENE$) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (@GENE$-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-@GENE$) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (@CHEMICAL$) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or @GENE$ agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @GENE$ modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (@GENE$-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-@GENE$) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (@GENE$-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-@GENE$) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (@GENE$-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-@GENE$), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of @GENE$ (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (@GENE$, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, @GENE$) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (@GENE$-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-@GENE$) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), @CHEMICAL$ antagonist, or modulators of metabotropic glutamate receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or @GENE$ agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by @GENE$ modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (@GENE$-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-@GENE$) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (@GENE$-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-@GENE$) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (@GENE$-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-@GENE$), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of @CHEM-GENE$ (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (@GENE$, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, @GENE$) in PRC, and cholinergic antagonist (M1-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (@GENE$-M5) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-@GENE$) or GABA(A) agonist in PPC.	0
Results from microinfusion studies show that anticonvulsant efficacy is obtained by GABA(A) modulators or cholinergic antagonists (M1-M5) in AT, cholinergic antagonists (M1-M5) in MS, combined glutamatergic (NMDA) and cholinergic antagonist (M1-M4), AMPA antagonist, or modulators of metabotropic @CHEMICAL$ receptors (mGluR5, mGluR2/3) in PRC, and cholinergic antagonist (M1-M5) or @GENE$ agonist in PPC.	0
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of @GENE$ (COX-2).	2
BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-@CHEMICAL$ anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (@GENE$).	2
METHODS: We conducted a case-control study to measure the association between selective @GENE$ inhibitors, particularly @CHEMICAL$, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.	2
METHODS: We conducted a case-control study to measure the association between selective @GENE$ inhibitors, particularly celecoxib, @CHEMICAL$, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.	2
METHODS: We conducted a case-control study to measure the association between selective @GENE$ inhibitors, particularly celecoxib, rofecoxib, @CHEMICAL$ and non-specific NSAID subgroups, and breast cancer risk.	2
With exposure to @CHEMICAL$, a selective @GENE$ inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.	2
With exposure to @CHEMICAL$, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective @GENE$ inhibitors in breast cancer prophylaxis.	2
Intracerebroventricular administration of SMS 201-995 (5 micrograms/rat), a @CHEM-GENE$ analogue, induced barrel rotation in rats.	0
Intracerebroventricular administration of @CHEMICAL$ (5 micrograms/rat), a @GENE$ analogue, induced barrel rotation in rats.	0
wt., IP) 3 days or 7 days prior to the injection of @CHEMICAL$ significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by @GENE$ (1 microgram/rat, ICV).	0
wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by @CHEMICAL$, but not that induced by @GENE$ (1 microgram/rat, ICV).	0
wt., IP) 3 days or 7 days prior to the injection of SMS 201-995 significantly inhibited the response rate of barrel rotation induced by SMS 201-995, but not that induced by @CHEM-GENE$ (1 microgram/rat, ICV).	0
The suppressive effect of @CHEMICAL$ on barrel rotation could be partially countered by MK-329, a selective peripheral @GENE$ (CCK-A) receptor antagonist.	2
The suppressive effect of @CHEMICAL$ on barrel rotation could be partially countered by MK-329, a selective peripheral CCK @GENE$ antagonist.	2
The suppressive effect of ceruletide on barrel rotation could be partially countered by @CHEMICAL$, a selective peripheral @GENE$ (CCK-A) receptor antagonist.	4
The suppressive effect of ceruletide on barrel rotation could be partially countered by @CHEMICAL$, a selective peripheral CCK @GENE$ antagonist.	4
These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by @CHEMICAL$ in a long-lasting manner possibly acting through @GENE$.	0
These findings suggest that @CHEMICAL$ specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through @GENE$.	2
Effects of the @CHEM-GENE$ antagonist chlorcyclizine on rat fetal palate development.	0
Effects of the @GENE$ antagonist @CHEMICAL$ on rat fetal palate development.	4
BACKGROUND: The effects of @CHEM-GENE$ antagonist chlorcyclizine on rat palate development were characterized following in utero exposure.	0
BACKGROUND: The effects of @GENE$ antagonist @CHEMICAL$ on rat palate development were characterized following in utero exposure.	4
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, @GENE$, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, Bmp2, @GENE$, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, Bmp2, Bmp4, @GENE$, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, @GENE$, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, @GENE$, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included Wnt5a, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and @GENE$ but the magnitude of the change was relatively small (1.5- to 2-fold).	0
The altered genes associated with @CHEMICAL$-induced cleft palate included @GENE$, Bmp2, Bmp4, Fgf10, Fgfr2, Msx1, and Insig1 but the magnitude of the change was relatively small (1.5- to 2-fold).	0
PURPOSE: The purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of @CHEM-GENE$ (GABA(A)-Rs) in the mechanisms of general anesthesia.	0
PURPOSE: The purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of @CHEMICAL$ type A receptors (@GENE$) in the mechanisms of general anesthesia.	0
PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate @GENE$-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of @CHEMICAL$ residues in the transmembrane domain that are critical for the drug actions in vitro.	0
PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of @GENE$ subunits of varying sensitivity led to identification of @CHEMICAL$ residues in the transmembrane domain that are critical for the drug actions in vitro.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane @CHEMICAL$ that were affinity labelled in purified @GENE$. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane @CHEMICAL$ that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of @GENE$ at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane @CHEMICAL$ that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the @GENE$.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified @GENE$. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit @CHEMICAL$ binding pocket at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of @CHEM-GENE$ at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit @CHEMICAL$ binding pocket at the @GENE$.	0
Using a photo incorporable analogue of the general anesthetic, @CHEMICAL$, we identified two transmembrane amino acids that were affinity labelled in purified @GENE$. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, @CHEMICAL$, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of @GENE$ at the beta/alpha interface.	0
Using a photo incorporable analogue of the general anesthetic, @CHEMICAL$, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the @GENE$.	0
Role of extracellular calcium and @GENE$ in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high @CHEMICAL$ in GH4C1 cells.	0
Role of extracellular calcium and calmodulin in @GENE$ secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high @CHEMICAL$ in GH4C1 cells.	0
Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, @GENE$, and high @CHEMICAL$ in GH4C1 cells.	0
Role of extracellular @CHEMICAL$ and @GENE$ in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells.	0
Role of extracellular @CHEMICAL$ and calmodulin in @GENE$ secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells.	0
Role of extracellular @CHEMICAL$ and calmodulin in prolactin secretion induced by hyposmolarity, @GENE$, and high K+ in GH4C1 cells.	0
The mechanism by which 30% medium hyposmolarity induces PRL secretion by GH4C1 cells was compared with that induced by 100 nmol/l @GENE$ or 30 mmol/l @CHEMICAL$.	0
The mechanism by which 30% medium hyposmolarity induces @GENE$ secretion by GH4C1 cells was compared with that induced by 100 nmol/l TRH or 30 mmol/l @CHEMICAL$.	0
Removing medium @CHEMICAL$, blocking @GENE$ with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium @CHEMICAL$, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting @GENE$ activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking @CHEM-GENE$ with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking @CHEMICAL$ channels with 50 mumol/l verapamil, or inhibiting @GENE$ activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking @GENE$ with 50 mumol/l @CHEMICAL$, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	2
Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l @CHEMICAL$, or inhibiting @GENE$ activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking @GENE$ with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l @CHEMICAL$, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting @GENE$ activation with 20 mumol/l @CHEMICAL$, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	2
Removing medium Ca2+, blocking @GENE$ with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l @CHEMICAL$ or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting @GENE$ activation with 20 mumol/l trifluoperazine, 10 mumol/l @CHEMICAL$ or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.	2
Removing medium Ca2+, blocking @GENE$ with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l @CHEMICAL$ almost completely blocked hyposmolarity-induced secretion.	0
Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting @GENE$ activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l @CHEMICAL$ almost completely blocked hyposmolarity-induced secretion.	2
The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the @CHEMICAL$-@GENE$ interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).	0
The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the @CHEMICAL$-calmodulin interaction, depressed hyposmolarity-induced @GENE$ secretion in a dose-dependent manner (r = -0.991, p less than 0.01).	0
The smooth muscle relaxant, @CHEMICAL$, which is believed relatively specific in inhibiting the Ca2(+)-@GENE$ interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).	0
The smooth muscle relaxant, @CHEMICAL$, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced @GENE$ secretion in a dose-dependent manner (r = -0.991, p less than 0.01).	2
The above drugs also blocked or decreased high @CHEMICAL$-induced secretion, but had much less effect on @GENE$-induced secretion.	0
Secretion induced by @GENE$, hyposmolarity, or high @CHEMICAL$ was optimal at pH 7.3-7.65 and was significantly depressed at pH 6.0 or 8.0, indicating that release of hormone induced by all 3 stimuli is due to an active cell process requiring a physiologic extracellular pH and is not produced by nonspecific cell toxicity.	0
The data suggest hyposmolarity and high @CHEMICAL$ may share some similarities in their mechanism of stimulating secretion, which is different from that of @GENE$.	0
Use of (Gyro) Gy and @CHEM-GENE$ transgenic mice to study functions of spermine.	0
Use of (Gyro) Gy and @GENE$ transgenic mice to study functions of @CHEMICAL$.	0
Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking @CHEM-GENE$ (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking @CHEMICAL$ synthase (@GENE$) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either @CHEMICAL$ or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking @GENE$ (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either @CHEMICAL$ or spermidine (which also -prevent the production of spermine) is lethal, but male mice lacking spermine synthase (@GENE$) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either putrescine or @CHEMICAL$ (which also -prevent the production of spermine) is lethal, but male mice lacking @GENE$ (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either putrescine or @CHEMICAL$ (which also -prevent the production of spermine) is lethal, but male mice lacking spermine synthase (@GENE$) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of @CHEMICAL$) is lethal, but male mice lacking @GENE$ (SpmS) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
Loss of any of the enzymes needed to make either putrescine or spermidine (which also -prevent the production of @CHEMICAL$) is lethal, but male mice lacking spermine synthase (@GENE$) due to a deletion of part of the X chromosome are viable on the B6C3H background.	0
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement @CHEMICAL$ and this can be accomplished by breeding with CAG-@GENE$ mice that express SpmS from a ubiquitous promoter.	5
An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement @CHEMICAL$ and this can be accomplished by breeding with CAG-SMS mice that express @GENE$ from a ubiquitous promoter.	5
@CHEMICAL$ (XL184), a novel @GENE$ and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	2
@CHEMICAL$ (XL184), a novel MET and @GENE$ inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	2
Cabozantinib (@CHEMICAL$), a novel @GENE$ and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	2
Cabozantinib (@CHEMICAL$), a novel MET and @GENE$ inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	2
@CHEMICAL$ (XL184) is a small-molecule @GENE$ inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward @GENE$ and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and @GENE$ (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (@GENE$), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other @GENE$ that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including @GENE$, KIT, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, @GENE$, AXL, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, @GENE$, and FLT3.	2
@CHEMICAL$ (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and @GENE$.	2
Cabozantinib (@CHEMICAL$) is a small-molecule @GENE$ inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward @GENE$ and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and @GENE$ (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (@GENE$), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other @GENE$ that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including @GENE$, KIT, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, @GENE$, AXL, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, @GENE$, and FLT3.	2
Cabozantinib (@CHEMICAL$) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and @GENE$.	2
Cabozantinib (XL184) is a small-molecule @GENE$ inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward @GENE$ and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and @GENE$ (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (@GENE$), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other @CHEM-GENE$ that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including @GENE$, KIT, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, @GENE$, AXL, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, @GENE$, and FLT3.	0
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor @CHEMICAL$ kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and @GENE$.	0
Treatment with @CHEMICAL$ inhibited @GENE$ and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.	2
Treatment with @CHEMICAL$ inhibited MET and @GENE$ phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.	2
Importantly, treatment with @CHEMICAL$ did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of @GENE$ signaling that do not target MET.	2
Importantly, treatment with @CHEMICAL$ did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target @GENE$.	0
Collectively, these data suggest that @CHEMICAL$ is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated @GENE$ and VEGFR signaling.	2
Collectively, these data suggest that @CHEMICAL$ is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and @GENE$ signaling.	2
@CHEMICAL$ suppresses osteoclastogenesis induced by @GENE$ and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.	0
To search for an inhibitor of cancer-induced bone loss, we investigated the effect of @CHEMICAL$, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by @GENE$ (RANKL) and tumour cells.	0
To search for an inhibitor of cancer-induced bone loss, we investigated the effect of @CHEMICAL$, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (@GENE$) and tumour cells.	0
To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thiocolchicoside, a semi-synthetic @CHEMICAL$ derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by @GENE$ (RANKL) and tumour cells.	0
To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thiocolchicoside, a semi-synthetic @CHEMICAL$ derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (@GENE$) and tumour cells.	0
EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of @CHEMICAL$ on @GENE$-induced NF-kappaB signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells.	0
EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of @CHEMICAL$ on RANKL-induced @GENE$ signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells.	0
KEY RESULTS: @CHEMICAL$ suppressed osteoclastogenesis induced by @GENE$, and by breast cancer and multiple myeloma cells.	0
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced @GENE$ activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of @GENE$ (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (@GENE$) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of @GENE$ (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (@GENE$) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of @GENE$.	2
Inhibition of the @GENE$ pathway was responsible for this effect since the @CHEMICAL$ inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	0
Inhibition of the NF-kappaB pathway was responsible for this effect since the @CHEMICAL$ inhibited @GENE$-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.	2
CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that @CHEMICAL$ significantly suppressed osteoclastogenesis induced by @GENE$ and tumour cells via the NF-kappaB signalling pathway.	2
CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that @CHEMICAL$ significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the @GENE$ signalling pathway.	2
@CHEM-GENE$ genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction.	0
@GENE$ genotypes and haplotypes modify the responses to @CHEMICAL$ in patients with erectile dysfunction.	0
Although genetic polymorphisms in the endothelial @CHEMICAL$ synthase (@GENE$) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.	0
Although genetic polymorphisms in the endothelial @CHEMICAL$ synthase (eNOS) gene may impair endogenous NO formation, there is little information about how @GENE$ polymorphisms and haplotypes affect the responses to sildenafil.	0
Although genetic polymorphisms in the @CHEM-GENE$ (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.	0
Although genetic polymorphisms in the endothelial nitric oxide synthase (@GENE$) gene may impair endogenous @CHEMICAL$ formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.	5
Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous @CHEMICAL$ formation, there is little information about how @GENE$ polymorphisms and haplotypes affect the responses to sildenafil.	0
Although genetic polymorphisms in the @GENE$ (eNOS) gene may impair endogenous @CHEMICAL$ formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.	5
Although genetic polymorphisms in the endothelial nitric oxide synthase (@GENE$) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to @CHEMICAL$.	0
Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how @GENE$ polymorphisms and haplotypes affect the responses to @CHEMICAL$.	0
Although genetic polymorphisms in the @GENE$ (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to @CHEMICAL$.	0
Our findings show evidence that @GENE$ polymorphisms affect the responses of PED and clinical ED patients to @CHEMICAL$.	0
@CHEMICAL$ induces the expression of @GENE$ and inducible nitric oxide synthase.	1
@CHEMICAL$ induces the expression of cyclooxygenase-2 and @GENE$.	1
Mercury induces the expression of @GENE$ and inducible @CHEMICAL$ synthase.	0
Mercury induces the expression of cyclooxygenase-2 and @CHEM-GENE$.	0
NF-κB activation induces numerous proinflammatory gene products including @GENE$, cyclooxygenase-2 (COX-2), and inducible @CHEMICAL$ synthase (iNOS).	0
NF-κB activation induces numerous proinflammatory gene products including cytokines, @GENE$ (COX-2), and inducible @CHEMICAL$ synthase (iNOS).	0
NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (@GENE$), and inducible @CHEMICAL$ synthase (iNOS).	0
NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and @CHEM-GENE$ (iNOS).	0
NF-κB activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible @CHEMICAL$ synthase (@GENE$).	0
@GENE$ activation induces numerous proinflammatory gene products including cytokines, cyclooxygenase-2 (COX-2), and inducible @CHEMICAL$ synthase (iNOS).	0
Here, we report biochemical evidence that @CHEMICAL$ alone induces @GENE$ activation, resulting in the induced expression of COX-2 and iNOS.	1
Here, we report biochemical evidence that @CHEMICAL$ alone induces NF-κB activation, resulting in the induced expression of @GENE$ and iNOS.	1
Here, we report biochemical evidence that @CHEMICAL$ alone induces NF-κB activation, resulting in the induced expression of COX-2 and @GENE$.	1
Pharmacological evidence of functional inhibitory @CHEM-GENE$ on mouse arousal-related cholinergic laterodorsal tegmental neurons.	0
Therefore, electrophysiological responses and changes in levels of intracellular @CHEMICAL$ in mouse cholinergic LDT neurons following application of specific @GENE$ agonists and antagonists were examined.	0
Unexpectedly, both the @GENE$specific agonist, @CHEMICAL$, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.	3
Unexpectedly, both the mGluR(5)specific agonist, @CHEMICAL$, and the @GENE$ (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the mGluR(5)specific agonist, @CHEMICAL$, and the group II mGluR (@GENE$) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the @GENE$specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, @CHEMICAL$ (LY), induced a TTX-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the @GENE$ (mGlu(2/3)) agonist, @CHEMICAL$ (LY), induced a TTX-insensitive outward current/hyperpolarization.	3
Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (@GENE$) agonist, @CHEMICAL$ (LY), induced a TTX-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the @GENE$specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a @CHEMICAL$-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the @GENE$ (mGlu(2/3)) agonist, LY379268 (LY), induced a @CHEMICAL$-insensitive outward current/hyperpolarization.	0
Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (@GENE$) agonist, LY379268 (LY), induced a @CHEMICAL$-insensitive outward current/hyperpolarization.	0
Both outward currents were significantly reduced by the @GENE$ antagonist @CHEMICAL$ and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.	4
Both outward currents were significantly reduced by the mGluR antagonist @CHEMICAL$ and the CHPG-induced current was blocked by the specific @GENE$ antagonist MTEP.	0
Both outward currents were significantly reduced by the @GENE$ antagonist MCPG and the @CHEMICAL$-induced current was blocked by the specific mGluR(5) antagonist MTEP.	0
Both outward currents were significantly reduced by the mGluR antagonist MCPG and the @CHEMICAL$-induced current was blocked by the specific @GENE$ antagonist MTEP.	0
Both outward currents were significantly reduced by the @GENE$ antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist @CHEMICAL$.	0
Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific @GENE$ antagonist @CHEMICAL$.	4
The large-conductance, @CHEM-GENE$ blocker, iberiotoxin, attenuated CHPG actions.	0
The large-conductance, @CHEM-GENE$ blocker, iberiotoxin, attenuated CHPG actions.	0
The large-conductance, @GENE$ blocker, iberiotoxin, attenuated @CHEMICAL$ actions.	0
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of @CHEM-GENE$ and mGluR(1), but also inhibition via actions at mGluR(5) and mGluR(2/3) on these neurons.	0
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic @CHEMICAL$ receptors and @GENE$, but also inhibition via actions at mGluR(5) and mGluR(2/3) on these neurons.	0
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic @CHEMICAL$ receptors and mGluR(1), but also inhibition via actions at @GENE$ and mGluR(2/3) on these neurons.	0
Effects of glutamatergic input would be, thus, expected not only to be excitation via stimulation of ionotropic @CHEMICAL$ receptors and mGluR(1), but also inhibition via actions at mGluR(5) and @GENE$ on these neurons.	0
This article is part of a Special Issue entitled '@CHEM-GENE$'.	0
We have examined the effectiveness of two novel @GENE$ selective inhibitors, @CHEMICAL$ and AR678, in a panel of melanoma cell lines and normal cell types.	2
We have examined the effectiveness of two novel @GENE$ selective inhibitors, AR323 and @CHEMICAL$, in a panel of melanoma cell lines and normal cell types.	2
@CHEMICAL$ inhibits @GENE$ signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.	2
@CHEMICAL$ inhibits mTOR signaling, activates @GENE$, and induces autophagy in colorectal cancer cells.	1
Aspirin inhibits @CHEM-GENE$ signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.	0
Aspirin inhibits @CHEMICAL$ signaling, activates @GENE$, and induces autophagy in colorectal cancer cells.	0
Aspirin inhibits @GENE$ signaling, activates @CHEMICAL$-activated protein kinase, and induces autophagy in colorectal cancer cells.	0
Aspirin inhibits mTOR signaling, activates @CHEM-GENE$, and induces autophagy in colorectal cancer cells.	0
Cancer cells have defects in signaling via the @CHEM-GENE$ (mTOR), which regulates proliferation.	0
Cancer cells have defects in signaling via the mechanistic target of @CHEMICAL$ (@GENE$), which regulates proliferation.	0
Cancer cells have defects in signaling via the @GENE$ (@CHEMICAL$), which regulates proliferation.	0
Cancer cells have defects in signaling via the mechanistic target of rapamycin (@CHEM-GENE$), which regulates proliferation.	0
We investigated whether @CHEMICAL$ affects @GENE$ (AMPK) and mTOR signaling in CRC cells.	0
We investigated whether @CHEMICAL$ affects adenosine monophosphate-activated protein kinase (@GENE$) and mTOR signaling in CRC cells.	0
We investigated whether @CHEMICAL$ affects adenosine monophosphate-activated protein kinase (AMPK) and @GENE$ signaling in CRC cells.	0
We investigated whether aspirin affects @CHEM-GENE$ (AMPK) and mTOR signaling in CRC cells.	0
We investigated whether aspirin affects @CHEMICAL$-activated protein kinase (@GENE$) and mTOR signaling in CRC cells.	0
We investigated whether aspirin affects @CHEMICAL$-activated protein kinase (AMPK) and @GENE$ signaling in CRC cells.	0
We investigated whether aspirin affects @GENE$ (AMPK) and @CHEMICAL$ signaling in CRC cells.	0
We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (@GENE$) and @CHEMICAL$ signaling in CRC cells.	0
We investigated whether aspirin affects adenosine monophosphate-activated protein kinase (AMPK) and @CHEM-GENE$ signaling in CRC cells.	0
METHODS: The effects of @CHEMICAL$ on @GENE$ signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of @CHEMICAL$ on mTOR signaling, the @GENE$, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of @CHEMICAL$ on mTOR signaling, the ribosomal protein S6, @GENE$ (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of @CHEMICAL$ on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (@GENE$), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of @CHEMICAL$ on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and @GENE$ (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of @CHEMICAL$ on mTOR signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (@GENE$) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEM-GENE$ signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEMICAL$ signaling, the @GENE$, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEMICAL$ signaling, the ribosomal protein S6, @GENE$ (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEMICAL$ signaling, the ribosomal protein S6, S6 kinase 1 (@GENE$), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEMICAL$ signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and @GENE$ (4E-BP1) were examined in CRC cells by immunoblotting.	0
METHODS: The effects of aspirin on @CHEMICAL$ signaling, the ribosomal protein S6, S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (@GENE$) were examined in CRC cells by immunoblotting.	0
Phosphorylation of @GENE$ was measured; the effects of loss of AMPKalpha on the @CHEMICAL$-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of @GENE$ on the @CHEMICAL$-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the @CHEMICAL$-induced effects of @GENE$ were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the @CHEMICAL$-induced effects of mTOR were determined using small interfering RNA (siRNA) in CRC cells and in @GENE$-/-) mouse embryonic fibroblasts.	0
Phosphorylation of @GENE$ was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of @CHEMICAL$ were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of @GENE$ on the aspirin-induced effects of @CHEMICAL$ were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of @CHEM-GENE$ were determined using small interfering RNA (siRNA) in CRC cells and in AMPK(alpha1/alpha2-/-) mouse embryonic fibroblasts.	0
Phosphorylation of AMPK was measured; the effects of loss of AMPKalpha on the aspirin-induced effects of @CHEMICAL$ were determined using small interfering RNA (siRNA) in CRC cells and in @GENE$-/-) mouse embryonic fibroblasts.	0
RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the @CHEM-GENE$ effectors S6K1 and 4E-BP1.	0
RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the @CHEMICAL$ effectors @GENE$ and 4E-BP1.	0
RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the @CHEMICAL$ effectors S6K1 and @GENE$.	0
RESULTS: Aspirin reduced @GENE$ signaling in CRC cells by inhibiting the @CHEMICAL$ effectors S6K1 and 4E-BP1.	0
RESULTS: @CHEMICAL$ reduced mTOR signaling in CRC cells by inhibiting the @GENE$ effectors S6K1 and 4E-BP1.	2
RESULTS: @CHEMICAL$ reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors @GENE$ and 4E-BP1.	2
RESULTS: @CHEMICAL$ reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and @GENE$.	2
RESULTS: @CHEMICAL$ reduced @GENE$ signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.	2
RESULTS: Aspirin reduced @CHEMICAL$ signaling in CRC cells by inhibiting the @GENE$ effectors S6K1 and 4E-BP1.	0
RESULTS: Aspirin reduced @CHEMICAL$ signaling in CRC cells by inhibiting the mTOR effectors @GENE$ and 4E-BP1.	0
RESULTS: Aspirin reduced @CHEMICAL$ signaling in CRC cells by inhibiting the mTOR effectors S6K1 and @GENE$.	0
RESULTS: Aspirin reduced @CHEM-GENE$ signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1.	0
@CHEMICAL$ changed nucleotide ratios and activated @GENE$ in CRC cells.	1
@CHEM-GENE$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	0
@CHEMICAL$ was still inhibited by aspirin in CRC cells after siRNA knockdown of @GENE$, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	0
@CHEMICAL$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating @GENE$-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	0
@CHEMICAL$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and @GENE$-independent mechanisms of aspirin-induced inhibition of mTOR.	0
@CHEMICAL$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @GENE$.	0
@GENE$ was still inhibited by @CHEMICAL$ in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	2
mTOR was still inhibited by @CHEMICAL$ in CRC cells after siRNA knockdown of @GENE$, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	0
mTOR was still inhibited by @CHEMICAL$ in CRC cells after siRNA knockdown of AMPKalpha, indicating @GENE$-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR.	0
mTOR was still inhibited by @CHEMICAL$ in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and @GENE$-independent mechanisms of aspirin-induced inhibition of mTOR.	0
mTOR was still inhibited by @CHEMICAL$ in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @GENE$.	0
@GENE$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of @CHEMICAL$-induced inhibition of mTOR.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of @GENE$, indicating AMPK-dependent and AMPK-independent mechanisms of @CHEMICAL$-induced inhibition of mTOR.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating @GENE$-dependent and AMPK-independent mechanisms of @CHEMICAL$-induced inhibition of mTOR.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and @GENE$-independent mechanisms of @CHEMICAL$-induced inhibition of mTOR.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of @CHEMICAL$-induced inhibition of @GENE$.	2
@GENE$ was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @CHEMICAL$.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of @GENE$, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @CHEMICAL$.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating @GENE$-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @CHEMICAL$.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and @GENE$-independent mechanisms of aspirin-induced inhibition of @CHEMICAL$.	0
mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of @CHEM-GENE$.	0
@CHEMICAL$ induced autophagy, a feature of @GENE$ inhibition.	2
Aspirin induced autophagy, a feature of @CHEM-GENE$ inhibition.	0
Aspirin and @CHEMICAL$ (an activator of @GENE$) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.	1
Aspirin and @CHEMICAL$ (an activator of AMPK) increased inhibition of @GENE$ and Akt, as well as autophagy in CRC cells.	2
Aspirin and @CHEMICAL$ (an activator of AMPK) increased inhibition of mTOR and @GENE$, as well as autophagy in CRC cells.	2
Aspirin and metformin (an activator of @GENE$) increased inhibition of @CHEMICAL$ and Akt, as well as autophagy in CRC cells.	0
Aspirin and metformin (an activator of AMPK) increased inhibition of @CHEM-GENE$ and Akt, as well as autophagy in CRC cells.	0
Aspirin and metformin (an activator of AMPK) increased inhibition of @CHEMICAL$ and @GENE$, as well as autophagy in CRC cells.	0
@CHEMICAL$ and metformin (an activator of @GENE$) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells.	1
@CHEMICAL$ and metformin (an activator of AMPK) increased inhibition of @GENE$ and Akt, as well as autophagy in CRC cells.	2
@CHEMICAL$ and metformin (an activator of AMPK) increased inhibition of mTOR and @GENE$, as well as autophagy in CRC cells.	2
Rectal mucosal samples from patients given @CHEMICAL$ had reduced phosphorylation of @GENE$ and S6.	2
Rectal mucosal samples from patients given @CHEMICAL$ had reduced phosphorylation of S6K1 and @GENE$.	2
CONCLUSIONS: @CHEMICAL$ is an inhibitor of @GENE$ and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.	2
CONCLUSIONS: @CHEMICAL$ is an inhibitor of mTOR and an activator of @GENE$, targeting regulators of intracellular energy homeostasis and metabolism.	1
CONCLUSIONS: Aspirin is an inhibitor of @CHEM-GENE$ and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism.	0
CONCLUSIONS: Aspirin is an inhibitor of @CHEMICAL$ and an activator of @GENE$, targeting regulators of intracellular energy homeostasis and metabolism.	0
Oncogenic @GENE$ expression is associated with derangement of the @CHEMICAL$/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration.	0
Oncogenic K-ras expression is associated with derangement of the @CHEMICAL$/@GENE$ pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration.	0
Oncogenic @GENE$ expression is associated with derangement of the cAMP/PKA pathway and @CHEMICAL$-reversible alterations of mitochondrial dynamics and respiration.	0
Oncogenic K-ras expression is associated with derangement of the cAMP/@GENE$ pathway and @CHEMICAL$-reversible alterations of mitochondrial dynamics and respiration.	0
In previous papers, it has been shown that @GENE$ transformed mouse cells are much more sensitive as compared with normal cells to @CHEMICAL$ withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of mitochondrial complex I.	0
In previous papers, it has been shown that K-ras transformed mouse cells are much more sensitive as compared with normal cells to @CHEMICAL$ withdrawal (undergoing apoptosis) and present a high glycolytic rate and a strong reduction of @GENE$.	0
Recent observations suggest that transformed cells have a derangement in the @CHEMICAL$/@GENE$ (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions.	0
Recent observations suggest that transformed cells have a derangement in the @CHEMICAL$/cAMP-dependent protein kinase (cAMP/@GENE$) pathway, which is known to regulate several mitochondrial functions.	0
Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/@CHEM-GENE$ (cAMP/PKA) pathway, which is known to regulate several mitochondrial functions.	0
Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/@CHEMICAL$-dependent protein kinase (cAMP/@GENE$) pathway, which is known to regulate several mitochondrial functions.	0
Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/@GENE$ (@CHEMICAL$/PKA) pathway, which is known to regulate several mitochondrial functions.	0
Recent observations suggest that transformed cells have a derangement in the cyclic adenosine monophosphate/cAMP-dependent protein kinase (@CHEMICAL$/@GENE$) pathway, which is known to regulate several mitochondrial functions.	0
Herein, the derangement of the @CHEMICAL$/@GENE$ pathway and its impact on transformation-linked changes of mitochondrial functions is investigated.	0
Exogenous stimulation of @GENE$ activity, achieved by @CHEMICAL$ treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	1
Exogenous stimulation of PKA activity, achieved by @CHEMICAL$ treatment, protected @GENE$-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by @CHEMICAL$ treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced @GENE$ activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	1
Exogenous stimulation of @GENE$ activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by @CHEMICAL$ deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected @GENE$-transformed cells from apoptosis induced by @CHEMICAL$ deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	2
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by @CHEMICAL$ deprivation, enhanced @GENE$ activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of @GENE$ activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular @CHEMICAL$ (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected @GENE$-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular @CHEMICAL$ (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced @GENE$ activity, intracellular @CHEMICAL$ (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of @GENE$ activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (@CHEMICAL$) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected @GENE$-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (@CHEMICAL$) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced @GENE$ activity, intracellular adenosine triphosphate (@CHEMICAL$) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.	0
Exogenous stimulation of @GENE$ activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive @CHEMICAL$ species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected @GENE$-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive @CHEMICAL$ species (ROS) levels.	0
Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced @GENE$ activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive @CHEMICAL$ species (ROS) levels.	0
These findings support the notion that @CHEMICAL$ shortage-induced apoptosis, specific of @GENE$-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
These findings support the notion that @CHEMICAL$ shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of @GENE$ signaling that leads to mitochondrial complex I decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
These findings support the notion that @CHEMICAL$ shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to @GENE$ decrease, reduction of ATP formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
These findings support the notion that glucose shortage-induced apoptosis, specific of @GENE$-transformed cells, is associated to a derangement of PKA signaling that leads to mitochondrial complex I decrease, reduction of @CHEMICAL$ formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of @GENE$ signaling that leads to mitochondrial complex I decrease, reduction of @CHEMICAL$ formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
These findings support the notion that glucose shortage-induced apoptosis, specific of K-ras-transformed cells, is associated to a derangement of PKA signaling that leads to @GENE$ decrease, reduction of @CHEMICAL$ formation, prevalence of mitochondrial fission over fusion, and thereby opening new approaches for development of anticancer drugs.	0
@CHEMICAL$ inhibits myofibroblast differentiation in nasal polyp-derived fibroblasts via the @GENE$ pathway.	0
NPDFs were pre-treated with @CHEMICAL$ prior to induction by @GENE$.	0
In @GENE$-induced NPDFs, @CHEMICAL$ significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and collagen protein levels.	2
In TGF-β1-induced NPDFs, @CHEMICAL$ significantly inhibited the expression of @GENE$ and collagen type I mRNA and reduced α-SMA and collagen protein levels.	2
In TGF-β1-induced NPDFs, @CHEMICAL$ significantly inhibited the expression of α-SMA and @GENE$ mRNA and reduced α-SMA and collagen protein levels.	2
In TGF-β1-induced NPDFs, @CHEMICAL$ significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced @GENE$ and collagen protein levels.	2
In TGF-β1-induced NPDFs, @CHEMICAL$ significantly inhibited the expression of α-SMA and collagen type I mRNA and reduced α-SMA and @GENE$ protein levels.	2
@CHEMICAL$ only suppressed the expression of @GENE$ among the evaluated signaling molecules.	2
@CHEMICAL$ (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of @GENE$ and α-SMA in TGF-β1-induced NPDFs.	2
@CHEMICAL$ (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and @GENE$ in TGF-β1-induced NPDFs.	2
@CHEMICAL$ (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and α-SMA in @GENE$-induced NPDFs.	2
@CHEMICAL$ (a specific inhibitor of @GENE$ kinase) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs.	2
@CHEMICAL$ (a specific inhibitor of p38 @GENE$) markedly suppressed the increased expression of collagen type I and α-SMA in TGF-β1-induced NPDFs.	2
@CHEMICAL$ exerts suppressive effects on phenotype changes and ECM production in NPDFs via @GENE$ signaling pathway interference.	0
@GENE$ is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and @CHEMICAL$.	0
@GENE$ is a direct protein target for immunomodulatory and antiproliferative activities of @CHEMICAL$ and pomalidomide.	0
The ubiquitously expressed E3 ligase protein @GENE$ (CRBN) has been identified as the primary teratogenic target of @CHEMICAL$.	0
The ubiquitously expressed E3 ligase protein cereblon (@GENE$) has been identified as the primary teratogenic target of @CHEMICAL$.	0
Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, @CHEMICAL$, bound endogenous @GENE$ and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, @CHEMICAL$, bound endogenous CRBN and recombinant @GENE$-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, @CHEMICAL$, bound endogenous CRBN and recombinant CRBN-@GENE$ (DDB1) complexes.	0
Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, @CHEMICAL$, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (@GENE$) complexes.	0
Our studies demonstrate that @CHEMICAL$, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous @GENE$ and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that @CHEMICAL$, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant @GENE$-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that @CHEMICAL$, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-@GENE$ (DDB1) complexes.	0
Our studies demonstrate that @CHEMICAL$, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (@GENE$) complexes.	0
Our studies demonstrate that thalidomide, @CHEMICAL$ and another immunomodulatory drug, pomalidomide, bound endogenous @GENE$ and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that thalidomide, @CHEMICAL$ and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant @GENE$-DNA damage binding protein-1 (DDB1) complexes.	0
Our studies demonstrate that thalidomide, @CHEMICAL$ and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-@GENE$ (DDB1) complexes.	0
Our studies demonstrate that thalidomide, @CHEMICAL$ and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (@GENE$) complexes.	0
@GENE$ mediated antiproliferative activities of @CHEMICAL$ and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells.	0
CRBN mediated antiproliferative activities of @CHEMICAL$ and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced @GENE$ production in T cells.	0
@GENE$ mediated antiproliferative activities of lenalidomide and @CHEMICAL$ in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells.	0
CRBN mediated antiproliferative activities of lenalidomide and @CHEMICAL$ in myeloma cells, as well as lenalidomide- and pomalidomide-induced @GENE$ production in T cells.	0
@GENE$ mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as @CHEMICAL$- and pomalidomide-induced cytokine production in T cells.	0
CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as @CHEMICAL$- and pomalidomide-induced @GENE$ production in T cells.	1
@GENE$ mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and @CHEMICAL$-induced cytokine production in T cells.	0
CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and @CHEMICAL$-induced @GENE$ production in T cells.	1
@CHEMICAL$ and pomalidomide inhibited autoubiquitination of @GENE$ in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).	2
@CHEMICAL$ and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type @GENE$, but not thalidomide-binding defective CRBN(YW/AA).	2
@CHEMICAL$ and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective @GENE$(YW/AA).	0
Lenalidomide and @CHEMICAL$ inhibited autoubiquitination of @GENE$ in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).	2
Lenalidomide and @CHEMICAL$ inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type @GENE$, but not thalidomide-binding defective CRBN(YW/AA).	2
Lenalidomide and @CHEMICAL$ inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective @GENE$(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of @GENE$ in HEK293T cells expressing @CHEMICAL$-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing @CHEMICAL$-binding competent wild-type @GENE$, but not thalidomide-binding defective CRBN(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing @CHEMICAL$-binding competent wild-type CRBN, but not thalidomide-binding defective @GENE$(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of @GENE$ in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not @CHEMICAL$-binding defective CRBN(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type @GENE$, but not @CHEMICAL$-binding defective CRBN(YW/AA).	0
Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not @CHEMICAL$-binding defective @GENE$(YW/AA).	0
Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in c-myc and IRF4 expression and increases in p21(@GENE$) expression.	1
Overexpression of @GENE$ wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression.	0
Overexpression of CRBN wild-type protein, but not @GENE$(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression.	0
Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in @GENE$ and IRF4 expression and increases in p21(WAF-1) expression.	2
Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in c-myc and @GENE$ expression and increases in p21(WAF-1) expression.	2
Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified @CHEMICAL$-mediated reductions in c-myc and IRF4 expression and increases in @GENE$(WAF-1) expression.	1
Long-term selection for @CHEMICAL$ resistance in H929 myeloma cell lines was accompanied by a reduction in @GENE$, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.	2
Long-term selection for @CHEMICAL$ resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, @GENE$ protein was undetectable.	0
Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in @GENE$, while in DF15R myeloma cells resistant to both @CHEMICAL$ and lenalidomide, CRBN protein was undetectable.	0
Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both @CHEMICAL$ and lenalidomide, @GENE$ protein was undetectable.	0
Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in @GENE$, while in DF15R myeloma cells resistant to both pomalidomide and @CHEMICAL$, CRBN protein was undetectable.	0
Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and @CHEMICAL$, @GENE$ protein was undetectable.	0
Our biophysical, biochemical and gene silencing studies show that @GENE$ is a proximate, therapeutically important molecular target of @CHEMICAL$ and pomalidomide.	0
Our biophysical, biochemical and gene silencing studies show that @GENE$ is a proximate, therapeutically important molecular target of lenalidomide and @CHEMICAL$.	0
Therefore, we studied whether GLT had potential for inhibition or induction of @GENE$ (CYP) and an influence on the action of @CHEMICAL$.	0
Therefore, we studied whether GLT had potential for inhibition or induction of cytochrome P450 (@GENE$) and an influence on the action of @CHEMICAL$.	0
These @CHEMICAL$, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed @GENE$.	2
In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of @GENE$ activities and of @CHEMICAL$ 1'-hydroxylation than grapefruit juice.	0
@CHEMICAL$ is an oral @GENE$ inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.	2
@CHEMICAL$ is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the @GENE$ fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.	2
@CHEMICAL$ is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing @GENE$.	0
Crizotinib is an oral @CHEM-GENE$ inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.	0
Crizotinib is an oral @CHEMICAL$ kinase inhibitor (TKI), which silences the protein product of the @GENE$ fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.	0
Crizotinib is an oral @CHEMICAL$ kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing @GENE$.	0
Emerging data suggest that @CHEMICAL$ may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the @GENE$ oncogene, or translocation of the ROS1 oncogene.	0
Emerging data suggest that @CHEMICAL$ may also have activity in other subsets of lung cancer, including tumors demonstrating amplification or mutation of the MET oncogene, or translocation of the @GENE$ oncogene.	0
@CHEMICAL$ has demonstrated efficacy against @GENE$-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.	0
To clarify if the behavioral interaction between @CHEMICAL$ and @GENE$ reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.	0
To clarify if the behavioral interaction between ethanol and @CHEM-GENE$ reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v.	0
@CHEM-GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	0
@GENE$ agonists, @CHEMICAL$ (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	3
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (@CHEMICAL$), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	3
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), @CHEMICAL$, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	3
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, @CHEMICAL$, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	3
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, @CHEMICAL$ and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.	4
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and @CHEMICAL$ as well as enprofylline on ethanol-(i.p.	4
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as @CHEMICAL$ on ethanol-(i.p.	4
@GENE$ agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on @CHEMICAL$-(i.p.	0
@CHEM-GENE$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
@CHEMICAL$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @GENE$ modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
@CHEMICAL$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which @GENE$ agonists and antagonists were given i.p.	0
@GENE$ agonists and antagonists dose dependently accentuated and attenuated, respectively, @CHEMICAL$-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, @CHEMICAL$-induced motor incoordination, thereby suggesting a central mechanism of @GENE$ modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, @CHEMICAL$-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which @GENE$ agonists and antagonists were given i.p.	0
@GENE$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @CHEMICAL$ modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @CHEM-GENE$ modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @CHEMICAL$ modulation of this effect of ethanol and confirmed our previous reports in which @GENE$ agonists and antagonists were given i.p.	0
@GENE$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of @CHEMICAL$ and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @GENE$ modulation of this effect of @CHEMICAL$ and confirmed our previous reports in which adenosine agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of @CHEMICAL$ and confirmed our previous reports in which @GENE$ agonists and antagonists were given i.p.	0
@GENE$ agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which @CHEMICAL$ agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of @GENE$ modulation of this effect of ethanol and confirmed our previous reports in which @CHEMICAL$ agonists and antagonists were given i.p.	0
Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which @CHEM-GENE$ agonists and antagonists were given i.p.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@CHEM-GENE$ interactions.	0
Enprofylline, a weak @GENE$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@CHEMICAL$ interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of @GENE$, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@CHEMICAL$ interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain @GENE$ mechanism(s) in ethanol-@CHEMICAL$ interactions.	0
@CHEMICAL$, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@GENE$ interactions.	0
@CHEMICAL$, a weak @GENE$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	4
@CHEMICAL$, a weak adenosine antagonist but potent inhibitor of @GENE$, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	2
@CHEMICAL$, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain @GENE$ mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak @CHEMICAL$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@GENE$ interactions.	0
Enprofylline, a weak @CHEM-GENE$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak @CHEMICAL$ antagonist but potent inhibitor of @GENE$, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak @CHEMICAL$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain @GENE$ mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of @CHEMICAL$ phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-@GENE$ interactions.	0
Enprofylline, a weak @GENE$ antagonist but potent inhibitor of @CHEMICAL$ phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of @CHEM-GENE$, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of @CHEMICAL$ phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain @GENE$ mechanism(s) in ethanol-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in @CHEMICAL$-@GENE$ interactions.	0
Enprofylline, a weak @GENE$ antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in @CHEMICAL$-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of @GENE$, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in @CHEMICAL$-adenosine interactions.	0
Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain @GENE$ mechanism(s) in @CHEMICAL$-adenosine interactions.	0
Results from R-PIA and @CHEMICAL$ experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of @GENE$ subtype.	0
Results from R-PIA and N6-(S-phenylisopropyl)adenosine experiments showed nearly a 40-fold greater potency of R-vs. S-diastereoisomer, suggesting predominance of @CHEM-GENE$ subtype.	0
However, @CHEMICAL$ data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of @GENE$.	0
However, 5'-(N-cyclopropyl)-carboxamidoadenosine data indicate complexity of the mechanism(s) and point toward an additional involvement of a yet unknown subtype of @CHEM-GENE$.	0
No effect of ethanol on blood or brain levels of @CHEMICAL$ was noted and sufficient amount of the latter entered the brain to suggest @GENE$ activation adequate to produce behavioral interaction with ethanol.	0
No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest @CHEM-GENE$ activation adequate to produce behavioral interaction with ethanol.	0
No effect of ethanol on blood or brain levels of [3H]R-PIA was noted and sufficient amount of the latter entered the brain to suggest @GENE$ activation adequate to produce behavioral interaction with @CHEMICAL$.	0
There was no escape of i.c.v.-administered [3H]R-PIA from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of @CHEMICAL$-@GENE$ interaction.	0
There was no escape of i.c.v.-administered [3H]R-PIA from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of ethanol-@CHEM-GENE$ interaction.	0
There was no escape of i.c.v.-administered @CHEMICAL$ from brain to the peripheral circulation ruling out a peripheral and supporting a central mechanism of ethanol-@GENE$ interaction.	0
@CHEMICAL$, a @GENE$ inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased @GENE$-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of @GENE$ and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and @GENE$, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, @GENE$- and tumor necrosis factor-alpha (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and @GENE$ (TNF-α)-induced NF-κB reporter gene activity.	2
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (@GENE$)-induced NF-κB reporter gene activity.	0
@CHEMICAL$, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-β1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-β1- and tumor necrosis factor-alpha (TNF-α)-induced @GENE$ reporter gene activity.	2
@CHEMICAL$ also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and @GENE$ markers of apoptosis.	1
@CHEMICAL$ highlights the therapeutic potential of agents targeting @GENE$ as a key node in this pro-oncogenic TGF-β-NF-κB signal pathway.	2
@CHEMICAL$ highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic @GENE$-NF-κB signal pathway.	0
@CHEMICAL$ highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-β-@GENE$ signal pathway.	0
The atypical antidepressant @CHEMICAL$ exhibits agonist activity at @GENE$.	3
We previously reported that @CHEMICAL$ antidepressants act as agonists at distinct @GENE$.	3
Here, we investigated the effect of the atypical antidepressant @CHEMICAL$ at cloned and native @GENE$.	0
EXPERIMENTAL APPROACH: Effects of @CHEMICAL$ were examined in CHO cells transfected with @GENE$, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and MAPK phosphorylation.	0
EXPERIMENTAL APPROACH: Effects of @CHEMICAL$ were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPgammaS binding and @GENE$ phosphorylation.	0
EXPERIMENTAL APPROACH: Effects of mianserin were examined in CHO cells transfected with @GENE$, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of @CHEMICAL$ binding and MAPK phosphorylation.	0
EXPERIMENTAL APPROACH: Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of @CHEMICAL$ binding and @GENE$ phosphorylation.	0
KEY RESULTS: @CHEMICAL$ displayed 12- and 18-fold higher affinity for @GENE$ respectively.	0
In @CHEMICAL$ assays, mianserin selectively activated @GENE$.	0
In [(35)S]GTPgammaS assays, @CHEMICAL$ selectively activated @GENE$.	1
The agonist activity was antagonized by the selective @GENE$ blocker @CHEMICAL$ (nor-BNI).	4
The agonist activity was antagonized by the selective @GENE$ blocker nor-binaltorphimine (@CHEMICAL$).	4
The @CHEMICAL$ analogue mirtazapine also displayed @GENE$ agonist activity.	3
The mianserin analogue @CHEMICAL$ also displayed @GENE$ agonist activity.	3
@CHEMICAL$ and mirtazapine increased @GENE$ phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI.	0
@CHEMICAL$ and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing @GENE$ and C6 cells, and these effects were antagonized by nor-BNI.	0
Mianserin and @CHEMICAL$ increased @GENE$ phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI.	0
Mianserin and @CHEMICAL$ increased ERK1/2 phosphorylation in CHO cells expressing @GENE$ and C6 cells, and these effects were antagonized by nor-BNI.	0
Mianserin and mirtazapine increased @GENE$ phosphorylation in CHO cells expressing kappa-opioid receptors and C6 cells, and these effects were antagonized by @CHEMICAL$.	0
Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing @GENE$ and C6 cells, and these effects were antagonized by @CHEMICAL$.	0
In rat striatum and nucleus accumbens, @CHEMICAL$ stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full @GENE$ agonists (-)-U50,488 and dynorphin A.	0
In rat striatum and nucleus accumbens, @CHEMICAL$ stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and @GENE$.	0
In rat striatum and nucleus accumbens, mianserin stimulated @CHEMICAL$ binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full @GENE$ agonists (-)-U50,488 and dynorphin A.	0
In rat striatum and nucleus accumbens, mianserin stimulated @CHEMICAL$ binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and @GENE$.	0
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a @CHEMICAL$-sensitive manner with maximal effects lower than those of the full @GENE$ agonists (-)-U50,488 and dynorphin A.	0
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a @CHEMICAL$-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and @GENE$.	0
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full @GENE$ agonists @CHEMICAL$ and dynorphin A.	3
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists @CHEMICAL$ and @GENE$.	0
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full @GENE$ agonists (-)-U50,488 and @CHEMICAL$.	3
In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and @CHEM-GENE$.	0
When combined, mianserin antagonized the effects of the full @GENE$ agonists in @CHEMICAL$ assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in @CHEMICAL$ assays and reduced the stimulation of @GENE$ MAPK and ERK1/2 phosphorylation by dynorphin A.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in @CHEMICAL$ assays and reduced the stimulation of p38 @GENE$ and ERK1/2 phosphorylation by dynorphin A.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in @CHEMICAL$ assays and reduced the stimulation of p38 MAPK and @GENE$ phosphorylation by dynorphin A.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in @CHEMICAL$ assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by @GENE$.	0
When combined, mianserin antagonized the effects of the full @GENE$ agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by @CHEMICAL$.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of @GENE$ MAPK and ERK1/2 phosphorylation by @CHEMICAL$.	1
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 @GENE$ and ERK1/2 phosphorylation by @CHEMICAL$.	1
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and @GENE$ phosphorylation by @CHEMICAL$.	0
When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by @CHEM-GENE$.	0
When combined, @CHEMICAL$ antagonized the effects of the full @GENE$ agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A.	4
When combined, @CHEMICAL$ antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of @GENE$ MAPK and ERK1/2 phosphorylation by dynorphin A.	2
When combined, @CHEMICAL$ antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 @GENE$ and ERK1/2 phosphorylation by dynorphin A.	2
When combined, @CHEMICAL$ antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and @GENE$ phosphorylation by dynorphin A.	0
When combined, @CHEMICAL$ antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by @GENE$.	0
CONCLUSIONS AND IMPLICATIONS: In different cell systems, @CHEMICAL$ directly activates @GENE$, displaying partial agonist activity at brain receptors.	3
7-Dehydrocholesterol (7-DHC) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding @CHEM-GENE$ (DHCR7).	0
7-Dehydrocholesterol (7-DHC) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding @CHEMICAL$-Δ(7)-reductase (@GENE$).	0
7-Dehydrocholesterol (@CHEMICAL$) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding @GENE$ (DHCR7).	0
7-Dehydrocholesterol (@CHEMICAL$) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding 3β-hydroxysterol-Δ(7)-reductase (@GENE$).	0
@CHEMICAL$ (7-DHC) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding @GENE$ (DHCR7).	0
@CHEMICAL$ (7-DHC) accumulates in tissues and fluids of patients with Smith-Lemli-Opitz syndrome (SLOS), which is caused by mutations in the gene encoding 3β-hydroxysterol-Δ(7)-reductase (@GENE$).	0
As the high oxidizability of @CHEMICAL$ may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including @CHEMICAL$, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, @CHEMICAL$ (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (@CHEMICAL$), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and @CHEMICAL$ (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (@CHEMICAL$) that are formed from the oxidation of 7-DHC, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of @CHEMICAL$, arachidonic acid and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, @CHEMICAL$ and docosahexaenoic acid, respectively.	0
As the high oxidizability of 7-DHC may lead to systemic oxidative stress in SLOS patients, we report here lipid biomarkers of oxidative stress in a @GENE$-KO mouse model of SLOS, including oxysterols, isoprostanes (IsoPs), and neuroprostanes (NeuroPs) that are formed from the oxidation of 7-DHC, arachidonic acid and @CHEMICAL$, respectively.	0
In addition to a previously described @CHEMICAL$, 3β,5α-dihydroxycholest-7-en-6-one (DHCEO), we provide evidence for the chemical structures of three new oxysterols in the brain and/or liver tissue of @GENE$-KO mice, two of which were quantified.	0
In addition to a previously described oxysterol, @CHEMICAL$ (DHCEO), we provide evidence for the chemical structures of three new oxysterols in the brain and/or liver tissue of @GENE$-KO mice, two of which were quantified.	0
In addition to a previously described oxysterol, 3β,5α-dihydroxycholest-7-en-6-one (@CHEMICAL$), we provide evidence for the chemical structures of three new oxysterols in the brain and/or liver tissue of @GENE$-KO mice, two of which were quantified.	0
In addition to a previously described oxysterol, 3β,5α-dihydroxycholest-7-en-6-one (DHCEO), we provide evidence for the chemical structures of three new @CHEMICAL$ in the brain and/or liver tissue of @GENE$-KO mice, two of which were quantified.	0
We find that levels of @CHEMICAL$ and NeuroPs are also elevated in brain and/or liver tissues of @GENE$-KO mice relative to matching WT mice.	0
We find that levels of IsoPs and @CHEMICAL$ are also elevated in brain and/or liver tissues of @GENE$-KO mice relative to matching WT mice.	0
Urinary Smad1, fasting plasma @CHEMICAL$ (FPG), fasting serum C-Peptide (C-P), hemoglobin A1C (@GENE$), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
Urinary Smad1, fasting plasma @CHEMICAL$ (FPG), fasting serum C-Peptide (C-P), hemoglobin A1C (HbA1c), @GENE$, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
Urinary @GENE$, fasting plasma @CHEMICAL$ (FPG), fasting serum C-Peptide (C-P), hemoglobin A1C (HbA1c), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
Urinary Smad1, fasting plasma @CHEMICAL$ (FPG), fasting serum @GENE$ (C-P), hemoglobin A1C (HbA1c), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
Urinary Smad1, fasting plasma @CHEMICAL$ (FPG), fasting serum C-Peptide (@GENE$), hemoglobin A1C (HbA1c), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
Urinary Smad1, fasting plasma @CHEMICAL$ (FPG), fasting serum C-Peptide (C-P), @GENE$ (HbA1c), cystatin C, and other chemistry laboratory parameters of T2DM participants and controls were measured.	0
@CHEMICAL$ restores cognitive deficits and improves @GENE$ and Tau pathologies in a senescence-accelerated mouse model.	0
@CHEMICAL$ restores cognitive deficits and improves amyloid and @GENE$ pathologies in a senescence-accelerated mouse model.	0
In the present study we tested whether @CHEMICAL$, a @GENE$ antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).	4
@GENE$ hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of @CHEMICAL$-treated mice, an effect probably related to a decrease in JNK1 expression.	0
Tau hyperphosphorylation (PHF-1 epitope) shown by SAMP8 mice at this age was also decreased in the hippocampus of @CHEMICAL$-treated mice, an effect probably related to a decrease in @GENE$ expression.	0
Interestingly, @CHEMICAL$ also phosphorylated @GENE$ in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3β phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation.	0
Interestingly, @CHEMICAL$ also phosphorylated Akt in SAMP8 mice, which was associated with an increase of @GENE$ phosphorylation, contributing therefore to the reductions in Tau hyperphosphorylation.	0
Interestingly, @CHEMICAL$ also phosphorylated Akt in SAMP8 mice, which was associated with an increase of glycogen synthase kinase-3β phosphorylation, contributing therefore to the reductions in @GENE$ hyperphosphorylation.	0
Synaptic pathology in SAMP8 mice, as shown by decreases in @GENE$ and BDNF, was also counteracted by @CHEMICAL$ treatment.	0
Synaptic pathology in SAMP8 mice, as shown by decreases in synaptophysin and @GENE$, was also counteracted by @CHEMICAL$ treatment.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in @GENE$ (TCF7L2) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (@GENE$) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of @GENE$, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, @GENE$, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @CHEM-GENE$ (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (@GENE$), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), @GENE$ (GLP-1) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (@GENE$) as well as insulin sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @CHEMICAL$-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as @GENE$ sensitivity and endogenous glucose production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in @GENE$ (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (@GENE$) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of @GENE$, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, @GENE$, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, @GENE$ (GIP), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (@GENE$), glucagon-like peptide-1 (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), @GENE$ (GLP-1) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (@GENE$) as well as insulin sensitivity and endogenous @CHEMICAL$ production.	0
We characterised 62 non-diabetic, middle-aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7-like 2 (TCF7L2) with regard to secretion of insulin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) as well as @GENE$ sensitivity and endogenous @CHEMICAL$ production.	0
We found no significant differences in endogenous @CHEMICAL$ production, hepatic @GENE$ sensitivity or fasting concentrations of glucose, insulin, glucagon and GLP-1 between the groups.	0
We found no significant differences in endogenous @CHEMICAL$ production, hepatic insulin sensitivity or fasting concentrations of glucose, @GENE$, glucagon and GLP-1 between the groups.	0
We found no significant differences in endogenous @CHEMICAL$ production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, @GENE$ and GLP-1 between the groups.	0
We found no significant differences in endogenous @CHEMICAL$ production, hepatic insulin sensitivity or fasting concentrations of glucose, insulin, glucagon and @GENE$ between the groups.	0
We found no significant differences in endogenous glucose production, hepatic @GENE$ sensitivity or fasting concentrations of @CHEMICAL$, insulin, glucagon and GLP-1 between the groups.	0
We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of @CHEMICAL$, @GENE$, glucagon and GLP-1 between the groups.	0
We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of @CHEMICAL$, insulin, @GENE$ and GLP-1 between the groups.	0
We found no significant differences in endogenous glucose production, hepatic insulin sensitivity or fasting concentrations of @CHEMICAL$, insulin, glucagon and @GENE$ between the groups.	0
Effect of @CHEMICAL$ on lipid peroxidation, @GENE$(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of @CHEMICAL$ on lipid peroxidation, heme oxygenase 1(@GENE$), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of @CHEMICAL$ on lipid peroxidation, heme oxygenase 1(HO-1), @GENE$ (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of @CHEMICAL$ on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (@GENE$), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of @CHEMICAL$ on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), @GENE$ (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of @CHEMICAL$ on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (@GENE$), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEM-GENE$(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEMICAL$ oxygenase 1(@GENE$), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEMICAL$ oxygenase 1(HO-1), @GENE$ (COX), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEMICAL$ oxygenase 1(HO-1), cyclooxygenase (@GENE$), interleukin 5 (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEMICAL$ oxygenase 1(HO-1), cyclooxygenase (COX), @GENE$ (IL-5), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @CHEMICAL$ oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (@GENE$), nitric oxide (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @GENE$(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(@GENE$), cyclooxygenase (COX), interleukin 5 (IL-5), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), @GENE$ (COX), interleukin 5 (IL-5), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (@GENE$), interleukin 5 (IL-5), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), @GENE$ (IL-5), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (@GENE$), @CHEMICAL$ (NO) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, @GENE$(HO-1), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(@GENE$), cyclooxygenase (COX), interleukin 5 (IL-5), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), @GENE$ (COX), interleukin 5 (IL-5), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (@GENE$), interleukin 5 (IL-5), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), @GENE$ (IL-5), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
Effect of chalcones on lipid peroxidation, heme oxygenase 1(HO-1), cyclooxygenase (COX), interleukin 5 (@GENE$), nitric oxide (@CHEMICAL$) and expression of cell adhesion molecules (CAM) is summarized stepwise.	0
@CHEMICAL$ generation and @GENE$-dependent reverse cholesterol transport: not all roads lead to Rome.	0
Oxysterol generation and @GENE$-dependent reverse @CHEMICAL$ transport: not all roads lead to Rome.	0
Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (@GENE$) to increase expression of genes mediating removal of excess @CHEMICAL$ from cells in the reverse cholesterol transport pathway.	0
Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of @GENE$ (LXRs) to increase expression of genes mediating removal of excess @CHEMICAL$ from cells in the reverse cholesterol transport pathway.	0
Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (@GENE$) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse @CHEMICAL$ transport pathway.	0
Cell cholesterol metabolism is a tightly regulated process, dependent in part on activation of @GENE$ (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse @CHEMICAL$ transport pathway.	0
Cell @CHEMICAL$ metabolism is a tightly regulated process, dependent in part on activation of nuclear liver X receptors (@GENE$) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway.	0
Cell @CHEMICAL$ metabolism is a tightly regulated process, dependent in part on activation of @GENE$ (LXRs) to increase expression of genes mediating removal of excess cholesterol from cells in the reverse cholesterol transport pathway.	0
@GENE$ are thought to be activated predominantly by @CHEMICAL$ generated enzymatically from cholesterol in different cell organelles.	1
@GENE$ are thought to be activated predominantly by oxysterols generated enzymatically from @CHEMICAL$ in different cell organelles.	0
Defects resulting in slowed release of @CHEMICAL$ from late endosomes and lysosomes or reduction in @GENE$ activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation.	0
Defects resulting in slowed release of @CHEMICAL$ from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired @GENE$-dependent gene activation.	0
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in @CHEM-GENE$ activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation.	0
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in @CHEMICAL$-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired @GENE$-dependent gene activation.	0
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in @GENE$ activity lead to specific blocks in @CHEMICAL$ production and impaired LXR-dependent gene activation.	5
Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in @CHEMICAL$ production and impaired @GENE$-dependent gene activation.	0
The purpose of this review is to summarize current knowledge about @CHEMICAL$-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of @GENE$-dependent genes.	0
The purpose of this review is to summarize current knowledge about @CHEMICAL$-dependent activation by @GENE$ of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.	1
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse @CHEMICAL$ transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of @GENE$-dependent genes.	0
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by @GENE$ of genes involved in reverse @CHEMICAL$ transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.	0
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell @CHEMICAL$ homeostasis can teach us about the critical pathways of oxysterol generation for expression of @GENE$-dependent genes.	0
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by @GENE$ of genes involved in reverse cholesterol transport, and what these defects of cell @CHEMICAL$ homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.	0
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of @CHEMICAL$ generation for expression of @GENE$-dependent genes.	0
The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by @GENE$ of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of @CHEMICAL$ generation for expression of LXR-dependent genes.	0
@CHEMICAL$ makes multiple adducts on free histidine, but does not form an adduct on histidine 438 of @GENE$.	0
Cresyl saligenin phosphate makes multiple adducts on free histidine, but does not form an adduct on @CHEMICAL$ 438 of @GENE$.	0
Cresyl saligenin phosphate makes multiple adducts on free @CHEMICAL$, but does not form an adduct on histidine 438 of @GENE$.	0
@CHEMICAL$ irreversibly inhibits @GENE$ (BChE) in human plasma by forming adducts on the active site serine (Ser-198).	2
@CHEMICAL$ irreversibly inhibits butyrylcholinesterase (@GENE$) in human plasma by forming adducts on the active site serine (Ser-198).	2
CBDP irreversibly inhibits @GENE$ (BChE) in human plasma by forming adducts on the active site @CHEMICAL$ (Ser-198).	0
CBDP irreversibly inhibits butyrylcholinesterase (@GENE$) in human plasma by forming adducts on the active site @CHEMICAL$ (Ser-198).	0
CBDP irreversibly inhibits @GENE$ (BChE) in human plasma by forming adducts on the active site serine (@CHEMICAL$-198).	0
CBDP irreversibly inhibits butyrylcholinesterase (@GENE$) in human plasma by forming adducts on the active site serine (@CHEMICAL$-198).	0
Inhibited @GENE$ undergoes aging to release @CHEMICAL$ and o-cresol.	0
Inhibited @GENE$ undergoes aging to release saligenin and @CHEMICAL$.	0
Mass spectral analysis of @CHEMICAL$-inhibited @GENE$ digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.	2
Mass spectral analysis of CBDP-inhibited @GENE$ digested with @CHEMICAL$-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.	0
Mass spectral analysis of CBDP-inhibited @GENE$ digested with Glu-C showed an @CHEMICAL$ adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.	0
Mass spectral analysis of CBDP-inhibited @GENE$ digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on @CHEMICAL$ 499, a residue far from the active site, but not on His-438.	0
Mass spectral analysis of CBDP-inhibited @GENE$ digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on @CHEMICAL$-438.	0
@CHEMICAL$ deficiency impairs the @GENE$-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.	0
@CHEMICAL$ deficiency impairs the somatostatinergic receptor-effector system and leads to @GENE$ overactivation and cell death in the rat hippocampus.	0
Vitamin E deficiency impairs the @GENE$-effector system and leads to @CHEMICAL$ phosphatase overactivation and cell death in the rat hippocampus.	0
Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to @CHEM-GENE$ overactivation and cell death in the rat hippocampus.	0
We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by @CHEMICAL$ in the rat dentate gyrus, increasing @GENE$ phosphorylation.	1
We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by α-tocopherol in the rat dentate gyrus, increasing @CHEM-GENE$ phosphorylation.	0
To gain a better understanding of the molecular actions of @CHEMICAL$ and examine the link among vitamin E, @GENE$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of @CHEMICAL$ and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the @GENE$ signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among @CHEMICAL$, @GENE$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among @CHEMICAL$, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the @GENE$ signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, @CHEM-GENE$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the somatostatin signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, @CHEMICAL$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the @GENE$ signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, @GENE$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of @CHEMICAL$ on the somatostatin signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of @CHEMICAL$ on the @GENE$ signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, @GENE$ and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the @CHEMICAL$ signaling pathway and neuronal survival in the rat hippocampus.	0
To gain a better understanding of the molecular actions of tocopherols and examine the link among vitamin E, somatostatin and neuronal survival, we have investigated the effects of a deficiency and subsequent administration of tocopherol on the @CHEM-GENE$ signaling pathway and neuronal survival in the rat hippocampus.	0
No changes in @CHEM-GENE$ expression were detected in vitamin-E-deficient rats.	0
No changes in @GENE$ expression were detected in @CHEMICAL$-deficient rats.	0
These rats, however, showed a significant increase in the @CHEMICAL$ receptor density and dissociation constant, which correlated with a significant increase in the protein levels of @GENE$.	0
These rats, however, showed a significant increase in the @CHEM-GENE$ density and dissociation constant, which correlated with a significant increase in the protein levels of somatostatin receptors.	0
These rats, however, showed a significant increase in the somatostatin receptor density and dissociation constant, which correlated with a significant increase in the protein levels of @CHEM-GENE$.	0
These rats, however, showed a significant increase in the @GENE$ density and dissociation constant, which correlated with a significant increase in the protein levels of @CHEMICAL$ receptors.	0
Nevertheless, @CHEMICAL$ deficiency impaired the ability of the @GENE$ to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality.	0
Nevertheless, @CHEMICAL$ deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and @GENE$ by diminishing Gi protein functionality.	0
Nevertheless, @CHEMICAL$ deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing @GENE$ functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the @CHEM-GENE$ to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the @CHEMICAL$ receptors to couple to the effectors adenylyl cyclase and @GENE$ by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the @CHEMICAL$ receptors to couple to the effectors adenylyl cyclase and phosphotyrosine phosphatase by diminishing @GENE$ functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the @GENE$ to couple to the effectors @CHEMICAL$ cyclase and phosphotyrosine phosphatase by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors @CHEMICAL$ cyclase and @GENE$ by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors @CHEMICAL$ cyclase and phosphotyrosine phosphatase by diminishing @GENE$ functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the @GENE$ to couple to the effectors adenylyl cyclase and @CHEMICAL$ phosphatase by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and @CHEM-GENE$ by diminishing Gi protein functionality.	0
Nevertheless, vitamin E deficiency impaired the ability of the somatostatin receptors to couple to the effectors adenylyl cyclase and @CHEMICAL$ phosphatase by diminishing @GENE$ functionality.	0
Furthermore, @CHEMICAL$ deficiency significantly increased @GENE$ activity and PTPη expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, @CHEMICAL$ deficiency significantly increased phosphotyrosine phosphatase activity and @GENE$ expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, @CHEMICAL$ deficiency significantly increased phosphotyrosine phosphatase activity and PTPη expression, as well as @GENE$ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, @CHEMICAL$ deficiency significantly increased phosphotyrosine phosphatase activity and PTPη expression, as well as PKCδ activation, and decreased @GENE$ phosphorylation.	0
Furthermore, vitamin E deficiency significantly increased @CHEM-GENE$ activity and PTPη expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, vitamin E deficiency significantly increased @CHEMICAL$ phosphatase activity and @GENE$ expression, as well as PKCδ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, vitamin E deficiency significantly increased @CHEMICAL$ phosphatase activity and PTPη expression, as well as @GENE$ activation, and decreased extracellular-signal-regulated kinase phosphorylation.	0
Furthermore, vitamin E deficiency significantly increased @CHEMICAL$ phosphatase activity and PTPη expression, as well as PKCδ activation, and decreased @GENE$ phosphorylation.	0
Altogether, our results prove the importance of @CHEMICAL$ homeostasis in the @GENE$-effector system and suggest a possible mechanism by which this vitamin may regulate the neuronal cell survival in the adult hippocampus.	0
Altogether, our results prove the importance of vitamin E homeostasis in the @CHEM-GENE$-effector system and suggest a possible mechanism by which this vitamin may regulate the neuronal cell survival in the adult hippocampus.	0
@GENE$ sensitizes to @CHEMICAL$ by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.	0
CCAAT/Enhancer-binding protein-homologous protein sensitizes to @CHEMICAL$ by modulating @GENE$ and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.	0
CCAAT/Enhancer-binding protein-homologous protein sensitizes to @CHEMICAL$ by modulating p21 and @GENE$/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.	0
CCAAT/Enhancer-binding protein-homologous protein sensitizes to @CHEMICAL$ by modulating p21 and PI3K/@GENE$ signal pathway in FRO anaplastic thyroid carcinoma cells.	0
In the present study, we evaluated the effects of @CHEMICAL$ on cell survival, @GENE$, and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	0
In the present study, we evaluated the effects of @CHEMICAL$ on cell survival, p21, and @GENE$/Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	0
In the present study, we evaluated the effects of @CHEMICAL$ on cell survival, p21, and PI3K/@GENE$ signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells.	0
Moreover, we investigated the roles of @GENE$ in cell survival under condition of @CHEMICAL$ treatment in FRO ATC cells.	0
After @CHEMICAL$ treatment, cell viability, @GENE$, and caspase-3 protein levels were not changed.	0
After @CHEMICAL$ treatment, cell viability, PARP-1, and @GENE$ protein levels were not changed.	0
@CHEM-GENE$ protein levels were not altered.	0
In SU5416-treated situation, cell viability was not different before and after administration of either @GENE$ siRNA or @CHEMICAL$ whereas it was lessened after co-administration of p21 siRNA and LY294002.	0
In SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or @CHEMICAL$ whereas it was lessened after co-administration of @GENE$ siRNA and LY294002.	0
In SU5416-treated situation, cell viability was not different before and after administration of either @GENE$ siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and @CHEMICAL$.	0
In SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of @GENE$ siRNA and @CHEMICAL$.	0
In @CHEMICAL$-treated situation, cell viability was not different before and after administration of either @GENE$ siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002.	0
In @CHEMICAL$-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of @GENE$ siRNA and LY294002.	0
Compared to @CHEMICAL$ treatment alone, cell viability was reduced with @GENE$ plasmid but it was unchanged with CHOP siRNA.	0
Compared to @CHEMICAL$ treatment alone, cell viability was reduced with CHOP plasmid but it was unchanged with @GENE$ siRNA.	0
While @GENE$ plasmid transfection diminished p21 and @CHEMICAL$-Akt protein levels, CHOP siRNA transfection did not alter the protein levels.	0
While CHOP plasmid transfection diminished @GENE$ and @CHEMICAL$-Akt protein levels, CHOP siRNA transfection did not alter the protein levels.	0
While CHOP plasmid transfection diminished p21 and @CHEM-GENE$ protein levels, CHOP siRNA transfection did not alter the protein levels.	0
While CHOP plasmid transfection diminished p21 and @CHEMICAL$-Akt protein levels, @GENE$ siRNA transfection did not alter the protein levels.	0
In conclusion, these results suggest that @GENE$ may sensitize FRO ATC cells to @CHEMICAL$ thereby inhibiting cell survival by modulating p21 and PI3K/Akt signal pathway.	0
In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to @CHEMICAL$ thereby inhibiting cell survival by modulating @GENE$ and PI3K/Akt signal pathway.	0
In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to @CHEMICAL$ thereby inhibiting cell survival by modulating p21 and @GENE$/Akt signal pathway.	0
In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to @CHEMICAL$ thereby inhibiting cell survival by modulating p21 and PI3K/@GENE$ signal pathway.	0
Furthermore, these findings imply that @GENE$ may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to @CHEMICAL$.	0
Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the @CHEM-GENE$, metal-responsive transcription factor-1 and the nuclear receptor family of transcription factors.	0
Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the @CHEMICAL$ receptor, @GENE$ and the nuclear receptor family of transcription factors.	0
Additionally, more specific mechanisms exist where xenobiotics act as ligands, including the @CHEMICAL$ receptor, metal-responsive transcription factor-1 and the @GENE$ family of transcription factors.	0
@CHEMICAL$ is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of @GENE$ (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	0
@CHEMICAL$ is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (@GENE$-APL) that shares many common structural elements with morphinan-based opioids.	0
@CHEMICAL$ is a reversible, competitive @GENE$ (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	2
@CHEMICAL$ is a reversible, competitive acetylcholinesterase (@GENE$) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	2
Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of @CHEM-GENE$ (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	0
Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic @CHEMICAL$ receptors (@GENE$-APL) that shares many common structural elements with morphinan-based opioids.	0
Galantamine is a reversible, competitive @GENE$ (AChE) inhibitor and allosteric potentiating ligand of nicotinic @CHEMICAL$ receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	0
Galantamine is a reversible, competitive acetylcholinesterase (@GENE$) inhibitor and allosteric potentiating ligand of nicotinic @CHEMICAL$ receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.	0
Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of @GENE$ (nAChR-APL) that shares many common structural elements with @CHEMICAL$-based opioids.	0
Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (@GENE$-APL) that shares many common structural elements with @CHEMICAL$-based opioids.	0
Galantamine is a reversible, competitive @GENE$ (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with @CHEMICAL$-based opioids.	0
Galantamine is a reversible, competitive acetylcholinesterase (@GENE$) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with @CHEMICAL$-based opioids.	0
The structurally diverse opioids @CHEMICAL$ and eseroline, like galantamine, are also @GENE$-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids @CHEMICAL$ and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for @GENE$, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids @CHEMICAL$ and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective @GENE$-APL development.	0
The structurally diverse opioids codeine and @CHEMICAL$, like galantamine, are also @GENE$-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids codeine and @CHEMICAL$, like galantamine, are also nAChR-APL that have greatly diminished affinity for @GENE$, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids codeine and @CHEMICAL$, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective @GENE$-APL development.	0
The structurally diverse opioids codeine and eseroline, like @CHEMICAL$, are also @GENE$-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids codeine and eseroline, like @CHEMICAL$, are also nAChR-APL that have greatly diminished affinity for @GENE$, representing potential lead compounds for selective nAChR-APL development.	0
The structurally diverse opioids codeine and eseroline, like @CHEMICAL$, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective @GENE$-APL development.	0
Treatment options for DUB are: combined oral contraceptives (COCs), @CHEMICAL$, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), @GENE$ analogues, Danazol and Levonorgestrel releasing intra uterine system (LNG IUS).	0
Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), @CHEMICAL$ (anti-fibrinolytic), @GENE$ analogues, Danazol and Levonorgestrel releasing intra uterine system (LNG IUS).	0
Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), @CHEM-GENE$ analogues, Danazol and Levonorgestrel releasing intra uterine system (LNG IUS).	0
Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), @GENE$ analogues, @CHEMICAL$ and Levonorgestrel releasing intra uterine system (LNG IUS).	0
Treatment options for DUB are: combined oral contraceptives (COCs), progestogens, non steroidal anti inflammatory drugs (NSAIDs), tranexamic acid (anti-fibrinolytic), @GENE$ analogues, Danazol and @CHEMICAL$ releasing intra uterine system (LNG IUS).	0
Role of oestrogen receptors on the modulation of @CHEM-GENE$-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	0
Role of @GENE$ on the modulation of @CHEMICAL$-diaphorase-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	0
Role of @CHEMICAL$ receptors on the modulation of @GENE$-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	0
Role of @CHEM-GENE$ on the modulation of NADPH-diaphorase-positive cell number in supraoptic and paraventricular nuclei of ovariectomised female rats.	0
Modulation of the nitric oxide producing system (demonstrated via the @CHEM-GENE$ histochemical reaction) by oestradiol has been established in several structures of the rat brain.	0
Modulation of the nitric oxide producing system (demonstrated via the @GENE$ histochemical reaction) by @CHEMICAL$ has been established in several structures of the rat brain.	0
Modulation of the @CHEMICAL$ producing system (demonstrated via the @GENE$ histochemical reaction) by oestradiol has been established in several structures of the rat brain.	5
The present study aimed to explore the possible regulation of @CHEM-GENE$ activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of @CHEMICAL$-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @GENE$ (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of @CHEMICAL$-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (@GENE$ and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of @CHEMICAL$-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and @GENE$) in this regulation.	0
The present study aimed to explore the possible regulation of @GENE$ activity by @CHEMICAL$ in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by @CHEMICAL$ in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @GENE$ (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by @CHEMICAL$ in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (@GENE$ and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by @CHEMICAL$ in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and @GENE$) in this regulation.	0
The present study aimed to explore the possible regulation of @GENE$ activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @CHEMICAL$ receptors (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @CHEM-GENE$ (ERα and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @CHEMICAL$ receptors (@GENE$ and ERβ) in this regulation.	0
The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of @CHEMICAL$ receptors (ERα and @GENE$) in this regulation.	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-@CHEMICAL$ [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-@CHEMICAL$ [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	3
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-@CHEMICAL$ [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-@CHEMICAL$ [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [@CHEMICAL$], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [@CHEMICAL$], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	3
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [@CHEMICAL$], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [@CHEMICAL$], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-@CHEMICAL$ [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-@CHEMICAL$ [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-@CHEMICAL$ [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	4
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-@CHEMICAL$ [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [@CHEMICAL$]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [@CHEMICAL$]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [@CHEMICAL$]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	4
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [@CHEMICAL$]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-@CHEMICAL$] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-@CHEMICAL$] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-@CHEMICAL$] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	4
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-@CHEMICAL$] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-@CHEMICAL$ (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-@CHEMICAL$ (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-@CHEMICAL$ (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-@CHEMICAL$ (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	4
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (@CHEMICAL$).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (@CHEMICAL$).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (@CHEMICAL$).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (@CHEMICAL$).	4
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of @CHEMICAL$, a selective @GENE$ agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of @CHEMICAL$, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of @CHEMICAL$, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of @CHEMICAL$, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-@CHEMICAL$ [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	3
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-@CHEMICAL$ [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-@CHEMICAL$ [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-@CHEMICAL$ [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective @GENE$ agonist-PPT [@CHEMICAL$], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	3
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [@CHEMICAL$], a selective @GENE$ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [@CHEMICAL$], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective @GENE$ antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [@CHEMICAL$], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective @GENE$ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).	0
The number of @CHEMICAL$-diaphorase positive elements in the SON and the PVN was modulated by both @GENE$ but, depending on the nucleus, ERα and ERβ ligands induced different effects.	0
The number of @CHEMICAL$-diaphorase positive elements in the SON and the PVN was modulated by both ERs but, depending on the nucleus, @GENE$ and ERβ ligands induced different effects.	0
The number of @CHEMICAL$-diaphorase positive elements in the SON and the PVN was modulated by both ERs but, depending on the nucleus, ERα and @GENE$ ligands induced different effects.	0
The number of @CHEM-GENE$ positive elements in the SON and the PVN was modulated by both ERs but, depending on the nucleus, ERα and ERβ ligands induced different effects.	0
These results suggest that the regulation of nitrergic system by @GENE$ may play a role in the control of @CHEMICAL$-dependent physiological mechanisms regulated by the SON and the PVN.	0
The residence time of a stoichiometric bioscavenger, human butyrylcholinesterase (@GENE$), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (@CHEMICAL$, anti-muscarinic, anticonvulsant).	0
The residence time of a stoichiometric bioscavenger, @GENE$ (huBuChE), in the plasma more closely matches that of VX than do the residence times of conventional therapy drugs (@CHEMICAL$, anti-muscarinic, anticonvulsant).	0
A combination of nerve agent therapy drugs (@CHEMICAL$, anti-muscarinic, anticonvulsant) with @GENE$ (i.m.)	0
@CHEMICAL$ sensitizes @GENE$-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.	0
@CHEMICAL$ sensitizes TRAIL-induced apoptosis via the upregulation of @GENE$ in an eIF2α/CHOP-dependent manner.	1
@CHEMICAL$ sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an @GENE$/CHOP-dependent manner.	1
@CHEMICAL$ sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/@GENE$-dependent manner.	1
Therefore, we examined whether @CHEMICAL$ (VA) sensitize @GENE$-induced apoptosis in cancer cells by induction of ER stress.	0
Furthermore, @CHEMICAL$, a specific @GENE$ phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.	1
Furthermore, @CHEMICAL$, a specific eIF2α phosphorylation-inducing agent, increased @GENE$ and DR5 expression in the presence of VA.	1
Furthermore, @CHEMICAL$, a specific eIF2α phosphorylation-inducing agent, increased CHOP and @GENE$ expression in the presence of VA.	1
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the @CHEM-GENE$ PHEX gene (phosphate-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the @CHEMICAL$-metallopeptidase @GENE$ gene (phosphate-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the @CHEMICAL$-metallopeptidase PHEX gene (phosphate-regulating gene with homologies to @GENE$ on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the @GENE$ PHEX gene (@CHEMICAL$-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the zinc-metallopeptidase @GENE$ gene (@CHEMICAL$-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal phosphate wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the zinc-metallopeptidase PHEX gene (@CHEMICAL$-regulating gene with homologies to @GENE$ on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal @CHEMICAL$ wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the @GENE$ PHEX gene (phosphate-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal @CHEMICAL$ wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the zinc-metallopeptidase @GENE$ gene (phosphate-regulating gene with homologies to endopeptidase on the X chromosome).	0
X-linked hypophosphatemia (XLH/HYP)-with renal @CHEMICAL$ wasting, hypophosphatemia, osteomalacia, and tooth abscesses-is caused by mutations in the zinc-metallopeptidase PHEX gene (phosphate-regulating gene with homologies to @GENE$ on the X chromosome).	0
Inactivating mutations in @GENE$ lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic @CHEMICAL$- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, @CHEM-GENE$ (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic @CHEMICAL$- and aspartate-rich motif (@GENE$)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic @CHEMICAL$- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the @GENE$ family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic @CHEMICAL$- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (@GENE$).	0
Inactivating mutations in @GENE$ lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and @CHEMICAL$-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, @CHEM-GENE$ (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and @CHEMICAL$-rich motif (@GENE$)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and @CHEMICAL$-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the @GENE$ family (small, integrin-binding ligand N-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and @CHEMICAL$-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (@GENE$).	0
Inactivating mutations in @GENE$ lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand @CHEMICAL$-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, @GENE$ (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand @CHEMICAL$-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and aspartate-rich motif (@GENE$)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (small, integrin-binding ligand @CHEMICAL$-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the @GENE$ family (small, integrin-binding ligand @CHEMICAL$-linked glycoproteins).	0
Inactivating mutations in PHEX lead to distal renal effects (implying accumulation of a secreted, circulating phosphaturic factor) and accumulation in bone and teeth of mineralization-inhibiting, acidic serine- and aspartate-rich motif (ASARM)-containing peptides, which are proteolytically derived from the mineral-binding matrix proteins of the SIBLING family (@CHEM-GENE$).	0
Targeted disruption of @CHEM-GENE$ protects against aging, S-nitrosation, and insulin resistance in muscle of male mice.	0
Targeted disruption of inducible @CHEMICAL$ synthase protects against aging, S-nitrosation, and @GENE$ resistance in muscle of male mice.	0
Targeted disruption of @GENE$ protects against aging, @CHEMICAL$-nitrosation, and insulin resistance in muscle of male mice.	0
Targeted disruption of inducible nitric oxide synthase protects against aging, @CHEMICAL$-nitrosation, and @GENE$ resistance in muscle of male mice.	0
Here, we explored the role of @CHEM-GENE$ (iNOS) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible @CHEMICAL$ synthase (@GENE$) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible @CHEMICAL$ synthase (iNOS) in the S-nitrosation of proteins involved in the early steps of the @GENE$-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible @CHEMICAL$ synthase (iNOS) in the S-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and @GENE$ resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of @GENE$ (iNOS) in the @CHEMICAL$-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible nitric oxide synthase (@GENE$) in the @CHEMICAL$-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible nitric oxide synthase (iNOS) in the @CHEMICAL$-nitrosation of proteins involved in the early steps of the @GENE$-signaling pathway and insulin resistance in the skeletal muscle of aged mice.	0
Here, we explored the role of inducible nitric oxide synthase (iNOS) in the @CHEMICAL$-nitrosation of proteins involved in the early steps of the insulin-signaling pathway and @GENE$ resistance in the skeletal muscle of aged mice.	0
Aging increased @GENE$ expression and @CHEMICAL$-nitrosation of major proteins involved in insulin signaling, thereby reducing insulin sensitivity in skeletal muscle.	0
Aging increased iNOS expression and @CHEMICAL$-nitrosation of major proteins involved in @GENE$ signaling, thereby reducing insulin sensitivity in skeletal muscle.	0
Aging increased iNOS expression and @CHEMICAL$-nitrosation of major proteins involved in insulin signaling, thereby reducing @GENE$ sensitivity in skeletal muscle.	0
Conversely, aged @GENE$-null mice were protected from @CHEMICAL$-nitrosation-induced insulin resistance.	0
Conversely, aged iNOS-null mice were protected from @CHEMICAL$-nitrosation-induced @GENE$ resistance.	0
Moreover, pharmacological treatment with an @GENE$ inhibitor and acute exercise reduced iNOS-induced @CHEMICAL$-nitrosation and increased insulin sensitivity in the muscle of aged animals.	0
Moreover, pharmacological treatment with an iNOS inhibitor and acute exercise reduced @GENE$-induced @CHEMICAL$-nitrosation and increased insulin sensitivity in the muscle of aged animals.	0
Moreover, pharmacological treatment with an iNOS inhibitor and acute exercise reduced iNOS-induced @CHEMICAL$-nitrosation and increased @GENE$ sensitivity in the muscle of aged animals.	0
These findings indicate that the @GENE$ resistance observed in aged mice is mainly mediated through the @CHEMICAL$-nitrosation of the insulin-signaling pathway.	0
These findings indicate that the insulin resistance observed in aged mice is mainly mediated through the @CHEMICAL$-nitrosation of the @GENE$-signaling pathway.	0
Single nucleotide polymorphisms (SNPs) in the @CHEM-GENE$ (COMT) gene have been related to cognitive function.	0
Single nucleotide polymorphisms (SNPs) in the @CHEMICAL$-O-methyltransferase (@GENE$) gene have been related to cognitive function.	0
Single nucleotide polymorphisms (SNPs) in the @CHEM-GENE$ (COMT) gene have been related to cognitive function.	0
Single nucleotide polymorphisms (SNPs) in the catechol-@CHEMICAL$-methyltransferase (@GENE$) gene have been related to cognitive function.	0
Both microtubule and actin are required for @GENE$-induced @CHEMICAL$ uptake.	0
Both microtubule and @GENE$ are required for insulin-induced @CHEMICAL$ uptake.	0
Disruption of microtubule prevented @GENE$-induced actin remodeling and distal insulin signal transduction, with reduction in surface @CHEMICAL$ transporter isoform 4 (GLUT4) and glucose uptake.	0
Disruption of microtubule prevented insulin-induced @GENE$ remodeling and distal insulin signal transduction, with reduction in surface @CHEMICAL$ transporter isoform 4 (GLUT4) and glucose uptake.	0
Disruption of microtubule prevented insulin-induced actin remodeling and distal @GENE$ signal transduction, with reduction in surface @CHEMICAL$ transporter isoform 4 (GLUT4) and glucose uptake.	0
Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface @CHEM-GENE$ (GLUT4) and glucose uptake.	0
Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface @CHEMICAL$ transporter isoform 4 (@GENE$) and glucose uptake.	0
Disruption of microtubule prevented @GENE$-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and @CHEMICAL$ uptake.	0
Disruption of microtubule prevented insulin-induced @GENE$ remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and @CHEMICAL$ uptake.	0
Disruption of microtubule prevented insulin-induced actin remodeling and distal @GENE$ signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and @CHEMICAL$ uptake.	0
Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface @GENE$ (GLUT4) and @CHEMICAL$ uptake.	5
Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (@GENE$) and @CHEMICAL$ uptake.	5
Though microtubule mediated @GENE$ remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ.	0
Though microtubule mediated actin remodeling through @GENE$, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ.	0
Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of @GENE$, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ.	0
Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from @GENE$-induced actin remodeling, which relied on the activity of PI3-kinase and PKCζ.	0
Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from insulin-induced @GENE$ remodeling, which relied on the activity of PI3-kinase and PKCζ.	0
Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of @GENE$ and PKCζ.	0
Though microtubule mediated actin remodeling through PKCζ, reorganization of microtubule depended on @CHEMICAL$ phosphorylation of insulin receptor, the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and @GENE$.	0
Quantitative analysis of the interaction of @GENE$ with chemicals and @CHEMICAL$ receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	0
Quantitative analysis of the interaction of constitutive androstane receptor with chemicals and @CHEM-GENE$ using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	0
Quantitative analysis of the interaction of @CHEM-GENE$ with chemicals and steroid receptor coactivator 1 using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	0
Quantitative analysis of the interaction of constitutive @CHEMICAL$ receptor with chemicals and @GENE$ using surface plasmon resonance biosensor systems: a case study of the Baikal seal (Pusa sibirica) and the mouse.	0
The constitutive @CHEMICAL$ receptor (@GENE$) not only displays a high basal transcriptional activity but also acts as a ligand-dependent transcriptional factor.	0
The @CHEM-GENE$ (CAR) not only displays a high basal transcriptional activity but also acts as a ligand-dependent transcriptional factor.	0
The objectives of this study are to establish a high-throughput tool to screen @GENE$ ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and @CHEMICAL$ receptor coactivator 1 (SRC1).	0
The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how @GENE$ proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and @CHEMICAL$ receptor coactivator 1 (SRC1).	0
The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (@GENE$) and the mouse (mCAR) interact with chemicals and @CHEMICAL$ receptor coactivator 1 (SRC1).	0
The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (@GENE$) interact with chemicals and @CHEMICAL$ receptor coactivator 1 (SRC1).	0
The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and @CHEM-GENE$ (SRC1).	0
The objectives of this study are to establish a high-throughput tool to screen CAR ligands and to clarify how CAR proteins from the Baikal seal (bsCAR) and the mouse (mCAR) interact with chemicals and @CHEMICAL$ receptor coactivator 1 (@GENE$).	0
Androstanol and @CHEMICAL$, estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both @GENE$.	0
Androstanol and androstenol, @CHEMICAL$, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both @GENE$.	0
Androstanol and androstenol, estrone, @CHEMICAL$, TCPOBOP, and CITCO showed compound-specific but similar affinities for both @GENE$.	0
Androstanol and androstenol, estrone, 17β-estradiol, @CHEMICAL$, and CITCO showed compound-specific but similar affinities for both @GENE$.	0
Androstanol and androstenol, estrone, 17β-estradiol, TCPOBOP, and @CHEMICAL$ showed compound-specific but similar affinities for both @GENE$.	0
@CHEMICAL$ and androstenol, estrone, 17β-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both @GENE$.	0
@CHEM-GENE$ blockade impairs the muscarinic conversion of sub-threshold transient depression into long-lasting LTD in the hippocampus-prefrontal cortex pathway in vivo: correlation with gamma oscillations.	0
Other groups received either an infusion of the selective @CHEM-GENE$ antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).	0
Other groups received either an infusion of the selective @GENE$ antagonist (@CHEMICAL$; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).	4
Other groups received either an infusion of the selective @GENE$ antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to @CHEMICAL$ preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).	0
Our results show that @CHEMICAL$ converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that @GENE$ pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.	0
Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, @CHEMICAL$ does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that @GENE$ pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.	0
Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that @CHEM-GENE$ pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.	0
Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that @GENE$ pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since @CHEMICAL$ microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.	2
Our results show that PILO converts a transient cortical depression induced by LFS600 into a robust LTD, stable for at least 4 h. When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that @GENE$ pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by @CHEMICAL$.	0
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and @CHEM-GENE$.	0
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the @GENE$ and @CHEMICAL$ acetyltransferase.	0
Metabolism of @CHEMICAL$ and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and @GENE$.	5
Metabolism of @CHEMICAL$ and 1,12-diamino-3,6,9-triazadodecane by the @GENE$ and thialysine acetyltransferase.	5
Metabolism of triethylenetetramine and @CHEMICAL$ by the spermidine/spermine-N(1)-acetyltransferase and @GENE$.	5
Metabolism of triethylenetetramine and @CHEMICAL$ by the @GENE$ and thialysine acetyltransferase.	5
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the @CHEMICAL$/spermine-N(1)-acetyltransferase and @GENE$.	0
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the @CHEM-GENE$ and thialysine acetyltransferase.	0
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/@CHEMICAL$-N(1)-acetyltransferase and @GENE$.	0
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the @CHEM-GENE$ and thialysine acetyltransferase.	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @CHEM-GENE$ (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @CHEMICAL$/spermine-N(1)-acetyltransferase (@GENE$) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @CHEMICAL$/spermine-N(1)-acetyltransferase (SSAT1) and by @GENE$ (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @CHEMICAL$/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (@GENE$) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @CHEM-GENE$ (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/@CHEMICAL$-N(1)-acetyltransferase (@GENE$) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/@CHEMICAL$-N(1)-acetyltransferase (SSAT1) and by @GENE$ (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/@CHEMICAL$-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (@GENE$) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme @GENE$ (SSAT1) and by @CHEMICAL$ acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (@GENE$) and by @CHEMICAL$ acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by @CHEM-GENE$ (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by @CHEMICAL$ acetyltransferase (@GENE$) to its monoacetylated derivative (MAT).	0
We recently showed that @CHEMICAL$ is metabolized in vitro by polyamine catabolic enzyme @GENE$ (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	5
We recently showed that @CHEMICAL$ is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (@GENE$) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	5
We recently showed that @CHEMICAL$ is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by @GENE$ (SSAT2) to its monoacetylated derivative (MAT).	5
We recently showed that @CHEMICAL$ is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (@GENE$) to its monoacetylated derivative (MAT).	5
We recently showed that TETA is metabolized in vitro by @CHEMICAL$ catabolic enzyme @GENE$ (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	5
We recently showed that TETA is metabolized in vitro by @CHEMICAL$ catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (@GENE$) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).	5
We recently showed that TETA is metabolized in vitro by @CHEMICAL$ catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by @GENE$ (SSAT2) to its monoacetylated derivative (MAT).	0
We recently showed that TETA is metabolized in vitro by @CHEMICAL$ catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (@GENE$) to its monoacetylated derivative (MAT).	0
The acetylation of @CHEMICAL$ is increased in @GENE$-overexpressing mice compared with wild-type mice.	5
However, @GENE$-deficient mice metabolize @CHEMICAL$ at the same rate as the wild-type mice, indicating the existence of another N-acetylase respons 2ible for its metabolism in mice.	0
However, SSAT1-deficient mice metabolize @CHEMICAL$ at the same rate as the wild-type mice, indicating the existence of another @GENE$ respons 2ible for its metabolism in mice.	5
Here, we show that siRNA-mediated knockdown of @GENE$ in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of @CHEMICAL$ to MAT.	5
Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the @GENE$-deficient or wild-type mice reduced the metabolism of @CHEMICAL$ to MAT.	0
By contrast, @CHEMICAL$(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by @GENE$ in HEPG2 cells and in wild-type primary hepatocytes.	5
By contrast, @CHEMICAL$(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of @GENE$ and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.	5
By contrast, 1,12-diamino-3,6,9-triazadodecane(@CHEMICAL$), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by @GENE$ in HEPG2 cells and in wild-type primary hepatocytes.	5
By contrast, 1,12-diamino-3,6,9-triazadodecane(@CHEMICAL$), a charge-deficient spermine analog, was an extremely poor substrate of @GENE$ and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.	5
By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient @CHEMICAL$ analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by @GENE$ in HEPG2 cells and in wild-type primary hepatocytes.	5
By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient @CHEMICAL$ analog, was an extremely poor substrate of @GENE$ and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.	5
Thus, despite the similar structures of @CHEMICAL$ and SpmTrien, @GENE$ is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1.	0
Thus, despite the similar structures of @CHEMICAL$ and SpmTrien, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by @GENE$.	0
Thus, despite the similar structures of TETA and @CHEMICAL$, @GENE$ is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1.	0
Thus, despite the similar structures of TETA and @CHEMICAL$, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by @GENE$.	0
Thus, despite the similar structures of TETA and SpmTrien, @GENE$ is the main acetylator of @CHEMICAL$, whereas SpmTrien is primarily acetylated by SSAT1.	5
Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of @CHEMICAL$, whereas SpmTrien is primarily acetylated by @GENE$.	0
Thus, despite the similar structures of TETA and SpmTrien, @GENE$ is the main acetylator of TETA, whereas @CHEMICAL$ is primarily acetylated by SSAT1.	0
Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas @CHEMICAL$ is primarily acetylated by @GENE$.	5
In vitro metabolism of the @GENE$ receptor antagonist @CHEMICAL$.	4
The metabolism of @CHEMICAL$ has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed @GENE$ (rCYP).	0
The metabolism of @CHEMICAL$ has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (@GENE$).	0
The @GENE$ data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of @CHEMICAL$.	0
The rCYP data was normalized relative to the levels of each @GENE$ form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of @CHEMICAL$.	0
The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each @GENE$ in the metabolism of @CHEMICAL$.	5
@GENE$ has shown to be an essential component in P450 3A4 catalyzed @CHEMICAL$ formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.	0
Cytochrome b5 has shown to be an essential component in @GENE$ catalyzed @CHEMICAL$ formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.	5
Cytochrome b5 has shown to be an essential component in P450 3A4 catalyzed @CHEMICAL$ formation and provides insights on the disconnect between human liver microsomes data and that of @GENE$.	0
The mutant Fc domain (@GENE$) contained a total of 5 @CHEMICAL$ substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb).	0
The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 @CHEMICAL$ substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; @GENE$-R131:FcγRIIb).	0
The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 @CHEMICAL$ substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:@GENE$).	0
The mutant @GENE$ (AglycoT-Fc1004) contained a total of 5 @CHEMICAL$ substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb).	0
In utero exposure to @CHEMICAL$ (VPA), a @GENE$ (HDAC) inhibitor, causes neural tube, heart, and limb defects.	2
In utero exposure to @CHEMICAL$ (VPA), a histone deacetylase (@GENE$) inhibitor, causes neural tube, heart, and limb defects.	2
In utero exposure to valproic acid (@CHEMICAL$), a @GENE$ (HDAC) inhibitor, causes neural tube, heart, and limb defects.	2
In utero exposure to valproic acid (@CHEMICAL$), a histone deacetylase (@GENE$) inhibitor, causes neural tube, heart, and limb defects.	2
@CHEMICAL$ (VPD), the amide derivative of VPA, does not inhibit @GENE$ activity and is a weak teratogen in vivo.	0
Valpromide (@CHEMICAL$), the amide derivative of VPA, does not inhibit @GENE$ activity and is a weak teratogen in vivo.	0
Valpromide (VPD), the @CHEMICAL$ derivative of VPA, does not inhibit @GENE$ activity and is a weak teratogen in vivo.	0
Valpromide (VPD), the amide derivative of @CHEMICAL$, does not inhibit @GENE$ activity and is a weak teratogen in vivo.	0
@CHEMICAL$ caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its @GENE$ inhibitory effect.	2
The signaling of both @GENE$ and Runx2, key regulators of chondrogenesis, was downregulated by @CHEMICAL$.	2
The signaling of both Sox9 and @GENE$, key regulators of chondrogenesis, was downregulated by @CHEMICAL$.	2
In contrast, @CHEMICAL$ had little effect on limb morphology and no significant effect on @GENE$ activity or the expression of marker genes.	0
Disturbances in these signaling pathways are likely to be a consequence of @GENE$ inhibition because @CHEMICAL$ did not affect their expressions.	0
@GENE$ potentiates the cytotoxicity of @CHEMICAL$ in Hepa1c1c7 cells: roles of caspase activation and oxidative stress.	0
Tumor necrosis factor-alpha potentiates the cytotoxicity of @CHEMICAL$ in Hepa1c1c7 cells: roles of @GENE$ activation and oxidative stress.	0
We demonstrated previously that @GENE$ (TNF-α) plays an important role in a rat model of @CHEMICAL$-induced hepatotoxicity under inflammatory stress.	0
We demonstrated previously that tumor necrosis factor-alpha (@GENE$) plays an important role in a rat model of @CHEMICAL$-induced hepatotoxicity under inflammatory stress.	0
In this study, we developed a model in vitro to study the roles of @GENE$ activation and oxidative stress in TNF potentiation of @CHEMICAL$ cytotoxicity.	0
In this study, we developed a model in vitro to study the roles of caspase activation and oxidative stress in @GENE$ potentiation of @CHEMICAL$ cytotoxicity.	0
@CHEMICAL$ caused cell death in Hepa1c1c7 cells, and @GENE$ cotreatment potentiated its toxicity.	0
Activation of @GENE$ was observed in @CHEMICAL$/TNF-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity.	0
Activation of caspases 9 and 3/7 was observed in @CHEMICAL$/@GENE$-cotreated cells, and caspase inhibitors provided minor protection from cytotoxicity.	0
Intracellular reactive @CHEMICAL$ species (ROS) generation and lipid peroxidation were observed after treatment with AMD and were further elevated by @GENE$ cotreatment.	0
Intracellular reactive oxygen species (ROS) generation and lipid peroxidation were observed after treatment with @CHEMICAL$ and were further elevated by @GENE$ cotreatment.	0
Adding water-soluble antioxidants (@CHEMICAL$, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/@GENE$-induced cytotoxicity and did not influence the effect of AMD alone.	0
Adding water-soluble antioxidants (trolox, @CHEMICAL$, glutathione, or ascorbate) produced only minor attenuation of AMD/@GENE$-induced cytotoxicity and did not influence the effect of AMD alone.	0
Adding water-soluble antioxidants (trolox, N-acetylcysteine, @CHEMICAL$, or ascorbate) produced only minor attenuation of AMD/@GENE$-induced cytotoxicity and did not influence the effect of AMD alone.	0
Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or @CHEMICAL$) produced only minor attenuation of AMD/@GENE$-induced cytotoxicity and did not influence the effect of AMD alone.	0
Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of @CHEMICAL$/@GENE$-induced cytotoxicity and did not influence the effect of AMD alone.	0
Adding water-soluble antioxidants (trolox, N-acetylcysteine, glutathione, or ascorbate) produced only minor attenuation of AMD/@GENE$-induced cytotoxicity and did not influence the effect of @CHEMICAL$ alone.	0
On the other hand, @CHEMICAL$ (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/@GENE$ cotreatment.	0
On the other hand, α-tocopherol (@CHEMICAL$), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from AMD/@GENE$ cotreatment.	0
On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented @CHEMICAL$ toxicity and caused pronounced reduction in cytotoxicity from AMD/@GENE$ cotreatment.	0
On the other hand, α-tocopherol (TOCO), which reduced lipid peroxidation and ROS generation, prevented AMD toxicity and caused pronounced reduction in cytotoxicity from @CHEMICAL$/@GENE$ cotreatment.	0
@CHEMICAL$ plus a @GENE$ inhibitor completely abolished AMD/TNF-induced cytotoxicity.	2
@CHEMICAL$ plus a pancaspase inhibitor completely abolished AMD/@GENE$-induced cytotoxicity.	0
α-TOCO plus a @GENE$ inhibitor completely abolished @CHEMICAL$/TNF-induced cytotoxicity.	0
α-TOCO plus a pancaspase inhibitor completely abolished @CHEMICAL$/@GENE$-induced cytotoxicity.	0
In summary, activation of @GENE$ and oxidative stress were observed after AMD/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated @CHEMICAL$/TNF-induced cytotoxicity.	0
In summary, activation of caspases and oxidative stress were observed after AMD/@GENE$ cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated @CHEMICAL$/TNF-induced cytotoxicity.	0
In summary, activation of caspases and oxidative stress were observed after AMD/TNF cotreatment, and @GENE$ inhibitors and a lipid-soluble free-radical scavenger attenuated @CHEMICAL$/TNF-induced cytotoxicity.	0
In summary, activation of caspases and oxidative stress were observed after AMD/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated @CHEMICAL$/@GENE$-induced cytotoxicity.	0
In summary, activation of @GENE$ and oxidative stress were observed after @CHEMICAL$/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.	1
In summary, activation of caspases and oxidative stress were observed after @CHEMICAL$/@GENE$ cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.	0
In summary, activation of caspases and oxidative stress were observed after @CHEMICAL$/TNF cotreatment, and @GENE$ inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/TNF-induced cytotoxicity.	0
In summary, activation of caspases and oxidative stress were observed after @CHEMICAL$/TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD/@GENE$-induced cytotoxicity.	0
@CHEMICAL$ residues at the N- and C-termini are essential for the folding of active @GENE$ polypeptide.	0
Human serum butyrylcholinesterase (@GENE$) is currently the most suitable bioscavenger for the prophylaxis of highly toxic @CHEMICAL$ (OP) nerve agents.	5
@GENE$ (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic @CHEMICAL$ (OP) nerve agents.	5
Studies have indicated that the three-dimensional structure and the domains of @GENE$ (@CHEMICAL$ pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs.	0
@GENE$ and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and @CHEMICAL$ influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and @CHEMICAL$ influx transporter @GENE$.	0
Claudin-3 and @GENE$ regulate sensitivity to cisplatin by controlling expression of the copper and @CHEMICAL$ influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the @CHEM-GENE$ CTR1.	0
@GENE$ and claudin-4 regulate sensitivity to @CHEMICAL$ by controlling expression of the copper and cisplatin influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to @CHEMICAL$ by controlling expression of the copper and cisplatin influx transporter @GENE$.	0
Claudin-3 and @GENE$ regulate sensitivity to @CHEMICAL$ by controlling expression of the copper and cisplatin influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to @CHEMICAL$ by controlling expression of the @GENE$ CTR1.	0
@GENE$ and claudin-4 regulate sensitivity to cisplatin by controlling expression of the @CHEMICAL$ and cisplatin influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the @CHEMICAL$ and cisplatin influx transporter @GENE$.	0
Claudin-3 and @GENE$ regulate sensitivity to cisplatin by controlling expression of the @CHEMICAL$ and cisplatin influx transporter CTR1.	0
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the @CHEM-GENE$ CTR1.	0
We found that knockdown of the expression of either @GENE$ or CLDN4 produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to @CHEMICAL$ (cDDP).	0
We found that knockdown of the expression of either CLDN3 or @GENE$ produced marked changes in the phenotype of ovarian cancer cells, including an increase in resistance to @CHEMICAL$ (cDDP).	0
The net accumulation of platinum (@CHEMICAL$) and the Pt-DNA adduct levels were reduced in @GENE$KD and CLDN4KD cells.	0
The net accumulation of platinum (@CHEMICAL$) and the Pt-DNA adduct levels were reduced in CLDN3KD and @GENE$KD cells.	0
The net accumulation of platinum (Pt) and the @CHEMICAL$-DNA adduct levels were reduced in @GENE$KD and CLDN4KD cells.	0
The net accumulation of platinum (Pt) and the @CHEMICAL$-DNA adduct levels were reduced in CLDN3KD and @GENE$KD cells.	0
The net accumulation of @CHEMICAL$ (Pt) and the Pt-DNA adduct levels were reduced in @GENE$KD and CLDN4KD cells.	0
The net accumulation of @CHEMICAL$ (Pt) and the Pt-DNA adduct levels were reduced in CLDN3KD and @GENE$KD cells.	0
The endogenous mRNA levels of @CHEMICAL$ influx transporter CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of @GENE$ restored their sensitivity to cDDP.	0
The endogenous mRNA levels of @CHEM-GENE$ CTR1 were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP.	0
The endogenous mRNA levels of @CHEMICAL$ influx transporter @GENE$ were found to be significantly reduced in the knockdown cells, and exogenous expression of CTR1 restored their sensitivity to cDDP.	0
Baseline @CHEMICAL$ (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in @GENE$KD and CLDN4KD cells.	0
Baseline @CHEMICAL$ (Cu) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and @GENE$KD cells.	0
Baseline copper (@CHEMICAL$) level, Cu uptake, and Cu cytotoxicity were also reduced in @GENE$KD and CLDN4KD cells.	0
Baseline copper (@CHEMICAL$) level, Cu uptake, and Cu cytotoxicity were also reduced in CLDN3KD and @GENE$KD cells.	0
Baseline copper (Cu) level, @CHEMICAL$ uptake, and Cu cytotoxicity were also reduced in @GENE$KD and CLDN4KD cells.	0
Baseline copper (Cu) level, @CHEMICAL$ uptake, and Cu cytotoxicity were also reduced in CLDN3KD and @GENE$KD cells.	0
Baseline copper (Cu) level, Cu uptake, and @CHEMICAL$ cytotoxicity were also reduced in @GENE$KD and CLDN4KD cells.	0
Baseline copper (Cu) level, Cu uptake, and @CHEMICAL$ cytotoxicity were also reduced in CLDN3KD and @GENE$KD cells.	0
@CHEMICAL$-dependent @GENE$ activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA.	0
@CHEMICAL$-dependent tyrosinase activity was also markedly reduced in both types of @GENE$ knockdown cells when incubated with the substrate l-DOPA.	0
Cu-dependent @GENE$ activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate @CHEMICAL$.	5
Cu-dependent tyrosinase activity was also markedly reduced in both types of @GENE$ knockdown cells when incubated with the substrate @CHEMICAL$.	0
These results indicate that @GENE$ and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the @CHEMICAL$ transporter CTR1.	0
These results indicate that CLDN3 and @GENE$ affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the @CHEMICAL$ transporter CTR1.	0
These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the @CHEM-GENE$ CTR1.	0
These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the @CHEMICAL$ transporter @GENE$.	0
Protein expression of @GENE$ also decreased and corresponded with reduced in vitro glucuronidation of @CHEMICAL$ in S9 fractions from livers of pregnant mice.	2
Conversely, @GENE$ mRNAs increased 100 to 500% at various time points in pregnant and lactating mice and corresponded with enhanced in vitro sulfation of @CHEMICAL$ in liver S9 fractions.	0
@CHEMICAL$ attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/@GENE$ signaling.	2
@CHEMICAL$ attenuates renal fibrosis via @GENE$-mediated inhibition of transforming growth factor-beta/Smad signaling.	0
@CHEMICAL$ attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of @GENE$/Smad signaling.	2
This study examines whether @CHEMICAL$ (DMF), which stimulates @GENE$, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.	0
This study examines whether @CHEMICAL$ (DMF), which stimulates Nrf2, prevents renal fibrosis via the @GENE$-mediated suppression of TGF-beta signaling.	0
This study examines whether @CHEMICAL$ (DMF), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of @GENE$ signaling.	0
This study examines whether dimethylfumarate (@CHEMICAL$), which stimulates @GENE$, prevents renal fibrosis via the Nrf2-mediated suppression of TGF-beta signaling.	0
This study examines whether dimethylfumarate (@CHEMICAL$), which stimulates Nrf2, prevents renal fibrosis via the @GENE$-mediated suppression of TGF-beta signaling.	0
This study examines whether dimethylfumarate (@CHEMICAL$), which stimulates Nrf2, prevents renal fibrosis via the Nrf2-mediated suppression of @GENE$ signaling.	0
Results showed that @CHEMICAL$ increased nuclear levels of @GENE$, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	1
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of @GENE$ (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-@GENE$) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased @GENE$, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, @GENE$ (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (@GENE$), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), @GENE$ and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and @GENE$ expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that @CHEMICAL$ increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in @GENE$-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that DMF increased nuclear levels of @GENE$, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of @GENE$ (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	1
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-@GENE$) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased @GENE$, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	2
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, @GENE$ (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	2
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (@GENE$), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	2
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), @GENE$ and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	2
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and @GENE$ expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	2
Results showed that DMF increased nuclear levels of Nrf2, and both @CHEMICAL$ and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in @GENE$-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).	0
Additionally, @CHEMICAL$ and Ad-@GENE$ repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.	0
Additionally, @CHEMICAL$ and Ad-Nrf2 repressed @GENE$-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.	2
Additionally, @CHEMICAL$ and Ad-Nrf2 repressed TGF-beta-stimulated @GENE$ activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.	2
Additionally, @CHEMICAL$ and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting @GENE$ phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.	2
Additionally, @CHEMICAL$ and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of @GENE$ expression.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as @GENE$, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, @GENE$ and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEM-GENE$ (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (@GENE$) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on @GENE$-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an @GENE$-independent anti-fibrotic activity of DMF.	0
However, downregulation of the @GENE$ (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (@GENE$)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven @GENE$ target genes such as NQO1, HO-1 and @CHEMICAL$ S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as @GENE$, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, @GENE$ and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @CHEM-GENE$ (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (@GENE$) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on @GENE$-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an @GENE$-independent anti-fibrotic activity of DMF.	0
However, downregulation of the @GENE$ (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (@GENE$)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven @GENE$ target genes such as NQO1, HO-1 and glutathione @CHEMICAL$-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as @GENE$, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, @GENE$ and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @GENE$ (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (@GENE$) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on @GENE$-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	2
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an @GENE$-independent anti-fibrotic activity of DMF.	0
However, downregulation of the @GENE$ (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (@GENE$)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven @GENE$ target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of @CHEMICAL$ on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as @GENE$, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, @GENE$ and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and @GENE$ (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (@GENE$) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on @GENE$-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an @GENE$-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the @GENE$ (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (@GENE$)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
However, downregulation of the antioxidant response element (ARE)-driven @GENE$ target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta-induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of @CHEMICAL$.	0
Finally, @CHEMICAL$ suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and @GENE$, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.	2
Finally, @CHEMICAL$ suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, @GENE$ and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.	2
Finally, @CHEMICAL$ suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and @GENE$ expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.	2
Finally, @CHEMICAL$ suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of @GENE$ and phospho-Smad3, respectively.	1
Finally, @CHEMICAL$ suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and @GENE$, respectively.	2
In summary, @CHEMICAL$ attenuated renal fibrosis via the @GENE$-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.	0
In summary, @CHEMICAL$ attenuated renal fibrosis via the Nrf2-mediated inhibition of @GENE$/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.	2
In summary, @CHEMICAL$ attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/@GENE$ signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.	2
In summary, @CHEMICAL$ attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an @GENE$-independent manner, suggesting that DMF could be used to treat renal fibrosis.	0
In summary, DMF attenuated renal fibrosis via the @GENE$-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that @CHEMICAL$ could be used to treat renal fibrosis.	0
In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of @GENE$/Smad3 signaling in an ARE-independent manner, suggesting that @CHEMICAL$ could be used to treat renal fibrosis.	0
In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/@GENE$ signaling in an ARE-independent manner, suggesting that @CHEMICAL$ could be used to treat renal fibrosis.	0
In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an @GENE$-independent manner, suggesting that @CHEMICAL$ could be used to treat renal fibrosis.	0
Our results showed that bone remodeling was significantly decreased in @GENE$(-/-) and CCR1(-/-) mice and in animals treated with @CHEMICAL$-RANTES (an antagonist of CCR5 and CCR1).	0
Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and @GENE$(-/-) mice and in animals treated with @CHEMICAL$-RANTES (an antagonist of CCR5 and CCR1).	0
Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with @CHEMICAL$-RANTES (an antagonist of @GENE$ and CCR1).	4
Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with @CHEMICAL$-RANTES (an antagonist of CCR5 and @GENE$).	4
mRNA levels of @GENE$ (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (@GENE$), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand @GENE$, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, @GENE$ (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (@GENE$) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and @GENE$/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/@GENE$ (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (@GENE$) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	2
mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-α) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of @GENE$(-/-) mice and in the group treated with @CHEMICAL$-RANTES.	0
@CHEMICAL$-RANTES treatment also reduced the levels of @GENE$ and metalloproteinase 13 (MMP13).	2
@CHEMICAL$-RANTES treatment also reduced the levels of cathepsin K and @GENE$ (MMP13).	2
@CHEMICAL$-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (@GENE$).	2
The expression of the osteoblast markers runt-related transcription factor 2 (@GENE$) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and @CHEMICAL$-RANTES-treated mice.	2
The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and @GENE$ was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and @CHEMICAL$-RANTES-treated mice.	2
The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while @GENE$ (OCN) was augmented in CCL3(-/-) and @CHEMICAL$-RANTES-treated mice.	1
The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (@GENE$) was augmented in CCL3(-/-) and @CHEMICAL$-RANTES-treated mice.	1
The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in @GENE$(-/-) and @CHEMICAL$-RANTES-treated mice.	0
The expression of the osteoblast markers @GENE$ (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and @CHEMICAL$-RANTES-treated mice.	2
@CHEM-GENE$ channel blockers and its structural analysis for drug design.	0
The human @CHEMICAL$-a-go-go-related gene (@GENE$) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The @CHEM-GENE$ (hERG) is a K+ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The human @CHEMICAL$-a-go-go-related gene (hERG) is a @GENE$ protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The human ether-a-go-go-related gene (@GENE$) is a @CHEMICAL$ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The @GENE$ (hERG) is a @CHEMICAL$ channel protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The human ether-a-go-go-related gene (hERG) is a @CHEM-GENE$ protein mainly expressed in the heart and the nervous systems and its blockade by non-cardiovascular acting drugs resulted in tachycardia and sudden death.	0
The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and @CHEMICAL$ carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and @GENE$ blocking activity.	2
The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of @CHEMICAL$ that possessed positive ionotropic effect and @GENE$ blocking activity.	2
The @CHEMICAL$ (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and @GENE$ blocking activity.	2
The quinolizidine alkaloids (natural products) such as @CHEMICAL$, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and @GENE$ blocking activity.	2
The quinolizidine alkaloids (natural products) such as oxymatrine, @CHEMICAL$, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and @GENE$ blocking activity.	2
The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, @CHEMICAL$ and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and @GENE$ blocking activity.	2
Multifunctional targets of dietary @CHEMICAL$ in disease: a case for the @GENE$ network and energy metabolism.	0
The CCL2/CCR2 pathway and the energy sensor @CHEMICAL$-activated protein kinase (@GENE$) are attractive therapeutic targets as a part of preventive management of disease.	0
The @GENE$/CCR2 pathway and the energy sensor @CHEMICAL$-activated protein kinase (AMPK) are attractive therapeutic targets as a part of preventive management of disease.	0
The CCL2/@GENE$ pathway and the energy sensor @CHEMICAL$-activated protein kinase (AMPK) are attractive therapeutic targets as a part of preventive management of disease.	0
The CCL2/CCR2 pathway and the energy sensor @CHEM-GENE$ (AMPK) are attractive therapeutic targets as a part of preventive management of disease.	0
Several effects of @CHEMICAL$ are useful in this scenario, including a reduction in the activities of @GENE$ and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.	2
Several effects of @CHEMICAL$ are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through @GENE$ inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.	2
Several effects of @CHEMICAL$ are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, @GENE$ activators, calorie-restriction mimetics or epigenetic regulators.	1
Inhibition of @GENE$/EGFR activation with @CHEMICAL$ blocks migration and invasion of MDA-MB-231 cells.	2
Inhibition of EGF/@GENE$ activation with @CHEMICAL$ blocks migration and invasion of MDA-MB-231 cells.	2
We use @GENE$ as a metastatic inducer of MDA-MB-231 cells to investigate the effect of @CHEMICAL$ on cell migration and invasion.	0
@CHEMICAL$ suppressed @GENE$-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	2
@CHEMICAL$ suppressed EGF-mediated protein levels of @GENE$ and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	2
@CHEMICAL$ suppressed EGF-mediated protein levels of c-Jun and @GENE$, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	2
@CHEMICAL$ suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced @GENE$ expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity.	2
@CHEMICAL$ abrogated @GENE$-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.	2
@CHEMICAL$ abrogated EGF-induced phosphorylation of @GENE$ (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt.	2
@CHEMICAL$ abrogated EGF-induced phosphorylation of EGF receptor (@GENE$) and phosphatidylinositol 3-kinase (PI3K)/Akt.	2
@CHEMICAL$ abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and @GENE$ (PI3K)/Akt.	2
@CHEMICAL$ abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (@GENE$)/Akt.	2
@CHEMICAL$ abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/@GENE$.	2
NFD abrogated @GENE$-induced phosphorylation of EGF receptor (EGFR) and @CHEMICAL$ 3-kinase (PI3K)/Akt.	0
NFD abrogated EGF-induced phosphorylation of @GENE$ (EGFR) and @CHEMICAL$ 3-kinase (PI3K)/Akt.	0
NFD abrogated EGF-induced phosphorylation of EGF receptor (@GENE$) and @CHEMICAL$ 3-kinase (PI3K)/Akt.	0
NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and @CHEM-GENE$ (PI3K)/Akt.	0
NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and @CHEMICAL$ 3-kinase (@GENE$)/Akt.	0
NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and @CHEMICAL$ 3-kinase (PI3K)/@GENE$.	0
The specific @GENE$ inhibitor, @CHEMICAL$, blocked significantly EGF-induced cell migration and invasion.	2
The specific PI3K inhibitor, @CHEMICAL$, blocked significantly @GENE$-induced cell migration and invasion.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that @GENE$/Akt activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/@GENE$ activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of @GENE$ activation.	2
Furthermore, the @GENE$ inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited @GENE$-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced @GENE$ expression, cell migration and invasion, as well as the activation of PI3K/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of @GENE$/Akt, suggesting that PI3K/Akt activation occur downstream of EGFR activation.	2
Furthermore, the EGFR inhibitor @CHEMICAL$ inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K/@GENE$, suggesting that PI3K/Akt activation occur downstream of EGFR activation.	2
These findings suggest that @CHEMICAL$ inhibited the @GENE$-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression.	2
These findings suggest that @CHEMICAL$ inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via @GENE$-dependent PI3K/Akt signaling, leading to the down-regulation of MMP-9 expression.	2
These findings suggest that @CHEMICAL$ inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent @GENE$/Akt signaling, leading to the down-regulation of MMP-9 expression.	2
These findings suggest that @CHEMICAL$ inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/@GENE$ signaling, leading to the down-regulation of MMP-9 expression.	2
These findings suggest that @CHEMICAL$ inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K/Akt signaling, leading to the down-regulation of @GENE$ expression.	2
Exchange protein directly activated by cAMP (EPAC) and @GENE$ (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger @CHEMICAL$.	0
Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (@GENE$) are two intracellular receptors that mediate the effects of the prototypic second messenger @CHEMICAL$.	0
@GENE$ (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger @CHEMICAL$.	0
Exchange protein directly activated by cAMP (@GENE$) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger @CHEMICAL$.	0
Exchange protein directly activated by @CHEMICAL$ (EPAC) and @GENE$ (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Exchange protein directly activated by @CHEMICAL$ (EPAC) and cAMP-dependent protein kinase (@GENE$) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
@CHEM-GENE$ (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Exchange protein directly activated by @CHEMICAL$ (@GENE$) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Exchange protein directly activated by cAMP (EPAC) and @CHEM-GENE$ (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Exchange protein directly activated by cAMP (EPAC) and @CHEMICAL$-dependent protein kinase (@GENE$) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
@GENE$ (EPAC) and @CHEMICAL$-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Exchange protein directly activated by cAMP (@GENE$) and @CHEMICAL$-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP.	0
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide @GENE$ antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	4
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular @GENE$-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated @GENE$ activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and @GENE$ phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as @GENE$-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of @CHEMICAL$ (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated @GENE$ secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide @GENE$ antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	4
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular @GENE$-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated @GENE$ activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and @GENE$ phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as @GENE$-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (@CHEMICAL$), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated @GENE$ secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ @GENE$ antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	4
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ EPAC antagonist that is capable of specifically blocking intracellular @GENE$-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated @GENE$ activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and @GENE$ phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as @GENE$-mediated insulin secretion in pancreatic β cells.	2
Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic @CHEMICAL$ EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated @GENE$ secretion in pancreatic β cells.	2
@CHEMICAL$ directly inhibits @GENE$ secretion through AMP-activated protein kinase in rat primary gastric cells.	2
@CHEMICAL$ directly inhibits ghrelin secretion through @GENE$ in rat primary gastric cells.	0
Metformin directly inhibits @GENE$ secretion through @CHEMICAL$-activated protein kinase in rat primary gastric cells.	0
Metformin directly inhibits ghrelin secretion through @CHEM-GENE$ in rat primary gastric cells.	0
@CHEMICAL$ treatment is also associated with lower circulating levels of the @GENE$ ghrelin.	2
@CHEMICAL$ treatment is also associated with lower circulating levels of the orexigenic hormone @GENE$.	2
To test whether @CHEMICAL$ directly affects @GENE$ cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether @CHEMICAL$ directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of @GENE$ secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether @CHEMICAL$ directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, @GENE$ gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether @CHEMICAL$ directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of @GENE$ (AMPK) were examined.	0
To test whether @CHEMICAL$ directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (@GENE$) were examined.	0
To test whether Metformin directly affects @GENE$ cells, rat primary stomach cells were treated with @CHEMICAL$ and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with @CHEMICAL$ and the levels of @GENE$ secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with @CHEMICAL$ and the levels of ghrelin secretion, @GENE$ gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with @CHEMICAL$ and the levels of ghrelin secretion, proghrelin gene expression and activation of @GENE$ (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with @CHEMICAL$ and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (@GENE$) were examined.	0
To test whether Metformin directly affects @GENE$ cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of @CHEMICAL$-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of @GENE$ secretion, proghrelin gene expression and activation of @CHEMICAL$-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, @GENE$ gene expression and activation of @CHEMICAL$-activated protein kinase (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of @CHEM-GENE$ (AMPK) were examined.	0
To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of @CHEMICAL$-activated protein kinase (@GENE$) were examined.	0
@CHEMICAL$ significantly reduced @GENE$ secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	2
@CHEMICAL$ significantly reduced ghrelin secretion and @GENE$ mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	2
@CHEMICAL$ significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the @GENE$ inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	0
@CHEMICAL$ significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the @GENE$ activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	0
@CHEMICAL$ significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited @GENE$ secretion.	0
Metformin significantly reduced @GENE$ secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor @CHEMICAL$. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	1
Metformin significantly reduced ghrelin secretion and @GENE$ mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor @CHEMICAL$. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	1
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the @GENE$ inhibitor @CHEMICAL$. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	2
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor @CHEMICAL$. Furthermore, the @GENE$ activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor @CHEMICAL$. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited @GENE$ secretion.	0
Metformin significantly reduced @GENE$ secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator @CHEMICAL$ (AICAR) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and @GENE$ mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator @CHEMICAL$ (AICAR) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the @GENE$ inhibitor compound C. Furthermore, the AMPK activator @CHEMICAL$ (AICAR) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the @GENE$ activator @CHEMICAL$ (AICAR) significantly inhibited ghrelin secretion.	1
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator @CHEMICAL$ (AICAR) significantly inhibited @GENE$ secretion.	0
Metformin significantly reduced @GENE$ secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (@CHEMICAL$) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and @GENE$ mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (@CHEMICAL$) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the @GENE$ inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (@CHEMICAL$) significantly inhibited ghrelin secretion.	0
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the @GENE$ activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (@CHEMICAL$) significantly inhibited ghrelin secretion.	1
Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (@CHEMICAL$) significantly inhibited @GENE$ secretion.	2
Finally, @CHEMICAL$ treatment caused a significant increase in the level of @GENE$.	1
Our results show that @CHEMICAL$ directly inhibits stomach ghrelin production and secretion through @GENE$.	0
Our results show that @CHEMICAL$ directly inhibits stomach @GENE$ production and secretion through AMPK.	2
Fungicide @CHEMICAL$ and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the @GENE$ signaling pathway.	0
Fungicide @CHEMICAL$ and environmental pollutant dioxin induce the @GENE$ transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.	1
Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the @CHEM-GENE$ signaling pathway.	0
Fungicide prochloraz and environmental pollutant dioxin induce the @GENE$ transporter in bovine mammary epithelial cells by the @CHEMICAL$ receptor signaling pathway.	0
Fungicide prochloraz and environmental pollutant @CHEMICAL$ induce the ABCG2 transporter in bovine mammary epithelial cells by the @GENE$ signaling pathway.	0
Fungicide prochloraz and environmental pollutant @CHEMICAL$ induce the @GENE$ transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway.	1
Using computer analysis, we recently identified nuclear @GENE$ (AhR) binding sites termed "@CHEMICAL$ response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (@GENE$) binding sites termed "@CHEMICAL$ response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed "@CHEM-GENE$" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed "@CHEMICAL$ response elements" (@GENE$) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed "@CHEMICAL$ response elements" (DREs) in the 5'-untranslated region (5'-UTR) of @GENE$ ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear aryl hydrocarbon receptor (AhR) binding sites termed "@CHEMICAL$ response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter @GENE$ (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEM-GENE$ (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEMICAL$ receptor (@GENE$) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEMICAL$ receptor (AhR) binding sites termed "@GENE$" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEMICAL$ receptor (AhR) binding sites termed "dioxin response elements" (@GENE$) in the 5'-untranslated region (5'-UTR) of efflux transporter ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEMICAL$ receptor (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of @GENE$ ABCG2 (Accession No.	0
Using computer analysis, we recently identified nuclear @CHEMICAL$ receptor (AhR) binding sites termed "dioxin response elements" (DREs) in the 5'-untranslated region (5'-UTR) of efflux transporter @GENE$ (Accession No.	0
As these regulatory motifs mediate regulation of target genes by @GENE$ agonists including @CHEMICAL$ and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.	3
As these regulatory motifs mediate regulation of target genes by AhR agonists including @CHEMICAL$ and prochloraz, we have systematically investigated the effect of both contaminants on functional @GENE$ transport activity in primary bovine mammary epithelial cells.	0
As these regulatory motifs mediate regulation of target genes by @GENE$ agonists including TCDD and @CHEMICAL$, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells.	3
As these regulatory motifs mediate regulation of target genes by AhR agonists including TCDD and @CHEMICAL$, we have systematically investigated the effect of both contaminants on functional @GENE$ transport activity in primary bovine mammary epithelial cells.	0
@CHEMICAL$ or prochloraz doubled @GENE$-mediated Hoechst H33342 secretion.	0
TCDD or @CHEMICAL$ doubled @GENE$-mediated Hoechst H33342 secretion.	0
TCDD or prochloraz doubled @GENE$-mediated @CHEMICAL$ secretion.	5
This effect was almost completely reversed by specific @GENE$ inhibitor @CHEMICAL$.	2
Receptor binding was significantly reduced by specific @GENE$ antagonist @CHEMICAL$.	4
Induction of @GENE$ by @CHEMICAL$ and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.	1
Induction of AhR by @CHEMICAL$ and prochloraz resulted in a time- and dose-dependent increase of @GENE$ gene expression and transporter protein levels.	1
Induction of @GENE$ by TCDD and @CHEMICAL$ resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels.	1
Induction of AhR by TCDD and @CHEMICAL$ resulted in a time- and dose-dependent increase of @GENE$ gene expression and transporter protein levels.	1
Through identification of mammary @GENE$ as a novel target gene of pesticide @CHEMICAL$ and dioxin, our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.	0
Through identification of mammary @GENE$ as a novel target gene of pesticide prochloraz and @CHEMICAL$, our results may therefore help to improve the protection of breast-feeding infants and the consumer of dairy products.	0
We found that @CHEMICAL$ NPs were highly cytotoxic to hepatocytes (LC(50) @GENE$: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.	0
We found that @CHEMICAL$ NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing @GENE$ release.	2
We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) @CHEM-GENE$: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing albumin release.	0
We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) @CHEMICAL$ dehydrogenase: 2.5 μg/cm(2)) and affected hepatocyte homeostasis by reducing @GENE$ release.	0
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of @GENE$ (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.	1
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (@GENE$)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.	1
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/@GENE$, IL-1RI, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.	1
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, @GENE$, and tumor necrosis factor-α expression in both models and increased IL-8 protein release in vitro.	1
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and @GENE$ expression in both models and increased IL-8 protein release in vitro.	1
We observed similar effects of @CHEMICAL$ NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-α expression in both models and increased @GENE$ protein release in vitro.	1
@GENE$ modulates @CHEMICAL$ sensitivity of the prostaglandin EP3 receptor.	0
Extracellular loop II modulates @CHEMICAL$ sensitivity of the @GENE$.	0
@GENE$ modulates GTP sensitivity of the @CHEMICAL$ EP3 receptor.	0
Extracellular loop II modulates GTP sensitivity of the @CHEM-GENE$.	0
Unlike the majority of @GENE$, the prostaglandin E(2) (@CHEMICAL$) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Unlike the majority of G protein-coupled receptors, the @CHEM-GENE$ binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Unlike the majority of @GENE$, the prostaglandin E(2) (PGE(2)) @CHEMICAL$ 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Unlike the majority of G protein-coupled receptors, the @CHEM-GENE$ binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Unlike the majority of @GENE$, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of @CHEMICAL$ (GTPγS).	0
Unlike the majority of G protein-coupled receptors, the @GENE$ binds agonist with high affinity that is insensitive to the presence of @CHEMICAL$ (GTPγS).	0
Unlike the majority of @GENE$, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (@CHEMICAL$).	0
Unlike the majority of G protein-coupled receptors, the @GENE$ binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (@CHEMICAL$).	0
Unlike the majority of @GENE$, the @CHEMICAL$ (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Unlike the majority of G protein-coupled receptors, the @CHEM-GENE$ binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPγS).	0
Seven point mutations were introduced into the conserved motif in the @GENE$ (ECII) of EP3, resulting in acquisition of @CHEMICAL$-sensitive agonist binding.	0
Seven point mutations were introduced into the conserved motif in the second extracellular loop (@GENE$) of EP3, resulting in acquisition of @CHEMICAL$-sensitive agonist binding.	0
Seven point mutations were introduced into the conserved motif in the second extracellular loop (ECII) of @GENE$, resulting in acquisition of @CHEMICAL$-sensitive agonist binding.	0
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the @GENE$ receptor, conditions where high GTP levels are present; however, high affinity binding @CHEMICAL$ was observed in broken cell preparations washed free of GTP.	0
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the @GENE$ receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of @CHEMICAL$.	0
Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the @GENE$ receptor, conditions where high @CHEMICAL$ levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP.	0
The @CHEMICAL$ binding of @GENE$ in broken cell membrane fractions was inhibited by addition of GTPγS (IC(50) 21 ± 1.8 nM).	0
The [(3)H]PGE(2) binding of @GENE$ in broken cell membrane fractions was inhibited by addition of @CHEMICAL$ (IC(50) 21 ± 1.8 nM).	0
Moreover, mutation of @GENE$ can alter this coupled equilibrium from @CHEMICAL$-insensitive agonist binding to more conventional GTP-sensitive binding.	0
Moreover, mutation of @GENE$ can alter this coupled equilibrium from GTP-insensitive agonist binding to more conventional @CHEMICAL$-sensitive binding.	0
This suggests that for the mutant receptors, @GENE$ plays a critical role in linking the agonist bound receptor conformation to the G protein @CHEMICAL$ bound state.	0
This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the @GENE$ @CHEMICAL$ bound state.	0
PB induction of the @GENE$-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEMICAL$ synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for β-catenin signaling in the dysregulation of Dlk1-Dio3 ncRNAs.	0
PB induction of the Dlk1-@GENE$ cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEMICAL$ synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for β-catenin signaling in the dysregulation of Dlk1-Dio3 ncRNAs.	0
PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEM-GENE$-positive hypertrophic perivenous hepatocytes, suggesting a role for β-catenin signaling in the dysregulation of Dlk1-Dio3 ncRNAs.	0
PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEMICAL$ synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for @GENE$ signaling in the dysregulation of Dlk1-Dio3 ncRNAs.	0
PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEMICAL$ synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for β-catenin signaling in the dysregulation of @GENE$-Dio3 ncRNAs.	0
PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to @CHEMICAL$ synthetase-positive hypertrophic perivenous hepatocytes, suggesting a role for β-catenin signaling in the dysregulation of Dlk1-@GENE$ ncRNAs.	0
The carcinogenic relevance of @GENE$-Dio3 locus ncRNA induction was further supported by in vivo genetic dependence on constitutive @CHEMICAL$ receptor and β-catenin pathways.	0
The carcinogenic relevance of Dlk1-@GENE$ locus ncRNA induction was further supported by in vivo genetic dependence on constitutive @CHEMICAL$ receptor and β-catenin pathways.	0
The carcinogenic relevance of Dlk1-Dio3 locus ncRNA induction was further supported by in vivo genetic dependence on @CHEM-GENE$ and β-catenin pathways.	0
The carcinogenic relevance of Dlk1-Dio3 locus ncRNA induction was further supported by in vivo genetic dependence on constitutive @CHEMICAL$ receptor and @GENE$ pathways.	0
In this study we report the effects of @GENE$ on learning and memory in intact rats pretreated with the anabolic androgenic @CHEMICAL$ nandrolone.	0
In this study we report the effects of @GENE$ on learning and memory in intact rats pretreated with the anabolic androgenic steroid @CHEMICAL$.	0
Male Wistar rats received @CHEMICAL$ (15 mg/kg) or peanut oil every third day for 3 weeks and were subsequently treated with recombinant @GENE$ (1.0 IU/kg) or saline for 10 consecutive days.	0
In addition, @GENE$ was demonstrated to increase the body weight gain and was able to attenuate the reduced body weight seen in @CHEMICAL$-treated animals.	0
In general, the rats treated with @CHEMICAL$ alone did not exhibit any pronounced alteration in memory compared with controls in the MWM, and in many cases @GENE$ did not induce any alteration.	0
In conclusion, @GENE$ improves spatial memory in intact rats and can reverse certain effects induced by anabolic androgenic @CHEMICAL$.	0
Blood pressure was increased in rats exposed to IH, and treatment with the @GENE$ inhibitor @CHEMICAL$ [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg/day) lowered blood pressure in IH but not sham group rats.	2
Blood pressure was increased in rats exposed to IH, and treatment with the @GENE$ inhibitor OSU-03012 [@CHEMICAL$] (33 mg/day) lowered blood pressure in IH but not sham group rats.	2
Interestingly, @GENE$ was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich @CHEMICAL$ kinase 2, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with @GENE$, nectin-3, afadin, Src, proline-rich @CHEMICAL$ kinase 2, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, @GENE$, afadin, Src, proline-rich @CHEMICAL$ kinase 2, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, @GENE$, Src, proline-rich @CHEMICAL$ kinase 2, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, @GENE$, proline-rich @CHEMICAL$ kinase 2, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, @CHEM-GENE$, annexin II, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich @CHEMICAL$ kinase 2, @GENE$, and actin.	0
Interestingly, ICAM2 was found to associate with β1-integrin, nectin-3, afadin, Src, proline-rich @CHEMICAL$ kinase 2, annexin II, and @GENE$.	0
Following CdCl₂ treatment, @GENE$ was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during @CHEMICAL$-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for @GENE$ by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during @CHEMICAL$-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of @GENE$ to actin during @CHEMICAL$-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to @GENE$ during @CHEMICAL$-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	2
Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during @CHEMICAL$-induced germ cell loss, suggesting that a loss of @GENE$-actin interactions might have facilitated junction restructuring.	0
Following CdCl₂ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during @CHEMICAL$-induced germ cell loss, suggesting that a loss of ICAM2-@GENE$ interactions might have facilitated junction restructuring.	0
Following @CHEMICAL$ treatment, @GENE$ was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	1
Following @CHEMICAL$ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for @GENE$ by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following @CHEMICAL$ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of @GENE$ to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following @CHEMICAL$ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to @GENE$ during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.	0
Following @CHEMICAL$ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of @GENE$-actin interactions might have facilitated junction restructuring.	0
Following @CHEMICAL$ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl₂-induced germ cell loss, suggesting that a loss of ICAM2-@GENE$ interactions might have facilitated junction restructuring.	0
The catalytic competence of @GENE$ in the synthesis of @CHEMICAL$ from 5-methoxytryptamine in the brain: an in vitro study.	5
The catalytic competence of @GENE$ in the synthesis of serotonin from @CHEMICAL$ in the brain: an in vitro study.	5
The aim of present study was to identify @GENE$ (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to @CHEMICAL$, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
The aim of present study was to identify rat cytochrome P450 (@GENE$) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to @CHEMICAL$, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
The aim of present study was to identify @GENE$ (CYP) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of @CHEMICAL$ synthesis may take place in the brain.	0
The aim of present study was to identify rat cytochrome P450 (@GENE$) isoforms which can catalyze the O-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of @CHEMICAL$ synthesis may take place in the brain.	0
The aim of present study was to identify @GENE$ (CYP) isoforms which can catalyze the @CHEMICAL$-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
The aim of present study was to identify rat cytochrome P450 (@GENE$) isoforms which can catalyze the @CHEMICAL$-demethylation of 5-methoxytryptamine to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
The aim of present study was to identify @GENE$ (CYP) isoforms which can catalyze the O-demethylation of @CHEMICAL$ to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
The aim of present study was to identify rat cytochrome P450 (@GENE$) isoforms which can catalyze the O-demethylation of @CHEMICAL$ to serotonin, and to find out whether that alternative pathway of serotonin synthesis may take place in the brain.	0
Of the @GENE$ isoforms studied, CYP2D isoforms were the most efficient in catalyzing the @CHEMICAL$-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.	0
Of the rat CYP isoforms studied, @GENE$ isoforms were the most efficient in catalyzing the @CHEMICAL$-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.	5
Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the @CHEMICAL$-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the @GENE$.	5
Of the @GENE$ isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of @CHEMICAL$ to serotonin, but they were less effective than the human isoform CYP2D6.	0
Of the rat CYP isoforms studied, @GENE$ isoforms were the most efficient in catalyzing the O-demethylation of @CHEMICAL$ to serotonin, but they were less effective than the human isoform CYP2D6.	5
Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of @CHEMICAL$ to serotonin, but they were less effective than the @GENE$.	5
Of the @GENE$ isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to @CHEMICAL$, but they were less effective than the human isoform CYP2D6.	0
Of the rat CYP isoforms studied, @GENE$ isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to @CHEMICAL$, but they were less effective than the human isoform CYP2D6.	5
Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to @CHEMICAL$, but they were less effective than the @GENE$.	5
The reaction was inhibited by the specific @GENE$ inhibitors @CHEMICAL$ and fluoxetine.	2
The reaction was inhibited by the specific @GENE$ inhibitors quinine and @CHEMICAL$.	2
Human liver microsomes of the wild-type @GENE$ metabolized @CHEMICAL$ to serotonin more effectively than did the defective CYP2D6*4*4 ones.	5
Human liver microsomes of the wild-type CYP2D6 metabolized @CHEMICAL$ to serotonin more effectively than did the defective @GENE$*4*4 ones.	5
Human liver microsomes of the wild-type @GENE$ metabolized 5-methoxytryptamine to @CHEMICAL$ more effectively than did the defective CYP2D6*4*4 ones.	5
Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to @CHEMICAL$ more effectively than did the defective @GENE$*4*4 ones.	5
The obtained results indicate that @GENE$ isoforms catalyze the formation of @CHEMICAL$ from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.	5
The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of @CHEMICAL$ from 5-methoxytryptamine, and that the deficit or genetic defect of @GENE$ may affect serotonin metabolism in the brain.	0
The obtained results indicate that @GENE$ isoforms catalyze the formation of serotonin from @CHEMICAL$, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.	5
The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from @CHEMICAL$, and that the deficit or genetic defect of @GENE$ may affect serotonin metabolism in the brain.	0
The obtained results indicate that @GENE$ isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect @CHEMICAL$ metabolism in the brain.	0
The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of @GENE$ may affect @CHEMICAL$ metabolism in the brain.	5
@CHEM-GENE$ signaling as a target for novel breast cancer therapeutics.	0
In breast cancer (BC) epithelial cells, the mitogenic action of @CHEMICAL$ is transduced through binding to two receptors, @GENE$ and ERβ, which act as transcription factors.	0
In breast cancer (BC) epithelial cells, the mitogenic action of @CHEMICAL$ is transduced through binding to two receptors, ERα and @GENE$, which act as transcription factors.	0
Anti-@CHEMICAL$ (AEs) and @GENE$ inhibitors (AIs) are used clinically to arrest the estrogen-dependent growth of BC.	0
Anti-estrogens (AEs) and @GENE$ inhibitors (AIs) are used clinically to arrest the @CHEMICAL$-dependent growth of BC.	0
@CHEMICAL$ effects are mediated not only through nuclear @GENE$ but also through cytoplasmic/membrane ERs and G-protein-coupled ERs.	0
@CHEMICAL$ effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane @GENE$ and G-protein-coupled ERs.	0
@CHEMICAL$ effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and @GENE$-coupled ERs.	0
@CHEMICAL$ effects are mediated not only through nuclear ERs but also through cytoplasmic/membrane ERs and G-protein-coupled @GENE$.	0
The partners of extra-nuclear @GENE$ include PI3K and the @CHEMICAL$ kinase Src.	0
The partners of extra-nuclear ERα include @GENE$ and the @CHEMICAL$ kinase Src.	0
The partners of extra-nuclear ERα include PI3K and the @CHEM-GENE$ Src.	0
The partners of extra-nuclear ERα include PI3K and the @CHEMICAL$ kinase @GENE$.	0
@GENE$-mediated signaling also modulates the @CHEMICAL$ response.	0
@CHEMICAL$ induces apoptosis through suppression of @GENE$ signaling pathway in HL-60 cells.	2
Western blot analysis indicated that @CHEMICAL$ inhibits the @GENE$/MEKK1/JNK pathway.	2
Western blot analysis indicated that @CHEMICAL$ inhibits the CDC42/@GENE$/JNK pathway.	2
Western blot analysis indicated that @CHEMICAL$ inhibits the CDC42/MEKK1/@GENE$ pathway.	2
Taken together, our study suggested, for the first time, that the pro-apoptotic effects of @CHEMICAL$ on HL-60 cells were mediated through @GENE$ signaling pathway.	0
Administration of low, but not high, doses of oral @CHEMICAL$ in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of @GENE$.	1
@GENE$ is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the KIR-Keap1 complex.	0
Keap1 is expressed in differentiating osteoclast-like cells and the @GENE$ mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the KIR-Keap1 complex.	0
Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the @GENE$-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the KIR-Keap1 complex.	0
Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-@GENE$ interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the KIR-Keap1 complex.	0
Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the @GENE$-Keap1 complex.	0
Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical @CHEMICAL$ bonds required to stabilise the KIR-@GENE$ complex.	0
@GENE$ suppresses postischemic @CHEMICAL$ intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.	0
Orexin-A suppresses postischemic @CHEMICAL$ intolerance and neuronal damage through hypothalamic @GENE$.	0
@GENE$ (a @CHEMICAL$-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism.	0
Orexin-A (a @CHEMICAL$-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (@GENE$; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism.	0
Orexin-A (a @CHEMICAL$-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the @GENE$ family) play roles in many physiologic functions, including regulation of glucose metabolism.	0
Orexin-A (a @CHEMICAL$-sensing neuropeptide in the hypothalamus) and @GENE$ (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism.	0
@GENE$ (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of @CHEMICAL$ metabolism.	0
Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (@GENE$; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of @CHEMICAL$ metabolism.	0
Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the @GENE$ family) play roles in many physiologic functions, including regulation of @CHEMICAL$ metabolism.	0
Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and @GENE$ (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of @CHEMICAL$ metabolism.	0
Small interfering RNA directed @GENE$, orexin-A, and @CHEMICAL$ [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus.	0
Small interfering RNA directed BDNF, @GENE$, and @CHEMICAL$ [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus.	0
Small interfering RNA directed BDNF, orexin-A, and @CHEMICAL$ [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific @GENE$ antagonist] were administered directly into the hypothalamus.	4
Small interfering RNA directed @GENE$, orexin-A, and SB334867 [@CHEMICAL$; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus.	0
Small interfering RNA directed BDNF, @GENE$, and SB334867 [@CHEMICAL$; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus.	0
Small interfering RNA directed BDNF, orexin-A, and SB334867 [@CHEMICAL$; a specific @GENE$ antagonist] were administered directly into the hypothalamus.	4
Intrahypothalamic administration of @GENE$ (1 or 5 pmol/mouse) significantly and dose-dependently suppressed the development of postischemic @CHEMICAL$ intolerance on day 1 and development of neuronal damage on day 3.	0
The MCAO-induced decrease in @GENE$ levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of @CHEMICAL$ as well as by hypothalamic BDNF knockdown.	2
The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by @GENE$, and this effect of orexin-A was reversed by the administration of @CHEMICAL$ as well as by hypothalamic BDNF knockdown.	0
The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of @GENE$ was reversed by the administration of @CHEMICAL$ as well as by hypothalamic BDNF knockdown.	2
The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of @CHEMICAL$ as well as by hypothalamic @GENE$ knockdown.	0
These results suggest that suppression of postischemic @CHEMICAL$ intolerance by @GENE$ assists in the prevention of cerebral ischemic neuronal damage.	0
@CHEMICAL$ modulates intercellular adhesion through inhibition of @GENE$.	2
Filtering and analysis of data identified three oncogenic pathways interfered by @CHEMICAL$: @GENE$/ERK pathway, cell adhesion and β-catenin/Wnt signaling.	0
Filtering and analysis of data identified three oncogenic pathways interfered by @CHEMICAL$: MAPK/@GENE$ pathway, cell adhesion and β-catenin/Wnt signaling.	0
Filtering and analysis of data identified three oncogenic pathways interfered by @CHEMICAL$: MAPK/ERK pathway, cell adhesion and @GENE$/Wnt signaling.	0
Filtering and analysis of data identified three oncogenic pathways interfered by @CHEMICAL$: MAPK/ERK pathway, cell adhesion and β-catenin/@GENE$ signaling.	0
@GENE$ emerged as a consensus target of @CHEMICAL$, orchestrating these pathways.	0
Moreover, @CHEMICAL$ treatment restored membranous expression of adhesion molecules @GENE$ and β-catenin.	1
Moreover, @CHEMICAL$ treatment restored membranous expression of adhesion molecules E-cadherin and @GENE$.	1
@GENE$ expression was elevated in APC(min) polyps and @CHEMICAL$ treatment reduced its expression.	2
Our data demonstrates novel pharmacological mechanism of @CHEMICAL$ in modulation of cell adhesion and role of @GENE$ in APC(min) polyposis.	0
We propose that inhibition of @GENE$ expression by @CHEMICAL$ can impede with neoplastic progression in colorectal carcinogenesis.	2
The mechanism of @GENE$ inhibition and induction of membranous translocation of adhesion proteins by @CHEMICAL$ might be independent of its known anti-inflammatory action.	2
Cholestatic effect of @CHEMICAL$ in rats is mediated via decreased expression of @GENE$.	0
Accordingly, the main @CHEM-GENE$ on the hepatocyte canalicular membrane, multidrug resistance-associated protein 2 (Mrp2), was significantly decreased at the protein level.	0
Accordingly, the main @CHEMICAL$ transporter on the hepatocyte canalicular membrane, @GENE$ (Mrp2), was significantly decreased at the protein level.	0
Accordingly, the main @CHEMICAL$ transporter on the hepatocyte canalicular membrane, multidrug resistance-associated protein 2 (@GENE$), was significantly decreased at the protein level.	0
While protein levels of the main @CHEM-GENE$ were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by EGCG.	0
While protein levels of the main hepatic @CHEMICAL$ transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, @GENE$, was significantly increased by EGCG.	0
While protein levels of the main @GENE$ were unchanged, the rate-limiting enzyme in the @CHEMICAL$ synthesis, Cyp7a1, was significantly increased by EGCG.	0
While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the @CHEMICAL$ synthesis, @GENE$, was significantly increased by EGCG.	0
While protein levels of the main @GENE$ were unchanged, the rate-limiting enzyme in the bile acid synthesis, Cyp7a1, was significantly increased by @CHEMICAL$.	0
While protein levels of the main hepatic bile acid transporters were unchanged, the rate-limiting enzyme in the bile acid synthesis, @GENE$, was significantly increased by @CHEMICAL$.	0
In contrast, @CHEMICAL$ markedly downregulated major @GENE$ (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.	2
In contrast, @CHEMICAL$ markedly downregulated major bile acid transporters (@GENE$ and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.	2
In contrast, @CHEMICAL$ markedly downregulated major bile acid transporters (Asbt and @GENE$) and regulatory molecules (Shp and Fgf15) in the ileum.	2
In contrast, @CHEMICAL$ markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (@GENE$ and Fgf15) in the ileum.	2
In contrast, @CHEMICAL$ markedly downregulated major bile acid transporters (Asbt and Ostα) and regulatory molecules (Shp and @GENE$) in the ileum.	2
In contrast, EGCG markedly downregulated major @CHEM-GENE$ (Asbt and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.	0
In contrast, EGCG markedly downregulated major @CHEMICAL$ transporters (@GENE$ and Ostα) and regulatory molecules (Shp and Fgf15) in the ileum.	0
In contrast, EGCG markedly downregulated major @CHEMICAL$ transporters (Asbt and @GENE$) and regulatory molecules (Shp and Fgf15) in the ileum.	0
In contrast, EGCG markedly downregulated major @CHEMICAL$ transporters (Asbt and Ostα) and regulatory molecules (@GENE$ and Fgf15) in the ileum.	0
In contrast, EGCG markedly downregulated major @CHEMICAL$ transporters (Asbt and Ostα) and regulatory molecules (Shp and @GENE$) in the ileum.	0
This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through @GENE$ upregulation, and to decrease bile production through reduction in Mrp2-mediated @CHEMICAL$-independent bile flow.	0
This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in @GENE$-mediated @CHEMICAL$-independent bile flow.	0
This study shows ability of @CHEMICAL$ to raise plasma bile acid concentrations, mainly through @GENE$ upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.	1
This study shows ability of @CHEMICAL$ to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in @GENE$-mediated bile acid-independent bile flow.	0
This study shows ability of EGCG to raise plasma @CHEMICAL$ concentrations, mainly through @GENE$ upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.	0
This study shows ability of EGCG to raise plasma @CHEMICAL$ concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in @GENE$-mediated bile acid-independent bile flow.	0
Consistent with an adult-onset isolated GHD model, mutant animals are hypoglycemic and display increased @GENE$ sensitivity and @CHEMICAL$ clearance.	0
@CHEM-GENE$ of type 6 (5-HT6): from neuroscience to clinical pharmacology.	0
@CHEMICAL$ receptors of type 6 (@GENE$): from neuroscience to clinical pharmacology.	0
The serotonin (@CHEMICAL$) receptors of type 6 (5-HT6) are quite different from all other @GENE$, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The serotonin (@CHEMICAL$) receptors of type 6 (@GENE$) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @CHEM-GENE$ of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other @GENE$, as they include a short third cytoplasmatic loop and a long @CHEMICAL$-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The serotonin (5-HT) receptors of type 6 (@GENE$) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long @CHEMICAL$-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @GENE$ of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long @CHEMICAL$-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @CHEMICAL$ (5-HT) receptors of type 6 (5-HT6) are quite different from all other @GENE$, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @CHEMICAL$ (5-HT) receptors of type 6 (@GENE$) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @CHEM-GENE$ of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other @CHEM-GENE$, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The serotonin (5-HT) receptors of type 6 (@GENE$) are quite different from all other @CHEMICAL$ receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
The @GENE$ of type 6 (5-HT6) are quite different from all other @CHEMICAL$ receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.	0
A lot of controversies still exist regarding their binding affinity, effects of @GENE$ ligands on brain @CHEMICAL$, behavioral syndromes regulated by them, and brain distribution.	0
Expression of @CHEM-GENE$ (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction.	0
Expression of @CHEMICAL$-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of @GENE$ (ColQ) of acetylcholinesterase at the rat neuromuscular junction.	0
Expression of @CHEMICAL$-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (@GENE$) of acetylcholinesterase at the rat neuromuscular junction.	0
Expression of @CHEMICAL$-responsive element binding proteins (CREBs) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of @GENE$ at the rat neuromuscular junction.	0
Expression of @CHEMICAL$-responsive element binding proteins (@GENE$) in fast- and slow-twitch muscles: A signaling pathway to account for the synaptic expression of collagen-tailed subunit (ColQ) of acetylcholinesterase at the rat neuromuscular junction.	0
@GENE$ is expressed at the neuromuscular junction (NMJ) in fast-twitch muscle, and this expression depends on trophic factors supplied by motor neurons signaling via a @CHEMICAL$-dependent pathway in muscle.	0
To further elucidate the molecular basis of @GENE$ synaptic expression, here we investigated the expression and localization of @CHEMICAL$-responsive element binding protein (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats.	0
To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of @CHEM-GENE$ (CREB) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats.	0
To further elucidate the molecular basis of ColQ-1a's synaptic expression, here we investigated the expression and localization of @CHEMICAL$-responsive element binding protein (@GENE$) at the synaptic and extra-synaptic regions of fast- and slow-twitch muscles from adult rats.	0
These results reveal, for the first time, the differential distribution of @GENE$ in fast- and slow-twitch muscles, which might support the crucial role of @CHEMICAL$-dependent signaling in controlling the synapse-specific expression of ColQ-1a in fast-twitch muscles.	0
These results reveal, for the first time, the differential distribution of P-CREB in fast- and slow-twitch muscles, which might support the crucial role of @CHEMICAL$-dependent signaling in controlling the synapse-specific expression of @GENE$ in fast-twitch muscles.	0
Analysis of @CHEM-GENE$ (ADH5): characterisation of rat ADH5 with comparisons to the corresponding human variant.	0
Analysis of mammalian @CHEMICAL$ dehydrogenase 5 (@GENE$): characterisation of rat ADH5 with comparisons to the corresponding human variant.	0
Analysis of mammalian @CHEMICAL$ dehydrogenase 5 (ADH5): characterisation of @GENE$ with comparisons to the corresponding human variant.	0
@CHEMICAL$ dehydrogenase 5 (@GENE$) is a member of the mammalian alcohol dehydrogenase family of yet undefined functions.	0
@CHEMICAL$ dehydrogenase 5 (ADH5) is a member of the @GENE$ family of yet undefined functions.	0
@CHEM-GENE$ (ADH5) is a member of the mammalian alcohol dehydrogenase family of yet undefined functions.	0
Alcohol dehydrogenase 5 (@GENE$) is a member of the mammalian @CHEMICAL$ dehydrogenase family of yet undefined functions.	0
Alcohol dehydrogenase 5 (ADH5) is a member of the @CHEM-GENE$ family of yet undefined functions.	0
@GENE$ (ADH5) is a member of the mammalian @CHEMICAL$ dehydrogenase family of yet undefined functions.	0
A @CHEM-GENE$ structure of similar type has been isolated at the cDNA level using human ADH5 as a screening probe, where the rat cDNA structure displayed several atypical properties.	0
A rat @CHEMICAL$ dehydrogenase structure of similar type has been isolated at the cDNA level using @GENE$ as a screening probe, where the rat cDNA structure displayed several atypical properties.	0
However, no soluble @GENE$ protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other mammalian ADHs, including fused to @CHEMICAL$-S-transferase.	0
However, no soluble ADH5 protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other @GENE$, including fused to @CHEMICAL$-S-transferase.	0
However, no soluble @GENE$ protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other mammalian ADHs, including fused to glutathione-@CHEMICAL$-transferase.	0
However, no soluble ADH5 protein could be heterologously expressed in Escherichia coli cells with expression systems successfully used for other @GENE$, including fused to glutathione-@CHEMICAL$-transferase.	0
SAR beyond protein-ligand interactions: By combining structure-affinity relationships, protein-ligand modeling studies, and quantum mechanical calculations, we show that ligand conformational energies and basicity play critical roles in ligand binding to the @CHEM-GENE$, a GPCR that plays a key role in inflammation.	0
SAR beyond protein-ligand interactions: By combining structure-affinity relationships, protein-ligand modeling studies, and quantum mechanical calculations, we show that ligand conformational energies and basicity play critical roles in ligand binding to the @CHEMICAL$ H4 receptor, a @GENE$ that plays a key role in inflammation.	0
@CHEMICAL$ inhibits LPS plus @GENE$-induced inflammatory response in astrocytes primary cultures.	2
To further investigate the protective effect and underlying mechanism of @CHEMICAL$, astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) catalpol for 1h prior to LPS plus @GENE$ stimulation.	0
To further investigate the protective effect and underlying mechanism of catalpol, astrocytes were pretreated with low (0.1mM) and high dose (0.5mM) @CHEMICAL$ for 1h prior to LPS plus @GENE$ stimulation.	0
Biochemical analyses showed that @CHEMICAL$ and ROS production and @GENE$ activity were significantly reduced by catalpol.	0
Biochemical analyses showed that NO and ROS production and @GENE$ activity were significantly reduced by @CHEMICAL$.	2
Data at transcriptional level also demonstrated that @CHEMICAL$ potently attenuated gene expressions involved in inflammation, such as @GENE$, COX-2 and TLR4.	2
Data at transcriptional level also demonstrated that @CHEMICAL$ potently attenuated gene expressions involved in inflammation, such as iNOS, @GENE$ and TLR4.	2
Data at transcriptional level also demonstrated that @CHEMICAL$ potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and @GENE$.	2
In addition, our exploration further revealed that the suppressive action of @CHEMICAL$ on inflammation was mediated via inhibiting nuclear factor-κB (@GENE$) activation.	2
In addition, our exploration further revealed that the suppressive action of @CHEMICAL$ on inflammation was mediated via inhibiting @GENE$ (NF-κB) activation.	2
Collectively, these results suggest that @CHEMICAL$ can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of @GENE$ could be the major determinant for its anti-inflammatory mechanism.	2
@GENE$ treatment of complex IV prevented trimer formation in the absence of @CHEMICAL$.	0
@GENE$ inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum @CHEMICAL$.	2
@GENE$ inhibitory effect by @CHEMICAL$-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.	2
@GENE$ inhibitory effect by dammarane-type @CHEMICAL$ from hydrolyzate of total Gynostemma pentaphyllum saponins.	2
@CHEM-GENE$ inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.	0
Protein @CHEMICAL$ phosphatase 1B (PTP1B) is an important factor in non-@GENE$-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity.	0
@CHEM-GENE$ (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity.	0
Protein @CHEMICAL$ phosphatase 1B (@GENE$) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (@GENE$ - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - @GENE$ - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and @GENE$) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (@GENE$: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: @GENE$, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, @GENE$ and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and @GENE$); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased @GENE$ (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (@GENE$) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (@GENE$ and p38MAPK) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and @GENE$) and @CHEMICAL$-dependent protein kinase (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEM-GENE$ (PKA) activities.	0
The earlier responses, at day 3 after injection, included hyperphosphorylation of intermediate filament (IF) proteins from astrocyte (glial fibrillary acidic protein - GFAP - and vimentin) and neuron (low-, medium- and high molecular weight neurofilament subunits: NF-L, NF-M and NF-H); increased mitogen-activated protein kinase (MAPK) (Erk and p38MAPK) and @CHEMICAL$-dependent protein kinase (@GENE$) activities.	0
Also, reactive astrogliosis takes part of the early responses to the insult with @CHEMICAL$, evidenced by upregulated @GENE$ in Western blot, PCR and immunofluorescence analysis.	1
Six days after @CHEMICAL$ injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for @GENE$, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death.	0
Six days after @CHEMICAL$ injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in @GENE$ positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death.	0
Six days after (PhTe)(2) injection we found persistent astrogliosis, increased @CHEMICAL$ (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for @GENE$, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death.	0
Six days after (PhTe)(2) injection we found persistent astrogliosis, increased @CHEMICAL$ (PI) positive cells in @GENE$ positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death.	0
Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for @GENE$, suggesting that the in vivo exposure to @CHEMICAL$ progressed to neuronal death.	2
Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in @GENE$ positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN, suggesting that the in vivo exposure to @CHEMICAL$ progressed to neuronal death.	0
Neurodegeneration was related with decreased @CHEMICAL$ uptake and decreased @GENE$ immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in (PhTe)(2) injected rat.	0
Neurodegeneration was related with decreased @CHEMICAL$ uptake and decreased Akt immunoreactivity, however @GENE$ (Ser9) was not altered in (PhTe)(2) injected rat.	0
Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased @GENE$ immunoreactivity, however phospho-GSK-3-β (@CHEMICAL$9) was not altered in (PhTe)(2) injected rat.	0
Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however @GENE$ (@CHEMICAL$9) was not altered in (PhTe)(2) injected rat.	0
Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased @GENE$ immunoreactivity, however phospho-GSK-3-β (Ser9) was not altered in @CHEMICAL$ injected rat.	2
Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however @GENE$ (Ser9) was not altered in @CHEMICAL$ injected rat.	0
Therefore, the present results show that the earlier cerebellar responses to @CHEMICAL$ include disruption of cytoskeletal homeostasis that could be related with @GENE$ and PKA activation and reactive astrogliosis.	1
Therefore, the present results show that the earlier cerebellar responses to @CHEMICAL$ include disruption of cytoskeletal homeostasis that could be related with MAPK and @GENE$ activation and reactive astrogliosis.	1
The later events of the neurodegenerative process are characterized by persistent astrogliosis and activation of apoptotic neuronal death through @GENE$ mediated mechanisms, which could be related with @CHEMICAL$ excitotoxicity.	0
Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted @CHEMICAL$ substrate by the cancer-associated @GENE$ (hNQO1).	5
Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted @CHEMICAL$ substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (@GENE$).	5
Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated @CHEM-GENE$ (hNQO1).	0
Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:@CHEMICAL$ oxidoreductase isozyme 1 (@GENE$).	0
Fluorescence of the reporter dye is turned on by rapid removal of the @CHEMICAL$ quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated @GENE$ (hNQO1).	0
Fluorescence of the reporter dye is turned on by rapid removal of the @CHEMICAL$ quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (@GENE$).	0
Synthesis, biological evaluation, and molecular modeling of @CHEMICAL$ derivatives as potent @GENE$ inhibitors with anti-heart-failure activity in vivo.	2
Within the @CHEMICAL$ scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-@GENE$ antagonism, which was demonstrated to be mediated via the orthosteric site.	4
Within the TPBP scaffold, either electronic or steric perturbations to the central @CHEMICAL$ ring led to a loss of selective M(1) allosteric agonism and afforded pan-@GENE$ antagonism, which was demonstrated to be mediated via the orthosteric site.	4
Additional SAR around a related M(1) allosteric agonist family (@CHEMICAL$) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-@GENE$ orthosteric antagonism.	4
The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a @GENE$ substrate, @CHEMICAL$, and its major metabolite, 9-hydroxyrisperidone, in rats.	5
The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a @GENE$ substrate, risperidone, and its major metabolite, @CHEMICAL$, in rats.	5
The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of @CHEMICAL$ and 9-hydroxyrisperidone, by inhibiting @GENE$.	0
The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of risperidone and @CHEMICAL$, by inhibiting @GENE$.	0
Design, synthesis and structure-activity relationship of new @GENE$ analogues containing @CHEMICAL$ derivatives in position 2.	0
Design, synthesis and structure-activity relationship of new @CHEM-GENE$ analogues containing proline derivatives in position 2.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @CHEM-GENE$ modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @GENE$ modified in the @CHEMICAL$-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @GENE$ modified in the N-terminal part of the molecule with @CHEMICAL$ derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @GENE$ modified in the N-terminal part of the molecule with proline derivatives: @CHEMICAL$ (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @GENE$ modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (@CHEMICAL$) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.	0
In this study, we present the synthesis and pharmacological properties of new analogues of @GENE$ modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and @CHEMICAL$.	0
We also determined their binding affinity to the @CHEM-GENE$.	0
On the other hand, peptides modified with @CHEMICAL$, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to @GENE$.	4
On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to @CHEM-GENE$.	0
The results of this study provide useful information about the structure-activity relationship of @CHEM-GENE$ analogues and can help to design compounds with desired biological properties.	0
@GENE$ and female reproduction: when @CHEMICAL$ meets fertility!	0
@GENE$ and LXR β are nuclear receptors activated by @CHEMICAL$, oxidized derivatives of cholesterol.	1
Liver X Receptor (LXR) α and @GENE$ are nuclear receptors activated by @CHEMICAL$, oxidized derivatives of cholesterol.	1
@GENE$ and LXR β are nuclear receptors activated by oxysterols, oxidized derivatives of @CHEMICAL$.	0
Liver X Receptor (LXR) α and @GENE$ are nuclear receptors activated by oxysterols, oxidized derivatives of @CHEMICAL$.	0
Since their discovery, the role of @GENE$ in the control of @CHEMICAL$ homeostasis has been widely described.	0
This review will try to enlighten on the @GENE$ as a molecular link between dietary @CHEMICAL$ and reproductive diseases in women.	0
@GENE$ regulates @CHEMICAL$-induced FSHβ gene expression.	0
β-catenin regulates @CHEM-GENE$-induced FSHβ gene expression.	0
β-catenin regulates @CHEMICAL$-induced @GENE$ gene expression.	1
The regulation of @GENE$ synthesis by @CHEMICAL$ plays an essential role in the neuroendocrine control of reproduction.	0
The regulation of gonadotropin synthesis by @CHEM-GENE$ plays an essential role in the neuroendocrine control of reproduction.	0
For example, involvement of @GENE$ in LHβ induction by @CHEMICAL$ has been discovered.	0
For example, involvement of β-catenin in LHβ induction by @CHEM-GENE$ has been discovered.	0
@CHEM-GENE$ caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.	0
@CHEMICAL$ caused a sustained increase in nuclear @GENE$ levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.	1
@CHEMICAL$ caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by @GENE$ (JNK) inhibition.	0
@CHEMICAL$ caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun N-terminal kinase (@GENE$) inhibition.	0
@GENE$ caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun @CHEMICAL$-terminal kinase (JNK) inhibition.	0
GnRH caused a sustained increase in nuclear @GENE$ levels, which was significantly reduced by c-Jun @CHEMICAL$-terminal kinase (JNK) inhibition.	0
GnRH caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by @CHEM-GENE$ (JNK) inhibition.	0
GnRH caused a sustained increase in nuclear β-catenin levels, which was significantly reduced by c-Jun @CHEMICAL$-terminal kinase (@GENE$) inhibition.	0
Small interfering RNA-mediated knockdown of @GENE$ mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of @GENE$ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.	1
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEM-GENE$ depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on @GENE$ and that regulation of FSHβ by β-catenin occurred independently of the JNK-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of @GENE$ by β-catenin occurred independently of the JNK-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of FSHβ by @GENE$ occurred independently of the JNK-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the @GENE$-c-jun pathway.	0
Small interfering RNA-mediated knockdown of β-catenin mRNA demonstrated that induction of FSHβ mRNA by @CHEMICAL$ depended on β-catenin and that regulation of FSHβ by β-catenin occurred independently of the JNK-@GENE$ pathway.	0
In LβT2 cells transfected with @GENE$ luciferase fusion constructs, @CHEMICAL$ responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by β-catenin knockdown.	0
In LβT2 cells transfected with FSHβ promoter luciferase fusion constructs, @CHEM-GENE$ responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by β-catenin knockdown.	0
In LβT2 cells transfected with FSHβ promoter luciferase fusion constructs, @CHEMICAL$ responsiveness was conferred by the proximal promoter (-944/-1) and was markedly decreased by @GENE$ knockdown.	0
However, none of the @GENE$ in that region were required for promoter activation by @CHEMICAL$.	0
However, none of the T-cell factor/lymphoid enhancer factor binding sites in that region were required for promoter activation by @CHEM-GENE$.	0
Furthermore, knockdown of @GENE$ significantly attenuated @CHEMICAL$-induced FSHβ expression.	0
Furthermore, knockdown of Brms1L significantly attenuated @CHEM-GENE$-induced FSHβ expression.	0
Furthermore, knockdown of Brms1L significantly attenuated @CHEMICAL$-induced @GENE$ expression.	1
Thus, our findings indicate that the expression of @GENE$ depends on β-catenin activity and contributes to FSHβ induction by @CHEMICAL$.	0
Thus, our findings indicate that the expression of Brms1L depends on @GENE$ activity and contributes to FSHβ induction by @CHEMICAL$.	0
Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to @GENE$ induction by @CHEMICAL$.	1
Thus, our findings indicate that the expression of Brms1L depends on β-catenin activity and contributes to FSHβ induction by @CHEM-GENE$.	0
@GENE$ (P-gp) is an efflux pump belonging to the @CHEMICAL$-binding cassette transporter superfamily expressed in several organs.	0
P-glycoprotein (@GENE$) is an efflux pump belonging to the @CHEMICAL$-binding cassette transporter superfamily expressed in several organs.	0
P-glycoprotein (P-gp) is an @GENE$ belonging to the @CHEMICAL$-binding cassette transporter superfamily expressed in several organs.	0
P-glycoprotein (P-gp) is an efflux pump belonging to the @CHEM-GENE$ superfamily expressed in several organs.	0
The herbicide @CHEMICAL$ (PQ) is a @GENE$ substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.	5
The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether @CHEMICAL$ (DOX), a known @GENE$ inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.	1
The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (@CHEMICAL$), a known @GENE$ inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.	1
In conclusion, in this cellular model, @CHEMICAL$ effectively protects against PQ toxicity by inducing @GENE$ and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	1
In conclusion, in this cellular model, @CHEMICAL$ effectively protects against PQ toxicity by inducing P-gp and through the interaction with the @GENE$, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	0
In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing @GENE$ and through the interaction with the @CHEMICAL$ transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	0
In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the @CHEM-GENE$, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.	0
Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of @CHEM-GENE$.	0
@GENE$ (Sir2) enzymes or sirtuins are a family of NAD(+)-dependent protein N(ε)-acetyl-lysine (@CHEMICAL$) deacetylases.	0
Silent information regulator 2 (@GENE$) enzymes or sirtuins are a family of NAD(+)-dependent protein N(ε)-acetyl-lysine (@CHEMICAL$) deacetylases.	0
Silent information regulator 2 (Sir2) enzymes or @GENE$ are a family of NAD(+)-dependent protein N(ε)-acetyl-lysine (@CHEMICAL$) deacetylases.	0
Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of @CHEM-GENE$.	0
@GENE$ (Sir2) enzymes or sirtuins are a family of @CHEMICAL$-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases.	0
Silent information regulator 2 (@GENE$) enzymes or sirtuins are a family of @CHEMICAL$-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases.	0
Silent information regulator 2 (Sir2) enzymes or @GENE$ are a family of @CHEMICAL$-dependent protein N(ε)-acetyl-lysine (AcK) deacetylases.	0
Silent information regulator 2 (Sir2) enzymes or sirtuins are a family of @CHEM-GENE$.	0
@GENE$ (Sir2) enzymes or sirtuins are a family of NAD(+)-dependent protein @CHEMICAL$ (AcK) deacetylases.	0
Silent information regulator 2 (@GENE$) enzymes or sirtuins are a family of NAD(+)-dependent protein @CHEMICAL$ (AcK) deacetylases.	0
Silent information regulator 2 (Sir2) enzymes or @GENE$ are a family of NAD(+)-dependent protein @CHEMICAL$ (AcK) deacetylases.	0
The selective @GENE$ inhibitor @CHEMICAL$ (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.	2
The selective @GENE$ inhibitor P505-15 (@CHEMICAL$) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.	2
The selective @GENE$ inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of @CHEMICAL$ in chronic lymphocytic leukemia.	0
@GENE$ (BCR) associated kinases including spleen @CHEMICAL$ kinase (SYK) contribute to the pathogenesis of B-cell malignancies.	0
B-cell receptor (@GENE$) associated kinases including spleen @CHEMICAL$ kinase (SYK) contribute to the pathogenesis of B-cell malignancies.	0
B-cell receptor (BCR) associated @GENE$ including spleen @CHEMICAL$ kinase (SYK) contribute to the pathogenesis of B-cell malignancies.	0
B-cell receptor (BCR) associated kinases including @CHEM-GENE$ (SYK) contribute to the pathogenesis of B-cell malignancies.	0
B-cell receptor (BCR) associated kinases including spleen @CHEMICAL$ kinase (@GENE$) contribute to the pathogenesis of B-cell malignancies.	0
@CHEMICAL$ (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule @GENE$ inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.	2
@CHEMICAL$ (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (@GENE$ IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.	2
@CHEMICAL$ (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-@GENE$ activity that is at least 80-fold greater than its affinity for other kinases.	2
@CHEMICAL$ (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other @GENE$.	0
P505-15 (also known as @CHEMICAL$) is a novel, highly selective, and orally bioavailable small molecule @GENE$ inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.	2
P505-15 (also known as @CHEMICAL$) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (@GENE$ IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.	2
P505-15 (also known as @CHEMICAL$) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-@GENE$ activity that is at least 80-fold greater than its affinity for other kinases.	2
P505-15 (also known as @CHEMICAL$) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other @GENE$.	0
@CHEMICAL$ successfully inhibited @GENE$-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL.	2
@CHEMICAL$ successfully inhibited SYK-mediated @GENE$ signaling and decreased cell viability in NHL and CLL.	2
Alleles of @GENE$ (RPO21) with elevated slippage rates were identified among @CHEMICAL$-sensitive mutants and were also isolated using a slippage-dependent reporter gene.	0
Alleles of RPB1 (@GENE$) with elevated slippage rates were identified among @CHEMICAL$-sensitive mutants and were also isolated using a slippage-dependent reporter gene.	0
@GENE$ expression was suppressed by means of RNA interference technology, and the overall outcome of this treatment on the hepatocellular proteome and metabolome was investigated using tandem mass tag-based differential protein profiling and @CHEMICAL$ NMR spectroscopy, respectively.	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @CHEMICAL$ synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and @GENE$).	0
Global protein profiling revealed a number of targets of the @GENE$ knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @CHEMICAL$ synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (@GENE$, glucose-regulated protein 75, thiosulphate sulphurtransferase and @CHEMICAL$ synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @GENE$, thiosulphate sulphurtransferase and @CHEMICAL$ synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @GENE$ and @CHEMICAL$ synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @CHEM-GENE$) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @CHEMICAL$ synthase) and detoxifying enzymes (@GENE$ and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and @GENE$).	0
Global protein profiling revealed a number of targets of the @GENE$ knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (@GENE$, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @GENE$, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @GENE$ and adenosine triphosphate synthase) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @GENE$) and detoxifying enzymes (@CHEMICAL$ S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEM-GENE$ and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and @GENE$).	0
Global protein profiling revealed a number of targets of the @GENE$ knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (@GENE$, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @GENE$, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @GENE$ and adenosine triphosphate synthase) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and @GENE$) and detoxifying enzymes (glutathione @CHEMICAL$-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@CHEM-GENE$ and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEMICAL$-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and @GENE$).	0
Global protein profiling revealed a number of targets of the @GENE$ knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEMICAL$-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (@GENE$, @CHEMICAL$-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEM-GENE$, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEMICAL$-regulated protein 75, @GENE$ and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEMICAL$-regulated protein 75, thiosulphate sulphurtransferase and @GENE$) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @CHEMICAL$-regulated protein 75, thiosulphate sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@GENE$ and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @CHEMICAL$ sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and @GENE$).	0
Global protein profiling revealed a number of targets of the @GENE$ knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @CHEMICAL$ sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (@GENE$, glucose-regulated protein 75, @CHEMICAL$ sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, @GENE$, @CHEMICAL$ sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @CHEM-GENE$ and adenosine triphosphate synthase) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @CHEMICAL$ sulphurtransferase and @GENE$) and detoxifying enzymes (glutathione S-transferase μ 2 and cytochrome P450 2C70).	0
Global protein profiling revealed a number of targets of the connexin43 knock-down procedure, including mitochondrial proteins (heat shock protein 60, glucose-regulated protein 75, @CHEMICAL$ sulphurtransferase and adenosine triphosphate synthase) and detoxifying enzymes (@GENE$ and cytochrome P450 2C70).	0
At the metabolomic level, @GENE$ silencing caused no overt changes, though there was some evidence for a subtle increase in intracellular @CHEMICAL$ quantities.	0
@CHEM-GENE$ is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.	0
@GENE$ is a target of @CHEMICAL$ and enhances its anticancer activity in lung adenocarcinoma cells.	0
We have demonstrated that @CHEM-GENE$ (AhR) is overexpressed in lung adenocarcinoma (AD).	0
We have demonstrated that @CHEMICAL$ receptor (@GENE$) is overexpressed in lung adenocarcinoma (AD).	0
@CHEMICAL$ (17-AAG), an @GENE$ inhibitor, is currently under evaluation for its anticancer activity in clinical trials.	2
17-Allylamino-17-demethoxygeldanamycin (@CHEMICAL$), an @GENE$ inhibitor, is currently under evaluation for its anticancer activity in clinical trials.	2
Here we investigated whether @GENE$ plays a role in @CHEMICAL$-mediated anticancer activity by functioning as a downstream target or by modulating its anticancer efficacy.	0
Although treatment with @CHEMICAL$ reduced @GENE$ levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG.	2
Although treatment with @CHEMICAL$ reduced AhR levels and @GENE$-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG.	2
Although treatment with @CHEMICAL$ reduced AhR levels and AhR-regulated gene expression in lung AD cells, @GENE$ expression increased anticancer activity of 17-AAG.	0
Although treatment with 17-AAG reduced @GENE$ levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of @CHEMICAL$.	0
Although treatment with 17-AAG reduced AhR levels and @GENE$-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of @CHEMICAL$.	0
Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, @GENE$ expression increased anticancer activity of @CHEMICAL$.	0
In addition, @CHEMICAL$ treatment reduced cell viability, @GENE$, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.	2
In addition, @CHEMICAL$ treatment reduced cell viability, CDK2, @GENE$, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.	2
In addition, @CHEMICAL$ treatment reduced cell viability, CDK2, CDK4, @GENE$, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells.	2
In addition, @CHEMICAL$ treatment reduced cell viability, CDK2, CDK4, cyclin E, @GENE$, and phosphorylated Rb levels in AhR-expressing lung AD cells.	2
In addition, @CHEMICAL$ treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and @GENE$ levels in AhR-expressing lung AD cells.	2
In addition, @CHEMICAL$ treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in @GENE$-expressing lung AD cells.	0
@CHEM-GENE$ (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells.	0
@CHEMICAL$:quinone oxidoreductase (@GENE$), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells.	0
@CHEMICAL$:quinone oxidoreductase (NQO1), which is regulated by @GENE$, was shown to increase anticancer activity of 17-AAG in cells.	0
@CHEM-GENE$ (NQO1), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells.	0
NAD(P)H:@CHEMICAL$ oxidoreductase (@GENE$), which is regulated by AhR, was shown to increase anticancer activity of 17-AAG in cells.	0
NAD(P)H:@CHEMICAL$ oxidoreductase (NQO1), which is regulated by @GENE$, was shown to increase anticancer activity of 17-AAG in cells.	0
@GENE$ (NQO1), which is regulated by AhR, was shown to increase anticancer activity of @CHEMICAL$ in cells.	0
NAD(P)H:quinone oxidoreductase (@GENE$), which is regulated by AhR, was shown to increase anticancer activity of @CHEMICAL$ in cells.	0
NAD(P)H:quinone oxidoreductase (NQO1), which is regulated by @GENE$, was shown to increase anticancer activity of @CHEMICAL$ in cells.	0
Knockdown of @GENE$ expression attenuated the reduction of cell cycle regulators by @CHEMICAL$ treatment in AhR overexpressed cells.	0
Knockdown of NQO1 expression attenuated the reduction of cell cycle regulators by @CHEMICAL$ treatment in @GENE$ overexpressed cells.	0
We demonstrated that @GENE$ protein not only functions as a downstream target of @CHEMICAL$, but also enhances anticancer activity of 17-AAG in lung AD cells.	0
We demonstrated that @GENE$ protein not only functions as a downstream target of 17-AAG, but also enhances anticancer activity of @CHEMICAL$ in lung AD cells.	0
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and @CHEM-GENE$.	0
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in @GENE$ and @CHEMICAL$ kinase.	0
Pharmacogenomics of @CHEMICAL$ metabolism: functional analysis of genetic variants in cytidine deaminase and @GENE$.	0
Pharmacogenomics of @CHEMICAL$ metabolism: functional analysis of genetic variants in @GENE$ and deoxycytidine kinase.	0
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in @CHEMICAL$ deaminase and @GENE$.	0
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in @CHEM-GENE$ and deoxycytidine kinase.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @CHEMICAL$ deaminase (CDA) and deoxycytidine kinase (@GENE$), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @CHEM-GENE$ (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @CHEMICAL$ deaminase (@GENE$) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @CHEMICAL$ deaminase (CDA) and @GENE$ (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
@CHEMICAL$ (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (@GENE$), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
@CHEMICAL$ (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @GENE$ (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
@CHEMICAL$ (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (@GENE$) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
@CHEMICAL$ (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and @GENE$ (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and @CHEMICAL$ kinase (@GENE$), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by @GENE$ (CDA) and @CHEMICAL$ kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (@GENE$) and @CHEMICAL$ kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and @CHEM-GENE$ (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	0
Gemcitabine (@CHEMICAL$, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (@GENE$), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (@CHEMICAL$, 2',2'-difluorodeoxycytidine) is metabolized by @GENE$ (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (@CHEMICAL$, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (@GENE$) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (@CHEMICAL$, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and @GENE$ (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (dFdC, @CHEMICAL$) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (@GENE$), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (dFdC, @CHEMICAL$) is metabolized by @GENE$ (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (dFdC, @CHEMICAL$) is metabolized by cytidine deaminase (@GENE$) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Gemcitabine (dFdC, @CHEMICAL$) is metabolized by cytidine deaminase (CDA) and @GENE$ (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.	5
Wild-type enzymes and variants of @GENE$ (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (@GENE$ and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and @GENE$) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and @GENE$ (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (@GENE$, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, @GENE$, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and @GENE$) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (@CHEMICAL$), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of @GENE$ (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (@GENE$ and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and @GENE$) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and @GENE$ (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (@GENE$, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, @GENE$, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and @GENE$) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), @CHEMICAL$, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of @GENE$ (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (@GENE$ and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and @GENE$) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and @GENE$ (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (@GENE$, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, @GENE$, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and @GENE$) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite @CHEMICAL$ (dFdU) as substrates.	5
Wild-type enzymes and variants of @GENE$ (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	5
Wild-type enzymes and variants of CDA (@GENE$ and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of CDA (Lys27Gln and @GENE$) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and @GENE$ (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (@GENE$, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, @GENE$, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and @GENE$) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (@CHEMICAL$) as substrates.	0
Wild-type enzymes and variants of @GENE$ (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (@GENE$ and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and @GENE$) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and @GENE$ (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (@GENE$, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, @GENE$, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and @GENE$) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for @CHEMICAL$ (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.	5
All three @GENE$ proteins showed similar K(m) and V(max) for @CHEMICAL$ and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.	5
All three CDA proteins showed similar K(m) and V(max) for @CHEMICAL$ and dFdC deamination, except for @GENE$70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.	0
All three @GENE$ proteins showed similar K(m) and V(max) for Ara-C and @CHEMICAL$ deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.	5
All three CDA proteins showed similar K(m) and V(max) for Ara-C and @CHEMICAL$ deamination, except for @GENE$70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.	0
All three @GENE$ proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for @CHEMICAL$ deamination.	0
All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for @GENE$70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for @CHEMICAL$ deamination.	5
All four @GENE$ proteins yielded comparable metabolic activity for @CHEMICAL$ and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	5
All four DCK proteins yielded comparable metabolic activity for @CHEMICAL$ and dFdC monophosphorylation, except for @GENE$24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	0
All four @GENE$ proteins yielded comparable metabolic activity for Ara-C and @CHEMICAL$ monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	5
All four DCK proteins yielded comparable metabolic activity for Ara-C and @CHEMICAL$ monophosphorylation, except for @GENE$24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	0
All four @GENE$ proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of @CHEMICAL$ monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	0
All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for @GENE$24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of @CHEMICAL$ monophosphorylation due to a 40% decrease in K(m) (P < 0.05).	5
@GENE$ did not significantly contribute to @CHEMICAL$ monophosphorylation.	0
In conclusion, the @GENE$ substitution does not significantly modulate CDA activity toward @CHEMICAL$, and therefore would not contribute to interindividual variability in response to gemcitabine.	5
In conclusion, the Lys27Gln substitution does not significantly modulate @GENE$ activity toward @CHEMICAL$, and therefore would not contribute to interindividual variability in response to gemcitabine.	5
In conclusion, the @GENE$ substitution does not significantly modulate CDA activity toward dFdC, and therefore would not contribute to interindividual variability in response to @CHEMICAL$.	0
In conclusion, the Lys27Gln substitution does not significantly modulate @GENE$ activity toward dFdC, and therefore would not contribute to interindividual variability in response to @CHEMICAL$.	0
The higher in vitro catalytic efficiency of @GENE$24Val toward @CHEMICAL$ monophosphorylation may be relevant to dFdC clinical response.	5
The higher in vitro catalytic efficiency of @GENE$24Val toward dFdC monophosphorylation may be relevant to @CHEMICAL$ clinical response.	5
Discovery of @CHEMICAL$ based @GENE$ inhibitors.	2
A series of compounds based on a @CHEMICAL$ scaffold that are potent and selective inhibitors of @GENE$ (TNIK) activity are described.	2
A series of compounds based on a @CHEMICAL$ scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (@GENE$) activity are described.	2
@CHEMICAL$-based inhibitors of @GENE$.	2
Boron-based inhibitors of @CHEM-GENE$.	0
Inhibition of the @GENE$-depalmitoylating enzyme @CHEMICAL$ protein thioesterases APT1 and -2 is a new approach to modulating the Ras cycle.	0
Inhibition of the Ras-depalmitoylating enzyme @CHEM-GENE$ is a new approach to modulating the Ras cycle.	0
Inhibition of the Ras-depalmitoylating enzyme @CHEMICAL$ protein thioesterases APT1 and -2 is a new approach to modulating the @GENE$ cycle.	0
Here we present @CHEMICAL$ and borinic acid derivatives as a new class of potent and nontoxic @GENE$ inhibitors.	2
Here we present boronic and @CHEMICAL$ derivatives as a new class of potent and nontoxic @GENE$ inhibitors.	2
Phytoestrogen @CHEMICAL$ protects against endothelial barrier dysfunction in vascular endothelial cells through @GENE$-mediated suppression of RhoA signaling.	0
Phytoestrogen @CHEMICAL$ protects against endothelial barrier dysfunction in vascular endothelial cells through PKA-mediated suppression of @GENE$ signaling.	0
Here, we report that @CHEMICAL$ at physiologically relevant concentrations (0.1-10 μM) significantly inhibited @GENE$-induced increase in endothelial monolayer permeability.	2
@CHEMICAL$ also reduced the formation of stress fibers by @GENE$ and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).	2
@CHEMICAL$ also reduced the formation of stress fibers by thrombin and suppressed @GENE$-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).	2
@CHEMICAL$ also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of @GENE$ (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).	2
@CHEMICAL$ also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (@GENE$) on Ser(19)/Thr(18) in endothelial cells (ECs).	2
Genistein also reduced the formation of stress fibers by @GENE$ and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on @CHEMICAL$(19)/Thr(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed @GENE$-induced phosphorylation of myosin light chain (MLC) on @CHEMICAL$(19)/Thr(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of @GENE$ (MLC) on @CHEMICAL$(19)/Thr(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (@GENE$) on @CHEMICAL$(19)/Thr(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by @GENE$ and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/@CHEMICAL$(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed @GENE$-induced phosphorylation of myosin light chain (MLC) on Ser(19)/@CHEMICAL$(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of @GENE$ (MLC) on Ser(19)/@CHEMICAL$(18) in endothelial cells (ECs).	0
Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (@GENE$) on Ser(19)/@CHEMICAL$(18) in endothelial cells (ECs).	0
@CHEMICAL$ had no effect on resting intracellular [Ca(2+)] or @GENE$-induced increase in Ca(2+) mobilization.	0
Genistein had no effect on resting intracellular [@CHEMICAL$] or @GENE$-induced increase in Ca(2+) mobilization.	0
Genistein had no effect on resting intracellular [Ca(2+)] or @GENE$-induced increase in @CHEMICAL$ mobilization.	0
Addition of the inhibitors of @CHEM-GENE$ or estrogen receptor did not alter the protective effect of genistein.	0
Addition of the inhibitors of endothelial @CHEMICAL$ synthase or @GENE$ did not alter the protective effect of genistein.	0
Addition of the inhibitors of @GENE$ or @CHEMICAL$ receptor did not alter the protective effect of genistein.	0
Addition of the inhibitors of endothelial nitric oxide synthase or @CHEM-GENE$ did not alter the protective effect of genistein.	0
Addition of the inhibitors of @GENE$ or estrogen receptor did not alter the protective effect of @CHEMICAL$.	0
Addition of the inhibitors of endothelial nitric oxide synthase or @GENE$ did not alter the protective effect of @CHEMICAL$.	0
@GENE$ inhibitor blocked the protective effect of @CHEMICAL$ on endothelial permeability and also ablated thrombin-induced MLC-phosphorylation in ECs.	0
RhoA inhibitor blocked the protective effect of @CHEMICAL$ on endothelial permeability and also ablated @GENE$-induced MLC-phosphorylation in ECs.	0
RhoA inhibitor blocked the protective effect of @CHEMICAL$ on endothelial permeability and also ablated thrombin-induced @GENE$-phosphorylation in ECs.	0
Inhibition of @GENE$ significantly attenuated the effect of @CHEMICAL$ on thrombin-induced EC permeability, MLC phosphorylation, and RhoA membrane translocation in ECs.	0
Inhibition of PKA significantly attenuated the effect of @CHEMICAL$ on @GENE$-induced EC permeability, MLC phosphorylation, and RhoA membrane translocation in ECs.	0
Inhibition of PKA significantly attenuated the effect of @CHEMICAL$ on thrombin-induced EC permeability, @GENE$ phosphorylation, and RhoA membrane translocation in ECs.	0
Inhibition of PKA significantly attenuated the effect of @CHEMICAL$ on thrombin-induced EC permeability, MLC phosphorylation, and @GENE$ membrane translocation in ECs.	0
Furthermore, @GENE$ diminished @CHEMICAL$ production in ECs, which were prevented by treatment with genistein.	0
Furthermore, @GENE$ diminished cAMP production in ECs, which were prevented by treatment with @CHEMICAL$.	2
These findings demonstrated that @CHEMICAL$ improves @GENE$-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.	0
These findings demonstrated that @CHEMICAL$ improves thrombin-induced endothelial barrier dysfunction in ECs through @GENE$-mediated suppression of RhoA signaling.	0
These findings demonstrated that @CHEMICAL$ improves thrombin-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of @GENE$ signaling.	0
The main outcome measures were serum @CHEMICAL$, lipids, and @GENE$, and anthropometric measurements.	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum @CHEMICAL$ (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and @GENE$ (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum @CHEMICAL$ (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in @GENE$ (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum @CHEMICAL$ (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (@GENE$; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum @CHEMICAL$ (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h @GENE$ (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum @CHEMICAL$ (FSG; P=.001), total cholesterol (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (@GENE$; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total @CHEMICAL$ (P=.0001), serum triglycerides (TG; P=.0001), and @GENE$ (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total @CHEMICAL$ (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in @GENE$ (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total @CHEMICAL$ (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (@GENE$; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total @CHEMICAL$ (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h @GENE$ (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total @CHEMICAL$ (P=.0001), serum triglycerides (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (@GENE$; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum @CHEMICAL$ (TG; P=.0001), and @GENE$ (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum @CHEMICAL$ (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in @GENE$ (FCP; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum @CHEMICAL$ (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (@GENE$; P=.0004) and 2-h postprandial C-peptide (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum @CHEMICAL$ (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h @GENE$ (PCP; P=.002).	0
The intervention resulted in significant decreases in subscapular skin fold thickness (SSFT; P=.002), fasting serum glucose (FSG; P=.001), total cholesterol (P=.0001), serum @CHEMICAL$ (TG; P=.0001), and low-density lipoprotein (P=.0009), and significant increases in fasting C-peptide (FCP; P=.0004) and 2-h postprandial C-peptide (@GENE$; P=.002).	0
As possible long-term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2-h postprandial serum @CHEMICAL$ (P=.000), TG (P=.003), and HbA1C (P=.043), and significant increases in @GENE$ (P=.002) and PCP (P=.003) were observed.	0
As possible long-term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2-h postprandial serum @CHEMICAL$ (P=.000), TG (P=.003), and HbA1C (P=.043), and significant increases in FCP (P=.002) and @GENE$ (P=.003) were observed.	0
As possible long-term effects of honey after its withdrawal, statistically significant reductions in midarm circumference (P=.000), triceps skin fold thickness (P=.006), SSFT (P=.003), FSG (P=.005), 2-h postprandial serum @CHEMICAL$ (P=.000), TG (P=.003), and @GENE$ (P=.043), and significant increases in FCP (P=.002) and PCP (P=.003) were observed.	0
Evaluation of drug interactions of @CHEMICAL$ (a @GENE$ agonist) with statins: from in vitro data to clinical study design.	3
This work investigated the drug interaction potential of @CHEMICAL$, a novel GPR119 agonist, with the @GENE$ inhibitors simvastatin and rosuvastatin.	0
This work investigated the drug interaction potential of @CHEMICAL$, a novel @GENE$ agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.	3
This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the @GENE$ inhibitors @CHEMICAL$ and rosuvastatin.	2
This work investigated the drug interaction potential of GSK1292263, a novel @GENE$ agonist, with the HMG-coA reductase inhibitors @CHEMICAL$ and rosuvastatin.	0
This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the @GENE$ inhibitors simvastatin and @CHEMICAL$.	2
This work investigated the drug interaction potential of GSK1292263, a novel @GENE$ agonist, with the HMG-coA reductase inhibitors simvastatin and @CHEMICAL$.	0
In vitro experiments assessed the inhibition of @GENE$ and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of @CHEMICAL$ (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).	0
In vitro experiments assessed the inhibition of transporters and @GENE$ enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of @CHEMICAL$ (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).	0
In vitro experiments assessed the inhibition of @GENE$ and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of @CHEMICAL$ (40 mg single dose) and rosuvastatin (10 mg single dose).	0
In vitro experiments assessed the inhibition of transporters and @GENE$ enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of @CHEMICAL$ (40 mg single dose) and rosuvastatin (10 mg single dose).	0
In vitro experiments assessed the inhibition of @GENE$ and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and @CHEMICAL$ (10 mg single dose).	0
In vitro experiments assessed the inhibition of transporters and @GENE$ enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and @CHEMICAL$ (10 mg single dose).	0
In vitro experiments assessed the inhibition of @GENE$ and CYP enzymes by @CHEMICAL$, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).	2
In vitro experiments assessed the inhibition of transporters and @GENE$ enzymes by @CHEMICAL$, and a clinical drug interaction study investigated the effect of GSK1292263 (300 mg BID) on the pharmacokinetic profile of simvastatin (40 mg single dose) and rosuvastatin (10 mg single dose).	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards @GENE$ (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (@GENE$, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, @GENE$, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, @GENE$, 2D6, 3A4), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, @GENE$, 3A4), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, @GENE$), Pgp, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), @GENE$, OATP1B3, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, @GENE$, or OCT2.	2
In vitro, @CHEMICAL$ demonstrated little/weak inhibition (IC50 values >30 μM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or @GENE$.	2
However, @CHEMICAL$ inhibited @GENE$ and OATP1B1, which are transporters involved in statin disposition.	2
However, @CHEMICAL$ inhibited BCRP and @GENE$, which are transporters involved in statin disposition.	2
In the clinical study, small increases in the AUC(0-inf) of @CHEMICAL$ [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and @GENE$.	0
In the clinical study, small increases in the AUC(0-inf) of @CHEMICAL$ [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal @GENE$ and CYP3A4.	0
In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and @CHEMICAL$ [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and @GENE$.	0
In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and @CHEMICAL$ [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal @GENE$ and CYP3A4.	0
In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with @CHEMICAL$, which is consistent with an inhibitory effect on intestinal BCRP and @GENE$.	2
In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with @CHEMICAL$, which is consistent with an inhibitory effect on intestinal @GENE$ and CYP3A4.	2
In contrast, @CHEMICAL$ did not inhibit @GENE$ based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)].	0
In contrast, GSK1292263 did not inhibit @GENE$ based on the lack of changes in @CHEMICAL$ acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)].	0
This study provides a mechanistic understanding of the in vivo inhibition of @GENE$ and enzymes by @CHEMICAL$.	2
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @GENE$ (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (@GENE$) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @GENE$ (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (@GENE$) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEM-GENE$ (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (@GENE$) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and @GENE$ (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @CHEMICAL$ dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (@GENE$) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEM-GENE$ (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (@GENE$) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and @GENE$ (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and NO synthase (@GENE$) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @GENE$ (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (@GENE$) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and @GENE$ (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (@GENE$) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @CHEMICAL$ peroxidase (GPx) mimetics and NO synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like @GENE$ (GPx) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (@GENE$) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEM-GENE$ (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEMICAL$ synthase (@GENE$) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like @GENE$ (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (@GENE$) mimetics and nuclear factor-erythroid 2 related factor 2 (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and @GENE$ (Nrf2) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
In addition, other antioxidants like superoxide dismutase (SOD) mimetics and nuclear factor-erythroid 2 related factor 2 (@GENE$) are shown to decrease markers of oxidative stress in patients with emphysema, while others like glutathione peroxidase (GPx) mimetics and @CHEMICAL$ synthase (iNOS) can prevent both inflammation and oxidative stress in clinical trials in vivo (or in mouse models).	0
Proteins @GENE$ and Dan1 were not found to be involved in @CHEMICAL$ import.	0
Proteins Aus1 and @GENE$ were not found to be involved in @CHEMICAL$ import.	0
The presence of @CHEMICAL$ hormones most probably causes the degradation of the @GENE$ permease and impairment of tryptophan import.	2
The presence of steroid hormones most probably causes the degradation of the @GENE$ permease and impairment of @CHEMICAL$ import.	0
Disruption of the @GENE$ also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent @CHEMICAL$ (MMS).	0
Disruption of the cell-cycle boxes also affected growth in a @GENE$-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent @CHEMICAL$ (MMS).	0
Disruption of the @GENE$ also affected growth in a DNA polymerase-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (@CHEMICAL$).	0
Disruption of the cell-cycle boxes also affected growth in a @GENE$-defective strain background where mismatch repair is essential, particularly in the presence of the DNA damaging agent methyl methane sulfonate (@CHEMICAL$).	0
Promoter replacements conferring constitutive expression of @GENE$ revealed that the transcriptional induction in response to @CHEMICAL$ is required to maintain induced levels of Msh2.	0
Promoter replacements conferring constitutive expression of MSH2 revealed that the transcriptional induction in response to @CHEMICAL$ is required to maintain induced levels of @GENE$.	0
Inhibition of Th1/Th17 responses via suppression of @GENE$ and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside @CHEMICAL$.	2
Inhibition of Th1/Th17 responses via suppression of STAT1 and @GENE$ activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside @CHEMICAL$.	2
Inhibition of Th1/Th17 responses via suppression of @GENE$ and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural @CHEMICAL$ glucoside icariin.	2
Inhibition of Th1/Th17 responses via suppression of STAT1 and @GENE$ activation contributes to the amelioration of murine experimental colitis by a natural @CHEMICAL$ glucoside icariin.	2
Further study showed that @CHEMICAL$ dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory @GENE$ levels of activated T cells.	2
Moreover, @CHEMICAL$ treatment inhibited the phosphorylations of @GENE$ and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.	2
Moreover, @CHEMICAL$ treatment inhibited the phosphorylations of STAT1 and @GENE$ in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively.	2
The present study examined the effect of insulin-mediated activation of the @CHEM-GENE$ (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.	0
The present study examined the effect of insulin-mediated activation of the mammalian target of @CHEMICAL$ complex 1 (@GENE$) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.	0
The present study examined the effect of @GENE$-mediated activation of the mammalian target of @CHEMICAL$ complex 1 (MTORC1) signaling network on the proliferation of primary culture of theca-interstitial (T-I) cells.	0
Pharmacological inhibition of @GENE$ with @CHEMICAL$ abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	2
Pharmacological inhibition of MTORC1 with @CHEMICAL$ abrogated the @GENE$-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	2
Pharmacological inhibition of MTORC1 with @CHEMICAL$ abrogated the insulin-induced phosphorylation of @GENE$, RPS6KB1 and its downstream effector, RPS6.	2
Pharmacological inhibition of MTORC1 with @CHEMICAL$ abrogated the insulin-induced phosphorylation of EIF4EBP1, @GENE$ and its downstream effector, RPS6.	2
Pharmacological inhibition of MTORC1 with @CHEMICAL$ abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, @GENE$.	2
Furthermore, @GENE$-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by @CHEMICAL$.	2
Furthermore, insulin-stimulated T-I cell proliferation and the expression of @GENE$ CDK4, CCND3 and PCNA were also blocked by @CHEMICAL$.	2
Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins @GENE$, CCND3 and PCNA were also blocked by @CHEMICAL$.	2
Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, @GENE$ and PCNA were also blocked by @CHEMICAL$.	2
Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and @GENE$ were also blocked by @CHEMICAL$.	2
@CHEM-GENE$ play an important role in recognizing chromatin modifications and recruiting regulatory proteins to specific genes.	0
@GENE$ has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the @CHEMICAL$-terminal PHD fingers of AF10.	0
AF10 has mostly been studied in the context of the leukemic @GENE$-AF10 fusion protein, which lacks the @CHEMICAL$-terminal PHD fingers of AF10.	0
AF10 has mostly been studied in the context of the leukemic MLL-@GENE$ fusion protein, which lacks the @CHEMICAL$-terminal PHD fingers of AF10.	0
AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the @CHEM-GENE$ of AF10.	0
AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the @CHEMICAL$-terminal PHD fingers of @GENE$.	0
In this study, we used genetic and biochemical approaches to examine the @GENE$ region of the Caenorhabditis elegans ortholog of AF10, @CHEMICAL$ finger protein 1 (ZFP-1).	0
In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of @GENE$, @CHEMICAL$ finger protein 1 (ZFP-1).	0
In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10, @CHEM-GENE$ (ZFP-1).	0
In this study, we used genetic and biochemical approaches to examine the PHD1-PHD2 region of the Caenorhabditis elegans ortholog of AF10, @CHEMICAL$ finger protein 1 (@GENE$).	0
We demonstrate that the @GENE$ region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to @CHEMICAL$ 4-methylated histone H3 tails.	0
We demonstrate that the PHD1-PHD2 region is essential for viability and that the first @GENE$ contributes to the preferred binding of PHD1-PHD2 to @CHEMICAL$ 4-methylated histone H3 tails.	0
We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of @GENE$ to @CHEMICAL$ 4-methylated histone H3 tails.	0
Synthesis and evaluation of @CHEMICAL$ derivatives as potent @GENE$ agonists with high water solubility.	3
We report the discovery of novel series of highly potent @GENE$ agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various @CHEMICAL$ onto the N(9)-position of the adenine moiety.	3
We report the discovery of novel series of highly potent @GENE$ agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the @CHEMICAL$(9)-position of the adenine moiety.	3
We report the discovery of novel series of highly potent @GENE$ agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the @CHEMICAL$ moiety.	3
We report the discovery of novel series of highly potent @GENE$ agonists based on @CHEMICAL$, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety.	3
The introduction of the @CHEMICAL$ group resulted in not only improved water solubility but also enhanced @GENE$ agonistic activity.	3
Discovery of liver-targeted inhibitors of @CHEM-GENE$ (SCD1).	0
Discovery of liver-targeted inhibitors of @CHEMICAL$ desaturase (@GENE$).	0
Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for @CHEMICAL$ (CoA) desaturase 1 (@GENE$) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	0
Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for @CHEM-GENE$ (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	0
Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (@CHEMICAL$) desaturase 1 (@GENE$) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	0
Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for @CHEM-GENE$ (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	0
Inhibitors based on a @CHEMICAL$ scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (@GENE$) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	2
Inhibitors based on a @CHEMICAL$ scaffold were discovered for @GENE$ (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.	2
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (@CHEMICAL$) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and @CHEMICAL$ (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (@CHEMICAL$) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and @CHEMICAL$ (TXB(2)) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (@CHEMICAL$) levels and increased nitric oxide (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (@GENE$) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and @GENE$ (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (@GENE$).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced @GENE$ (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (@GENE$) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased @GENE$ (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (@GENE$) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic low density lipoprotein receptor (LDLR) and scavenger receptor B1 (SR-B1).	0
Compared to the HC group, aqueous Mate tea extract significantly reduced endothelin (ET) and thromboxane B(2) (TXB(2)) levels and increased @CHEMICAL$ (NO) and 6-keto prostaglandin F(1α) (6-keto-PGF(1α)) levels in the blood, reduced the pathological damage of vascular endothelial cells, decreased intercellular adhesion molecule-1 (ICAM-1) protein expression in the thoracic aorta, and upregulated mRNA expression of hepatic @GENE$ (LDLR) and scavenger receptor B1 (SR-B1).	0
Development of hypoxia-inducible factor (HIF)-1α inhibitors: effect of @CHEMICAL$ substituents on @GENE$ transcriptional activity under hypoxia.	0
Development of @GENE$ inhibitors: effect of @CHEMICAL$ substituents on HIF transcriptional activity under hypoxia.	0
A series of substituted @CHEMICAL$ were synthesized and evaluated for their ability to inhibit hypoxia-induced @GENE$ transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay.	0
A series of substituted @CHEMICAL$ were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the @GENE$-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay.	0
A series of substituted @CHEMICAL$ were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (@GENE$-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the MTT assay.	0
A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced @GENE$ transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the @CHEMICAL$ assay.	0
A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the @GENE$-dependent firefly luciferase reporter construct (HRE-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the @CHEMICAL$ assay.	0
A series of substituted ortho-carboranylphenoxyacetanilides were synthesized and evaluated for their ability to inhibit hypoxia-induced HIF-1 transcriptional activity using a cell-based reporter assay in HeLa cells expressing the HRE-dependent firefly luciferase reporter construct (@GENE$-Luc) and constitutively expressing CMV-driven Renilla luciferase reporter, and their ability to inhibit cell growth (GI(50)) using the @CHEMICAL$ assay.	0
The @CHEM-GENE$ (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of ETB (IC(50): 10.9 ± 0.63 μM).	0
The porcine heart @CHEMICAL$ dehydrogenase (@GENE$) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of ETB (IC(50): 10.9 ± 0.63 μM).	0
The porcine heart @CHEMICAL$ dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited @GENE$ chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of ETB (IC(50): 10.9 ± 0.63 μM).	0
The @GENE$ (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of @CHEMICAL$ (IC(50): 10.9 ± 0.63 μM).	0
The porcine heart malate dehydrogenase (@GENE$) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of @CHEMICAL$ (IC(50): 10.9 ± 0.63 μM).	0
The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited @GENE$ chaperone activity (IC(50): 6.80 ± 0.25 μM) and this inhibition activity was higher than that of @CHEMICAL$ (IC(50): 10.9 ± 0.63 μM).	2
@CHEMICAL$ and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated @GENE$ in rat testes.	2
@CHEMICAL$ and raisanberine alleviate intermittent hypoxia induced abnormal @GENE$ and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	0
@CHEMICAL$ and raisanberine alleviate intermittent hypoxia induced abnormal StAR and @GENE$ and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	0
Apocynin and @CHEMICAL$ alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated @GENE$ in rat testes.	2
Apocynin and @CHEMICAL$ alleviate intermittent hypoxia induced abnormal @GENE$ and 3β-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	0
Apocynin and @CHEMICAL$ alleviate intermittent hypoxia induced abnormal StAR and @GENE$ and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	5
Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3β-HSD and low @CHEMICAL$ by suppressing endoplasmic reticulum stress and activated @GENE$ in rat testes.	0
Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal @GENE$ and 3β-HSD and low @CHEMICAL$ by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	0
Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and @GENE$ and low @CHEMICAL$ by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, @CHEMICAL$ (apocynin) an inhibitor of @GENE$ and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	2
We hypothesized that hypoxia induced testicular damage is mediated by an activated @GENE$ (NOX), therefore, @CHEMICAL$ (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (@GENE$), therefore, @CHEMICAL$ (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (@CHEMICAL$) an inhibitor of @GENE$ and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	2
We hypothesized that hypoxia induced testicular damage is mediated by an activated @GENE$ (NOX), therefore, APO (@CHEMICAL$) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (@GENE$), therefore, APO (@CHEMICAL$) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of @GENE$ and @CHEMICAL$ (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated @GENE$ (NOX), therefore, APO (apocynin) an inhibitor of NOX and @CHEMICAL$ (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (@GENE$), therefore, APO (apocynin) an inhibitor of NOX and @CHEMICAL$ (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of @GENE$ and raisanberine (RS), a @CHEMICAL$ influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated @GENE$ (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a @CHEMICAL$ influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (@GENE$), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a @CHEMICAL$ influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated @CHEMICAL$ oxidase (NOX), therefore, APO (apocynin) an inhibitor of @GENE$ and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated @CHEM-GENE$ (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
We hypothesized that hypoxia induced testicular damage is mediated by an activated @CHEMICAL$ oxidase (@GENE$), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis.	0
Hypoxic rats displayed lower serum @CHEMICAL$ and higher @GENE$ and FSH.	0
Hypoxic rats displayed lower serum @CHEMICAL$ and higher LH and @GENE$.	0
@CHEMICAL$ and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and @GENE$ in testes.	2
Coming full circle: contributions of central and peripheral @CHEM-GENE$ actions to energy balance.	0
The neuropeptide @CHEM-GENE$ has emerged as an important anorexigen in the regulation of energy balance.	0
The neuropeptide @GENE$ has emerged as an important @CHEMICAL$ in the regulation of energy balance.	0
Systemic administration of @CHEMICAL$ recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating @GENE$ contributes to energy regulation.	0
Systemic administration of @CHEM-GENE$ recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating oxytocin contributes to energy regulation.	0
Systemic administration of oxytocin recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating @CHEM-GENE$ contributes to energy regulation.	0
Systemic administration of @GENE$ recapitulates many of its effects when administered centrally, raising the questions of whether and to what extent circulating @CHEMICAL$ contributes to energy regulation.	0
Its therapeutic potential to treat metabolic conditions remains to be determined, but data from diet-induced and genetically obese rodent models as well as application of @CHEM-GENE$ in humans in other areas of research have revealed promising results thus far.	0
@CHEMICAL$ suppresses cell survival via @GENE$-mediated proteasomal degradation of ΔNp63 protein.	0
@CHEMICAL$ suppresses cell survival via Pirh2-mediated proteasomal degradation of @GENE$ protein.	0
Here we found that @CHEMICAL$, a frontline agent for acute promyelocytic leukemia, inhibits @GENE$ but not TAp63 expression in time- and dose-dependent manners.	2
Here we found that @CHEMICAL$, a frontline agent for acute promyelocytic leukemia, inhibits ΔNp63 but not @GENE$ expression in time- and dose-dependent manners.	0
In addition, we found that @CHEMICAL$ decreases the stability of @GENE$ protein via a proteasome-dependent pathway but has little effect on the level of ΔNp63 transcript.	2
In addition, we found that @CHEMICAL$ decreases the stability of ΔNp63 protein via a @GENE$-dependent pathway but has little effect on the level of ΔNp63 transcript.	0
In addition, we found that @CHEMICAL$ decreases the stability of ΔNp63 protein via a proteasome-dependent pathway but has little effect on the level of @GENE$ transcript.	0
Furthermore, we found that @CHEMICAL$ activates the @GENE$ and consequently induces Pirh2 expression.	1
Furthermore, we found that @CHEMICAL$ activates the Pirh2 promoter and consequently induces @GENE$ expression.	1
Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, @CHEMICAL$-induced degradation of @GENE$ protein.	2
Consistent with this, we found that knockdown of @GENE$ inhibits, whereas ectopic expression of Pirh2 enhances, @CHEMICAL$-induced degradation of ΔNp63 protein.	0
Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of @GENE$ enhances, @CHEMICAL$-induced degradation of ΔNp63 protein.	0
Importantly, we found that knockdown of @GENE$ sensitizes, whereas ectopic expression of ΔNp63 inhibits, growth suppression induced by @CHEMICAL$.	0
Importantly, we found that knockdown of ΔNp63 sensitizes, whereas ectopic expression of @GENE$ inhibits, growth suppression induced by @CHEMICAL$.	0
Together, these data suggest that @CHEMICAL$ degrades @GENE$ protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.	2
Together, these data suggest that @CHEMICAL$ degrades ΔNp63 protein at least in part via @GENE$-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to arsenic-induced death.	0
Together, these data suggest that @CHEMICAL$ degrades ΔNp63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of @GENE$ expression facilitates tumor cells to arsenic-induced death.	2
Together, these data suggest that arsenic degrades @GENE$ protein at least in part via Pirh2-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to @CHEMICAL$-induced death.	0
Together, these data suggest that arsenic degrades ΔNp63 protein at least in part via @GENE$-dependent proteolysis and that inhibition of ΔNp63 expression facilitates tumor cells to @CHEMICAL$-induced death.	0
Together, these data suggest that arsenic degrades ΔNp63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of @GENE$ expression facilitates tumor cells to @CHEMICAL$-induced death.	0
@CHEMICAL$, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating @GENE$-cdc2 via ATM-Chk1/2 activation.	2
@CHEMICAL$, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-@GENE$ via ATM-Chk1/2 activation.	2
@CHEMICAL$, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via @GENE$-Chk1/2 activation.	1
@CHEMICAL$, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-@GENE$ activation.	0
@CHEMICAL$ induced G2/M phase cell cycle arrest and modulated the levels of @GENE$ and p-Cdc2 in Hec1A cells.	0
@CHEMICAL$ induced G2/M phase cell cycle arrest and modulated the levels of cyclin B and @GENE$ in Hec1A cells.	0
Knockdown of @GENE$ using specific siRNAs partially abrogated @CHEMICAL$-induced cell growth inhibition.	0
Additional mechanistic studies revealed that @CHEMICAL$ treatment resulted in an increase in phosphorylation of @GENE$ and ATM-Chk1/2.	1
Additional mechanistic studies revealed that @CHEMICAL$ treatment resulted in an increase in phosphorylation of Cdc25C and @GENE$-Chk1/2.	1
Additional mechanistic studies revealed that @CHEMICAL$ treatment resulted in an increase in phosphorylation of Cdc25C and ATM-@GENE$.	0
Ku55933, an @GENE$ inhibitor, reversed @CHEMICAL$-induced cell growth inhibition, in part.	0
Moreover, @CHEMICAL$ treatment resulted in phosphorylation of @GENE$, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin.	0
Moreover, @CHEMICAL$ treatment resulted in phosphorylation of ERK, and pretreatment with the @GENE$ inhibitor, PD98059, attenuated cell growth inhibition by jaceosidin.	0
Moreover, jaceosidin treatment resulted in phosphorylation of @GENE$, and pretreatment with the ERK inhibitor, @CHEMICAL$, attenuated cell growth inhibition by jaceosidin.	0
Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the @GENE$ inhibitor, @CHEMICAL$, attenuated cell growth inhibition by jaceosidin.	2
Moreover, jaceosidin treatment resulted in phosphorylation of @GENE$, and pretreatment with the ERK inhibitor, PD98059, attenuated cell growth inhibition by @CHEMICAL$.	0
Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the @GENE$ inhibitor, PD98059, attenuated cell growth inhibition by @CHEMICAL$.	0
These data suggest that @CHEMICAL$, isolated from Japanese mugwort, modulates the @GENE$/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.	0
These data suggest that @CHEMICAL$, isolated from Japanese mugwort, modulates the ERK/@GENE$/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.	0
These data suggest that @CHEMICAL$, isolated from Japanese mugwort, modulates the ERK/ATM/@GENE$ pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.	0
These data suggest that @CHEMICAL$, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the @GENE$-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.	2
These data suggest that @CHEMICAL$, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-@GENE$ complex, followed by G2/M cell cycle arrest in endometrial cancer cells.	2
@GENE$-EphrinA5 interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local @CHEMICAL$/glutamate balance during hypoglycemia.	0
EphA5-@GENE$ interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local @CHEMICAL$/glutamate balance during hypoglycemia.	0
@GENE$-EphrinA5 interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local glutamine/@CHEMICAL$ balance during hypoglycemia.	0
EphA5-@GENE$ interactions within the ventromedial hypothalamus influence counterregulatory hormone release and local glutamine/@CHEMICAL$ balance during hypoglycemia.	0
Given the similarities between islet and ventromedial hypothalamus (VMH) @CHEMICAL$ sensing, we tested the hypothesis that the @GENE$/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.	0
Given the similarities between islet and ventromedial hypothalamus (VMH) @CHEMICAL$ sensing, we tested the hypothesis that the EphA5/@GENE$ system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.	0
Counterregulatory responses and glutamine/glutamate concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic @CHEMICAL$ clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of @GENE$-Fc, chronic VMH knockdown, or overexpression of ephrinA5 using an adenoassociated viral construct.	0
Counterregulatory responses and glutamine/glutamate concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic @CHEMICAL$ clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of ephrinA5-Fc, chronic VMH knockdown, or overexpression of @GENE$ using an adenoassociated viral construct.	0
Counterregulatory responses and @CHEMICAL$/glutamate concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of @GENE$-Fc, chronic VMH knockdown, or overexpression of ephrinA5 using an adenoassociated viral construct.	0
Counterregulatory responses and @CHEMICAL$/glutamate concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of ephrinA5-Fc, chronic VMH knockdown, or overexpression of @GENE$ using an adenoassociated viral construct.	0
Counterregulatory responses and glutamine/@CHEMICAL$ concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of @GENE$-Fc, chronic VMH knockdown, or overexpression of ephrinA5 using an adenoassociated viral construct.	0
Counterregulatory responses and glutamine/@CHEMICAL$ concentrations in the VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake male Sprague-Dawley rats that received an acute VMH microinjection of ephrinA5-Fc, chronic VMH knockdown, or overexpression of @GENE$ using an adenoassociated viral construct.	0
Overexpression of VMH ephrinA5 transiently increased local @CHEMICAL$ concentrations, whereas @GENE$ knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.	0
Overexpression of VMH @GENE$ transiently increased local @CHEMICAL$ concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.	0
Overexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas @GENE$ knockdown produced profound suppression of VMH interstitial fluid @CHEMICAL$ concentrations in the basal state and during hypoglycemia.	0
Overexpression of VMH @GENE$ transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid @CHEMICAL$ concentrations in the basal state and during hypoglycemia.	0
Changes in @GENE$/EphA5 interactions within the VMH, a key brain @CHEMICAL$-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.	0
Changes in ephrinA5/@GENE$ interactions within the VMH, a key brain @CHEMICAL$-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.	0
Changes in @GENE$/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore @CHEMICAL$ homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.	0
Changes in ephrinA5/@GENE$ interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore @CHEMICAL$ homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.	0
Changes in @GENE$/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in @CHEMICAL$/glutamine cycling.	0
Changes in ephrinA5/@GENE$ interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in @CHEMICAL$/glutamine cycling.	0
Changes in @GENE$/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/@CHEMICAL$ cycling.	0
Changes in ephrinA5/@GENE$ interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/@CHEMICAL$ cycling.	0
Electrical Stimuli Release @CHEMICAL$ to Increase @GENE$ Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.	0
Electrical Stimuli Release @CHEMICAL$ to Increase GLUT4 Translocation and Glucose Uptake via @GENE$-Akt-AS160 in Skeletal Muscle Cells.	0
Electrical Stimuli Release @CHEMICAL$ to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-@GENE$-AS160 in Skeletal Muscle Cells.	0
Electrical Stimuli Release @CHEMICAL$ to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-@GENE$ in Skeletal Muscle Cells.	0
Electrical Stimuli Release ATP to Increase @GENE$ Translocation and @CHEMICAL$ Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.	5
Electrical Stimuli Release ATP to Increase GLUT4 Translocation and @CHEMICAL$ Uptake via @GENE$-Akt-AS160 in Skeletal Muscle Cells.	0
Electrical Stimuli Release ATP to Increase GLUT4 Translocation and @CHEMICAL$ Uptake via PI3Kγ-@GENE$-AS160 in Skeletal Muscle Cells.	0
Electrical Stimuli Release ATP to Increase GLUT4 Translocation and @CHEMICAL$ Uptake via PI3Kγ-Akt-@GENE$ in Skeletal Muscle Cells.	0
Skeletal muscle @CHEMICAL$ uptake in response to exercise is preserved in @GENE$-resistant conditions, but the signals involved are debated.	0
@CHEMICAL$ is released from skeletal muscle by contractile activity and can autocrinely signal through @GENE$, and we hypothesized it may influence glucose uptake.	0
ATP is released from skeletal muscle by contractile activity and can autocrinely signal through @GENE$, and we hypothesized it may influence @CHEMICAL$ uptake.	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent @CHEMICAL$ (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent @CHEMICAL$ (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent @CHEMICAL$ (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent 2-NBD-Glucose (@CHEMICAL$) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (@CHEMICAL$) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (@CHEMICAL$) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and @CHEMICAL$-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and @CHEMICAL$-dependent 2-NBDG uptake were inhibited by @GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and @CHEMICAL$-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent @CHEMICAL$ uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent @CHEMICAL$ uptake were inhibited by @GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent @CHEMICAL$ uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @CHEMICAL$ phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @CHEM-GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @CHEMICAL$ phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation, ATP, and @GENE$ each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (@CHEMICAL$).	0
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @GENE$ and by purinergic receptor blockade (@CHEMICAL$).	2
Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (@CHEMICAL$).	2
Electrical stimulation, @CHEMICAL$, and @GENE$ each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin).	0
Electrical stimulation, @CHEMICAL$, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by @GENE$ and by purinergic receptor blockade (suramin).	0
Electrical stimulation, @CHEMICAL$, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by @GENE$ blockade (suramin).	0
Electrical stimulation transiently elevated extracellular @CHEMICAL$ and caused @GENE$ phosphorylation that was additive to insulin and inhibited by suramin.	0
Electrical stimulation transiently elevated extracellular @CHEMICAL$ and caused Akt phosphorylation that was additive to @GENE$ and inhibited by suramin.	0
Electrical stimulation transiently elevated extracellular ATP and caused @GENE$ phosphorylation that was additive to insulin and inhibited by @CHEMICAL$.	2
Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to @GENE$ and inhibited by @CHEMICAL$.	0
Exogenous @CHEMICAL$ transiently activated @GENE$ and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.	1
Exogenous @CHEMICAL$ transiently activated Akt and, inhibiting @GENE$ (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous @CHEMICAL$ transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (@GENE$) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous @CHEMICAL$ transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or @GENE$ as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous @CHEMICAL$ transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative @GENE$ mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous @CHEMICAL$ transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and @GENE$ phosphorylation.	0
Exogenous ATP transiently activated @GENE$ and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting @GENE$ (PI3K) or Akt as well as dominant-negative Akt mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (@GENE$) or Akt as well as dominant-negative Akt mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or @GENE$ as well as dominant-negative Akt mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative @GENE$ mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced @CHEMICAL$-dependent 2-NBDG uptake and @GENE$ phosphorylation.	0
Exogenous ATP transiently activated @GENE$ and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent @CHEMICAL$ uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting @GENE$ (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent @CHEMICAL$ uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (@GENE$) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent @CHEMICAL$ uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or @GENE$ as well as dominant-negative Akt mutant, reduced ATP-dependent @CHEMICAL$ uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative @GENE$ mutant, reduced ATP-dependent @CHEMICAL$ uptake and Akt phosphorylation.	0
Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent @CHEMICAL$ uptake and @GENE$ phosphorylation.	0
ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the @GENE$ (PI3Kγ) inhibitor @CHEMICAL$.	2
ATP-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (@GENE$) inhibitor @CHEMICAL$.	2
ATP-dependent 2-NBDG uptake was also inhibited by the @GENE$ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor @CHEMICAL$.	0
@CHEMICAL$-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the @GENE$ (PI3Kγ) inhibitor AS605240.	0
@CHEMICAL$-dependent 2-NBDG uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (@GENE$) inhibitor AS605240.	0
@CHEMICAL$-dependent 2-NBDG uptake was also inhibited by the @GENE$ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240.	0
ATP-dependent @CHEMICAL$ uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the @GENE$ (PI3Kγ) inhibitor AS605240.	0
ATP-dependent @CHEMICAL$ uptake was also inhibited by the G protein βγ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (@GENE$) inhibitor AS605240.	0
ATP-dependent @CHEMICAL$ uptake was also inhibited by the @GENE$ subunit-interacting peptide βark-ct and by the phosphatidylinositol 3-kinase-γ (PI3Kγ) inhibitor AS605240.	0
@CHEMICAL$ caused translocation of @GENE$myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving @GENE$/Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/@GENE$ reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative @GENE$ or PI3Kγ kinase-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or @GENE$ kinase-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ @GENE$-dead mutants, and potentiated by myristoylated PI3Kγ.	0
@CHEMICAL$ caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160/Rab8A reduced by dominant-negative Akt or PI3Kγ kinase-dead mutants, and potentiated by @GENE$.	0
@CHEMICAL$ stimulated 2-NBDG uptake in normal and @GENE$-resistant adult muscle fibers, resembling the reported effect of exercise.	0
ATP stimulated @CHEMICAL$ uptake in normal and @GENE$-resistant adult muscle fibers, resembling the reported effect of exercise.	0
Hence, the @CHEMICAL$-induced pathway may be tapped to bypass @GENE$ resistance.	0
The @GENE$/IRF5 interaction occurred on the @CHEMICAL$ and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/@GENE$ interaction occurred on the @CHEMICAL$ and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the @CHEMICAL$ and amino termini of @GENE$; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the @CHEMICAL$ and amino termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce @GENE$ protein stability.	0
The @GENE$/IRF5 interaction occurred on the carboxyl and @CHEMICAL$ termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/@GENE$ interaction occurred on the carboxyl and @CHEMICAL$ termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the carboxyl and @CHEMICAL$ termini of @GENE$; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the carboxyl and @CHEMICAL$ termini of IRF5; a single internal deletion from amino acids 455 to 466 (Δ455-466) was found to significantly reduce @GENE$ protein stability.	0
The @GENE$/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from @CHEMICAL$ 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/@GENE$ interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from @CHEMICAL$ 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the carboxyl and amino termini of @GENE$; a single internal deletion from @CHEMICAL$ 455 to 466 (Δ455-466) was found to significantly reduce IRF5 protein stability.	0
The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from @CHEMICAL$ 455 to 466 (Δ455-466) was found to significantly reduce @GENE$ protein stability.	0
Structure-based design, synthesis and evaluation of novel @CHEMICAL$ derivatives as @GENE$ inhibitors and potential for cancer polypharmacology.	2
A series of @CHEMICAL$ derivatives were synthesized and evaluated for telomerase inhibition, @GENE$ expression and suppression of cancer cell growth in vitro.	0
A series of @CHEMICAL$ derivatives were synthesized and evaluated for @GENE$ inhibition, hTERT expression and suppression of cancer cell growth in vitro.	2
The data also showed significant decrease in the levels of serum @CHEMICAL$, @GENE$ and follicle stimulating hormone and significant increase in the level of serum prolactin in Al-intoxicated rats.	0
The data also showed significant decrease in the levels of serum @CHEMICAL$, leutinizing hormone and @GENE$ and significant increase in the level of serum prolactin in Al-intoxicated rats.	0
The data also showed significant decrease in the levels of serum @CHEMICAL$, leutinizing hormone and follicle stimulating hormone and significant increase in the level of serum @GENE$ in Al-intoxicated rats.	0
The data also showed significant decrease in the levels of serum testosterone, @GENE$ and follicle stimulating hormone and significant increase in the level of serum prolactin in @CHEMICAL$-intoxicated rats.	0
The data also showed significant decrease in the levels of serum testosterone, leutinizing hormone and @GENE$ and significant increase in the level of serum prolactin in @CHEMICAL$-intoxicated rats.	0
The data also showed significant decrease in the levels of serum testosterone, leutinizing hormone and follicle stimulating hormone and significant increase in the level of serum @GENE$ in @CHEMICAL$-intoxicated rats.	0
@CHEMICAL$ inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced @GENE$-antioxidant response element signaling.	1
@CHEMICAL$ inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-@GENE$ signaling.	1
@CHEMICAL$ inhibits @GENE$-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.	2
Trichostatin A inhibits transforming growth factor-β-induced reactive @CHEMICAL$ species accumulation and myofibroblast differentiation via enhanced @GENE$-antioxidant response element signaling.	0
Trichostatin A inhibits transforming growth factor-β-induced reactive @CHEMICAL$ species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-@GENE$ signaling.	0
Trichostatin A inhibits @GENE$-induced reactive @CHEMICAL$ species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.	0
The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by @CHEMICAL$ on @GENE$ (TGF-β)-induced myofibroblast differentiation of corneal fibroblasts in vitro.	0
The present study aimed at investigating the role of reactive oxygen species (ROS) scavenging by @CHEMICAL$ on transforming growth factor-β (@GENE$-induced myofibroblast differentiation of corneal fibroblasts in vitro.	0
The present study aimed at investigating the role of reactive @CHEMICAL$ species (ROS) scavenging by TSA on @GENE$ (TGF-β)-induced myofibroblast differentiation of corneal fibroblasts in vitro.	0
The present study aimed at investigating the role of reactive @CHEMICAL$ species (ROS) scavenging by TSA on transforming growth factor-β (@GENE$-induced myofibroblast differentiation of corneal fibroblasts in vitro.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of @CHEMICAL$, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of @CHEMICAL$, the @GENE$ inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of @CHEMICAL$, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of @CHEMICAL$, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of @CHEMICAL$, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of @CHEMICAL$, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the @CHEMICAL$ oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @CHEM-GENE$ inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @CHEMICAL$ oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @CHEMICAL$ oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @CHEMICAL$ oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @CHEMICAL$ oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the NAD(P)H oxidase inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @GENE$ inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	2
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor @CHEMICAL$ (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @GENE$ inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	2
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (@CHEMICAL$), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @GENE$ inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant @CHEMICAL$ (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @GENE$ inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the @GENE$-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (@CHEMICAL$), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator sulforaphane, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with @GENE$ in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator @CHEMICAL$, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the @GENE$ inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator @CHEMICAL$, or small interfering RNA.	0
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the @GENE$-antioxidant response element (Nrf2-ARE) activator @CHEMICAL$, or small interfering RNA.	1
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-@GENE$ (Nrf2-ARE) activator @CHEMICAL$, or small interfering RNA.	1
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (@GENE$-ARE) activator @CHEMICAL$, or small interfering RNA.	1
Human immortalized corneal fibroblasts were treated with TGF-β in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-@GENE$) activator @CHEMICAL$, or small interfering RNA.	1
ROS, @CHEMICAL$, intracellular glutathione (GSH) level, cellular total antioxidant capacity, and the activation of @GENE$-ARE signaling were determined with various assays.	0
ROS, @CHEMICAL$, intracellular glutathione (GSH) level, cellular total antioxidant capacity, and the activation of Nrf2-@GENE$ signaling were determined with various assays.	0
ROS, H(2)O(2), intracellular @CHEMICAL$ (GSH) level, cellular total antioxidant capacity, and the activation of @GENE$-ARE signaling were determined with various assays.	0
ROS, H(2)O(2), intracellular @CHEMICAL$ (GSH) level, cellular total antioxidant capacity, and the activation of Nrf2-@GENE$ signaling were determined with various assays.	0
ROS, H(2)O(2), intracellular glutathione (@CHEMICAL$) level, cellular total antioxidant capacity, and the activation of @GENE$-ARE signaling were determined with various assays.	0
ROS, H(2)O(2), intracellular glutathione (@CHEMICAL$) level, cellular total antioxidant capacity, and the activation of Nrf2-@GENE$ signaling were determined with various assays.	0
Treatment with @CHEMICAL$ and the @GENE$-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC.	0
Treatment with @CHEMICAL$ and the Nrf2-@GENE$ activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC.	0
Treatment with @CHEMICAL$ and the Nrf2-ARE activator resulted in increased inhibition of the @GENE$-induced myofibroblast differentiation as compared with treatment with DPI or NAC.	2
Treatment with TSA and the @GENE$-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with @CHEMICAL$ or NAC.	0
Treatment with TSA and the Nrf2-@GENE$ activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with @CHEMICAL$ or NAC.	0
Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the @GENE$-induced myofibroblast differentiation as compared with treatment with @CHEMICAL$ or NAC.	0
Treatment with TSA and the @GENE$-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or @CHEMICAL$.	0
Treatment with TSA and the Nrf2-@GENE$ activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or @CHEMICAL$.	0
Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the @GENE$-induced myofibroblast differentiation as compared with treatment with DPI or @CHEMICAL$.	0
Furthermore, @CHEMICAL$ also decreased cellular ROS and H(2)O(2) accumulation induced by @GENE$, whereas it elevated intracellular GSH level and cellular total antioxidant capacity.	2
Furthermore, TSA also decreased cellular ROS and @CHEMICAL$ accumulation induced by @GENE$, whereas it elevated intracellular GSH level and cellular total antioxidant capacity.	0
Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by @GENE$, whereas it elevated intracellular @CHEMICAL$ level and cellular total antioxidant capacity.	0
In addition, @CHEMICAL$ induced @GENE$ nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.	0
In addition, @CHEMICAL$ induced Nrf2 nuclear translocation and up-regulated the expression of @GENE$-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.	1
In addition, @CHEMICAL$ induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-@GENE$ downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.	1
In addition, @CHEMICAL$ induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas @GENE$ knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation.	0
In addition, TSA induced @GENE$ nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of @CHEMICAL$ on myofibroblast differentiation.	0
In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of @GENE$-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of @CHEMICAL$ on myofibroblast differentiation.	0
In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-@GENE$ downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of @CHEMICAL$ on myofibroblast differentiation.	0
In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas @GENE$ knockdown by RNA interference blocked the inhibition of @CHEMICAL$ on myofibroblast differentiation.	0
In conclusion, this study provides the first evidence implicating that @CHEMICAL$ inhibits @GENE$-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.	2
In conclusion, this study provides the first evidence implicating that @CHEMICAL$ inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced @GENE$-ARE signaling.	1
In conclusion, this study provides the first evidence implicating that @CHEMICAL$ inhibits TGF-β-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-@GENE$ signaling.	1
@CHEMICAL$ discrimination and antagonism by @GENE$ neutral and inverse agonist antagonists.	0
@CHEM-GENE$ (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	0
@CHEMICAL$ receptor 1 (@GENE$) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	0
@GENE$ (CB(1)) inverse agonists (e.g., @CHEMICAL$) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	3
Cannabinoid receptor 1 (@GENE$) inverse agonists (e.g., @CHEMICAL$) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.	3
In the present studies, the @GENE$ inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist @CHEMICAL$ were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the @GENE$ neutral antagonist @CHEMICAL$ were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	4
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist @CHEMICAL$ were compared for their ability to modify @GENE$-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist @CHEMICAL$ were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel @GENE$ full agonist AM4054.	0
In the present studies, the @GENE$ inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist @CHEMICAL$.	0
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the @GENE$ neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist @CHEMICAL$.	0
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify @GENE$-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist @CHEMICAL$.	0
In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel @GENE$ full agonist @CHEMICAL$.	3
In the present studies, the @GENE$ inverse agonist @CHEMICAL$ (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	3
In the present studies, the CB(1) inverse agonist @CHEMICAL$ (rimonabant) and the @GENE$ neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist @CHEMICAL$ (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify @GENE$-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist @CHEMICAL$ (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel @GENE$ full agonist AM4054.	0
In the present studies, the @GENE$ inverse agonist SR141716A (@CHEMICAL$) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	3
In the present studies, the CB(1) inverse agonist SR141716A (@CHEMICAL$) and the @GENE$ neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist SR141716A (@CHEMICAL$) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify @GENE$-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.	0
In the present studies, the CB(1) inverse agonist SR141716A (@CHEMICAL$) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel @GENE$ full agonist AM4054.	0
Results indicate that @CHEMICAL$ serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	1
Results indicate that @CHEMICAL$ serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	0
Results indicate that AM4054 serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist @CHEMICAL$, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	0
Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist @CHEMICAL$, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	3
Results indicate that AM4054 serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist @CHEMICAL$ and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	0
Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist @CHEMICAL$ and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	3
Results indicate that AM4054 serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist @CHEMICAL$ produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	0
Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist @CHEMICAL$ produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	4
Results indicate that AM4054 serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the @CHEMICAL$ dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	0
Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the @CHEMICAL$ dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.	3
Results indicate that AM4054 serves as an effective @GENE$ discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of @CHEMICAL$.	0
Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the @GENE$ agonist Δ(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of @CHEMICAL$.	3
In early pregnancy, there were no significant differences in @GENE$ sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-@CHEMICAL$-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.	0
In early pregnancy, there were no significant differences in insulin sensitivity (@GENE$ sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-@CHEMICAL$-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.	0
In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for @GENE$ resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-@CHEMICAL$-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.	0
In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and @GENE$ secretion (a ratio of the total area-under-the-insulin-curve to the total area-under-the-@CHEMICAL$-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.	0
In early pregnancy, there were no significant differences in insulin sensitivity (insulin sensitivity index derived from OGTT [ISOGTT] and homeostasis model assessment for insulin resistance [HOMA-IR]) and insulin secretion (a ratio of the total area-under-the-@GENE$-curve to the total area-under-the-@CHEMICAL$-curve [AUCins/glu] and insulinogenic index [IGI]) between the NGT and late-onset GDM groups.	0
@CHEMICAL$ and apixaban, are potent, oral direct inhibitors of @GENE$-bound, clot-associated or free FXa.	2
@CHEMICAL$ and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free @GENE$.	2
rivaroxaban and @CHEMICAL$, are potent, oral direct inhibitors of @GENE$-bound, clot-associated or free FXa.	2
rivaroxaban and @CHEMICAL$, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free @GENE$.	2
Since both are substrates, co-administration of @CHEMICAL$ and apixaban with strong @GENE$ and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of @CHEMICAL$ and apixaban with strong cytochrome P450 (CYP) 3A4 and @GENE$ (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of @CHEMICAL$ and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (@GENE$) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of @CHEMICAL$ and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong @GENE$ and P-gp inducers.	0
Since both are substrates, co-administration of @CHEMICAL$ and apixaban with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and @GENE$ inducers.	0
Since both are substrates, co-administration of rivaroxaban and @CHEMICAL$ with strong @GENE$ and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of rivaroxaban and @CHEMICAL$ with strong cytochrome P450 (CYP) 3A4 and @GENE$ (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of rivaroxaban and @CHEMICAL$ with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (@GENE$) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and P-gp inducers.	0
Since both are substrates, co-administration of rivaroxaban and @CHEMICAL$ with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong @GENE$ and P-gp inducers.	0
Since both are substrates, co-administration of rivaroxaban and @CHEMICAL$ with strong cytochrome P450 (CYP) 3A4 and permeability glycoprotein (P-gp) inhibitors and inducers can result in substantial changes in plasma concentrations due to altered clearance rates; consequently, their concomitant use is contraindicated and caution is required when used concomitantly with strong CYP3A4 and @GENE$ inducers.	0
Although parenteral oral direct @GENE$ inhibitors (DTIs), such as @CHEMICAL$ and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.	2
Although parenteral oral direct thrombin inhibitors (DTIs), such as @CHEMICAL$ and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic @GENE$ antagonists.	0
Although parenteral oral direct @GENE$ inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as @CHEMICAL$ are novel synthetic thrombin antagonists.	0
Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as @CHEMICAL$ are novel synthetic @GENE$ antagonists.	4
@CHEMICAL$ has an advantage over the indirect @GENE$ inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.	2
@CHEMICAL$ has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and @GENE$-bound thrombin.	2
@CHEMICAL$ has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound @GENE$.	2
The reversible binding of @CHEMICAL$ may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent @GENE$ inhibitors, e.g.	2
Results revealed that @CHEMICAL$, @GENE$ (LDL) and glutathion peroxidase (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that @CHEMICAL$, low-density lipoprotein (@GENE$) and glutathion peroxidase (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that @CHEMICAL$, low-density lipoprotein (LDL) and @GENE$ (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that @CHEMICAL$, low-density lipoprotein (LDL) and glutathion peroxidase (@GENE$) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that cholesterol, @GENE$ (LDL) and @CHEMICAL$ peroxidase (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that cholesterol, low-density lipoprotein (@GENE$) and @CHEMICAL$ peroxidase (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that cholesterol, low-density lipoprotein (LDL) and @CHEM-GENE$ (GPx) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
Results revealed that cholesterol, low-density lipoprotein (LDL) and @CHEMICAL$ peroxidase (@GENE$) enzyme were significantly higher in the 38 smoker sprayers than in the 42 nonsmoker sprayers.	0
@CHEMICAL$ and @GENE$ were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
@CHEMICAL$ and LDL were correlated with smoking index and @GENE$ (HDL), superoxide dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
@CHEMICAL$ and LDL were correlated with smoking index and high-density lipoprotein (@GENE$), superoxide dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
@CHEMICAL$ and LDL were correlated with smoking index and high-density lipoprotein (HDL), @GENE$ (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
@CHEMICAL$ and LDL were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (@GENE$) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and @GENE$ were correlated with smoking index and high-density lipoprotein (HDL), @CHEMICAL$ dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and @GENE$ (HDL), @CHEMICAL$ dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (@GENE$), @CHEMICAL$ dismutase (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), @CHEM-GENE$ (SOD) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), @CHEMICAL$ dismutase (@GENE$) enzyme and zinc (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and @GENE$ were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (SOD) enzyme and @CHEMICAL$ (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and @GENE$ (HDL), superoxide dismutase (SOD) enzyme and @CHEMICAL$ (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (@GENE$), superoxide dismutase (SOD) enzyme and @CHEMICAL$ (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), @GENE$ (SOD) enzyme and @CHEMICAL$ (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (@GENE$) enzyme and @CHEMICAL$ (Zn) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and @GENE$ were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (SOD) enzyme and zinc (@CHEMICAL$) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and @GENE$ (HDL), superoxide dismutase (SOD) enzyme and zinc (@CHEMICAL$) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (@GENE$), superoxide dismutase (SOD) enzyme and zinc (@CHEMICAL$) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), @GENE$ (SOD) enzyme and zinc (@CHEMICAL$) were inversely correlated with duration of pesticides' exposure.	0
Cholesterol and LDL were correlated with smoking index and high-density lipoprotein (HDL), superoxide dismutase (@GENE$) enzyme and zinc (@CHEMICAL$) were inversely correlated with duration of pesticides' exposure.	0
In nonsmokers, @GENE$ and @CHEMICAL$ were negatively correlated with SOD and correlated with malondialdehyde (MDA), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, LDL and @CHEMICAL$ were negatively correlated with @GENE$ and correlated with malondialdehyde (MDA), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, @GENE$ and cholesterol were negatively correlated with SOD and correlated with @CHEMICAL$ (MDA), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, LDL and cholesterol were negatively correlated with @GENE$ and correlated with @CHEMICAL$ (MDA), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, @GENE$ and cholesterol were negatively correlated with SOD and correlated with malondialdehyde (@CHEMICAL$), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, LDL and cholesterol were negatively correlated with @GENE$ and correlated with malondialdehyde (@CHEMICAL$), and cholesterol was negatively correlated with Zn.	0
In nonsmokers, @GENE$ and cholesterol were negatively correlated with SOD and correlated with malondialdehyde (MDA), and @CHEMICAL$ was negatively correlated with Zn.	0
In nonsmokers, LDL and cholesterol were negatively correlated with @GENE$ and correlated with malondialdehyde (MDA), and @CHEMICAL$ was negatively correlated with Zn.	0
In nonsmokers, @GENE$ and cholesterol were negatively correlated with SOD and correlated with malondialdehyde (MDA), and cholesterol was negatively correlated with @CHEMICAL$.	0
In nonsmokers, LDL and cholesterol were negatively correlated with @GENE$ and correlated with malondialdehyde (MDA), and cholesterol was negatively correlated with @CHEMICAL$.	0
@GENE$ was negatively correlated with @CHEMICAL$ in all the sprayers, but was correlated with GPx in smokers and with Zn in nonsmokers.	0
HDL was negatively correlated with @CHEMICAL$ in all the sprayers, but was correlated with @GENE$ in smokers and with Zn in nonsmokers.	0
@GENE$ was negatively correlated with MDA in all the sprayers, but was correlated with GPx in smokers and with @CHEMICAL$ in nonsmokers.	0
HDL was negatively correlated with MDA in all the sprayers, but was correlated with @GENE$ in smokers and with @CHEMICAL$ in nonsmokers.	0
In smokers, LDL was negatively correlated with GPx, HDL was negatively correlated with @CHEMICAL$ and triglycerides and @GENE$ were negatively correlated with Zn.	0
In smokers, @GENE$ was negatively correlated with GPx, HDL was negatively correlated with @CHEMICAL$ and triglycerides and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with @GENE$, HDL was negatively correlated with @CHEMICAL$ and triglycerides and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with GPx, @GENE$ was negatively correlated with @CHEMICAL$ and triglycerides and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with GPx, HDL was negatively correlated with MDA and @CHEMICAL$ and @GENE$ were negatively correlated with Zn.	0
In smokers, @GENE$ was negatively correlated with GPx, HDL was negatively correlated with MDA and @CHEMICAL$ and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with @GENE$, HDL was negatively correlated with MDA and @CHEMICAL$ and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with GPx, @GENE$ was negatively correlated with MDA and @CHEMICAL$ and very-low-density lipoprotein were negatively correlated with Zn.	0
In smokers, LDL was negatively correlated with GPx, HDL was negatively correlated with MDA and triglycerides and @GENE$ were negatively correlated with @CHEMICAL$.	0
In smokers, @GENE$ was negatively correlated with GPx, HDL was negatively correlated with MDA and triglycerides and very-low-density lipoprotein were negatively correlated with @CHEMICAL$.	0
In smokers, LDL was negatively correlated with @GENE$, HDL was negatively correlated with MDA and triglycerides and very-low-density lipoprotein were negatively correlated with @CHEMICAL$.	0
In smokers, LDL was negatively correlated with GPx, @GENE$ was negatively correlated with MDA and triglycerides and very-low-density lipoprotein were negatively correlated with @CHEMICAL$.	0
@CHEMICAL$ was negatively correlated with @GENE$, GPx and Zn.	0
@CHEMICAL$ was negatively correlated with SOD, @GENE$ and Zn.	0
MDA was negatively correlated with @GENE$, GPx and @CHEMICAL$.	0
MDA was negatively correlated with SOD, @GENE$ and @CHEMICAL$.	0
Fluorescence lifetime analysis and effect of @CHEMICAL$ ions on binding of NADH to @GENE$.	0
Fluorescence lifetime analysis and effect of magnesium ions on binding of @CHEMICAL$ to @GENE$.	0
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to @CHEM-GENE$.	0
@CHEM-GENE$ (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids.	0
@CHEMICAL$ dehydrogenase 1 (@GENE$) catalyzes the oxidation of toxic aldehydes to carboxylic acids.	0
@GENE$ (ALDH1A1) catalyzes the oxidation of toxic @CHEMICAL$ to carboxylic acids.	5
Aldehyde dehydrogenase 1 (@GENE$) catalyzes the oxidation of toxic @CHEMICAL$ to carboxylic acids.	5
@GENE$ (ALDH1A1) catalyzes the oxidation of toxic aldehydes to @CHEMICAL$.	5
Aldehyde dehydrogenase 1 (@GENE$) catalyzes the oxidation of toxic aldehydes to @CHEMICAL$.	5
Physiologic levels of Mg(2+) ions decrease @GENE$ activity in part by increasing @CHEMICAL$ binding affinity to the enzyme.	0
Physiologic levels of @CHEMICAL$ ions decrease @GENE$ activity in part by increasing NADH binding affinity to the enzyme.	2
We used this technique to investigate the effects of @CHEMICAL$ ions on the @GENE$-NADH binding characteristics and enzyme catalysis.	0
We used this technique to investigate the effects of Mg(2+) ions on the @GENE$-@CHEMICAL$ binding characteristics and enzyme catalysis.	0
From the resolved free and bound @CHEMICAL$ fluorescence signatures, the KD values for both NADH conformations in @GENE$ ranged from about 24 μM to 1 μM for Mg(2+) ion concentrations of 0-6000 μM, respectively.	0
From the resolved free and bound NADH fluorescence signatures, the KD values for both @CHEMICAL$ conformations in @GENE$ ranged from about 24 μM to 1 μM for Mg(2+) ion concentrations of 0-6000 μM, respectively.	0
From the resolved free and bound NADH fluorescence signatures, the KD values for both NADH conformations in @GENE$ ranged from about 24 μM to 1 μM for @CHEMICAL$ ion concentrations of 0-6000 μM, respectively.	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM @CHEMICAL$) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM @CHEMICAL$) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-@CHEMICAL$ complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-@CHEMICAL$ complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of @CHEMICAL$ ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of @CHEMICAL$ ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-@CHEMICAL$ complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-@CHEMICAL$ complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM @CHEMICAL$.	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM @CHEMICAL$.	0
As the @CHEMICAL$ ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	2
As the @CHEMICAL$ ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM Mg(2+)) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM @CHEMICAL$) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the @GENE$-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 μM @CHEMICAL$) to 0.050 s(-1) (6000 μM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the @GENE$-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 μM Mg(2+).	0
This shift in conformational population at higher @CHEMICAL$ ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the @GENE$ pocket.	2
This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the @CHEMICAL$ in the @GENE$ pocket.	0
The results from monitoring enzyme catalysis in the absence of @CHEMICAL$ suggests that the @GENE$-NADH complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.	0
The results from monitoring enzyme catalysis in the absence of magnesium suggests that the @GENE$-@CHEMICAL$ complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.	0
Interestingly, @CHEMICAL$ increased proteins' levels of @GENE$ (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	1
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (@GENE$), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	0
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (APP), @GENE$ (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	1
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (APP), β-secretase (@GENE$) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	1
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the @GENE$ receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	1
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter @GENE$, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.	1
Interestingly, @CHEMICAL$ increased proteins' levels of amyloid precursor protein (APP), β-secretase (BACE-1) and the amyloid β-peptide transporter receptor for advanced glycation end products, and decreased @GENE$ levels.	2
The activity of @CHEM-GENE$ was down-regulated while the level of malondialdehyde was up-regulated in rat brain.	0
The activity of @GENE$ was down-regulated while the level of @CHEMICAL$ was up-regulated in rat brain.	0
Moreover, @CHEMICAL$ resulted in activation of astrocytes, up-regulation of @GENE$ in cortex and down-regulation of ADAM-10 in hippocampus and cortex.	1
Moreover, @CHEMICAL$ resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of @GENE$ in hippocampus and cortex.	2
Regulation of sexual reproduction by @CHEMICAL$ involves the activation of @GENE$ (ERs) in the hypothalamus.	1
Regulation of sexual reproduction by @CHEMICAL$ involves the activation of estrogen receptors (@GENE$) in the hypothalamus.	1
Regulation of sexual reproduction by estradiol involves the activation of @CHEM-GENE$ (ERs) in the hypothalamus.	0
Regulation of sexual reproduction by estradiol involves the activation of @CHEMICAL$ receptors (@GENE$) in the hypothalamus.	0
Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant @CHEMICAL$ elevated plasma membrane @GENE$ protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.	1
Using surface biotinylation, we observed that treatment of N-38 neurons with @CHEMICAL$ or with a membrane impermeant estradiol elevated plasma membrane @GENE$ protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.	1
Insertion of @GENE$ was blocked by the ER antagonist @CHEMICAL$ or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).	2
Insertion of ERα was blocked by the @GENE$ antagonist @CHEMICAL$ or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).	4
Insertion of ERα was blocked by the ER antagonist @CHEMICAL$ or with the @GENE$ (PKC) pathway inhibitor bisindolylmaleimide (BIS).	0
Insertion of ERα was blocked by the ER antagonist @CHEMICAL$ or with the protein kinase C (@GENE$) pathway inhibitor bisindolylmaleimide (BIS).	0
Insertion of @GENE$ was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor @CHEMICAL$ (BIS).	2
Insertion of ERα was blocked by the @GENE$ antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor @CHEMICAL$ (BIS).	0
Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the @GENE$ (PKC) pathway inhibitor @CHEMICAL$ (BIS).	2
Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (@GENE$) pathway inhibitor @CHEMICAL$ (BIS).	2
Insertion of @GENE$ was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (@CHEMICAL$).	2
Insertion of ERα was blocked by the @GENE$ antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (@CHEMICAL$).	0
Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the @GENE$ (PKC) pathway inhibitor bisindolylmaleimide (@CHEMICAL$).	2
Insertion of ERα was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (@GENE$) pathway inhibitor bisindolylmaleimide (@CHEMICAL$).	2
Downstream membrane-initiated signaling was confirmed by @CHEMICAL$ activation of @GENE$ (PKCθ) and the release of intracellular calcium.	0
Downstream membrane-initiated signaling was confirmed by @CHEMICAL$ activation of PKC-theta (@GENE$) and the release of intracellular calcium.	0
These results indicate that membrane @GENE$ levels in N-38 neurons are dynamically autoregulated by @CHEMICAL$.	1
One of these compounds is @CHEMICAL$ (EHT), which ameliorates the phenotype of @GENE$ transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.	0
One of these compounds is eicosanoyl-5-hydroxytryptamide (@CHEMICAL$), which ameliorates the phenotype of @GENE$ transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation.	0
Reductions in striatal @CHEMICAL$ and @GENE$ content were also less pronounced with EHT treatment.	0
Reductions in striatal dopamine and @CHEM-GENE$ content were also less pronounced with EHT treatment.	0
Reductions in striatal dopamine and @GENE$ content were also less pronounced with @CHEMICAL$ treatment.	1
The neuroinflammatory response to @CHEMICAL$ was markedly attenuated, and indices of oxidative stress and @GENE$ activation were significantly prevented with EHT.	0
The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and @GENE$ activation were significantly prevented with @CHEMICAL$.	2
In cultured primary microglia and astrocytes, @CHEMICAL$ had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced @GENE$ activation, iNOS induction, and nitric oxide production.	2
In cultured primary microglia and astrocytes, @CHEMICAL$ had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, @GENE$ induction, and nitric oxide production.	2
In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced @GENE$ activation, iNOS induction, and @CHEMICAL$ production.	0
In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, @GENE$ induction, and @CHEMICAL$ production.	0
Additionally, in SH-SY5Y cells, @CHEMICAL$-induced demethylation of @GENE$ (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.	2
Additionally, in SH-SY5Y cells, @CHEMICAL$-induced demethylation of phosphoprotein phosphatase 2A (@GENE$), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT.	2
Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of @GENE$ (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by @CHEMICAL$.	1
Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (@GENE$), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by @CHEMICAL$.	1
These findings indicate that the neuroprotective effect of @CHEMICAL$ against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of @GENE$.	0
These findings indicate that the neuroprotective effect of EHT against @CHEMICAL$ is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of @GENE$.	0
It is physiologically generated by @CHEM-GENE$, cystathionine-β-synthase, and 3-mercaptopyruvate sulfurtransferase.	0
It is physiologically generated by @CHEMICAL$-γ-lyase, @GENE$, and 3-mercaptopyruvate sulfurtransferase.	0
It is physiologically generated by @CHEMICAL$-γ-lyase, cystathionine-β-synthase, and @GENE$.	0
It is physiologically generated by @GENE$, @CHEMICAL$-β-synthase, and 3-mercaptopyruvate sulfurtransferase.	0
It is physiologically generated by cystathionine-γ-lyase, @CHEM-GENE$, and 3-mercaptopyruvate sulfurtransferase.	0
It is physiologically generated by cystathionine-γ-lyase, @CHEMICAL$-β-synthase, and @GENE$.	0
It is physiologically generated by @GENE$, cystathionine-β-synthase, and @CHEMICAL$ sulfurtransferase.	0
It is physiologically generated by cystathionine-γ-lyase, @GENE$, and @CHEMICAL$ sulfurtransferase.	0
It is physiologically generated by cystathionine-γ-lyase, cystathionine-β-synthase, and @CHEM-GENE$.	0
Substantial evidence shows that @CHEMICAL$ is involved in aging by inhibiting free-radical reactions, activating @GENE$, and probably interacting with the age-related gene Klotho.	1
Substantial evidence shows that @CHEMICAL$ is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene @GENE$.	0
Induction of @GENE$ through p38 MAPK/Nrf2 signaling pathway by @CHEMICAL$ extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.	1
Induction of HO-1 through @GENE$ MAPK/Nrf2 signaling pathway by @CHEMICAL$ extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.	1
Induction of HO-1 through p38 @GENE$/Nrf2 signaling pathway by @CHEMICAL$ extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.	1
Induction of HO-1 through p38 MAPK/@GENE$ signaling pathway by @CHEMICAL$ extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.	0
We recently proposed that @CHEM-GENE$ (HO-1) negatively regulates HMGB1 in inflammatory conditions.	0
We recently proposed that @CHEMICAL$ oxygenase-1 (@GENE$) negatively regulates HMGB1 in inflammatory conditions.	0
We recently proposed that @CHEMICAL$ oxygenase-1 (HO-1) negatively regulates @GENE$ in inflammatory conditions.	0
We investigated whether @CHEMICAL$ extract of Inula helenium L. (EIH) activates @GENE$ MAPK/Nrf2/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice.	0
We investigated whether @CHEMICAL$ extract of Inula helenium L. (EIH) activates p38 @GENE$/Nrf2/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice.	0
We investigated whether @CHEMICAL$ extract of Inula helenium L. (EIH) activates p38 MAPK/@GENE$/HO-1 pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice.	0
We investigated whether @CHEMICAL$ extract of Inula helenium L. (EIH) activates p38 MAPK/Nrf2/@GENE$ pathways in RAW264.7 cells and reduces inflammation in CLP-induced septic mice.	0
The induction of @GENE$ by EIH was inhibited by @CHEMICAL$ but not by SP600125, PD98059, nor LY294002.	2
The induction of @GENE$ by EIH was inhibited by SB203580 but not by @CHEMICAL$, PD98059, nor LY294002.	0
The induction of @GENE$ by EIH was inhibited by SB203580 but not by SP600125, @CHEMICAL$, nor LY294002.	0
The induction of @GENE$ by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor @CHEMICAL$.	0
Most importantly, administration of EIH significantly reduced not only increase in blood @GENE$, ALT, AST, BUN, @CHEMICAL$ levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by ZnPPIX, a HO-1 inhibitor.	0
Most importantly, administration of EIH significantly reduced not only increase in blood HMGB1, @GENE$ AST, BUN, @CHEMICAL$ levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by ZnPPIX, a HO-1 inhibitor.	0
Most importantly, administration of EIH significantly reduced not only increase in blood HMGB1, ALT, @GENE$, BUN, @CHEMICAL$ levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by ZnPPIX, a HO-1 inhibitor.	0
Most importantly, administration of EIH significantly reduced not only increase in blood HMGB1, ALT, AST, BUN, @CHEMICAL$ levels but also decrease macrophage infiltrate in the liver of septic mice, which were reversed by ZnPPIX, a @GENE$ inhibitor.	0
More robust @GENE$ secretion and microparticle generation with PAR4-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at @CHEMICAL$ 19 and threonine 18.	0
More robust FV secretion and microparticle generation with @GENE$-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at @CHEMICAL$ 19 and threonine 18.	0
More robust @GENE$ secretion and microparticle generation with PAR4-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at serine 19 and @CHEMICAL$ 18.	0
More robust FV secretion and microparticle generation with @GENE$-AP was attributable to stronger and more sustained phosphorylation of myosin light chain at serine 19 and @CHEMICAL$ 18.	0
We demonstrate that two @CHEM-GENE$ family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO.	0
We demonstrate that two @CHEMICAL$ mono-oxygenase family members, @GENE$ and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO.	0
We demonstrate that two @CHEMICAL$ mono-oxygenase family members, FMO1 and @GENE$, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO.	0
We demonstrate that two @GENE$ family members, FMO1 and FMO3, oxidize @CHEMICAL$ (TMA), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, @GENE$ and FMO3, oxidize @CHEMICAL$ (TMA), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, FMO1 and @GENE$, oxidize @CHEMICAL$ (TMA), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two @GENE$ family members, FMO1 and FMO3, oxidize trimethylamine (@CHEMICAL$), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, @GENE$ and FMO3, oxidize trimethylamine (@CHEMICAL$), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, FMO1 and @GENE$, oxidize trimethylamine (@CHEMICAL$), derived from gut flora metabolism of choline, to TMAO.	5
We demonstrate that two @GENE$ family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of @CHEMICAL$, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, @GENE$ and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of @CHEMICAL$, to TMAO.	5
We demonstrate that two flavin mono-oxygenase family members, FMO1 and @GENE$, oxidize trimethylamine (TMA), derived from gut flora metabolism of @CHEMICAL$, to TMAO.	5
We demonstrate that two @GENE$ family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to @CHEMICAL$.	5
We demonstrate that two flavin mono-oxygenase family members, @GENE$ and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to @CHEMICAL$.	5
We demonstrate that two flavin mono-oxygenase family members, FMO1 and @GENE$, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to @CHEMICAL$.	5
@GENE$ overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases @CHEMICAL$ levels.	0
FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing @GENE$ decreases @CHEMICAL$ levels.	5
@GENE$ overexpression in mice significantly increases plasma @CHEMICAL$ levels while silencing FMO3 decreases TMAO levels.	5
FMO3 overexpression in mice significantly increases plasma @CHEMICAL$ levels while silencing @GENE$ decreases TMAO levels.	0
In mice, this reduction in @GENE$ expression is due primarily to downregulation by @CHEMICAL$.	2
@GENE$ expression is induced by dietary @CHEMICAL$ by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor.	1
FMO3 expression is induced by dietary @CHEMICAL$ by a mechanism that involves the @GENE$ (FXR), a bile acid-activated nuclear receptor.	0
FMO3 expression is induced by dietary @CHEMICAL$ by a mechanism that involves the farnesoid X receptor (@GENE$), a bile acid-activated nuclear receptor.	0
@GENE$ expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a @CHEMICAL$-activated nuclear receptor.	0
FMO3 expression is induced by dietary bile acids by a mechanism that involves the @GENE$ (FXR), a @CHEMICAL$-activated nuclear receptor.	1
FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (@GENE$), a @CHEMICAL$-activated nuclear receptor.	1
Analysis of natural genetic variation among inbred strains of mice indicates that @GENE$ and @CHEMICAL$ are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.	5
Analysis of natural genetic variation among inbred strains of mice indicates that @GENE$ and TMAO are significantly correlated, and @CHEMICAL$ levels explain 11% of the variation in atherosclerosis.	0
Crystal structures of E2 in the @CHEM-GENE$ (ER) confirm the importance of the A ring in stabilizing E2 in the ER.	0
Crystal structures of E2 in the @CHEMICAL$ receptor (@GENE$) confirm the importance of the A ring in stabilizing E2 in the ER.	0
Crystal structures of E2 in the @CHEMICAL$ receptor (ER) confirm the importance of the A ring in stabilizing E2 in the @GENE$.	0
However, other @CHEMICAL$, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other @CHEMICAL$, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other @CHEMICAL$, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including @CHEMICAL$, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other steroids, including @CHEMICAL$, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other steroids, including @CHEMICAL$, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including Δ(5)-androstenediol, @CHEMICAL$ and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, @CHEMICAL$ and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, @CHEMICAL$ and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and @CHEMICAL$, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and @CHEMICAL$, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and @CHEMICAL$, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a @CHEMICAL$ and a C19 methyl group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a @CHEMICAL$ and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a @CHEMICAL$ and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 @CHEMICAL$ group, also mediate physiological responses through binding to @GENE$ (ERα) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 @CHEMICAL$ group, also mediate physiological responses through binding to estrogen receptor-α (@GENE$) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 @CHEMICAL$ group, also mediate physiological responses through binding to estrogen receptor-α (ERα) and @GENE$.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @CHEM-GENE$ (ERα) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @CHEMICAL$ receptor-α (@GENE$) and ERβ.	0
However, other steroids, including Δ(5)-androstenediol, 5α-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3β-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to @CHEMICAL$ receptor-α (ERα) and @GENE$.	0
Moreover, selective @CHEMICAL$ response modulators (SERMs) with diverse structures also regulate transcription of @GENE$ and ERβ.	0
Moreover, selective @CHEMICAL$ response modulators (SERMs) with diverse structures also regulate transcription of ERα and @GENE$.	0
Further studies of the role of these @CHEMICAL$ and SERMs in regulating responses mediated by @GENE$ and ERβ a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.	0
Further studies of the role of these @CHEMICAL$ and SERMs in regulating responses mediated by ERα and @GENE$ a variety of tissues, during different stages of development, are likely to uncover additional estrogenic activities.	0
Synthesis of @CHEMICAL$ derivatives: discovery of a potent and selective @GENE$ inhibitor for the treatment of Alzheimer's disease.	2
Phosphodiesterase type 5 (@GENE$) mediates the degradation of @CHEMICAL$ in a variety of tissues including brain.	5
@GENE$ (PDE5) mediates the degradation of @CHEMICAL$ in a variety of tissues including brain.	5
Recent studies have demonstrated the importance of the @CHEMICAL$/cGMP/cAMP-responsive element-binding protein (@GENE$) pathway to the process of learning and memory.	0
Recent studies have demonstrated the importance of the @CHEMICAL$/cGMP/@GENE$ (CREB) pathway to the process of learning and memory.	0
Recent studies have demonstrated the importance of the nitric oxide/@CHEMICAL$/cAMP-responsive element-binding protein (@GENE$) pathway to the process of learning and memory.	0
Recent studies have demonstrated the importance of the nitric oxide/@CHEMICAL$/@GENE$ (CREB) pathway to the process of learning and memory.	0
Recent studies have demonstrated the importance of the nitric oxide/cGMP/@CHEMICAL$-responsive element-binding protein (@GENE$) pathway to the process of learning and memory.	0
Recent studies have demonstrated the importance of the nitric oxide/cGMP/@CHEM-GENE$ (CREB) pathway to the process of learning and memory.	0
Fragment-based design, synthesis, and biological evaluation of @CHEMICAL$ derivatives as novel @GENE$ inhibitors.	2
We have previously reported a nanomolar inhibitor of antiapoptotic @GENE$ protein, @CHEMICAL$ (S1).	2
A novel potent compound, @CHEMICAL$ (12c), which binds @GENE$ with an IC(50) value of 54 nM was obtained.	2
PURPOSE: @GENE$ deficiency is a recently described inborn error of @CHEMICAL$ pathway.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of @GENE$ (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (@GENE$) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and @GENE$ (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (@GENE$) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between @CHEM-GENE$ (mAChRs) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (@GENE$) and β(2) adrenoceptor (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and @GENE$ (β(2)AR) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
Our findings by combined analyses of gene polymorphisms of two separate genes present evidences that such is the case with human body in a clinical setting: 1) an integrated effect of epidermal growth factor receptor (EGFR) and protease activated receptor-1 (PAR-1) on susceptibility to airway hyperresponsiveness (AHR), and 2) a crosstalk effect between muscarinic @CHEMICAL$ receptor (mAChRs) and β(2) adrenoceptor (@GENE$) on bronchodilatory response to anticholinergic agents in patients with COPD.	0
@CHEMICAL$, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the @GENE$ dimer that governs erythropoiesis.	1
Peginesatide, a @CHEMICAL$ (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the @GENE$ dimer that governs erythropoiesis.	1
Peginesatide, a polyethylene glycol (@CHEMICAL$)ylated peptide-based erythropoiesis-stimulating agent, stimulates the @GENE$ dimer that governs erythropoiesis.	1
Recent evidence suggests that processes other than @CHEMICAL$ binding, such as phosphorylation of @GENE$ (RLC) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys.	0
Recent evidence suggests that processes other than @CHEMICAL$ binding, such as phosphorylation of myosin regulatory light chain (@GENE$) also controls contraction of vertebrate striated muscle (Cooke, R. (2011) Biophys.	0
Electron paramagnetic resonance (EPR) studies using @CHEMICAL$ analog spin label probes showed that dephosphorylated myosin heads are highly ordered in the relaxed fibers and have very low @GENE$ activity.	0
Electron paramagnetic resonance (EPR) studies using @CHEMICAL$ analog spin label probes showed that @GENE$ heads are highly ordered in the relaxed fibers and have very low ATPase activity.	0
We find that: (i) relaxed cross-bridges, but not active ones, are statistically better ordered in muscle where the @GENE$ is dephosporylated compared with phosphorylated RLC; (ii) relaxed phosphorylated and dephosphorylated cross-bridges rotate equally slowly; and (iii) active phosphorylated cross-bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full @CHEMICAL$ saturation.	0
We find that: (i) relaxed cross-bridges, but not active ones, are statistically better ordered in muscle where the RLC is dephosporylated compared with @GENE$; (ii) relaxed phosphorylated and dephosphorylated cross-bridges rotate equally slowly; and (iii) active phosphorylated cross-bridges rotate considerably faster than dephosphorylated ones during isometric contraction but the duty cycle remained the same, suggesting that both phosphorylated and dephosphorylated muscles develop the same isometric tension at full @CHEMICAL$ saturation.	0
There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which @CHEMICAL$-@GENE$ signaling promotes pathological fibrosis remain to be fully elucidated.	0
There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, @GENE$, in fibrotic diseases, but the mechanisms by which @CHEMICAL$-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated.	0
There has been much recent interest in @CHEMICAL$ (LPA) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which LPA-@GENE$ signaling promotes pathological fibrosis remain to be fully elucidated.	0
There has been much recent interest in @CHEMICAL$ (LPA) signaling through one of its receptors, @GENE$, in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated.	0
There has been much recent interest in lysophosphatidic acid (@CHEMICAL$) signaling through one of its receptors, LPA1, in fibrotic diseases, but the mechanisms by which LPA-@GENE$ signaling promotes pathological fibrosis remain to be fully elucidated.	0
There has been much recent interest in lysophosphatidic acid (@CHEMICAL$) signaling through one of its receptors, @GENE$, in fibrotic diseases, but the mechanisms by which LPA-LPA1 signaling promotes pathological fibrosis remain to be fully elucidated.	0
Using a mouse peritoneal fibrosis model, we demonstrate central roles for @CHEMICAL$ and @GENE$ in fibroblast proliferation.	0
@GENE$-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of @CHEMICAL$ by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.	0
LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of @CHEMICAL$ by driving @GENE$-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.	0
LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of @CHEMICAL$ by driving MRTF-dependent @GENE$ expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.	1
LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of @CHEMICAL$ by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. @GENE$-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.	0
LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of @CHEMICAL$ by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through @GENE$-dependent fibroblast proliferation.	0
Cooperative effects for @GENE$ differ between @CHEMICAL$ and its metabolites.	0
We hypothesized that @CHEMICAL$ metabolites have lower affinity than styrene toward @GENE$ and limited ability to induce cooperative effects during metabolism.	0
We hypothesized that styrene metabolites have lower affinity than @CHEMICAL$ toward @GENE$ and limited ability to induce cooperative effects during metabolism.	0
To test the hypothesis, we determined the potency and mechanism of inhibition for @CHEMICAL$ and its metabolites toward oxidation of 4-nitrophenol using @GENE$ Supersomes® and human liver microsomes.	0
To test the hypothesis, we determined the potency and mechanism of inhibition for styrene and its metabolites toward oxidation of @CHEMICAL$ using @GENE$ Supersomes® and human liver microsomes.	0
Styrene oxide and @CHEMICAL$ possessed similar affinity for @GENE$.	0
@CHEMICAL$ and 4-vinylphenol possessed similar affinity for @GENE$.	0
Its pathogenesis is complex, and involves a state of 'lipotoxicity' in which @GENE$ resistance, with increased @CHEMICAL$ release from adipose tissue to the liver, play a key role in the onset of a 'lipotoxic liver disease' and its progression to NASH.	0
@GENE$ in @CHEMICAL$ metabolism.	0
@CHEMICAL$ are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, @GENE$, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	1
@CHEMICAL$ are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and @GENE$, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	1
@CHEMICAL$ are signaling molecules that activate @GENE$, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	1
@CHEMICAL$ are signaling molecules that activate nuclear receptors, such as @GENE$, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	1
@CHEMICAL$ are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @GENE$, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	1
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, @CHEM-GENE$, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive @CHEMICAL$ receptor, and @GENE$, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate @GENE$, such as farnesoid X receptor, pregnane X receptor, constitutive @CHEMICAL$ receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as @GENE$, pregnane X receptor, constitutive @CHEMICAL$ receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @GENE$, constitutive @CHEMICAL$ receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, @GENE$, and @CHEMICAL$ receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and @CHEM-GENE$, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate @GENE$, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and @CHEMICAL$ receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as @GENE$, pregnane X receptor, constitutive androstane receptor, and @CHEMICAL$ receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @GENE$, constitutive androstane receptor, and @CHEMICAL$ receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, @GENE$, and vitamin D receptor, and play a critical role in the regulation of lipid, @CHEMICAL$, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and @GENE$, and play a critical role in the regulation of lipid, @CHEMICAL$, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate @GENE$, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, @CHEMICAL$, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as @GENE$, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, @CHEMICAL$, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @GENE$, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, @CHEMICAL$, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @CHEMICAL$ X receptor, @GENE$, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @CHEMICAL$ X receptor, constitutive androstane receptor, and @GENE$, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate @GENE$, such as farnesoid X receptor, @CHEMICAL$ X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as @GENE$, @CHEMICAL$ X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, @CHEM-GENE$, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.	0
These @GENE$ regulate phase I oxidation, phase II conjugation, and phase III transport in @CHEMICAL$ and drug metabolism in the digestive system.	0
Green tea @CHEMICAL$ leads to global improvement among Alzheimer's disease-related phenotypes in NSE/hAPP-@GENE$ Tg mice.	0
Green tea @CHEMICAL$ leads to global improvement among Alzheimer's disease-related phenotypes in @GENE$/hAPP-C105 Tg mice.	0
Green tea @CHEMICAL$ leads to global improvement among Alzheimer's disease-related phenotypes in NSE/@GENE$-C105 Tg mice.	0
Moreover, GTC-treated groups showed lower levels of total @CHEMICAL$ and @GENE$ cholesterol, whereas the level of high-density lipoprotein cholesterol increased.	0
Moreover, GTC-treated groups showed lower levels of total @CHEMICAL$ and low-density lipoprotein cholesterol, whereas the level of @GENE$ cholesterol increased.	0
Moreover, GTC-treated groups showed lower levels of total cholesterol and @GENE$ @CHEMICAL$, whereas the level of high-density lipoprotein cholesterol increased.	0
Moreover, GTC-treated groups showed lower levels of total cholesterol and low-density lipoprotein @CHEMICAL$, whereas the level of @GENE$ cholesterol increased.	0
Moreover, GTC-treated groups showed lower levels of total cholesterol and @GENE$ cholesterol, whereas the level of high-density lipoprotein @CHEMICAL$ increased.	0
Moreover, GTC-treated groups showed lower levels of total cholesterol and low-density lipoprotein cholesterol, whereas the level of @GENE$ @CHEMICAL$ increased.	0
Mechanistically, @GENE$ is recruited to DSBs via the @CHEMICAL$-terminal phospho-SQ/TQ domain of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the @CHEM-GENE$ of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the @CHEMICAL$-terminal phospho-SQ/TQ domain of @GENE$, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the @CHEMICAL$-terminal phospho-SQ/TQ domain of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of @GENE$.	0
Mechanistically, @GENE$ is recruited to DSBs via the N-terminal @CHEMICAL$-SQ/TQ domain of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the @CHEM-GENE$ of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the N-terminal @CHEMICAL$-SQ/TQ domain of @GENE$, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of RIF1.	0
Mechanistically, RIF1 is recruited to DSBs via the N-terminal @CHEMICAL$-SQ/TQ domain of 53BP1, and DSBs generated by ionizing radiation or during CSR are hyperresected in the absence of @GENE$.	0
Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and @CHEMICAL$113-Arg122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-@CHEMICAL$122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for @GENE$ binding, @CHEMICAL$113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for @GENE$ binding, Leu113-@CHEMICAL$122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., @CHEMICAL$70-Asp78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-@CHEMICAL$78, Tyr82-Glu96, and Leu113-Arg122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-Asp78, @CHEMICAL$82-Glu96, and Leu113-Arg122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
Out of the three putative sites (i.e., Tyr70-Asp78, Tyr82-@CHEMICAL$96, and Leu113-Arg122) available on OPG for @GENE$ binding, Leu113-Arg122 was used as a template for peptide synthesis.	0
The peptide @CHEMICAL$ (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited @GENE$-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide @CHEMICAL$ (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-@GENE$ binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide @CHEMICAL$ (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and @GENE$ induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
The peptide @CHEMICAL$ (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced @GENE$ activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of @CHEMICAL$ with a serine residue in the template sequence, significantly (p<0.05) inhibited @GENE$-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of @CHEMICAL$ with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-@GENE$ binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of @CHEMICAL$ with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and @GENE$ induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of @CHEMICAL$ with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced @GENE$ activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a @CHEMICAL$ residue in the template sequence, significantly (p<0.05) inhibited @GENE$-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a @CHEMICAL$ residue in the template sequence, significantly (p<0.05) inhibited RANK-@GENE$ binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	0
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a @CHEMICAL$ residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and @GENE$ induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a @CHEMICAL$ residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced @GENE$ activity and formation of multinucleated osteoclasts without any cytotoxicity.	2
Results confirmed that @CHEMICAL$ peptide inhibited pro-inflammatory @GENE$ in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-κB.	2
Results confirmed that @CHEMICAL$ peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on @GENE$ induced nuclear translocation of NF-κB.	2
Results confirmed that @CHEMICAL$ peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of @GENE$.	2
@GENE$ polymerization was measured by @CHEMICAL$-TRITC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (Rho GTPases).	0
Actin polymerization was measured by @CHEMICAL$-TRITC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (@GENE$ induction), and pull-down assays (Rho GTPases).	0
Actin polymerization was measured by @CHEMICAL$-TRITC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (@GENE$ GTPases).	0
Actin polymerization was measured by @CHEMICAL$-TRITC staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (Rho @GENE$).	0
@GENE$ polymerization was measured by phalloidin-@CHEMICAL$ staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (Rho GTPases).	0
Actin polymerization was measured by phalloidin-@CHEMICAL$ staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (@GENE$ induction), and pull-down assays (Rho GTPases).	0
Actin polymerization was measured by phalloidin-@CHEMICAL$ staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (@GENE$ GTPases).	0
Actin polymerization was measured by phalloidin-@CHEMICAL$ staining, and cell activation was determined by reverse transcription quantitative PCR analysis, L929 cytotoxicity assay (cytokine induction), and pull-down assays (Rho @GENE$).	0
RESULTS: In contrast to immune stimulatory sequence ISS 1018, BCG DNA spontaneously formed nanoparticulate structures and induced @GENE$ polymerization as did synthetic @CHEMICAL$ nanoparticles.	0
Co-incubation with @CHEMICAL$ nanoparticles amplified the responsiveness of macrophages toward the @GENE$ ligand ISS 1018.	0
The activation of @GENE$ was induced by @CHEMICAL$ nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation.	1
In this small library of novel bioactive macrocyclic @CHEMICAL$ derivatives, designed to evaluate structure-activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and octanol/water partition coefficient were identified that can contribute to the development of new selective @GENE$ reversal agents.	0
In this small library of novel bioactive macrocyclic lathyrane diterpene derivatives, designed to evaluate structure-activity relationships essential in overcoming multidrug resistance (MDR), some correlations between MDR reversal and molecular weight, accessible solvent areas, and @CHEMICAL$/water partition coefficient were identified that can contribute to the development of new selective @GENE$ reversal agents.	0
Osteoblasts survive the @CHEMICAL$ treatment by activation of @GENE$-mediated pathway.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, @GENE$, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, @GENE$, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, Chk2, @GENE$, and p21(waf1/cip1) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, Chk2, p53, and @GENE$(waf1/cip1) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, Chk2, p53, and p21(@GENE$/cip1) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/@GENE$) were reduced by an ATM inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-H2AX, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an @GENE$ inhibitor.	1
Additionally, these effects of @CHEMICAL$ on γ-@GENE$, Chk1, Chk2, p53, and p21(waf1/cip1) were reduced by an ATM inhibitor.	1
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired @CHEMICAL$ tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired @CHEMICAL$ tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (@CHEMICAL$) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (@CHEMICAL$) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal @CHEMICAL$ tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal @CHEMICAL$ tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between @CHEMICAL$ and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between @CHEMICAL$ and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma @CHEMICAL$ concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma 25-hydroxyvitamin D (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma @CHEMICAL$ concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma @CHEMICAL$ (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo insulin sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
OBJECTIVETo 1) determine if plasma @CHEMICAL$ (25[OH]D) concentrations differ among obese youth with normal glucose tolerance (NGT) versus prediabetes versus type 2 diabetes, and 2) assess the relationships between 25(OH)D and in vivo insulin sensitivity and β-cell function in this cohort.RESEARCH DESIGN AND METHODSPlasma 25(OH)D concentrations were examined in banked specimens in 9- to 20-year-old obese youth (n = 175; male 42.3%, black 46.3%) (NGT, n = 105; impaired glucose tolerance [IGT], n = 43; type 2 diabetes, n = 27) who had in vivo @GENE$ sensitivity and secretion measured by hyperinsulinemic-euglycemic and hyperglycemic clamp techniques and had an assessment of total body composition and abdominal adiposity.RESULTSThe mean age and BMI of the subjects were 14.3 ± 2.1 years and 35.7 ± 5.6 kg/m(2), respectively.	0
Furthermore, there was no association between @CHEMICAL$ and in vivo @GENE$ sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between @CHEMICAL$ and in vivo insulin sensitivity or β-cell function relative to @GENE$ sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between @CHEMICAL$ and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between @CHEMICAL$ and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to @GENE$ sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo @GENE$ sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma @CHEMICAL$ concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to @GENE$ sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma @CHEMICAL$ concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma @CHEMICAL$ concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma @CHEMICAL$ concentrations across the glucose tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to @GENE$ sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo @GENE$ sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the @CHEMICAL$ tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to @GENE$ sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the @CHEMICAL$ tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the @CHEMICAL$ tolerance groups, and 2) no relationship between 25(OH)D and in vivo @GENE$ sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the @CHEMICAL$ tolerance groups, and 2) no relationship between 25(OH)D and in vivo insulin sensitivity and β-cell function relative to @GENE$ sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo @GENE$ sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between @CHEMICAL$ and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to @GENE$ sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between @CHEMICAL$ and in vivo insulin sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between @CHEMICAL$ and in vivo @GENE$ sensitivity and β-cell function relative to insulin sensitivity in any of the groups.	0
Furthermore, there was no association between 25(OH)D and in vivo insulin sensitivity or β-cell function relative to insulin sensitivity (disposition index) in all groups combined or in each group separately.CONCLUSIONSOur data in obese youth show 1) no differences in plasma 25(OH)D concentrations across the glucose tolerance groups, and 2) no relationship between @CHEMICAL$ and in vivo insulin sensitivity and β-cell function relative to @GENE$ sensitivity in any of the groups.	0
In the current study dietary relevant mixtures of @CHEMICAL$ and their metabolites, lignans and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their @GENE$ activating abilities.	0
In the current study dietary relevant mixtures of isoflavones and their metabolites, @CHEMICAL$ and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their @GENE$ activating abilities.	0
In the current study dietary relevant mixtures of isoflavones and their metabolites, lignans and their metabolites, @CHEMICAL$, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their @GENE$ activating abilities.	0
Furthermore, a mixture of @CHEMICAL$ parent compounds, and a mixture of isoflavonoid metabolites were found to have @GENE$ activating abilities.	1
Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of @CHEMICAL$ metabolites were found to have @GENE$ activating abilities.	1
Both @CHEMICAL$, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of @GENE$-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	2
Both @CHEMICAL$, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a @GENE$-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	0
Both @CHEMICAL$, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker @GENE$ was unaltered on activated T cells.	0
Both fatty acids, but @CHEMICAL$ to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of @GENE$-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	2
Both fatty acids, but @CHEMICAL$ to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a @GENE$-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	0
Both fatty acids, but @CHEMICAL$ to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker @GENE$ was unaltered on activated T cells.	0
Both fatty acids, but DHA to a lesser extent compared with @CHEMICAL$, selectively and dose-dependently reduced the percentage of @GENE$-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	2
Both fatty acids, but DHA to a lesser extent compared with @CHEMICAL$, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a @GENE$-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells.	0
Both fatty acids, but DHA to a lesser extent compared with @CHEMICAL$, selectively and dose-dependently reduced the percentage of cytokine-expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)γ-dependent fashion, whereas the expression of the cell surface marker @GENE$ was unaltered on activated T cells.	0
In monocytes, both @CHEMICAL$ and DHA increased @GENE$ without affecting tumor necrosis factor (TNF)-α and IL-6.	1
In monocytes, both @CHEMICAL$ and DHA increased interleukin (IL)-10 without affecting @GENE$ and IL-6.	0
In monocytes, both @CHEMICAL$ and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and @GENE$.	0
In monocytes, both EPA and @CHEMICAL$ increased @GENE$ without affecting tumor necrosis factor (TNF)-α and IL-6.	1
In monocytes, both EPA and @CHEMICAL$ increased interleukin (IL)-10 without affecting @GENE$ and IL-6.	0
In monocytes, both EPA and @CHEMICAL$ increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-α and @GENE$.	0
Encapsulation of @GENE$ and Nod2 receptor ligands into @CHEMICAL$ nanoparticles potentiates their immune properties.	0
Encapsulation of Nod1 and @GENE$ receptor ligands into @CHEMICAL$ nanoparticles potentiates their immune properties.	0
As activation of intracytoplasmic @GENE$ is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and Nod2 receptor ligands into @CHEMICAL$ (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of @GENE$ and Nod2 receptor ligands into @CHEMICAL$ (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and @GENE$ receptor ligands into @CHEMICAL$ (PLA) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
As activation of intracytoplasmic @GENE$ is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and Nod2 receptor ligands into Poly(Lactic Acid) (@CHEMICAL$) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of @GENE$ and Nod2 receptor ligands into Poly(Lactic Acid) (@CHEMICAL$) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
As activation of intracytoplasmic NLRs is able to induce proinflammatory molecules, the added value of encapsulation of Nod1 and @GENE$ receptor ligands into Poly(Lactic Acid) (@CHEMICAL$) biodegradable nanocarriers to modulate their immune properties on human dendritic cells (DCs) maturation has been evaluated.	0
@GENE$ ligands encapsulated into @CHEMICAL$ NPs were efficiently taken up by DCs and subsequently induced a strong up-regulation of maturation markers and the enhancement of proinflammatory cytokine secretion by DCs.	0
Nod ligands encapsulated into @CHEMICAL$ NPs were efficiently taken up by DCs and subsequently induced a strong up-regulation of maturation markers and the enhancement of proinflammatory @GENE$ secretion by DCs.	0
Furthermore, co-injection of encapsulated @GENE$-ligands with @CHEMICAL$ particles carrying Gag p24 HIV-1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum.	0
Furthermore, co-injection of encapsulated Nod-ligands with @CHEMICAL$ particles carrying @GENE$ HIV-1 antigen allowed a 100 fold increase in antibody responses in comparison to Alum.	0
These results suggest that encapsulation of @GENE$ ligands into @CHEMICAL$-NPs could be an effective way to improve vaccine efficiency.	0
In the in vitro model we observed high permeability of @CHEMICAL$ and isoimperatorin with the @GENE$-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.	5
In the in vitro model we observed high permeability of imperatorin and @CHEMICAL$ with the @GENE$-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.	5
In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the @GENE$-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of @CHEMICAL$ with 0.82.	5
Involvement of @GENE$ and the actin cytoskeleton in the antitumorigenic action of @CHEMICAL$.	0
Involvement of Src and the @GENE$ cytoskeleton in the antitumorigenic action of @CHEMICAL$.	0
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive @CHEM-GENE$ (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	0
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive @CHEMICAL$ (SAH) hydrolase (@GENE$), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	0
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive @CHEM-GENE$ (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	0
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (@CHEMICAL$) hydrolase (@GENE$), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	0
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive @GENE$ (SAHH), enhanced the level of @CHEMICAL$ and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	5
Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (@GENE$), enhanced the level of @CHEMICAL$ and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	5
Treatment with @CHEMICAL$ (AdOx), an inhibitor of transmethylation-suppressive @GENE$ (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	2
Treatment with @CHEMICAL$ (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (@GENE$), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	2
Treatment with adenosine dialdehyde (@CHEMICAL$), an inhibitor of transmethylation-suppressive @GENE$ (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	2
Treatment with adenosine dialdehyde (@CHEMICAL$), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (@GENE$), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.	2
Through immunoblotting analysis, it was found that @CHEMICAL$ was capable of indirectly diminishing the phosphorylation of oncogenic @GENE$ and its kinase activity.	2
Through immunoblotting analysis, it was found that @CHEMICAL$ was capable of indirectly diminishing the phosphorylation of oncogenic Src and its @GENE$ activity.	2
Interestingly, @CHEMICAL$ disrupted @GENE$ cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses.	2
Interestingly, @CHEMICAL$ disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of @GENE$ and p85/PI3K, which is linked to various tumorigenic responses.	2
Interestingly, @CHEMICAL$ disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and @GENE$/PI3K, which is linked to various tumorigenic responses.	2
Interestingly, @CHEMICAL$ disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/@GENE$, which is linked to various tumorigenic responses.	2
In agreement with these data, the exogenous treatment of @CHEMICAL$ or inhibition of @GENE$ by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of @CHEMICAL$ or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on @GENE$, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	2
In agreement with these data, the exogenous treatment of @CHEMICAL$ or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of @GENE$ cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of @CHEMICAL$ or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between @GENE$ and Src.	0
In agreement with these data, the exogenous treatment of @CHEMICAL$ or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and @GENE$.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of @GENE$ by specific siRNA or another type of inhibitor, @CHEMICAL$ (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	2
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, @CHEMICAL$ (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on @GENE$, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, @CHEMICAL$ (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of @GENE$ cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, @CHEMICAL$ (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between @GENE$ and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, @CHEMICAL$ (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and @GENE$.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of @GENE$ by specific siRNA or another type of inhibitor, 3-deazaadenosine (@CHEMICAL$), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	2
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (@CHEMICAL$), similarly resulted in antitumorigenic responses, suppressive activity on @GENE$, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (@CHEMICAL$), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of @GENE$ cytoskeleton, and a change of the colocalization pattern between actin and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (@CHEMICAL$), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between @GENE$ and Src.	0
In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (@CHEMICAL$), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and @GENE$.	0
Taken together, these results suggest that @CHEMICAL$/@GENE$-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and Src kinase activity.	0
Taken together, these results suggest that @CHEMICAL$/SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the @GENE$ cytoskeleton and Src kinase activity.	0
Taken together, these results suggest that @CHEMICAL$/SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and @GENE$ kinase activity.	0
Taken together, these results suggest that @CHEMICAL$/SAHH-mediated transmethylation could be linked to the tumorigenic processes through cross-regulation between the actin cytoskeleton and Src @GENE$ activity.	0
Synthesis of derivatives of @CHEMICAL$ and their inhibitory activities against matrix metalloproteinase-1 (@GENE$).	2
Synthesis of derivatives of @CHEMICAL$ and their inhibitory activities against @GENE$ (MMP-1).	2
A series of @GENE$ inhibitors have been identified based upon a @CHEMICAL$ scaffold using structure-based drug design methods.	2
All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as @GENE$ (COX-2)-derived @CHEMICAL$ (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.	5
All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (@GENE$)-derived @CHEMICAL$ (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.	5
All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as @GENE$ (COX-2)-derived prostaglandin E2 (@CHEMICAL$) inhibitory activity of murine macrophage RAW 264.7 cell line.	5
All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (@GENE$)-derived prostaglandin E2 (@CHEMICAL$) inhibitory activity of murine macrophage RAW 264.7 cell line.	5
We observed that @GENE$ drives the evasion of reactive-@CHEMICAL$ stress-induced melanocyte senescence, caused by activated receptor tyrosine kinase signaling.	0
We observed that MYC drives the evasion of reactive-@CHEMICAL$ stress-induced melanocyte senescence, caused by activated @GENE$ signaling.	0
We observed that @GENE$ drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated receptor @CHEMICAL$ kinase signaling.	0
We observed that MYC drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated @CHEM-GENE$ signaling.	0
Both, @GENE$ overexpression and Miz1 knockdown led to a strong reduction of endogenous reactive-@CHEMICAL$ species (ROS), DNA damage and senescence.	0
Both, MYC overexpression and @GENE$ knockdown led to a strong reduction of endogenous reactive-@CHEMICAL$ species (ROS), DNA damage and senescence.	0
Importantly, pharmacological inhibition of @GENE$ in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects such as proliferation, @CHEMICAL$ resistance and soft agar growth.	0
Importantly, pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and @GENE$ knockdown reduced tumorigenic effects such as proliferation, @CHEMICAL$ resistance and soft agar growth.	0
These agents include newer @GENE$-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free @CHEMICAL$ receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and @GENE$ agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free @CHEMICAL$ receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @GENE$ inhibitors, free @CHEMICAL$ receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, @CHEM-GENE$ agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free @CHEMICAL$ receptor agonists, @GENE$ inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free @CHEMICAL$ receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, @GENE$ activators, and several others that may enter clinical use over the next decade.	0
These agents include newer @GENE$-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, @CHEMICAL$ dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and @GENE$ agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, @CHEMICAL$ dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @GENE$ inhibitors, free fatty acid receptor agonists, @CHEMICAL$ dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, @GENE$ agonists, @CHEMICAL$ dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, @CHEM-GENE$ inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, @CHEMICAL$ dehydrogenase type 1 inhibitors, @GENE$ activators, and several others that may enter clinical use over the next decade.	0
These agents include newer @GENE$-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEMICAL$-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and @GENE$ agonists, as well as new therapeutic classes such as @CHEMICAL$-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEM-GENE$ inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEMICAL$-coupled glucose cotransporter 2 inhibitors, @GENE$ agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEMICAL$-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, @GENE$ inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEMICAL$-coupled glucose cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, @GENE$ activators, and several others that may enter clinical use over the next decade.	0
These agents include newer @GENE$-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled @CHEMICAL$ cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and @GENE$ agonists, as well as new therapeutic classes such as sodium-coupled @CHEMICAL$ cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as @CHEM-GENE$ inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled @CHEMICAL$ cotransporter 2 inhibitors, @GENE$ agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled @CHEMICAL$ cotransporter 2 inhibitors, free fatty acid receptor agonists, @GENE$ inhibitors, glucokinase activators, and several others that may enter clinical use over the next decade.	0
These agents include newer incretin-based therapies and PPAR agonists, as well as new therapeutic classes such as sodium-coupled @CHEMICAL$ cotransporter 2 inhibitors, free fatty acid receptor agonists, 11-β-hydroxysteroid dehydrogenase type 1 inhibitors, @GENE$ activators, and several others that may enter clinical use over the next decade.	0
In @CHEM-GENE$ deficiency (mutations in AUH), it derives from leucine degradation.	0
In @CHEMICAL$ hydratase deficiency (mutations in @GENE$), it derives from leucine degradation.	0
In @GENE$ deficiency (mutations in AUH), it derives from @CHEMICAL$ degradation.	0
In 3-methylglutaconyl-CoA hydratase deficiency (mutations in @GENE$), it derives from @CHEMICAL$ degradation.	0
It had higher levels of @CHEMICAL$ (p-HPEA-EDA), a nutraceutical compound exerting actions against @GENE$ and COX2 (cycloxygenases).	0
It had higher levels of @CHEMICAL$ (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and @GENE$ (cycloxygenases).	0
It had higher levels of @CHEMICAL$ (p-HPEA-EDA), a nutraceutical compound exerting actions against COX1 and COX2 (@GENE$).	0
It had higher levels of oleocanthal (@CHEMICAL$), a nutraceutical compound exerting actions against @GENE$ and COX2 (cycloxygenases).	0
It had higher levels of oleocanthal (@CHEMICAL$), a nutraceutical compound exerting actions against COX1 and @GENE$ (cycloxygenases).	0
It had higher levels of oleocanthal (@CHEMICAL$), a nutraceutical compound exerting actions against COX1 and COX2 (@GENE$).	0
Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the @GENE$ (LOX)-pathway (one having as precursors the @CHEMICAL$ containing a cis-cis-1,4-pentadiene system).	5
Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (@GENE$)-pathway (one having as precursors the @CHEMICAL$ containing a cis-cis-1,4-pentadiene system).	5
Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the @GENE$ (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a @CHEMICAL$ system).	5
Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (@GENE$)-pathway (one having as precursors the polyunsaturated fatty acids containing a @CHEMICAL$ system).	5
Oligomeric Pro-Hyp-Gly- (POG-) peptides, wherein the @GENE$ is supported by @CHEMICAL$-terminal capping, exhibit silica precipitation properties (O, Hyp = (2S,4R)hydroxyproline).	0
Oligomeric @CHEMICAL$- (POG-) peptides, wherein the @GENE$ is supported by C-terminal capping, exhibit silica precipitation properties (O, Hyp = (2S,4R)hydroxyproline).	0
Oligomeric Pro-Hyp-Gly- (POG-) peptides, wherein the @GENE$ is supported by C-terminal capping, exhibit @CHEMICAL$ precipitation properties (O, Hyp = (2S,4R)hydroxyproline).	0
Oligomeric Pro-Hyp-Gly- (POG-) peptides, wherein the @GENE$ is supported by C-terminal capping, exhibit silica precipitation properties (O, @CHEMICAL$ = (2S,4R)hydroxyproline).	0
Oligomeric Pro-Hyp-Gly- (POG-) peptides, wherein the @GENE$ is supported by C-terminal capping, exhibit silica precipitation properties (O, Hyp = @CHEMICAL$).	0
As quantified by a molybdate assay, the length of the covalently tethered @GENE$ (number of POG units) determines the amount of amorphous @CHEMICAL$ obtained from silicic acid solution.	0
As quantified by a molybdate assay, the length of the covalently tethered @GENE$ (number of POG units) determines the amount of amorphous silica obtained from @CHEMICAL$ solution.	0
Although lacking charged side chains, the synthetic @GENE$ precipitate large quantities of @CHEMICAL$ resulting in micrometer-sized spheres of varying surface morphologies as analyzed by scanning electron microscopy.	0
Hence, @CHEMICAL$-enclosed @GENE$ have promising perspectives as composite materials.	0
The contrasting activity of @CHEMICAL$ versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, @GENE$ dependence, and apoptosis pathway.	0
The contrasting activity of iodido versus @CHEMICAL$ and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, @GENE$ dependence, and apoptosis pathway.	0
The contrasting activity of iodido versus chlorido ruthenium and @CHEMICAL$ anticancer complexes: control of cell selectivity, cross-resistance, @GENE$ dependence, and apoptosis pathway.	0
The @CHEMICAL$ complexes retain potency in @GENE$ mutant colon cells.	0
In general, antiproliferative activity is greatly enhanced by low levels of the @CHEM-GENE$ inhibitor l-buthionine sulfoxime.	0
In general, antiproliferative activity is greatly enhanced by low levels of the @GENE$ inhibitor @CHEMICAL$.	2
@CHEMICAL$-dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and @GENE$ (Slc30a4) transporter.	0
@CHEMICAL$-dependent lysosomal enlargement in TRPML1-deficient cells involves MTF-1 transcription factor and ZnT4 (@GENE$) transporter.	0
@CHEMICAL$-dependent lysosomal enlargement in @GENE$-deficient cells involves MTF-1 transcription factor and ZnT4 (Slc30a4) transporter.	0
@CHEMICAL$-dependent lysosomal enlargement in TRPML1-deficient cells involves @GENE$ transcription factor and ZnT4 (Slc30a4) transporter.	0
Cellular @CHEMICAL$ is controlled by @GENE$ and by zinc transporters.	5
Cellular @CHEMICAL$ is controlled by zinc-chelating proteins and by @GENE$.	5
Cellular zinc is controlled by @CHEM-GENE$ and by zinc transporters.	0
Cellular zinc is controlled by @CHEMICAL$-chelating proteins and by @GENE$.	0
Cellular zinc is controlled by @GENE$ and by @CHEMICAL$ transporters.	0
Cellular zinc is controlled by zinc-chelating proteins and by @CHEM-GENE$.	0
The recent identification of @CHEMICAL$ permeability of the lysosomal @GENE$ TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	0
The recent identification of @CHEMICAL$ permeability of the lysosomal ion channel @GENE$ (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	5
The recent identification of @CHEMICAL$ permeability of the lysosomal ion channel TRPML1 (@GENE$), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	5
The recent identification of @CHEMICAL$ permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in @GENE$, suggested a role for TRPML1 in zinc transport.	0
The recent identification of @CHEMICAL$ permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for @GENE$ in zinc transport.	0
The recent identification of zinc permeability of the lysosomal @GENE$ TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal @CHEMICAL$ levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	0
The recent identification of zinc permeability of the lysosomal ion channel @GENE$ (transient receptor potential mucolipin 1), and the evidence of abnormal @CHEMICAL$ levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (@GENE$), and the evidence of abnormal @CHEMICAL$ levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal @CHEMICAL$ levels in cells deficient in @GENE$, suggested a role for TRPML1 in zinc transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal @CHEMICAL$ levels in cells deficient in TRPML1, suggested a role for @GENE$ in zinc transport.	0
The recent identification of zinc permeability of the lysosomal @GENE$ TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in @CHEMICAL$ transport.	0
The recent identification of zinc permeability of the lysosomal ion channel @GENE$ (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in @CHEMICAL$ transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (@GENE$), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in @CHEMICAL$ transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in @GENE$, suggested a role for TRPML1 in @CHEMICAL$ transport.	0
The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for @GENE$ in @CHEMICAL$ transport.	5
In agreement with the previously published data, an acute siRNA (small interfering RNA)-driven @GENE$ KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and @CHEMICAL$ staining, when cells are exposed to high concentrations of zinc.	0
In agreement with the previously published data, an acute siRNA (small interfering RNA)-driven @GENE$ KD (knockdown) leads to the build-up of large cytoplasmic vesicles positive for LysoTracker™ and zinc staining, when cells are exposed to high concentrations of @CHEMICAL$.	0
We now show that lysosomal enlargement and @CHEMICAL$ build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (@GENE$) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and @CHEMICAL$ build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @GENE$.	0
We now show that lysosomal enlargement and @CHEMICAL$ build-up in @GENE$-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and @CHEMICAL$ build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @GENE$ MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and @CHEMICAL$ build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor @GENE$ (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to @CHEMICAL$ are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (@GENE$) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to @CHEMICAL$ are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @GENE$.	0
We now show that lysosomal enlargement and zinc build-up in @GENE$-KD cells exposed to @CHEMICAL$ are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to @CHEMICAL$ are ameliorated by KD of the @GENE$ MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to @CHEMICAL$ are ameliorated by KD of the zinc-sensitive transcription factor @GENE$ (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @CHEMICAL$-sensitive transcription factor MTF-1 (@GENE$) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @CHEMICAL$-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @GENE$.	0
We now show that lysosomal enlargement and zinc build-up in @GENE$-KD cells exposed to zinc are ameliorated by KD of the @CHEMICAL$-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @CHEM-GENE$ MTF-1 (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @CHEMICAL$-sensitive transcription factor @GENE$ (metal-regulatory-element-binding transcription factor-1) or the zinc transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (@GENE$) or the @CHEMICAL$ transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @CHEM-GENE$.	0
We now show that lysosomal enlargement and zinc build-up in @GENE$-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @CHEMICAL$ transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the @GENE$ MTF-1 (metal-regulatory-element-binding transcription factor-1) or the @CHEMICAL$ transporter ZnT4.	0
We now show that lysosomal enlargement and zinc build-up in TRPML1-KD cells exposed to zinc are ameliorated by KD of the zinc-sensitive transcription factor @GENE$ (metal-regulatory-element-binding transcription factor-1) or the @CHEMICAL$ transporter ZnT4.	0
@GENE$ KD is associated with a build-up of cytoplasmic @CHEMICAL$ and with enhanced transcriptional response of mRNA for MT2a (metallothionein 2a).	0
TRPML1 KD is associated with a build-up of cytoplasmic @CHEMICAL$ and with enhanced transcriptional response of mRNA for @GENE$ (metallothionein 2a).	0
TRPML1 KD is associated with a build-up of cytoplasmic @CHEMICAL$ and with enhanced transcriptional response of mRNA for MT2a (@GENE$).	0
@GENE$ KD did not suppress lysosomal secretion, but it did delay @CHEMICAL$ leak from the lysosomes into the cytoplasm.	0
These results underscore a role for @GENE$ in @CHEMICAL$ metabolism.	5
Furthermore, they suggest that @GENE$ works in concert with ZnT4 to regulate @CHEMICAL$ translocation between the cytoplasm and lysosomes.	5
Furthermore, they suggest that TRPML1 works in concert with @GENE$ to regulate @CHEMICAL$ translocation between the cytoplasm and lysosomes.	5
Similarly, intraperitoneal administration of @CHEMICAL$ (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of @CHEMICAL$ (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of @CHEMICAL$ (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of @CHEMICAL$ (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, @CHEMICAL$, superoxide dismutase, @GENE$, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, @CHEMICAL$, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, @CHEMICAL$, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, @CHEMICAL$, @GENE$, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @CHEMICAL$ dismutase, @GENE$, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, @CHEMICAL$ dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, @CHEMICAL$ dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @CHEM-GENE$, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free @CHEMICAL$, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free @CHEMICAL$, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free @CHEMICAL$, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free @CHEMICAL$, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free sulfhydryl, protein @CHEMICAL$, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein @CHEMICAL$, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein @CHEMICAL$, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free sulfhydryl, protein @CHEMICAL$, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free sulfhydryl, protein carbonyl, @CHEMICAL$, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, @CHEMICAL$, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, @CHEMICAL$, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free sulfhydryl, protein carbonyl, @CHEMICAL$, liver lipid peroxide contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid @CHEMICAL$ contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid @CHEMICAL$ contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid @CHEMICAL$ contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid @CHEMICAL$ contents, and antioxidant capacity in d-galactose mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, superoxide dismutase, @GENE$, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in @CHEMICAL$ mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum @GENE$, alkaline phosphatase, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in @CHEMICAL$ mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, @GENE$, bilirubin, superoxide dismutase, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in @CHEMICAL$ mediated oxidative stress induced mice.	0
Similarly, intraperitoneal administration of α-santalol (100mg/kg BW) and sandalwood oil (1g/kg BW) for two weeks modulated parameters such as serum aminotransferases, alkaline phosphatase, bilirubin, @GENE$, catalase, free sulfhydryl, protein carbonyl, nitric oxide, liver lipid peroxide contents, and antioxidant capacity in @CHEMICAL$ mediated oxidative stress induced mice.	0
@GENE$ upsurge precedes standard biomarkers of hepatotoxicity in @CHEMICAL$-injected mice.	1
The tocolytic agent @CHEMICAL$ acts on the @GENE$ and is an effective treatment option for preterm labor.	0
Importantly, expression of the acute-phase reactant @GENE$ (SAA) significantly increased after @CHEMICAL$ injection, with values indicating the largest fold-change.	1
Importantly, expression of the acute-phase reactant serum amyloid A (@GENE$) significantly increased after @CHEMICAL$ injection, with values indicating the largest fold-change.	1
This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as @CHEM-GENE$ and alanine aminotransferase.	0
This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as @CHEMICAL$ aminotransferase and @GENE$.	0
This large increase in blood @GENE$ levels serves as a more sensitive biomarker than conventional liver enzymes, such as @CHEMICAL$ aminotransferase and alanine aminotransferase.	0
This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as @GENE$ and @CHEMICAL$ aminotransferase.	0
This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and @CHEM-GENE$.	0
This large increase in blood @GENE$ levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and @CHEMICAL$ aminotransferase.	0
The increase in @GENE$ expression is specific to @CHEMICAL$-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.	1
The increase in SAA expression is specific to @CHEMICAL$-induced liver damage, because @GENE$ expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.	0
The increase in @GENE$ expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as @CHEMICAL$, valproic acid, or metformin.	0
The increase in SAA expression is specific to ritodrine-induced liver damage, because @GENE$ expression was not induced by other hepatotoxic drugs such as @CHEMICAL$, valproic acid, or metformin.	0
The increase in @GENE$ expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, @CHEMICAL$, or metformin.	0
The increase in SAA expression is specific to ritodrine-induced liver damage, because @GENE$ expression was not induced by other hepatotoxic drugs such as acetaminophen, @CHEMICAL$, or metformin.	0
The increase in @GENE$ expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or @CHEMICAL$.	0
The increase in SAA expression is specific to ritodrine-induced liver damage, because @GENE$ expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or @CHEMICAL$.	0
Our in vitro studies showed that @CHEMICAL$ (cAMP) accumulation was not a primary cause of the ritodrine-induced @GENE$ increase.	0
Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (@CHEMICAL$) accumulation was not a primary cause of the ritodrine-induced @GENE$ increase.	0
Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the @CHEMICAL$-induced @GENE$ increase.	1
@CHEMICAL$-avibactam: a novel cephalosporin/@GENE$ inhibitor combination.	2
Ceftazidime-@CHEMICAL$: a novel cephalosporin/@GENE$ inhibitor combination.	2
Ceftazidime-avibactam: a novel @CHEMICAL$/@GENE$ inhibitor combination.	0
Avibactam (formerly @CHEMICAL$, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of @GENE$ and some Ambler class D enzymes.	0
Avibactam (formerly @CHEMICAL$, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some @GENE$ enzymes.	2
Avibactam (formerly @CHEMICAL$, AVE1330A) is a synthetic non-β-lactam, @GENE$ inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.	2
@CHEMICAL$ (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of @GENE$ and some Ambler class D enzymes.	0
@CHEMICAL$ (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some @GENE$ enzymes.	2
@CHEMICAL$ (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, @GENE$ inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.	2
Avibactam (formerly NXL104, @CHEMICAL$) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of @GENE$ and some Ambler class D enzymes.	0
Avibactam (formerly NXL104, @CHEMICAL$) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some @GENE$ enzymes.	2
Avibactam (formerly NXL104, @CHEMICAL$) is a synthetic non-β-lactam, @GENE$ inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.	2
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-@CHEMICAL$, β-lactamase inhibitor that inhibits the activities of @GENE$ and some Ambler class D enzymes.	0
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-@CHEMICAL$, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some @GENE$ enzymes.	0
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-@CHEMICAL$, @GENE$ inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes.	0
Although not a @CHEMICAL$, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to @GENE$.	0
Although not a β-lactam, the chemical structure of @CHEMICAL$ closely resembles portions of the cephem bicyclic ring system, and avibactam has been shown to bond covalently to @GENE$.	0
Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the @CHEMICAL$ bicyclic ring system, and avibactam has been shown to bond covalently to @GENE$.	0
Although not a β-lactam, the chemical structure of avibactam closely resembles portions of the cephem bicyclic ring system, and @CHEMICAL$ has been shown to bond covalently to @GENE$.	0
The addition of @CHEMICAL$ greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of @GENE$ enzyme(s).	2
The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of @CHEMICAL$ versus most species of Enterobacteriaceae depending on the presence or absence of @GENE$ enzyme(s).	2
Pharmacodynamic data suggest that @CHEMICAL$-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	2
Pharmacodynamic data suggest that ceftazidime-@CHEMICAL$ is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	2
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by @CHEMICAL$ alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	0
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that @CHEMICAL$-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	0
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-@CHEMICAL$ is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	0
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard @CHEMICAL$ therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates.	0
Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus @GENE$-producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by @CHEMICAL$-resistant Gram-negative isolates.	0
@CHEMICAL$-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus @GENE$-producing Gram-negative bacilli.	0
Ceftazidime-@CHEMICAL$ appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus @GENE$-producing Gram-negative bacilli.	0
Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, @CHEMICAL$ serves to broaden the spectrum of ceftazidime versus @GENE$-producing Gram-negative bacilli.	2
Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of @CHEMICAL$ versus @GENE$-producing Gram-negative bacilli.	2
Potential future roles for @CHEMICAL$-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing @GENE$ (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for @CHEMICAL$-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (@GENE$), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for @CHEMICAL$-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), @GENE$ (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for @CHEMICAL$-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (@GENE$) and/or AmpC ß-lactamases.	0
Potential future roles for @CHEMICAL$-avibactam include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or @GENE$.	0
Potential future roles for ceftazidime-@CHEMICAL$ include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing @GENE$ (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for ceftazidime-@CHEMICAL$ include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (@GENE$), Klebsiella pneumoniae carbapenemases (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for ceftazidime-@CHEMICAL$ include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), @GENE$ (KPCs) and/or AmpC ß-lactamases.	0
Potential future roles for ceftazidime-@CHEMICAL$ include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (@GENE$) and/or AmpC ß-lactamases.	0
Potential future roles for ceftazidime-@CHEMICAL$ include the treatment of suspected or documented infections caused by resistant Gram-negative-bacilli producing extended-spectrum ß-lactamase (ESBL), Klebsiella pneumoniae carbapenemases (KPCs) and/or @GENE$.	0
Cell proliferation and apoptosis rate were measured in HDMVEC by @CHEMICAL$ (BrdU) incorporation and @GENE$ and caspase 7 activity, respectively.	0
Cell proliferation and apoptosis rate were measured in HDMVEC by @CHEMICAL$ (BrdU) incorporation and caspase 3 and @GENE$ activity, respectively.	0
Cell proliferation and apoptosis rate were measured in HDMVEC by bromodeoxyuridine (@CHEMICAL$) incorporation and @GENE$ and caspase 7 activity, respectively.	0
Cell proliferation and apoptosis rate were measured in HDMVEC by bromodeoxyuridine (@CHEMICAL$) incorporation and caspase 3 and @GENE$ activity, respectively.	0
In a genome-wide meta-analysis of a population-based discovery cohort (n = 33 533), rs838133 in @GENE$ (19q13.33), rs197273 near TRAF family member-associated NF-kappa-B activator (TANK) (2p24.2), and rs10163409 in FTO (16q12.2) were among the top associations (P < 10(-5)) for percentage of total caloric intake from protein and @CHEMICAL$.	0
In a genome-wide meta-analysis of a population-based discovery cohort (n = 33 533), rs838133 in FGF21 (19q13.33), rs197273 near @GENE$ (TANK) (2p24.2), and rs10163409 in FTO (16q12.2) were among the top associations (P < 10(-5)) for percentage of total caloric intake from protein and @CHEMICAL$.	0
In a genome-wide meta-analysis of a population-based discovery cohort (n = 33 533), rs838133 in FGF21 (19q13.33), rs197273 near TRAF family member-associated NF-kappa-B activator (@GENE$) (2p24.2), and rs10163409 in FTO (16q12.2) were among the top associations (P < 10(-5)) for percentage of total caloric intake from protein and @CHEMICAL$.	0
In a genome-wide meta-analysis of a population-based discovery cohort (n = 33 533), rs838133 in FGF21 (19q13.33), rs197273 near TRAF family member-associated NF-kappa-B activator (TANK) (2p24.2), and rs10163409 in @GENE$ (16q12.2) were among the top associations (P < 10(-5)) for percentage of total caloric intake from protein and @CHEMICAL$.	0
Here we show that @GENE$ and Trim33 cooperatively repress @CHEMICAL$ receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver.	0
Here we show that Trim24 and @GENE$ cooperatively repress @CHEMICAL$ receptor-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver.	0
Here we show that Trim24 and Trim33 cooperatively repress @CHEM-GENE$-dependent activity of VL30-class endogenous retroviruses (ERVs) in liver.	0
Here we show that Trim24 and Trim33 cooperatively repress @CHEMICAL$ receptor-dependent activity of @GENE$-class endogenous retroviruses (ERVs) in liver.	0
Moreover, treatment of high-fat-diet-fed @GENE$-knockout mice with a selective cyclooxygenase-2 inhibitor, @CHEMICAL$, improved vascular function, and also attenuated obesity.	0
Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective @GENE$ inhibitor, @CHEMICAL$, improved vascular function, and also attenuated obesity.	2
Activation of the anti-cancer agent @CHEMICAL$ by the @GENE$ enzyme system.	0
Upamostat (Mesupron®) is a new small molecule @CHEM-GENE$ inhibitor.	0
@CHEMICAL$ (Mesupron®) is a new small molecule @GENE$ inhibitor.	2
Upamostat (@CHEMICAL$®) is a new small molecule @GENE$ inhibitor.	2
The recently discovered @CHEMICAL$ enzyme "@GENE$" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered @CHEMICAL$ enzyme "mitochondrial Amidoxime Reducing Component" (@GENE$) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered @CHEMICAL$ enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its @GENE$ cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered @CHEMICAL$ enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins @GENE$ and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered @CHEMICAL$ enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and @GENE$ the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "@CHEM-GENE$" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial @CHEMICAL$ Reducing Component" (@GENE$) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial @CHEMICAL$ Reducing Component" (mARC) catalyses together with its @GENE$ cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial @CHEMICAL$ Reducing Component" (mARC) catalyses together with its electron transport proteins @GENE$ and NADH cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial @CHEMICAL$ Reducing Component" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and @GENE$ the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "@GENE$" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and @CHEMICAL$ cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (@GENE$) catalyses together with its electron transport proteins cytochrome b(5) and @CHEMICAL$ cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its @GENE$ cytochrome b(5) and @CHEMICAL$ cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins @GENE$ and @CHEMICAL$ cytochrome b(5) reductase the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and @CHEM-GENE$ the reduction of N-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "@GENE$" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of @CHEMICAL$-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (@GENE$) catalyses together with its electron transport proteins cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of @CHEMICAL$-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its @GENE$ cytochrome b(5) and NADH cytochrome b(5) reductase the reduction of @CHEMICAL$-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins @GENE$ and NADH cytochrome b(5) reductase the reduction of @CHEMICAL$-hydroxylated prodrugs.	0
The recently discovered molybdenum enzyme "mitochondrial Amidoxime Reducing Component" (mARC) catalyses together with its electron transport proteins cytochrome b(5) and @GENE$ the reduction of @CHEMICAL$-hydroxylated prodrugs.	0
In vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an @GENE$-dependent @CHEMICAL$-reduction of upamostat.	0
In vitro biotransformation assays with porcine subcellular fractions and the reconstituted human enzymes demonstrate an @GENE$-dependent N-reduction of @CHEMICAL$.	0
Protein phosphatase 2A is one of four major classes of @CHEM-GENE$.	0
@GENE$ is one of four major classes of @CHEMICAL$/threonine phosphatases.	0
Protein phosphatase 2A is one of four major classes of @CHEM-GENE$.	0
@GENE$ is one of four major classes of serine/@CHEMICAL$ phosphatases.	0
We have reported that @GENE$ clones are sensitive to reactive @CHEMICAL$ species (ROS) treatment by inducing autophagic cell death.	0
We found that this interaction is highly specific, requires the @CHEM-GENE$ of USP22, and is disrupted by the inactivating H363Y mutation within SIRT1.	0
We found that this interaction is highly specific, requires the @CHEMICAL$-UBP domain of @GENE$, and is disrupted by the inactivating H363Y mutation within SIRT1.	0
We found that this interaction is highly specific, requires the @CHEMICAL$-UBP domain of USP22, and is disrupted by the inactivating @GENE$ mutation within SIRT1.	0
We found that this interaction is highly specific, requires the @CHEMICAL$-UBP domain of USP22, and is disrupted by the inactivating H363Y mutation within @GENE$.	0
Moreover, we show that @GENE$ is acetylated on multiple @CHEMICAL$ residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple @CHEMICAL$ residues and that alteration of a single lysine (K129) within the @GENE$ is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple @CHEMICAL$ residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the @GENE$ with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple @CHEMICAL$ residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core @GENE$ complex.	0
Moreover, we show that @GENE$ is acetylated on multiple lysine residues and that alteration of a single @CHEMICAL$ (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single @CHEMICAL$ (K129) within the @GENE$ is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single @CHEMICAL$ (K129) within the ZnF-UBP domain is sufficient to alter interaction of the @GENE$ with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single @CHEMICAL$ (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core @GENE$ complex.	0
Moreover, we show that @GENE$ is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the @CHEMICAL$-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the @CHEM-GENE$ is sufficient to alter interaction of the DUBm with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the @CHEMICAL$-UBP domain is sufficient to alter interaction of the @GENE$ with the core SAGA complex.	0
Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single lysine (K129) within the @CHEMICAL$-UBP domain is sufficient to alter interaction of the DUBm with the core @GENE$ complex.	0
Characterization of @GENE$ and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro @CHEMICAL$ exposure.	0
Characterization of cytosolic glutathione peroxidase and @GENE$ genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro @CHEMICAL$ exposure.	0
Characterization of @CHEM-GENE$ and phospholipid-hydroperoxide glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
Characterization of cytosolic @CHEMICAL$ peroxidase and @GENE$ genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
Characterization of @GENE$ and phospholipid-@CHEMICAL$ glutathione peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
Characterization of cytosolic glutathione peroxidase and @CHEM-GENE$ genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
Characterization of @GENE$ and phospholipid-hydroperoxide @CHEMICAL$ peroxidase genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
Characterization of cytosolic glutathione peroxidase and @CHEM-GENE$ genes in rainbow trout (Oncorhynchus mykiss) and their modulation by in vitro selenium exposure.	0
@CHEM-GENE$ (GPxs) is the largest and the most studied selenoprotein family.	0
@CHEMICAL$ peroxidase (@GENE$) is the largest and the most studied selenoprotein family.	0
@CHEMICAL$ peroxidase (GPxs) is the largest and the most studied @GENE$ family.	0
@CHEM-GENE$ (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic @CHEMICAL$ peroxidase (@GENE$, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic @CHEMICAL$ peroxidase (cGPx, @GENE$) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic @CHEMICAL$ peroxidase (cGPx, GPx1) and @GENE$ (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic @CHEMICAL$ peroxidase (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (@GENE$, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic @CHEMICAL$ peroxidase (cGPx, GPx1) and phospholipid hydroperoxide glutathione peroxidase (PHGPx, @GENE$) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
@GENE$ (cGPx, GPx1) and phospholipid @CHEMICAL$ glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (@GENE$, GPx1) and phospholipid @CHEMICAL$ glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, @GENE$) and phospholipid @CHEMICAL$ glutathione peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and @CHEM-GENE$ (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid @CHEMICAL$ glutathione peroxidase (@GENE$, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid @CHEMICAL$ glutathione peroxidase (PHGPx, @GENE$) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
@GENE$ (cGPx, GPx1) and phospholipid hydroperoxide @CHEMICAL$ peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (@GENE$, GPx1) and phospholipid hydroperoxide @CHEMICAL$ peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, @GENE$) and phospholipid hydroperoxide @CHEMICAL$ peroxidase (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and @CHEM-GENE$ (PHGPx, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide @CHEMICAL$ peroxidase (@GENE$, GPx4) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Cytosolic glutathione peroxidase (cGPx, GPx1) and phospholipid hydroperoxide @CHEMICAL$ peroxidase (PHGPx, @GENE$) are widely distributed throughout tissues, and play a pivotal role in regulating the oxidative status in the cell.	0
Transcripts of @GENE$ genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the GPx1 genes were more responsive to @CHEMICAL$ exposure in vitro, especially to the organic form.	0
Transcripts of GPx4 genes were more highly expressed in most tissues examined in vivo (except blood, head kidney and spleen), whereas those of the @GENE$ genes were more responsive to @CHEMICAL$ exposure in vitro, especially to the organic form.	0
Interestingly, @GENE$ was the most sensitive to @CHEMICAL$ availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells.	0
Interestingly, GPx1a was the most sensitive to @CHEMICAL$ availability in non stressful conditions, whereas @GENE$ and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells.	0
Interestingly, GPx1a was the most sensitive to @CHEMICAL$ availability in non stressful conditions, whereas GPx1b1 and @GENE$ were highly induced by exposure to selenium levels that had some toxic effects on the cells.	0
Interestingly, @GENE$ was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to @CHEMICAL$ levels that had some toxic effects on the cells.	0
Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas @GENE$ and GPx1b2 were highly induced by exposure to @CHEMICAL$ levels that had some toxic effects on the cells.	1
Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and @GENE$ were highly induced by exposure to @CHEMICAL$ levels that had some toxic effects on the cells.	1
Our results lead us to conclude that trout @GENE$ transcripts expression level may represent a sensitive biomarker for @CHEMICAL$ intake, helping to evaluate if selenium concentration and chemical speciation impact on cell homeostasis.	0
Our results lead us to conclude that trout @GENE$ transcripts expression level may represent a sensitive biomarker for selenium intake, helping to evaluate if @CHEMICAL$ concentration and chemical speciation impact on cell homeostasis.	0
@CHEMICAL$ exposure (20 mg/kg) increased @GENE$(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.	1
@CHEMICAL$ exposure (20 mg/kg) increased p38(@GENE$) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.	1
@CHEMICAL$ exposure (20 mg/kg) increased p38(MAPK) and @GENE$ phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.	1
@CHEMICAL$ exposure (20 mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased @GENE$-Thr-34 phosphorylation.	2
@CHEMICAL$ (10 and 20 mg/kg) increased @GENE$ activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).	1
Mn (10 and 20 mg/kg) increased @GENE$ activity and @CHEMICAL$ production (a biological marker of lipid peroxidation).	0
Notably, the antioxidant @CHEMICAL$™ reversed the Mn (20 mg/kg)-dependent augmentation in @GENE$(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	2
Notably, the antioxidant @CHEMICAL$™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(@GENE$) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	2
Notably, the antioxidant @CHEMICAL$™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced @GENE$ activity and F(2)-isoprostane production.	2
Notably, the antioxidant Trolox™ reversed the @CHEMICAL$ (20 mg/kg)-dependent augmentation in @GENE$(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	1
Notably, the antioxidant Trolox™ reversed the @CHEMICAL$ (20 mg/kg)-dependent augmentation in p38(@GENE$) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	1
Notably, the antioxidant Trolox™ reversed the @CHEMICAL$ (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced @GENE$ activity and F(2)-isoprostane production.	0
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in @GENE$(MAPK) phosphorylation and reduced the @CHEMICAL$ (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	0
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(@GENE$) phosphorylation and reduced the @CHEMICAL$ (20 mg/kg)-induced caspase activity and F(2)-isoprostane production.	0
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the @CHEMICAL$ (20 mg/kg)-induced @GENE$ activity and F(2)-isoprostane production.	1
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in @GENE$(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and @CHEMICAL$ production.	0
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(@GENE$) phosphorylation and reduced the Mn (20 mg/kg)-induced caspase activity and @CHEMICAL$ production.	0
Notably, the antioxidant Trolox™ reversed the Mn (20 mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20 mg/kg)-induced @GENE$ activity and @CHEMICAL$ production.	0
These findings are the first to show that long-term exposure to @CHEMICAL$ during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, @GENE$(MAPK) phosphorylation and caspase activity in the striatum.	1
These findings are the first to show that long-term exposure to @CHEMICAL$ during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(@GENE$) phosphorylation and caspase activity in the striatum.	1
These findings are the first to show that long-term exposure to @CHEMICAL$ during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and @GENE$ activity in the striatum.	1
@CHEMICAL$ (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and @GENE$ (IL-1β).	2
@CHEMICAL$ (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1β (@GENE$).	2
Nocapyrone H (1) reduced the pro-inflammatory factor such as @CHEMICAL$ (NO), prostaglandin E2 (PGE2) and @GENE$ (IL-1β).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as @CHEMICAL$ (NO), prostaglandin E2 (PGE2) and interleukin-1β (@GENE$).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (@CHEMICAL$), prostaglandin E2 (PGE2) and @GENE$ (IL-1β).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (@CHEMICAL$), prostaglandin E2 (PGE2) and interleukin-1β (@GENE$).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), @CHEMICAL$ (PGE2) and @GENE$ (IL-1β).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), @CHEMICAL$ (PGE2) and interleukin-1β (@GENE$).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (@CHEMICAL$) and @GENE$ (IL-1β).	0
Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (@CHEMICAL$) and interleukin-1β (@GENE$).	0
Investigating the enteroenteric recirculation of @CHEMICAL$, a @GENE$ inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.	2
Additionally, the role of @GENE$ (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
Additionally, the role of P-gp (@GENE$; abcb1) and BCRP (breast cancer resistance protein; abcg2) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
Additionally, the role of P-gp (P-glycoprotein; @GENE$) and BCRP (breast cancer resistance protein; abcg2) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
Additionally, the role of P-gp (P-glycoprotein; abcb1) and @GENE$ (breast cancer resistance protein; abcg2) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (@GENE$; abcg2) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
Additionally, the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; @GENE$) in @CHEMICAL$ disposition was evaluated in experiments using transporter inhibitors and transporter knockout (KO) rats.	0
The fecal elimination, IC, and systemic clearance of @CHEMICAL$ were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual @GENE$ and P-gp inhibitor).	0
The fecal elimination, IC, and systemic clearance of @CHEMICAL$ were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and @GENE$ inhibitor).	0
The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with @CHEMICAL$, a dual @GENE$ and P-gp inhibitor).	2
The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with @CHEMICAL$, a dual BCRP and @GENE$ inhibitor).	2
@GENE$ appeared to play a more important role for absorption and intestinal and renal elimination of @CHEMICAL$ than P-gp in transporter-KO rats after oral and i.v.	5
BCRP appeared to play a more important role for absorption and intestinal and renal elimination of @CHEMICAL$ than @GENE$ in transporter-KO rats after oral and i.v.	5
Cloning, Characterization, and @CHEMICAL$ and Thiol Inhibition Studies of an @GENE$ from Trypanosoma cruzi, the Causative Agent of Chagas Disease.	2
Cloning, Characterization, and Sulfonamide and @CHEMICAL$ Inhibition Studies of an @GENE$ from Trypanosoma cruzi, the Causative Agent of Chagas Disease.	2
The enzyme (TcCA) has a very high catalytic activity for the @CHEMICAL$ hydration reaction, being similar kinetically to the human (h) isoform @GENE$, although it is devoid of the His64 proton shuttle.	5
The enzyme (@GENE$) has a very high catalytic activity for the @CHEMICAL$ hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle.	5
The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform @GENE$, although it is devoid of the @CHEMICAL$64 proton shuttle.	0
The enzyme (@GENE$) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the @CHEMICAL$64 proton shuttle.	0
A large number of @CHEMICAL$ and some 5-mercapto-1,3,4-thiadiazoles were investigated as @GENE$ inhibitors.	2
A large number of aromatic/heterocyclic sulfonamides and some @CHEMICAL$ were investigated as @GENE$ inhibitors.	2
@CHEMICAL$ eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no @GENE$ positive (3β-HSD(pos)) cells in the interstitium.	0
@CHEMICAL$ eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no 3β-hydroxysteroid dehydrogenase positive (@GENE$(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-@CHEMICAL$, as judged by undetectable serum testosterone level and no @GENE$ positive (3β-HSD(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-@CHEMICAL$, as judged by undetectable serum testosterone level and no 3β-hydroxysteroid dehydrogenase positive (@GENE$(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum @CHEMICAL$ level and no @GENE$ positive (3β-HSD(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum @CHEMICAL$ level and no 3β-hydroxysteroid dehydrogenase positive (@GENE$(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no @CHEM-GENE$ positive (3β-HSD(pos)) cells in the interstitium.	0
EDS eliminated all Leydig cells in the control testis on day 4 post-EDS, as judged by undetectable serum testosterone level and no @CHEMICAL$ dehydrogenase positive (@GENE$(pos)) cells in the interstitium.	0
However, in @CHEMICAL$-treated groups, there were detectable serum testosterone concentrations and some oval-shaped @GENE$(pos) cells in the interstitium.	0
However, in DEHP-treated groups, there were detectable serum @CHEMICAL$ concentrations and some oval-shaped @GENE$(pos) cells in the interstitium.	0
These 3β-HSD(pos) cells were not stained by the antibody against @CHEM-GENE$ (11β-HSD1), a marker for Leydig cells at a more advanced stage.	0
These 3β-HSD(pos) cells were not stained by the antibody against @CHEMICAL$ dehydrogenase 1 (@GENE$1), a marker for Leydig cells at a more advanced stage.	0
These @GENE$(pos) cells were not stained by the antibody against @CHEMICAL$ dehydrogenase 1 (11β-HSD1), a marker for Leydig cells at a more advanced stage.	0
However, there were detectable concentrations of @GENE$, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, @GENE$ and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, Cyp11a1 and @GENE$ mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of @GENE$, Hsd17b3 and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, @GENE$ and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and @GENE$ in the @CHEMICAL$-treated testes, indicating that these 3β-HSD(pos) cells were newly formed progenitor Leydig cells.	0
However, there were detectable concentrations of Lhcgr, Cyp11a1 and Cyp17a1 mRNAs but undetectable concentrations of Insl3, Hsd17b3 and Hsd11b1 in the @CHEMICAL$-treated testes, indicating that these @GENE$(pos) cells were newly formed progenitor Leydig cells.	0
The mRNA level for @GENE$ (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-@CHEMICAL$, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	1
The mRNA level for nestin (@GENE$, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-@CHEMICAL$, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	1
The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-@CHEMICAL$, but not in the DEHP treated testes, suggesting that these @GENE$ positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	0
The mRNA level for @GENE$ (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the @CHEMICAL$ treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	0
The mRNA level for nestin (@GENE$, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the @CHEMICAL$ treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	0
The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the @CHEMICAL$ treated testes, suggesting that these @GENE$ positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.	0
The mRNA level for @GENE$ (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the @CHEMICAL$-treated testes.	0
The mRNA level for nestin (@GENE$, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the @CHEMICAL$-treated testes.	0
The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS, but not in the DEHP treated testes, suggesting that these @GENE$ positive stem cells were differentiated into progenitor Leydig cells in the @CHEMICAL$-treated testes.	0
@CHEM-GENE$ pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and CREB.	0
@CHEMICAL$ pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of PKA and @GENE$.	1
@CHEMICAL$ pulse frequency-dependent stimulation of @GENE$ transcription is mediated via activation of PKA and CREB.	1
@CHEMICAL$ pulse frequency-dependent stimulation of FSHβ transcription is mediated via activation of @GENE$ and CREB.	1
Expression of pituitary @GENE$ and LH, under the control of pulsatile @CHEMICAL$, is essential for fertility.	0
Expression of pituitary FSH and @GENE$, under the control of pulsatile @CHEMICAL$, is essential for fertility.	0
Expression of pituitary FSH and LH, under the control of pulsatile @CHEM-GENE$, is essential for fertility.	0
@CHEM-GENE$ (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood.	0
@CHEMICAL$ response element-binding protein (@GENE$) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood.	0
@CHEMICAL$ response element-binding protein (CREB) has been implicated in the regulation of @GENE$ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood.	0
@CHEMICAL$ response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile @GENE$ regulates CREB activation remain poorly understood.	0
@CHEMICAL$ response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile GnRH regulates @GENE$ activation remain poorly understood.	0
@GENE$ (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile @CHEMICAL$ regulates CREB activation remain poorly understood.	0
cAMP response element-binding protein (@GENE$) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile @CHEMICAL$ regulates CREB activation remain poorly understood.	0
cAMP response element-binding protein (CREB) has been implicated in the regulation of @GENE$ gene expression, but the molecular mechanisms by which pulsatile @CHEMICAL$ regulates CREB activation remain poorly understood.	0
cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile @CHEM-GENE$ regulates CREB activation remain poorly understood.	0
cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHβ gene expression, but the molecular mechanisms by which pulsatile @CHEMICAL$ regulates @GENE$ activation remain poorly understood.	1
We hypothesized that @GENE$ is activated by a distinct signaling pathway in response to pulsatile @CHEMICAL$ in a frequency-dependent manner to dictate the FSHβ transcriptional response.	1
We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile @CHEM-GENE$ in a frequency-dependent manner to dictate the FSHβ transcriptional response.	0
We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile @CHEMICAL$ in a frequency-dependent manner to dictate the @GENE$ transcriptional response.	0
@CHEM-GENE$ stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.	0
@CHEMICAL$ stimulation of @GENE$ phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.	1
@CHEMICAL$ stimulation of CREB phosphorylation (@GENE$) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.	1
@CHEMICAL$ stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a @GENE$ (PKA) inhibitor, H89.	0
@CHEMICAL$ stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (@GENE$) inhibitor, H89.	0
@GENE$ stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, @CHEMICAL$.	0
GnRH stimulation of @GENE$ phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, @CHEMICAL$.	2
GnRH stimulation of CREB phosphorylation (@GENE$) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (PKA) inhibitor, @CHEMICAL$.	2
GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a @GENE$ (PKA) inhibitor, @CHEMICAL$.	2
GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LβT2 cell line was attenuated by a protein kinase A (@GENE$) inhibitor, @CHEMICAL$.	2
A @GENE$ (DNPKA) reduced @CHEMICAL$-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (@GENE$) reduced @CHEMICAL$-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @CHEM-GENE$-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @CHEMICAL$-stimulated @GENE$ and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	1
A dominant negative PKA (DNPKA) reduced @CHEMICAL$-stimulated pCREB and markedly decreased @GENE$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @CHEMICAL$-stimulated pCREB and markedly decreased GnRH stimulation of @GENE$ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @CHEMICAL$-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and @GENE$LUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @CHEMICAL$-stimulated pCREB and markedly decreased GnRH stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on @GENE$LUC activity, indicating relative specificity of this pathway.	0
A @GENE$ (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (@GENE$) reduced GnRH-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced @GENE$-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced GnRH-stimulated @GENE$ and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased @CHEM-GENE$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	0
A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of @GENE$ mRNA and FSHβLUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	1
A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and @GENE$LUC activity, but had little effect on LHβLUC activity, indicating relative specificity of this pathway.	1
A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased @CHEMICAL$ stimulation of FSHβ mRNA and FSHβLUC activity, but had little effect on @GENE$LUC activity, indicating relative specificity of this pathway.	0
In perifusion studies, @GENE$ mRNA levels and FSHβLUC activities were increased by pulsatile @CHEMICAL$, with significantly greater increases at low compared with high pulse frequencies.	1
In perifusion studies, FSHβ mRNA levels and @GENE$LUC activities were increased by pulsatile @CHEMICAL$, with significantly greater increases at low compared with high pulse frequencies.	1
In perifusion studies, FSHβ mRNA levels and FSHβLUC activities were increased by pulsatile @CHEM-GENE$, with significantly greater increases at low compared with high pulse frequencies.	0
@GENE$ markedly reduced these @CHEMICAL$-stimulated FSHβ responses at both low and high pulse frequencies.	0
DNPKA markedly reduced these @CHEM-GENE$-stimulated FSHβ responses at both low and high pulse frequencies.	0
DNPKA markedly reduced these @CHEMICAL$-stimulated @GENE$ responses at both low and high pulse frequencies.	1
Correlating with @GENE$ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high @CHEMICAL$ pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.	1
Correlating with FSHβ activation, both @GENE$ activity and levels of pCREB were increased to a greater extent by low compared with high @CHEMICAL$ pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.	1
Correlating with FSHβ activation, both PKA activity and levels of @GENE$ were increased to a greater extent by low compared with high @CHEMICAL$ pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.	1
Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high @CHEM-GENE$ pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.	0
Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high @CHEMICAL$ pulse frequencies, and the induction of @GENE$ was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.	1
Correlating with FSHβ activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high @CHEMICAL$ pulse frequencies, and the induction of pCREB was also attenuated by overexpression of @GENE$ at both low and high pulse frequencies.	0
Taken together, these data indicate that a @GENE$-mediated signaling pathway mediates @CHEMICAL$ activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates @CHEM-GENE$ activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates @CHEMICAL$ activation of @GENE$ at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHβ activation.	1
Taken together, these data indicate that a PKA-mediated signaling pathway mediates @CHEMICAL$ activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @GENE$ signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates @CHEMICAL$ activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent @GENE$ activation.	0
Taken together, these data indicate that a @GENE$-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @CHEMICAL$ signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates @GENE$ activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @CHEMICAL$ signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of @GENE$ at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @CHEMICAL$ signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @CHEM-GENE$ signal to result in frequency-dependent FSHβ activation.	0
Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic @CHEMICAL$ signal to result in frequency-dependent @GENE$ activation.	1
@CHEMICAL$ alleviates hepatocyte steatosis through activating @GENE$ signaling pathway.	1
@CHEMICAL$, an effective compound derived from foxtail-like sophora herb and seed, has been reported that it can alleviate non-alcoholic steatohepatitis (NASH) in rats and affect @GENE$ synthesis.	0
While @CHEMICAL$ treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of @GENE$ expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).	2
While @CHEMICAL$ treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of @GENE$ expression (>1.48-fold).	1
Moreover, compared with the model group, @CHEMICAL$ could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and @GENE$ (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.	1
Moreover, compared with the model group, @CHEMICAL$ could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce @GENE$ (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.	2
Moreover, compared with the model group, @CHEMICAL$ could significantly increase P-AMPKα (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and @GENE$ (<0.20-fold) protein expression.	2
Moreover, compared with the model group, @CHEMICAL$ could significantly increase @GENE$ (>5.82-fold), AMPKα (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.	1
Moreover, compared with the model group, @CHEMICAL$ could significantly increase P-AMPKα (>5.82-fold), @GENE$ (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4α (<0.20-fold) protein expression.	1
We concluded that @CHEMICAL$ could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of @GENE$.	1
@CHEMICAL$ (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
@CHEMICAL$ (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
@CHEMICAL$ (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
@CHEMICAL$ (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (@CHEMICAL$), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (@CHEMICAL$), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (@CHEMICAL$), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (@CHEMICAL$), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), @CHEMICAL$ (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), @CHEMICAL$ (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), @CHEMICAL$ (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), @CHEMICAL$ (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (@CHEMICAL$) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (@CHEMICAL$) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (@CHEMICAL$) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (@CHEMICAL$) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total @CHEMICAL$ (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total @CHEMICAL$ (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total @CHEMICAL$ (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total @CHEMICAL$ (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-@CHEMICAL$) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-@CHEMICAL$) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-@CHEMICAL$) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-@CHEMICAL$) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @CHEM-GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @CHEMICAL$ reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @CHEMICAL$ reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @CHEMICAL$ reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and @CHEMICAL$ peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and @CHEMICAL$ peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @CHEM-GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @CHEMICAL$ peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (@CHEMICAL$-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (@CHEMICAL$-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (@CHEMICAL$-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@CHEM-GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, @CHEMICAL$ (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, @CHEMICAL$ (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, @CHEMICAL$ (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, @CHEMICAL$ (MDA) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (@CHEMICAL$) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (@CHEMICAL$) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (@CHEMICAL$) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (@CHEMICAL$) level, as well as 4-hydroxynonenal (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as @CHEMICAL$ (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as @CHEMICAL$ (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as @CHEMICAL$ (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as @CHEMICAL$ (4-HNE) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (@CHEMICAL$) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (@CHEMICAL$) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (@CHEMICAL$) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (@CHEMICAL$) and MDA modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, @GENE$ (GR) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and @CHEMICAL$ modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (@GENE$) and GSH peroxidase (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and @CHEMICAL$ modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and @GENE$ (GSH-Px) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and @CHEMICAL$ modified proteins in homogenates of cerebral cortex were measured.	0
Glutathione (GSH), oxidized glutathione (GSSG) and total thiol (total-SH) content, GSH reductase (GR) and GSH peroxidase (@GENE$) activities, malondialdehyde (MDA) level, as well as 4-hydroxynonenal (4-HNE) and @CHEMICAL$ modified proteins in homogenates of cerebral cortex were measured.	0
@CHEMICAL$ and total-SH content, GSH/GSSG ratio, @GENE$ activity significantly decreased in cerebral cortex of rats, coupling with the increase of MDA level.	0
GSH and total-@CHEMICAL$ content, GSH/GSSG ratio, @GENE$ activity significantly decreased in cerebral cortex of rats, coupling with the increase of MDA level.	0
GSH and total-SH content, @CHEMICAL$/GSSG ratio, @GENE$ activity significantly decreased in cerebral cortex of rats, coupling with the increase of MDA level.	0
GSH and total-SH content, GSH/@CHEMICAL$ ratio, @GENE$ activity significantly decreased in cerebral cortex of rats, coupling with the increase of MDA level.	0
GSH and total-SH content, GSH/GSSG ratio, @GENE$ activity significantly decreased in cerebral cortex of rats, coupling with the increase of @CHEMICAL$ level.	0
@CHEM-GENE$ activities in cerebral cortex of rats also increased.	0
To evaluate to what extent the regional differences in expression of @GENE$ and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of @CHEMICAL$ across different small intestinal segments (duodenum, proximal jejunum and ileum).	5
To evaluate to what extent the regional differences in expression of P-gp and @GENE$ affect the absorption of a dual substrate, we investigated the transport of @CHEMICAL$ across different small intestinal segments (duodenum, proximal jejunum and ileum).	5
The involvement of @GENE$ in the absorption of @CHEMICAL$ was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.	5
The involvement of P-gp in the absorption of @CHEMICAL$ was clearly shown by coperfusion of darunavir with the @GENE$ inhibitor zosuquidar.	0
The involvement of @GENE$ in the absorption of darunavir was clearly shown by coperfusion of @CHEMICAL$ with the P-gp inhibitor zosuquidar.	0
The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of @CHEMICAL$ with the @GENE$ inhibitor zosuquidar.	0
The involvement of @GENE$ in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor @CHEMICAL$.	0
The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the @GENE$ inhibitor @CHEMICAL$.	2
Involvement of @GENE$ mediated metabolism in the absorption of @CHEMICAL$ could not be demonstrated in this rat model.	5
Upon studying the drug-drug interaction of @CHEMICAL$ with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on @GENE$ as the main mechanism for the increased transport of darunavir across the small intestine.	0
Upon studying the drug-drug interaction of darunavir with @CHEMICAL$, data were indicative for an inhibitory effect of ketoconazole on @GENE$ as the main mechanism for the increased transport of darunavir across the small intestine.	0
Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of @CHEMICAL$ on @GENE$ as the main mechanism for the increased transport of darunavir across the small intestine.	2
Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on @GENE$ as the main mechanism for the increased transport of @CHEMICAL$ across the small intestine.	5
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and @GENE$ (TNF- α).	2
In HaCaT cells, @CHEMICAL$ and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (@GENE$).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and @GENE$ (TNF- α).	2
In HaCaT cells, buthanol and @CHEMICAL$ fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (@GENE$).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and @GENE$ (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% @CHEMICAL$ C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (@GENE$).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and @GENE$ (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, @CHEMICAL$ (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (@GENE$).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and @GENE$ (TNF- α).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (@CHEMICAL$) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-α (@GENE$).	2
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including @GENE$ (COX-2), inducible @CHEMICAL$ synthase (iNOS), and tumor necrosis factor-α (TNF- α).	0
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (@GENE$), inducible @CHEMICAL$ synthase (iNOS), and tumor necrosis factor-α (TNF- α).	0
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), @CHEM-GENE$ (iNOS), and tumor necrosis factor-α (TNF- α).	0
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible @CHEMICAL$ synthase (@GENE$), and tumor necrosis factor-α (TNF- α).	0
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible @CHEMICAL$ synthase (iNOS), and @GENE$ (TNF- α).	0
In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible @CHEMICAL$ synthase (iNOS), and tumor necrosis factor-α (@GENE$).	0
In another experiment, topical application of CFB, CFE or @CHEMICAL$ prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of @GENE$, iNOS, and TNF-α.	2
In another experiment, topical application of CFB, CFE or @CHEMICAL$ prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, @GENE$, and TNF-α.	2
In another experiment, topical application of CFB, CFE or @CHEMICAL$ prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and @GENE$.	2
Inhibition of @CHEM-GENE$ attenuates food deprivation-induced increases in ingestive behavior.	0
The octanoylation of ghrelin is critical for its orexigenic functions and is dependent upon ghrelin @CHEMICAL$-acyltransferase (@GENE$) catalyzation.	0
The octanoylation of @GENE$ is critical for its orexigenic functions and is dependent upon ghrelin @CHEMICAL$-acyltransferase (GOAT) catalyzation.	0
The octanoylation of ghrelin is critical for its orexigenic functions and is dependent upon @CHEM-GENE$ (GOAT) catalyzation.	0
Interaction of silymarin @CHEMICAL$ with @GENE$.	0
The present study examined the effect of silymarin @CHEMICAL$ on @GENE$-, OATP1B3-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	0
The present study examined the effect of silymarin @CHEMICAL$ on OATP1B1-, @GENE$-, and OATP2B1-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	0
The present study examined the effect of silymarin @CHEMICAL$ on OATP1B1-, OATP1B3-, and @GENE$-mediated transport in cell lines stably expressing these transporters and in human hepatocytes.	0
In overexpressing cell lines, @GENE$- and OATP1B3-mediated @CHEMICAL$ uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.	5
In overexpressing cell lines, OATP1B1- and @GENE$-mediated @CHEMICAL$ uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.	5
In overexpressing cell lines, OATP1B1- and OATP1B3-mediated @CHEMICAL$ uptake and @GENE$-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.	0
In overexpressing cell lines, @GENE$- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated @CHEMICAL$ uptake were inhibited by most of the silymarin flavonolignans investigated.	0
In overexpressing cell lines, OATP1B1- and @GENE$-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated @CHEMICAL$ uptake were inhibited by most of the silymarin flavonolignans investigated.	0
In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and @GENE$-mediated @CHEMICAL$ uptake were inhibited by most of the silymarin flavonolignans investigated.	5
In overexpressing cell lines, @GENE$- and OATP1B3-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin @CHEMICAL$ investigated.	2
In overexpressing cell lines, OATP1B1- and @GENE$-mediated estradiol-17β-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin @CHEMICAL$ investigated.	2
In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17β-glucuronide uptake and @GENE$-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin @CHEMICAL$ investigated.	2
@GENE$-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), @CHEMICAL$ (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, @GENE$-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), @CHEMICAL$ (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, OATP1B3-, and @GENE$-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), @CHEMICAL$ (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
@GENE$-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), @CHEMICAL$ (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, @GENE$-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), @CHEMICAL$ (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, OATP1B3-, and @GENE$-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), @CHEMICAL$ (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
@GENE$-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and @CHEMICAL$ (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, @GENE$-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and @CHEMICAL$ (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
OATP1B1-, OATP1B3-, and @GENE$-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 µM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 µM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 µM, respectively), and @CHEMICAL$ (IC50 values of 9.0, 36.4, and 3.6 µM, respectively).	2
Furthermore, silymarin, @CHEMICAL$, and silybin B (100 µM) significantly inhibited @GENE$-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.	2
Furthermore, silymarin, silybin A, and @CHEMICAL$ (100 µM) significantly inhibited @GENE$-mediated estradiol-17β-glucuronide and rosuvastatin uptake into human hepatocytes.	2
Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited @GENE$-mediated @CHEMICAL$ and rosuvastatin uptake into human hepatocytes.	5
Furthermore, silymarin, silybin A, and silybin B (100 µM) significantly inhibited @GENE$-mediated estradiol-17β-glucuronide and @CHEMICAL$ uptake into human hepatocytes.	5
The extent of silymarin-drug interactions depends on @GENE$ isoform specificity and concentrations of @CHEMICAL$ at the site of drug transport.	0
Higher than customary doses of silymarin, or formulations with improved bioavailability, may increase the risk of @CHEMICAL$ interactions with @GENE$ substrates in patients.	0
Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to @CHEMICAL$ is shown to transform the adhesion of model proteins @GENE$ and fibrinogen upon them.	0
Selective oxidation of ω-tertiary amine self-assembled thiol monolayers to @CHEMICAL$ is shown to transform the adhesion of model proteins lysozyme and @GENE$ upon them.	0
Selective oxidation of @CHEMICAL$ self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins @GENE$ and fibrinogen upon them.	0
Selective oxidation of @CHEMICAL$ self-assembled thiol monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and @GENE$ upon them.	0
Selective oxidation of ω-tertiary amine self-assembled @CHEMICAL$ monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins @GENE$ and fibrinogen upon them.	0
Selective oxidation of ω-tertiary amine self-assembled @CHEMICAL$ monolayers to tertiary amine N-oxides is shown to transform the adhesion of model proteins lysozyme and @GENE$ upon them.	0
Oxidation with hydrogen peroxide was similarly assessed, and adhesion of @GENE$ and fibrinogen from @CHEMICAL$ buffered saline was then assayed by QCM and imaged by AFM.	0
Oxidation with hydrogen peroxide was similarly assessed, and adhesion of lysozyme and @GENE$ from @CHEMICAL$ buffered saline was then assayed by QCM and imaged by AFM.	0
Oxidation with @CHEMICAL$ was similarly assessed, and adhesion of @GENE$ and fibrinogen from phosphate buffered saline was then assayed by QCM and imaged by AFM.	0
Oxidation with @CHEMICAL$ was similarly assessed, and adhesion of lysozyme and @GENE$ from phosphate buffered saline was then assayed by QCM and imaged by AFM.	0
@CHEMICAL$-functionalized sensors adsorbed multilayers of aggregated @GENE$, whereas tertiary amine N-oxides and triethylene glycol-terminated monolayers are consistent with small protein aggregates.	0
Tertiary amine-functionalized sensors adsorbed multilayers of aggregated @GENE$, whereas @CHEMICAL$ and triethylene glycol-terminated monolayers are consistent with small protein aggregates.	0
Tertiary amine-functionalized sensors adsorbed multilayers of aggregated @GENE$, whereas tertiary amine N-oxides and @CHEMICAL$-terminated monolayers are consistent with small protein aggregates.	0
Further investigation demonstrated that 8k reduced @CHEMICAL$-induced activation of mitochondrial apoptosis by inhibiting the expression of @GENE$ and elevating the expression of Bcl-2.	1
Further investigation demonstrated that 8k reduced @CHEMICAL$-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of @GENE$.	2
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of @GENE$ (achieved by administering insulin plus @CHEMICAL$, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).	1
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering @GENE$ plus @CHEMICAL$, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus @CHEMICAL$, glucose only, glucose and @GENE$, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus @CHEMICAL$, glucose only, glucose and GLP-1, and glucose and @GENE$ combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of @GENE$ (achieved by administering insulin plus glucose, @CHEMICAL$ only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).	1
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering @GENE$ plus glucose, @CHEMICAL$ only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, @CHEMICAL$ only, glucose and @GENE$, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, @CHEMICAL$ only, glucose and GLP-1, and glucose and @GENE$ combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of @GENE$ (achieved by administering insulin plus glucose, glucose only, @CHEMICAL$ and GLP-1, and glucose and GLP-1 combined with arginine).	1
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering @GENE$ plus glucose, glucose only, @CHEMICAL$ and GLP-1, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, @CHEMICAL$ and @GENE$, and glucose and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, @CHEMICAL$ and GLP-1, and glucose and @GENE$ combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of @GENE$ (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and @CHEMICAL$ and GLP-1 combined with arginine).	1
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering @GENE$ plus glucose, glucose only, glucose and GLP-1, and @CHEMICAL$ and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and @GENE$, and @CHEMICAL$ and GLP-1 combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and @CHEMICAL$ and @GENE$ combined with arginine).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of @GENE$ (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with @CHEMICAL$).	1
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering @GENE$ plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with @CHEMICAL$).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and @GENE$, and glucose and GLP-1 combined with @CHEMICAL$).	0
Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and @GENE$ combined with @CHEMICAL$).	0
@GENE$ levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and @CHEMICAL$).	0
Insulin levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log(10)HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, @GENE$ first and second phases, and @CHEMICAL$).	0
Administration of the beta cell secretagogues @GENE$ and @CHEMICAL$ led to a significant increase in HR, but this was not paired with a significant reduction in HRV measures.	0
@GENE$ is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of @CHEMICAL$- and C-terminal propeptides.	0
@GENE$ is an angiogenic and lymphangiogenic glycoprotein that can be proteolytically processed generating various forms differing in subunit composition due to the presence or absence of N- and @CHEMICAL$-terminal propeptides.	0
We report for the first time that @GENE$ binds heparin, and that the @CHEMICAL$-terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length VEGF-D completely prevents heparin binding).	0
We report for the first time that VEGF-D binds heparin, and that the @CHEMICAL$-terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length @GENE$ completely prevents heparin binding).	0
We also show that removal of either the @CHEMICAL$- or C-terminal propeptide is required for @GENE$ to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
We also show that removal of either the @CHEMICAL$- or C-terminal propeptide is required for VEGF-D to drive formation of @GENE$/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
We also show that removal of either the @CHEMICAL$- or C-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/@GENE$ heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
We also show that removal of either the N- or @CHEMICAL$-terminal propeptide is required for @GENE$ to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
We also show that removal of either the N- or @CHEMICAL$-terminal propeptide is required for VEGF-D to drive formation of @GENE$/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
We also show that removal of either the N- or @CHEMICAL$-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/@GENE$ heterodimers which have recently been shown to positively regulate angiogenic sprouting.	0
In a mouse tumor model, removal of only the @CHEMICAL$-terminal propeptide from full-length @GENE$ was sufficient to enhance angiogenesis and tumor growth.	0
To test this hypothesis, constructs were evaluated consisting of an @GENE$: human @CHEMICAL$ binding protein 12 (FKBP) attached to an ELP.	0
To test this hypothesis, constructs were evaluated consisting of an immunophilin: @CHEM-GENE$ (FKBP) attached to an ELP.	0
To test this hypothesis, constructs were evaluated consisting of an immunophilin: human @CHEMICAL$ binding protein 12 (@GENE$) attached to an ELP.	0
To test this hypothesis, constructs were evaluated consisting of an immunophilin: human @CHEMICAL$ binding protein 12 (FKBP) attached to an @GENE$.	0
The @GENE$ antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with @CHEMICAL$ and D-cycloserine.	0
The @GENE$ antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and @CHEMICAL$.	0
The @GENE$ antagonist @CHEMICAL$ prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine.	4
RATIONALE: The selective @GENE$ antagonist @CHEMICAL$ has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure.	4
Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial @CHEM-GENE$ agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	0
Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial @GENE$ agonist, @CHEMICAL$ (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	3
Effects of @CHEMICAL$ were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial @GENE$ agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	0
Effects of SSR125543 were compared to those of the @CHEMICAL$ reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial @GENE$ agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	0
Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, @CHEMICAL$ (10 mg/kg/day), and the partial @GENE$ agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	0
Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10 mg/kg/day), and the partial @CHEM-GENE$ agonist, D-cycloserine (10 mg/kg/day), two compounds which have demonstrated clinical efficacy against PTSD.	0
CONCLUSIONS: These findings confirm that the @GENE$ antagonist @CHEMICAL$ is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.	4
Synthesis and structure-activity relationships of @CHEMICAL$ as allosteric CC-chemokine receptor 4 (@GENE$) antagonists.	0
Synthesis and structure-activity relationships of @CHEMICAL$ as allosteric @GENE$ (CCR4) antagonists.	0
A series of @CHEMICAL$ were synthesized and examined as @GENE$ antagonists.	4
@CHEMICAL$ antagonists bind to @GENE$ at an intracellular allosteric site denoted site II.	0
Rice with high @CHEMICAL$ content in seed endosperm has been developed by insertion of @GENE$ gene under the control of the endosperm specific glutelin promoter into the genome of indica rice line IR68144.	0
Rice with high @CHEMICAL$ content in seed endosperm has been developed by insertion of soybean ferritin gene under the control of the endosperm specific @GENE$ into the genome of indica rice line IR68144.	0
Repeated Low Dose Administration of the @CHEM-GENE$ Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.	0
Repeated Low Dose Administration of the @CHEMICAL$ Lipase Inhibitor JZL184 Retains @GENE$ Receptor Mediated Antinociceptive and Gastroprotective Effects.	0
Repeated Low Dose Administration of the @GENE$ Inhibitor @CHEMICAL$ Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.	2
Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor @CHEMICAL$ Retains @GENE$ Receptor Mediated Antinociceptive and Gastroprotective Effects.	0
The @CHEMICAL$ lipase (@GENE$) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects.	0
The @CHEM-GENE$ (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects.	0
The monoacylglycerol lipase (@GENE$) inhibitor @CHEMICAL$ produces antinociceptive and anti-inflammatory effects.	2
The @GENE$ (MAGL) inhibitor @CHEMICAL$ produces antinociceptive and anti-inflammatory effects.	2
However, repeated administration of high dose @CHEMICAL$ (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of @GENE$ agonists, and CB(1) receptor downregulation and desensitization.	0
However, repeated administration of high dose @CHEMICAL$ (40 mg/kg) causes dependence, antinociceptive tolerance, cross-tolerance to the pharmacological effects of cannabinoid receptor agonists, and @GENE$ receptor downregulation and desensitization.	0
Mice given daily injections of high dose @CHEMICAL$ (≥16 mg/kg) for six days displayed decreased @GENE$ receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.	2
Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased @GENE$ receptor density and function in brain, as assessed in @CHEMICAL$ binding and CP55,940-stimulated [(35)S]GTPγS binding assays, respectively.	0
Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased @GENE$ receptor density and function in brain, as assessed in [(3)H]SR141716A binding and @CHEMICAL$-stimulated [(35)S]GTPγS binding assays, respectively.	0
Mice given daily injections of high dose JZL184 (≥16 mg/kg) for six days displayed decreased @GENE$ receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [@CHEMICAL$]GTPγS binding assays, respectively.	0
In contrast, normal @GENE$ receptor expression and function were maintained following repeated administration of low dose @CHEMICAL$ (≤8 mg/kg).	0
In our previous study, we identified the @CHEM-GENE$ (ERα) as a relevant enhancer of leptin-induced signal transduction leading to transactivation of signal transducer and activator of transcription 3 (Stat3).	0
In our previous study, we identified the @CHEMICAL$ receptor alpha (@GENE$) as a relevant enhancer of leptin-induced signal transduction leading to transactivation of signal transducer and activator of transcription 3 (Stat3).	0
In our previous study, we identified the @CHEMICAL$ receptor alpha (ERα) as a relevant enhancer of @GENE$-induced signal transduction leading to transactivation of signal transducer and activator of transcription 3 (Stat3).	0
In our previous study, we identified the @CHEMICAL$ receptor alpha (ERα) as a relevant enhancer of leptin-induced signal transduction leading to transactivation of @GENE$ (Stat3).	0
In our previous study, we identified the @CHEMICAL$ receptor alpha (ERα) as a relevant enhancer of leptin-induced signal transduction leading to transactivation of signal transducer and activator of transcription 3 (@GENE$).	0
Design and synthesis of @CHEMICAL$ as potent @GENE$-FVIIa inhibitors.	2
Design and synthesis of @CHEMICAL$ as potent TF-@GENE$ inhibitors.	2
@CHEMICAL$ were designed and synthesized as potent TF-@GENE$ inhibitors.	2
@CHEMICAL$ were designed and synthesized as potent @GENE$-FVIIa inhibitors.	2
An X-ray crystal structure of optimized compound 9b bound in the active site of @GENE$ showed that the bicyclic scaffold provides 5 @CHEMICAL$ bonding interactions in addition to projecting groups for interactions within the S1, S2 and S3 pockets.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the @GENE$-Elongin B-Elogin C (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-@GENE$-Elogin C (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-@GENE$ (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (@GENE$) complex.	0
While @GENE$ in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including @GENE$ (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (@GENE$) mRNA, HIF-1α is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.	0
While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, @GENE$ is degraded under normoxia, which involves its @CHEMICAL$ hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.	0
Circulating levels of insulin and @GENE$ reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain @CHEMICAL$ and lipid homeostasis.	0
Circulating levels of @GENE$ and glucagon reflect the nutritional state of animals and elicit regulatory responses in the liver that maintain @CHEMICAL$ and lipid homeostasis.	0
Introduction of the acetylation-mimicking (@GENE$) or -deficient (K259R) mutations promotes or inhibits Foxa2 activity, respectively, and adenoviral expression of Foxa2-K259Q augments expression of genes involved in @CHEMICAL$ oxidation and ketogenesis.	0
Introduction of the acetylation-mimicking (K259Q) or -deficient (@GENE$) mutations promotes or inhibits Foxa2 activity, respectively, and adenoviral expression of Foxa2-K259Q augments expression of genes involved in @CHEMICAL$ oxidation and ketogenesis.	0
Introduction of the acetylation-mimicking (K259Q) or -deficient (K259R) mutations promotes or inhibits @GENE$ activity, respectively, and adenoviral expression of Foxa2-K259Q augments expression of genes involved in @CHEMICAL$ oxidation and ketogenesis.	0
Introduction of the acetylation-mimicking (K259Q) or -deficient (K259R) mutations promotes or inhibits Foxa2 activity, respectively, and adenoviral expression of @GENE$-K259Q augments expression of genes involved in @CHEMICAL$ oxidation and ketogenesis.	0
Introduction of the acetylation-mimicking (K259Q) or -deficient (K259R) mutations promotes or inhibits Foxa2 activity, respectively, and adenoviral expression of Foxa2-@GENE$ augments expression of genes involved in @CHEMICAL$ oxidation and ketogenesis.	0
In addition, SCPP11 (at 50mg/kg) could also increased in thymus indexes as well as @GENE$ and TNF-α levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of @CHEMICAL$ of RAW264.7 in vitro.	0
In addition, SCPP11 (at 50mg/kg) could also increased in thymus indexes as well as IL-2 and @GENE$ levels in serum in vivo and significantly enhance the phagocytosis activity and the productions of @CHEMICAL$ of RAW264.7 in vitro.	0
Fragment-based drug design and identification of @CHEMICAL$, a novel orally bioavailable @GENE$ inhibitor for cancer therapy.	2
The most potent compound 5 (@CHEMICAL$) has demonstrated to inhibit @GENE$ activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	2
The most potent compound 5 (@CHEMICAL$) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of @GENE$, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	2
The most potent compound 5 (@CHEMICAL$) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved @GENE$, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.	1
Furthermore, compound 5 significantly suppressed @CHEM-GENE$ (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.	0
Furthermore, compound 5 significantly suppressed @CHEMICAL$ receptor (@GENE$)-negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.	0
To map supercoiling, we used @CHEMICAL$ as a DNA structure probe to show that the human genome is organized into @GENE$.	0
The effects of the @GENE$ inhibitor @CHEMICAL$ on cognitive performance in healthy adults: a behavioral- electroencephalography study.	2
Therefore, we examined whether the @GENE$-I @CHEMICAL$ improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.	2
Statins are inhibitors of the enzyme @CHEM-GENE$, the rate-limiting step in cholesterol biosynthesis.	0
Statins are inhibitors of the enzyme @GENE$, the rate-limiting step in @CHEMICAL$ biosynthesis.	5
We found that @CHEMICAL$ withdrawal decreased levels of nitric oxide and @GENE$ activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that @CHEMICAL$ withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased @GENE$ activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of @CHEMICAL$ and @GENE$ activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of @CHEMICAL$ and mitochondrial superoxide dismutase activity, whereas increased @GENE$ activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and @CHEM-GENE$ activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial @CHEMICAL$ dismutase activity, whereas increased @GENE$ activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and @GENE$ activity, whereas increased @CHEMICAL$ oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased @CHEM-GENE$ activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and @GENE$ activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker @CHEMICAL$ in the cerebral cortex.	0
We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased @GENE$ activity and immunoreactivity for the protein nitration marker @CHEMICAL$ in the cerebral cortex.	1
@GENE$, @CHEMICAL$-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @CHEM-GENE$ and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @CHEMICAL$-S-transferase and @GENE$ activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
@GENE$, glutathione-@CHEMICAL$-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @CHEM-GENE$ and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, glutathione-@CHEMICAL$-transferase and @GENE$ activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
@GENE$, glutathione-S-transferase and @CHEMICAL$ oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @GENE$ and @CHEMICAL$ oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, glutathione-S-transferase and @CHEM-GENE$ activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
@GENE$, glutathione-S-transferase and xanthine oxidase activities were not altered by @CHEMICAL$ treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @GENE$ and xanthine oxidase activities were not altered by @CHEMICAL$ treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, glutathione-S-transferase and @GENE$ activities were not altered by @CHEMICAL$ treatment or withdrawal, as well as protein carbonyl and 4-hydroxy-2-nonenal immunoreactivity.	0
@GENE$, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein @CHEMICAL$ and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, @GENE$ and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein @CHEMICAL$ and 4-hydroxy-2-nonenal immunoreactivity.	0
Catalase, glutathione-S-transferase and @GENE$ activities were not altered by atorvastatin treatment or withdrawal, as well as protein @CHEMICAL$ and 4-hydroxy-2-nonenal immunoreactivity.	0
@GENE$, glutathione-S-transferase and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and @CHEMICAL$ immunoreactivity.	0
Catalase, @GENE$ and xanthine oxidase activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and @CHEMICAL$ immunoreactivity.	0
Catalase, glutathione-S-transferase and @GENE$ activities were not altered by atorvastatin treatment or withdrawal, as well as protein carbonyl and @CHEMICAL$ immunoreactivity.	0
Immunoprecipitation of @GENE$ followed by analysis of @CHEMICAL$ revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying the atorvastatin withdrawal-induced decrease in enzyme activity.	0
Immunoprecipitation of mitochondrial SOD followed by analysis of @CHEMICAL$ revealed increased levels of nitrated @GENE$, suggesting the mechanism underlying the atorvastatin withdrawal-induced decrease in enzyme activity.	0
Immunoprecipitation of @GENE$ followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated mitochondrial SOD, suggesting the mechanism underlying the @CHEMICAL$ withdrawal-induced decrease in enzyme activity.	0
Immunoprecipitation of mitochondrial SOD followed by analysis of 3-nitrotyrosine revealed increased levels of nitrated @GENE$, suggesting the mechanism underlying the @CHEMICAL$ withdrawal-induced decrease in enzyme activity.	0
Altogether, our results indicate the @CHEMICAL$ withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in @GENE$ activity and mitochondrial superoxide dismutase activities may underlie such harmful effects.	0
Altogether, our results indicate the @CHEMICAL$ withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in NADPH oxidase activity and @GENE$ activities may underlie such harmful effects.	0
Altogether, our results indicate the atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in @CHEM-GENE$ activity and mitochondrial superoxide dismutase activities may underlie such harmful effects.	0
Altogether, our results indicate the atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in @CHEMICAL$ oxidase activity and @GENE$ activities may underlie such harmful effects.	0
Altogether, our results indicate the atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in @GENE$ activity and mitochondrial @CHEMICAL$ dismutase activities may underlie such harmful effects.	0
Altogether, our results indicate the atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex, and that changes in NADPH oxidase activity and @CHEM-GENE$ activities may underlie such harmful effects.	0
for 15 days or along with a @GENE$ agonist @CHEMICAL$ (Bzf; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.	3
for 15 days or along with a @GENE$ agonist bezafibrate (@CHEMICAL$; 30 μg/100 g BW, oral) and were found to improve in the Bzf co-treated condition.	3
for 15 days or along with a @GENE$ agonist bezafibrate (Bzf; 30 μg/100 g BW, oral) and were found to improve in the @CHEMICAL$ co-treated condition.	0
Hyperthyroidism-induced oxidative stress, reduction in @GENE$ activity, and myocardial @CHEMICAL$ concentration were also significantly checked by Bzf.	0
Hyperthyroidism-induced oxidative stress, reduction in @GENE$ activity, and myocardial ATP concentration were also significantly checked by @CHEMICAL$.	0
Since pathologies are often related to inflammation, an inflammatory HUVEC culture condition with @GENE$ stimulation has been introduced and suggested to be widely applied for studying nanocarriers, since cellular uptake in this assay was clearly increased for @CHEMICAL$ contents ⩾20mol.%.	0
Molecular mechanism regulating 24-hour rhythm of @CHEM-GENE$ expression in mouse ventral striatum.	0
The @CHEMICAL$ D3 receptor (@GENE$) in the ventral striatum is thought to influence motivation and motor functions.	0
The @CHEM-GENE$ (DRD3) in the ventral striatum is thought to influence motivation and motor functions.	0
The transcription of @GENE$ was enhanced by the @CHEMICAL$-related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα.	0
The transcription of DRD3 was enhanced by the @CHEM-GENE$ (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα.	0
The transcription of DRD3 was enhanced by the @CHEMICAL$-related orphan receptor α (@GENE$), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of RORα.	0
The transcription of DRD3 was enhanced by the @CHEMICAL$-related orphan receptor α (RORα), and its activation was inhibited by the @GENE$ REV-ERBα, an endogenous antagonist of RORα.	0
The transcription of DRD3 was enhanced by the @CHEMICAL$-related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor @GENE$, an endogenous antagonist of RORα.	0
The transcription of DRD3 was enhanced by the @CHEMICAL$-related orphan receptor α (RORα), and its activation was inhibited by the orphan receptor REV-ERBα, an endogenous antagonist of @GENE$.	0
The serum or @CHEMICAL$-induced oscillation in the expression of @GENE$ in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock.	0
The serum or @CHEMICAL$-induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of @GENE$, suggesting that REV-ERBα functions as a regulator of DRD3 oscillations in the cellular autonomous clock.	0
The serum or @CHEMICAL$-induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that @GENE$ functions as a regulator of DRD3 oscillations in the cellular autonomous clock.	0
The serum or @CHEMICAL$-induced oscillation in the expression of DRD3 in cells was abrogated by the downregulation or overexpression of REV-ERBα, suggesting that REV-ERBα functions as a regulator of @GENE$ oscillations in the cellular autonomous clock.	0
Moreover, the effects of the @GENE$ agonist @CHEMICAL$ (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.	3
Moreover, the effects of the DRD3 agonist @CHEMICAL$ (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when @GENE$ proteins were abundant.	3
Moreover, the effects of the @GENE$ agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (@CHEMICAL$)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.	3
Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (@CHEMICAL$)-induced locomotor hypoactivity were significantly increased when @GENE$ proteins were abundant.	3
Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid @GENE$ antagonist @CHEMICAL$: asymmetric synthesis, neuroactivity, and structural characterization.	4
Studies on an @CHEMICAL$ @GENE$ antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization.	0
Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid @CHEM-GENE$ antagonist IKM-159: asymmetric synthesis, neuroactivity, and structural characterization.	0
@CHEMICAL$ was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as @GENE$-selective antagonists.	4
IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as @CHEM-GENE$-selective antagonists.	0
IKM-159 was developed and identified as a member of a new class of heterotricyclic @CHEMICAL$ analogues that act as @GENE$-selective antagonists.	4
Racemic IKM-159 was crystallized with the ligand-binding domain of @GENE$, and the structure revealed a complex containing @CHEMICAL$ at the glutamate binding site.	0
@CHEMICAL$ was crystallized with the ligand-binding domain of @GENE$, and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site.	0
@CHEMICAL$ locks the @GENE$ in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.	2
@CHEMICAL$ locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of @GENE$.	4
A total of 68 chemicals including derivatives of naphthalene, @CHEMICAL$, fluoranthene, pyrene, biphenyl, and flavone were examined for their abilities to interact with @GENE$.	0
A total of 68 chemicals including derivatives of naphthalene, phenanthrene, @CHEMICAL$, pyrene, biphenyl, and flavone were examined for their abilities to interact with @GENE$.	0
A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, @CHEMICAL$, biphenyl, and flavone were examined for their abilities to interact with @GENE$.	0
A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, pyrene, @CHEMICAL$, and flavone were examined for their abilities to interact with @GENE$.	0
A total of 68 chemicals including derivatives of naphthalene, phenanthrene, fluoranthene, pyrene, biphenyl, and @CHEMICAL$ were examined for their abilities to interact with @GENE$.	0
A total of 68 chemicals including derivatives of @CHEMICAL$, phenanthrene, fluoranthene, pyrene, biphenyl, and flavone were examined for their abilities to interact with @GENE$.	0
Fifty-one of these 68 chemicals induced stronger Type I binding spectra (@CHEMICAL$ low- to high-spin state shift) with @GENE$ than those seen with P450 2A6, i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for P450 2A13.	0
Fifty-one of these 68 chemicals induced stronger Type I binding spectra (@CHEMICAL$ low- to high-spin state shift) with P450 2A13 than those seen with @GENE$, i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for P450 2A13.	0
Fifty-one of these 68 chemicals induced stronger Type I binding spectra (@CHEMICAL$ low- to high-spin state shift) with P450 2A13 than those seen with P450 2A6, i.e., the spectral binding intensities (ΔAmax/Ks ratio) determined with these chemicals were always higher for @GENE$.	0
In addition, benzo[c]phenanthrene, @CHEMICAL$, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, @CHEMICAL$, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, @CHEMICAL$, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, @CHEMICAL$, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, @CHEMICAL$, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, @CHEMICAL$, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, @CHEMICAL$, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, @CHEMICAL$, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, @CHEMICAL$, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, @CHEMICAL$, and galangin were found to induce a Type I spectral change only with @GENE$.	0
In addition, benzo[c]phenanthrene, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and @CHEMICAL$ were found to induce a Type I spectral change only with @GENE$.	0
In addition, @CHEMICAL$, fluoranthene, 2,3-dihydroxy-2,3-dihydrofluoranthene, pyrene, 1-hydroxypyrene, 1-nitropyrene, 1-acetylpyrene, 2-acetylpyrene, 2,5,2',5'-tetrachlorobiphenyl, 7-hydroxyflavone, chrysin, and galangin were found to induce a Type I spectral change only with @GENE$.	0
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, @CHEMICAL$, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
@CHEMICAL$ 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	5
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by @CHEMICAL$, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, @CHEMICAL$, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, @CHEMICAL$, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, @CHEMICAL$, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, @CHEMICAL$, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, @CHEMICAL$, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, @CHEMICAL$, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, @CHEMICAL$, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, @CHEMICAL$, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, @CHEMICAL$, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, @CHEMICAL$, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.	2
Coumarin 7-hydroxylation, catalyzed by @GENE$, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and @CHEMICAL$; these chemicals induced Type I spectral changes with low Ks values.	2
Full agonists to the @GENE$, such as @CHEMICAL$, have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.	3
Nevertheless, @GENE$ is involved in the expression of genes that control @CHEMICAL$ and lipid metabolism and is an important target for drugs against type 2 diabetes, dyslipidemia, atherosclerosis, and cardiovascular disease.	0
The @GENE$ of the @CHEMICAL$(1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures.	0
The EL of the @CHEM-GENE$ receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures.	0
This study involved development of a peptide to characterize the intrinsic structure of the @CHEM-GENE$ GPCR second EL.	0
This study involved development of a peptide to characterize the intrinsic structure of the @CHEMICAL$(1) @GENE$ second EL.	0
This study involved development of a peptide to characterize the intrinsic structure of the @CHEMICAL$(1) GPCR second @GENE$.	0
The loop was embedded between two helices that assemble into a @GENE$, which served as a receptor-mimetic folding constraint (@CHEMICAL$(1)-CC-EL2 peptide).	0
The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint (@CHEM-GENE$-CC-EL2 peptide).	0
The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint (@CHEMICAL$(1)-CC-@GENE$ peptide).	0
In contrast, the @GENE$ sequence showed well-defined structure only near its @CHEMICAL$-terminal residues.	0
The NMR ensemble was combined with a computational model of the @CHEM-GENE$ receptor that had previously been validated.	0
The @CHEMICAL$ hydroxylation index reflects @GENE$ activity in healthy Japanese volunteers.	5
PURPOSE: @CHEMICAL$ has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with @GENE$ genotype groups.	5
The aim of this study was to investigate whether the 1-point, 4-h postdose @CHEMICAL$ hydroxylation index (HI) of racemic omeprazole reflects the three @GENE$ genotype groups in Japanese individuals.	0
The aim of this study was to investigate whether the 1-point, 4-h postdose (R)-omeprazole hydroxylation index (HI) of @CHEMICAL$ reflects the three @GENE$ genotype groups in Japanese individuals.	0
Additionally, there was a significant difference in plasma concentrations of @CHEMICAL$ among @GENE$ genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.	5
Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among @GENE$ genotype groups, whereas no significant differences were observed in that of @CHEMICAL$.	5
CONCLUSION: Our findings demonstrate that @CHEMICAL$ HI correlated better with @GENE$ genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.	5
CONCLUSION: Our findings demonstrate that @CHEMICAL$ HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in @GENE$ genotype groups prior to omeprazole treatment.	0
CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with @GENE$ genotype groups than @CHEMICAL$ HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.	5
CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than @CHEMICAL$ HI, and these results may be useful for classification among patients in @GENE$ genotype groups prior to omeprazole treatment.	0
Induction of @GENE$, transporters, and drug metabolizing enzymes by @CHEMICAL$.	0
Many transporters and DMEs are regulated by @GENE$ [XRs; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [@GENE$; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., @GENE$ (PXR), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (@GENE$), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), @CHEM-GENE$ (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (@GENE$), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (CAR), and @GENE$ (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (@GENE$)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive @CHEMICAL$ receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on @GENE$.	0
Many transporters and DMEs are regulated by @GENE$ [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [@GENE$; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., @GENE$ (PXR), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (@GENE$), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), @GENE$ (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (@GENE$), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and @CHEM-GENE$ (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (@GENE$)]; however, there is a paucity of information regarding the influence of opioids on XRs.	0
Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and @CHEMICAL$ receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on @GENE$.	0
The objective of this study was to determine the influence of @CHEMICAL$ administration (15 mg/kg intraperitoneally twice daily for 8 days) on liver expression of @GENE$, transporters, and DMEs in rats.	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of @GENE$, CAR, or AhR by @CHEMICAL$ or its major metabolites (noroxycodone and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, @GENE$, or AhR by @CHEMICAL$ or its major metabolites (noroxycodone and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or @GENE$ by @CHEMICAL$ or its major metabolites (noroxycodone and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of @GENE$, CAR, or AhR by oxycodone or its major metabolites (@CHEMICAL$ and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, @GENE$, or AhR by oxycodone or its major metabolites (@CHEMICAL$ and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or @GENE$ by oxycodone or its major metabolites (@CHEMICAL$ and oxymorphone).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of @GENE$, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and @CHEMICAL$).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, @GENE$, or AhR by oxycodone or its major metabolites (noroxycodone and @CHEMICAL$).	0
Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or @GENE$ by oxycodone or its major metabolites (noroxycodone and @CHEMICAL$).	0
Neither @CHEMICAL$ nor its metabolites activated @GENE$, CAR, or AhR.	0
Neither @CHEMICAL$ nor its metabolites activated PXR, @GENE$, or AhR.	0
Neither @CHEMICAL$ nor its metabolites activated PXR, CAR, or @GENE$.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated @CHEMICAL$ administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of @GENE$, CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated @CHEMICAL$ administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, @GENE$, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated @CHEMICAL$ administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and @GENE$), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that @CHEMICAL$ alters the expression of many transporters and DMEs (without direct activation of @GENE$, CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that @CHEMICAL$ alters the expression of many transporters and DMEs (without direct activation of PXR, @GENE$, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that @CHEMICAL$ alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and @GENE$), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of @GENE$, CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with @CHEMICAL$.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, @GENE$, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with @CHEMICAL$.	0
Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and @GENE$), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with @CHEMICAL$.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including @GENE$ (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (@GENE$), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @GENE$ (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (@GENE$), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @GENE$ (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (@GENE$), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @GENE$ (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (@GENE$), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-@CHEMICAL$ metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (@GENE$), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEM-GENE$ (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (@GENE$), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), @GENE$ (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (@GENE$), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @GENE$ (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (@GENE$), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @GENE$ (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (@GENE$), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @CHEMICAL$ adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (@GENE$), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @GENE$ (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (@GENE$), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEM-GENE$ (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (@GENE$), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), @GENE$ (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (@GENE$), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @GENE$ (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (@GENE$), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @CHEMICAL$-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (@GENE$), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @GENE$ (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (@GENE$), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @GENE$ (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (@GENE$), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEM-GENE$ (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (@GENE$), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), @GENE$ (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (@GENE$), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @CHEMICAL$ reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (@GENE$), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @GENE$ (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (@GENE$), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @GENE$ (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (@GENE$), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @GENE$ (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (@GENE$), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEM-GENE$ (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (@GENE$), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and @GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @CHEMICAL$-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (@GENE$), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including @GENE$ (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (@GENE$), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), @GENE$ (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (@GENE$), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), @GENE$ (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (@GENE$), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), @GENE$ (Ahcy), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (@GENE$), and @CHEMICAL$ dehydrogenase 1 (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEM-GENE$ (Mthfd1), was observed.	0
Strain-dependent down-regulation of several key one-carbon metabolism genes, including methionine adenosyltransferase 1α (Mat1a), cystathionine-β-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-homocysteinase (Ahcy), and @CHEMICAL$ dehydrogenase 1 (@GENE$), was observed.	0
The pleiotropic effects of @CHEMICAL$ are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of @GENE$ (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of @CHEMICAL$ are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (@GENE$, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of @CHEMICAL$ are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, @GENE$ and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of @CHEMICAL$ are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and @GENE$), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of @CHEMICAL$ are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), @GENE$ and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, @CHEMICAL$ (atRA), which regulates the expression of a battery of target genes through several families of @GENE$ (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, @CHEMICAL$ (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (@GENE$, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, @CHEMICAL$ (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, @GENE$ and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, @CHEMICAL$ (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and @GENE$), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, @CHEMICAL$ (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), @GENE$ and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (@CHEMICAL$), which regulates the expression of a battery of target genes through several families of @GENE$ (RARs, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (@CHEMICAL$), which regulates the expression of a battery of target genes through several families of nuclear receptors (@GENE$, RXRs and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (@CHEMICAL$), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, @GENE$ and PPARβ/δ), polymorphic retinoic acid (RA) response elements and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (@CHEMICAL$), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and @GENE$), polymorphic retinoic acid (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (@CHEMICAL$), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), @GENE$ and multiple coregulators.	1
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of @GENE$ (RARs, RXRs and PPARβ/δ), polymorphic @CHEMICAL$ (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (@GENE$, RXRs and PPARβ/δ), polymorphic @CHEMICAL$ (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, @GENE$ and PPARβ/δ), polymorphic @CHEMICAL$ (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and @GENE$), polymorphic @CHEMICAL$ (RA) response elements and multiple coregulators.	0
The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARβ/δ), @CHEM-GENE$ and multiple coregulators.	0
However, @CHEMICAL$ itself proved recently to be active and @GENE$ to be present in the cytosol to regulate translation and cell plasticity.	0
Interestingly, @GENE$ expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	1
Interestingly, miR-21 expression positively correlated with urine @GENE$ @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), @GENE$, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, @GENE$ (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (@GENE$), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (ColIV), and @GENE$ (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (@GENE$); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin @CHEMICAL$ ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and @GENE$ protein.	0
Interestingly, @GENE$ expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	2
Interestingly, miR-21 expression positively correlated with urine @GENE$ creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), @GENE$, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, @GENE$ (ColIV), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (@GENE$), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and @GENE$ (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (@GENE$); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and MMP-9 protein.	0
Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with @CHEMICAL$ clearance ratio (Ccr) and @GENE$ protein.	0
Modification of the Catalytic Function of @GENE$ by Formation of @CHEMICAL$ Bonds.	0
Modification of the Catalytic Function of @CHEM-GENE$ by Formation of Disulfide Bonds.	0
The @GENE$ catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous @CHEMICAL$ and bile acids.	5
The @GENE$ catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and @CHEMICAL$.	5
We have examined the hypothesis that the formation of @CHEMICAL$ bonds in @GENE$ can reversibly regulate the catalytic function of the enzyme.	0
Three @CHEMICAL$ oxidants were used as model compounds to investigate their effects on homogeneous preparations of @GENE$: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide).	0
Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of @GENE$: @CHEMICAL$, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (diamide).	0
Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of @GENE$: glutathione disulfide, @CHEMICAL$, and 1,1'-azobis(N,N-dimethylformamide) (diamide).	0
Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of @GENE$: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and @CHEMICAL$) (diamide).	0
Three thiol oxidants were used as model compounds to investigate their effects on homogeneous preparations of @GENE$: glutathione disulfide, 5,5'-dithiobis(2-nitrobenzoic acid), and 1,1'-azobis(N,N-dimethylformamide) (@CHEMICAL$).	0
Studies on the kinetics of the @GENE$-catalyzed sulfation of @CHEMICAL$ (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.	5
Studies on the kinetics of the @GENE$-catalyzed sulfation of dehydroepiandrosterone (@CHEMICAL$) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.	5
Studies on the kinetics of the @GENE$-catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of @CHEMICAL$ bond formation on the substrate inhibition characteristics of the enzyme.	0
Thus, the formation of @CHEMICAL$ bonds in @GENE$ is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates.	0
Synthesis of novel @CHEM-GENE$ antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.	0
@CHEMICAL$ receptor (ER) antagonists are valuable in the treatment of @GENE$-positive human breast cancer.	0
@CHEM-GENE$ (ER) antagonists are valuable in the treatment of ER-positive human breast cancer.	0
@CHEMICAL$ receptor (@GENE$) antagonists are valuable in the treatment of ER-positive human breast cancer.	0
In this study, we designed and synthesized nine new derivatives of @CHEMICAL$ (E2) with a bulky side chain attached to its C-7α position, and determined their @GENE$ antagonistic activity using in vitro bioassays.	0
Computational docking analysis was conducted to model the interaction of these antagonists with the @GENE$ and showed that they could tightly bind to the ERα in a manner similar to that of @CHEMICAL$, a pure ER antagonist.	0
Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the @GENE$ in a manner similar to that of @CHEMICAL$, a pure ER antagonist.	0
Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of @CHEMICAL$, a pure @GENE$ antagonist.	4
These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce @GENE$ antagonists with ER affinity comparable to that of @CHEMICAL$.	0
These results provide an example that attachment of a bulky side chain to the C-7α position of E2 can produce ER antagonists with @GENE$ affinity comparable to that of @CHEMICAL$.	4
Discovery of @CHEMICAL$ (TASP0382088): a potent and selective @GENE$ inhibitor as a topical drug for alopecia.	2
Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (@CHEMICAL$): a potent and selective @GENE$ inhibitor as a topical drug for alopecia.	2
@CHEMICAL$ 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as @GENE$ or ALK5) inhibitor.	2
@CHEMICAL$ 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or @GENE$) inhibitor.	2
@CHEMICAL$ 11 (TASP0382088) was synthesized and evaluated as @GENE$ (also known as activin receptor-like kinase 5 or ALK5) inhibitor.	2
7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (@CHEMICAL$) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as @GENE$ or ALK5) inhibitor.	2
7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (@CHEMICAL$) was synthesized and evaluated as transforming growth factor-β (TGF-β) type I receptor (also known as activin receptor-like kinase 5 or @GENE$) inhibitor.	2
7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (@CHEMICAL$) was synthesized and evaluated as @GENE$ (also known as activin receptor-like kinase 5 or ALK5) inhibitor.	2
ARF represses @CHEM-GENE$ transactivation in prostate cancer.	0
@CHEM-GENE$ (AR) signaling is essential for prostate cancer (PCa) development in humans.	0
@CHEMICAL$ receptor (@GENE$) signaling is essential for prostate cancer (PCa) development in humans.	0
Here, we provide evidence that @GENE$ physically interacts with AR and functions as an AR corespressor in both an @CHEMICAL$-dependent and androgen-independent manner.	0
Here, we provide evidence that p14ARF physically interacts with @GENE$ and functions as an AR corespressor in both an @CHEMICAL$-dependent and androgen-independent manner.	0
Here, we provide evidence that p14ARF physically interacts with AR and functions as an @GENE$ corespressor in both an @CHEMICAL$-dependent and androgen-independent manner.	0
Here, we provide evidence that @GENE$ physically interacts with AR and functions as an AR corespressor in both an androgen-dependent and @CHEMICAL$-independent manner.	0
Here, we provide evidence that p14ARF physically interacts with @GENE$ and functions as an AR corespressor in both an androgen-dependent and @CHEMICAL$-independent manner.	0
Here, we provide evidence that p14ARF physically interacts with AR and functions as an @GENE$ corespressor in both an androgen-dependent and @CHEMICAL$-independent manner.	0
Overexpression of @GENE$ in PCa cells significantly attenuates the activities of @CHEMICAL$ response region (ARR2)-probasin and prostate-specific antigen (PSA) promoters.	0
Overexpression of p14ARF in PCa cells significantly attenuates the activities of @CHEM-GENE$ (ARR2)-probasin and prostate-specific antigen (PSA) promoters.	0
Overexpression of p14ARF in PCa cells significantly attenuates the activities of @CHEMICAL$ response region (@GENE$)-probasin and prostate-specific antigen (PSA) promoters.	0
Overexpression of p14ARF in PCa cells significantly attenuates the activities of @CHEMICAL$ response region (ARR2)-@GENE$.	0
Furthermore, we demonstrated that @GENE$ binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins.	0
Furthermore, we demonstrated that p14ARF binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of @GENE$, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins.	0
Furthermore, we demonstrated that p14ARF binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of AR, and the @GENE$ of p14ARF is required for the interaction of p14ARF and AR proteins.	0
Furthermore, we demonstrated that p14ARF binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of @GENE$ is required for the interaction of p14ARF and AR proteins.	0
Furthermore, we demonstrated that p14ARF binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of @GENE$ and AR proteins.	0
Furthermore, we demonstrated that p14ARF binds to both the @CHEMICAL$-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and @GENE$ proteins.	0
@GENE$ perturbs the @CHEMICAL$-induced interaction between the N terminus and C terminus of AR.	0
p14ARF perturbs the @CHEMICAL$-induced interaction between the N terminus and C terminus of @GENE$.	0
@GENE$ perturbs the androgen-induced interaction between the @CHEMICAL$ terminus and C terminus of AR.	0
p14ARF perturbs the androgen-induced interaction between the @CHEMICAL$ terminus and C terminus of @GENE$.	0
@GENE$ perturbs the androgen-induced interaction between the N terminus and @CHEMICAL$ terminus of AR.	0
p14ARF perturbs the androgen-induced interaction between the N terminus and @CHEMICAL$ terminus of @GENE$.	0
Relative expression of c@GENE$ and inflammation markers through the induction of @CHEMICAL$-mediated stress in Caco-2 cells.	0
Relative expression of @CHEM-GENE$ and inflammation markers through the induction of 7-ketosterol-mediated stress in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (@GENE$, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, @GENE$, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, @GENE$, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, @GENE$) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (@GENE$, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, @GENE$, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, @GENE$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to @CHEMICAL$ absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, @GENE$) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (@GENE$, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, @GENE$, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, @GENE$, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, @GENE$) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (@GENE$, ABCG5/8, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, @GENE$, @CHEMICAL$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEM-GENE$, ACAT) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @CHEMICAL$, @GENE$) produced by 7-ketosterols (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (@GENE$, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, @GENE$, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, @GENE$, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, @GENE$) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (@GENE$, ABCG5/8, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, @GENE$, HMGCoA, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @GENE$, ACAT) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, @GENE$) produced by @CHEMICAL$ (stigmasterol/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (@GENE$, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, @GENE$, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, @GENE$, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, @GENE$) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (@GENE$, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, @GENE$, HMGCoA, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @GENE$, ACAT) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, @GENE$) produced by 7-ketosterols (@CHEMICAL$/cholesterol) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (@GENE$, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, @GENE$, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, @GENE$, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, @GENE$) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (@GENE$, ABCG5/8, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, @GENE$, HMGCoA, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, @GENE$, ACAT) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
This study evaluates the production of inflammatory biomarkers (IL-1β, IL-8, IL-10, TNFα) and the influence of gene expression transporters and enzymes related to cholesterol absorption and metabolism (NPC1L1, ABCG5/8, HMGCoA, @GENE$) produced by 7-ketosterols (stigmasterol/@CHEMICAL$) in Caco-2 cells.	0
In non-pre-treated cells, only @GENE$ were down-regulated by @CHEMICAL$, showing a greater influence upon ABCG5 expression.	2
In non-pre-treated cells, only efflux transporters were down-regulated by @CHEMICAL$, showing a greater influence upon @GENE$ expression.	0
Cell-pre-incubation with @CHEM-GENE$ induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.	0
Cell-pre-incubation with @CHEMICAL$ induced changes in @GENE$ expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.	0
Cell-pre-incubation with @CHEMICAL$ induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced @GENE$ expression only in 7-ketocholesterol-incubated cells.	0
Cell-pre-incubation with @GENE$ induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in @CHEMICAL$-incubated cells.	0
Cell-pre-incubation with bradykinin induced changes in @GENE$ expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in @CHEMICAL$-incubated cells.	0
Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced @GENE$ expression only in @CHEMICAL$-incubated cells.	2
Cell-pre-incubation with @GENE$ induced changes in ABCG expression levels after @CHEMICAL$-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.	0
Cell-pre-incubation with bradykinin induced changes in @GENE$ expression levels after @CHEMICAL$-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol-incubated cells.	0
Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after @CHEMICAL$-incubation; however, the energetic metabolism inhibition reduced @GENE$ expression only in 7-ketocholesterol-incubated cells.	0
In non-pre-treated cells, @CHEM-GENE$ was up-regulated by both 7-ketosterols.	0
In non-pre-treated cells, @GENE$ was up-regulated by both @CHEMICAL$.	1
These results suggest that internalization and excretion of @CHEMICAL$ is probably influenced by [Ca]i, which also could mediate @GENE$ activity in POPs metabolism.	0
These results suggest that internalization and excretion of 7-ketostigmasterol is probably influenced by [@CHEMICAL$]i, which also could mediate @GENE$ activity in POPs metabolism.	0
These results suggest that internalization and excretion of 7-ketostigmasterol is probably influenced by [Ca]i, which also could mediate @CHEM-GENE$ activity in POPs metabolism.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@CHEMICAL$ diphosphohydrolase), @GENE$, 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@CHEMICAL$ diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), @GENE$ and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@CHEMICAL$ diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @GENE$ (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@CHEMICAL$ diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (@GENE$) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as @GENE$ (@CHEMICAL$ diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@CHEM-GENE$), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), @CHEM-GENE$, 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (@CHEMICAL$ pyrophosphatase/phosphodiesterase), @GENE$ and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (@CHEMICAL$ pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @GENE$ (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (@CHEMICAL$ pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (@GENE$) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as @GENE$ (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (@CHEMICAL$ pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@GENE$), Ecto-NPP (@CHEMICAL$ pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), @GENE$, 5'-nucleotidase and @CHEMICAL$ deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), @GENE$ and @CHEMICAL$ deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @CHEM-GENE$ (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @CHEMICAL$ deaminase (@GENE$) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as @GENE$ (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @CHEMICAL$ deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (@GENE$), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @CHEMICAL$ deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), @GENE$, 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), @GENE$ and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and @GENE$ (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (@GENE$) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as @GENE$ (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
This study evaluated the effects of @CHEMICAL$ on ectonucleotidase activities such as NTPDase (@GENE$), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.	0
In lymphocytes, the NTPDase and @GENE$ activities were increased in all groups treated with @CHEMICAL$ when compared to control (P<0.05).	1
In lymphocytes, the @GENE$ and ADA activities were increased in all groups treated with @CHEMICAL$ when compared to control (P<0.05).	1
We demonstrate that activation of @GENE$ @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by @GENE$(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by B-RAF(@GENE$) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the @GENE$ is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a @GENE$ consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 @CHEMICAL$-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for @GENE$-mediated activation.	0
We demonstrate that activation of @GENE$ serine-727 and @CHEMICAL$-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 serine-727 and @CHEMICAL$-705 phosphorylations is promoted by @GENE$(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 serine-727 and @CHEMICAL$-705 phosphorylations is promoted by B-RAF(@GENE$) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 serine-727 and @CHEMICAL$-705 phosphorylations is promoted by B-RAF(V600E) activity and that the @GENE$ is dependent on a STAT consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 serine-727 and @CHEMICAL$-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a @GENE$ consensus-site for B-RAF-mediated activation.	0
We demonstrate that activation of STAT3 serine-727 and @CHEMICAL$-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for @GENE$-mediated activation.	0
@CHEM-GENE$ importance in vivo in xenobiotic metabolism: imidacloprid nitroreduction in mice.	0
@GENE$ importance in vivo in xenobiotic metabolism: @CHEMICAL$ nitroreduction in mice.	0
@CHEM-GENE$ (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems.	0
@CHEMICAL$ oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to @GENE$ (CYPs) and other detoxification systems.	0
@CHEMICAL$ oxidase (AOX) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (@GENE$) and other detoxification systems.	0
@CHEMICAL$ oxidase (@GENE$) metabolizes many xenobiotics in vitro, but its importance in vivo is usually unknown relative to cytochrome P450s (CYPs) and other detoxification systems.	0
Currently, the most important insecticides are @CHEMICAL$, which are metabolized in vitro by @GENE$ on reduction of the nitroimino group and by CYPs via oxidation reactions.	5
Currently, the most important insecticides are @CHEMICAL$, which are metabolized in vitro by AOX on reduction of the nitroimino group and by @GENE$ via oxidation reactions.	5
Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by @GENE$ on reduction of the @CHEMICAL$ group and by CYPs via oxidation reactions.	5
Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the @CHEMICAL$ group and by @GENE$ via oxidation reactions.	0
The procedure was to reduce liver @GENE$ activity by providing @CHEMICAL$ or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.	2
The procedure was to reduce liver AOX activity by providing @CHEMICAL$ or hydralazine in the drinking water or to use the @GENE$-deficient DBA/2 mouse strain.	0
The procedure was to reduce liver @GENE$ activity by providing tungsten or @CHEMICAL$ in the drinking water or to use the AOX-deficient DBA/2 mouse strain.	2
The procedure was to reduce liver AOX activity by providing tungsten or @CHEMICAL$ in the drinking water or to use the @GENE$-deficient DBA/2 mouse strain.	0
Liver @GENE$ activity was reduced by 45% with @CHEMICAL$ and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.	2
Liver AOX activity was reduced by 45% with @CHEMICAL$ and 61% with hydralazine and 81% in @GENE$-deficient mice relative to controls.	0
Liver @GENE$ activity was reduced by 45% with tungsten and 61% with @CHEMICAL$ and 81% in AOX-deficient mice relative to controls.	2
Liver AOX activity was reduced by 45% with tungsten and 61% with @CHEMICAL$ and 81% in @GENE$-deficient mice relative to controls.	0
When mice were treated ip with the major neonicotinoid @CHEMICAL$ (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the @GENE$-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid @CHEMICAL$ (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the @GENE$-deficient mice.	0
When mice were treated ip with the major neonicotinoid @CHEMICAL$ (IMI), metabolism by @GENE$ oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (@CHEMICAL$), metabolism by CYP oxidation reactions was not appreciably affected, whereas the @GENE$-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (@CHEMICAL$), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the @GENE$-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (@CHEMICAL$), metabolism by @GENE$ oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the @GENE$-generated @CHEMICAL$ metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	5
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated @CHEMICAL$ metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the @GENE$-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by @GENE$ oxidation reactions was not appreciably affected, whereas the AOX-generated @CHEMICAL$ metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the @GENE$-generated nitrosoguanidine metabolite was decreased by 30% with @CHEMICAL$ and 56% with hydralazine and 86% in the AOX-deficient mice.	2
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with @CHEMICAL$ and 56% with hydralazine and 86% in the @GENE$-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by @GENE$ oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with @CHEMICAL$ and 56% with hydralazine and 86% in the AOX-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the @GENE$-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with @CHEMICAL$ and 86% in the AOX-deficient mice.	2
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with @CHEMICAL$ and 86% in the @GENE$-deficient mice.	0
When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by @GENE$ oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with @CHEMICAL$ and 86% in the AOX-deficient mice.	0
The other @CHEMICAL$ nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the @GENE$-deficient mice, respectively.	0
The other IMI nitroreduction metabolite, desnitro-@CHEMICAL$, was decreased by 55%, 65%, and 81% with tungsten, hydralazine, and in the @GENE$-deficient mice, respectively.	0
The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with @CHEMICAL$, hydralazine, and in the @GENE$-deficient mice, respectively.	0
The other IMI nitroreduction metabolite, desnitro-IMI, was decreased by 55%, 65%, and 81% with tungsten, @CHEMICAL$, and in the @GENE$-deficient mice, respectively.	0
Thus, decreasing liver @GENE$ activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of @CHEMICAL$-treated mice.	5
Possible @GENE$ involvement in @CHEMICAL$ metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.	5
Possible AOX involvement in @CHEMICAL$ metabolism in insects was evaluated using @GENE$-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.	5
Possible AOX involvement in @CHEMICAL$ metabolism in insects was evaluated using AOX-expressing and @GENE$-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.	0
Possible @GENE$ involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in @CHEMICAL$ nitroreduction or sensitivity between the two strains.	0
Possible AOX involvement in IMI metabolism in insects was evaluated using @GENE$-expressing and AOX-deficient Drosophila, but no differences were found in @CHEMICAL$ nitroreduction or sensitivity between the two strains.	0
Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and @GENE$-deficient Drosophila, but no differences were found in @CHEMICAL$ nitroreduction or sensitivity between the two strains.	0
This is the first study to establish the in vivo relevance of @GENE$ in @CHEMICAL$ metabolism in mammals and one of the first for xenobiotics in general.	5
Of the compounds active in the present assay system, the most potent compound 7, @CHEMICAL$, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and @GENE$ (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.	2
Of the compounds active in the present assay system, the most potent compound 7, @CHEMICAL$, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (@GENE$) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.	2
Of the compounds active in the present assay system, the most potent compound 7, @CHEMICAL$, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a @GENE$ agonist.	0
Of the compounds active in the present assay system, the most potent compound 7, @CHEMICAL$, significantly suppressed the induction of @GENE$ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.	2
Of the compounds active in the present assay system, the most potent compound 7, @CHEMICAL$, significantly suppressed the induction of peroxisome proliferator activated receptor γ (@GENE$ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPARγ agonist.	2
Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and @GENE$ (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by @CHEMICAL$, a PPARγ agonist.	0
Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (@GENE$) protein expression, and inhibited adipocyte differentiation induced by @CHEMICAL$, a PPARγ agonist.	0
Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by @CHEMICAL$, a @GENE$ agonist.	3
Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of @GENE$ (PPARγ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by @CHEMICAL$, a PPARγ agonist.	0
Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-β-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor γ (@GENE$ and CCAAT/enhancer binding protein α (C/EBPα) protein expression, and inhibited adipocyte differentiation induced by @CHEMICAL$, a PPARγ agonist.	0
@CHEMICAL$: a unique class of @GENE$ inhibitors.	2
Based on our previously published work on @GENE$ antagonists, we have synthesized a series of @CHEMICAL$ that inhibit the CXCR4/CXCL12 interaction.	0
Based on our previously published work on CXCR4 antagonists, we have synthesized a series of @CHEMICAL$ that inhibit the @GENE$/CXCL12 interaction.	2
Based on our previously published work on CXCR4 antagonists, we have synthesized a series of @CHEMICAL$ that inhibit the CXCR4/@GENE$ interaction.	2
These data demonstrate that @CHEMICAL$ are a unique class of @GENE$ inhibitors with high potency.	2
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of @CHEMICAL$-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of @CHEMICAL$-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of @CHEMICAL$-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of @CHEMICAL$-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of @CHEMICAL$-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of @CHEMICAL$ and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of @CHEMICAL$ and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of @CHEMICAL$ and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of @CHEMICAL$ and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of @CHEMICAL$ and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and @CHEMICAL$ in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and @CHEMICAL$ in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and @CHEMICAL$ in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and @CHEMICAL$ in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and @CHEMICAL$ in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of @CHEMICAL$ biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of @CHEMICAL$ biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of @CHEMICAL$ biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of @CHEMICAL$ biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of @CHEMICAL$ biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, @CHEMICAL$ synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @CHEM-GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @CHEMICAL$ synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @CHEMICAL$ synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @CHEMICAL$ synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and @CHEMICAL$ synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and @CHEMICAL$ synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @CHEM-GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @CHEMICAL$ synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @CHEMICAL$ synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of @CHEMICAL$ biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of @CHEMICAL$ biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of @CHEMICAL$ biosynthetic enzymes, carbamoylphosphate synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of @CHEMICAL$ biosynthetic enzymes, @GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of @CHEMICAL$ biosynthetic enzymes, carbamoylphosphate synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @CHEMICAL$ synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @CHEMICAL$ synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @CHEMICAL$ synthase II and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @CHEM-GENE$ and CTP synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @CHEMICAL$ synthase II and @GENE$.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, @GENE$, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @CHEMICAL$ synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, @GENE$, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @CHEMICAL$ synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and @GENE$, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @CHEMICAL$ synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, @GENE$ and @CHEMICAL$ synthase.	0
At 6 h after injection of the compound (400 mg/kg) into rats bearing hepatoma 3924A, the pools of L-glutamine and L-glutamate in the tumor decreased to 33% and 71%, respectively, of control levels; the drug selectively inhibited the activities of L-glutamine-requiring enzymes of purine nucleotide biosynthesis, amidophosphoribosyltransferase, FGAM synthase, and GMP synthase, to 21%, 1%, and 69%, respectively, without significantly altering the activities of pyrimidine biosynthetic enzymes, carbamoylphosphate synthase II and @CHEM-GENE$.	0
Measurement of Transport Activities of @CHEMICAL$ in @GENE$ and Multidrug Resistance-Associated Proteins Using LC-MS/MS.	5
Measurement of Transport Activities of @CHEMICAL$ in Bile Salt Export Pump and @GENE$ Using LC-MS/MS.	5
Measurement of Transport Activities of 3β-Hydroxy-Δ(5)-bile Acids in @CHEM-GENE$ and Multidrug Resistance-Associated Proteins Using LC-MS/MS.	0
Measurement of Transport Activities of 3β-Hydroxy-Δ(5)-bile Acids in @CHEMICAL$ Export Pump and @GENE$ Using LC-MS/MS.	0
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from @GENE$-, and human @CHEMICAL$ export pump-expressing Sf9 cells for conjugated 3β-hydroxy-Δ(5)-bile acids.	0
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and @CHEM-GENE$-expressing Sf9 cells for conjugated 3β-hydroxy-Δ(5)-bile acids.	0
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from @GENE$-, and human bile salt export pump-expressing Sf9 cells for conjugated @CHEMICAL$.	0
The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and @GENE$-expressing Sf9 cells for conjugated @CHEMICAL$.	5
The present study demonstrated that @GENE$ vesicles accepted conjugated @CHEMICAL$ along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.	5
The present study demonstrated that @GENE$ vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common @CHEMICAL$ such as glycocholic acid and taurolithocholic acid 3-sulfate.	5
The present study demonstrated that @GENE$ vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as @CHEMICAL$ and taurolithocholic acid 3-sulfate.	5
The present study demonstrated that @GENE$ vesicles accepted conjugated 3β-hydroxy-Δ(5)-bile acids along with common bile acids such as glycocholic acid and @CHEMICAL$.	5
Here, we report that a specific 29-@CHEMICAL$ peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of @GENE$ to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling.	0
Here, we report that a specific 29-@CHEMICAL$ peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to @GENE$-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling.	0
Here, we report that a specific 29-@CHEMICAL$ peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced @GENE$ and Akt signaling.	0
Here, we report that a specific 29-@CHEMICAL$ peptide derived from the intracellular domain fragment of p75(NTR) interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and @GENE$ signaling.	0
Here, we report that a specific 29-@CHEMICAL$ peptide derived from the intracellular domain fragment of @GENE$ interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling.	0
An endogenous intracellular domain fragment of @GENE$ (p75(ICD)) containing these 29 @CHEMICAL$ is produced by regulated proteolysis of the full-length receptor.	0
An endogenous intracellular domain fragment of p75(NTR) (@GENE$) containing these 29 @CHEMICAL$ is produced by regulated proteolysis of the full-length receptor.	0
Synthesis and evaluation of @CHEMICAL$ as @GENE$ inhibitory anticancer agents.	2
A series of substituted @CHEMICAL$ has been synthesised and tested in vitro as potential pro-apoptotic @GENE$-inhibitory anticancer agents.	2
Active compounds, such as the @CHEMICAL$ analogue 6c, were found to exhibit sub-micromolar IC50 values in @GENE$ expressing human cancer cell lines.	2
@CHEM-GENE$, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.	0
@GENE$, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to @CHEMICAL$.	0
@CHEM-GENE$, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.	0
@GENE$, a phase II enzyme, was inhibited by both @CHEMICAL$ and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.	2
@GENE$, a phase II enzyme, was inhibited by both arsenic and @CHEMICAL$ but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.	2
@GENE$, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in @CHEMICAL$-treated animals pre-exposed to nicotine.	0
Upon @CHEMICAL$ pre-exposure, brain @GENE$ increased, while monoamine oxidase (MAO) decreased.	1
Upon @CHEMICAL$ pre-exposure, brain acetylcholinesterase increased, while @GENE$ (MAO) decreased.	2
Upon @CHEMICAL$ pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (@GENE$) decreased.	2
The toxic effects of @GENE$ significantly attenuated with @CHEMICAL$ pre-exposure.	2
We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the @GENE$ inhibitor, @CHEMICAL$ (FAD).	2
We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the @GENE$ inhibitor, fadrozole (@CHEMICAL$).	2
For model development, we used plasma @CHEMICAL$ (E2) concentrations and ovarian @GENE$ mRNA data from two time-course experiments, each of which included both an exposure and a depuration phase, and plasma E2 data from a third 4-day study.	0
The model accurately predicted @GENE$ mRNA fold changes for controls and three @CHEMICAL$ doses (0, 0.5, and 3 µg/l) and plasma E2 dose response from the 4-day study.	0
@CHEMICAL$ Reveals a Cysteine-Dependent Desensitization Mechanism of @GENE$.	0
Benzoquinone Reveals a @CHEMICAL$-Dependent Desensitization Mechanism of @GENE$.	0
Electrophilic chemicals activate both insect and vertebrate @GENE$ via covalent modification of @CHEMICAL$ residues in the amino-terminal region.	0
Electrophilic chemicals activate both insect and vertebrate @GENE$ via covalent modification of cysteine residues in the @CHEMICAL$-terminal region.	0
Although naturally occurring electrophilic plant compounds, such as mustard oil and @CHEMICAL$, are @GENE$ agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.	3
Although naturally occurring electrophilic plant compounds, such as mustard oil and @CHEMICAL$, are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate @GENE$.	0
We characterized the effects of the electrophilic arthropod defensive compound @CHEMICAL$ (pBQN) on the @GENE$ channel.	0
We characterized the effects of the electrophilic arthropod defensive compound para-benzoquinone (@CHEMICAL$) on the @GENE$ channel.	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type @GENE$ or TRPA1 with three @CHEMICAL$-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or @GENE$ with three @CHEMICAL$-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three @CHEMICAL$-substituted cysteines crucial for electrophile activation (@GENE$, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three @CHEMICAL$-substituted cysteines crucial for electrophile activation (C621S, @GENE$, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three @CHEMICAL$-substituted cysteines crucial for electrophile activation (C621S, C641S, @GENE$).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type @GENE$ or TRPA1 with three serine-substituted @CHEMICAL$ crucial for electrophile activation (C621S, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or @GENE$ with three serine-substituted @CHEMICAL$ crucial for electrophile activation (C621S, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted @CHEMICAL$ crucial for electrophile activation (@GENE$, C641S, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted @CHEMICAL$ crucial for electrophile activation (C621S, @GENE$, C665S).	0
We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted @CHEMICAL$ crucial for electrophile activation (C621S, C641S, @GENE$).	0
We found that @CHEMICAL$ activates @GENE$ starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.	1
The current reduction we found at higher @CHEMICAL$ concentrations was a cysteine-dependent desensitization of @GENE$, and did not require prior activation.	0
Interestingly, following @CHEMICAL$ desensitization, wild-type @GENE$ had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant TRPA1 retained its full response.	0
Interestingly, following @CHEMICAL$ desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant @GENE$ retained its full response.	0
Interestingly, following pBQN desensitization, wild-type @GENE$ had dramatically reduced response to the nonelectrophile agonist @CHEMICAL$, whereas the triple cysteine mutant TRPA1 retained its full response.	3
Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist @CHEMICAL$, whereas the triple cysteine mutant @GENE$ retained its full response.	3
Interestingly, following pBQN desensitization, wild-type @GENE$ had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple @CHEMICAL$ mutant TRPA1 retained its full response.	0
Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple @CHEMICAL$ mutant @GENE$ retained its full response.	0
Our results suggest that modification of multiple @CHEMICAL$ residues by electrophilic compounds can generate both activation and desensitization of the @GENE$ channel.	0
Synthesis and in-silico studies of some @CHEMICAL$ derivatives as potential @GENE$ inhibitors.	2
Multilevel regulation of @CHEM-GENE$ reaction cycle by s-nitrosylation.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of @GENE$ (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (@GENE$), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the @GENE$, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of @GENE$ (Trx)-dependent peroxidases.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (@GENE$)-dependent peroxidases.	0
In this study we investigated how @CHEMICAL$/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent @GENE$.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of @GENE$ (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of mammalian peroxiredoxin-1 (@GENE$), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the @GENE$, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of @GENE$ (Trx)-dependent peroxidases.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (@GENE$)-dependent peroxidases.	0
In this study we investigated how NO/@CHEMICAL$ may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-Cys Prxs, a group of thioredoxin (Trx)-dependent @GENE$.	0
In this study we investigated how NO/SNO may affect the redox cycle of @GENE$ (Prx1), a representative of the 2-@CHEMICAL$ Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (@GENE$), a representative of the 2-@CHEMICAL$ Prxs, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the @CHEM-GENE$, a group of thioredoxin (Trx)-dependent peroxidases.	0
In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-@CHEMICAL$ Prxs, a group of @GENE$ (Trx)-dependent peroxidases.	0
In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-@CHEMICAL$ Prxs, a group of thioredoxin (@GENE$)-dependent peroxidases.	0
In this study we investigated how NO/SNO may affect the redox cycle of mammalian peroxiredoxin-1 (Prx1), a representative of the 2-@CHEMICAL$ Prxs, a group of thioredoxin (Trx)-dependent @GENE$.	0
We found that, both in a cell-free system and in cells, @CHEMICAL$/SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the S-nitrosylation of @GENE$, causing structural and functional alterations.	0
We found that, both in a cell-free system and in cells, NO/@CHEMICAL$ donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the S-nitrosylation of @GENE$, causing structural and functional alterations.	0
We found that, both in a cell-free system and in cells, NO/SNO donors such as @CHEMICAL$ and S-nitrosoglutathione readily induced the S-nitrosylation of @GENE$, causing structural and functional alterations.	0
We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and @CHEMICAL$ readily induced the S-nitrosylation of @GENE$, causing structural and functional alterations.	0
We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the @CHEMICAL$-nitrosylation of @GENE$, causing structural and functional alterations.	0
In particular, nitrosylation promoted @CHEMICAL$ formation involving the pair of catalytic cysteines (Cys-52 and Cys-173) and disrupted the oligomeric structure of @GENE$, leading to loss of peroxidase activity.	0
In particular, nitrosylation promoted @CHEMICAL$ formation involving the pair of catalytic cysteines (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of @GENE$ activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic @CHEMICAL$ (Cys-52 and Cys-173) and disrupted the oligomeric structure of @GENE$, leading to loss of peroxidase activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic @CHEMICAL$ (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of @GENE$ activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (@CHEMICAL$-52 and Cys-173) and disrupted the oligomeric structure of @GENE$, leading to loss of peroxidase activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (@CHEMICAL$-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of @GENE$ activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and @CHEMICAL$-173) and disrupted the oligomeric structure of @GENE$, leading to loss of peroxidase activity.	0
In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and @CHEMICAL$-173) and disrupted the oligomeric structure of Prx1, leading to loss of @GENE$ activity.	0
A highly potent inhibition of the @GENE$ catalytic reaction by @CHEMICAL$/SNO was seen in assays employing the coupled Prx-Trx system.	2
A highly potent inhibition of the peroxidase catalytic reaction by @CHEMICAL$/SNO was seen in assays employing the coupled @GENE$-Trx system.	0
A highly potent inhibition of the peroxidase catalytic reaction by @CHEMICAL$/SNO was seen in assays employing the coupled Prx-@GENE$ system.	0
A highly potent inhibition of the @GENE$ catalytic reaction by NO/@CHEMICAL$ was seen in assays employing the coupled Prx-Trx system.	2
A highly potent inhibition of the peroxidase catalytic reaction by NO/@CHEMICAL$ was seen in assays employing the coupled @GENE$-Trx system.	0
A highly potent inhibition of the peroxidase catalytic reaction by NO/@CHEMICAL$ was seen in assays employing the coupled Prx-@GENE$ system.	0
In this setting, @CHEMICAL$ (10 μm) effectively blocked the @GENE$-mediated regeneration of oxidized Prx1.	2
In this setting, @CHEMICAL$ (10 μm) effectively blocked the Trx-mediated regeneration of @GENE$.	2
This effect appeared to be due to both competition between @CHEMICAL$ and @GENE$ for the Trx system and direct modulation by S-nitrosocysteine of Trx reductase activity.	0
This effect appeared to be due to both competition between @CHEMICAL$ and Prx1 for the @GENE$ system and direct modulation by S-nitrosocysteine of Trx reductase activity.	0
This effect appeared to be due to both competition between @CHEMICAL$ and Prx1 for the Trx system and direct modulation by S-nitrosocysteine of @GENE$ activity.	0
This effect appeared to be due to both competition between S-nitrosocysteine and @GENE$ for the Trx system and direct modulation by @CHEMICAL$ of Trx reductase activity.	0
This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the @GENE$ system and direct modulation by @CHEMICAL$ of Trx reductase activity.	0
This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the Trx system and direct modulation by @CHEMICAL$ of @GENE$ activity.	0
Our findings that NO/@CHEMICAL$ target both @GENE$ and Trx reductase may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	0
Our findings that NO/@CHEMICAL$ target both Prx and @GENE$ may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	0
Our findings that @CHEMICAL$/SNO target both @GENE$ and Trx reductase may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	0
Our findings that @CHEMICAL$/SNO target both Prx and @GENE$ may have implications for understanding the impact of nitrosylation on cellular redox homeostasis.	0
Platycodi Radix attenuates @CHEMICAL$-induced liver fibrosis in rats by inducing @GENE$-mediated antioxidant enzymes.	0
@CHEMICAL$ treatment for 4weeks led to marked liver fibrosis as assessed by serum biochemistry, histopathological examination, and hepatic lipid peroxidation and @GENE$ content.	0
CK significantly inhibited @CHEMICAL$-induced increases in serum @GENE$ (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	1
CK significantly inhibited @CHEMICAL$-induced increases in serum alanine aminotransferase (@GENE$) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	1
CK significantly inhibited @CHEMICAL$-induced increases in serum alanine aminotransferase (ALT) and @GENE$ (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	1
CK significantly inhibited @CHEMICAL$-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (@GENE$) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	1
CK significantly inhibited @CHEMICAL$-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and @GENE$ content.	1
CK significantly inhibited DMN-induced increases in serum @CHEM-GENE$ (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum @CHEMICAL$ aminotransferase (@GENE$) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum @CHEMICAL$ aminotransferase (ALT) and @GENE$ (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum @CHEMICAL$ aminotransferase (ALT) and aspartate aminotransferase (@GENE$) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum @CHEMICAL$ aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and @GENE$ content.	0
CK significantly inhibited DMN-induced increases in serum @GENE$ (ALT) and @CHEMICAL$ aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (@GENE$) and @CHEMICAL$ aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and @CHEM-GENE$ (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and @CHEMICAL$ aminotransferase (@GENE$) activities, fibrosis score, and hepatic malondialdehyde and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and @CHEMICAL$ aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and @GENE$ content.	0
CK significantly inhibited DMN-induced increases in serum @GENE$ (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic @CHEMICAL$ and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (@GENE$) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic @CHEMICAL$ and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and @GENE$ (AST) activities, fibrosis score, and hepatic @CHEMICAL$ and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (@GENE$) activities, fibrosis score, and hepatic @CHEMICAL$ and collagen content.	0
CK significantly inhibited DMN-induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic @CHEMICAL$ and @GENE$ content.	0
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in @GENE$ (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (@GENE$), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), @GENE$ (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (@GENE$), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and @GENE$ (TNF-α) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (@GENE$) mRNA, and collagen type I and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and @GENE$ and α-smooth muscle actin protein.	1
Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited @CHEMICAL$-induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-α (TNF-α) mRNA, and collagen type I and @GENE$ protein.	1
@CHEMICAL$-induced cyclooxygenase-2 (COX-2) expression and @GENE$ (NF-κB) activation was reduced by CK treatment.	1
@CHEMICAL$-induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (@GENE$) activation was reduced by CK treatment.	1
@CHEMICAL$-induced @GENE$ (COX-2) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment.	1
@CHEMICAL$-induced cyclooxygenase-2 (@GENE$) expression and nuclear factor-kappa B (NF-κB) activation was reduced by CK treatment.	1
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEM-GENE$ (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (@GENE$), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), @GENE$ (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (@GENE$), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), @GENE$ (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (@GENE$), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @CHEMICAL$ synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (@GENE$) in HepG2 cells.	0
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @GENE$ (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (@GENE$), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEM-GENE$ (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (@GENE$), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), @GENE$ (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (@GENE$), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @CHEMICAL$ oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (@GENE$) in HepG2 cells.	0
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @GENE$ (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (@GENE$), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @GENE$ (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (@GENE$), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEM-GENE$ (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (@GENE$), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and @GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEMICAL$ quinone oxidoreductase 1 (NQO1), and glutathione-S-transferase (@GENE$) in HepG2 cells.	0
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @GENE$ (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (@GENE$), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @GENE$ (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (@GENE$), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @CHEM-GENE$ (NQO1), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (@GENE$), and glutathione-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and @GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H @CHEMICAL$ oxidoreductase 1 (NQO1), and glutathione-S-transferase (@GENE$) in HepG2 cells.	0
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @GENE$ (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (@GENE$), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @GENE$ (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (@GENE$), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @GENE$ (NQO1), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (@GENE$), and @CHEMICAL$-S-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEM-GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEMICAL$-S-transferase (@GENE$) in HepG2 cells.	0
Furthermore, CK induced activation of @GENE$ (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (@GENE$)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as @GENE$ (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (@GENE$), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), @GENE$ (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (@GENE$), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), @GENE$ (NQO1), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (@GENE$), and glutathione-@CHEMICAL$-transferase (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and @CHEM-GENE$ (GST) in HepG2 cells.	0
Furthermore, CK induced activation of nuclear erythroid 2-related factor 2 (Nrf2)-mediated antioxidant enzymes such as γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione-@CHEMICAL$-transferase (@GENE$) in HepG2 cells.	0
These results demonstrated that CK attenuates @CHEMICAL$-induced liver fibrosis through the activation of @GENE$-mediated antioxidant enzymes.	0
Altered antioxidant levels were demonstrated by depletion of @CHEMICAL$ (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of @CHEMICAL$ (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (@CHEMICAL$), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (@CHEMICAL$), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced @CHEMICAL$ to oxidized glutathione (GSH/GSSG) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced @CHEMICAL$ to oxidized glutathione (GSH/GSSG) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to @CHEMICAL$ (GSH/GSSG) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to @CHEMICAL$ (GSH/GSSG) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (@CHEMICAL$/GSSG) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (@CHEMICAL$/GSSG) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/@CHEMICAL$) and an increased @GENE$ (Nrf2) activation.	0
Altered antioxidant levels were demonstrated by depletion of reduced glutathione (GSH), a decreased ratio of reduced glutathione to oxidized glutathione (GSH/@CHEMICAL$) and an increased NF-E2-related Factor 2 (@GENE$) activation.	0
Enzyme assays showed that @CHEM-GENE$ (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that @CHEMICAL$ dismutase (@GENE$) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that @CHEMICAL$ dismutase (SOD) activity was elevated whereas @GENE$ (CAT) and glutathione-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that @CHEMICAL$ dismutase (SOD) activity was elevated whereas catalase (@GENE$) and glutathione-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that @CHEMICAL$ dismutase (SOD) activity was elevated whereas catalase (CAT) and @GENE$ (GST) activities were depressed.	0
Enzyme assays showed that @CHEMICAL$ dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-S-transferase (@GENE$) activities were depressed.	0
Enzyme assays showed that @GENE$ (SOD) activity was elevated whereas catalase (CAT) and @CHEMICAL$-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (@GENE$) activity was elevated whereas catalase (CAT) and @CHEMICAL$-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas @GENE$ (CAT) and @CHEMICAL$-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (@GENE$) and @CHEMICAL$-S-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and @CHEM-GENE$ (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and @CHEMICAL$-S-transferase (@GENE$) activities were depressed.	0
Enzyme assays showed that @GENE$ (SOD) activity was elevated whereas catalase (CAT) and glutathione-@CHEMICAL$-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (@GENE$) activity was elevated whereas catalase (CAT) and glutathione-@CHEMICAL$-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas @GENE$ (CAT) and glutathione-@CHEMICAL$-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (@GENE$) and glutathione-@CHEMICAL$-transferase (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and @CHEM-GENE$ (GST) activities were depressed.	0
Enzyme assays showed that superoxide dismutase (SOD) activity was elevated whereas catalase (CAT) and glutathione-@CHEMICAL$-transferase (@GENE$) activities were depressed.	0
Further analyses revealed that @CHEMICAL$-QD exposure resulted in apoptosis, indicated by changes in levels of @GENE$ activity, poly ADP-ribose polymerase (PARP) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that @CHEMICAL$-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, @GENE$ (PARP) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that @CHEMICAL$-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (@GENE$) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of @GENE$ activity, @CHEMICAL$ polymerase (PARP) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, @CHEM-GENE$ (PARP) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, @CHEMICAL$ polymerase (@GENE$) cleavage and phosphatidylserine externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of @GENE$ activity, poly ADP-ribose polymerase (PARP) cleavage and @CHEMICAL$ externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, @GENE$ (PARP) cleavage and @CHEMICAL$ externalization.	0
Further analyses revealed that CdTe-QD exposure resulted in apoptosis, indicated by changes in levels of caspase-3 activity, poly ADP-ribose polymerase (@GENE$) cleavage and @CHEMICAL$ externalization.	0
Extrinsic apoptotic pathway markers such as @GENE$ levels and caspase-8 activity increased as a result of @CHEMICAL$-QD exposure.	1
Extrinsic apoptotic pathway markers such as Fas levels and @GENE$ activity increased as a result of @CHEMICAL$-QD exposure.	1
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of @GENE$ (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (@GENE$) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial @GENE$, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial @GENE$ (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (@GENE$) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic @GENE$. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, @GENE$ (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (@GENE$) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as @CHEM-GENE$ (JNK), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (@GENE$), extracellular signal-regulated kinases (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), @GENE$ (Erk1/2), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (@GENE$), and p38 were all activated.	0
Involvement of the intrinsic/mitochondrial apoptotic pathway was indicated by decreased levels of B-cell lymphoma 2 (Bcl2) protein and mitochondrial cytochrome c, and by increased levels of mitochondrial Bcl-2-associated X protein (Bax) and cytosolic cytochrome c. Further, mitogen-activated protein kinases (MAPKs) such as c-Jun @CHEMICAL$-terminal kinases (JNK), extracellular signal-regulated kinases (Erk1/2), and @GENE$ were all activated.	0
Our findings reveal that @CHEMICAL$-QDs cause oxidative stress, interfere with antioxidant defenses and activate protein @GENE$, leading to apoptosis via both extrinsic and intrinsic pathways.	1
Anti-apoptotic cardioprotective effects of @GENE$ gene silencing against ischemia-reperfusion injury: Use of @CHEMICAL$-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier.	0
Anti-apoptotic cardioprotective effects of @GENE$ gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight @CHEMICAL$ as a cardiac siRNA-carrier.	0
Herein, we report ischemic-reperfused myocardial infarction (MI) repair with siRNA against @CHEM-GENE$ (SHP-1), which is known as a key factor involved in regulating the progress of apoptosis in many cell types.	0
Herein, we report ischemic-reperfused myocardial infarction (MI) repair with siRNA against Src homology region 2 domain-containing @CHEMICAL$ phosphatase-1 (@GENE$), which is known as a key factor involved in regulating the progress of apoptosis in many cell types.	0
A low molecular weight @CHEMICAL$ modified with deoxycholic acid (PEI1.8-DA)-based delivery strategy was suggested for the cardiac application of @GENE$ siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles.	0
A low molecular weight polyethyleneimine modified with @CHEMICAL$ (PEI1.8-DA)-based delivery strategy was suggested for the cardiac application of @GENE$ siRNA to overcome the poor gene delivery efficiency to myocardium due to the highly charged structures of the compact cardiac muscles.	0
Compared to control @GENE$, ABLP HDLs showed a 40% decrease of @CHEMICAL$ and an 11-fold increased malondialdehyde concentration.	0
Compared to control HDLs, ABLP @GENE$ showed a 40% decrease of @CHEMICAL$ and an 11-fold increased malondialdehyde concentration.	0
Compared to control @GENE$, ABLP HDLs showed a 40% decrease of α-tocopherol and an 11-fold increased @CHEMICAL$ concentration.	0
Compared to control HDLs, ABLP @GENE$ showed a 40% decrease of α-tocopherol and an 11-fold increased @CHEMICAL$ concentration.	0
Puerarin administration enhanced @CHEMICAL$ (GSH) activity, @GENE$ (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced @CHEMICAL$ (GSH) activity, glial cell line-derived neurotrophic factor (@GENE$) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced @CHEMICAL$ (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and @GENE$/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced @CHEMICAL$ (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/@GENE$ pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (@CHEMICAL$) activity, @GENE$ (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (@CHEMICAL$) activity, glial cell line-derived neurotrophic factor (@GENE$) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (@CHEMICAL$) activity, glial cell line-derived neurotrophic factor (GDNF) expression and @GENE$/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (@CHEMICAL$) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/@GENE$ pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, @GENE$ (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate @CHEMICAL$ injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (@GENE$) expression and PI3K/Akt pathway activation, which might ameliorate @CHEMICAL$ injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and @GENE$/Akt pathway activation, which might ameliorate @CHEMICAL$ injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/@GENE$ pathway activation, which might ameliorate @CHEMICAL$ injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, @GENE$ (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive @CHEMICAL$ species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (@GENE$) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive @CHEMICAL$ species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and @GENE$/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive @CHEMICAL$ species (ROS) formation in mice.	0
Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/@GENE$ pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive @CHEMICAL$ species (ROS) formation in mice.	0
@CHEMICAL$ administration enhanced glutathione (GSH) activity, @GENE$ (GDNF) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	1
@CHEMICAL$ administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (@GENE$) expression and PI3K/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	1
@CHEMICAL$ administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and @GENE$/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	1
@CHEMICAL$ administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K/@GENE$ pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice.	1
In addition to the effect on ROS, @CHEMICAL$ ameliorated MPTP-reduced @GENE$ (Lamp 2A) expression.	0
In addition to the effect on ROS, @CHEMICAL$ ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (@GENE$) expression.	2
In addition to the effect on ROS, puerarin ameliorated @CHEMICAL$-reduced @GENE$ (Lamp 2A) expression.	2
In addition to the effect on ROS, puerarin ameliorated @CHEMICAL$-reduced lysosome-associated membrane protein type 2A (@GENE$) expression.	2
Taken together, our data demonstrate that @CHEMICAL$ attenuates MPTP-induced dopaminergic neuronal degeneration via modulating @GENE$ expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that @CHEMICAL$ attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, @GENE$/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that @CHEMICAL$ attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/@GENE$ pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that @CHEMICAL$ attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of @GENE$ expression.	2
Taken together, our data demonstrate that puerarin attenuates @CHEMICAL$-induced dopaminergic neuronal degeneration via modulating @GENE$ expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates @CHEMICAL$-induced dopaminergic neuronal degeneration via modulating GDNF expression, @GENE$/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates @CHEMICAL$-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/@GENE$ pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates @CHEMICAL$-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of @GENE$ expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating @GENE$ expression, PI3K/Akt pathway and @CHEMICAL$ activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, @GENE$/Akt pathway and @CHEMICAL$ activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/@GENE$ pathway and @CHEMICAL$ activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and @CHEMICAL$ activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of @GENE$ expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating @GENE$ expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate @CHEMICAL$-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, @GENE$/Akt pathway and GSH activation, which subsequently ameliorate @CHEMICAL$-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/@GENE$ pathway and GSH activation, which subsequently ameliorate @CHEMICAL$-induced ROS formation and decrease of Lamp 2A expression.	0
Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K/Akt pathway and GSH activation, which subsequently ameliorate @CHEMICAL$-induced ROS formation and decrease of @GENE$ expression.	2
After 18 h incubation with 0.5 μM @CHEMICAL$ and subsequent red light irradiation (3.6 J/cm(2)), a high number of cells die by apoptosis, as evaluated by morphological alterations, immunofluorescent relocalization of @GENE$ from cytosol to mitochondria, and TUNEL assay.	0
The @GENE$ subunit contains several functional domains: the @CHEMICAL$-terminal heptad repeat (NHR) domains fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate.	0
The gp41 subunit contains several functional domains: the @CHEM-GENE$ fold a triple stranded coiled-coil forming a meta-stable prefusion intermediate.	0
With a @CHEMICAL$ modification at C-terminal, the inhibitor containing @GENE$ mutation represented higher anti-viral activity than C34-cholesterol combination without mutation.	0
With a cholesterol modification at @CHEMICAL$-terminal, the inhibitor containing @GENE$ mutation represented higher anti-viral activity than C34-cholesterol combination without mutation.	0
With a cholesterol modification at C-terminal, the inhibitor containing @GENE$ mutation represented higher anti-viral activity than C34-@CHEMICAL$ combination without mutation.	0
Our results revealed an important role of base excision repair (BER) as the @GENE$, ntg2, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and @CHEMICAL$.	0
Our results revealed an important role of base excision repair (BER) as the ntg1, @GENE$, apn1 and apn2 mutants showed pronounced sensitivity to essential oil and @CHEMICAL$.	0
Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, @GENE$ and apn2 mutants showed pronounced sensitivity to essential oil and @CHEMICAL$.	0
Our results revealed an important role of base excision repair (BER) as the ntg1, ntg2, apn1 and @GENE$ mutants showed pronounced sensitivity to essential oil and @CHEMICAL$.	0
In the absence of @GENE$ (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and @CHEMICAL$ are generating reactive oxygen species (ROS).	0
In the absence of superoxide dismutase (in @GENE$Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and @CHEMICAL$ are generating reactive oxygen species (ROS).	0
In the absence of @GENE$ (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive @CHEMICAL$ species (ROS).	0
In the absence of superoxide dismutase (in @GENE$Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive @CHEMICAL$ species (ROS).	0
In the absence of @CHEM-GENE$ (in sod1Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS).	0
In the absence of @CHEMICAL$ dismutase (in @GENE$Δ mutant strain) sensitivity to the essential oil and nerolidol increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS).	0
In the absence of @GENE$ (in sod1Δ mutant strain) sensitivity to the essential oil and @CHEMICAL$ increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS).	0
In the absence of superoxide dismutase (in @GENE$Δ mutant strain) sensitivity to the essential oil and @CHEMICAL$ increased indicating that this oil and nerolidol are generating reactive oxygen species (ROS).	0
The ROS production was confirmed by @CHEMICAL$ probing assay in @GENE$-deficient strains.	0
All tested compounds proved to be potent @GENE$ receptor and @CHEMICAL$ transporter protein (SERT) ligands.	0
All tested compounds proved to be potent 5-HT1A receptor and @CHEM-GENE$ (SERT) ligands.	0
All tested compounds proved to be potent 5-HT1A receptor and @CHEMICAL$ transporter protein (@GENE$) ligands.	0
The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [@CHEMICAL$]-@GENE$ and [(3)H]-SSB siRNA, respectively).	0
The radioactivity was rapidly and widely distributed throughout the body, and remained detectable in all tissues investigated at later time points (24 and 48 hours for [(3)H]-@GENE$ and [@CHEMICAL$]-SSB siRNA, respectively).	0
Instead, radiolabeled @CHEMICAL$ resulting from @GENE$ hydrolysis were observed.	5
The complexity of @GENE$ regulation has made it difficult to determine whether these different roles require different thresholds of kinase activity and whether the surge of activity as inhibitory @CHEMICAL$ are removed at mitotic onset is essential for cell proliferation.	0
The complexity of Cdk1 regulation has made it difficult to determine whether these different roles require different thresholds of @GENE$ activity and whether the surge of activity as inhibitory @CHEMICAL$ are removed at mitotic onset is essential for cell proliferation.	0
We rescued cells lethally depleted of endogenous @GENE$ with an exogenous Cdk1 conferring sensitivity to one @CHEMICAL$ analogue inhibitor (1NMPP1) and resistance to another (RO3306).	0
We rescued cells lethally depleted of endogenous Cdk1 with an exogenous @GENE$ conferring sensitivity to one @CHEMICAL$ analogue inhibitor (1NMPP1) and resistance to another (RO3306).	0
We rescued cells lethally depleted of endogenous @GENE$ with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (@CHEMICAL$) and resistance to another (RO3306).	0
We rescued cells lethally depleted of endogenous Cdk1 with an exogenous @GENE$ conferring sensitivity to one ATP analogue inhibitor (@CHEMICAL$) and resistance to another (RO3306).	0
We rescued cells lethally depleted of endogenous @GENE$ with an exogenous Cdk1 conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (@CHEMICAL$).	0
We rescued cells lethally depleted of endogenous Cdk1 with an exogenous @GENE$ conferring sensitivity to one ATP analogue inhibitor (1NMPP1) and resistance to another (@CHEMICAL$).	0
At no @CHEMICAL$ concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for @GENE$ are not simply controlled by different Cdk1 activity thresholds.	0
At no @CHEMICAL$ concentration was mitosis in rescued clones prevented without also inducing endoreduplication, suggesting that these two key roles for Cdk1 are not simply controlled by different @GENE$ activity thresholds.	0
We also rescued @CHEMICAL$-resistant clones using exogenous @GENE$ without inhibitory phosphorylation sites, indicating that the mitotic surge of Cdk1 activity is dispensable for cell proliferation.	0
We also rescued @CHEMICAL$-resistant clones using exogenous Cdk1 without inhibitory phosphorylation sites, indicating that the mitotic surge of @GENE$ activity is dispensable for cell proliferation.	0
Exploring the effect of N-substitution in @CHEMICAL$ on the interaction with @GENE$: discovery of a potential clinical candidate for treatment of methamphetamine abuse.	0
Exploring the effect of N-substitution in nor-lobelane on the interaction with @GENE$: discovery of a potential clinical candidate for treatment of @CHEMICAL$ abuse.	0
Exploring the effect of @CHEMICAL$-substitution in nor-lobelane on the interaction with @GENE$: discovery of a potential clinical candidate for treatment of methamphetamine abuse.	0
A series of @CHEMICAL$-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the @GENE$ and for their inhibition of vesicular [(3)H]dopamine uptake.	0
A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the @CHEM-GENE$ and for their inhibition of vesicular [(3)H]dopamine uptake.	0
A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the @GENE$ and for their inhibition of vesicular @CHEMICAL$ uptake.	5
A series of N-substituted @CHEMICAL$ analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the @GENE$ and for their inhibition of vesicular [(3)H]dopamine uptake.	0
A series of N-substituted lobelane analogues was synthesized and evaluated for their @CHEMICAL$ binding affinity at the @GENE$ and for their inhibition of vesicular [(3)H]dopamine uptake.	0
@CHEMICAL$ is highly bound to plasma proteins and has minimal interaction with @GENE$.	0
@CHEMICAL$ is not a potent reversible inhibitor of @GENE$ (testosterone).	0
IPI-926 is not a potent reversible inhibitor of @GENE$ (@CHEMICAL$).	0
@CHEMICAL$ is a moderate inhibitor of @GENE$ (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.	0
IPI-926 is a moderate inhibitor of @GENE$ (@CHEMICAL$) with KI values of 19, 16 and 4.5 µM, respectively.	0
@CHEMICAL$ is both a substrate and inhibitor (IC50 = 1.9 µM) of @GENE$.	5
Protection of @CHEMICAL$ against AGEs-induced endothelial dysfunction through inhibiting RAGE/@GENE$ pathway activation in human umbilical vein endothelial cells.	0
Protection of @CHEMICAL$ against AGEs-induced endothelial dysfunction through inhibiting @GENE$/NF-κB pathway activation in human umbilical vein endothelial cells.	0
The @GENE$ (SOD) activity and malondialdehyde (@CHEMICAL$) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The superoxide dismutase (@GENE$) activity and malondialdehyde (@CHEMICAL$) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The @GENE$ (SOD) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive @CHEMICAL$ species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The superoxide dismutase (@GENE$) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive @CHEMICAL$ species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The @GENE$ (SOD) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by @CHEMICAL$ (DCFH-DA) kit.	0
The superoxide dismutase (@GENE$) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by @CHEMICAL$ (DCFH-DA) kit.	0
The @GENE$ (SOD) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (@CHEMICAL$) kit.	0
The superoxide dismutase (@GENE$) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (@CHEMICAL$) kit.	0
The @CHEM-GENE$ (SOD) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The @CHEMICAL$ dismutase (@GENE$) activity and malondialdehyde (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The @GENE$ (SOD) activity and @CHEMICAL$ (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
The superoxide dismutase (@GENE$) activity and @CHEMICAL$ (MDA) level in cell supernatant were detected by kits while the intracellular reactive oxygen species (ROS) generation was determined by 2,7-dichlorodihydrofluorescin diacetate (DCFH-DA) kit.	0
GA significantly increased antioxidant enzyme @GENE$ activity and decreased peroxide degradation product @CHEMICAL$ level in a dose-dependent manner.	0
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma @CHEMICAL$, @GENE$ levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels.	0
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma @CHEMICAL$, insulin levels, @GENE$ resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels.	0
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma @CHEMICAL$, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-@GENE$ resistance index, beta cell function measured by HOMA-β index, leptin and adiponectin levels.	0
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma @CHEMICAL$, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, @GENE$ and adiponectin levels.	0
Forty premenopausal women with prolactinoma or idiopathic hyperprolactinemia were compared to 41 age-matched healthy premenopausal women with regard to body weight, body mass index, waist and hip circumferences, waist to hip ratio, fasting plasma @CHEMICAL$, insulin levels, insulin resistance measured by homeostasis model assessment (HOMA)-insulin resistance index, beta cell function measured by HOMA-β index, leptin and @GENE$ levels.	0
There was a positive correlation between @GENE$ levels and fasting plasma @CHEMICAL$ in hyperprolactinemic women.	0
Oral @CHEMICAL$ (BELVIQ(®)), a selective serotonin @GENE$ receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.	3
Oral lorcaserin (@CHEMICAL$(®)), a selective serotonin @GENE$ receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.	3
Oral lorcaserin (BELVIQ(®)), a selective @CHEMICAL$ @GENE$ receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.	0
Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a @CHEMICAL$ Moiety as Potent @GENE$ Inhibitors.	2
Design, Synthesis, Biological Evaluation, and Docking Studies of @CHEMICAL$ Derivatives with a 2-Cyanopyrrolidine Moiety as Potent @GENE$ Inhibitors.	2
Biological evaluation revealed that most tested compounds were potent @GENE$ (DPP-4) inhibitors, among them, the @CHEMICAL$ derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM.	0
Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (@GENE$) inhibitors, among them, the @CHEMICAL$ derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 μM.	0
Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the @CHEMICAL$ derivative 11h displayed the most potent @GENE$ inhibitory activity with an IC50 value of 0.247 μM.	2
In the current study, we crossed @GENE$.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, @CHEMICAL$ and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the @GENE$ knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, @CHEMICAL$ and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (@GENE$(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, @CHEMICAL$ and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong @GENE$ ligand, and two therapeutically relevant taxanes, @CHEMICAL$ and docetaxel.	0
In the current study, we crossed @GENE$.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and @CHEMICAL$.	0
In the current study, we crossed mdr1a.fLUC mice into the @GENE$ knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and @CHEMICAL$.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (@GENE$(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and @CHEMICAL$.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong @GENE$ ligand, and two therapeutically relevant taxanes, paclitaxel and @CHEMICAL$.	0
In the current study, we crossed @GENE$.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with @CHEMICAL$ (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the @GENE$ knockout (pxr(-/-)) genetic background and injected mice with @CHEMICAL$ (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (@GENE$(-/-)) genetic background and injected mice with @CHEMICAL$ (PCN), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with @CHEMICAL$ (PCN), a strong @GENE$ ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed @GENE$.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (@CHEMICAL$), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the @GENE$ knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (@CHEMICAL$), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (@GENE$(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (@CHEMICAL$), a strong PXR ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (@CHEMICAL$), a strong @GENE$ ligand, and two therapeutically relevant taxanes, paclitaxel and docetaxel.	0
In the current study, we crossed @GENE$.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant @CHEMICAL$, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the @GENE$ knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant @CHEMICAL$, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (@GENE$(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong PXR ligand, and two therapeutically relevant @CHEMICAL$, paclitaxel and docetaxel.	0
In the current study, we crossed mdr1a.fLUC mice into the pxr knockout (pxr(-/-)) genetic background and injected mice with pregnenolone-16α-carbonitrile (PCN), a strong @GENE$ ligand, and two therapeutically relevant @CHEMICAL$, paclitaxel and docetaxel.	0
All three agents induced mdr1a.fLUC expression (bioluminescence), but only @CHEMICAL$ and docetaxel appeared to act primarily via @GENE$.	0
All three agents induced @GENE$.fLUC expression (bioluminescence), but only @CHEMICAL$ and docetaxel appeared to act primarily via PXR.	0
All three agents induced mdr1a.fLUC expression (bioluminescence), but only PCN and @CHEMICAL$ appeared to act primarily via @GENE$.	0
All three agents induced @GENE$.fLUC expression (bioluminescence), but only PCN and @CHEMICAL$ appeared to act primarily via PXR.	0
@CHEMICAL$, a @GENE$ ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.	0
@CHEMICAL$, a CAR ligand, modestly induced @GENE$.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.	1
@CHEMICAL$, a CAR ligand, modestly induced mdr1a.fLUC in @GENE$(+/+) and pxr(-/-) strains, consistent with CAR's minor role in mdr1a regulation.	0
@CHEMICAL$, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and @GENE$(-/-) strains, consistent with CAR's minor role in mdr1a regulation.	0
@CHEMICAL$, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with @GENE$'s minor role in mdr1a regulation.	0
@CHEMICAL$, a CAR ligand, modestly induced mdr1a.fLUC in pxr(+/+) and pxr(-/-) strains, consistent with CAR's minor role in @GENE$ regulation.	0
The available X-ray structures contain only @GENE$ tetraloops which in addition differ in orientation (anti vs syn) of the @CHEMICAL$.	0
The available X-ray structures contain only UCCG @GENE$ which in addition differ in orientation (anti vs syn) of the @CHEMICAL$.	0
@GENE$ is unusual due to its 11-@CHEMICAL$ bulge.	0
The simulations indicate that the long bulge is a stalk-specific eight-@CHEMICAL$ insertion into consensual @GENE$ only subtly modifying its structural dynamics.	0
Still, even bsc0χOL3 is unable to fully stabilize an essential @CHEMICAL$-edge H-bond between the bulge and non-canonical stem of the @GENE$.	0
Still, even bsc0χOL3 is unable to fully stabilize an essential sugar-edge @CHEMICAL$-bond between the bulge and non-canonical stem of the @GENE$.	0
@CHEMICAL$ decreased expression of pro-inflammatory @GENE$, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and IL-8.	2
@CHEMICAL$ decreased expression of pro-inflammatory cytokines, such as @GENE$, interleukin (IL)-6, IL-1β, and IL-8.	2
@CHEMICAL$ decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, @GENE$ (IL)-6, IL-1β, and IL-8.	2
@CHEMICAL$ decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin @GENE$, IL-1β, and IL-8.	2
@CHEMICAL$ decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, @GENE$, and IL-8.	2
@CHEMICAL$ decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, and @GENE$.	2
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory @GENE$ was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	2
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with @GENE$ N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with c-Jun @GENE$, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and @GENE$ mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 @GENE$, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, @GENE$, and caspase-1.	0
The inhibitory effect of @CHEMICAL$ on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and @GENE$.	0
The inhibitory effect of galangin on theses pro-inflammatory @GENE$ was related with c-Jun @CHEMICAL$-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with @GENE$ @CHEMICAL$-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun @CHEM-GENE$, and p38 mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun @CHEMICAL$-terminal kinases, and @GENE$ mitogen-activated protein kinase, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun @CHEMICAL$-terminal kinases, and p38 @GENE$, nuclear factor-κB, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun @CHEMICAL$-terminal kinases, and p38 mitogen-activated protein kinase, @GENE$, and caspase-1.	0
The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun @CHEMICAL$-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-κB, and @GENE$.	0
Furthermore, @CHEMICAL$ attenuated @GENE$-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.	2
Furthermore, @CHEMICAL$ attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of @GENE$ at the inflamed tissue.	2
Furthermore, galangin attenuated @GENE$-mediated passive cutaneous anaphylaxis and the expression of @CHEMICAL$ receptor 1 at the inflamed tissue.	0
Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of @CHEM-GENE$ at the inflamed tissue.	0
Our results showed that @CHEMICAL$ down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory @GENE$.	2
Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking @CHEMICAL$ release and expression of pro-inflammatory @GENE$.	0
@GENE$ responded only to @CHEMICAL$.	0
@CHEMICAL$ attenuates metastasis via both @GENE$ and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.	2
@CHEMICAL$ attenuates metastasis via both ERK and @GENE$/Akt pathways in HGF-treated liver cancer HepG2 cells.	2
@CHEMICAL$ attenuates metastasis via both ERK and PI3K/@GENE$ pathways in HGF-treated liver cancer HepG2 cells.	2
@CHEMICAL$ attenuates metastasis via both ERK and PI3K/Akt pathways in @GENE$-treated liver cancer HepG2 cells.	0
We use @GENE$ as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including @CHEMICAL$, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including @CHEMICAL$, tricetin, tangeretin, and nobiletin on @GENE$/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including @CHEMICAL$, tricetin, tangeretin, and nobiletin on HGF/@GENE$-mediated tumor invasion and metastasis.	0
We use @GENE$ as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, @CHEMICAL$, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, @CHEMICAL$, tangeretin, and nobiletin on @GENE$/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, @CHEMICAL$, tangeretin, and nobiletin on HGF/@GENE$-mediated tumor invasion and metastasis.	0
We use @GENE$ as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, @CHEMICAL$, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, @CHEMICAL$, and nobiletin on @GENE$/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, @CHEMICAL$, and nobiletin on HGF/@GENE$-mediated tumor invasion and metastasis.	0
We use @GENE$ as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and @CHEMICAL$ on HGF/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and @CHEMICAL$ on @GENE$/c-Met-mediated tumor invasion and metastasis.	0
We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and @CHEMICAL$ on HGF/@GENE$-mediated tumor invasion and metastasis.	0
Among them, @CHEMICAL$ markedly inhibited @GENE$-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations.	2
Data also showed @CHEMICAL$ inhibited @GENE$-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.	2
Furthermore, @CHEMICAL$ could inhibit @GENE$-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.	2
Furthermore, @CHEMICAL$ could inhibit HGF-induced the membrane localization of phosphorylated @GENE$, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.	2
Furthermore, @CHEMICAL$ could inhibit HGF-induced the membrane localization of phosphorylated c-Met, @GENE$, and Akt, but not phosphorylated JNK1/2 and p38.	2
Furthermore, @CHEMICAL$ could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and @GENE$, but not phosphorylated JNK1/2 and p38.	2
Furthermore, @CHEMICAL$ could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not @GENE$ and p38.	0
Furthermore, @CHEMICAL$ could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and @GENE$.	0
Next, nobiletin significantly decreased the levels of @CHEM-GENE$ and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of @CHEMICAL$-ERK2 and @GENE$ in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of @CHEMICAL$-ERK2 and phospho-Akt in @GENE$ or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of @CHEMICAL$-ERK2 and phospho-Akt in ERK2 or @GENE$ siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of @GENE$ and @CHEMICAL$-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of phospho-ERK2 and @CHEM-GENE$ in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of phospho-ERK2 and @CHEMICAL$-Akt in @GENE$ or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, nobiletin significantly decreased the levels of phospho-ERK2 and @CHEMICAL$-Akt in ERK2 or @GENE$ siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	0
Next, @CHEMICAL$ significantly decreased the levels of @GENE$ and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	2
Next, @CHEMICAL$ significantly decreased the levels of phospho-ERK2 and @GENE$ in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	2
Next, @CHEMICAL$ significantly decreased the levels of phospho-ERK2 and phospho-Akt in @GENE$ or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	2
Next, @CHEMICAL$ significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or @GENE$ siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.	2
In conclusion, @CHEMICAL$ attenuates @GENE$-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.	2
In conclusion, @CHEMICAL$ attenuates HGF-induced HepG2 cells metastasis involving both @GENE$ and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.	2
In conclusion, @CHEMICAL$ attenuates HGF-induced HepG2 cells metastasis involving both ERK and @GENE$/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.	2
In conclusion, @CHEMICAL$ attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/@GENE$ pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.	2
However, plasma pro-@GENE$ and @CHEMICAL$ concentrations were closely correlated (P < .0001; r = 0.73).	0
T-Cells from @GENE$+ Human Subjects Are Activated with @CHEMICAL$ through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms.	0
The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from @GENE$+ drug-naive subjects and to explore the relationship between @CHEMICAL$ accumulation in antigen presenting cells and the T-cell response.	0
Seventy-four CD8+ clones expressing different @GENE$ were shown to proliferate and kill target cells via different mechanisms when exposed to @CHEMICAL$.	0
These data suggest that T-cells can be activated by @CHEMICAL$ through a direct interaction with surface and intracellular @GENE$ (MHC) molecules.	0
These data suggest that T-cells can be activated by @CHEMICAL$ through a direct interaction with surface and intracellular major histocompatibility complex (@GENE$) molecules.	0
With the former, @CHEMICAL$ seemingly participates in the @GENE$ T-cell receptor binding interaction.	0
With the former, @CHEMICAL$ seemingly participates in the MHC @GENE$ binding interaction.	0
In contrast, the latter pathway likely involves @GENE$ binding peptides displayed as a consequence of @CHEMICAL$ exposure, but not abacavir itself.	0
In contrast, the latter pathway likely involves @GENE$ binding peptides displayed as a consequence of abacavir exposure, but not @CHEMICAL$ itself.	0
The neurospecific @CHEMICAL$ 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the @GENE$ (LXR), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific @CHEMICAL$ 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (@GENE$), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific @CHEMICAL$ 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte @GENE$.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain @CHEMICAL$ into 24S-hydroxycholesterol (24OHC) which, via the @GENE$ (LXR), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain @CHEMICAL$ into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (@GENE$), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain @CHEMICAL$ into 24S-hydroxycholesterol (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte @GENE$.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into @CHEMICAL$ (24OHC) which, via the @GENE$ (LXR), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into @CHEMICAL$ (24OHC) which, via the liver X receptor (@GENE$), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into @CHEMICAL$ (24OHC) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte @GENE$.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (@CHEMICAL$) which, via the @GENE$ (LXR), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (@CHEMICAL$) which, via the liver X receptor (@GENE$), can increase the expression and synthesis of astrocyte ApoE.	0
The neurospecific cholesterol 24-hydroxylase converts excess brain cholesterol into 24S-hydroxycholesterol (@CHEMICAL$) which, via the liver X receptor (LXR), can increase the expression and synthesis of astrocyte @GENE$.	0
@CHEMICAL$ also increases @GENE$ (Aβ) deposition and tau pathology.	2
@CHEMICAL$ also increases Amyloid β (@GENE$) deposition and tau pathology.	2
@CHEMICAL$ also increases Amyloid β (Aβ) deposition and @GENE$ pathology.	2
@GENE$, @CHEMICAL$, tau and soluble APP were correlated in Alzheimer disease (AD) samples.	0
ApoE, @CHEMICAL$, @GENE$ and soluble APP were correlated in Alzheimer disease (AD) samples.	0
ApoE, @CHEMICAL$, tau and @GENE$ were correlated in Alzheimer disease (AD) samples.	0
Excess of @CHEMICAL$ converted into 24OHC may up-regulate @GENE$ synthesis which is a scavenger for Aβ and Tau.	1
Excess of @CHEMICAL$ converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for @GENE$ and Tau.	0
Excess of @CHEMICAL$ converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for Aβ and @GENE$.	0
Excess of cholesterol converted into @CHEMICAL$ may up-regulate @GENE$ synthesis which is a scavenger for Aβ and Tau.	1
Excess of cholesterol converted into @CHEMICAL$ may up-regulate ApoE synthesis which is a scavenger for @GENE$ and Tau.	0
Excess of cholesterol converted into @CHEMICAL$ may up-regulate ApoE synthesis which is a scavenger for Aβ and @GENE$.	0
In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of @CHEMICAL$, microvascular dysfunction and the decreased efficiency of @GENE$ as lipid transporter and Aβ scavenger.	0
In AD this protective mechanism seems to be inefficient, probably due to the presence of high concentrations of @CHEMICAL$, microvascular dysfunction and the decreased efficiency of ApoE4 as lipid transporter and @GENE$ scavenger.	0
Analysis of side chain @CHEMICAL$ in the CSF is likely to provided useful information about cholesterol metabolism and @GENE$ function in the pathogenesis of AD.	0
Analysis of side chain oxysterols in the CSF is likely to provided useful information about @CHEMICAL$ metabolism and @GENE$ function in the pathogenesis of AD.	0
Loss of @GENE$ Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of @CHEMICAL$.	0
Loss of @CHEM-GENE$ Activity in Cortical Astrocytes Decreases Glutamate Uptake and Induces Neurotoxic Release of ATP.	0
Loss of @GENE$ Activity in Cortical Astrocytes Decreases @CHEMICAL$ Uptake and Induces Neurotoxic Release of ATP.	0
The extent of @CHEM-GENE$ (CaMKII) inactivation in the brain following ischemia correlates with the extent of damage.	0
The extent of @CHEMICAL$/calmodulin-dependent protein kinase II (@GENE$) inactivation in the brain following ischemia correlates with the extent of damage.	0
We have previously shown that a loss of @GENE$ activity in neurons is detrimental to neuronal viability by inducing excitotoxic @CHEMICAL$ release.	0
In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular @CHEMICAL$ is reduced when @GENE$ is inhibited.	5
Furthermore, @GENE$ inhibition in astrocytes is associated with the rapid onset of intracellular @CHEMICAL$ oscillations.	0
Surprisingly, this rapid @CHEMICAL$ influx is blocked by the @GENE$ antagonist, omega-conotoxin.	0
Surprisingly, this rapid @CHEMICAL$ influx is blocked by the N-type calcium channel antagonist, @GENE$.	0
Surprisingly, this rapid calcium influx is blocked by the @CHEM-GENE$ antagonist, omega-conotoxin.	0
Surprisingly, this rapid calcium influx is blocked by the @CHEMICAL$-type calcium channel antagonist, @GENE$.	0
Surprisingly, this rapid calcium influx is blocked by the @CHEM-GENE$ antagonist, omega-conotoxin.	0
Surprisingly, this rapid calcium influx is blocked by the N-type @CHEMICAL$ channel antagonist, @GENE$.	0
While the function of @CHEM-GENE$ within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of @CHEMICAL$-type calcium channels within astrocytes is controversial, these @GENE$ have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of @CHEM-GENE$ within astrocytes is controversial, these voltage-gated calcium channels have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of N-type @CHEMICAL$ channels within astrocytes is controversial, these @GENE$ have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of @GENE$ within astrocytes is controversial, these voltage-gated @CHEMICAL$ channels have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of N-type calcium channels within astrocytes is controversial, these @CHEM-GENE$ have been linked to calcium-dependent vesicular gliotransmitter release.	0
While the function of @GENE$ within astrocytes is controversial, these voltage-gated calcium channels have been linked to @CHEMICAL$-dependent vesicular gliotransmitter release.	0
While the function of N-type calcium channels within astrocytes is controversial, these @GENE$ have been linked to @CHEMICAL$-dependent vesicular gliotransmitter release.	0
When extracellular @CHEMICAL$ and ATP levels are measured following @GENE$ inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase.	0
When extracellular glutamate and @CHEMICAL$ levels are measured following @GENE$ inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas ATP levels in the extracellular environment significantly increase.	0
When extracellular glutamate and ATP levels are measured following @GENE$ inhibition within our enriched astrocyte cultures, no alterations in @CHEMICAL$ levels are observed, whereas ATP levels in the extracellular environment significantly increase.	0
When extracellular glutamate and ATP levels are measured following @GENE$ inhibition within our enriched astrocyte cultures, no alterations in glutamate levels are observed, whereas @CHEMICAL$ levels in the extracellular environment significantly increase.	0
Extracellular @CHEMICAL$ accumulation associated with @GENE$ inhibition contributes both to calcium oscillations within astrocytes and ultimately cortical neuron toxicity.	0
Extracellular ATP accumulation associated with @GENE$ inhibition contributes both to @CHEMICAL$ oscillations within astrocytes and ultimately cortical neuron toxicity.	0
Thus, a loss of @GENE$ signaling within astrocytes dysregulates @CHEMICAL$ uptake and supports ATP release, two processes that would compromise neuronal survival following ischemic/excitotoxic insults.	0
Thus, a loss of @GENE$ signaling within astrocytes dysregulates glutamate uptake and supports @CHEMICAL$ release, two processes that would compromise neuronal survival following ischemic/excitotoxic insults.	0
@CHEMICAL$ as Novel Zinc Binding Group for Selective @GENE$ Inhibition.	2
3-Hydroxypyridin-2-thione as Novel @CHEMICAL$ Binding Group for Selective @GENE$ Inhibition.	2
Small molecules bearing hydroxamic acid as the @CHEMICAL$ binding group (ZBG) have been the most effective @GENE$ inhibitors (HDACi) to date.	2
Small molecules bearing hydroxamic acid as the @CHEMICAL$ binding group (ZBG) have been the most effective histone deacetylase inhibitors (@GENE$i) to date.	2
We have identified @CHEMICAL$ (3-HPT) as a novel ZBG that is compatible with @GENE$ inhibition.	2
We have identified 3-hydroxypyridin-2-thione (@CHEMICAL$) as a novel ZBG that is compatible with @GENE$ inhibition.	2
@CHEMICAL$ inhibits @GENE$ and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.	2
@CHEMICAL$ inhibits HDAC 6 and @GENE$ with an IC50 of 681 and 3675 nM, respectively.	2
Remarkably, @CHEMICAL$ gives no inhibition of @GENE$.	0
Subsequent optimization led to several novel @CHEMICAL$-based @GENE$i that are selective for HDAC 6 and HDAC 8.	2
Subsequent optimization led to several novel @CHEMICAL$-based HDACi that are selective for @GENE$ and HDAC 8.	2
Subsequent optimization led to several novel @CHEMICAL$-based HDACi that are selective for HDAC 6 and @GENE$.	2
When using double staining with @CHEMICAL$ for mineralized matrix and Alcian blue for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in @GENE$(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in α1(II)-Cre;Runx2(flox/flox) mice.	0
When using double staining with @CHEMICAL$ for mineralized matrix and Alcian blue for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in Runx2(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in @GENE$-Cre;Runx2(flox/flox) mice.	0
When using double staining with @CHEMICAL$ for mineralized matrix and Alcian blue for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in Runx2(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in α1(II)-Cre;@GENE$(flox/flox) mice.	0
When using double staining with Alizarin red for mineralized matrix and @CHEMICAL$ for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in @GENE$(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in α1(II)-Cre;Runx2(flox/flox) mice.	0
When using double staining with Alizarin red for mineralized matrix and @CHEMICAL$ for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in Runx2(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in @GENE$-Cre;Runx2(flox/flox) mice.	0
When using double staining with Alizarin red for mineralized matrix and @CHEMICAL$ for cartilaginous matrix, we observed previously that mineralization was totally absent at embryonic day 15.5 throughout the body in Runx2(-/-) mice, but was found in areas undergoing intramembranous ossification such as skull and clavicles in α1(II)-Cre;@GENE$(flox/flox) mice.	0
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in @CHEMICAL$ (34%), magnesium, phosphorus, selenium and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, @GENE$(-/-) mice.	0
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in calcium (34%), @CHEMICAL$, phosphorus, selenium and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, @GENE$(-/-) mice.	0
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in calcium (34%), magnesium, @CHEMICAL$, selenium and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, @GENE$(-/-) mice.	0
Here we tested the effect of chronic supplementation with a mineral extract from red marine algae - rich in calcium (34%), magnesium, phosphorus, @CHEMICAL$ and other trace minerals - in a clinically relevant model of spontaneous enterocolitis, @GENE$(-/-) mice.	0
Neuronal expression of @CHEM-GENE$ in central nervous system regulates body weight and energy homeostasis.	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @CHEMICAL$ synthase (@GENE$; UDP-glucose:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @CHEMICAL$ synthase (GCS; @GENE$).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @CHEM-GENE$ (GCS; UDP-glucose:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (@GENE$; @CHEMICAL$-glucose:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (GCS; @CHEM-GENE$).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @GENE$ (GCS; @CHEMICAL$-glucose:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (@GENE$; UDP-@CHEMICAL$:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (GCS; @CHEM-GENE$).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @GENE$ (GCS; UDP-@CHEMICAL$:ceramide glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (@GENE$; UDP-glucose:@CHEMICAL$ glucosyltransferase).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of glucosylceramide synthase (GCS; @CHEM-GENE$).	0
The present work demonstrates that hypothalamic integration of metabolic signals requires neuronal expression of @GENE$ (GCS; UDP-glucose:@CHEMICAL$ glucosyltransferase).	0
Consequently, mice with inducible forebrain neuron-specific deletion of the @CHEM-GENE$ gene (Ugcg) display obesity, hypothermia, and lower sympathetic activity.	0
Consequently, mice with inducible forebrain neuron-specific deletion of the @CHEMICAL$-glucose:ceramide glucosyltransferase gene (@GENE$) display obesity, hypothermia, and lower sympathetic activity.	0
Consequently, mice with inducible forebrain neuron-specific deletion of the @CHEM-GENE$ gene (Ugcg) display obesity, hypothermia, and lower sympathetic activity.	0
Consequently, mice with inducible forebrain neuron-specific deletion of the UDP-@CHEMICAL$:ceramide glucosyltransferase gene (@GENE$) display obesity, hypothermia, and lower sympathetic activity.	0
Consequently, mice with inducible forebrain neuron-specific deletion of the @CHEM-GENE$ gene (Ugcg) display obesity, hypothermia, and lower sympathetic activity.	0
Consequently, mice with inducible forebrain neuron-specific deletion of the UDP-glucose:@CHEMICAL$ glucosyltransferase gene (@GENE$) display obesity, hypothermia, and lower sympathetic activity.	0
Environmental pesticide exposure modulates @GENE$, arginase and @CHEMICAL$ decarboxylase expression in human placenta.	0
Environmental pesticide exposure modulates cytokines, @GENE$ and @CHEMICAL$ decarboxylase expression in human placenta.	0
Environmental pesticide exposure modulates cytokines, arginase and @CHEM-GENE$ expression in human placenta.	0
To evaluate the @GENE$ balance and enzymatic alterations induced by environmental pesticide exposure during pregnancy, this transversal study explored placentas derived from non-exposed women (control group-CG), and from women living in a rural area (rural group-RG), collected during intensive @CHEMICAL$ (OP) pesticide spraying season (RG-SS) and during non-spraying season (RG-NSS).	0
@GENE$ and @CHEMICAL$ decarboxylase (ODC) enzymes were induced in syncytiotrophoblast and endothelial cells.	0
Arginase and @CHEM-GENE$ (ODC) enzymes were induced in syncytiotrophoblast and endothelial cells.	0
Arginase and @CHEMICAL$ decarboxylase (@GENE$) enzymes were induced in syncytiotrophoblast and endothelial cells.	0
Native @GENE$ stimulates insulin secretion in a @CHEMICAL$-dependent manner, as well as suppressing glucagon production and slowing gastric emptying.	0
Native GLP-1 stimulates @GENE$ secretion in a @CHEMICAL$-dependent manner, as well as suppressing glucagon production and slowing gastric emptying.	0
Native GLP-1 stimulates insulin secretion in a @CHEMICAL$-dependent manner, as well as suppressing @GENE$ production and slowing gastric emptying.	0
Maqui berry (Aristotelia chilensis) and the constituent @CHEMICAL$ inhibit @GENE$ cell death induced by visible light.	1
These findings indicate that MBE and its @CHEMICAL$ suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of @GENE$ may be involved in the underlying mechanism.	2
After pretreatment with single @CHEMICAL$, cells were stimulated with pro-inflammatory cytokines (@GENE$, INF-γ, IL-1β).	0
After pretreatment with single @CHEMICAL$, cells were stimulated with pro-inflammatory cytokines (TNF-α, @GENE$, IL-1β).	0
After pretreatment with single @CHEMICAL$, cells were stimulated with pro-inflammatory cytokines (TNF-α, INF-γ, @GENE$).	0
After pretreatment with single @CHEMICAL$, cells were stimulated with pro-inflammatory @GENE$ (TNF-α, INF-γ, IL-1β).	0
Moreover, @CHEMICAL$ could also down-regulate the expression and activity of @GENE$ (MMP-9).	2
Moreover, @CHEMICAL$ could also down-regulate the expression and activity of matrix metalloproteinase-9 (@GENE$).	2
Treatment with @CHEMICAL$ or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of @GENE$ at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	1
Treatment with @CHEMICAL$ or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of @GENE$ at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	1
Treatment with @CHEMICAL$ or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of @GENE$, and decreased expression of Cdc25c.	1
Treatment with @CHEMICAL$ or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of @GENE$.	2
Treatment with EVn-50 or @CHEMICAL$ resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of @GENE$ at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	1
Treatment with EVn-50 or @CHEMICAL$ resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of @GENE$ at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	1
Treatment with EVn-50 or @CHEMICAL$ resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of @GENE$, and decreased expression of Cdc25c.	1
Treatment with EVn-50 or @CHEMICAL$ resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of @GENE$.	2
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of @GENE$ at @CHEMICAL$10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at @CHEMICAL$10, phosphorylation of @GENE$ at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at @CHEMICAL$10, phosphorylation of Cdk1 at Tyr15, expression of @GENE$, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at @CHEMICAL$10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of @GENE$.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of @GENE$ at Ser10, phosphorylation of Cdk1 at @CHEMICAL$15, expression of cyclin B1, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of @GENE$ at @CHEMICAL$15, expression of cyclin B1, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at @CHEMICAL$15, expression of @GENE$, and decreased expression of Cdc25c.	0
Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at @CHEMICAL$15, expression of cyclin B1, and decreased expression of @GENE$.	0
@GENE$ mediate the antinociceptive effect of @CHEMICAL$.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of @GENE$, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, @GENE$, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, @GENE$, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, @GENE$, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, @GENE$ and ASIC in its antinociceptive mechanism.	0
Methods The @CHEMICAL$-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and @GENE$ in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of @GENE$, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, @GENE$, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, @GENE$, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, @GENE$, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, @GENE$ and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by @CHEMICAL$ and formalin, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and @GENE$ in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of @GENE$, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, @GENE$, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, @GENE$, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, @GENE$, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, @GENE$ and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and @CHEMICAL$, were performed to evaluate the antinociceptive action of CAT and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and @GENE$ in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of @GENE$, PKA, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of PKC, @GENE$, TRPV1, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of PKC, PKA, @GENE$, TRPA1, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of PKC, PKA, TRPV1, @GENE$, TRPM8 and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of PKC, PKA, TRPV1, TRPA1, @GENE$ and ASIC in its antinociceptive mechanism.	0
Methods The acetic acid-induced writhing test and the paw-licking test, in which paw licking was induced by glutamate and formalin, were performed to evaluate the antinociceptive action of @CHEMICAL$ and to determine the involvement of PKC, PKA, TRPV1, TRPA1, TRPM8 and @GENE$ in its antinociceptive mechanism.	0
In an investigation into the participation of @GENE$ and ASICs in @CHEMICAL$'s antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of TRP channels and @GENE$ in @CHEMICAL$'s antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of @GENE$ and ASICs in CAT's antinociceptive mechanism, we used @CHEMICAL$ (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of TRP channels and @GENE$ in CAT's antinociceptive mechanism, we used @CHEMICAL$ (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of @GENE$ and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), @CHEMICAL$ (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of TRP channels and @GENE$ in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), @CHEMICAL$ (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of @GENE$ and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), @CHEMICAL$ (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of TRP channels and @GENE$ in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), @CHEMICAL$ (1.2mmol/paw) and acidified saline (2% acetic acid, pH 1.98).	0
In an investigation into the participation of @GENE$ and ASICs in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% @CHEMICAL$, pH 1.98).	0
In an investigation into the participation of TRP channels and @GENE$ in CAT's antinociceptive mechanism, we used capsaicin (2.2μg/paw), cinnamaldehyde (10mmol/paw), menthol (1.2mmol/paw) and acidified saline (2% @CHEMICAL$, pH 1.98).	0
Finally, the involvement of @GENE$ and PKA was also studied, and we showed that both play a role in the antinociceptive mechanism of @CHEMICAL$.	0
Finally, the involvement of PKC and @GENE$ was also studied, and we showed that both play a role in the antinociceptive mechanism of @CHEMICAL$.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, @GENE$, TRPM8, ASIC, glutamate receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, TRPV1, @GENE$, ASIC, glutamate receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, TRPV1, TRPM8, @GENE$, glutamate receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, @GENE$, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, @GENE$ and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of @CHEMICAL$ on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, PKC and @GENE$ participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, @GENE$, TRPM8, ASIC, @CHEMICAL$ receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, @GENE$, ASIC, @CHEMICAL$ receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, @GENE$, @CHEMICAL$ receptors, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, @CHEM-GENE$, PKC and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, @CHEMICAL$ receptors, @GENE$ and PKA participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, @CHEMICAL$ receptors, PKC and @GENE$ participate in CAT's antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, @GENE$, TRPM8, ASIC, glutamate receptors, PKC and PKA participate in @CHEMICAL$'s antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, @GENE$, ASIC, glutamate receptors, PKC and PKA participate in @CHEMICAL$'s antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, @GENE$, glutamate receptors, PKC and PKA participate in @CHEMICAL$'s antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, @GENE$, PKC and PKA participate in @CHEMICAL$'s antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, @GENE$ and PKA participate in @CHEMICAL$'s antinociceptive mechanism.	0
Conclusion The results of this work contribute information regarding the antinociceptive properties of CAT on acute pain and show that, at least in part, TRPV1, TRPM8, ASIC, glutamate receptors, PKC and @GENE$ participate in @CHEMICAL$'s antinociceptive mechanism.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEM-GENE$/progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEMICAL$/@GENE$ (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEMICAL$/progesterone receptors (@GENE$/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEMICAL$/progesterone receptors (ER/@GENE$) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEMICAL$/progesterone receptors (ER/PR) and @GENE$ (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @CHEMICAL$/progesterone receptors (ER/PR) and human epidermal growth factor receptor 2 (@GENE$), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for @GENE$/@CHEMICAL$ receptors (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/@CHEM-GENE$ (ER/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/@CHEMICAL$ receptors (@GENE$/PR) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/@CHEMICAL$ receptors (ER/@GENE$) and human epidermal growth factor receptor 2 (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/@CHEMICAL$ receptors (ER/PR) and @GENE$ (HER2), have been associated with poor prognosis and metastasis.	0
In particular, triple negative breast cancers (TNBCs), which do not express the genes for estrogen/@CHEMICAL$ receptors (ER/PR) and human epidermal growth factor receptor 2 (@GENE$), have been associated with poor prognosis and metastasis.	0
@CHEMICAL$ and 2-hydroxychalcone induced apoptosis by @GENE$ downregulation.	2
Xanthohumol and @CHEMICAL$ induced apoptosis by @GENE$ downregulation.	2
Importantly, @CHEMICAL$ and xanthohumol exerted more potent inhibitory effects on the proliferation, @GENE$ expression and invasive phenotype of MDA-MB-231 than chalcone.	2
Importantly, 2-hydroxychalcone and @CHEMICAL$ exerted more potent inhibitory effects on the proliferation, @GENE$ expression and invasive phenotype of MDA-MB-231 than chalcone.	2
Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, @GENE$ expression and invasive phenotype of MDA-MB-231 than @CHEMICAL$.	0
@CHEMICAL$ Derivatives as Novel @GENE$ Inhibitors.	2
4-Hydroxypyridazin-3(2H)-one Derivatives as Novel @CHEM-GENE$ Inhibitors.	0
@GENE$ (DAAO) catalyzes the oxidation of d-amino acids including @CHEMICAL$, a coagonist of the N-methyl-d-aspartate receptor.	5
d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including @CHEMICAL$, a coagonist of the @GENE$.	3
d-Amino acid oxidase (@GENE$) catalyzes the oxidation of d-amino acids including @CHEMICAL$, a coagonist of the N-methyl-d-aspartate receptor.	5
@CHEM-GENE$ (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor.	0
@CHEMICAL$ oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the @GENE$.	0
@CHEMICAL$ oxidase (@GENE$) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor.	0
@GENE$ (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the @CHEMICAL$ receptor.	0
d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the @CHEM-GENE$.	0
d-Amino acid oxidase (@GENE$) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the @CHEMICAL$ receptor.	0
@GENE$ (DAAO) catalyzes the oxidation of @CHEMICAL$ including d-serine, a coagonist of the N-methyl-d-aspartate receptor.	5
d-Amino acid oxidase (DAAO) catalyzes the oxidation of @CHEMICAL$ including d-serine, a coagonist of the @GENE$.	0
d-Amino acid oxidase (@GENE$) catalyzes the oxidation of @CHEMICAL$ including d-serine, a coagonist of the N-methyl-d-aspartate receptor.	5
We identified a series of @CHEMICAL$ derivatives as novel @GENE$ inhibitors with high potency and substantial cell permeability using fragment-based drug design.	2
@CHEMICAL$ exhibited the predicted binding mode and demonstrated high inhibitory activity for @GENE$ in enzyme- and cell-based assays.	2
Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and @CHEM-GENE$.	0
Comparative study on transcriptional activity of 17 parabens mediated by @GENE$ and @CHEMICAL$ receptor.	0
Comparative study on transcriptional activity of 17 @CHEMICAL$ mediated by estrogen receptor α and β and @GENE$.	0
Comparative study on transcriptional activity of 17 @CHEMICAL$ mediated by @GENE$ and androgen receptor.	0
Comparative study on transcriptional activity of 17 parabens mediated by @CHEMICAL$ receptor α and β and @GENE$.	0
Comparative study on transcriptional activity of 17 parabens mediated by @CHEM-GENE$ and androgen receptor.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by @CHEM-GENE$ (hERα), hERβ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human @CHEMICAL$ receptor α (@GENE$), hERβ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human @CHEMICAL$ receptor α (hERα), @GENE$ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human @CHEMICAL$ receptor α (hERα), hERβ and @GENE$ (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human @CHEMICAL$ receptor α (hERα), hERβ and androgen receptor (@GENE$) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by @GENE$ (hERα), hERβ and @CHEMICAL$ receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (@GENE$), hERβ and @CHEMICAL$ receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), @GENE$ and @CHEMICAL$ receptor (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and @CHEM-GENE$ (hAR) were investigated.	0
The structure-activity relationships of parabens which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and @CHEMICAL$ receptor (@GENE$) were investigated.	0
The structure-activity relationships of @CHEMICAL$ which are widely used as preservatives for transcriptional activities mediated by @GENE$ (hERα), hERβ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of @CHEMICAL$ which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (@GENE$), hERβ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of @CHEMICAL$ which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), @GENE$ and androgen receptor (hAR) were investigated.	0
The structure-activity relationships of @CHEMICAL$ which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and @GENE$ (hAR) were investigated.	0
The structure-activity relationships of @CHEMICAL$ which are widely used as preservatives for transcriptional activities mediated by human estrogen receptor α (hERα), hERβ and androgen receptor (@GENE$) were investigated.	0
Fourteen of 17 @CHEMICAL$ exhibited @GENE$ and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.	3
Fourteen of 17 @CHEMICAL$ exhibited hERα and/or @GENE$ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.	3
Fourteen of 17 @CHEMICAL$ exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 parabens showed @GENE$ agonistic or antagonistic activity.	0
Fourteen of 17 parabens exhibited @GENE$ and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 @CHEMICAL$ showed AR agonistic or antagonistic activity.	0
Fourteen of 17 parabens exhibited hERα and/or @GENE$ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 @CHEMICAL$ showed AR agonistic or antagonistic activity.	0
Fourteen of 17 parabens exhibited hERα and/or hERβ agonistic activity at concentrations of ⩽1×10(-5)M, whereas none of the 17 @CHEMICAL$ showed @GENE$ agonistic or antagonistic activity.	0
Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, @CHEMICAL$ (C7) and pentylparaben (C5) showed the most potent @GENE$ and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, @CHEMICAL$ (C7) and pentylparaben (C5) showed the most potent ERα and @GENE$ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and @CHEMICAL$ (C5) showed the most potent @GENE$ and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and @CHEMICAL$ (C5) showed the most potent ERα and @GENE$ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 @CHEMICAL$ with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent @GENE$ and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 @CHEMICAL$ with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and @GENE$ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 parabens with linear @CHEMICAL$ chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent @GENE$ and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Among 12 parabens with linear @CHEMICAL$ chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and @GENE$ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.	3
Most @CHEMICAL$ showing estrogenic activity exhibited @GENE$-agonistic activity at lower concentrations than those inducing ERα-agonistic activity.	3
Most @CHEMICAL$ showing estrogenic activity exhibited ERβ-agonistic activity at lower concentrations than those inducing @GENE$-agonistic activity.	3
The estrogenic activity of @CHEMICAL$ was markedly decreased by incubation with rat liver microsomes, and the decrease of activity was blocked by a @GENE$ inhibitor.	0
These results indicate that @CHEMICAL$ are selective agonists for @GENE$ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	3
These results indicate that @CHEMICAL$ are selective agonists for ERβ over @GENE$; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	3
These results indicate that @CHEMICAL$ are selective agonists for ERβ over ERα; their interactions with @GENE$ are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	0
These results indicate that @CHEMICAL$ are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by @GENE$, leading to attenuation of their estrogenic activity.	5
These results indicate that parabens are selective agonists for @GENE$ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the @CHEMICAL$ groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	0
These results indicate that parabens are selective agonists for ERβ over @GENE$; their interactions with ERα/β are dependent on the size and bulkiness of the @CHEMICAL$ groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	0
These results indicate that parabens are selective agonists for ERβ over ERα; their interactions with @GENE$ are dependent on the size and bulkiness of the @CHEMICAL$ groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.	0
These results indicate that parabens are selective agonists for ERβ over ERα; their interactions with ERα/β are dependent on the size and bulkiness of the @CHEMICAL$ groups; and they are metabolized by @GENE$, leading to attenuation of their estrogenic activity.	0
The cyclin D1 (@GENE$) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant @CHEMICAL$-based chemotherapy.	0
The cyclin D1 (CCND1) @GENE$ polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant @CHEMICAL$-based chemotherapy.	0
The @GENE$ (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant @CHEMICAL$-based chemotherapy.	0
Patients treated with @CHEMICAL$-based chemotherapy, carrying the @GENE$ rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019).	0
Patients treated with @CHEMICAL$-based chemotherapy, carrying the CCND1 @GENE$ genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019).	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein @CHEMICAL$/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein @CHEMICAL$, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive @CHEMICAL$ species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and @CHEMICAL$-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of @CHEMICAL$, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, @CHEMICAL$, total cholesterol, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total @CHEMICAL$, non-esterified fatty acids, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, @GENE$ cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified @CHEMICAL$, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The results showed that levels of glucose, @GENE$, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, @GENE$, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, @GENE$, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, @GENE$, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, @GENE$, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, @GENE$, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, @GENE$ @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very @GENE$ cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/@GENE$ cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while adiponectin was augmented by GS treatment.	0
The results showed that levels of glucose, leptin, insulin, C-peptide, resistin, tumor necrosis factor-α, interleukin-6, triglycerides, total cholesterol, non-esterified fatty acids, high-density lipoprotein @CHEMICAL$, very low-density lipoprotein cholesterol/low-density lipoprotein cholesterol, reactive oxygen species (ROS), and thiobarbituric acid-reactive substance (TBARS) in serum were down-regulated, while @GENE$ was augmented by GS treatment.	0
The administration of GS significantly decreased @CHEM-GENE$, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, @GENE$ ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, @GENE$, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, @GENE$, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, @GENE$, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, @GENE$, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, @GENE$ N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal @GENE$, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, @GENE$, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, @GENE$, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, @GENE$, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, @GENE$, and caspase-3 expressions.	0
The administration of GS significantly decreased @CHEMICAL$ regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and @GENE$ expressions.	0
The administration of GS significantly decreased @GENE$, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, @GENE$ ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, @GENE$, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, @CHEM-GENE$, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, @GENE$, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, @GENE$, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, @GENE$ N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal @GENE$, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, @GENE$, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, @GENE$, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, @GENE$, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, @GENE$, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible @CHEMICAL$ synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun N-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and @GENE$ expressions.	0
The administration of GS significantly decreased @GENE$, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, @GENE$ ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, @GENE$, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, @GENE$, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, @GENE$, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, @GENE$, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, @GENE$ @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal @GENE$, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, @GENE$, transforming growth factor-β1, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, @GENE$, Bax, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, @GENE$, cytochrome c, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, @GENE$, and caspase-3 expressions.	0
The administration of GS significantly decreased sterol regulatory element binding protein-1, nuclear factor-kappa ?>Bp65, cyclooxygenase-2, inducible nitric oxide synthase, monocyte chemotactic protein-1, intracellular adhesion molecule-1, phosphor c-Jun @CHEMICAL$-terminal kinase, activator protein-1, transforming growth factor-β1, Bax, cytochrome c, and @GENE$ expressions.	0
Compounds 16 and 19 were more active than the positive control @CHEMICAL$, a known inhibitor of the @GENE$ signaling pathway.	0
Wattakaka volubilis @CHEMICAL$ mixture (WVSM) and PPG (1-50μM) significantly inhibited the @GENE$ and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.	2
Wattakaka volubilis @CHEMICAL$ mixture (WVSM) and PPG (1-50μM) significantly inhibited the COX-2 and @GENE$ enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.	2
Wattakaka volubilis steroidal glycoside mixture (WVSM) and @CHEMICAL$ (1-50μM) significantly inhibited the @GENE$ and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.	2
Wattakaka volubilis steroidal glycoside mixture (WVSM) and @CHEMICAL$ (1-50μM) significantly inhibited the COX-2 and @GENE$ enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.	2
@GENE$ is a transmembrane glycoprotein that mediates @CHEMICAL$-dependent interactions between adjacent epithelial cells.	0
Fasting serum @GENE$, leptin, adiponectin, insulin, glucagon, @CHEMICAL$, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	0
Fasting serum ghrelin, @GENE$, adiponectin, insulin, glucagon, @CHEMICAL$, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	0
Fasting serum ghrelin, leptin, @GENE$, insulin, glucagon, @CHEMICAL$, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	0
Fasting serum ghrelin, leptin, adiponectin, @GENE$, glucagon, @CHEMICAL$, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	0
Fasting serum ghrelin, leptin, adiponectin, insulin, @GENE$, @CHEMICAL$, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).	0
Our findings indicate that serum @CHEMICAL$ levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal @GENE$ level <10 pg/ml (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum @CHEMICAL$ levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma @GENE$ response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum @CHEMICAL$ levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma ACTH response to @GENE$) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal @GENE$ level <10 pg/ml (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum @CHEMICAL$ ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma @GENE$ response to corticotrophin-releasing hormone) and (2) serum @CHEMICAL$ ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma ACTH response to @GENE$) and (2) serum @CHEMICAL$ ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal @GENE$ level <10 pg/ml (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum @CHEMICAL$ levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma @GENE$ response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum @CHEMICAL$ levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma ACTH response to @GENE$) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum @CHEMICAL$ levels, urine free cortisol levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal @GENE$ level <10 pg/ml (or poor plasma ACTH response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free @CHEMICAL$ levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma @GENE$ response to corticotrophin-releasing hormone) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free @CHEMICAL$ levels, adrenal scintigraphy, and clinical manifestation.	0
Our findings indicate that serum cortisol levels ≥1.8 μg/dl after 1 mg DST are useful to confirm the diagnosis of SCS if both of the following criteria are met: (1) basal ACTH level <10 pg/ml (or poor plasma ACTH response to @GENE$) and (2) serum cortisol ≥5 μg/dl at 21:00 to 23:00 h. If only one of (1) and (2) are met, we recommend that other clinical features are considered in the diagnosis of SCS, including serum dehydroepiandrosterone sulfate levels, urine free @CHEMICAL$ levels, adrenal scintigraphy, and clinical manifestation.	0
@CHEMICAL$ suppressed @GENE$-dependent ethanol hepatotoxicity via depleting heme pool and releasing CO.	2
Quercetin suppressed @GENE$-dependent @CHEMICAL$ hepatotoxicity via depleting heme pool and releasing CO.	0
Quercetin suppressed @GENE$-dependent ethanol hepatotoxicity via depleting heme pool and releasing @CHEMICAL$.	0
Naturally occuring quercetin protects hepatocytes from @CHEMICAL$-induced oxidative stress, and heme oxygenase-1 (@GENE$) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from @CHEMICAL$-induced oxidative stress, and @GENE$ (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and @CHEMICAL$ oxygenase-1 (@GENE$) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and @CHEM-GENE$ (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (@GENE$) induction and @CHEMICAL$ (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and @GENE$ (HO-1) induction and @CHEMICAL$ (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (@GENE$) induction and carbon monoxide (@CHEMICAL$) metabolite may be implicated in the beneficial effect.	0
Naturally occuring quercetin protects hepatocytes from ethanol-induced oxidative stress, and @GENE$ (HO-1) induction and carbon monoxide (@CHEMICAL$) metabolite may be implicated in the beneficial effect.	0
Naturally occuring @CHEMICAL$ protects hepatocytes from ethanol-induced oxidative stress, and heme oxygenase-1 (@GENE$) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
Naturally occuring @CHEMICAL$ protects hepatocytes from ethanol-induced oxidative stress, and @GENE$ (HO-1) induction and carbon monoxide (CO) metabolite may be implicated in the beneficial effect.	0
However, the precise mechanism by which quercetin counteracts @GENE$-mediated @CHEMICAL$ hepatotoxicity through HO-1 system is still remained unclear.	0
However, the precise mechanism by which quercetin counteracts CYP2E1-mediated @CHEMICAL$ hepatotoxicity through @GENE$ system is still remained unclear.	0
However, the precise mechanism by which @CHEMICAL$ counteracts @GENE$-mediated ethanol hepatotoxicity through HO-1 system is still remained unclear.	2
However, the precise mechanism by which @CHEMICAL$ counteracts CYP2E1-mediated ethanol hepatotoxicity through @GENE$ system is still remained unclear.	0
Our data showed that chronic @CHEMICAL$ over-activated @GENE$ but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).	1
Our data showed that chronic @CHEMICAL$ over-activated CYP2E1 but suppressed @GENE$ with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).	2
Our data showed that chronic ethanol over-activated @GENE$ but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by @CHEMICAL$ (100mg/kg.bw.).	0
Our data showed that chronic ethanol over-activated CYP2E1 but suppressed @GENE$ with concurrent hepatic oxidative damage, which was partially normalized by @CHEMICAL$ (100mg/kg.bw.).	0
@CHEMICAL$ (100μM) induced @GENE$ and depleted heme pool when incubated to human hepatocytes.	1
@CHEMICAL$-stimulated (100mM) @GENE$ upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.	1
@CHEMICAL$-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by @GENE$ inhibition with resultant heme accumulation.	2
Ethanol-stimulated (100mM) @GENE$ upregulation was suppressed by @CHEMICAL$ but further enhanced by HO-1 inhibition with resultant heme accumulation.	2
Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by @CHEMICAL$ but further enhanced by @GENE$ inhibition with resultant heme accumulation.	0
Ethanol-stimulated (100mM) @GENE$ upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant @CHEMICAL$ accumulation.	0
Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by @GENE$ inhibition with resultant @CHEMICAL$ accumulation.	5
@CHEMICAL$ scavenging blocked the suppression of quercetin only on @GENE$ activity.	2
CO scavenging blocked the suppression of @CHEMICAL$ only on @GENE$ activity.	0
CO donor dose-dependently inactivated CYP2E1 of @CHEMICAL$-incubated microsome, which was mimicked by @GENE$ substrate but abolished by CO scavenger.	0
CO donor dose-dependently inactivated @GENE$ of @CHEMICAL$-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.	1
@CHEMICAL$ donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by @GENE$ substrate but abolished by CO scavenger.	0
@CHEMICAL$ donor dose-dependently inactivated @GENE$ of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger.	2
CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by @GENE$ substrate but abolished by @CHEMICAL$ scavenger.	0
CO donor dose-dependently inactivated @GENE$ of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by @CHEMICAL$ scavenger.	2
Thus, @GENE$-mediated @CHEMICAL$ hepatotoxicity was alleviated by quercetin through HO-1 induction.	0
Thus, CYP2E1-mediated @CHEMICAL$ hepatotoxicity was alleviated by quercetin through @GENE$ induction.	0
Thus, @GENE$-mediated ethanol hepatotoxicity was alleviated by @CHEMICAL$ through HO-1 induction.	0
Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by @CHEMICAL$ through @GENE$ induction.	1
Depleted heme pool and @CHEMICAL$ releasing limited protein synthesis and inhibited enzymatic activity of @GENE$, respectively.	2
Novel racemic @CHEMICAL$ analogues as potent @GENE$ inhibitors.	2
Agonistic activity of @CHEMICAL$ on activation of @GENE$/AKT pathway in the rat uterus during the estrous cycle.	3
Agonistic activity of @CHEMICAL$ on activation of GSK 3β/@GENE$ pathway in the rat uterus during the estrous cycle.	1
We examined the ability of @CHEMICAL$ (ICI) to block uterine cell proliferation via protein kinase b/@GENE$ pathway in the uterus of the rat during the estrous cycle.	0
We examined the ability of @CHEMICAL$ (ICI) to block uterine cell proliferation via @GENE$/AKT pathway in the uterus of the rat during the estrous cycle.	0
We examined the ability of ICI 182,780 (@CHEMICAL$) to block uterine cell proliferation via protein kinase b/@GENE$ pathway in the uterus of the rat during the estrous cycle.	0
We examined the ability of ICI 182,780 (@CHEMICAL$) to block uterine cell proliferation via @GENE$/AKT pathway in the uterus of the rat during the estrous cycle.	0
Both @CHEMICAL$ treatments, induced a significant decrease (p<0.01) in uterine @GENE$ (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	2
Both @CHEMICAL$ treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (@GENE$) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	2
Both @CHEMICAL$ treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine @GENE$ (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both @CHEMICAL$ treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (@GENE$) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both @CHEMICAL$ treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of @GENE$, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @CHEM-GENE$ (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @CHEMICAL$ receptor alpha (@GENE$) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @CHEMICAL$ receptor alpha (ERα) content, had no effect on uterine @GENE$ (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @CHEMICAL$ receptor alpha (ERα) content, had no effect on uterine progesterone receptor (@GENE$) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @CHEMICAL$ receptor alpha (ERα) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of @GENE$, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine @GENE$ (ERα) content, had no effect on uterine @CHEMICAL$ receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (@GENE$) content, had no effect on uterine @CHEMICAL$ receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine @CHEM-GENE$ (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine @CHEMICAL$ receptor (@GENE$) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERα) content, had no effect on uterine @CHEMICAL$ receptor (PR) protein expression and caused marked nuclear localization of @GENE$, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.	0
Furthermore, we detected that @CHEMICAL$ treatment induced @GENE$ (Gsk3-β) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.	1
Furthermore, we detected that @CHEMICAL$ treatment induced glycogen synthase kinase (@GENE$) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.	1
Furthermore, we detected that @CHEMICAL$ treatment induced glycogen synthase kinase (Gsk3-β) Ser 9 phosphorylation, which correlates with @GENE$ nuclear localization.	0
We observed that the administration of @CHEMICAL$ at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of @GENE$ phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.	2
We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of @GENE$ phosphorylation at @CHEMICAL$ 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.	0
We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of @GENE$ phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas @CHEMICAL$ treatment at 00:00h on estrus day had no effect on these parameters.	0
The overall results indicate that @CHEMICAL$ may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the @GENE$ pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.	1
@CHEMICAL$ derived from Grundmann's ketone as a novel chemotype of @GENE$ inhibitors.	2
Aminopropylindenes derived from @CHEMICAL$ as a novel chemotype of @GENE$ inhibitors.	2
A series of @CHEMICAL$, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (@GENE$)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.	0
A series of @CHEMICAL$, designed as mimics of a cationic high energy intermediate in the @GENE$ (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.	0
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (@GENE$)-mediated cyclization of @CHEMICAL$ to lanosterol was prepared from Grundmann's ketone.	5
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the @GENE$ (OSC)-mediated cyclization of @CHEMICAL$ to lanosterol was prepared from Grundmann's ketone.	5
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (@GENE$)-mediated cyclization of 2,3-oxidosqualen to @CHEMICAL$ was prepared from Grundmann's ketone.	5
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the @GENE$ (OSC)-mediated cyclization of 2,3-oxidosqualen to @CHEMICAL$ was prepared from Grundmann's ketone.	5
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (@GENE$)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from @CHEMICAL$.	0
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the @GENE$ (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from @CHEMICAL$.	0
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the @CHEMICAL$ cyclase(1) (@GENE$)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.	0
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the @CHEM-GENE$ (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone.	0
A @CHEMICAL$ derivative showed promising inhibition of @GENE$ in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.	2
A N,N-dimethylaminopropyl derivative showed promising inhibition of @GENE$ in combination with low cytotoxicity, and showed significant reduction of @CHEMICAL$ biosynthesis in a human cell line.	5
The @CHEMICAL$ required for potentiation of skeletal muscle contraction is released via @GENE$ hemichannels.	5
During repetitive stimulation of skeletal muscle, extracellular @CHEMICAL$ levels raise, activating @GENE$, increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.	1
During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating @GENE$, increasing @CHEMICAL$ influx, and enhancing contractile force, a response called potentiation.	0
We found that @CHEMICAL$ appears to be released through @GENE$ hemichannels (Panx1 HCs).	0
We found that @CHEMICAL$ appears to be released through pannexin1 hemichannels (@GENE$ HCs).	0
Immunocytochemical analyses and function were consistent with @GENE$ localization to T-tubules intercalated with @CHEMICAL$ and ryanodine receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	0
Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with @CHEMICAL$ and @GENE$ in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	0
Immunocytochemical analyses and function were consistent with @GENE$ localization to T-tubules intercalated with dihydropyridine and @CHEMICAL$ receptors in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	0
Immunocytochemical analyses and function were consistent with pannexin1 localization to T-tubules intercalated with dihydropyridine and @CHEM-GENE$ in slow (soleus) and fast (extensor digitorum longus, EDL) muscles.	0
Consistent with two @CHEMICAL$ uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or @GENE$ (GLUT4), and blocked by dual blockade.	5
Consistent with two @CHEMICAL$ uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (@GENE$), and blocked by dual blockade.	5
Consistent with two glucose uptake pathways, induced uptake of @CHEMICAL$, a fluorescent glucose derivative, was decreased by inhibition of HCs or @GENE$ (GLUT4), and blocked by dual blockade.	5
Consistent with two glucose uptake pathways, induced uptake of @CHEMICAL$, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (@GENE$), and blocked by dual blockade.	5
Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent @CHEMICAL$ derivative, was decreased by inhibition of HCs or @GENE$ (GLUT4), and blocked by dual blockade.	0
Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent @CHEMICAL$ derivative, was decreased by inhibition of HCs or glucose transporter (@GENE$), and blocked by dual blockade.	0
Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or @CHEM-GENE$ (GLUT4), and blocked by dual blockade.	0
Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or @CHEMICAL$ transporter (@GENE$), and blocked by dual blockade.	0
ATP release, @CHEMICAL$ uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of @GENE$ knockout mice.	0
@CHEMICAL$ release, Etd(+) uptake, and potentiation induced by repetitive electrical stimulation were blocked by HC blockers and did not occur in muscles of @GENE$ knockout mice.	0
MRS2179, a @GENE$ blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles @CHEMICAL$ activates P2Y1 but not P2X receptors.	0
MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles @CHEMICAL$ activates @GENE$ but not P2X receptors.	1
MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles @CHEMICAL$ activates P2Y1 but not @GENE$.	0
Phosphorylation on @CHEMICAL$ and Thr residues of @GENE$ was increased during potentiation, possibly mediating HC opening.	0
Phosphorylation on Ser and @CHEMICAL$ residues of @GENE$ was increased during potentiation, possibly mediating HC opening.	0
Opening of @GENE$ HCs during repetitive activation allows efflux of @CHEMICAL$, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.	5
Opening of @GENE$ HCs during repetitive activation allows efflux of ATP, influx of @CHEMICAL$ and possibly Ca(2+) too, which are required for potentiation of contraction.	5
Opening of @GENE$ HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly @CHEMICAL$ too, which are required for potentiation of contraction.	5
The rate limiting enzyme of beta-oxidation (@GENE$) was significantly over-expressed in the liver with @CHEMICAL$ treatment.	1
These results indicate that @CHEMICAL$ suppresses body weight gain in mice, possibly at least related to the up-regulation of @GENE$ gene expression.	1
When dual angiogenic growth factors (GFs), such as @GENE$ (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (@GENE$) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and @GENE$ (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (@GENE$), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the @GENE$ release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	1
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of @GENE$, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core @CHEMICAL$ and more than 45% with HMW core PLGA.	1
When dual angiogenic growth factors (GFs), such as @GENE$ (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (@GENE$) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and @GENE$ (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (@GENE$), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	0
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the @GENE$ release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	1
When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of @GENE$, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core @CHEMICAL$.	1
Potency switch between CHK1 and @GENE$: Discovery of @CHEMICAL$- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.	2
Potency switch between CHK1 and MK2: Discovery of @CHEMICAL$- and imidazo[1,2-c]pyrimidine-based @GENE$ inhibitors.	2
Potency switch between @GENE$ and MK2: Discovery of @CHEMICAL$- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.	2
Potency switch between CHK1 and @GENE$: Discovery of imidazo[1,2-a]pyrazine- and @CHEMICAL$-based kinase inhibitors.	2
Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and @CHEMICAL$-based @GENE$ inhibitors.	2
Potency switch between @GENE$ and MK2: Discovery of imidazo[1,2-a]pyrazine- and @CHEMICAL$-based kinase inhibitors.	2
The Fer @CHEMICAL$ kinase is important for @GENE$-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo.	0
The @GENE$ @CHEMICAL$ kinase is important for platelet-derived growth factor-BB-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo.	0
The Fer @CHEM-GENE$ is important for platelet-derived growth factor-BB-induced Stat3 phosphorylation, colony formation in soft agar and tumor growth in vivo.	0
The Fer @CHEMICAL$ kinase is important for platelet-derived growth factor-BB-induced @GENE$ phosphorylation, colony formation in soft agar and tumor growth in vivo.	0
Fer is a cytoplasmic @CHEM-GENE$ that is activated in response to platelet-derived growth factor (PDGF) stimulation.	0
Fer is a cytoplasmic @CHEMICAL$ kinase that is activated in response to @GENE$ (PDGF) stimulation.	0
@GENE$ is a cytoplasmic @CHEMICAL$ kinase that is activated in response to platelet-derived growth factor (PDGF) stimulation.	0
Fer is a cytoplasmic @CHEMICAL$ kinase that is activated in response to platelet-derived growth factor (@GENE$) stimulation.	0
Discovery of @CHEMICAL$ and aryl amides as potent and selective @GENE$ antagonists for the treatment of obesity (Part I).	4
Discovery of aryl ureas and @CHEMICAL$ as potent and selective @GENE$ antagonists for the treatment of obesity (Part I).	4
Discovery of aryl ureas and aryl amides as potent and selective @CHEM-GENE$ antagonists for the treatment of obesity (Part I).	0
A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective @CHEM-GENE$ (H3R) antagonists.	0
A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective @CHEMICAL$ H3 receptor (@GENE$) antagonists.	0
A series of structurally novel @CHEMICAL$ was derived from optimization of the HTS lead as selective @GENE$ (H3R) antagonists.	4
A series of structurally novel @CHEMICAL$ was derived from optimization of the HTS lead as selective histamine H3 receptor (@GENE$) antagonists.	4
Structure and energetics of gas phase @CHEMICAL$-bonding in @GENE$ as studied by BIRD.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), I(-), @CHEMICAL$, H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (@CHEMICAL$, Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), @CHEMICAL$, I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), @CHEMICAL$, NO3(-), H2PO4(-), HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), I(-), NO3(-), @CHEMICAL$, HSO4(-), and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), @CHEMICAL$, and tosylate (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and @CHEMICAL$ (TsO(-))) have been studied in the gas phase by both experimental and theoretical methods.	0
Complexes of @GENE$ with a range of anions (Cl(-), Br(-), I(-), NO3(-), H2PO4(-), HSO4(-), and tosylate (@CHEMICAL$)) have been studied in the gas phase by both experimental and theoretical methods.	0
An increase in the energy required to remove the same anion from the @GENE$ when compared to the bidentate and monodentate receptors is explained as being due to the increase in @CHEMICAL$ bonding interactions.	0
An increase in the energy required to remove the same anion from the tridentate receptor when compared to the @GENE$ is explained as being due to the increase in @CHEMICAL$ bonding interactions.	0
In terms of the mechanisms, we found that @CHEMICAL$ amide hydrolase (@GENE$) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	0
In terms of the mechanisms, we found that @CHEM-GENE$ (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	0
In terms of the mechanisms, we found that fatty acid @CHEMICAL$ hydrolase (@GENE$) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	0
In terms of the mechanisms, we found that @CHEM-GENE$ (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	0
In terms of the mechanisms, we found that fatty acid amide hydrolase (@GENE$) which degrades @CHEMICAL$, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	5
In terms of the mechanisms, we found that @GENE$ (FAAH) which degrades @CHEMICAL$, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.	5
However, enzymes contributing to oxidative metabolism of @CHEMICAL$, namely @GENE$ and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.	5
However, enzymes contributing to oxidative metabolism of @CHEMICAL$, namely cyclooxygenase-1 and @GENE$, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.	5
However, enzymes contributing to oxidative metabolism of anandamide, namely @GENE$ and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of @CHEMICAL$.	5
However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and @GENE$, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of @CHEMICAL$.	5
@CHEMICAL$ is actively eliminated from neuronal cells by @GENE$.	5
High cholesterol turnover catalyzed by @CHEM-GENE$ is essential for neural functions, especially learning.	0
High @CHEMICAL$ turnover catalyzed by @GENE$ is essential for neural functions, especially learning.	5
Because @CHEMICAL$ (24-OHC), produced by @GENE$, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.	5
Because 24(S)-hydroxycholesterol (@CHEMICAL$), produced by @GENE$, induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.	5
Here, using differentiated SH-SY5Y neuron-like cells as a model, we examined whether @CHEMICAL$ is actively eliminated via @GENE$ induced by its accumulation.	0
The expression of @GENE$ and ABCG1 was induced by 24-OHC, as well as TO901317 and @CHEMICAL$, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and @GENE$ was induced by 24-OHC, as well as TO901317 and @CHEMICAL$, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and @CHEMICAL$, which are ligands of the @GENE$ LXR/RXR.	0
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and @CHEMICAL$, which are ligands of the nuclear receptors @GENE$/RXR.	0
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and @CHEMICAL$, which are ligands of the nuclear receptors LXR/@GENE$.	0
The expression of @GENE$ and ABCG1 was induced by @CHEMICAL$, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and @GENE$ was induced by @CHEMICAL$, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and ABCG1 was induced by @CHEMICAL$, as well as TO901317 and retinoic acid, which are ligands of the @GENE$ LXR/RXR.	0
The expression of ABCA1 and ABCG1 was induced by @CHEMICAL$, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors @GENE$/RXR.	0
The expression of ABCA1 and ABCG1 was induced by @CHEMICAL$, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/@GENE$.	0
The expression of @GENE$ and ABCG1 was induced by 24-OHC, as well as @CHEMICAL$ and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and @GENE$ was induced by 24-OHC, as well as @CHEMICAL$ and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.	1
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as @CHEMICAL$ and retinoic acid, which are ligands of the @GENE$ LXR/RXR.	0
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as @CHEMICAL$ and retinoic acid, which are ligands of the nuclear receptors @GENE$/RXR.	0
The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as @CHEMICAL$ and retinoic acid, which are ligands of the nuclear receptors LXR/@GENE$.	0
When the expression of @GENE$ and ABCG1 was induced, @CHEMICAL$ efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor.	0
When the expression of ABCA1 and @GENE$ was induced, @CHEMICAL$ efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor.	0
When the expression of ABCA1 and ABCG1 was induced, @CHEMICAL$ efflux was stimulated in the presence of @GENE$ (HDL), whereas apolipoprotein A-I was not an efficient acceptor.	0
When the expression of ABCA1 and ABCG1 was induced, @CHEMICAL$ efflux was stimulated in the presence of high density lipoprotein (@GENE$), whereas apolipoprotein A-I was not an efficient acceptor.	0
When the expression of ABCA1 and ABCG1 was induced, @CHEMICAL$ efflux was stimulated in the presence of high density lipoprotein (HDL), whereas @GENE$ was not an efficient acceptor.	0
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed @CHEMICAL$ efflux in the presence of @GENE$, whereas efflux in the presence of apolipoprotein A-I was marginal.	0
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed @CHEMICAL$ efflux in the presence of HDL, whereas efflux in the presence of @GENE$ was marginal.	0
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing @GENE$ or ABCG1; we clearly observed @CHEMICAL$ efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.	5
To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or @GENE$; we clearly observed @CHEMICAL$ efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.	5
Furthermore, the treatment of primary cerebral neurons with @GENE$/RXR ligands suppressed the toxicity of @CHEMICAL$.	0
Furthermore, the treatment of primary cerebral neurons with LXR/@GENE$ ligands suppressed the toxicity of @CHEMICAL$.	0
These results suggest that @GENE$ actively eliminates @CHEMICAL$ in the presence of HDL as a lipid acceptor and protects neuronal cells.	5
These results suggest that ABCA1 actively eliminates @CHEMICAL$ in the presence of @GENE$ as a lipid acceptor and protects neuronal cells.	0
Molecular docking studies were performed with @GENE$ (HSA: PDB 1E78), showing binding pattern with @CHEMICAL$ residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (@GENE$: PDB 1E78), showing binding pattern with @CHEMICAL$ residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with @CHEMICAL$ residues Arg218, Arg222 and Lys444, identifies the ligand-@GENE$ interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with @GENE$ (HSA: PDB 1E78), showing binding pattern with amino acid residues @CHEMICAL$218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (@GENE$: PDB 1E78), showing binding pattern with amino acid residues @CHEMICAL$218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues @CHEMICAL$218, Arg222 and Lys444, identifies the ligand-@GENE$ interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with @GENE$ (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, @CHEMICAL$222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (@GENE$: PDB 1E78), showing binding pattern with amino acid residues Arg218, @CHEMICAL$222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, @CHEMICAL$222 and Lys444, identifies the ligand-@GENE$ interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with @GENE$ (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and @CHEMICAL$444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (@GENE$: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and @CHEMICAL$444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.	0
Molecular docking studies were performed with Human Serum Albumin (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and @CHEMICAL$444, identifies the ligand-@GENE$ interaction for the transportation affinity of the ligand at the specific site of the target.	0
Synergistic enhancement of cancer therapy using a combination of @GENE$ targeted @CHEMICAL$ copolymer-drug conjugates and gold nanorod induced hyperthermia.	0
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of @GENE$ (HSP) targeted @CHEMICAL$ (HPMA) copolymer-drug conjugates.	0
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of heat shock protein (@GENE$) targeted @CHEMICAL$ (HPMA) copolymer-drug conjugates.	0
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of @GENE$ (HSP) targeted N-(2-hydroxypropyl)methacrylamide (@CHEMICAL$) copolymer-drug conjugates.	0
In this study, tumor hyperthermia was utilized as a means to increase the active delivery of heat shock protein (@GENE$) targeted N-(2-hydroxypropyl)methacrylamide (@CHEMICAL$) copolymer-drug conjugates.	0
Following hyperthermia, induced expression of cell surface @GENE$ (HSP) @CHEMICAL$ regulated protein 78kDa (GRP78) was utilized for targeted drug therapy.	0
Following hyperthermia, induced expression of cell surface heat shock protein (@GENE$) @CHEMICAL$ regulated protein 78kDa (GRP78) was utilized for targeted drug therapy.	0
Following hyperthermia, induced expression of cell surface heat shock protein (HSP) @CHEM-GENE$ (GRP78) was utilized for targeted drug therapy.	0
Following hyperthermia, induced expression of cell surface heat shock protein (HSP) @CHEMICAL$ regulated protein 78kDa (@GENE$) was utilized for targeted drug therapy.	0
Conjugates bearing the anticancer agents @CHEMICAL$ (AHGDM), docetaxel (DOC), or cisplatin and the @GENE$ targeting peptide WDLAWMFRLPVG were synthesized and characterized.	0
Conjugates bearing the anticancer agents aminohexylgeldanamycin (@CHEMICAL$), docetaxel (DOC), or cisplatin and the @GENE$ targeting peptide WDLAWMFRLPVG were synthesized and characterized.	0
Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), @CHEMICAL$ (DOC), or cisplatin and the @GENE$ targeting peptide WDLAWMFRLPVG were synthesized and characterized.	0
Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), docetaxel (@CHEMICAL$), or cisplatin and the @GENE$ targeting peptide WDLAWMFRLPVG were synthesized and characterized.	0
Conjugates bearing the anticancer agents aminohexylgeldanamycin (AHGDM), docetaxel (DOC), or @CHEMICAL$ and the @GENE$ targeting peptide WDLAWMFRLPVG were synthesized and characterized.	0
@GENE$ targeted @CHEMICAL$ and DOC conjugates demonstrated active binding comparable to native targeting peptide.	0
@GENE$ targeted AHGDM and @CHEMICAL$ conjugates demonstrated active binding comparable to native targeting peptide.	0
@GENE$ targeted @CHEMICAL$ conjugates exhibited high potency against DU145 cells with an IC50 of 2.4nM.	0
@GENE$ targeted @CHEMICAL$ and DOC conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively.	0
@GENE$ targeted AHGDM and @CHEMICAL$ conjugates demonstrated synergistic effects in combination with hyperthermia with combination index values of 0.65 and 0.45 respectively.	0
Based on these results, @GENE$ targeted @CHEMICAL$ conjugates were selected for in vivo evaluation.	0
In DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of @GENE$ targeted @CHEMICAL$ copolymer-docetaxel at 10mg/kg resulted in maintained tumor regression for a period of 30days.	0
In DU145 tumor bearing mice, a single treatment of tumor hyperthermia, induced via gold nanorod mediated plasmonic photothermal therapy, and intravenous administration of @GENE$ targeted HPMA copolymer-@CHEMICAL$ at 10mg/kg resulted in maintained tumor regression for a period of 30days.	0
Presynaptic @GENE$ modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a @CHEMICAL$ dependent manner.	0
Presynaptic CaMKIIα modulates @GENE$ activation in striatonigral terminals of the rat brain in a @CHEMICAL$ dependent manner.	0
Presynaptic @GENE$ modulates @CHEMICAL$ D3 receptor activation in striatonigral terminals of the rat brain in a Ca(2+) dependent manner.	0
Presynaptic CaMKIIα modulates @CHEM-GENE$ activation in striatonigral terminals of the rat brain in a Ca(2+) dependent manner.	0
In this study we examined whether the presynaptic effects of @GENE$ stimulation in the substantia nigra reticulata (SNr) are modulated by @CHEMICAL$ activation of CaMKIIα.	0
In this study we examined whether the presynaptic effects of D3 receptor stimulation in the substantia nigra reticulata (SNr) are modulated by @CHEMICAL$ activation of @GENE$.	0
In SNr synaptosomes two procedures that increase cytoplasmic @CHEMICAL$, ionomycin and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating @GENE$.	0
In SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), @CHEMICAL$ and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating @GENE$.	0
In SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and @CHEMICAL$-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating @GENE$.	0
In SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and K(+)-depolarization, blocked the additional stimulation of @CHEMICAL$ accumulation produced by coactivating @GENE$.	0
In SNr synaptosomes two procedures that increase cytoplasmic Ca(2+), ionomycin and K(+)-depolarization, blocked the additional stimulation of cAMP accumulation produced by coactivating @CHEM-GENE$.	0
The selective @GENE$ inhibitor @CHEMICAL$ reversed the blockade produced by ionomycin and K(+)-depolarization.	2
The selective @GENE$ inhibitor KN-62 reversed the blockade produced by @CHEMICAL$ and K(+)-depolarization.	2
The selective @GENE$ inhibitor KN-62 reversed the blockade produced by ionomycin and @CHEMICAL$-depolarization.	0
Immunoblot studies showed that K(+)-depolarization increased CaMKIIα phosphorylation in a @CHEMICAL$ sensitive manner and promoted @GENE$ binding to D3 receptors.	0
Immunoblot studies showed that K(+)-depolarization increased CaMKIIα phosphorylation in a @CHEMICAL$ sensitive manner and promoted CaMKIIα binding to @GENE$.	0
Immunoblot studies showed that K(+)-depolarization increased @GENE$ phosphorylation in a @CHEMICAL$ sensitive manner and promoted CaMKIIα binding to D3 receptors.	0
Immunoblot studies showed that @CHEMICAL$-depolarization increased CaMKIIα phosphorylation in a KN-62 sensitive manner and promoted @GENE$ binding to D3 receptors.	0
Immunoblot studies showed that @CHEMICAL$-depolarization increased CaMKIIα phosphorylation in a KN-62 sensitive manner and promoted CaMKIIα binding to @GENE$.	0
Immunoblot studies showed that @CHEMICAL$-depolarization increased @GENE$ phosphorylation in a KN-62 sensitive manner and promoted CaMKIIα binding to D3 receptors.	0
In @CHEMICAL$-depolarized tissues, @GENE$ potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62.	0
In @CHEMICAL$-depolarized tissues, D3 receptors potentiated @GENE$-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with KN-62.	0
In @CHEMICAL$-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when @GENE$ was blocked with KN-62.	0
In K(+)-depolarized tissues, @GENE$ potentiated D1 receptor-induced stimulation of @CHEMICAL$ release only when CaMKIIα was blocked with KN-62.	0
In K(+)-depolarized tissues, D3 receptors potentiated @GENE$-induced stimulation of @CHEMICAL$ release only when CaMKIIα was blocked with KN-62.	0
In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of @CHEMICAL$ release only when @GENE$ was blocked with KN-62.	0
In K(+)-depolarized tissues, @GENE$ potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with @CHEMICAL$.	0
In K(+)-depolarized tissues, D3 receptors potentiated @GENE$-induced stimulation of [(3)H]GABA release only when CaMKIIα was blocked with @CHEMICAL$.	0
In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when @GENE$ was blocked with @CHEMICAL$.	2
In the presence of this inhibitor, the selective @GENE$ agonist @CHEMICAL$ reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4 nM.	3
In the presence of this inhibitor, the selective D3 agonist @CHEMICAL$ reduced the ED50 for the @GENE$ agonist SKF 38393 from 56 to 4 nM.	0
In the presence of this inhibitor, the selective @GENE$ agonist PD 128,907 reduced the ED50 for the D1 agonist @CHEMICAL$ from 56 to 4 nM.	0
In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the @GENE$ agonist @CHEMICAL$ from 56 to 4 nM.	3
@CHEMICAL$ did not affect @GENE$ responses.	0
These experiments show that in striatonigral projections, @GENE$ inhibits the action of D3 receptors in a @CHEMICAL$ dependent manner blocking their modulatory effects on GABA release.	0
These experiments show that in striatonigral projections, CaMKIIα inhibits the action of @GENE$ in a @CHEMICAL$ dependent manner blocking their modulatory effects on GABA release.	0
These experiments show that in striatonigral projections, @GENE$ inhibits the action of D3 receptors in a Ca(2+) dependent manner blocking their modulatory effects on @CHEMICAL$ release.	0
These experiments show that in striatonigral projections, CaMKIIα inhibits the action of @GENE$ in a Ca(2+) dependent manner blocking their modulatory effects on @CHEMICAL$ release.	0
EA (15mg/kgb.w., p.o.×14days) treatment modulated enhanced @CHEMICAL$ level, lipid peroxidation, @GENE$ activity, nitric oxide production and protein carbonyl formation in lungs of rats exposed to toxic anticancer drugs.	0
EA (15mg/kgb.w., p.o.×14days) treatment modulated enhanced hydroxyproline level, lipid peroxidation, @GENE$ activity, @CHEMICAL$ production and protein carbonyl formation in lungs of rats exposed to toxic anticancer drugs.	0
EA (15mg/kgb.w., p.o.×14days) treatment modulated enhanced hydroxyproline level, lipid peroxidation, @GENE$ activity, nitric oxide production and protein @CHEMICAL$ formation in lungs of rats exposed to toxic anticancer drugs.	0
Effects of High @CHEMICAL$ and Glucose Concentrations over the Relative Expression of @GENE$, Bax, and Mfn2 in MIN6 Cells.	0
Effects of High @CHEMICAL$ and Glucose Concentrations over the Relative Expression of Bcl2, @GENE$, and Mfn2 in MIN6 Cells.	0
Effects of High @CHEMICAL$ and Glucose Concentrations over the Relative Expression of Bcl2, Bax, and @GENE$ in MIN6 Cells.	0
Effects of High Iron and @CHEMICAL$ Concentrations over the Relative Expression of @GENE$, Bax, and Mfn2 in MIN6 Cells.	0
Effects of High Iron and @CHEMICAL$ Concentrations over the Relative Expression of Bcl2, @GENE$, and Mfn2 in MIN6 Cells.	0
Effects of High Iron and @CHEMICAL$ Concentrations over the Relative Expression of Bcl2, Bax, and @GENE$ in MIN6 Cells.	0
The purpose of this study was to describe the effect of different @CHEMICAL$ and/or glucose concentrations over @GENE$, Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).	0
The purpose of this study was to describe the effect of different @CHEMICAL$ and/or glucose concentrations over Mfn2, @GENE$, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).	0
The purpose of this study was to describe the effect of different @CHEMICAL$ and/or glucose concentrations over Mfn2, Bax, and @GENE$ expressions in a β-pancreatic cell line (MIN6 cells).	0
The purpose of this study was to describe the effect of different iron and/or @CHEMICAL$ concentrations over @GENE$, Bax, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).	0
The purpose of this study was to describe the effect of different iron and/or @CHEMICAL$ concentrations over Mfn2, @GENE$, and Bcl2 expressions in a β-pancreatic cell line (MIN6 cells).	0
The purpose of this study was to describe the effect of different iron and/or @CHEMICAL$ concentrations over Mfn2, Bax, and @GENE$ expressions in a β-pancreatic cell line (MIN6 cells).	0
MIN6 cells were pre-incubated with different @CHEMICAL$ and/or glucose concentrations, and the relative mRNA abundance of the @GENE$/Bax ratio and of Mfn2 genes was measured by qRT-PCR.	0
MIN6 cells were pre-incubated with different @CHEMICAL$ and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/@GENE$ ratio and of Mfn2 genes was measured by qRT-PCR.	0
MIN6 cells were pre-incubated with different @CHEMICAL$ and/or glucose concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of @GENE$ genes was measured by qRT-PCR.	0
MIN6 cells were pre-incubated with different iron and/or @CHEMICAL$ concentrations, and the relative mRNA abundance of the @GENE$/Bax ratio and of Mfn2 genes was measured by qRT-PCR.	0
MIN6 cells were pre-incubated with different iron and/or @CHEMICAL$ concentrations, and the relative mRNA abundance of the Bcl2/@GENE$ ratio and of Mfn2 genes was measured by qRT-PCR.	0
MIN6 cells were pre-incubated with different iron and/or @CHEMICAL$ concentrations, and the relative mRNA abundance of the Bcl2/Bax ratio and of @GENE$ genes was measured by qRT-PCR.	0
@GENE$ (HO) activity, @CHEMICAL$ uptake, superoxide dismutase activity, and glutathione content were also determined.	0
Heme oxygenase (@GENE$) activity, @CHEMICAL$ uptake, superoxide dismutase activity, and glutathione content were also determined.	0
Heme oxygenase (HO) activity, @CHEMICAL$ uptake, @GENE$ activity, and glutathione content were also determined.	0
@GENE$ (HO) activity, iron uptake, @CHEMICAL$ dismutase activity, and glutathione content were also determined.	0
Heme oxygenase (@GENE$) activity, iron uptake, @CHEMICAL$ dismutase activity, and glutathione content were also determined.	0
Heme oxygenase (HO) activity, iron uptake, @CHEM-GENE$ activity, and glutathione content were also determined.	0
@GENE$ (HO) activity, iron uptake, superoxide dismutase activity, and @CHEMICAL$ content were also determined.	0
Heme oxygenase (@GENE$) activity, iron uptake, superoxide dismutase activity, and @CHEMICAL$ content were also determined.	0
Heme oxygenase (HO) activity, iron uptake, @GENE$ activity, and @CHEMICAL$ content were also determined.	0
The @GENE$/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after @CHEMICAL$ stimulation.	1
The Bcl2/@GENE$ ratio increased and Mfn2 expression decreased in MIN6 cells after @CHEMICAL$ stimulation.	1
The Bcl2/Bax ratio increased and @GENE$ expression decreased in MIN6 cells after @CHEMICAL$ stimulation.	2
Additionally, treatment with @CHEMICAL$/iron showed a higher @GENE$ activity.	1
Additionally, treatment with glucose/@CHEMICAL$ showed a higher @GENE$ activity.	1
Our study revealed that high @CHEMICAL$/Fe concentrations in MIN6 cells induced an increase of the @GENE$/Bax ratio, an indicator of increased cell apoptosis.	1
Our study revealed that high @CHEMICAL$/Fe concentrations in MIN6 cells induced an increase of the Bcl2/@GENE$ ratio, an indicator of increased cell apoptosis.	1
Our study revealed that high glucose/@CHEMICAL$ concentrations in MIN6 cells induced an increase of the @GENE$/Bax ratio, an indicator of increased cell apoptosis.	1
Our study revealed that high glucose/@CHEMICAL$ concentrations in MIN6 cells induced an increase of the Bcl2/@GENE$ ratio, an indicator of increased cell apoptosis.	1
This includes @GENE$ (NRPS) and polyketide synthases (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (@GENE$) and polyketide synthases (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (NRPS) and @GENE$ (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (@GENE$) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four @GENE$, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @GENE$, and an N-glycosyltransferase) necessary for further modifications of the core structure.	5
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the @CHEMICAL$ core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @GENE$) necessary for further modifications of the core structure.	5
This includes @GENE$ (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEMICAL$-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (@GENE$) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEMICAL$-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and @GENE$ (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEMICAL$-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (@GENE$) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEMICAL$-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four @GENE$, an @CHEMICAL$-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEM-GENE$, and an N-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @CHEMICAL$-methyltransferase, and an @GENE$) necessary for further modifications of the core structure.	0
This includes @GENE$ (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (@GENE$) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and @GENE$ (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (@GENE$) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four @GENE$, an O-methyltransferase, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an @GENE$, and an @CHEMICAL$-glycosyltransferase) necessary for further modifications of the core structure.	0
This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an @CHEM-GENE$) necessary for further modifications of the core structure.	0
The @GENE$ is predicted to transfer either glucose or a pseudosugar (@CHEMICAL$) to the aglycone.	0
The @CHEM-GENE$ is predicted to transfer either glucose or a pseudosugar (cyclitol) to the aglycone.	0
The @GENE$ is predicted to transfer either @CHEMICAL$ or a pseudosugar (cyclitol) to the aglycone.	0
Targeted disruption of the gene encoding the @CHEM-GENE$, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @CHEMICAL$-glycosyltransferase, @GENE$, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @CHEMICAL$-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @CHEMICAL$-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @GENE$ involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @GENE$, prlH, abolished @CHEMICAL$ production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	5
Targeted disruption of the gene encoding the N-glycosyltransferase, @GENE$, abolished @CHEMICAL$ production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	5
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished @CHEMICAL$ production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished @CHEMICAL$ production, and recombinant expression of PrlA confirms the activity of this enzyme as a @GENE$ involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @GENE$, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @CHEMICAL$ phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, @GENE$, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @CHEMICAL$ phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a @CHEMICAL$ phosphate cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @CHEM-GENE$ involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @GENE$, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar @CHEMICAL$ cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, @GENE$, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar @CHEMICAL$ cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a sugar @CHEMICAL$ cyclase involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @CHEM-GENE$ involved in the formation of the C7-cyclitol moiety.	0
Targeted disruption of the gene encoding the @GENE$, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the @CHEMICAL$-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, @GENE$, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the @CHEMICAL$-cyclitol moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the @CHEMICAL$-cyclitol moiety.	5
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @GENE$ involved in the formation of the @CHEMICAL$-cyclitol moiety.	5
Targeted disruption of the gene encoding the @GENE$, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-@CHEMICAL$ moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, @GENE$, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-@CHEMICAL$ moiety.	0
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of @GENE$ confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-@CHEMICAL$ moiety.	5
Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a @GENE$ involved in the formation of the C7-@CHEMICAL$ moiety.	5
@GENE$ is required for vesicular @CHEMICAL$ /H(+) -antiport activity.	0
@GENE$ is required for vesicular Ca(2+) /@CHEMICAL$ -antiport activity.	0
@GENE$, a vesicular protein interacting with membranes upon low-affinity @CHEMICAL$ -binding, plays a major role in excitation-release coupling, by synchronizing calcium entry with fast neurotransmitter release.	0
@GENE$, a vesicular protein interacting with membranes upon low-affinity Ca(2+) -binding, plays a major role in excitation-release coupling, by synchronizing @CHEMICAL$ entry with fast neurotransmitter release.	0
Here, we report that @GENE$ is necessary for expression of the vesicular @CHEMICAL$ /H(+) -antiport.	0
Here, we report that @GENE$ is necessary for expression of the vesicular Ca(2+) /@CHEMICAL$ -antiport.	0
The results were congruent and highly significant: @CHEMICAL$ /H(+) -antiport activity is detectable only in acidic organelles expressing functional @GENE$.	0
The results were congruent and highly significant: Ca(2+) /@CHEMICAL$ -antiport activity is detectable only in acidic organelles expressing functional @GENE$.	0
In contrast, @GENE$-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any @CHEMICAL$ /H(+) -antiport activity.	0
In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded @GENE$ was acutely photo-inactivated - were devoid of any @CHEMICAL$ /H(+) -antiport activity.	0
In contrast, @GENE$-deficient cells - and cells where transgenically encoded synaptotagmin-1 was acutely photo-inactivated - were devoid of any Ca(2+) /@CHEMICAL$ -antiport activity.	0
In contrast, synaptotagmin-1-deficient cells - and cells where transgenically encoded @GENE$ was acutely photo-inactivated - were devoid of any Ca(2+) /@CHEMICAL$ -antiport activity.	0
Therefore, in addition to its previously described functions, @GENE$ is involved in a rapid vesicular @CHEMICAL$ sequestration through a Ca(2+) /H(+) antiport.	0
Therefore, in addition to its previously described functions, @GENE$ is involved in a rapid vesicular Ca(2+) sequestration through a @CHEMICAL$ /H(+) antiport.	0
Therefore, in addition to its previously described functions, @GENE$ is involved in a rapid vesicular Ca(2+) sequestration through a Ca(2+) /@CHEMICAL$ antiport.	0
@CHEMICAL$ replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through @GENE$.	0
Estradiol replacement enhances @CHEMICAL$-stimulated locomotion in female C57BL/6 mice through @GENE$.	0
Estradiol replacement enhances cocaine-stimulated locomotion in female C57BL/6 mice through @CHEM-GENE$.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (@GENE$KO) were compared to WT littermates.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the @GENE$-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the @GENE$-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either @GENE$ (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (@GENE$KO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of @CHEMICAL$ effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or @GENE$ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist @CHEMICAL$ or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (@GENE$KO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the @GENE$-selective agonist @CHEMICAL$ or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	3
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist @CHEMICAL$ or the @GENE$-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist @CHEMICAL$ or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either @GENE$ (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist @CHEMICAL$ or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (@GENE$KO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist @CHEMICAL$ or the ERβ-selective agonist DPN were compared to Sham mice, and mice lacking either ERα (αERKO) or @GENE$ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (@GENE$KO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the @GENE$-selective agonist PPT or the ERβ-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the @GENE$-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either ERα (αERKO) or ERβ (βERKO) were compared to WT littermates.	3
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either @GENE$ (αERKO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either ERα (@GENE$KO) or ERβ (βERKO) were compared to WT littermates.	0
To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ERα-selective agonist PPT or the ERβ-selective agonist @CHEMICAL$ were compared to Sham mice, and mice lacking either ERα (αERKO) or @GENE$ (βERKO) were compared to WT littermates.	0
@GENE$KO mice displayed modestly attenuated behavioral responses to novelty and @CHEMICAL$ compared to αWT littermates, but no behavioral differences were found between βERKO and βWT mice.	0
αERKO mice displayed modestly attenuated behavioral responses to novelty and @CHEMICAL$ compared to αWT littermates, but no behavioral differences were found between @GENE$KO and βWT mice.	0
These results suggest that E2 enhances @CHEMICAL$-stimulated locomotion in mice predominantly through @GENE$.	0
The @GENE$ Regulates Vascular Smooth Muscle Cell Proliferation via Controlling @CHEMICAL$-dependent Signaling.	5
The @CHEM-GENE$ Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.	0
The @CHEM-GENE$ Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.	0
The @CHEM-GENE$ contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling.	0
The @CHEM-GENE$ contributes to a variety of cell activation processes in pathologies such as inflammation, carcinogenesis and vascular remodeling.	0
@GENE$ (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (@GENE$)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. @GENE$ blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of @GENE$ (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (@GENE$), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), @GENE$ and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and @GENE$ (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular @CHEMICAL$ concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (@GENE$).	0
@GENE$ (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (@GENE$)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. @GENE$ blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of @GENE$ (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (@GENE$), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), @GENE$ and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and @GENE$ (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([@CHEMICAL$]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (@GENE$).	0
@GENE$ (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (@GENE$)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. @GENE$ blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of @GENE$ (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (@GENE$), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), @GENE$ and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and @GENE$ (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [@CHEMICAL$]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (@GENE$).	0
@GENE$ (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (@GENE$)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. @GENE$ blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of @GENE$ (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (@GENE$), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), @GENE$ and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and @GENE$ (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [@CHEMICAL$]i and attenuating the expression of phosphorylated cAMP response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (@GENE$).	0
@GENE$ (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (@GENE$)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. @GENE$ blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of @CHEM-GENE$ (CREB), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (@GENE$), c-fos and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), @GENE$ and neuron-derived orphan receptor-1 (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), c-fos and @GENE$ (NOR-1).	0
Platelet-derived growth factor-BB (PDGF)-induced proliferation of human coronary artery VSMCs was attenuated by lowering intracellular Ca(2+) concentration ([Ca(2+)]i) and was enhanced by elevating [Ca(2+)]i. KCa3.1 blockade or knockdown inhibited proliferation by suppressing the rise in [Ca(2+)]i and attenuating the expression of phosphorylated @CHEMICAL$ response element binding protein (CREB), c-fos and neuron-derived orphan receptor-1 (@GENE$).	0
This anti-proliferative effect was abolished by elevating [@CHEMICAL$]i. KCa3.1 overexpression induced VSMC proliferation, and potentiated PDGF-induced proliferation, by inducing CREB phosphorylation, c-fos and @GENE$.	0
This anti-proliferative effect was abolished by elevating [@CHEMICAL$]i. @GENE$ overexpression induced VSMC proliferation, and potentiated PDGF-induced proliferation, by inducing CREB phosphorylation, c-fos and NOR-1.	0
This anti-proliferative effect was abolished by elevating [@CHEMICAL$]i. KCa3.1 overexpression induced VSMC proliferation, and potentiated @GENE$-induced proliferation, by inducing CREB phosphorylation, c-fos and NOR-1.	0
This anti-proliferative effect was abolished by elevating [@CHEMICAL$]i. KCa3.1 overexpression induced VSMC proliferation, and potentiated PDGF-induced proliferation, by inducing @GENE$ phosphorylation, c-fos and NOR-1.	0
This anti-proliferative effect was abolished by elevating [@CHEMICAL$]i. KCa3.1 overexpression induced VSMC proliferation, and potentiated PDGF-induced proliferation, by inducing CREB phosphorylation, @GENE$ and NOR-1.	0
Pharmacological stimulation of @GENE$ unexpectedly suppressed proliferation by inhibiting the rise in [@CHEMICAL$]i and abolishing the expression and activity of KCa3.1 and PDGF β-receptors.	0
Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [@CHEMICAL$]i and abolishing the expression and activity of @GENE$ and PDGF β-receptors.	0
Pharmacological stimulation of KCa3.1 unexpectedly suppressed proliferation by inhibiting the rise in [@CHEMICAL$]i and abolishing the expression and activity of KCa3.1 and @GENE$.	0
In conclusion, @GENE$ plays an important role in VSMC proliferation via controlling @CHEMICAL$-dependent signaling pathways and its modulation may therefore constitute a new therapeutic target for cell proliferative diseases such as atherosclerosis.	0
Reactive Metabolite Trapping Studies on @CHEMICAL$-based Inverse Agonists of the @GENE$.	3
The current study examined the bioactivation potential of @GENE$ inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and @CHEMICAL$ (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.	3
The current study examined the bioactivation potential of @GENE$ inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused @CHEMICAL$ motif in the core structure.	3
The current study examined the bioactivation potential of @GENE$ inverse agonists, @CHEMICAL$ (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.	3
Adenovirus-delivered @GENE$ treatment for @CHEMICAL$-induced acute lung injury.	0
Objective: In this study, the histopathological changes of the lungs after exposure to @CHEMICAL$ and the effect of @GENE$ treatment were examined.	0
The lung injury induced by @CHEMICAL$ was markedly reduced after the injection of Ad/@GENE$.	0
The increase of @GENE$ and IL-17 and decrease of vascular endothelial growth factor in the serum and bronchoalveolar lavage fluid of @CHEMICAL$-exposed animals were abolished by the administration of Ad/Ang1.	0
The increase of IL-1β and @GENE$ and decrease of vascular endothelial growth factor in the serum and bronchoalveolar lavage fluid of @CHEMICAL$-exposed animals were abolished by the administration of Ad/Ang1.	0
The increase of IL-1β and IL-17 and decrease of @GENE$ in the serum and bronchoalveolar lavage fluid of @CHEMICAL$-exposed animals were abolished by the administration of Ad/Ang1.	0
The increase of IL-1β and IL-17 and decrease of vascular endothelial growth factor in the serum and bronchoalveolar lavage fluid of @CHEMICAL$-exposed animals were abolished by the administration of Ad/@GENE$.	0
Discussion and conclusions: @GENE$ has the beneficial effects on @CHEMICAL$-induced lung injury.	0
The adenovirus-delivered @GENE$ may have the potential as a novel approach for the treatment of the acute lung injury caused by @CHEMICAL$ gas inhalation in humans.	0
Moreover, the active permethylated @CHEMICAL$ aglycon derivatives examined exhibit @GENE$ VRE antimicrobial activity at levels that approach (typically within 2-fold) their activity against sensitive bacteria.	0
Moreover, the active permethylated vancomycin aglycon derivatives examined exhibit @CHEM-GENE$ VRE antimicrobial activity at levels that approach (typically within 2-fold) their activity against sensitive bacteria.	0
To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (@GENE$), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% @CHEMICAL$.	0
To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), @GENE$-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% @CHEMICAL$.	0
To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (@GENE$-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% @CHEMICAL$.	0
To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and @GENE$ (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% @CHEMICAL$.	0
To identify the fatty acid (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (@GENE$) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% @CHEMICAL$.	0
To identify the @CHEMICAL$ (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (@GENE$), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP.	0
To identify the @CHEMICAL$ (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), @GENE$-null (Pparα-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP.	0
To identify the @CHEMICAL$ (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (@GENE$-null) and humanized PPARα (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP.	0
To identify the @CHEMICAL$ (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and @GENE$ (hPPARα) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP.	0
To identify the @CHEMICAL$ (FA) species involved and to understand the underlying mechanisms, pregnant Sv/129 wild-type (mPPARα), peroxisome proliferator-activated receptor α-null (Pparα-null) and humanized PPARα (@GENE$) mice were treated with diets containing 0%, 0.01%, 0.05% or 0.1% DEHP.	0
The plasma levels of @CHEMICAL$, α-linolenic acid, palmitic acid and oleic acid were higher in the pregnant control @GENE$ mice than in Ppara-null and hPPARa mice.	0
The plasma levels of @CHEMICAL$, α-linolenic acid, palmitic acid and oleic acid were higher in the pregnant control mPPARa mice than in @GENE$-null and hPPARa mice.	0
The plasma levels of @CHEMICAL$, α-linolenic acid, palmitic acid and oleic acid were higher in the pregnant control mPPARa mice than in Ppara-null and @GENE$ mice.	0
The plasma levels of linoleic acid, @CHEMICAL$, palmitic acid and oleic acid were higher in the pregnant control @GENE$ mice than in Ppara-null and hPPARa mice.	0
The plasma levels of linoleic acid, @CHEMICAL$, palmitic acid and oleic acid were higher in the pregnant control mPPARa mice than in @GENE$-null and hPPARa mice.	0
The plasma levels of linoleic acid, @CHEMICAL$, palmitic acid and oleic acid were higher in the pregnant control mPPARa mice than in Ppara-null and @GENE$ mice.	0
The plasma levels of linoleic acid, α-linolenic acid, @CHEMICAL$ and oleic acid were higher in the pregnant control @GENE$ mice than in Ppara-null and hPPARa mice.	0
The plasma levels of linoleic acid, α-linolenic acid, @CHEMICAL$ and oleic acid were higher in the pregnant control mPPARa mice than in @GENE$-null and hPPARa mice.	0
The plasma levels of linoleic acid, α-linolenic acid, @CHEMICAL$ and oleic acid were higher in the pregnant control mPPARa mice than in Ppara-null and @GENE$ mice.	0
The plasma levels of linoleic acid, α-linolenic acid, palmitic acid and @CHEMICAL$ were higher in the pregnant control @GENE$ mice than in Ppara-null and hPPARa mice.	0
The plasma levels of linoleic acid, α-linolenic acid, palmitic acid and @CHEMICAL$ were higher in the pregnant control mPPARa mice than in @GENE$-null and hPPARa mice.	0
The plasma levels of linoleic acid, α-linolenic acid, palmitic acid and @CHEMICAL$ were higher in the pregnant control mPPARa mice than in Ppara-null and @GENE$ mice.	0
@CHEMICAL$ exposure significantly decreased the levels of these four FAs only in pregnant @GENE$ mice.	0
However, @CHEMICAL$ exposure did not clearly influence @GENE$ nor elongase 2 and 5 expressions in the liver of all maternal mice.	0
However, @CHEMICAL$ exposure did not clearly influence FA desaturase 1 and 2 nor @GENE$ expressions in the liver of all maternal mice.	0
Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant @GENE$ mice than in other genotypes, and DEHP exposure decreased these specific FA concentrations only in mPPARα mice, similarly to @CHEMICAL$ levels.	0
Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant mPPARα mice than in other genotypes, and DEHP exposure decreased these specific FA concentrations only in @GENE$ mice, similarly to @CHEMICAL$ levels.	0
Taken together, the levels of plasma four FAs with shorter @CHEMICAL$ chains were higher in pregnant @GENE$ mice than in other genotypes, and DEHP exposure decreased these specific FA concentrations only in mPPARα mice, similarly to triglyceride levels.	0
Taken together, the levels of plasma four FAs with shorter @CHEMICAL$ chains were higher in pregnant mPPARα mice than in other genotypes, and DEHP exposure decreased these specific FA concentrations only in @GENE$ mice, similarly to triglyceride levels.	0
Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant @GENE$ mice than in other genotypes, and @CHEMICAL$ exposure decreased these specific FA concentrations only in mPPARα mice, similarly to triglyceride levels.	0
Taken together, the levels of plasma four FAs with shorter carbon chains were higher in pregnant mPPARα mice than in other genotypes, and @CHEMICAL$ exposure decreased these specific FA concentrations only in @GENE$ mice, similarly to triglyceride levels.	0
Posttranslational modification of the @GENE$ (NCAM) by polysialic acid (@CHEMICAL$) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	0
Posttranslational modification of the neural cell adhesion molecule (@GENE$) by polysialic acid (@CHEMICAL$) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	0
Posttranslational modification of the @GENE$ (NCAM) by @CHEMICAL$ (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	0
Posttranslational modification of the neural cell adhesion molecule (@GENE$) by @CHEMICAL$ (polySia) is well studied in the nervous system and described as a dynamic modulator of plastic processes like precursor cell migration, axon fasciculation, and synaptic plasticity.	0
Here, we describe a novel function of @GENE$ (@CHEMICAL$-NCAM) in innate immunity of the lung.	0
Here, we describe a novel function of polysialylated NCAM (@CHEM-GENE$) in innate immunity of the lung.	0
In mature lung tissue of healthy donors, @CHEMICAL$ was exclusively attached to the transmembrane isoform @GENE$ and located to intracellular compartments of epithelial cells.	0
In patients with chronic obstructive pulmonary disease, however, increased @CHEMICAL$ levels and processing of the @GENE$ carrier were observed.	0
Processing of @GENE$ was reproduced in a mouse model by @CHEMICAL$ administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1β.	0
Processing of polysialylated NCAM was reproduced in a mouse model by @CHEMICAL$ administration leading to an activation of the inflammasome and secretion of @GENE$.	1
As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by @GENE$ or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble @CHEMICAL$-NCAM.	0
As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced @GENE$-mediated ectodomain shedding, resulting in the secretion of soluble @CHEMICAL$-NCAM.	0
As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated @GENE$ shedding, resulting in the secretion of soluble @CHEMICAL$-NCAM.	0
As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble @CHEM-GENE$.	0
As shown in a cell culture model, polySia-@GENE$ was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble @CHEMICAL$-NCAM.	0
As shown in a cell culture model, @CHEMICAL$-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by @GENE$ or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM.	0
As shown in a cell culture model, @CHEMICAL$-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced @GENE$-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM.	0
As shown in a cell culture model, @CHEMICAL$-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated @GENE$ shedding, resulting in the secretion of soluble polySia-NCAM.	0
As shown in a cell culture model, @CHEMICAL$-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble @GENE$.	0
As shown in a cell culture model, @CHEMICAL$-@GENE$ was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1β or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM.	0
Interestingly, @CHEMICAL$ chains of secreted @GENE$ neutralized the cytotoxic activity of extracellular histones as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms.	0
Interestingly, @CHEMICAL$ chains of secreted NCAM neutralized the cytotoxic activity of extracellular @GENE$ as well as DNA/histone-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms.	0
Interestingly, @CHEMICAL$ chains of secreted NCAM neutralized the cytotoxic activity of extracellular histones as well as DNA/@GENE$-network-containing "neutrophil extracellular traps", which are formed during invasion of microorganisms.	0
Thus, shedding of @CHEM-GENE$ by lung epithelial cells may provide a host-protective mechanism to reduce tissue damage during inflammatory processes.	0
A double-labeling fluorescent technique (@CHEMICAL$ and propidium iodide) was used to validate the findings revealed by the FRET-based @GENE$ sensor.	0
A double-labeling fluorescent technique (yo pro-1 and @CHEMICAL$) was used to validate the findings revealed by the FRET-based @GENE$ sensor.	0
Furthermore, the activation of the FRET biosensor also confirms the endothelial cell apoptosis induced by the abnormal pulsatile shear stress and high @CHEMICAL$ concentration is through @GENE$ pathway.	0
Evaluation of the positive effects on @GENE$-resistance and β-cell measurements of vildagliptin in addition to @CHEMICAL$ in type 2 diabetic patients.	0
Evaluation of the positive effects on @GENE$-resistance and β-cell measurements of @CHEMICAL$ in addition to metformin in type 2 diabetic patients.	0
@CHEMICAL$+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, @GENE$ and insulin resistance measurements.	0
@CHEMICAL$+metformin were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and @GENE$ resistance measurements.	0
Vildagliptin+@CHEMICAL$ were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, @GENE$ and insulin resistance measurements.	0
Vildagliptin+@CHEMICAL$ were more effective than placebo+metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and @GENE$ resistance measurements.	0
Vildagliptin+metformin were more effective than placebo+@CHEMICAL$ in reducing body weight and BMI, glycemic control, HOMA-IR, @GENE$ and insulin resistance measurements.	0
Vildagliptin+metformin were more effective than placebo+@CHEMICAL$ in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and @GENE$ resistance measurements.	0
We also recorded a significant correlation between M value increase and the decrease of @GENE$, visfatin, and omentin-1 obtained with @CHEMICAL$+metformin.	0
We also recorded a significant correlation between M value increase and the decrease of vaspin, @GENE$, and omentin-1 obtained with @CHEMICAL$+metformin.	0
We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and @GENE$ obtained with @CHEMICAL$+metformin.	0
We also recorded a significant correlation between M value increase and the decrease of @GENE$, visfatin, and omentin-1 obtained with vildagliptin+@CHEMICAL$.	0
We also recorded a significant correlation between M value increase and the decrease of vaspin, @GENE$, and omentin-1 obtained with vildagliptin+@CHEMICAL$.	0
We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and @GENE$ obtained with vildagliptin+@CHEMICAL$.	0
@CHEMICAL$, in addition to metformin, proved to be effective in improving β-cell function and in reducing @GENE$ resistance measurements.	0
Vildagliptin, in addition to @CHEMICAL$, proved to be effective in improving β-cell function and in reducing @GENE$ resistance measurements.	0
@CHEMICAL$-stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (@GENE$ and accompanied by enhanced migration in MCF-7 breast cancer cells.	0
@CHEMICAL$-stimulated processing of @GENE$ is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.	1
@CHEMICAL$-stimulated processing of cyclin E is mediated via @GENE$ (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells.	0
@CHEMICAL$ (E2) has been recently shown to induce @GENE$ processing in breast cancer cells.	1
We therefore addressed possible effects of @CHEMICAL$ on the generation of cleaved @GENE$ and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).	0
We therefore addressed possible effects of @CHEMICAL$ on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both @GENE$ and estrogen receptor α (ERα).	0
We therefore addressed possible effects of @CHEMICAL$ on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and @GENE$ (ERα).	0
We therefore addressed possible effects of @CHEMICAL$ on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (@GENE$).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved @GENE$ and its signal mechanism(s) in @CHEMICAL$-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in @CHEMICAL$-responsive MCF-7 breast cancer cells that express both @GENE$ and estrogen receptor α (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in @CHEMICAL$-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and @GENE$ (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in @CHEMICAL$-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and estrogen receptor α (@GENE$).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved @GENE$ and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and @CHEMICAL$ receptor α (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both @GENE$ and @CHEMICAL$ receptor α (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and @CHEM-GENE$ (ERα).	0
We therefore addressed possible effects of tamoxifen on the generation of cleaved cyclin E and its signal mechanism(s) in estrogen-responsive MCF-7 breast cancer cells that express both G protein-coupled protein (GPR) 30 and @CHEMICAL$ receptor α (@GENE$).	0
@CHEMICAL$ (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of @GENE$ and migration, but rather triggered cyclin E cleavage coincident with augmented migration.	0
@CHEMICAL$ (OHT, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered @GENE$ cleavage coincident with augmented migration.	0
4-Hydroxytamoxifen (@CHEMICAL$, tamoxifen's active form) failed to prevent E2-induced proteolysis of @GENE$ and migration, but rather triggered cyclin E cleavage coincident with augmented migration.	0
4-Hydroxytamoxifen (@CHEMICAL$, tamoxifen's active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered @GENE$ cleavage coincident with augmented migration.	0
4-Hydroxytamoxifen (OHT, @CHEMICAL$'s active form) failed to prevent E2-induced proteolysis of @GENE$ and migration, but rather triggered cyclin E cleavage coincident with augmented migration.	0
4-Hydroxytamoxifen (OHT, @CHEMICAL$'s active form) failed to prevent E2-induced proteolysis of cyclin E and migration, but rather triggered @GENE$ cleavage coincident with augmented migration.	0
@CHEMICAL$-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither @GENE$ nor ERα.	0
@CHEMICAL$-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor @GENE$.	0
@CHEMICAL$-induced @GENE$ truncation also occurred in SK-BR-3 cells that express GPR30 and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.	0
@CHEMICAL$-induced cyclin E truncation also occurred in SK-BR-3 cells that express @GENE$ and lack ERα, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.	0
@CHEMICAL$-induced cyclin E truncation also occurred in SK-BR-3 cells that express GPR30 and lack @GENE$, but not in MDA-MB-231 cells that express neither GPR30 nor ERα.	0
Furthermore, @CHEMICAL$-stimulated cleavage of @GENE$ and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against GPR30.	0
Furthermore, @CHEMICAL$-stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a @GENE$ antagonist, or siRNA against GPR30.	0
Furthermore, @CHEMICAL$-stimulated cleavage of cyclin E and migration were tremendously attenuated by G15, a GPR30 antagonist, or siRNA against @GENE$.	0
In addition, inhibitors for @GENE$ or ERK1/2 remarkably suppressed @CHEMICAL$-induced truncation of cyclin E, suggesting involvement of EGFR signaling.	0
In addition, inhibitors for EGFR or @GENE$ remarkably suppressed @CHEMICAL$-induced truncation of cyclin E, suggesting involvement of EGFR signaling.	0
In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed @CHEMICAL$-induced truncation of @GENE$, suggesting involvement of EGFR signaling.	0
In addition, inhibitors for EGFR or ERK1/2 remarkably suppressed @CHEMICAL$-induced truncation of cyclin E, suggesting involvement of @GENE$ signaling.	0
Collectively, our data indicate that @CHEMICAL$ contributes to the production of proteolyzed @GENE$ via GPR30 with augmented migration in MCF-7 cells.	1
Collectively, our data indicate that @CHEMICAL$ contributes to the production of proteolyzed cyclin E via @GENE$ with augmented migration in MCF-7 cells.	0
Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of @CHEMICAL$-Free @GENE$ Mutants.	0
Mechanistic Aspects of @GENE$ Maturation from the Solution Structure of Cu(I) -Loaded hCCS Domain 1 and Analysis of @CHEMICAL$-Free hSOD1 Mutants.	0
Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of Cu(I) -Loaded @GENE$ and Analysis of @CHEMICAL$-Free hSOD1 Mutants.	0
Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of @CHEMICAL$ -Loaded hCCS Domain 1 and Analysis of Disulfide-Free @GENE$ Mutants.	0
Mechanistic Aspects of @GENE$ Maturation from the Solution Structure of @CHEMICAL$ -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants.	0
Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of @CHEMICAL$ -Loaded @GENE$ and Analysis of Disulfide-Free hSOD1 Mutants.	0
@CHEMICAL$ dismutase 1 (SOD1) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, @GENE$, a dimeric protein with three distinct domains in each monomer.	0
@CHEMICAL$ dismutase 1 (@GENE$) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, CCS, a dimeric protein with three distinct domains in each monomer.	0
@CHEMICAL$ dismutase 1 (SOD1) maturation within the cell is mainly accomplished with the @GENE$, CCS, a dimeric protein with three distinct domains in each monomer.	0
@CHEM-GENE$ (SOD1) maturation within the cell is mainly accomplished with the SOD1-specific chaperone, CCS, a dimeric protein with three distinct domains in each monomer.	0
We recently showed that the first domain of @GENE$ (hCCSD1) is responsible for @CHEMICAL$ transfer to its protein partner, human SOD1 (hSOD1).	0
We recently showed that the first domain of human CCS (@GENE$) is responsible for @CHEMICAL$ transfer to its protein partner, human SOD1 (hSOD1).	0
We recently showed that the first domain of human CCS (hCCSD1) is responsible for @CHEMICAL$ transfer to its protein partner, @GENE$ (hSOD1).	0
We recently showed that the first domain of human CCS (hCCSD1) is responsible for @CHEMICAL$ transfer to its protein partner, human SOD1 (@GENE$).	0
The NMR solution structure of the @CHEMICAL$-loaded form of @GENE$ reported here contributes further to characterization of the copper-transfer mechanism to hSOD1.	0
The NMR solution structure of the @CHEMICAL$-loaded form of hCCSD1 reported here contributes further to characterization of the copper-transfer mechanism to @GENE$.	0
NMR spectroscopy was also used to examine the @GENE$ mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants @GENE$, C146A, and C57A/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, @GENE$, and C57A/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and @GENE$/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/@GENE$, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in @GENE$, in order to investigate the role of these cysteines during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved @CHEMICAL$ bond in SOD1, in order to investigate the role of these cysteines during @GENE$ copper acquisition.	0
NMR spectroscopy was also used to examine the @GENE$ mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants @GENE$, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, @GENE$, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and @GENE$/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/@GENE$, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in @GENE$, in order to investigate the role of these @CHEMICAL$ during hSOD1 copper acquisition.	0
NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these @CHEMICAL$ during @GENE$ copper acquisition.	0
Together, the information on both @GENE$ and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the @CHEMICAL$-transfer process from hCCS to hSOD1.	0
Together, the information on both hCCS and @GENE$, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the @CHEMICAL$-transfer process from hCCS to hSOD1.	0
Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic @GENE$, allows us to propose important mechanistic aspects regarding the @CHEMICAL$-transfer process from hCCS to hSOD1.	0
Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the @CHEMICAL$-transfer process from @GENE$ to hSOD1.	0
Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the @CHEMICAL$-transfer process from hCCS to @GENE$.	0
@GENE$ Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth Retardation and Decreased @CHEMICAL$ Tolerance.	0
Design, Synthesis and Biological Evaluation of Aminoalkylindole Derivatives as @GENE$ Ligands with Potential for Treatment of @CHEMICAL$ Abuse.	0
Design, Synthesis and Biological Evaluation of @CHEMICAL$ Derivatives as @GENE$ Ligands with Potential for Treatment of Alcohol Abuse.	0
Attenuation of increased endocannabinoid signaling with a @GENE$ neutral antagonist might offer a new therapeutic direction for treatment of @CHEMICAL$ abuse.	0
We have recently reported that a mono-hydroxylated metabolite of the synthetic @CHEMICAL$ cannabinoid JHW-073 (3) exhibits neutral antagonist activity at @GENE$ and thus may serve as a promising lead for the development of novel alcohol abuse therapies.	4
We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid @CHEMICAL$ (3) exhibits neutral antagonist activity at @GENE$ and thus may serve as a promising lead for the development of novel alcohol abuse therapies.	4
We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at @GENE$ and thus may serve as a promising lead for the development of novel @CHEMICAL$ abuse therapies.	0
In the current study, we show that systematic modification of an @CHEMICAL$ scaffold identifies two new compounds with dual @GENE$ antagonist/CB2R agonist activity.	4
In the current study, we show that systematic modification of an @CHEMICAL$ scaffold identifies two new compounds with dual CB1R antagonist/@GENE$ agonist activity.	3
Similar to the @GENE$ antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral @CHEMICAL$ self-administration, without affecting total fluid intake and block the development of alcohol-conditioned place preference.	0
Similar to the @GENE$ antagonist/inverse agonist rimonabant, analogues 27 and 30 decrease oral alcohol self-administration, without affecting total fluid intake and block the development of @CHEMICAL$-conditioned place preference.	0
Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/@GENE$ agonist activity with potential for use as treatments of @CHEMICAL$ abuse.	0
Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual @GENE$ antagonist/CB2R agonist activity with potential for use as treatments of @CHEMICAL$ abuse.	0
Collectively, these initial findings suggest that design and systematic modification of @CHEMICAL$ such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist/@GENE$ agonist activity with potential for use as treatments of alcohol abuse.	3
Collectively, these initial findings suggest that design and systematic modification of @CHEMICAL$ such as 3 may lead to development of novel cannabinoid ligands with dual @GENE$ antagonist/CB2R agonist activity with potential for use as treatments of alcohol abuse.	4
Immunoregulatory effects of @CHEMICAL$ exerts anti-asthmatic effects via modulation of Th1/Th2 @GENE$ and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in ovalbumin-sensitized mice.	0
Immunoregulatory effects of @CHEMICAL$ exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3(+) regulatory T cells in @GENE$-sensitized mice.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The @CHEMICAL$ and eosin (HE) staining, Th1/Th2 and Th17 @GENE$ were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (Foxp3) was evaluated by western blotting.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The @CHEMICAL$ and eosin (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the @GENE$ (Foxp3) was evaluated by western blotting.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The @CHEMICAL$ and eosin (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (@GENE$) was evaluated by western blotting.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and @CHEMICAL$ (HE) staining, Th1/Th2 and Th17 @GENE$ were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (Foxp3) was evaluated by western blotting.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and @CHEMICAL$ (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the @GENE$ (Foxp3) was evaluated by western blotting.	0
Airway resistance (Raw) were measured by the forced oscillation technique, histological studies were evaluated by The hematoxylin and @CHEMICAL$ (HE) staining, Th1/Th2 and Th17 cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA), and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) was evaluated by Flow Cytometry (FCM), the forkhead/winged helix transcription factor (@GENE$) was evaluated by western blotting.	0
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the @GENE$ inhibitor @CHEMICAL$ in an advanced-aged diet-induced obesity mouse model.	2
METHODS: After 1 month of HFD alone, the mice were given the @GENE$ inhibitor @CHEMICAL$ for a further 11 months.	2
The improved survival rates for obese mice chronically treated with @CHEMICAL$ suggest that chronic @GENE$ inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.	2
Amelioration of @CHEMICAL$-induced @GENE$ resistance in C2C12 muscle cells by rooibos (Aspalathus linearis).	0
Increased levels of @CHEMICAL$ (FFAs), specifically saturated free fatty acids such as palmitate are associated with @GENE$ resistance of muscle, fat and liver.	0
Increased levels of free fatty acids (@CHEMICAL$), specifically saturated free fatty acids such as palmitate are associated with @GENE$ resistance of muscle, fat and liver.	0
Increased levels of free fatty acids (FFAs), specifically @CHEMICAL$ such as palmitate are associated with @GENE$ resistance of muscle, fat and liver.	0
Increased levels of free fatty acids (FFAs), specifically saturated free fatty acids such as @CHEMICAL$ are associated with @GENE$ resistance of muscle, fat and liver.	0
Rooibos (Aspalathus linearis) and its unique @CHEMICAL$, aspalathin, shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of @GENE$ resistance.	0
Rooibos (Aspalathus linearis) and its unique dihydrochalcone C-glucoside, @CHEMICAL$, shown to reduce hyperglycemia in diabetic rats, could play a role in preventing or ameliorating the development of @GENE$ resistance.	0
At a mechanistic level both extracts down-regulated @GENE$ activation, which is associated with @CHEMICAL$-induced insulin resistance.	0
At a mechanistic level both extracts down-regulated PKC θ activation, which is associated with @CHEMICAL$-induced @GENE$ resistance.	0
Protein levels of the @CHEM-GENE$ (GLUT4) involved in glucose transport via these two pathways were also increased.	0
Protein levels of the @CHEMICAL$ transporter (@GENE$) involved in glucose transport via these two pathways were also increased.	0
Protein levels of the @GENE$ (GLUT4) involved in @CHEMICAL$ transport via these two pathways were also increased.	5
Protein levels of the glucose transporter (@GENE$) involved in @CHEMICAL$ transport via these two pathways were also increased.	5
This in vitro study therefore confirms that rooibos can ameliorate @CHEMICAL$-induced @GENE$ resistance in C2C12 skeletal muscle cells.	0
@CHEMICAL$ stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via @GENE$-dependent MEK/ERK and PI3K/Akt activation.	0
@CHEMICAL$ stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent @GENE$/ERK and PI3K/Akt activation.	1
@CHEMICAL$ stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/@GENE$ and PI3K/Akt activation.	1
@CHEMICAL$ stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and @GENE$/Akt activation.	1
@CHEMICAL$ stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/@GENE$ activation.	1
Here we show that puerarin increases proliferation and differentiation and opposes @CHEMICAL$-induced apoptosis in human osteoblastic MG-63 cells containing two @GENE$ (ER) isoforms.	0
Here we show that puerarin increases proliferation and differentiation and opposes @CHEMICAL$-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (@GENE$) isoforms.	0
Here we show that puerarin increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two @CHEM-GENE$ (ER) isoforms.	0
Here we show that puerarin increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two @CHEMICAL$ receptor (@GENE$) isoforms.	0
Here we show that @CHEMICAL$ increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two @GENE$ (ER) isoforms.	0
Here we show that @CHEMICAL$ increases proliferation and differentiation and opposes cisplatin-induced apoptosis in human osteoblastic MG-63 cells containing two estrogen receptor (@GENE$) isoforms.	0
@CHEMICAL$ promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of @GENE$ expression.	0
Puerarin promotes proliferation by altering cell cycle distribution whereas @CHEMICAL$-mediated survival may be associated with up-regulation of @GENE$ expression.	1
Treatment with the @GENE$ antagonist @CHEMICAL$ abolishes the above actions of puerarin on osteoblast-derived cells.	4
Treatment with the @GENE$ antagonist ICI 182,780 abolishes the above actions of @CHEMICAL$ on osteoblast-derived cells.	0
Using small interfering double-stranded RNA technology, we further demonstrate that the effects of @CHEMICAL$ on proliferation, differentiation and survival are mediated by both @GENE$ and ERβ.	0
Using small interfering double-stranded RNA technology, we further demonstrate that the effects of @CHEMICAL$ on proliferation, differentiation and survival are mediated by both ERα and @GENE$.	0
Moreover, we also demonstrate that @CHEMICAL$ functions at least partially through activation of @GENE$/ERK and PI3K/Akt signaling.	1
Moreover, we also demonstrate that @CHEMICAL$ functions at least partially through activation of MEK/@GENE$ and PI3K/Akt signaling.	1
Moreover, we also demonstrate that @CHEMICAL$ functions at least partially through activation of MEK/ERK and @GENE$/Akt signaling.	1
Moreover, we also demonstrate that @CHEMICAL$ functions at least partially through activation of MEK/ERK and PI3K/@GENE$ signaling.	1
@GENE$ inhibits @CHEMICAL$-induced pulmonary fibrosis in rats.	0
There is no study to investigate @GENE$'s role in the development of pulmonary fibrosis induced by @CHEMICAL$.	0
In the current study, we used the rat model to explore the potential antifibrotic role of @GENE$ and its underlying mechanism in @CHEMICAL$-induced pulmonary fibrosis.	0
Control group received saline, @CHEMICAL$ group received silica and @GENE$ treated group received silica and BMP-7.	0
Control group received saline, @CHEMICAL$ group received silica and BMP-7 treated group received silica and @GENE$.	0
Control group received saline, silica group received @CHEMICAL$ and @GENE$ treated group received silica and BMP-7.	0
Control group received saline, silica group received @CHEMICAL$ and BMP-7 treated group received silica and @GENE$.	0
Control group received saline, silica group received silica and @GENE$ treated group received @CHEMICAL$ and BMP-7.	0
Control group received saline, silica group received silica and BMP-7 treated group received @CHEMICAL$ and @GENE$.	0
@GENE$ was administered to @CHEMICAL$-treated rats intraperitoneally at a dose of 300μg/kg/injection from day 8 to day 30 every other day.	0
After the animals were sacrificed on day 15 and 30, @CHEMICAL$ levels, the protein expressions of @GENE$/Smad and TGF-β/Smad signaling, and histopathology in lung tissues were analyzed.	0
After the animals were sacrificed on day 15 and 30, @CHEMICAL$ levels, the protein expressions of BMP/@GENE$ and TGF-β/Smad signaling, and histopathology in lung tissues were analyzed.	0
After the animals were sacrificed on day 15 and 30, @CHEMICAL$ levels, the protein expressions of BMP/Smad and @GENE$/Smad signaling, and histopathology in lung tissues were analyzed.	0
After the animals were sacrificed on day 15 and 30, @CHEMICAL$ levels, the protein expressions of BMP/Smad and TGF-β/@GENE$ signaling, and histopathology in lung tissues were analyzed.	0
The @CHEMICAL$ contents in @GENE$ treated groups were significantly lower than the silica groups (P<0.05).	0
The hydroxyproline contents in @GENE$ treated groups were significantly lower than the @CHEMICAL$ groups (P<0.05).	0
Histopathological results showed @GENE$ could reduce the progression of @CHEMICAL$ induced fibrosis.	0
Furthermore, the expression of @GENE$, a marker of BMP/Smad signaling, was significantly up-regulated in BMP-7 treated groups (P<0.05) compared with the @CHEMICAL$ groups.	0
Furthermore, the expression of p-Smad1/5/8, a marker of @GENE$/Smad signaling, was significantly up-regulated in BMP-7 treated groups (P<0.05) compared with the @CHEMICAL$ groups.	0
Furthermore, the expression of p-Smad1/5/8, a marker of BMP/@GENE$ signaling, was significantly up-regulated in BMP-7 treated groups (P<0.05) compared with the @CHEMICAL$ groups.	0
Furthermore, the expression of p-Smad1/5/8, a marker of BMP/Smad signaling, was significantly up-regulated in @GENE$ treated groups (P<0.05) compared with the @CHEMICAL$ groups.	0
On the contrary, the expression of @GENE$, a marker for TGF-β/Smad signaling, reduced significantly in BMP-7-treated groups compared with @CHEMICAL$ groups (P<0.05).	0
On the contrary, the expression of p-Smad2/3, a marker for @GENE$/Smad signaling, reduced significantly in BMP-7-treated groups compared with @CHEMICAL$ groups (P<0.05).	0
On the contrary, the expression of p-Smad2/3, a marker for TGF-β/@GENE$ signaling, reduced significantly in BMP-7-treated groups compared with @CHEMICAL$ groups (P<0.05).	0
On the contrary, the expression of p-Smad2/3, a marker for TGF-β/Smad signaling, reduced significantly in @GENE$-treated groups compared with @CHEMICAL$ groups (P<0.05).	0
In conclusion, the pulmonary fibrosis induced by @CHEMICAL$ in rats was significantly reduced with the therapeutic treatment of @GENE$.	0
The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of @CHEM-GENE$/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of @CHEMICAL$ 3-kinase/@GENE$ signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of @CHEMICAL$ 3-kinase/Akt signaling pathway: @GENE$ and endothelial apoptosis.	0
The preventive effect of uncarboxylated @GENE$ against free fatty acid-induced endothelial apoptosis through the activation of @CHEMICAL$ 3-kinase/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
The preventive effect of uncarboxylated osteocalcin against @CHEMICAL$-induced endothelial apoptosis through the activation of @GENE$/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
The preventive effect of uncarboxylated osteocalcin against @CHEMICAL$-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/@GENE$ signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
The preventive effect of uncarboxylated osteocalcin against @CHEMICAL$-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway: @GENE$ and endothelial apoptosis.	0
The preventive effect of uncarboxylated @GENE$ against @CHEMICAL$-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway: Uncarboxylated osteocalcin and endothelial apoptosis.	0
Apoptosis was evaluated using various methods including a terminal @CHEM-GENE$-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal @CHEMICAL$ transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved @GENE$, cleaved poly (ADP-ribose) polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal @CHEMICAL$ transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved @GENE$ and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal @CHEMICAL$ transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and @GENE$.	0
Apoptosis was evaluated using various methods including a terminal @GENE$-mediated @CHEMICAL$ nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated @CHEMICAL$ nick-end labeling analysis kit and Western blotting for cleaved @GENE$, cleaved poly (ADP-ribose) polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated @CHEMICAL$ nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved @GENE$ and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated @CHEMICAL$ nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved poly (ADP-ribose) polymerase and @GENE$.	0
Apoptosis was evaluated using various methods including a terminal @GENE$-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved @CHEMICAL$ polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved @GENE$, cleaved @CHEMICAL$ polymerase and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved @CHEM-GENE$ and Bcl-xL.	0
Apoptosis was evaluated using various methods including a terminal deoxyribonucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling analysis kit and Western blotting for cleaved caspase 3, cleaved @CHEMICAL$ polymerase and @GENE$.	0
The phosphorylations of @GENE$ and endothelial nitric oxide synthase (eNOS) as well as the level of @CHEMICAL$ were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and @GENE$ (eNOS) as well as the level of @CHEMICAL$ were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial nitric oxide synthase (@GENE$) as well as the level of @CHEMICAL$ were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial nitric oxide synthase (eNOS) as well as the level of @CHEMICAL$ were measured to confirm the effect of @GENE$ on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial nitric oxide synthase (eNOS) as well as the level of @CHEMICAL$ were measured to confirm the effect of ucOC on @GENE$ signaling pathway.	0
The phosphorylations of @GENE$ and endothelial @CHEMICAL$ synthase (eNOS) as well as the level of NO were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and @CHEM-GENE$ (eNOS) as well as the level of NO were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial @CHEMICAL$ synthase (@GENE$) as well as the level of NO were measured to confirm the effect of ucOC on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial @CHEMICAL$ synthase (eNOS) as well as the level of NO were measured to confirm the effect of @GENE$ on insulin signaling pathway.	0
The phosphorylations of Akt and endothelial @CHEMICAL$ synthase (eNOS) as well as the level of NO were measured to confirm the effect of ucOC on @GENE$ signaling pathway.	0
RESULTS: Pretreatment of @GENE$ (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the @CHEMICAL$ 3-kinase (PI3-kinase) inhibitor, wortmannin.	0
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in @GENE$-stimulated endothelial cells; effects were abolished by pretreatment with the @CHEMICAL$ 3-kinase (PI3-kinase) inhibitor, wortmannin.	0
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the @CHEM-GENE$ (PI3-kinase) inhibitor, wortmannin.	0
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the @CHEMICAL$ 3-kinase (@GENE$) inhibitor, wortmannin.	0
RESULTS: Pretreatment of @GENE$ (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, @CHEMICAL$.	0
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in @GENE$-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, @CHEMICAL$.	0
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the @GENE$ (PI3-kinase) inhibitor, @CHEMICAL$.	2
RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (@GENE$) inhibitor, @CHEMICAL$.	2
Treatment of @GENE$ (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and eNOS and @CHEMICAL$ secretion from endothelial cells in a PI3-kinase dependent manner.	0
Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of @GENE$ and eNOS and @CHEMICAL$ secretion from endothelial cells in a PI3-kinase dependent manner.	0
Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and @GENE$ and @CHEMICAL$ secretion from endothelial cells in a PI3-kinase dependent manner.	0
Treatment of ucOC (ranged from 0.3 to 30ng/ml) significantly increased the phosphorylation of Akt and eNOS and @CHEMICAL$ secretion from endothelial cells in a @GENE$ dependent manner.	0
Distinct role of @GENE$ in mediating @CHEMICAL$ generation downstream of both G12/13 and integrin αiibβ in platelets.	0
Distinct role of PYK2 in mediating @CHEMICAL$ generation downstream of both @GENE$ and integrin αiibβ in platelets.	0
Distinct role of PYK2 in mediating @CHEMICAL$ generation downstream of both G12/13 and @GENE$ in platelets.	0
@CHEM-GENE$ (Pyk2) is activated by various agonists in platelets.	0
@CHEMICAL$-rich tyrosine kinase 2 (@GENE$) is activated by various agonists in platelets.	0
@CHEM-GENE$ (Pyk2) is activated by various agonists in platelets.	0
Proline-rich @CHEMICAL$ kinase 2 (@GENE$) is activated by various agonists in platelets.	0
We found that platelet aggregation and secretion in response to @CHEMICAL$ and AYPGKF were diminished in the presence of @GENE$ inhibitors or in Pyk2-deficient platelets, suggesting that Pyk2 plays a positive regulatory role in platelet functional responses.	0
We found that platelet aggregation and secretion in response to @CHEMICAL$ and AYPGKF were diminished in the presence of Pyk2 inhibitors or in @GENE$-deficient platelets, suggesting that Pyk2 plays a positive regulatory role in platelet functional responses.	0
We found that platelet aggregation and secretion in response to @CHEMICAL$ and AYPGKF were diminished in the presence of Pyk2 inhibitors or in Pyk2-deficient platelets, suggesting that @GENE$ plays a positive regulatory role in platelet functional responses.	0
It has been shown that @CHEMICAL$-, but not @GENE$-, induced thromboxane (TxA2) generation depends on integrin signaling.	0
It has been shown that @CHEMICAL$-, but not thrombin-, induced thromboxane (TxA2) generation depends on @GENE$ signaling.	0
It has been shown that ADP-, but not @GENE$-, induced @CHEMICAL$ (TxA2) generation depends on integrin signaling.	0
It has been shown that ADP-, but not thrombin-, induced @CHEMICAL$ (TxA2) generation depends on @GENE$ signaling.	0
It has been shown that ADP-, but not @GENE$-, induced thromboxane (@CHEMICAL$) generation depends on integrin signaling.	0
It has been shown that ADP-, but not thrombin-, induced thromboxane (@CHEMICAL$) generation depends on @GENE$ signaling.	0
Unlike @CHEMICAL$, @GENE$ activates G12/13 pathways, and G12/13 pathways can substitute for integrin signaling for TxA2 generation.	0
Unlike @CHEMICAL$, thrombin activates @GENE$ pathways, and G12/13 pathways can substitute for integrin signaling for TxA2 generation.	0
Unlike @CHEMICAL$, thrombin activates G12/13 pathways, and @GENE$ pathways can substitute for integrin signaling for TxA2 generation.	0
Unlike @CHEMICAL$, thrombin activates G12/13 pathways, and G12/13 pathways can substitute for @GENE$ signaling for TxA2 generation.	0
Unlike ADP, @GENE$ activates G12/13 pathways, and G12/13 pathways can substitute for integrin signaling for @CHEMICAL$ generation.	0
Unlike ADP, thrombin activates @GENE$ pathways, and G12/13 pathways can substitute for integrin signaling for @CHEMICAL$ generation.	0
Unlike ADP, thrombin activates G12/13 pathways, and @GENE$ pathways can substitute for integrin signaling for @CHEMICAL$ generation.	0
Unlike ADP, thrombin activates G12/13 pathways, and G12/13 pathways can substitute for @GENE$ signaling for @CHEMICAL$ generation.	0
We found that @GENE$ was activated downstream of both G12/13 and integrin-mediated pathways, and both @CHEMICAL$- and AYPGKF-induced TxA2 generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both @GENE$ and integrin-mediated pathways, and both @CHEMICAL$- and AYPGKF-induced TxA2 generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both G12/13 and @GENE$-mediated pathways, and both @CHEMICAL$- and AYPGKF-induced TxA2 generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both G12/13 and integrin-mediated pathways, and both @CHEMICAL$- and AYPGKF-induced TxA2 generation was significantly diminished in @GENE$-deficient platelets.	0
We found that @GENE$ was activated downstream of both G12/13 and integrin-mediated pathways, and both 2-MeSADP- and AYPGKF-induced @CHEMICAL$ generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both @GENE$ and integrin-mediated pathways, and both 2-MeSADP- and AYPGKF-induced @CHEMICAL$ generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both G12/13 and @GENE$-mediated pathways, and both 2-MeSADP- and AYPGKF-induced @CHEMICAL$ generation was significantly diminished in Pyk2-deficient platelets.	0
We found that Pyk2 was activated downstream of both G12/13 and integrin-mediated pathways, and both 2-MeSADP- and AYPGKF-induced @CHEMICAL$ generation was significantly diminished in @GENE$-deficient platelets.	0
In addition, @CHEMICAL$ generation induced by co-stimulation of Gi and @GENE$ pathways, which is dependent on integrin signaling, was inhibited by blocking Pyk2.	0
In addition, @CHEMICAL$ generation induced by co-stimulation of Gi and Gz pathways, which is dependent on @GENE$ signaling, was inhibited by blocking Pyk2.	0
In addition, @CHEMICAL$ generation induced by co-stimulation of Gi and Gz pathways, which is dependent on integrin signaling, was inhibited by blocking @GENE$.	0
In addition, @CHEMICAL$ generation induced by co-stimulation of @GENE$ and Gz pathways, which is dependent on integrin signaling, was inhibited by blocking Pyk2.	0
Furthermore, inhibition of @CHEMICAL$-induced TxA2 generation by @GENE$ antagonist was not rescued by co-stimulation of G12/13 pathways in the presence of Pyk2 inhibitor.	0
Furthermore, inhibition of @CHEMICAL$-induced TxA2 generation by fibrinogen receptor antagonist was not rescued by co-stimulation of @GENE$ pathways in the presence of Pyk2 inhibitor.	0
Furthermore, inhibition of @CHEMICAL$-induced TxA2 generation by fibrinogen receptor antagonist was not rescued by co-stimulation of G12/13 pathways in the presence of @GENE$ inhibitor.	0
Furthermore, inhibition of 2-MeSADP-induced @CHEMICAL$ generation by @GENE$ antagonist was not rescued by co-stimulation of G12/13 pathways in the presence of Pyk2 inhibitor.	0
Furthermore, inhibition of 2-MeSADP-induced @CHEMICAL$ generation by fibrinogen receptor antagonist was not rescued by co-stimulation of @GENE$ pathways in the presence of Pyk2 inhibitor.	0
Furthermore, inhibition of 2-MeSADP-induced @CHEMICAL$ generation by fibrinogen receptor antagonist was not rescued by co-stimulation of G12/13 pathways in the presence of @GENE$ inhibitor.	0
We conclude that @GENE$ is a common signaling effector downstream of both G12/13 and integrin αIIbβ3 signaling which contributes to @CHEMICAL$ generation.	0
We conclude that Pyk2 is a common signaling effector downstream of both @GENE$ and integrin αIIbβ3 signaling which contributes to @CHEMICAL$ generation.	0
We conclude that Pyk2 is a common signaling effector downstream of both G12/13 and @GENE$ signaling which contributes to @CHEMICAL$ generation.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEM-GENE$ (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEMICAL$ peroxidase (@GENE$) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEMICAL$ peroxidase (APX) activity during the exponential growth and a more important role of @GENE$ (CAT) and glutathione reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEMICAL$ peroxidase (APX) activity during the exponential growth and a more important role of catalase (@GENE$) and glutathione reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEMICAL$ peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and @GENE$ (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @CHEMICAL$ peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and glutathione reductase (@GENE$) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in @GENE$ (APX) activity during the exponential growth and a more important role of catalase (CAT) and @CHEMICAL$ reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (@GENE$) activity during the exponential growth and a more important role of catalase (CAT) and @CHEMICAL$ reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of @GENE$ (CAT) and @CHEMICAL$ reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (@GENE$) and @CHEMICAL$ reductase (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and @CHEM-GENE$ (GR) activities during the slow growth phase.	0
Under control conditions, the AEA of biofilms were found to change throughout time with a significant increase in ascorbate peroxidase (APX) activity during the exponential growth and a more important role of catalase (CAT) and @CHEMICAL$ reductase (@GENE$) activities during the slow growth phase.	0
In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150μgL(-1) @CHEMICAL$ showed a higher @GENE$ activity than controls.	1
Chronic exposure to @CHEMICAL$ provoked then structural changes but also functional changes in the capacity of biofilm @GENE$ activity to respond to a sudden increase in concentration, suggesting a selection of species with higher antioxidant capacity.	0
A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous @CHEMICAL$ to the motor actions of @GENE$ (NOP receptor) ligands.	0
A combined pharmacological and genetic approach was undertaken to investigate the contribution of endogenous @CHEMICAL$ to the motor actions of nociceptin/orphanin FQ (N/OFQ) receptor (@GENE$) ligands.	0
The involvement of the various @GENE$ subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of @GENE$ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and @GENE$ antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using @GENE$/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/@GENE$ (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), @GENE$/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/@GENE$ (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and @GENE$ (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (@CHEMICAL$), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using @GENE$ knockout mice.	0
The involvement of the various @GENE$ subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of @GENE$ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and @GENE$ antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using @GENE$/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/@GENE$ (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), @GENE$/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/@GENE$ (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and @GENE$ (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (@CHEMICAL$, amisulpride) and D3 (S33084) receptor antagonists, and by using @GENE$ knockout mice.	0
The involvement of the various @GENE$ subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of @GENE$ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and @GENE$ antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using @GENE$/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/@GENE$ (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), @GENE$/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/@GENE$ (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and @GENE$ (S33084) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, @CHEMICAL$) and D3 (S33084) receptor antagonists, and by using @GENE$ knockout mice.	0
The involvement of the various @GENE$ subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of @GENE$ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and @GENE$ antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using @GENE$/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/@GENE$ (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), @GENE$/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/@GENE$ (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	0
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and @GENE$ (@CHEMICAL$) receptor antagonists, and by using D2 receptor knockout mice.	4
The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and D3 (@CHEMICAL$) receptor antagonists, and by using @GENE$ knockout mice.	0
@CHEMICAL$ also attenuated the hypolocomotion induced by the @GENE$ agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it.	0
Amisulpride also attenuated the hypolocomotion induced by the @GENE$ agonist @CHEMICAL$ and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it.	0
Amisulpride also attenuated the hypolocomotion induced by the @GENE$ agonist pramipexole and @CHEMICAL$ precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it.	0
Amisulpride also attenuated the hypolocomotion induced by the @GENE$ agonist pramipexole and dopamine precursor @CHEMICAL$, whereas raclopride (and S33084) worsened it.	0
Amisulpride also attenuated the hypolocomotion induced by the @GENE$ agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas @CHEMICAL$ (and S33084) worsened it.	0
Amisulpride also attenuated the hypolocomotion induced by the @GENE$ agonist pramipexole and dopamine precursor L-3,4-dihydroxyphenylalanine, whereas raclopride (and @CHEMICAL$) worsened it.	0
Motor facilitation induced by @GENE$ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and @GENE$ antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in @GENE$(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and @GENE$(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by @GENE$ antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in @GENE$(-/-) but preserved in D2L(-/-) mice.	0
Motor facilitation induced by N/OFQ and NOP receptor antagonists was lost in D2R(-/-) and D2L(-/-) mice whereas motor inhibition induced by NOP receptor antagonists (and @CHEMICAL$) was lost in D2R(-/-) but preserved in @GENE$(-/-) mice.	0
We demonstrate that motor actions of @GENE$ ligands rely on the modulation of endogenous @CHEMICAL$.	0
@CHEMICAL$ promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of @GENE$.	2
@CHEMICAL$ promotes @GENE$-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	0
@CHEMICAL$ promotes mTORC1-dependent phosphorylation of @GENE$ via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	1
@CHEMICAL$ promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via @GENE$ and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of @GENE$.	0
Haloperidol promotes @GENE$-dependent phosphorylation of ribosomal protein S6 via @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of @GENE$ via @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via @CHEM-GENE$ and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa and inhibition of @GENE$.	0
Haloperidol promotes @GENE$-dependent phosphorylation of ribosomal protein S6 via dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of @GENE$ via dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1.	0
Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via @CHEM-GENE$ and inhibition of protein phosphatase-1.	0
Here, we examined the effects produced by @CHEMICAL$, a typical antipsychotic drug, on the phosphorylation of @GENE$ at Ser240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.	0
Here, we examined the effects produced by haloperidol, a typical antipsychotic drug, on the phosphorylation of @GENE$ at @CHEMICAL$240/244 in the striatum, a brain region involved in neurodegenerative and neuropsychiatric disorders.	0
Administration of haloperidol increased @CHEMICAL$240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express @GENE$ (D2Rs).	0
Administration of haloperidol increased @CHEMICAL$240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (@GENE$).	0
Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of @CHEMICAL$-ergic medium spiny neurons (MSNs), which express @GENE$ (D2Rs).	0
Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of @CHEMICAL$-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (@GENE$).	0
Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express @CHEM-GENE$ (D2Rs).	0
Administration of haloperidol increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express @CHEMICAL$ D2 receptors (@GENE$).	0
Administration of @CHEMICAL$ increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express @GENE$ (D2Rs).	0
Administration of @CHEMICAL$ increased Ser240/244 phosphorylation in a subpopulation of GABA-ergic medium spiny neurons (MSNs), which express dopamine D2 receptors (@GENE$).	0
This effect was prevented by @CHEMICAL$, an inhibitor of the @GENE$ (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	2
This effect was prevented by @CHEMICAL$, an inhibitor of the mammalian target of rapamycin complex 1 (@GENE$), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	2
This effect was prevented by @CHEMICAL$, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the @GENE$ (S6K1).	0
This effect was prevented by @CHEMICAL$, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (@GENE$).	0
This effect was prevented by rapamycin, an inhibitor of the @CHEM-GENE$ (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	0
This effect was prevented by rapamycin, an inhibitor of the mammalian target of @CHEMICAL$ complex 1 (@GENE$), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	0
This effect was prevented by rapamycin, an inhibitor of the mammalian target of @CHEMICAL$ complex 1 (mTORC1), or by PF470867, a selective inhibitor of the @GENE$ (S6K1).	0
This effect was prevented by rapamycin, an inhibitor of the mammalian target of @CHEMICAL$ complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (@GENE$).	0
This effect was prevented by rapamycin, an inhibitor of the @GENE$ (mTORC1), or by @CHEMICAL$, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	0
This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (@GENE$), or by @CHEMICAL$, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	0
This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by @CHEMICAL$, a selective inhibitor of the @GENE$ (S6K1).	2
This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by @CHEMICAL$, a selective inhibitor of the p70 ribosomal S6 kinase 1 (@GENE$).	2
We also found that the effect of @CHEMICAL$ on Ser240/244 phosphorylation was prevented by functional inactivation of @GENE$ (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of @CHEMICAL$ on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (@GENE$), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of @CHEMICAL$ on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of @GENE$ (PP-1).	0
We also found that the effect of @CHEMICAL$ on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (@GENE$).	0
We also found that the effect of haloperidol on @CHEMICAL$240/244 phosphorylation was prevented by functional inactivation of @GENE$ (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on @CHEMICAL$240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (@GENE$), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on @CHEMICAL$240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of @GENE$ (PP-1).	0
We also found that the effect of haloperidol on @CHEMICAL$240/244 phosphorylation was prevented by functional inactivation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (@GENE$).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of @CHEM-GENE$ (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa (@GENE$), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of @GENE$ (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of @CHEMICAL$- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (@GENE$).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of @CHEM-GENE$ (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa (@GENE$), an endogenous inhibitor of protein phosphatase-1 (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of @GENE$ (PP-1).	0
We also found that the effect of haloperidol on Ser240/244 phosphorylation was prevented by functional inactivation of dopamine- and @CHEMICAL$-regulated phosphoprotein of 32 kDa (DARPP-32), an endogenous inhibitor of protein phosphatase-1 (@GENE$).	0
In line with this observation, incubation of striatal slices with @CHEMICAL$ and calyculin A, two inhibitors of @GENE$, increased Ser240/244 phosphorylation.	2
In line with this observation, incubation of striatal slices with okadaic acid and @CHEMICAL$, two inhibitors of @GENE$, increased Ser240/244 phosphorylation.	2
In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of @GENE$, increased @CHEMICAL$240/244 phosphorylation.	0
These results show that @CHEMICAL$ promotes @GENE$- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.	0
These results show that @CHEMICAL$ promotes mTORC1- and @GENE$-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.	0
These results show that @CHEMICAL$ promotes mTORC1- and S6K1-dependent phosphorylation of @GENE$ at Ser240/244, in a subpopulation of striatal MSNs expressing D2Rs.	1
These results show that @CHEMICAL$ promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240/244, in a subpopulation of striatal MSNs expressing @GENE$.	0
These results show that haloperidol promotes @GENE$- and S6K1-dependent phosphorylation of rpS6 at @CHEMICAL$240/244, in a subpopulation of striatal MSNs expressing D2Rs.	0
These results show that haloperidol promotes mTORC1- and @GENE$-dependent phosphorylation of rpS6 at @CHEMICAL$240/244, in a subpopulation of striatal MSNs expressing D2Rs.	0
These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of @GENE$ at @CHEMICAL$240/244, in a subpopulation of striatal MSNs expressing D2Rs.	0
These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at @CHEMICAL$240/244, in a subpopulation of striatal MSNs expressing @GENE$.	0
They also indicate that this effect is exerted by suppressing dephosphorylation at @CHEMICAL$240/244, through @GENE$-dependent activation of DARPP-32 and inhibition of PP-1.	0
They also indicate that this effect is exerted by suppressing dephosphorylation at @CHEMICAL$240/244, through PKA-dependent activation of @GENE$ and inhibition of PP-1.	0
They also indicate that this effect is exerted by suppressing dephosphorylation at @CHEMICAL$240/244, through PKA-dependent activation of DARPP-32 and inhibition of @GENE$.	0
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor @CHEMICAL$ with a mimic of the Arg-Gly-Asp (RGD) sequence of @GENE$ to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective @GENE$ inhibitor @CHEMICAL$ with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	2
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor @CHEMICAL$ with a mimic of the @GENE$ (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor @CHEMICAL$ with a mimic of the Arg-Gly-Asp (@GENE$) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the @CHEMICAL$ (RGD) sequence of @GENE$ to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective @GENE$ inhibitor rivaroxaban with a mimic of the @CHEMICAL$ (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the @CHEM-GENE$ (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	0
These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the @CHEMICAL$ (@GENE$) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.	0
Resulting from this study, a structurally novel class of submicromolar fibrinogen @GENE$ binding inhibitor bearing @CHEMICAL$ moiety is also described.	2
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants @CHEM-GENE$, glutathione peroxidase and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants @CHEMICAL$ dismutase, @GENE$ and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants @CHEMICAL$ dismutase, glutathione peroxidase and @GENE$ in the frontal cortex tissue.	0
Rats intoxicated with @CHEMICAL$ for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants @GENE$, glutathione peroxidase and catalase in the frontal cortex tissue.	2
Rats intoxicated with @CHEMICAL$ for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, @GENE$ and catalase in the frontal cortex tissue.	2
Rats intoxicated with @CHEMICAL$ for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and @GENE$ in the frontal cortex tissue.	2
Rats intoxicated with Cd for 30 days, significantly increased tissue @CHEMICAL$ (MDA) levels and significantly decreased enzymatic antioxidants @GENE$, glutathione peroxidase and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue @CHEMICAL$ (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, @GENE$ and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue @CHEMICAL$ (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and @GENE$ in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (@CHEMICAL$) levels and significantly decreased enzymatic antioxidants @GENE$, glutathione peroxidase and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (@CHEMICAL$) levels and significantly decreased enzymatic antioxidants superoxide dismutase, @GENE$ and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (@CHEMICAL$) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and @GENE$ in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants @GENE$, @CHEMICAL$ peroxidase and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, @CHEM-GENE$ and catalase in the frontal cortex tissue.	0
Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, @CHEMICAL$ peroxidase and @GENE$ in the frontal cortex tissue.	0
The @GENE$ immunopositivity was increased in degenerating neurons of the @CHEMICAL$ group.	1
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @GENE$ and the effect of @CHEMICAL$ on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of @CHEMICAL$ on growth, expression of marker of stem cells and thyroid differentiation (@GENE$, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of @CHEMICAL$ on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, @GENE$, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of @CHEMICAL$ on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, @GENE$, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of @CHEMICAL$ on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, @GENE$ expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @GENE$ and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, @CHEMICAL$ symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (@GENE$, thyroperoxidase, thyroglobulin, @CHEMICAL$ symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, @GENE$, thyroglobulin, @CHEMICAL$ symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, @GENE$, @CHEMICAL$ symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, @CHEM-GENE$ expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of @CHEMICAL$ to induce thyrosphere formation, the expression of @GENE$ and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of @CHEMICAL$ to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (@GENE$, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of @CHEMICAL$ to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, @GENE$, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of @CHEMICAL$ to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, @GENE$, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of @CHEMICAL$ to induce thyrosphere formation, the expression of oestrogen receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, @GENE$ expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @CHEM-GENE$ and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @CHEMICAL$ receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (@GENE$, thyroperoxidase, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @CHEMICAL$ receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, @GENE$, thyroglobulin, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @CHEMICAL$ receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, @GENE$, sodium iodide symporter expression) were analysed.	0
In thyroid stem/progenitor cells derived from nodular goitres the ability of 17beta-oestradiol to induce thyrosphere formation, the expression of @CHEMICAL$ receptors and the effect of 17beta-oestradiol on growth, expression of marker of stem cells and thyroid differentiation (TSH receptor, thyroperoxidase, thyroglobulin, @GENE$ expression) were analysed.	0
Thyroid stem and progenitor cells expressed @CHEM-GENE$ with an 8 time higher expression level of oestrogen receptor alpha mRNA compared to differentiated thyrocytes.	0
Thyroid stem and progenitor cells expressed @CHEMICAL$ receptor alpha and beta with an 8 time higher expression level of @GENE$ mRNA compared to differentiated thyrocytes.	0
Thyroid stem and progenitor cells expressed @GENE$ with an 8 time higher expression level of @CHEMICAL$ receptor alpha mRNA compared to differentiated thyrocytes.	0
Thyroid stem and progenitor cells expressed oestrogen receptor alpha and beta with an 8 time higher expression level of @CHEM-GENE$ mRNA compared to differentiated thyrocytes.	0
In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the @CHEM-GENE$, was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.	0
In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the @GENE$, was significantly inhibited by @CHEMICAL$.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.	2
In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the @GENE$, was significantly inhibited by 17beta-oestradiol.In conclusion, @CHEMICAL$ stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.	0
By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of @GENE$, ndhB-1255, and ndhD-2 is completely lost in roots and in @CHEMICAL$-treated seedlings.	0
By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, @GENE$, and ndhD-2 is completely lost in roots and in @CHEMICAL$-treated seedlings.	0
By contrast, the editing of some sites is completely lost or significantly reduced in other non-green tissues; for instance, the editing of ndhB-149, ndhB-1255, and @GENE$ is completely lost in roots and in @CHEMICAL$-treated seedlings.	0
The editing of @GENE$ is also completely lost in albino mutants and @CHEMICAL$-treated seedlings.	0
In addition, the expression of nucleus-encoded @GENE$ dependent transcripts is specifically induced by @CHEMICAL$, and the splicing of ndhB transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings.	0
In addition, the expression of nucleus-encoded RNA polymerase dependent transcripts is specifically induced by @CHEMICAL$, and the splicing of @GENE$ transcripts is significantly reduced in the albino mutants and inhibitor-treated seedlings.	0
Drug-drug interactions between @CHEM-GENE$ inhibitors (statins) and antiviral protease inhibitors.	0
Drug-drug interactions between @CHEMICAL$ reductase inhibitors (statins) and antiviral @GENE$ inhibitors.	0
The @CHEM-GENE$ inhibitors are a class of drugs also known as statins.	0
Drug-drug interactions are dependent on statins' pharmacokinetic profile: @CHEMICAL$, lovastatin and atorvastatin are metabolized through @GENE$, while the metabolism of the other statins is independent of this CYP.	5
Drug-drug interactions are dependent on statins' pharmacokinetic profile: @CHEMICAL$, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this @GENE$.	0
Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, @CHEMICAL$ and atorvastatin are metabolized through @GENE$, while the metabolism of the other statins is independent of this CYP.	5
Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, @CHEMICAL$ and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this @GENE$.	0
Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and @CHEMICAL$ are metabolized through @GENE$, while the metabolism of the other statins is independent of this CYP.	5
Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and @CHEMICAL$ are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this @GENE$.	0
All HIV PIs except @CHEMICAL$ are coadministered with a low dose of ritonavir, a potent @GENE$ inhibitor to improve their pharmacokinetic properties.	0
All HIV PIs except nelfinavir are coadministered with a low dose of @CHEMICAL$, a potent @GENE$ inhibitor to improve their pharmacokinetic properties.	2
The HCV-PIs @CHEMICAL$ and telaprevir are both, to different extents, inhibitors of @GENE$.	2
The HCV-PIs boceprevir and @CHEMICAL$ are both, to different extents, inhibitors of @GENE$.	2
Simvastatin and lovastatin metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or @CHEMICAL$, and therefore their coadministration is contraindicated.	0
Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or @CHEMICAL$, and therefore their coadministration is contraindicated.	2
@CHEMICAL$ and lovastatin metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	5
@CHEMICAL$ and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	0
Simvastatin and @CHEMICAL$ metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	5
Simvastatin and @CHEMICAL$ metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	0
Simvastatin and lovastatin metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as @CHEMICAL$- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	0
Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as @CHEMICAL$- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	2
Simvastatin and lovastatin metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or @CHEMICAL$-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	0
Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as ritonavir- or @CHEMICAL$-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.	2
Simvastatin and lovastatin metabolized through @GENE$ have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, @CHEMICAL$ or boceprevir, and therefore their coadministration is contraindicated.	0
Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent @GENE$ inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, @CHEMICAL$ or boceprevir, and therefore their coadministration is contraindicated.	2
@CHEMICAL$ is also a @GENE$ substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.	5
@CHEMICAL$ is also a CYP3A substrate, but less potent drug-drug interactions have been reported with @GENE$ inhibitors.	0
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective @GENE$ (ALK) inhibitor @CHEMICAL$ (LDK378) currently in phase 1 and phase 2 clinical trials.	0
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (@GENE$) inhibitor @CHEMICAL$ (LDK378) currently in phase 1 and phase 2 clinical trials.	0
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective @GENE$ (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (@CHEMICAL$) currently in phase 1 and phase 2 clinical trials.	0
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (@GENE$) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (@CHEMICAL$) currently in phase 1 and phase 2 clinical trials.	0
The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective @GENE$ inhibitor 15b (@CHEMICAL$) are described.	2
In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation @GENE$ inhibitor 4 (@CHEMICAL$).	2
Limitation of SRF was produced by the anticonvulsant @CHEMICAL$ (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant @CHEMICAL$ (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (@CHEMICAL$, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (@CHEMICAL$, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, @CHEMICAL$, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, @CHEMICAL$, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, @CHEMICAL$ and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, @CHEMICAL$ and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and @CHEMICAL$) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and @CHEMICAL$) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant @CHEMICAL$ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant @CHEMICAL$ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @CHEM-GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @CHEMICAL$ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (@CHEMICAL$) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (@CHEMICAL$) at high nanomolar concentrations and by a @GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a @CHEMICAL$ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @CHEM-GENE$ weak partial agonist (Ro 15-1788) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity @GENE$ (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (@CHEMICAL$) at micromolar concentrations.	0
Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a @GENE$ weak partial agonist (@CHEMICAL$) at micromolar concentrations.	3
The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the @CHEM-GENE$, including Ro 15-1788 and the beta CCs.	0
The limitation of SRF by @CHEMICAL$ was not prevented by inverse or partial agonists at the @GENE$, including Ro 15-1788 and the beta CCs.	0
The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the @GENE$, including @CHEMICAL$ and the beta CCs.	3
The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the @GENE$, including Ro 15-1788 and the @CHEMICAL$.	3
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to @GENE$ and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of @CHEMICAL$ channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central @GENE$, and that BDZs limit SRF by slowing recovery of @CHEMICAL$ channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of @CHEM-GENE$ from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of @CHEMICAL$, but not beta CCs, to @GENE$ and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of @CHEMICAL$, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central @GENE$, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of @CHEMICAL$, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of @GENE$ from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not @CHEMICAL$, to @GENE$ and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not @CHEMICAL$, to voltage-dependent sodium channels and not to high affinity central @GENE$, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not @CHEMICAL$, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of @GENE$ from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to @CHEM-GENE$ and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent @CHEMICAL$ channels and not to high affinity central @GENE$, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent @CHEMICAL$ channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of @GENE$ from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to @GENE$ and not to high affinity central @CHEMICAL$ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central @CHEM-GENE$, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central @CHEMICAL$ receptors, and that BDZs limit SRF by slowing recovery of @GENE$ from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to @GENE$ and not to high affinity central BDZ receptors, and that @CHEMICAL$ limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central @GENE$, and that @CHEMICAL$ limit SRF by slowing recovery of sodium channels from inactivation.	0
These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that @CHEMICAL$ limit SRF by slowing recovery of @GENE$ from inactivation.	1
The mitogenic effect of @CHEMICAL$ on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the @GENE$.	0
The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (@CHEMICAL$ and cyproterone acetate) which compete for binding to the @GENE$.	0
The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and @CHEMICAL$) which compete for binding to the @GENE$.	0
The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the @CHEM-GENE$.	0
In addition to effects on cell proliferation, @CHEMICAL$ increased the percentage of @GENE$ (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.	1
In addition to effects on cell proliferation, @CHEMICAL$ increased the percentage of alkaline phosphatase (@GENE$) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.	1
We conclude that @CHEMICAL$ can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the @GENE$ ALP, presumably by an androgen receptor mediated mechanism.	1
We conclude that @CHEMICAL$ can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker @GENE$, presumably by an androgen receptor mediated mechanism.	1
We conclude that @CHEMICAL$ can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an @GENE$ mediated mechanism.	0
We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the @GENE$ ALP, presumably by an @CHEMICAL$ receptor mediated mechanism.	0
We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker @GENE$, presumably by an @CHEMICAL$ receptor mediated mechanism.	0
We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an @CHEM-GENE$ mediated mechanism.	0
The effect of @CHEM-GENE$ antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma.	0
The effect of @GENE$ antagonism with @CHEMICAL$ on concentration-related AMP-induced bronchoconstriction in asthma.	4
The effect of @GENE$ antagonism with terfenadine on concentration-related @CHEMICAL$-induced bronchoconstriction in asthma.	0
Selective @CHEM-GENE$ antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20).	0
Selective @GENE$ antagonists inhibit adenosine 5'-monophosphate (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of @CHEMICAL$ required to produce a 20% decrease in FEV1 from baseline (PC20).	0
Selective @GENE$ antagonists inhibit @CHEMICAL$ (AMP)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20).	0
Selective @GENE$ antagonists inhibit adenosine 5'-monophosphate (@CHEMICAL$)-induced bronchoconstriction by greater than 80% when expressed as a percentage inhibition of the FEV1 time-response curve following inhalation of the provocation concentration of AMP required to produce a 20% decrease in FEV1 from baseline (PC20).	0
This 16.2-fold (range, 5.5-47.9) displacement to the right of the AMP concentration-response curve by a selective @CHEM-GENE$ antagonist emphasizes the central role of histamine in the airways response to this nucleotide.	0
This 16.2-fold (range, 5.5-47.9) displacement to the right of the AMP concentration-response curve by a selective @GENE$ antagonist emphasizes the central role of @CHEMICAL$ in the airways response to this nucleotide.	0
This 16.2-fold (range, 5.5-47.9) displacement to the right of the @CHEMICAL$ concentration-response curve by a selective @GENE$ antagonist emphasizes the central role of histamine in the airways response to this nucleotide.	0
@CHEMICAL$ (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (@GENE$) that inhibits B-cell antigen receptor signalling downstream of BTK.	2
@CHEMICAL$ (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits @GENE$ signalling downstream of BTK.	2
@CHEMICAL$ (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of @GENE$.	2
@CHEMICAL$ (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of @GENE$ (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	2
Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's @CHEMICAL$ kinase (@GENE$) that inhibits B-cell antigen receptor signalling downstream of BTK.	0
Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's @CHEMICAL$ kinase (BTK) that inhibits @GENE$ signalling downstream of BTK.	0
Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's @CHEMICAL$ kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of @GENE$.	0
Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of @CHEM-GENE$ (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	0
Ibrutinib (@CHEMICAL$) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (@GENE$) that inhibits B-cell antigen receptor signalling downstream of BTK.	2
Ibrutinib (@CHEMICAL$) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits @GENE$ signalling downstream of BTK.	2
Ibrutinib (@CHEMICAL$) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of @GENE$.	0
Ibrutinib (@CHEMICAL$) is a first-in-class, potent, orally administered, covalent inhibitor of @GENE$ (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.	2
Oral @CHEMICAL$ is indicated for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or @GENE$ mutation.	0
Given its efficacy and tolerability, once-daily, oral @CHEMICAL$ is an emerging treatment option for patients with relapsed/refractory MCL or CLL and CLL patients with del 17p or @GENE$ mutation.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective @GENE$ antagonists @CHEMICAL$ [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	4
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists @CHEMICAL$ [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte @GENE$ density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists @CHEMICAL$ [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma @GENE$ activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective @GENE$ antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], @CHEMICAL$ (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	4
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], @CHEMICAL$ (weak ISA) and mepindolol (strong ISA) on lymphocyte @GENE$ density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], @CHEMICAL$ (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma @GENE$ activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective @GENE$ antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and @CHEMICAL$ (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	4
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and @CHEMICAL$ (strong ISA) on lymphocyte @GENE$ density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and @CHEMICAL$ (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma @GENE$ activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective @GENE$ antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by @CHEMICAL$ (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte @GENE$ density--assessed by @CHEMICAL$ (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by @CHEMICAL$ (ICYP) binding--and plasma @GENE$ activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective @GENE$ antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (@CHEMICAL$) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte @GENE$ density--assessed by (+/-)-[125I]-iodocyanopindolol (@CHEMICAL$) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (@CHEMICAL$) binding--and plasma @GENE$ activity (PRA) were investigated in male healthy volunteers aged 23-35 years.	0
@CHEMICAL$ treatment (4 X 40 mg/day) increased the density of @GENE$ by 25% after 2 days; concomitantly PRA and heart rate were reduced.	1
Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although @CHEMICAL$ was not detectable in plasma after 24 h. The affinity of ICYP to @GENE$ was not changed during or after treatment.	0
@GENE$ density, however, declined slowly being still significantly increased after 3 days, although @CHEMICAL$ was not detectable in plasma after 24 h. The affinity of ICYP to beta 2-adrenoceptors was not changed during or after treatment.	0
Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of @CHEMICAL$ to @GENE$ was not changed during or after treatment.	0
@GENE$ density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of @CHEMICAL$ to beta 2-adrenoceptors was not changed during or after treatment.	0
@CHEMICAL$ treatment (2 X 5 mg/day) caused a 30% decrease of @GENE$ density and PRA after 2 days; both parameters remained reduced during treatment.	2
@CHEMICAL$ treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect @GENE$ density.	0
Inhibition of @GENE$ pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and @CHEMICAL$.	2
Inhibition of @GENE$ pathway of @CHEMICAL$ metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.	5
Inhibition of @GENE$ pathway of arachidonic acid metabolism in human neutrophils by @CHEMICAL$ and 5-aminosalicylic acid.	2
Interference with @GENE$ enzymes, rather than a @CHEMICAL$-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.	2
Interference with @GENE$ enzymes, rather than a steroid-like inhibition of @CHEMICAL$ release from intracellular phospholipids, seems to be the mode of action.	5
@CHEMICAL$: a @GENE$ antagonist with unique additional actions.	4
UNLABELLED: @CHEMICAL$ is a @GENE$ antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.	4
Evidence has been obtained in man for interaction with @GENE$ in the brain; and in the peripheral circulation @CHEMICAL$ does not, as do other beta blockers, increase peripheral vascular resistance, but reduces it.	0
It is suggested that all the additional actions of @CHEMICAL$ can be attributed to a partial agonist action on @GENE$.	3
@CHEM-GENE$ binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.	0
@GENE$ binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose @CHEMICAL$.	0
@GENE$ binding of @CHEMICAL$ in vivo: increased receptor number with low-dose alprazolam.	0
The apparent affinity of @CHEM-GENE$ for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.	0
The apparent affinity of @GENE$ for @CHEMICAL$ in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.	0
The apparent affinity of @GENE$ for clonazepam in mice receiving @CHEMICAL$ (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.	0
The apparent affinity of @GENE$ for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of @CHEMICAL$ increased receptor number.	1
Muscarinic cholinergic and @CHEM-GENE$ binding of phenothiazine drug metabolites.	0
Muscarinic cholinergic and @GENE$ binding of @CHEMICAL$ drug metabolites.	0
In vitro binding affinities of chlorpromazine, @CHEMICAL$, levomepromazine, perphenazine and some of their metabolites for @GENE$, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, @CHEMICAL$, levomepromazine, perphenazine and some of their metabolites for dopamine D2 receptors, @GENE$ in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, @CHEMICAL$, perphenazine and some of their metabolites for @GENE$, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, @CHEMICAL$, perphenazine and some of their metabolites for dopamine D2 receptors, @GENE$ in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, @CHEMICAL$ and some of their metabolites for @GENE$, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, @CHEMICAL$ and some of their metabolites for dopamine D2 receptors, @GENE$ in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, perphenazine and some of their metabolites for @CHEM-GENE$, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, perphenazine and some of their metabolites for @CHEMICAL$ D2 receptors, @GENE$ in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of @CHEMICAL$, fluphenazine, levomepromazine, perphenazine and some of their metabolites for @GENE$, alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.	0
In vitro binding affinities of @CHEMICAL$, fluphenazine, levomepromazine, perphenazine and some of their metabolites for dopamine D2 receptors, @GENE$ in rat brain were previously reported from our laboratories.	0
The present study reports the in vitro binding affinities of the same compounds for @GENE$ and for @CHEMICAL$ H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and 3H-mepyramine as radioligands.	0
The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for @CHEM-GENE$ in rat brain, using 3H-quinuclidinyl benzilate and 3H-mepyramine as radioligands.	0
The present study reports the in vitro binding affinities of the same compounds for @GENE$ and for histamine H1 receptors in rat brain, using @CHEMICAL$ and 3H-mepyramine as radioligands.	0
The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for @GENE$ in rat brain, using @CHEMICAL$ and 3H-mepyramine as radioligands.	0
The present study reports the in vitro binding affinities of the same compounds for @GENE$ and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and @CHEMICAL$ as radioligands.	0
The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for @GENE$ in rat brain, using 3H-quinuclidinyl benzilate and @CHEMICAL$ as radioligands.	0
Chlorpromazine, @CHEMICAL$, and their metabolites had 5-30 times higher binding affinities for @GENE$ than fluphenazine, perphenazine and their metabolites.	0
Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for @GENE$ than @CHEMICAL$, perphenazine and their metabolites.	0
Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for @GENE$ than fluphenazine, @CHEMICAL$ and their metabolites.	0
@CHEMICAL$, levomepromazine, and their metabolites had 5-30 times higher binding affinities for @GENE$ than fluphenazine, perphenazine and their metabolites.	0
@CHEMICAL$ was the most potent and fluphenazine the least potent of the four drugs in @GENE$ binding.	0
Levomepromazine was the most potent and @CHEMICAL$ the least potent of the four drugs in @GENE$ binding.	0
Levomepromazine was the most potent and fluphenazine the least potent of the four drugs in @CHEM-GENE$ binding.	0
@CHEMICAL$, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @GENE$ binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, @CHEMICAL$ and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @GENE$ binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and @CHEMICAL$ had only 10% of the potency of the parent drug in @GENE$ binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @CHEM-GENE$ binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @GENE$ binding, while the @CHEMICAL$-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @GENE$ binding, while the 7-hydroxy-metabolites of @CHEMICAL$ and perphenazine had about 75% of the potency of the parent drug in this binding system.	0
7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in @GENE$ binding, while the 7-hydroxy-metabolites of chlorpromazine and @CHEMICAL$ had about 75% of the potency of the parent drug in this binding system.	0
Their @CHEM-GENE$ binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and levomepromazine.	0
Their @GENE$ binding affinities indicate that metabolites may contribute to the sedative effects of @CHEMICAL$ and levomepromazine.	0
Their @GENE$ binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and @CHEMICAL$.	0
Some of these effects are known to be influenced by dietary levels of @CHEMICAL$. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of @CHEMICAL$ (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (@CHEMICAL$), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), @CHEMICAL$ (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (@CHEMICAL$), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and @CHEMICAL$ (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (@CHEMICAL$) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of @CHEMICAL$. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with @CHEMICAL$ (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm @CHEMICAL$), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with @CHEMICAL$, or an AIN-076 purified diet devoid of vitamin K. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of @CHEMICAL$. The retinoids had no effect on @GENE$ times of animals fed the supplemented diet.	0
Some of these effects are known to be influenced by dietary levels of vitamin K. We therefore compared the toxic effects of 13-cis-retinoic acid (13cisRA), retinyl acetate (ROAc), and N-(4-hydroxyphenyl)retinamide (4HPR) in male Sprague-Dawley rats maintained on diets containing different levels of vitamin K. Animals were fed either an NIH-07 diet supplemented with menadione (3.1 ppm vitamin K3), an NIH-07 diet not supplemented with menadione, or an AIN-076 purified diet devoid of vitamin K. The @CHEMICAL$ had no effect on @GENE$ times of animals fed the supplemented diet.	0
When @CHEMICAL$ was omitted from the diet, however, 4HPR-dosed animals had elevated @GENE$ times.	0
When menadione was omitted from the diet, however, @CHEMICAL$-dosed animals had elevated @GENE$ times.	1
@CHEMICAL$-dosed animals showed no change in @GENE$ times.	0
In the high-dose @CHEMICAL$ group, there was a twofold increase in @GENE$ times but only after prolonged dosing.	1
For all @CHEMICAL$-dosed groups maintained on the purified diet, changes in @GENE$ times occured as early as 1 week.	0
The order of effect was @CHEMICAL$ greater than ROAc greater than 13cisRA, with increases in @GENE$ times correlating with increases in hemorrhagic deaths.	1
The order of effect was 4HPR greater than @CHEMICAL$ greater than 13cisRA, with increases in @GENE$ times correlating with increases in hemorrhagic deaths.	1
The order of effect was 4HPR greater than ROAc greater than @CHEMICAL$, with increases in @GENE$ times correlating with increases in hemorrhagic deaths.	1
@CHEMICAL$ and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma @GENE$, an effect that correlated with retinoid-induced bone effects.	2
13cisRA and @CHEMICAL$, but not 4HPR, caused a dose-dependent reduction in plasma @GENE$, an effect that correlated with retinoid-induced bone effects.	2
13cisRA and ROAc, but not @CHEMICAL$, caused a dose-dependent reduction in plasma @GENE$, an effect that correlated with retinoid-induced bone effects.	2
13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma @GENE$, an effect that correlated with @CHEMICAL$-induced bone effects.	0
In contrast, serum @GENE$ was elevated in animals dosed with @CHEMICAL$ or 4HPR but not in those dose with ROAc.	1
In contrast, serum @GENE$ was elevated in animals dosed with 13cisRA or @CHEMICAL$ but not in those dose with ROAc.	1
In contrast, serum @GENE$ was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with @CHEMICAL$.	0
Hence, plasma @GENE$ is a better predictor of @CHEMICAL$-induced bone effects than serum alkaline phosphatase.	0
Hence, plasma osteocalcin is a better predictor of @CHEMICAL$-induced bone effects than serum @GENE$.	0
The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with tritiated diprenorphine and @CHEM-GENE$ (DADLE).	0
The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with tritiated diprenorphine and [D-Ala2, D-Leu5]@GENE$ (@CHEMICAL$).	0
The existence of multiple affinity states for the opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells has been demonstrated by competition binding studies with @CHEMICAL$ and [D-Ala2, D-Leu5]@GENE$ (DADLE).	0
However, in the presence of 100 mM @CHEMICAL$, which is required for opiate inhibition of @GENE$ activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.	2
However, in the presence of 100 mM Na+, which is required for opiate inhibition of @CHEM-GENE$ activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.	0
These multiple affinity states of receptor in the hybrid cells are agonist-specific, and the percentage of total @GENE$ in high affinity state is relatively constant in various concentrations of @CHEMICAL$.	0
Multiple affinity states of @GENE$ can be demonstrated further by Scatchard analysis of saturation binding studies with @CHEMICAL$.	0
Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between @CHEMICAL$ and piriprost, a @GENE$ inhibitor.	2
Inhibition of the @GENE$ of rat basophil leukemia cells by diethylcarbamazine, and synergism between @CHEMICAL$ and piriprost, a 5-lipoxygenase inhibitor.	0
Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and @CHEMICAL$, a @GENE$ inhibitor.	2
Inhibition of the @GENE$ of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and @CHEMICAL$, a 5-lipoxygenase inhibitor.	0
Inhibition of the @CHEMICAL$ synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a @GENE$ inhibitor.	0
Inhibition of the @CHEM-GENE$ of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.	0
Inhibition of the leukotriene synthetase of rat basophil leukemia cells by @CHEMICAL$, and synergism between diethylcarbamazine and piriprost, a @GENE$ inhibitor.	0
Inhibition of the @GENE$ of rat basophil leukemia cells by @CHEMICAL$, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.	2
Similar concentrations also inhibited the formation of @CHEMICAL$ (LTC4) by @GENE$, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.	5
Similar concentrations also inhibited the formation of leukotriene C4 (@CHEMICAL$) by @GENE$, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione.	5
Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by @GENE$, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling @CHEMICAL$ to glutathione.	5
Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by @GENE$, a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to @CHEMICAL$.	0
The EC50 for inhibition of the @CHEM-GENE$ of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.	0
The EC50 for inhibition of the @GENE$ of RBL cells was directly proportional to the @CHEMICAL$ concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4.	5
The EC50 for inhibition of the @GENE$ of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM @CHEMICAL$ to over 40 mM at 500 microM LTA4.	0
The EC50 for inhibition of the @GENE$ of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM @CHEMICAL$.	0
Kinetic analysis revealed that the inhibition of the @CHEM-GENE$ reaction by diethylcarbamazine was competitive with respect to LTA4.	0
Kinetic analysis revealed that the inhibition of the @GENE$ reaction by @CHEMICAL$ was competitive with respect to LTA4.	2
Kinetic analysis revealed that the inhibition of the @GENE$ reaction by diethylcarbamazine was competitive with respect to @CHEMICAL$.	0
In contrast to @CHEMICAL$, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.	2
In contrast to @CHEMICAL$, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @GENE$ of these cells.	2
In contrast to diethylcarbamazine, @CHEMICAL$ (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.	2
In contrast to diethylcarbamazine, @CHEMICAL$ (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @GENE$ of these cells.	0
In contrast to diethylcarbamazine, piriprost (@CHEMICAL$; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.	2
In contrast to diethylcarbamazine, piriprost (@CHEMICAL$; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @GENE$ of these cells.	0
In contrast to diethylcarbamazine, piriprost (U-60,257; @CHEMICAL$), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.	2
In contrast to diethylcarbamazine, piriprost (U-60,257; @CHEMICAL$), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @GENE$ of these cells.	0
In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of @CHEMICAL$ in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells.	5
In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of @CHEMICAL$ in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @GENE$ of these cells.	0
In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the @GENE$ step (EC50 5 microM), did not inhibit the @CHEMICAL$ synthetase of these cells.	0
In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the @CHEM-GENE$ of these cells.	0
These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of @CHEMICAL$ in the @GENE$ reaction.	5
These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the @CHEM-GENE$ reaction.	0
These results are consistent with the interpretation that both @CHEMICAL$ and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the @GENE$ reaction.	0
These results are consistent with the interpretation that both piriprost and @CHEMICAL$ inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the @GENE$ reaction.	0
These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit @CHEMICAL$ formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the @GENE$ reaction.	0
The test procedure was verified with respect to intestinal @CHEMICAL$ hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal @GENE$ activity by in vitro assay (R2 = 0.95) in a further group of subjects.	5
The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between @CHEMICAL$/lactulose excretion and log jejunal mucosal @GENE$ activity by in vitro assay (R2 = 0.95) in a further group of subjects.	5
The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/@CHEMICAL$ excretion and log jejunal mucosal @GENE$ activity by in vitro assay (R2 = 0.95) in a further group of subjects.	5
Differential @CHEMICAL$/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal @GENE$ deficiency.	5
Differential lactose/@CHEMICAL$/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal @GENE$ deficiency.	5
Differential lactose/lactulose/@CHEMICAL$ absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal @GENE$ deficiency.	5
Characteristics of the binding of @CHEMICAL$ to @GENE$.	0
To determine the factors that influence the interaction between @CHEMICAL$ and calmodulin, the binding of phenoxybenzamine to @GENE$ was determined by equilibrium dialysis under a variety of experimental conditions.	0
To determine the factors that influence the interaction between @CHEMICAL$ and @GENE$, the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions.	0
To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of @CHEMICAL$ to @GENE$ was determined by equilibrium dialysis under a variety of experimental conditions.	0
To determine the factors that influence the interaction between phenoxybenzamine and @GENE$, the binding of @CHEMICAL$ to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions.	0
This interaction was found to be similar in some respects to the interaction between @CHEMICAL$ and @GENE$.	0
It was saturable, with between 1 and 2 mol of @CHEMICAL$ bound to 1 mol of @GENE$.	0
The site at which @CHEMICAL$ bound to @GENE$ appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.	0
The site at which @CHEMICAL$ bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to @GENE$.	0
The site at which phenoxybenzamine bound to @GENE$ appears to be similar to that at which certain antipsychotic agents bind, since several of them, including @CHEMICAL$, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.	0
The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including @CHEMICAL$, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to @GENE$.	0
The site at which phenoxybenzamine bound to @GENE$ appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, @CHEMICAL$ and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.	0
The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, @CHEMICAL$ and spiroperidol, prevented the binding of phenoxybenzamine to @GENE$.	0
The site at which phenoxybenzamine bound to @GENE$ appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and @CHEMICAL$, prevented the binding of phenoxybenzamine to calmodulin.	0
The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and @CHEMICAL$, prevented the binding of phenoxybenzamine to @GENE$.	0
The site at which phenoxybenzamine bound to @GENE$ appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of @CHEMICAL$ to calmodulin.	0
The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of @CHEMICAL$ to @GENE$.	0
However, in contrast to the reversible binding of most @CHEMICAL$ to @GENE$, phenoxybenzamine bound to calmodulin irreversibly.	0
However, in contrast to the reversible binding of most @CHEMICAL$ to calmodulin, phenoxybenzamine bound to @GENE$ irreversibly.	0
However, in contrast to the reversible binding of most phenothiazines to @GENE$, @CHEMICAL$ bound to calmodulin irreversibly.	0
However, in contrast to the reversible binding of most phenothiazines to calmodulin, @CHEMICAL$ bound to @GENE$ irreversibly.	0
The binding of @CHEMICAL$ to @GENE$ was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of @CHEMICAL$ to calmodulin was fairly selective in that other @GENE$ agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of @CHEMICAL$ to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to @GENE$ when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to @GENE$ was fairly selective in that other alpha-adrenergic agents such as @CHEMICAL$, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other @GENE$ agents such as @CHEMICAL$, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as @CHEMICAL$, yohimbine and clonidine failed to bind to @GENE$ when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to @GENE$ was fairly selective in that other alpha-adrenergic agents such as prazosin, @CHEMICAL$ and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other @GENE$ agents such as prazosin, @CHEMICAL$ and clonidine failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, @CHEMICAL$ and clonidine failed to bind to @GENE$ when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to @GENE$ was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and @CHEMICAL$ failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other @GENE$ agents such as prazosin, yohimbine and @CHEMICAL$ failed to bind to calmodulin when examined under the same experimental conditions.	0
The binding of phenoxybenzamine to calmodulin was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and @CHEMICAL$ failed to bind to @GENE$ when examined under the same experimental conditions.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the @GENE$, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the S-100 protein, @GENE$ or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or @GENE$. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and @GENE$ may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain @GENE$-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, @CHEMICAL$ showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of @GENE$.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the @GENE$, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the S-100 protein, @GENE$ or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the S-100 protein, bovine serum albumin or @GENE$. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and @GENE$ may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain @GENE$-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no @CHEMICAL$-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of @GENE$.	0
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the @GENE$, bovine serum albumin or cytochrome c. The irreversible complex between @CHEMICAL$ and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, @GENE$ or cytochrome c. The irreversible complex between @CHEMICAL$ and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or @GENE$. The irreversible complex between @CHEMICAL$ and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between @CHEMICAL$ and @GENE$ may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.	0
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between @CHEMICAL$ and calmodulin may be useful for inhibiting certain @GENE$-dependent reactions and for studying the various biological functions of calmodulin.	2
In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between @CHEMICAL$ and calmodulin may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of @GENE$.	0
The following was demonstrated in the rat and confirmed in man: interaction of @CHEMICAL$ with the @GENE$, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of @CHEMICAL$ with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by @GENE$ analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the @CHEM-GENE$, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic @CHEMICAL$ receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by @GENE$ analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the @GENE$, antiandrogen activity against @CHEMICAL$ (in particular against the early transient rise induced by LHRH analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against @CHEMICAL$ (in particular against the early transient rise induced by @GENE$ analogs) and adrenal androgens.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the @GENE$, antiandrogen activity against testosterone (in particular against the early transient rise induced by LHRH analogs) and adrenal @CHEMICAL$.	0
The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testosterone (in particular against the early transient rise induced by @GENE$ analogs) and adrenal @CHEMICAL$.	0
@CHEM-GENE$: development of selective agonists and antagonists.	0
Adenosine modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of @CHEM-GENE$.	0
Adenosine modulates a variety of physiological functions through interaction with @GENE$, where agonists mediate inhibition and stimulation, respectively, of @CHEMICAL$ cyclase.	0
@CHEMICAL$ modulates a variety of physiological functions through interaction with A1 and A2 adenosine receptors, where agonists mediate inhibition and stimulation, respectively, of @GENE$.	0
@CHEMICAL$ modulates a variety of physiological functions through interaction with @GENE$, where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase.	0
Adenosine modulates a variety of physiological functions through interaction with A1 and A2 @CHEMICAL$ receptors, where agonists mediate inhibition and stimulation, respectively, of @GENE$.	0
Adenosine modulates a variety of physiological functions through interaction with @CHEM-GENE$, where agonists mediate inhibition and stimulation, respectively, of adenylate cyclase.	0
The involvement of @CHEM-GENE$ in these responses remains unresolved.	0
@CHEMICAL$ analogs in particular the N6-substituted compounds are more potent at @GENE$ than at A2 receptors.	0
@CHEMICAL$ analogs in particular the N6-substituted compounds are more potent at A1 receptors than at @GENE$.	0
Adenosine analogs in particular the @CHEMICAL$-substituted compounds are more potent at @GENE$ than at A2 receptors.	0
Adenosine analogs in particular the @CHEMICAL$-substituted compounds are more potent at A1 receptors than at @GENE$.	0
The subregion of the @CHEM-GENE$ that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.	0
The subregion of the @CHEMICAL$ receptor that interacts with the N6-substituent is different for @GENE$, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.	0
The subregion of the @GENE$ that interacts with the @CHEMICAL$-substituent is different for A1 and A2 receptors, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.	0
The subregion of the adenosine receptor that interacts with the @CHEMICAL$-substituent is different for @GENE$, particularly with respect to phenyl interactions, bulk tolerance and stereoselectivity.	0
The subregion of the @GENE$ that interacts with the N6-substituent is different for A1 and A2 receptors, particularly with respect to @CHEMICAL$ interactions, bulk tolerance and stereoselectivity.	0
The subregion of the adenosine receptor that interacts with the N6-substituent is different for @GENE$, particularly with respect to @CHEMICAL$ interactions, bulk tolerance and stereoselectivity.	0
Certain of the @CHEMICAL$ conjugates are highly selective for @GENE$.	0
@CHEMICAL$ are classical antagonists for @GENE$ for many of their pharmacological actions may be due to blockade of adenosine receptors.	4
@CHEMICAL$ are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of @GENE$.	2
Xanthines are classical antagonists for @CHEM-GENE$ for many of their pharmacological actions may be due to blockade of adenosine receptors.	0
Xanthines are classical antagonists for @CHEMICAL$ receptors for many of their pharmacological actions may be due to blockade of @GENE$.	0
Xanthines are classical antagonists for @GENE$ for many of their pharmacological actions may be due to blockade of @CHEMICAL$ receptors.	0
Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of @CHEM-GENE$.	0
@CHEMICAL$ and theophylline are virtually non-selective for @GENE$.	0
Caffeine and @CHEMICAL$ are virtually non-selective for @GENE$.	0
Replacement of the methyl groups of theophylline with @CHEMICAL$ or larger alkyl groups yields xanthines with selectivity for @GENE$, particularly when combined with an 8-phenyl moiety.	0
Replacement of the methyl groups of theophylline with n-propyl or larger @CHEMICAL$ groups yields xanthines with selectivity for @GENE$, particularly when combined with an 8-phenyl moiety.	0
Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields @CHEMICAL$ with selectivity for @GENE$, particularly when combined with an 8-phenyl moiety.	0
Replacement of the methyl groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for @GENE$, particularly when combined with an @CHEMICAL$ moiety.	0
Replacement of the @CHEMICAL$ groups of theophylline with n-propyl or larger alkyl groups yields xanthines with selectivity for @GENE$, particularly when combined with an 8-phenyl moiety.	0
Replacement of the methyl groups of @CHEMICAL$ with n-propyl or larger alkyl groups yields xanthines with selectivity for @GENE$, particularly when combined with an 8-phenyl moiety.	0
Certain analogs of @CHEMICAL$ in which the methyl group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for @GENE$.	0
Certain analogs of caffeine in which the @CHEMICAL$ group at the 1- or 7-position is replaced with a propargyl or propyl group display selectivity for @GENE$.	0
Certain analogs of caffeine in which the methyl group at the 1- or 7-position is replaced with a propargyl or @CHEMICAL$ group display selectivity for @GENE$.	0
The profile of a series of @CHEMICAL$ analogs or of xanthine antagonists can be used to define the nature of @GENE$.	0
The profile of a series of adenosine analogs or of @CHEMICAL$ antagonists can be used to define the nature of @GENE$.	0
The profile of a series of adenosine analogs or of xanthine antagonists can be used to define the nature of @CHEM-GENE$.	0
Inhibition of testicular @GENE$ from laboratory animals and man by @CHEMICAL$ and its isomers.	2
The inhibitory effect of @CHEMICAL$ and (+/-)-gossypol acetic acid upon testicular cytosolic @GENE$ was measured in vitro.	2
The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and @CHEMICAL$ upon testicular cytosolic @GENE$ was measured in vitro.	2
@CHEMICAL$ (0-100 mumol/l) inhibited @GENE$ prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.	2
@GENE$ activity measured in vitro in serum of men and hamsters was unaffected by @CHEMICAL$.	0
@CHEMICAL$ and its isomers were non-competitive inhibitors of @GENE$ with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.	2
@CHEMICAL$ and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of @GENE$ and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.	0
@CHEMICAL$ and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of @GENE$ with respect to the substrate alpha-ketobutyrate.	0
Gossypol and its isomers were non-competitive inhibitors of @GENE$ with respect to the coenzyme @CHEMICAL$, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.	0
Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme @CHEMICAL$, competitive inhibitors of @GENE$ and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.	2
Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme @CHEMICAL$, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of @GENE$ with respect to the substrate alpha-ketobutyrate.	0
Gossypol and its isomers were non-competitive inhibitors of @GENE$ with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate @CHEMICAL$.	0
Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of @GENE$ and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate @CHEMICAL$.	0
Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of @GENE$ with respect to the substrate @CHEMICAL$.	5
Co-incubation with @GENE$ or poly-L-lysine but not lysine protected human and hamster LDH-X from @CHEMICAL$.	0
Co-incubation with human serum albumin or poly-L-lysine but not lysine protected @GENE$ from @CHEMICAL$.	0
Co-incubation with @GENE$ or @CHEMICAL$ but not lysine protected human and hamster LDH-X from gossypol.	0
Co-incubation with human serum albumin or @CHEMICAL$ but not lysine protected @GENE$ from gossypol.	0
Co-incubation with @GENE$ or poly-L-lysine but not @CHEMICAL$ protected human and hamster LDH-X from gossypol.	0
Co-incubation with human serum albumin or poly-L-lysine but not @CHEMICAL$ protected @GENE$ from gossypol.	0
Inactivation of @CHEM-GENE$ and prostacyclin synthase by phenylbutazone.	0
Inactivation of @CHEMICAL$ synthase and @GENE$ by phenylbutazone.	0
Inactivation of @GENE$ and @CHEMICAL$ synthase by phenylbutazone.	0
Inactivation of prostaglandin H synthase and @CHEM-GENE$ by phenylbutazone.	0
Inactivation of @GENE$ and prostacyclin synthase by @CHEMICAL$.	2
Inactivation of prostaglandin H synthase and @GENE$ by @CHEMICAL$.	2
Phenylbutazone (@CHEMICAL$), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of @GENE$ (PHS).	0
Phenylbutazone (@CHEMICAL$), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (@GENE$).	0
@CHEMICAL$ (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of @GENE$ (PHS).	0
@CHEMICAL$ (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (@GENE$).	0
Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of @CHEM-GENE$ (PHS).	0
Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of @CHEMICAL$ synthase (@GENE$).	0
Most reducing cofactors for the peroxidase protect @GENE$ and @CHEMICAL$ synthase from inactivation by hydroperoxides.	0
Most reducing cofactors for the peroxidase protect PHS and @CHEM-GENE$ from inactivation by hydroperoxides.	0
Most reducing cofactors for the peroxidase protect @GENE$ and prostacyclin synthase from inactivation by @CHEMICAL$.	2
Most reducing cofactors for the peroxidase protect PHS and @GENE$ from inactivation by @CHEMICAL$.	2
Using ram seminal vesicle microsomes as a source of @GENE$ and @CHEMICAL$ synthase, we have examined the interaction of PB and exogenous hydroperoxides.	0
Using ram seminal vesicle microsomes as a source of PHS and @CHEM-GENE$, we have examined the interaction of PB and exogenous hydroperoxides.	0
Using ram seminal vesicle microsomes as a source of @GENE$ and prostacyclin synthase, we have examined the interaction of @CHEMICAL$ and exogenous hydroperoxides.	0
Using ram seminal vesicle microsomes as a source of PHS and @GENE$, we have examined the interaction of @CHEMICAL$ and exogenous hydroperoxides.	0
Using ram seminal vesicle microsomes as a source of @GENE$ and prostacyclin synthase, we have examined the interaction of PB and exogenous @CHEMICAL$.	0
Using ram seminal vesicle microsomes as a source of PHS and @GENE$, we have examined the interaction of PB and exogenous @CHEMICAL$.	0
Chromatographic analysis of the metabolism of @CHEMICAL$ in this system revealed that PB-dependent inactivation of @GENE$ is markedly increased in the presence of 100 microM H2O2.	5
Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that @CHEMICAL$-dependent inactivation of @GENE$ is markedly increased in the presence of 100 microM H2O2.	0
Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of @GENE$ is markedly increased in the presence of 100 microM @CHEMICAL$.	2
@CHEM-GENE$ is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM.	0
@GENE$ is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at @CHEMICAL$ concentrations near 25 microM.	0
@GENE$ is even more sensitive to inactivation by the combined @CHEMICAL$ and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM.	0
@GENE$ is even more sensitive to inactivation by the combined PB and @CHEMICAL$ treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM.	0
This @CHEMICAL$- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on @GENE$.	0
This PB- and @CHEMICAL$-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on @GENE$.	0
This PB- and H2O2-dependent inactivation is demonstrable whether @CHEMICAL$ is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on @GENE$.	0
This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from @CHEMICAL$ or is added exogenously, supporting a direct effect of the treatment on @GENE$.	0
This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on @CHEM-GENE$.	0
As PB undergoes @CHEMICAL$-dependent co-oxygenation catalyzed by @GENE$, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	0
As PB undergoes @CHEMICAL$-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of @GENE$ and prostacyclin synthase.	0
As PB undergoes @CHEMICAL$-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and @GENE$.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by @GENE$, we propose that it is an oxygenated derivative of @CHEMICAL$, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of @CHEMICAL$, rather than the parent compound, which is responsible for the inactivation of @GENE$ and prostacyclin synthase.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of @CHEMICAL$, rather than the parent compound, which is responsible for the inactivation of PHS and @GENE$.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by @GENE$, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and @CHEMICAL$ synthase.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of @GENE$ and @CHEMICAL$ synthase.	0
As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and @CHEM-GENE$.	0
As @CHEMICAL$ undergoes peroxide-dependent co-oxygenation catalyzed by @GENE$, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	0
As @CHEMICAL$ undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of @GENE$ and prostacyclin synthase.	0
As @CHEMICAL$ undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and @GENE$.	0
Drug-protein interactions: isolation and characterization of covalent adducts of @CHEMICAL$ and @GENE$.	0
@CHEMICAL$, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels @GENE$ in the presence of calcium.	0
Phenoxybenzamine, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels @GENE$ in the presence of @CHEMICAL$.	0
Phenoxybenzamine, an alpha-adrenergic antagonist containing a @CHEMICAL$ group, labels @GENE$ in the presence of calcium.	0
Adducts of @GENE$ and @CHEMICAL$ were separated by high-performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol/mol.	0
Each adduct had a reduced ability to activate @CHEM-GENE$ and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate @CHEMICAL$ phosphodiesterase and @GENE$, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate @CHEMICAL$ phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-@GENE$ adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate @GENE$ and myosin light chain kinase, and the @CHEMICAL$ binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and @GENE$, and the @CHEMICAL$ binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the @CHEMICAL$ binding capacities of the phenoxybenzamine-@GENE$ adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate @GENE$ and myosin light chain kinase, and the chlorpromazine binding capacities of the @CHEMICAL$-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and @GENE$, and the chlorpromazine binding capacities of the @CHEMICAL$-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the @CHEMICAL$-@GENE$ adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.	0
Each adduct had a reduced ability to activate @GENE$ and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of @CHEMICAL$ incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and @GENE$, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of @CHEMICAL$ incorporation into each adduct.	0
Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-@GENE$ adducts were diminished to the extent of @CHEMICAL$ incorporation into each adduct.	0
Isolation and characterization of labeled peptides from @CHEMICAL$-modified @GENE$ indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label.	0
Isolation and characterization of labeled peptides from phenoxybenzamine-modified @GENE$ indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained @CHEMICAL$ label.	0
@CHEM-GENE$ activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane.	0
@GENE$ activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (@CHEMICAL$-resistant) activity at the fat cell membrane.	0
@GENE$ activities in brown adipose tissue of the rat: identification of @CHEMICAL$-sensitive (clorgyline-resistant) activity at the fat cell membrane.	0
@CHEM-GENE$ activity, previously described in homogenates of brown adipose tissue of the rat, has now been investigated in preparations of isolated fat cells.	0
It was found that the specific activities of both @CHEM-GENE$ (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both @CHEMICAL$ oxidase A (@GENE$) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both @CHEMICAL$ oxidase A (MAO) and of the @GENE$ (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both @CHEMICAL$ oxidase A (MAO) and of the semicarbazide-sensitive clorgyline-resistant amine oxidase (@GENE$) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both @GENE$ (MAO) and of the @CHEMICAL$-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (@GENE$) and of the @CHEMICAL$-sensitive clorgyline-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (MAO) and of the @CHEM-GENE$ (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (MAO) and of the @CHEMICAL$-sensitive clorgyline-resistant amine oxidase (@GENE$) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both @GENE$ (MAO) and of the semicarbazide-sensitive @CHEMICAL$-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (@GENE$) and of the semicarbazide-sensitive @CHEMICAL$-resistant amine oxidase (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (MAO) and of the @CHEM-GENE$ (SSAO) were higher in isolated fat cells than in the original whole tissue.	0
It was found that the specific activities of both monoamine oxidase A (MAO) and of the semicarbazide-sensitive @CHEMICAL$-resistant amine oxidase (@GENE$) were higher in isolated fat cells than in the original whole tissue.	0
In plasma membranes prepared from these isolated brown fat cells by @CHEMICAL$ extraction there was a similar enrichment of activity of @GENE$ and of the plasma membrane marker enzyme, phosphodiesterase I.	1
In plasma membranes prepared from these isolated brown fat cells by @CHEMICAL$ extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, @GENE$.	0
Positive staining of mitochondria was achieved in the presence of the @GENE$ substrate, @CHEMICAL$.	5
Staining around the edges of the brown fat cells was observed with the @GENE$ substrates, @CHEMICAL$ and benzylamine.	5
Staining around the edges of the brown fat cells was observed with the @GENE$ substrates, tyramine and @CHEMICAL$.	5
Staining was largely absent when substrate was omitted or after pretreatment with the irreversible @GENE$ inhibitor, @CHEMICAL$ and the slowly reversible inhibitor, semicarbazide.	2
Staining was largely absent when substrate was omitted or after pretreatment with the irreversible @GENE$ inhibitor, hydralazine and the slowly reversible inhibitor, @CHEMICAL$.	2
@CHEM-GENE$ and role of amdinocillin in causing bacterial cell death.	0
@GENE$ and role of @CHEMICAL$ in causing bacterial cell death.	0
These proteins have been designated @CHEM-GENE$.	0
They can be separated into distinct entities through the use of @CHEMICAL$ gel electrophoresis and binding of radioactive 14C-labeled penicillin G. Six major proteins have been defined in the Enterobacteriaceae, @GENE$.	0
They can be separated into distinct entities through the use of acrylamide gel electrophoresis and binding of radioactive @CHEMICAL$. Six major proteins have been defined in the Enterobacteriaceae, @GENE$.	0
They can be separated into distinct entities through the use of acrylamide gel electrophoresis and binding of radioactive 14C-labeled penicillin G. Six major proteins have been defined in the Enterobacteriaceae, @CHEM-GENE$.	0
Selection of mutants has shown that there are three essential proteins: @CHEM-GENE$, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: @CHEMICAL$-binding protein 1, which is divided into @GENE$, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: @CHEMICAL$-binding protein 1, which is divided into penicillin-binding protein 1Bs, a @GENE$, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: @CHEMICAL$-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and @GENE$, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: @CHEMICAL$-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for @GENE$.	0
Selection of mutants has shown that there are three essential proteins: @GENE$, which is divided into @CHEMICAL$-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @CHEM-GENE$, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @CHEMICAL$-binding protein 1Bs, a @GENE$, and penicillin-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @CHEMICAL$-binding protein 1Bs, a peptidoglycan transpeptidase, and @GENE$, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @CHEMICAL$-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for @GENE$.	0
Selection of mutants has shown that there are three essential proteins: @GENE$, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and @CHEMICAL$-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @GENE$, a peptidoglycan transpeptidase, and @CHEMICAL$-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a @GENE$, and @CHEMICAL$-binding protein 1A, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and @CHEM-GENE$, which acts as a replacement for penicillin-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and @CHEMICAL$-binding protein 1A, which acts as a replacement for @GENE$.	0
Selection of mutants has shown that there are three essential proteins: @GENE$, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for @CHEMICAL$-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into @GENE$, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for @CHEMICAL$-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a @GENE$, and penicillin-binding protein 1A, which acts as a replacement for @CHEMICAL$-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and @GENE$, which acts as a replacement for @CHEMICAL$-binding protein 1Bs.	0
Selection of mutants has shown that there are three essential proteins: penicillin-binding protein 1, which is divided into penicillin-binding protein 1Bs, a peptidoglycan transpeptidase, and penicillin-binding protein 1A, which acts as a replacement for @CHEM-GENE$.	0
@CHEM-GENE$ is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme.	0
@CHEMICAL$-binding protein 2 is a @GENE$-elongation initiating enzyme and penicillin-binding protein 3 is a septal murein-synthesizing enzyme.	0
@CHEMICAL$-binding protein 2 is a murein-elongation initiating enzyme and @GENE$ is a septal murein-synthesizing enzyme.	0
@CHEMICAL$-binding protein 2 is a murein-elongation initiating enzyme and penicillin-binding protein 3 is a septal @GENE$-synthesizing enzyme.	0
@GENE$ is a murein-elongation initiating enzyme and @CHEMICAL$-binding protein 3 is a septal murein-synthesizing enzyme.	0
Penicillin-binding protein 2 is a @GENE$-elongation initiating enzyme and @CHEMICAL$-binding protein 3 is a septal murein-synthesizing enzyme.	0
Penicillin-binding protein 2 is a murein-elongation initiating enzyme and @CHEM-GENE$ is a septal murein-synthesizing enzyme.	0
Penicillin-binding protein 2 is a murein-elongation initiating enzyme and @CHEMICAL$-binding protein 3 is a septal @GENE$-synthesizing enzyme.	0
@CHEM-GENE$ are not essential for bacterial survival.	0
Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to @CHEM-GENE$ produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to @CHEMICAL$-binding protein 2 produces round cells, and binding to @GENE$ produces long filaments.	0
Binding of penicillins to @GENE$ produces lysis, binding to @CHEMICAL$-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to @GENE$ produces round cells, and binding to @CHEMICAL$-binding protein 3 produces long filaments.	0
Binding of penicillins to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to @CHEM-GENE$ produces long filaments.	0
Binding of penicillins to @GENE$ produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to @CHEMICAL$-binding protein 3 produces long filaments.	0
Binding of @CHEMICAL$ to penicillin-binding protein 1Bs produces lysis, binding to @GENE$ produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
Binding of @CHEMICAL$ to penicillin-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to @GENE$ produces long filaments.	0
Binding of @CHEMICAL$ to @GENE$ produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
Binding of penicillins to @CHEMICAL$-binding protein 1Bs produces lysis, binding to @GENE$ produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
Binding of penicillins to @CHEMICAL$-binding protein 1Bs produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to @GENE$ produces long filaments.	0
Binding of penicillins to @CHEM-GENE$ produces lysis, binding to penicillin-binding protein 2 produces round cells, and binding to penicillin-binding protein 3 produces long filaments.	0
@CHEMICAL$ is a beta-amidino penicillanic acid derivative that binds specifically to @GENE$.	0
Amdinocillin is a @CHEMICAL$ derivative that binds specifically to @GENE$.	0
Amdinocillin is a beta-amidino penicillanic acid derivative that binds specifically to @CHEM-GENE$.	0
The compound is more @GENE$ stable than @CHEMICAL$ and has no major delay in entry into the periplasmic space as do some penicillins.	0
The compound is more @GENE$ stable than ampicillin and has no major delay in entry into the periplasmic space as do some @CHEMICAL$.	0
This agent acts synergistically with many @CHEMICAL$, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as @CHEMICAL$, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as ampicillin, @CHEMICAL$, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with @CHEMICAL$, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, @CHEMICAL$, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, @CHEMICAL$, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or @CHEMICAL$ to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the @GENE$ of the bacterial cell wall.	1
Loss of alpha 2-macroglobulin and @GENE$ surface binding induced by phenothiazines and @CHEMICAL$.	0
Loss of @GENE$ and epidermal growth factor surface binding induced by phenothiazines and @CHEMICAL$.	0
Loss of alpha 2-macroglobulin and @GENE$ surface binding induced by @CHEMICAL$ and naphthalene sulfonamides.	0
Loss of @GENE$ and epidermal growth factor surface binding induced by @CHEMICAL$ and naphthalene sulfonamides.	0
We have found that certain @CHEMICAL$ [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain @CHEMICAL$ [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain @CHEMICAL$ [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., @CHEMICAL$ (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., @CHEMICAL$ (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., @CHEMICAL$ (W-7)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (@CHEMICAL$)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (@CHEMICAL$)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (@CHEMICAL$)] and phenothiazines [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and @CHEMICAL$ [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and @CHEMICAL$ [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and @CHEMICAL$ [e.g., trifluoperazine (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., @CHEMICAL$ (TFP)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., @CHEMICAL$ (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., @CHEMICAL$ (TFP)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (@CHEMICAL$)] induce a loss of cell-surface receptors for @GENE$, and epidermal growth factor (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (@CHEMICAL$)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and @GENE$ (EGF) in fibroblasts.	0
We have found that certain naphthalenesulfonamides [e.g., N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7)] and phenothiazines [e.g., trifluoperazine (@CHEMICAL$)] induce a loss of cell-surface receptors for alpha 2-macroglobulin, and epidermal growth factor (@GENE$) in fibroblasts.	0
The extent of @GENE$ loss is less than for alpha 2-macroglobulin, and the EGF receptors do not reappear at the surface when @CHEMICAL$ is removed.	0
The extent of EGF receptor loss is less than for @GENE$, and the EGF receptors do not reappear at the surface when @CHEMICAL$ is removed.	0
The extent of EGF receptor loss is less than for alpha 2-macroglobulin, and the @GENE$ do not reappear at the surface when @CHEMICAL$ is removed.	0
@CHEMICAL$ did not induce a loss of cell surface @GENE$, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of W-7 was specific for membrane receptors and not a result of bulk depletion of plasma membrane.	0
W-7 did not induce a loss of cell surface @GENE$, a membrane protein which is excluded from coated pits and which is not internalized, indicating that the effect of @CHEMICAL$ was specific for membrane receptors and not a result of bulk depletion of plasma membrane.	0
Since both @CHEMICAL$ and W-7 are potent inhibitors of @GENE$, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.	2
Since both @CHEMICAL$ and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of @GENE$ was responsible for the loss of receptors.	0
Since both TFP and @CHEMICAL$ are potent inhibitors of @GENE$, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.	2
Since both TFP and @CHEMICAL$ are potent inhibitors of calmodulin, we investigated the possibility that inhibition of @GENE$ was responsible for the loss of receptors.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of @CHEMICAL$; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using @CHEMICAL$-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the @CHEMICAL$ induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of @CHEMICAL$-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	2
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) @CHEMICAL$, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	2
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a @CHEMICAL$ that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
Three lines of evidence suggest that @GENE$ inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several @GENE$ functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	2
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of @GENE$ into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of @GENE$ over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled @GENE$, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected @GENE$, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a @GENE$, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.	0
Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as @CHEMICAL$ at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled @GENE$.	0
From these results, it is proposed that @CHEM-GENE$ activity determines p-HPAA concentrations by regulating p-tyrosine availability.	0
From these results, it is proposed that @GENE$ activity determines @CHEMICAL$ concentrations by regulating p-tyrosine availability.	0
From these results, it is proposed that @GENE$ activity determines p-HPAA concentrations by regulating @CHEMICAL$ availability.	5
Demonstration of @CHEM-GENE$ on human platelets by flow cytometry.	0
@GENE$ conjugated with histamine (FHA-HIS) has been used for the demonstration of @CHEMICAL$ receptors on human platelets.	0
Fluoresceinated human albumin conjugated with histamine (FHA-HIS) has been used for the demonstration of @CHEM-GENE$ on human platelets.	0
Fluoresceinated human albumin conjugated with histamine (@GENE$-HIS) has been used for the demonstration of @CHEMICAL$ receptors on human platelets.	0
@GENE$ conjugated with @CHEMICAL$ (FHA-HIS) has been used for the demonstration of histamine receptors on human platelets.	0
Fluoresceinated human albumin conjugated with @CHEMICAL$ (FHA-HIS) has been used for the demonstration of @GENE$ on human platelets.	0
Fluoresceinated human albumin conjugated with @CHEMICAL$ (@GENE$-HIS) has been used for the demonstration of histamine receptors on human platelets.	0
The binding of @GENE$-HIS was inhibited on 35-79% of the platelets by the @CHEMICAL$ H1 receptor antagonists diphenhydramine and clemastine.	0
The binding of FHA-HIS was inhibited on 35-79% of the platelets by the @CHEM-GENE$ antagonists diphenhydramine and clemastine.	0
The binding of @GENE$-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists @CHEMICAL$ and clemastine.	2
The binding of FHA-HIS was inhibited on 35-79% of the platelets by the @GENE$ antagonists @CHEMICAL$ and clemastine.	4
The binding of @GENE$-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and @CHEMICAL$.	2
The binding of FHA-HIS was inhibited on 35-79% of the platelets by the @GENE$ antagonists diphenhydramine and @CHEMICAL$.	4
The @CHEM-GENE$ antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets.	0
The @CHEMICAL$ H2 receptor antagonist cimetidine blocked the @GENE$-HIS binding on 14-37% of the platelets.	0
The @GENE$ antagonist @CHEMICAL$ blocked the FHA-HIS binding on 14-37% of the platelets.	4
The histamine H2 receptor antagonist @CHEMICAL$ blocked the @GENE$-HIS binding on 14-37% of the platelets.	2
It is concluded that @CHEM-GENE$ as well as H2 receptors occur on human platelets but the receptors are not equally distributed in the platelet population.	0
It is concluded that @CHEMICAL$ H1 as well as @GENE$ occur on human platelets but the receptors are not equally distributed in the platelet population.	0
The effect of @CHEMICAL$ deficiency on @GENE$ isoenzymes in rat liver.	0
The effect of vitamin B6 deficiency on @CHEM-GENE$ isoenzymes in rat liver.	0
The effect of vitamin B6 deficiency on @CHEM-GENE$ isoenzymes in rat liver.	0
@GENE$ (AGT) in the liver catalyzes most of the @CHEMICAL$ transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	5
Alanine:glyoxylate aminotransferase (@GENE$) in the liver catalyzes most of the @CHEMICAL$ transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	5
@CHEM-GENE$ (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	0
@CHEMICAL$:glyoxylate aminotransferase (@GENE$) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	0
@CHEM-GENE$ (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	0
Alanine:@CHEMICAL$ aminotransferase (@GENE$) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J.	0
The effects of @CHEMICAL$ deficiency on hepatic @GENE$ isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria.	0
The effects of @CHEMICAL$ deficiency on hepatic AGT isoenzymes, designated @GENE$ and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria.	0
The effects of @CHEMICAL$ deficiency on hepatic AGT isoenzymes, designated AGT 1 and @GENE$, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria.	0
The effects of @CHEMICAL$ deficiency on hepatic AGT isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; @GENE$ is located both in the peroxisomes and in the mitochondria, and AGT 2 only in the mitochondria.	0
The effects of @CHEMICAL$ deficiency on hepatic AGT isoenzymes, designated AGT 1 and AGT 2, respectively, were examined with male rats; AGT 1 is located both in the peroxisomes and in the mitochondria, and @GENE$ only in the mitochondria.	0
The holo activity of combined peroxisomal and mitochondrial @GENE$ with a low Km for @CHEMICAL$ rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).	5
The holo activity of combined peroxisomal and mitochondrial @GENE$ with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the @CHEMICAL$-deficient diet (by 50% in 5 days, by 86% in 14 days).	0
The holo activity of AGT 2 with a high Km for @CHEMICAL$ decreased more slowly than @GENE$ (by 33% in 14 days, by 60% in 28 days).	5
The holo activity of @GENE$ with a high Km for @CHEMICAL$ decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).	5
Urinary excretion of @CHEMICAL$ began to increase in 8-9 days, when @GENE$ remained intact but most of AGT 1 is depleted.	0
Urinary excretion of @CHEMICAL$ began to increase in 8-9 days, when AGT 2 remained intact but most of @GENE$ is depleted.	0
When the defect in the @CHEMICAL$ transamination in vivo in vitamin B6 deficiency is considered, these findings suggest that it is due to the deficiency of @GENE$.	0
When the defect in the glyoxylate transamination in vivo in @CHEMICAL$ deficiency is considered, these findings suggest that it is due to the deficiency of @GENE$.	0
The importance of peroxisomal @GENE$ is discussed, since peroxisomes have been described to be probably the major site of @CHEMICAL$ formation.	0
How do volatile anesthetics inhibit @CHEM-GENE$?	0
Volatile anesthetics at concentrations that are used in clinical practice to induce anesthesia selectively inhibit activity of the plasma membrane @CHEM-GENE$ (Kosk-Kosicka, D., and Roszczynska, G. (1993) Anesthesiology 79, 774-780).	0
We have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte @CHEM-GENE$ by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic tryptophans and of an extrinsic probe attached in the active site of the enzyme.	0
We have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte @GENE$ by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic @CHEMICAL$ and of an extrinsic probe attached in the active site of the enzyme.	0
Similar changes have been observed in the @CHEM-GENE$.	0
We propose that volatile anesthetics inhibit @CHEM-GENE$ by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and adenylate kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit @CHEMICAL$-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for @GENE$, hemoglobin, and adenylate kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit @CHEMICAL$-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, @GENE$, and adenylate kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit @CHEMICAL$-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and @GENE$ (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit @GENE$ by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and @CHEMICAL$ kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit Ca(2+)-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for @GENE$, hemoglobin, and @CHEMICAL$ kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit Ca(2+)-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, @GENE$, and @CHEMICAL$ kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
We propose that volatile anesthetics inhibit Ca(2+)-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and @CHEM-GENE$ (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv.	0
Several in vitro studies were conducted to evaluate the effect of @CHEMICAL$ on 4 primary enzymes of the pathways of arachidonic acid metabolism, @GENE$, cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of @CHEMICAL$ on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, @GENE$, 5-lipoxygenase and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of @CHEMICAL$ on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, @GENE$ and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of @CHEMICAL$ on 4 primary enzymes of the pathways of arachidonic acid metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and @GENE$.	0
Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of @CHEMICAL$ metabolism, @GENE$, cyclo-oxygenase 2, 5-lipoxygenase and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of @CHEMICAL$ metabolism, cyclo-oxygenase 1, @GENE$, 5-lipoxygenase and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of @CHEMICAL$ metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, @GENE$ and 15-lipoxygenase.	0
Several in vitro studies were conducted to evaluate the effect of triclosan on 4 primary enzymes of the pathways of @CHEMICAL$ metabolism, cyclo-oxygenase 1, cyclo-oxygenase 2, 5-lipoxygenase and @GENE$.	0
@CHEMICAL$ inhibited both @GENE$ and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.	2
@CHEMICAL$ inhibited both cyclooxygenase 1 and @GENE$ with IC-50 values of 43 microM and 227 microM, respectively.	2
@CHEMICAL$ also inhibited @GENE$ with an IC-50 of 43 microM.	2
The @GENE$ was similarly inhibited by @CHEMICAL$ with an IC-50 of 61 microM.	2
Hence, @CHEMICAL$ has the ability to inhibit both the @GENE$ and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.	2
Hence, @CHEMICAL$ has the ability to inhibit both the cyclo-oxygenase and @GENE$ pathways of arachidonic acid metabolism with similar efficacy.	2
Hence, triclosan has the ability to inhibit both the @GENE$ and lipoxygenase pathways of @CHEMICAL$ metabolism with similar efficacy.	5
Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and @GENE$ pathways of @CHEMICAL$ metabolism with similar efficacy.	5
In cell culture experiments, it was found that @CHEMICAL$ inhibited @GENE$ induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.	2
In cell culture experiments, it was found that triclosan inhibited @GENE$ induced @CHEMICAL$ production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.	5
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (@CHEMICAL$) bound to @GENE$ (transcobalamin, TC).	0
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (@CHEMICAL$) bound to transcobalamin II (@GENE$, TC).	0
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (@CHEMICAL$) bound to transcobalamin II (transcobalamin, @GENE$).	0
Extracellular @CHEMICAL$ (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to @GENE$ (transcobalamin, TC).	0
Extracellular @CHEMICAL$ (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (@GENE$, TC).	0
Extracellular @CHEMICAL$ (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (transcobalamin, @GENE$).	0
Extracellular Cbl (protein bound and free) and intracellular @CHEMICAL$ (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to @GENE$ (transcobalamin, TC).	0
Extracellular Cbl (protein bound and free) and intracellular @CHEMICAL$ (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (@GENE$, TC).	0
Extracellular Cbl (protein bound and free) and intracellular @CHEMICAL$ (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (CN-Cbl) bound to transcobalamin II (transcobalamin, @GENE$).	0
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of @CHEMICAL$ (CN-Cbl) bound to @GENE$ (transcobalamin, TC).	0
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of @CHEMICAL$ (CN-Cbl) bound to transcobalamin II (@GENE$, TC).	0
Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of @CHEMICAL$ (CN-Cbl) bound to transcobalamin II (transcobalamin, @GENE$).	0
Intracellular protein-bound @CHEMICAL$ fractionated with @GENE$ (MS) and methylmalonyl-CoA mutase (MU) activity.	0
Intracellular protein-bound @CHEMICAL$ fractionated with methionine synthase (@GENE$) and methylmalonyl-CoA mutase (MU) activity.	0
Intracellular protein-bound @CHEMICAL$ fractionated with methionine synthase (MS) and @GENE$ (MU) activity.	0
Intracellular protein-bound @CHEMICAL$ fractionated with methionine synthase (MS) and methylmalonyl-CoA mutase (@GENE$) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with @CHEM-GENE$ (MS) and methylmalonyl-CoA mutase (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with @CHEMICAL$ synthase (@GENE$) and methylmalonyl-CoA mutase (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with @CHEMICAL$ synthase (MS) and @GENE$ (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with @CHEMICAL$ synthase (MS) and methylmalonyl-CoA mutase (@GENE$) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with @GENE$ (MS) and @CHEMICAL$ mutase (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (@GENE$) and @CHEMICAL$ mutase (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and @CHEM-GENE$ (MU) activity.	0
Intracellular protein-bound [57Co]Cbl fractionated with methionine synthase (MS) and @CHEMICAL$ mutase (@GENE$) activity.	0
Cells propagated in medium containing @CHEMICAL$ and homocysteine showed a substantial increase in @GENE$ activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.	1
Cells propagated in medium containing N5-methyltetrahydrofolate and @CHEMICAL$ showed a substantial increase in @GENE$ activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.	1
Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in @GENE$ activity which paralleled the increase in the intracellular concentration of @CHEMICAL$ and the Cbl bound to the enzyme.	0
Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in @GENE$ activity which paralleled the increase in the intracellular concentration of Me-Cbl and the @CHEMICAL$ bound to the enzyme.	0
@CHEMICAL$ binding and activation of @GENE$ in GH4ZR7 cells.	1
Ergovaline binding and activation of @CHEM-GENE$ in GH4ZR7 cells.	0
Ergovaline inhibition of radioligand binding to the D2 @CHEMICAL$ receptor and ergot alkaloid inhibition of @GENE$ (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 @CHEMICAL$ receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (@GENE$)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 @CHEMICAL$ receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a @GENE$, were evaluated.	0
Ergovaline inhibition of radioligand binding to the @CHEM-GENE$ and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
@CHEMICAL$ inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of @GENE$ (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
@CHEMICAL$ inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (@GENE$)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
@CHEMICAL$ inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a @GENE$, were evaluated.	0
@CHEMICAL$ inhibition of radioligand binding to the @GENE$ and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and @CHEMICAL$ inhibition of @GENE$ (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	2
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and @CHEMICAL$ inhibition of vasoactive intestinal peptide (@GENE$)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	2
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and @CHEMICAL$ inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a @GENE$, were evaluated.	0
Ergovaline inhibition of radioligand binding to the @GENE$ and @CHEMICAL$ inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of @GENE$ (VIP)-stimulated @CHEMICAL$ production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	5
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (@GENE$)-stimulated @CHEMICAL$ production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	5
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated @CHEMICAL$ production in GH4ZR7 cells, stably transfected with a @GENE$, were evaluated.	0
Ergovaline inhibition of radioligand binding to the @GENE$ and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated @CHEMICAL$ production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of @GENE$ (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 @CHEMICAL$ receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (@GENE$)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 @CHEMICAL$ receptor, were evaluated.	0
Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a @CHEM-GENE$, were evaluated.	0
Ergovaline inhibition of radioligand binding to the @GENE$ and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 @CHEMICAL$ receptor, were evaluated.	0
@CHEMICAL$ inhibition of the binding of the @GENE$-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).	0
Ergovaline inhibition of the binding of the @GENE$-specific radioligand, @CHEMICAL$, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).	0
Ergovaline inhibition of the binding of the @GENE$-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas @CHEMICAL$ was much less potent (370 +/- 160 nM).	0
@CHEMICAL$ were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated @CHEMICAL$ production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	5
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for @CHEMICAL$, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for ergovaline, @CHEMICAL$, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, @CHEMICAL$, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, @CHEMICAL$, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Ergot alkaloids were also effective in inhibiting @GENE$-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and @CHEMICAL$ of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.	2
Inhibition of @CHEMICAL$ production by ergovaline was blocked by the @GENE$ antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM).	0
Inhibition of cyclic AMP production by @CHEMICAL$ was blocked by the @GENE$ antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM).	0
Inhibition of cyclic AMP production by ergovaline was blocked by the @CHEM-GENE$ antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM).	0
Inhibition of cyclic AMP production by ergovaline was blocked by the @GENE$ antagonist, @CHEMICAL$ (IC50, 300 +/- 150 nM).	4
Our results indicate that ergot compounds, especially @CHEMICAL$, bind to @GENE$ and elicit second messenger responses similar to that of dopamine.	0
Our results indicate that ergot compounds, especially ergovaline, bind to @CHEM-GENE$ and elicit second messenger responses similar to that of dopamine.	0
Our results indicate that ergot compounds, especially ergovaline, bind to @GENE$ and elicit second messenger responses similar to that of @CHEMICAL$.	0
These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several @CHEMICAL$ including ergovaline, may be due to @GENE$ activation.	1
These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including @CHEMICAL$, may be due to @GENE$ activation.	1
These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline, may be due to @CHEM-GENE$ activation.	0
Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: @CHEMICAL$ is selective for the @GENE$.	0
Binding of antipsychotic drugs at @GENE$: @CHEMICAL$ is selective for the alpha 1B-adrenoceptors.	0
The binding of the antipsychotic drugs risperidone, (+)-butaclamol, @CHEMICAL$, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, @CHEMICAL$, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, @CHEMICAL$, thioridazine and YM-09151-2 was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, @CHEMICAL$ and YM-09151-2 was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs risperidone, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and @CHEMICAL$ was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs @CHEMICAL$, (+)-butaclamol, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the @GENE$.	0
The binding of the antipsychotic drugs risperidone, @CHEMICAL$, clozapine, haloperidol, spiperone, thioridazine and YM-09151-2 was studied at the subtypes of the @GENE$.	0
Saturation experiments showed that @CHEMICAL$ labelled a single population of binding sites in the spleen (@GENE$) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	0
Saturation experiments showed that @CHEMICAL$ labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (@GENE$ and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	0
Saturation experiments showed that @CHEMICAL$ labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (alpha 1A and @GENE$) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).	0
With the exception of @CHEMICAL$, all the antipsychotic drugs tested failed to show selectivity for either of the @GENE$ subtypes.	0
@CHEMICAL$ was 120-fold more selective for the @GENE$ with respect to the alpha 1A-adrenoceptor (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).	0
@CHEMICAL$ was 120-fold more selective for the alpha 1B-adrenoceptor with respect to the @GENE$ (Ki values: 2.3 +/- 1.2 nM and 283.6 +/- 174.1 nM respectively).	0
Mediation of @CHEMICAL$-induced contractions of rat aorta by the @GENE$ subtype.	0
The subtypes of @GENE$ mediating contractions to exogenous @CHEMICAL$ (NA) in rat aorta have been examined in both biochemical and functional studies.	0
The subtypes of @GENE$ mediating contractions to exogenous noradrenaline (@CHEMICAL$) in rat aorta have been examined in both biochemical and functional studies.	0
Incubation of rat aortic membranes with the irreversible @GENE$ antagonist, @CHEMICAL$ (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	4
Incubation of rat aortic membranes with the irreversible @GENE$ antagonist, chloroethylclonidine (@CHEMICAL$: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	4
Incubation of rat aortic membranes with the irreversible @GENE$ antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of @CHEMICAL$ binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).	0
The affinity of the same antagonists for the @GENE$ was evaluated by utilizing membranes from rat hippocampus pretreated with @CHEMICAL$, and rat liver, respectively.	0
@CHEMICAL$ and phentolamine were confirmed as selective for the @GENE$, whereas spiperone was alpha 1B-selective.	0
5-Methylurapidil and @CHEMICAL$ were confirmed as selective for the @GENE$, whereas spiperone was alpha 1B-selective.	0
5-Methylurapidil and phentolamine were confirmed as selective for the @GENE$, whereas @CHEMICAL$ was alpha 1B-selective.	0
Beta 2- but not @GENE$ are involved in @CHEMICAL$ enhancement of aggressive behavior in long-term isolated mice.	0
The effects of several @GENE$ antagonists on the @CHEMICAL$-induced increase in aggressive behavior in long-term isolated mice were examined.	0
Intraperitoneal administration of @CHEMICAL$ (2.5-10 mg/kg), a nonselective @GENE$ antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.	4
Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective @GENE$ antagonist, dose dependently attenuated the @CHEMICAL$-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.	0
@CHEMICAL$ (1.25-5 mg/kg, IP), a selective @GENE$ antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.	4
@CHEMICAL$ (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective @GENE$ antagonist, did not affect it.	0
ICI118,551 HCl (1.25-5 mg/kg, IP), a selective @GENE$ antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas @CHEMICAL$ (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.	0
ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas @CHEMICAL$ (5-20 mg/kg, IP), a selective @GENE$ antagonist, did not affect it.	4
Moreover, @CHEMICAL$ (0.1-0.5 mg/kg, IP), a lipophilic @GENE$ agonist, significantly increased the duration of basal aggressive behavior.	3
Taken together with our previous finding that the @CHEMICAL$-induced enhancement of aggressive behavior can be blocked by yohimbine, an @GENE$ antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.	0
Taken together with our previous finding that the @CHEMICAL$-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also @GENE$ stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.	0
Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by @CHEMICAL$, an @GENE$ antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.	4
Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by @CHEMICAL$, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also @GENE$ stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.	0
@GENE$ subtypes mediating the regulation and modulation of @CHEMICAL$ sensitization in rabbit thoracic aorta.	0
In beta-escin-skinned strips of @CHEMICAL$-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective @GENE$ antagonist WB 4101 (100 nM).	0
In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of @CHEMICAL$ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective @GENE$ antagonist WB 4101 (100 nM).	0
In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by @CHEMICAL$ was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective @GENE$ antagonist WB 4101 (100 nM).	0
In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by @CHEMICAL$ or clonidine; this enhancement was inhibited by the selective @GENE$ antagonist WB 4101 (100 nM).	0
In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or @CHEMICAL$; this enhancement was inhibited by the selective @GENE$ antagonist WB 4101 (100 nM).	0
In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective @GENE$ antagonist @CHEMICAL$ (100 nM).	4
Furthermore, the phosphorylation of @GENE$ produced by @CHEMICAL$ was greater than that produced by clonidine.	1
Furthermore, the phosphorylation of @GENE$ produced by norepinephrine was greater than that produced by @CHEMICAL$.	1
These results suggest that both @GENE$) increase the Ca2+ sensitivity of contractile elements, and that the @CHEMICAL$ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the @CHEMICAL$ sensitization produced by @GENE$ is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the @CHEMICAL$ sensitization produced by alpha 1A-subtype receptors is mediated through @GENE$ and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the @CHEMICAL$ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and @GENE$, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both @GENE$) increase the @CHEMICAL$ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the @CHEMICAL$ sensitivity of contractile elements, and that the Ca2+ sensitization produced by @GENE$ is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the @CHEMICAL$ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through @GENE$ and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the @CHEMICAL$ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and @GENE$, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of @GENE$ or GLUT1 to investigate the role of @CHEMICAL$ transporter isoforms in mediating STZ cytotoxicity.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or @GENE$ to investigate the role of @CHEMICAL$ transporter isoforms in mediating STZ cytotoxicity.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of @CHEM-GENE$ isoforms in mediating STZ cytotoxicity.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of @GENE$ or GLUT1 to investigate the role of glucose transporter isoforms in mediating @CHEMICAL$ cytotoxicity.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or @GENE$ to investigate the role of glucose transporter isoforms in mediating @CHEMICAL$ cytotoxicity.	0
In the current study, we have used insulinoma (RIN) and AtT-20ins cell lines engineered for overexpression of GLUT2 or GLUT1 to investigate the role of @GENE$ isoforms in mediating @CHEMICAL$ cytotoxicity.	0
The in vivo effects of @CHEMICAL$ were evaluated by implantation of RIN cells expressing or lacking @GENE$ into athymic nude rats.	0
The drug had a potent cytotoxic effect on RIN cells expressing @GENE$, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood @CHEMICAL$ levels of treated animals.	5
The drug had a potent cytotoxic effect on RIN cells expressing GLUT2, but had no effect on cells lacking @GENE$ expression, as indicated by histological analysis and measurement of the blood @CHEMICAL$ levels of treated animals.	0
The preferential cytotoxic effect of @CHEMICAL$ on GLUT2-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as @GENE$- and GLUT1-overexpressing AtT-20ins cells.	0
The preferential cytotoxic effect of @CHEMICAL$ on GLUT2-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as GLUT2- and @GENE$-overexpressing AtT-20ins cells.	0
The preferential cytotoxic effect of @CHEMICAL$ on @GENE$-expressing cell lines was confirmed by in vitro analysis of GLUT2-expressing and untransfected RIN cells, as well as GLUT2- and GLUT1-overexpressing AtT-20ins cells.	0
The preferential cytotoxic effect of @CHEMICAL$ on GLUT2-expressing cell lines was confirmed by in vitro analysis of @GENE$-expressing and untransfected RIN cells, as well as GLUT2- and GLUT1-overexpressing AtT-20ins cells.	0
Consistent with these data, only @GENE$-expressing RIN or AtT-20ins cells transported @CHEMICAL$ efficiently.	5
We conclude that expression of @GENE$ is required for efficient killing of neuroendocrine cells by @CHEMICAL$, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.	5
We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by @CHEMICAL$, and this effect is related to specific recognition of the drug as a transported substrate by @GENE$ but not GLUT1.	5
We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by @CHEMICAL$, and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not @GENE$.	0
Inhibitory effects of @CHEMICAL$ analogues on @GENE$ induced whole blood clot lysis.	2
The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (@CHEMICAL$) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received @GENE$ (t-PA).	0
The lysine analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (@CHEMICAL$) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (@GENE$).	0
The lysine analogues @CHEMICAL$ (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received @GENE$ (t-PA).	0
The lysine analogues @CHEMICAL$ (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (@GENE$).	0
The @CHEMICAL$ analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received @GENE$ (t-PA).	0
The @CHEMICAL$ analogues epsilon-aminocaproic acid (EACA) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (@GENE$).	0
The lysine analogues epsilon-aminocaproic acid (@CHEMICAL$) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received @GENE$ (t-PA).	0
The lysine analogues epsilon-aminocaproic acid (@CHEMICAL$) and trans-4-amino-methyl cyclohexane carboxylic acid (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (@GENE$).	0
The lysine analogues epsilon-aminocaproic acid (EACA) and @CHEMICAL$ (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received @GENE$ (t-PA).	0
The lysine analogues epsilon-aminocaproic acid (EACA) and @CHEMICAL$ (AMCA) are used to prevent excessive bleeding in patients with coagulopathies, such as hemophilia and thrombocytopenia, or in those who have received tissue plasminogen activator (@GENE$).	0
The present study utilized blood from normal volunteers and 125I-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. @CHEMICAL$ (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous @GENE$. @CHEMICAL$ (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. @CHEMICAL$ (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	2
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. @CHEMICAL$ (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a lysine analogue.	2
The present study utilized blood from normal volunteers and 125I-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and @CHEMICAL$ (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous @GENE$. AMCA (0.06 mM) and @CHEMICAL$ (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and @CHEMICAL$ (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	2
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and @CHEMICAL$ (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a lysine analogue.	2
The present study utilized blood from normal volunteers and 125I-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a @CHEMICAL$ analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous @GENE$. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a @CHEMICAL$ analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a @CHEMICAL$ analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a @CHEMICAL$ analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a @CHEMICAL$ analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous @GENE$. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a @CHEMICAL$ analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a @CHEMICAL$ analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a @CHEMICAL$ analogue.	0
The present study utilized blood from normal volunteers and @CHEMICAL$-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and @CHEMICAL$-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous @GENE$. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and @CHEMICAL$-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and @CHEMICAL$-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-@GENE$ in a dilute whole blood clot assay to determine the relative concentrations of @CHEMICAL$ analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of @CHEMICAL$ analogues required for inhibition of clot lysis induced by exogenous @GENE$. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	2
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of @CHEMICAL$ analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous @GENE$ or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.	0
The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of @CHEMICAL$ analogues required for inhibition of clot lysis induced by exogenous t-PA. AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous @GENE$ and a lysine analogue.	0
However, their inhibitory effect was markedly reduced if clots were formed in the presence of @GENE$ and then exposed to either of the @CHEMICAL$ analogues.	2
The data suggest that @CHEMICAL$ analogues, even at low concentrations, reduce the rate of @GENE$ induced whole blood clot lysis by several mechanisms.	2
@CHEMICAL$ enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via @GENE$ activation.	1
Histamine enhances the depolarizing afterpotential of immunohistochemically identified @CHEMICAL$ neurons in the rat supraoptic nucleus via @GENE$ activation.	0
The enhancement of the depolarizing afterpotential by @CHEMICAL$ was mimicked by the @GENE$ agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by @CHEMICAL$ was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the @GENE$ antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by @CHEMICAL$ was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @GENE$ antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @CHEM-GENE$ agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @CHEMICAL$ H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the @GENE$ antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @CHEMICAL$ H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @GENE$ antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @GENE$ agonist @CHEMICAL$ and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	3
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist @CHEMICAL$ and was reduced or blocked by the @GENE$ antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist @CHEMICAL$ and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @GENE$ antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @GENE$ agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist @CHEMICAL$, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the @GENE$ antagonist @CHEMICAL$, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.	4
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist @CHEMICAL$, but was not blocked or reduced in the presence of the @GENE$ antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @GENE$ agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @CHEMICAL$ H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the @GENE$ antagonist promethazine, but was not blocked or reduced in the presence of the @CHEMICAL$ H2-receptor antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @CHEM-GENE$ antagonist, cimetidine.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the @GENE$ agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, @CHEMICAL$.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the @GENE$ antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, @CHEMICAL$.	0
The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the @GENE$ antagonist, @CHEMICAL$.	4
In summary, these results show that the excitatory effect of @CHEMICAL$ on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the @GENE$-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.	1
In summary, these results show that the excitatory effect of histamine on immunohistochemically identified @CHEMICAL$ neurons in the supraoptic nucleus is due in part to the @GENE$-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.	0
It has a particular selectivity profile for the known nuclear @CHEM-GENE$ with low affinity for RAR alpha and no transactivating potential for RXR alpha.	0
It has a particular selectivity profile for the known nuclear @CHEMICAL$ receptors with low affinity for @GENE$ and no transactivating potential for RXR alpha.	0
It has a particular selectivity profile for the known nuclear @CHEMICAL$ receptors with low affinity for RAR alpha and no transactivating potential for @GENE$.	0
Furthermore, @CHEMICAL$ does not bind to members of the cellular @GENE$ family.	0
Furthermore, adapalene does not bind to members of the cellular @CHEM-GENE$ family.	0
The goal of the present study was to compare the effects of three potent reference @GENE$ inhibitors (@CHEMICAL$, CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys.	2
The goal of the present study was to compare the effects of three potent reference @GENE$ inhibitors (remikiren, @CHEMICAL$, and enalkiren) in sodium-depleted normotensive squirrel monkeys.	2
The goal of the present study was to compare the effects of three potent reference @GENE$ inhibitors (remikiren, CGP 38560A, and @CHEMICAL$) in sodium-depleted normotensive squirrel monkeys.	2
The goal of the present study was to compare the effects of three potent reference @GENE$ inhibitors (remikiren, CGP 38560A, and enalkiren) in @CHEMICAL$-depleted normotensive squirrel monkeys.	0
Finally, the three drugs were compared with the @GENE$ inhibitor @CHEMICAL$.	2
One possible explanation is that, in our model, @CHEMICAL$ in contrast to CGP 38560A and enalkiren is able to inhibit @GENE$ in a functionally important extraplasmatic compartment.	2
One possible explanation is that, in our model, remikiren in contrast to @CHEMICAL$ and enalkiren is able to inhibit @GENE$ in a functionally important extraplasmatic compartment.	2
One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and @CHEMICAL$ is able to inhibit @GENE$ in a functionally important extraplasmatic compartment.	2
Inhibition of @GENE$-primed eosinophil chemotaxis by @CHEMICAL$.	2
These @GENE$ have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and @GENE$ (NAF)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and neutrophil-activating factor (@GENE$)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and neutrophil-activating factor (NAF)/@GENE$, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward @GENE$ (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, @CHEMICAL$, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (@GENE$).	0
These @GENE$ have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and @GENE$ (NAF)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and neutrophil-activating factor (@GENE$)/IL-8, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and neutrophil-activating factor (NAF)/@GENE$, but not toward complement fragment C5a (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and neutrophil-activating factor (NAF)/IL-8, but not toward @GENE$ (C5a).	0
These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (@CHEMICAL$) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (@GENE$).	0
Here the effect of @CHEMICAL$ on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with @GENE$ or IL-3 toward FMLP, NAF/IL-8 was evaluated.	0
Here the effect of @CHEMICAL$ on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with GM-CSF or @GENE$ toward FMLP, NAF/IL-8 was evaluated.	0
Here the effect of @CHEMICAL$ on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with GM-CSF or IL-3 toward FMLP, @GENE$/IL-8 was evaluated.	0
Here the effect of @CHEMICAL$ on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with GM-CSF or IL-3 toward FMLP, NAF/@GENE$ was evaluated.	0
RESULTS: @CHEMICAL$ inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of @GENE$ primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	2
RESULTS: @CHEMICAL$ inhibited the chemotactic response toward FMLP and @GENE$/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	2
RESULTS: @CHEMICAL$ inhibited the chemotactic response toward FMLP and NAF/@GENE$ of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	2
RESULTS: @CHEMICAL$ inhibited the chemotactic response toward FMLP and NAF/IL-8 of @GENE$ primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	2
RESULTS: Nedocromil sodium inhibited the chemotactic response toward @CHEMICAL$ and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of @GENE$ primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	0
RESULTS: Nedocromil sodium inhibited the chemotactic response toward @CHEMICAL$ and @GENE$/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	0
RESULTS: Nedocromil sodium inhibited the chemotactic response toward @CHEMICAL$ and NAF/@GENE$ of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	0
RESULTS: Nedocromil sodium inhibited the chemotactic response toward @CHEMICAL$ and NAF/IL-8 of @GENE$ primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L).	0
CONCLUSIONS: The chemotactic responses toward @GENE$ were inhibited by @CHEMICAL$ at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L).	2
Dominant expression of mRNA for @CHEM-GENE$ in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.	0
@CHEMICAL$-independent prostaglandin D synthase [@GENE$; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
@CHEMICAL$-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; @GENE$, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
@CHEMICAL$-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, @GENE$] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
@CHEMICAL$-independent @GENE$ [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [@GENE$; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of @CHEMICAL$ in the central nervous system.	5
Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; @GENE$, EC 5.3.99.2] is an enzyme responsible for biosynthesis of @CHEMICAL$ in the central nervous system.	5
Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, @GENE$] is an enzyme responsible for biosynthesis of @CHEMICAL$ in the central nervous system.	5
Glutathione-independent @GENE$ [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of @CHEMICAL$ in the central nervous system.	5
Glutathione-independent @CHEMICAL$ synthase [@GENE$; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent @CHEMICAL$ synthase [prostaglandin-H2 D-isomerase; @GENE$, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent @CHEMICAL$ synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, @GENE$] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent @CHEM-GENE$ [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [@CHEM-GENE$; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [@CHEMICAL$ D-isomerase; @GENE$, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [@CHEMICAL$ D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, @GENE$] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent @GENE$ [@CHEMICAL$ D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [@GENE$; @CHEMICAL$ D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; @CHEM-GENE$, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; @CHEMICAL$ D-isomerase, @GENE$] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
Glutathione-independent @GENE$ [prostaglandin-H2 D-isomerase; @CHEMICAL$ D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system.	0
It was further revealed that @CHEM-GENE$ activity was considerably greater in the isolated leptomeninges (14.2 nmol per min per mg of protein) and choroid plexus (7.0 nmol per min per mg of protein) than the activity in the whole brain (2.0 nmol per min per mg of protein).	0
cDNA cloning and functional properties of @CHEM-GENE$ EAA3 (GluR5) in homomeric and heteromeric configuration.	0
cDNA cloning and functional properties of human @CHEMICAL$ receptor @GENE$ (GluR5) in homomeric and heteromeric configuration.	0
cDNA cloning and functional properties of human @CHEMICAL$ receptor EAA3 (@GENE$) in homomeric and heteromeric configuration.	0
We have isolated a new member of the @CHEM-GENE$ family from a fetal brain cDNA library.	0
This cDNA clone, designated @GENE$, shares a 90% @CHEMICAL$ identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% @CHEMICAL$ identity with the previously reported @GENE$ cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% @CHEMICAL$ identity with the previously reported rat GluR5-2b cDNA splice variant and differed from @GENE$ in the amino and carboxy terminal regions.	0
This cDNA clone, designated @GENE$, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the @CHEMICAL$ and carboxy terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported @GENE$ cDNA splice variant and differed from human GluR5-1d in the @CHEMICAL$ and carboxy terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from @GENE$ in the @CHEMICAL$ and carboxy terminal regions.	0
This cDNA clone, designated @GENE$, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and @CHEMICAL$ terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported @GENE$ cDNA splice variant and differed from human GluR5-1d in the amino and @CHEMICAL$ terminal regions.	0
This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from @GENE$ in the amino and @CHEMICAL$ terminal regions.	0
Cell lines stably expressing @GENE$ protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, @CHEMICAL$, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).	0
Cell lines stably expressing EAA3a protein formed homomeric @GENE$ responsive, in order of decreasing affinity to domoate, @CHEMICAL$, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).	0
Cell lines stably expressing @GENE$ protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, @CHEMICAL$ and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).	0
Cell lines stably expressing EAA3a protein formed homomeric @GENE$ responsive, in order of decreasing affinity to domoate, kainate, @CHEMICAL$ and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).	0
Cell lines stably expressing @GENE$ protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and @CHEMICAL$ (AMPA).	0
Cell lines stably expressing EAA3a protein formed homomeric @GENE$ responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and @CHEMICAL$ (AMPA).	0
Cell lines stably expressing @GENE$ protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (@CHEMICAL$).	0
Cell lines stably expressing EAA3a protein formed homomeric @GENE$ responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (@CHEMICAL$).	0
@CHEMICAL$-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
@CHEMICAL$-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
@CHEMICAL$-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-@GENE$ antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not @CHEMICAL$ and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not @CHEMICAL$ and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not @CHEMICAL$ and were attenuated by the non-@GENE$ antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not cyclothiazide and were attenuated by the @CHEMICAL$ (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not cyclothiazide and were attenuated by the @CHEMICAL$ (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the @CHEM-GENE$ antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (@CHEMICAL$) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (@CHEMICAL$) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-@CHEM-GENE$ antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist @CHEMICAL$ (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist @CHEMICAL$ (6-cyano-7-nitro-quinoxalinedione).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-@GENE$ antagonist @CHEMICAL$ (6-cyano-7-nitro-quinoxalinedione).	4
Kainate-evoked currents showed partial desensitization that was reduced on incubation with @GENE$ (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (@CHEMICAL$).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (@GENE$) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (@CHEMICAL$).	0
Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-@GENE$ antagonist CNQX (@CHEMICAL$).	4
@CHEMICAL$ and AMPA activated the heteromeric channel with significantly higher affinities than observed for @GENE$ alone.	0
Kainate and @CHEMICAL$ activated the heteromeric channel with significantly higher affinities than observed for @GENE$ alone.	0
Ligand binding studies with the recombinant @GENE$ receptor expressed in mammalian cells indicated a high affinity @CHEMICAL$ binding site (Kd = 120 +/- 15.0 nM).	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > @CHEMICAL$ > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > @CHEMICAL$.	0
The relative potency of compounds in displacing @CHEMICAL$ binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > @CHEMICAL$ > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > @CHEMICAL$ = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = @CHEMICAL$ > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > @CHEMICAL$ (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (@CHEMICAL$) = CNQX > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = @CHEMICAL$ > AMPA > dihydrokainate > NMDA.	0
The relative potency of compounds in displacing [3H]-kainate binding to @GENE$ receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > @CHEMICAL$ > dihydrokainate > NMDA.	0
One group of experimental animals was treated with @GENE$ (5-LO) inhibitor, @CHEMICAL$ (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.	2
One group of experimental animals was treated with 5-lipoxygenase (@GENE$) inhibitor, @CHEMICAL$ (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.	2
One group of experimental animals was treated with @GENE$ (5-LO) inhibitor, diethylcarbamazine (@CHEMICAL$, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.	2
One group of experimental animals was treated with 5-lipoxygenase (@GENE$) inhibitor, diethylcarbamazine (@CHEMICAL$, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.	2
Although @CHEMICAL$ exerts local antioxidant activity with beneficial effects on lung tissue, this @GENE$ inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.	2
@CHEMICAL$, the first prostate-selective @GENE$ antagonist.	4
@GENE$ is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the @CHEMICAL$-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.	0
PC3 is a @GENE$ that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the @CHEMICAL$-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of @GENE$ to insulin by cleaving the proinsulin molecule on the @CHEMICAL$-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to @GENE$ by cleaving the proinsulin molecule on the @CHEMICAL$-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the @GENE$ molecule on the @CHEMICAL$-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.	0
@GENE$ is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and @CHEMICAL$-peptide.	0
PC3 is a @GENE$ that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and @CHEMICAL$-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of @GENE$ to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and @CHEMICAL$-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to @GENE$ by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and @CHEMICAL$-peptide.	0
PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the @GENE$ molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and @CHEMICAL$-peptide.	0
Expressions of @GENE$ and PC3, but not PC2, are coordinately regulated by @CHEMICAL$, consistent with the important role of PC3 in regulating proinsulin processing.	1
Expressions of insulin and @GENE$, but not PC2, are coordinately regulated by @CHEMICAL$, consistent with the important role of PC3 in regulating proinsulin processing.	1
Expressions of insulin and PC3, but not @GENE$, are coordinately regulated by @CHEMICAL$, consistent with the important role of PC3 in regulating proinsulin processing.	0
Expressions of insulin and PC3, but not PC2, are coordinately regulated by @CHEMICAL$, consistent with the important role of @GENE$ in regulating proinsulin processing.	0
Expressions of insulin and PC3, but not PC2, are coordinately regulated by @CHEMICAL$, consistent with the important role of PC3 in regulating @GENE$ processing.	0
Single-strand conformational analysis and @CHEMICAL$ sequencing of the entire coding region of the @GENE$ gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.	0
Single-strand conformational analysis and @CHEMICAL$ sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (@GENE$) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.	0
Single-strand conformational analysis and @CHEMICAL$ sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (@GENE$), neither of which was associated with NIDDM in this population.	0
@CHEMICAL$ administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and @GENE$ binding sites and their relationship to behaviour.	0
@CHEMICAL$ administration in the olfactory bulbectomized rat: changes in brain @GENE$ and 5-HT2A binding sites and their relationship to behaviour.	0
The effects of repeated administration of the tricyclic antidepressant drug, desipramine (@CHEMICAL$), on behaviour (locomotor activity and rearing) and the number and affinity of brain @GENE$ and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
The effects of repeated administration of the tricyclic antidepressant drug, desipramine (@CHEMICAL$), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and @GENE$ receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
The effects of repeated administration of the @CHEMICAL$ antidepressant drug, desipramine (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain @GENE$ and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
The effects of repeated administration of the @CHEMICAL$ antidepressant drug, desipramine (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and @GENE$ receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
The effects of repeated administration of the tricyclic antidepressant drug, @CHEMICAL$ (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain @GENE$ and 5-HT2A receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
The effects of repeated administration of the tricyclic antidepressant drug, @CHEMICAL$ (DMI), on behaviour (locomotor activity and rearing) and the number and affinity of brain beta-adrenoceptor and @GENE$ receptor binding sites were examined in olfactory bulbectomized (OB) and sham-operated control rats.	0
After 7 days of @CHEMICAL$ administration the number of @GENE$ was lower in frontal and occipital cortex and hippocampus.	2
Administration of @CHEMICAL$ for 14 or 21 days did not further reduce the number of @GENE$.	0
The @CHEMICAL$ induced reduction in @GENE$ did not differ in OB and sham-operated control rats.	2
@CHEMICAL$ administration for up to 21 days produced a progressive reduction in the number of @GENE$ receptors in frontal cortex, without significant alterations in occipital cortex.	2
The time course of the reduction in the number of @GENE$ receptors was similar to that of the @CHEMICAL$-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.	2
The time course of the reduction in the number of 5-HT2A receptors was similar to that of the @CHEMICAL$-induced behavioural changes whereas that for the reduction in @GENE$ was clearly different.	2
The present results suggest that the action of @CHEMICAL$ in this animal model is unlikely to be directly related to a reduction in @GENE$ but may be related to a reduction in frontal cortical 5-HT2A receptors.	2
The present results suggest that the action of @CHEMICAL$ in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical @GENE$ receptors.	2
Binding of @CHEMICAL$ to @GENE$ may be involved in its inhibition of tumor necrosis factor alpha production.	0
Binding of @CHEMICAL$ to alpha1-acid glycoprotein may be involved in its inhibition of @GENE$ production.	2
The immunomodulatory activity of @CHEMICAL$ has been ascribed to the selective inhibition of @GENE$ from monocytes.	2
We show that the binding of thalidomide photoaffinity label to authentic @GENE$ is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of @CHEMICAL$.	0
We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of @GENE$ from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of @CHEMICAL$.	0
We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that @GENE$ may be involved in the immunomodulatory activity of @CHEMICAL$.	0
We show that the binding of @CHEMICAL$ photoaffinity label to authentic @GENE$ is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.	0
We show that the binding of @CHEMICAL$ photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of @GENE$ from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.	0
We show that the binding of @CHEMICAL$ photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that @GENE$ may be involved in the immunomodulatory activity of thalidomide.	0
We show that the binding of thalidomide photoaffinity label to authentic @GENE$ is competed with both @CHEMICAL$ and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.	0
We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both @CHEMICAL$ and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of @GENE$ from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.	2
We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both @CHEMICAL$ and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that @GENE$ may be involved in the immunomodulatory activity of thalidomide.	0
@CHEM-GENE$ heterogeneity in rat hippocampal neurons revealed by differential sensitivity to cyclothiazide.	0
@GENE$ heterogeneity in rat hippocampal neurons revealed by differential sensitivity to @CHEMICAL$.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of @GENE$ desensitization by @CHEMICAL$, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid @GENE$ desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by @CHEMICAL$, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of @CHEMICAL$ (AMPA) receptor desensitization by glutamate, and the extent of attenuation of @GENE$ desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of @CHEMICAL$ @GENE$ desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (@CHEMICAL$) receptor desensitization by glutamate, and the extent of attenuation of @GENE$ desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid @CHEM-GENE$ desensitization by glutamate, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by @CHEMICAL$, and the extent of attenuation of @GENE$ desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid @GENE$ desensitization by @CHEMICAL$, and the extent of attenuation of AMPA receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor desensitization by glutamate, and the extent of attenuation of @CHEM-GENE$ desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The kinetics of onset of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid @GENE$ desensitization by glutamate, and the extent of attenuation of @CHEMICAL$ receptor desensitization by cyclothiazide, showed pronounced cell-to-cell variation in cultures of rat hippocampal neurons.	0
The amplitudes of these components varied widely between cells, suggesting the existence of at least three populations of @CHEM-GENE$ subtypes, the relative density of which varied from cell to cell.	0
The complex patterns of sensitivity to @CHEMICAL$ seen in hippocampal neurons could be reconstituted by assembly of recombinant @GENE$ subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and GluR-B subunits.	0
The complex patterns of sensitivity to @CHEMICAL$ seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the @GENE$ and GluR-B subunits.	0
The complex patterns of sensitivity to @CHEMICAL$ seen in hippocampal neurons could be reconstituted by assembly of recombinant AMPA receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and @GENE$ subunits.	0
The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant @CHEM-GENE$ subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and GluR-B subunits.	0
The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant @CHEMICAL$ receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the @GENE$ and GluR-B subunits.	0
The complex patterns of sensitivity to cyclothiazide seen in hippocampal neurons could be reconstituted by assembly of recombinant @CHEMICAL$ receptor subunits generated from cDNAs encoding the flip (i) and flop (o) splice variants of the GluR-A and @GENE$ subunits.	0
Recovery from modulation by @CHEMICAL$ was slower for @GENE$ and GluR-AoBi than for GluR-AiBo and GluR-AoBo.	0
Recovery from modulation by @CHEMICAL$ was slower for GluR-AiBi and @GENE$ than for GluR-AiBo and GluR-AoBo.	0
Recovery from modulation by @CHEMICAL$ was slower for GluR-AiBi and GluR-AoBi than for @GENE$ and GluR-AoBo.	0
Recovery from modulation by @CHEMICAL$ was slower for GluR-AiBi and GluR-AoBi than for GluR-AiBo and @GENE$.	0
Coexpression of the flip and flop splice variants of @GENE$, in the absence of GluR-B, revealed that heteromeric @CHEMICAL$ receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of @GENE$, revealed that heteromeric @CHEMICAL$ receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric @CHEM-GENE$ with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric @CHEMICAL$ receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations @GENE$ or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric @CHEMICAL$ receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or @GENE$, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric @CHEMICAL$ receptors with intermediate sensitivity to cyclothiazide, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the @GENE$ subunit.	0
Coexpression of the flip and flop splice variants of @GENE$, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of @GENE$, revealed that heteromeric AMPA receptors with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric @GENE$ with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations @GENE$ or GluR-AiBo, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations GluR-AoBi or @GENE$, could be generated independently of the presence of the GluR-B subunit.	0
Coexpression of the flip and flop splice variants of GluR-A, in the absence of GluR-B, revealed that heteromeric AMPA receptors with intermediate sensitivity to @CHEMICAL$, similar to responses observed for the combinations GluR-AoBi or GluR-AiBo, could be generated independently of the presence of the @GENE$ subunit.	0
However, recovery from modulation by @CHEMICAL$ was twofold slower for @GENE$ than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.	0
However, recovery from modulation by @CHEMICAL$ was twofold slower for GluR-AiBi than for homomeric @GENE$, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.	0
However, recovery from modulation by @CHEMICAL$ was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the @GENE$ and GluR-B subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.	0
However, recovery from modulation by @CHEMICAL$ was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and @GENE$ subunits are not functionally equivalent in controlling sensitivity to cyclothiazide.	0
However, recovery from modulation by cyclothiazide was twofold slower for @GENE$ than for homomeric GluR-Ai, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to @CHEMICAL$.	0
However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric @GENE$, indicating that the GluR-A and GluR-B subunits are not functionally equivalent in controlling sensitivity to @CHEMICAL$.	0
However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the @GENE$ and GluR-B subunits are not functionally equivalent in controlling sensitivity to @CHEMICAL$.	0
However, recovery from modulation by cyclothiazide was twofold slower for GluR-AiBi than for homomeric GluR-Ai, indicating that the GluR-A and @GENE$ subunits are not functionally equivalent in controlling sensitivity to @CHEMICAL$.	0
These results demonstrate that @CHEM-GENE$ expressed in hippocampal neurons are assembled in a variety of subunit and splice variant combinations that might serve as a mechanism to fine-tune the kinetics of synaptic transmission.	0
Striatal dopamine, @CHEM-GENE$, and vesicular monoamine transporter in chronic cocaine users.	0
Striatal dopamine, @CHEMICAL$ transporter, and @GENE$ in chronic cocaine users.	0
Striatal dopamine, @GENE$, and vesicular @CHEMICAL$ transporter in chronic cocaine users.	0
Striatal dopamine, dopamine transporter, and @CHEM-GENE$ in chronic cocaine users.	0
Striatal dopamine, @GENE$, and vesicular monoamine transporter in chronic @CHEMICAL$ users.	0
Striatal dopamine, dopamine transporter, and @GENE$ in chronic @CHEMICAL$ users.	0
Striatal @CHEMICAL$, @GENE$, and vesicular monoamine transporter in chronic cocaine users.	0
Striatal @CHEMICAL$, dopamine transporter, and @GENE$ in chronic cocaine users.	0
We measured levels of @CHEMICAL$, as well as two DA nerve terminal indices, namely, the @GENE$ (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of @CHEMICAL$, as well as two DA nerve terminal indices, namely, the DA transporter (@GENE$) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of @CHEMICAL$, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the @GENE$ (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of @CHEMICAL$, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (@GENE$) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two @CHEMICAL$ nerve terminal indices, namely, the @GENE$ (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two @CHEMICAL$ nerve terminal indices, namely, the DA transporter (@GENE$) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two @CHEMICAL$ nerve terminal indices, namely, the DA transporter (DAT) and the @GENE$ (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two @CHEMICAL$ nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (@GENE$) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @CHEM-GENE$ (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @CHEMICAL$ transporter (@GENE$) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @CHEMICAL$ transporter (DAT) and the @GENE$ (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @CHEMICAL$ transporter (DAT) and the vesicular monoamine transporter (@GENE$) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @GENE$ (DAT) and the vesicular @CHEMICAL$ transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (@GENE$) and the vesicular @CHEMICAL$ transporter (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the @CHEM-GENE$ (VMAT2) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular @CHEMICAL$ transporter (@GENE$) in autopsied brain of 12 chronic cocaine users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the @GENE$ (DAT) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic @CHEMICAL$ users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (@GENE$) and the vesicular monoamine transporter (VMAT2) in autopsied brain of 12 chronic @CHEMICAL$ users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the @GENE$ (VMAT2) in autopsied brain of 12 chronic @CHEMICAL$ users.	0
We measured levels of DA, as well as two DA nerve terminal indices, namely, the DA transporter (DAT) and the vesicular monoamine transporter (@GENE$) in autopsied brain of 12 chronic @CHEMICAL$ users.	0
Striatal @GENE$ protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas DAT determined by @CHEMICAL$ binding was normal.	0
Striatal DAT protein (-25 to -46%) and @GENE$ (-17 to -22%) were reduced, whereas DAT determined by @CHEMICAL$ binding was normal.	0
Striatal DAT protein (-25 to -46%) and VMAT2 (-17 to -22%) were reduced, whereas @GENE$ determined by @CHEMICAL$ binding was normal.	0
In conclusion, our data suggest that chronic @CHEMICAL$ use is associated with modestly reduced levels of striatal DA and the @GENE$ in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.	2
In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal @CHEMICAL$ and the @GENE$ in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.	0
In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal DA and the @CHEM-GENE$ in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.	0
Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a @CHEM-GENE$, similar to hepatocyte growth factor activator.	0
Purification and characterization of a novel @GENE$ (PHBP) from human plasma: it has three EGF, a kringle and a @CHEMICAL$ protease domain, similar to hepatocyte growth factor activator.	0
Purification and characterization of a novel hyaluronan-binding protein (@GENE$) from human plasma: it has three EGF, a kringle and a @CHEMICAL$ protease domain, similar to hepatocyte growth factor activator.	0
Thus, @GENE$ was a heterodimer composed of 50-kDa and 17-kDa subunits, bridged by a @CHEMICAL$ linkage.	0
Both subunits had novel @CHEMICAL$ sequences, indicating that @GENE$ was a novel hyaluronan-binding protein in human plasma.	0
The @CHEMICAL$ sequence deduced from the nucleotide sequence of the cloned @GENE$ cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).	0
The @CHEMICAL$ sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of @GENE$ (HGFA).	0
The @CHEMICAL$ sequence deduced from the nucleotide sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator (@GENE$).	0
The amino acid sequence deduced from the @CHEMICAL$ sequence of the cloned @GENE$ cDNA exhibited significant homology to that of hepatocyte growth factor activator (HGFA).	0
The amino acid sequence deduced from the @CHEMICAL$ sequence of the cloned PHBP cDNA exhibited significant homology to that of @GENE$ (HGFA).	0
The amino acid sequence deduced from the @CHEMICAL$ sequence of the cloned PHBP cDNA exhibited significant homology to that of hepatocyte growth factor activator (@GENE$).	0
The predicted structure of @GENE$ showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three @GENE$, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a @GENE$ and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEM-GENE$, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although @GENE$ has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a @GENE$, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an @GENE$, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a @GENE$, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an @GENE$, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a @GENE$, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @CHEMICAL$ protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @GENE$, from its N-terminus.	0
The predicted structure of @GENE$ showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three @GENE$, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a @GENE$ and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @GENE$, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although @GENE$ has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a @GENE$, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an @GENE$, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a @GENE$, an EGF domain, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an @GENE$, a kringle domain, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a @GENE$, and a serine protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its @CHEMICAL$-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @GENE$, from its N-terminus.	0
The predicted structure of @GENE$ showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three @GENE$, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a @GENE$ and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @GENE$, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although @GENE$ has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a @GENE$, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an @GENE$, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a @GENE$, an EGF domain, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an @GENE$, a kringle domain, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a @GENE$, and a @CHEMICAL$ protease domain, from its N-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @CHEM-GENE$, from its N-terminus.	0
The predicted structure of @GENE$ showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three @GENE$, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a @GENE$ and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a @GENE$, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although @GENE$ has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a @GENE$, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an @GENE$, a fibronectin type I domain, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a @GENE$, an EGF domain, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an @GENE$, a kringle domain, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a @GENE$, and a serine protease domain, from its @CHEMICAL$-terminus.	0
The predicted structure of PHBP showed three epidermal growth factor (EGF) domains, a kringle domain and a serine protease domain, from its N-terminus, although HGFA has a fibronectin type II domain, an EGF domain, a fibronectin type I domain, an EGF domain, a kringle domain, and a @GENE$, from its @CHEMICAL$-terminus.	0
It appears likely that the @CHEM-GENE$ blocked by cimetidine obviated the pulmonary vasodilator effect of tolazoline therapy.	0
It appears likely that the @GENE$ blocked by @CHEMICAL$ obviated the pulmonary vasodilator effect of tolazoline therapy.	2
It appears likely that the @GENE$ blocked by cimetidine obviated the pulmonary vasodilator effect of @CHEMICAL$ therapy.	0
Interactions of @CHEMICAL$ and cyclothiazide at @GENE$: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.	0
Interactions of 2,3-benzodiazepines and @CHEMICAL$ at @GENE$: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.	0
Interactions of 2,3-benzodiazepines and cyclothiazide at @CHEM-GENE$: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.	0
@CHEMICAL$ decreased the peak amplitude of hippocampal area CA1 @GENE$-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.	2
GYKI 52466 decreased the peak amplitude of hippocampal area CA1 @CHEM-GENE$-mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +/- 0.8 microM) with no apparent effect on response kinetics.	0
@CHEMICAL$ prolonged the decay time constant of @GENE$-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c.	2
Cyclothiazide prolonged the decay time constant of @CHEM-GENE$-mediated e.p.s.cs (EC50 35.7 +/- 6.5 microM) with less pronounced effects in slowing e.p.s.c.	0
@CHEMICAL$ (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on @GENE$-mediated e.p.s.c.	0
Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of @CHEMICAL$ on @GENE$-mediated e.p.s.c.	0
Cyclothiazide (330 microM) shifted the concentration-response curve for the effects of GYKI 52466 on @CHEM-GENE$-mediated e.p.s.c.	0
Likewise, @CHEMICAL$ (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on @GENE$-mediated e.p.s.c.	0
Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of @CHEMICAL$ on @GENE$-mediated e.p.s.c.	0
Likewise, GYKI 52466 (30-100 microM)) shifted the concentration-response curve for the effects of cyclothiazide on @CHEM-GENE$-mediated e.p.s.c.	0
In conclusion, @CHEMICAL$ and the 2,3-benzodiazepines seem to bind to different sites on @GENE$ but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.	0
In conclusion, cyclothiazide and the @CHEMICAL$ seem to bind to different sites on @GENE$ but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.	0
In conclusion, cyclothiazide and the 2,3-benzodiazepines seem to bind to different sites on @CHEM-GENE$ but exert strong allosteric interactions with one another and with other domains such as the agonist recognition site.	0
The interactions of @CHEMICAL$ and cyclothiazide on @GENE$-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.	0
The interactions of GYKI 52466 and @CHEMICAL$ on @GENE$-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.	0
The interactions of GYKI 52466 and cyclothiazide on @CHEM-GENE$-mediated e.p.s.cs in area CA1 of hippocampal slices provide evidence that the decay time constant of these synaptic events are not governed by desensitization.	0
Comparison of ligand binding affinities at human I1-@CHEMICAL$ binding sites and the high affinity state of @GENE$ subtypes.	0
Comparison of ligand binding affinities at @CHEM-GENE$ and the high affinity state of alpha-2 adrenoceptor subtypes.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at @GENE$ (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of @GENE$) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at @GENE$, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, @GENE$ and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and @GENE$ stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic @CHEM-GENE$ (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-@CHEMICAL$ receptors (@GENE$), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at @GENE$ (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of @GENE$) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at @GENE$, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, @GENE$ and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and @GENE$ stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic @GENE$ (I1), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (@GENE$), the affinities of 22 ligands for @CHEMICAL$ binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at @CHEM-GENE$ (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of @GENE$) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at @GENE$, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, @GENE$ and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and @GENE$ stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic @GENE$ (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (@GENE$), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-@CHEMICAL$ binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at @GENE$ (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of @GENE$) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at @GENE$, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at human alpha-2A, @GENE$ and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at human alpha-2A, alpha-2B and @GENE$ stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic @GENE$ (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
To identify selective compounds for nonadrenergic I1-imidazoline receptors (@GENE$), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under @CHEMICAL$ mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.	0
Competition curves at the platelet @CHEM-GENE$ were biphasic for most compounds.	0
@CHEMICAL$, an endogenous neurotransmitter candidate for the @GENE$, was identified as the most selective agent for a subcomponent of platelet I1 sites.	0
@CHEMICAL$, an endogenous neurotransmitter candidate for the I1-imidazoline receptor, was identified as the most selective agent for a subcomponent of platelet @GENE$.	0
Agmatine, an endogenous neurotransmitter candidate for the @CHEM-GENE$, was identified as the most selective agent for a subcomponent of platelet I1 sites.	0
Agmatine, an endogenous neurotransmitter candidate for the I1-@CHEMICAL$ receptor, was identified as the most selective agent for a subcomponent of platelet @GENE$.	0
The affinity of @CHEMICAL$ at the high affinity component of platelet @GENE$ was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over alpha-2C adrenoceptors.	0
The affinity of @CHEMICAL$ at the high affinity component of platelet I1 sites was 1400-fold selective over @GENE$, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over alpha-2C adrenoceptors.	0
The affinity of @CHEMICAL$ at the high affinity component of platelet I1 sites was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over @GENE$ and 800-fold selective over alpha-2C adrenoceptors.	0
The affinity of @CHEMICAL$ at the high affinity component of platelet I1 sites was 1400-fold selective over alpha-2A adrenoceptors, 5000-fold selective over alpha-2B adrenoceptors and 800-fold selective over @GENE$.	0
@CHEMICAL$ and tizanidine also displayed selectivities for a high affinity component of the platelet @GENE$ over alpha-2 adrenoceptors.	0
@CHEMICAL$ and tizanidine also displayed selectivities for a high affinity component of the platelet I1 binding sites over @GENE$.	0
Moxonidine and @CHEMICAL$ also displayed selectivities for a high affinity component of the platelet @GENE$ over alpha-2 adrenoceptors.	0
Moxonidine and @CHEMICAL$ also displayed selectivities for a high affinity component of the platelet I1 binding sites over @GENE$.	0
@CHEMICAL$ was the most selective compound for the high affinity state of the @GENE$, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively.	0
@CHEMICAL$ was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than @GENE$, alpha-2C and platelet I1-midazoline binding sites, respectively.	0
@CHEMICAL$ was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, @GENE$ and platelet I1-midazoline binding sites, respectively.	0
@CHEMICAL$ was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet @GENE$, respectively.	0
Naphazoline was the most selective compound for the high affinity state of the @GENE$, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-@CHEMICAL$ binding sites, respectively.	0
Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than @GENE$, alpha-2C and platelet I1-@CHEMICAL$ binding sites, respectively.	0
Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, @GENE$ and platelet I1-@CHEMICAL$ binding sites, respectively.	0
Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet @CHEM-GENE$, respectively.	0
@CHEMICAL$ displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the @GENE$ as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-imidazoline sites.	0
@CHEMICAL$ displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to @GENE$- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-imidazoline sites.	0
@CHEMICAL$ displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or @GENE$, and was > 100,000- fold selective over platelet I1-imidazoline sites.	0
@CHEMICAL$ displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet @GENE$.	0
Norepinephrine displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the @GENE$ as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-@CHEMICAL$ sites.	0
Norepinephrine displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to @GENE$- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet I1-@CHEMICAL$ sites.	0
Norepinephrine displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or @GENE$, and was > 100,000- fold selective over platelet I1-@CHEMICAL$ sites.	0
Norepinephrine displayed, respectively, 18- and 31-fold selectivity for the high affinity state of the alpha-2C adrenoceptor as compared to alpha-2A- or alpha-2B adrenoceptors, and was > 100,000- fold selective over platelet @CHEM-GENE$.	0
Thus, @GENE$ and the platelet I1-@CHEMICAL$ binding site can be clearly discriminated based on their affinities for certain compounds.	0
Thus, human alpha-2 adrenoceptors and the platelet @CHEM-GENE$ can be clearly discriminated based on their affinities for certain compounds.	0
Activation of cytoprotective @CHEM-GENE$ by minoxidil as a possible explanation for its hair growth-stimulating effect.	0
Activation of cytoprotective @GENE$ by @CHEMICAL$ as a possible explanation for its hair growth-stimulating effect.	1
These NSAIDs are well-known inhibitors of both the cytoprotective isoform of @CHEM-GENE$ (PGHS-1) and of the inducible form (PGHS-2).	0
These NSAIDs are well-known inhibitors of both the cytoprotective isoform of @CHEMICAL$ endoperoxide synthase-1 (@GENE$) and of the inducible form (PGHS-2).	0
These NSAIDs are well-known inhibitors of both the cytoprotective isoform of @CHEMICAL$ endoperoxide synthase-1 (PGHS-1) and of the inducible form (@GENE$).	0
We thus speculated that activation of @GENE$ might be a mechanism by which @CHEMICAL$ (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.	1
We thus speculated that activation of @GENE$ might be a mechanism by which minoxidil (@CHEMICAL$) stimulates hair growth in vivo.	1
We demonstrate here that @CHEMICAL$ is a potent activator of purified @GENE$ (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.	1
We demonstrate here that minoxidil is a potent activator of purified @GENE$ (AC50 = 80 microM), as assayed by @CHEMICAL$ consumption and PGE2 production.	0
Clonal T cells defined as a predominance of a single @GENE$ gene usage, in one case verified by TCR CDR3 fragment analysis and @CHEMICAL$ sequencing, emerged within the CD52-/CD8+ cell population during Campath-1H therapy in 2 CLL patients, both achieving a long-lasting remission.	0
Clonal T cells defined as a predominance of a single T cell receptor (TCR) V gene usage, in one case verified by @GENE$ CDR3 fragment analysis and @CHEMICAL$ sequencing, emerged within the CD52-/CD8+ cell population during Campath-1H therapy in 2 CLL patients, both achieving a long-lasting remission.	0
Female precocious puberty may require hyperactivity of both @GENE$ axes because of the "two-cell' arrangement required for ovarian @CHEMICAL$ production.	0
Evolution of the @CHEM-GENE$ family and the organization of the Drosophila glutamyl-prolyl-tRNA synthetase gene.	0
Evolution of the @CHEMICAL$-tRNA synthetase family and the organization of the Drosophila @GENE$ gene.	0
Evolution of the @GENE$ family and the organization of the Drosophila @CHEMICAL$-prolyl-tRNA synthetase gene.	0
Evolution of the aminoacyl-tRNA synthetase family and the organization of the Drosophila @CHEM-GENE$ gene.	0
In Drosophila, @GENE$ is a multifunctional synthetase encoded by a unique gene and composed of three domains: the @CHEMICAL$- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	0
In Drosophila, @GENE$ is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and @CHEMICAL$-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	0
In Drosophila, @CHEM-GENE$ is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	0
In Drosophila, @GENE$ is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of @CHEMICAL$ and proline tRNA species, respectively, and the central domain is made of 75 amino acids repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	0
In Drosophila, @GENE$ is a multifunctional synthetase encoded by a unique gene and composed of three domains: the amino- and carboxy-terminal domains catalyze the aminoacylation of glutamic acid and proline tRNA species, respectively, and the central domain is made of 75 @CHEMICAL$ repeated six times amongst which 46 are highly conserved and constitute the repeated motifs [Cerini, C., Kerjan, P., Astier, M., Gratecos, D., Mirande, M. & Semeriva, M. (1991) EMBO J.	0
The small mRNA promoter resides in the 4th intron and evidence is provided that the mRNA encodes only the domain corresponding to @CHEM-GENE$ and is functional in vivo.	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and @CHEMICAL$ for the @GENE$, retinoic acid receptors (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and @CHEMICAL$ for the nuclear transcription factors, @GENE$ (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and @CHEMICAL$ for the nuclear transcription factors, retinoic acid receptors (@GENE$).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and tretinoin for the @GENE$, @CHEMICAL$ receptors (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and tretinoin for the nuclear transcription factors, @CHEM-GENE$ (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and tretinoin for the nuclear transcription factors, @CHEMICAL$ receptors (@GENE$).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of @CHEMICAL$ and tretinoin for the @GENE$, retinoic acid receptors (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of @CHEMICAL$ and tretinoin for the nuclear transcription factors, @GENE$ (RARs).	0
Binding and transactivation assays were used to compare affinities and transcriptional activities of @CHEMICAL$ and tretinoin for the nuclear transcription factors, retinoic acid receptors (@GENE$).	0
The @GENE$ RAR beta and RAR gamma mediate the @CHEMICAL$ activity of adapalene.	0
The nuclear gene transcription factors @GENE$ and RAR gamma mediate the @CHEMICAL$ activity of adapalene.	0
The nuclear gene transcription factors RAR beta and @GENE$ mediate the @CHEMICAL$ activity of adapalene.	0
The @GENE$ RAR beta and RAR gamma mediate the retinoid activity of @CHEMICAL$.	0
The nuclear gene transcription factors @GENE$ and RAR gamma mediate the retinoid activity of @CHEMICAL$.	0
The nuclear gene transcription factors RAR beta and @GENE$ mediate the retinoid activity of @CHEMICAL$.	0
This study was designed to determine the gastroprotective properties of @CHEMICAL$ (CNT), a novel prokinetic benzamide derivative agonist of @GENE$ and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of @CHEMICAL$ (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and @GENE$ receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of @CHEMICAL$ (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and @GENE$ antagonist, on mucosal injury produced by 50% (v/v) ethanol.	4
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic @CHEMICAL$ derivative agonist of @GENE$ and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic @CHEMICAL$ derivative agonist of 5-HT4 and @GENE$ receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic @CHEMICAL$ derivative agonist of 5-HT4 and 5-HT1 receptors and @GENE$ antagonist, on mucosal injury produced by 50% (v/v) ethanol.	4
This study was designed to determine the gastroprotective properties of cinitapride (@CHEMICAL$), a novel prokinetic benzamide derivative agonist of @GENE$ and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of cinitapride (@CHEMICAL$), a novel prokinetic benzamide derivative agonist of 5-HT4 and @GENE$ receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.	3
This study was designed to determine the gastroprotective properties of cinitapride (@CHEMICAL$), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and @GENE$ antagonist, on mucosal injury produced by 50% (v/v) ethanol.	4
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of @GENE$ and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) @CHEMICAL$.	0
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and @GENE$ receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) @CHEMICAL$.	0
This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and @GENE$ antagonist, on mucosal injury produced by 50% (v/v) @CHEMICAL$.	0
On the contrary, pretreatment with @CHEMICAL$ worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, @GENE$ content or PGE2 levels, although the non-protein SH fraction was significantly decreased.	0
On the contrary, pretreatment with 5-HT worsened @CHEMICAL$-induced erosions, however, did not affect gastric mucus secretion, @GENE$ content or PGE2 levels, although the non-protein SH fraction was significantly decreased.	0
On the contrary, pretreatment with 5-HT worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, @GENE$ content or @CHEMICAL$ levels, although the non-protein SH fraction was significantly decreased.	0
On the contrary, pretreatment with 5-HT worsened ethanol-induced erosions, however, did not affect gastric mucus secretion, @GENE$ content or PGE2 levels, although the non-protein @CHEMICAL$ fraction was significantly decreased.	0
We suggest that @CHEMICAL$ dependent mechanisms through @GENE$ receptor blockade and 5-HT1 receptor activation could be also involved.	0
We suggest that @CHEMICAL$ dependent mechanisms through 5-HT2 receptor blockade and @GENE$ receptor activation could be also involved.	0
When the cloned @GENE$ was transfected into COS 1 cells, salmon calcitonin stimulated intracellular @CHEMICAL$ accumulation with an EC50 of 0.1 nM, whereas human calcitonin was >250-fold less potent (EC50 27.6 nM).	0
When the cloned guinea pig calcitonin receptor was transfected into COS 1 cells, @GENE$ stimulated intracellular @CHEMICAL$ accumulation with an EC50 of 0.1 nM, whereas human calcitonin was >250-fold less potent (EC50 27.6 nM).	0
When the cloned guinea pig calcitonin receptor was transfected into COS 1 cells, salmon calcitonin stimulated intracellular @CHEMICAL$ accumulation with an EC50 of 0.1 nM, whereas @GENE$ was >250-fold less potent (EC50 27.6 nM).	0
Stimulation of the transfected @GENE$ by salmon calcitonin also resulted in @CHEMICAL$ hydrolysis with an EC50 of 2.5 nM.	0
@CHEM-GENE$ is a specific partner for the Grb2 isoform Grb3-3.	0
@CHEMICAL$ deaminase is a specific partner for the @GENE$ isoform Grb3-3.	0
@CHEMICAL$ deaminase is a specific partner for the Grb2 isoform @GENE$.	0
We have identified @CHEM-GENE$, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.	0
We have identified @CHEMICAL$ deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a @GENE$ binding protein that is not able to bind to Grb2.	0
We have identified @CHEMICAL$ deaminase, an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to @GENE$.	0
We have identified @GENE$, an enzyme involved in @CHEMICAL$ metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.	5
We have identified adenosine deaminase, an enzyme involved in @CHEMICAL$ metabolism whose deficiency is associated with severe combined immunodeficiency, as a @GENE$ binding protein that is not able to bind to Grb2.	0
We have identified adenosine deaminase, an enzyme involved in @CHEMICAL$ metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to @GENE$.	0
@CHEMICAL$ inhibition of @GENE$.	2
Alendronate inhibition of @CHEM-GENE$.	0
Here we report that @CHEMICAL$ is a potent inhibitor of the @GENE$ (PTPmeg1).	2
Here we report that @CHEMICAL$ is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (@GENE$).	2
Here we report that alendronate is a potent inhibitor of the @CHEM-GENE$ (PTPmeg1).	0
Here we report that alendronate is a potent inhibitor of the protein-@CHEMICAL$-phosphatase-meg1 (@GENE$).	0
Two substrates were employed in this study: fluorescein @CHEMICAL$ and the phosphotyrosyl peptide @GENE$-pY527.	0
With either substrate, @CHEMICAL$ was a slow binding inhibitor of @GENE$.	2
Among the other @CHEMICAL$ studied, alendronate was more potent and selective for @GENE$.	2
Among the other bisphosphonates studied, @CHEMICAL$ was more potent and selective for @GENE$.	2
The hydrolysis of fluorescein @CHEMICAL$ by @GENE$ and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	5
The hydrolysis of fluorescein @CHEMICAL$ by PTP epsilon and @GENE$ was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	5
The hydrolysis of fluorescein @CHEMICAL$ by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; @GENE$, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	0
The hydrolysis of fluorescein diphosphate by @GENE$ and PTPmeg1 was sensitive to @CHEMICAL$, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	0
The hydrolysis of fluorescein diphosphate by PTP epsilon and @GENE$ was sensitive to @CHEMICAL$, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	0
The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to @CHEMICAL$, with IC50 values of less than 1 microM; @GENE$, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.	0
The hydrolysis of fluorescein diphosphate by @GENE$ and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM @CHEMICAL$.	0
The hydrolysis of fluorescein diphosphate by PTP epsilon and @GENE$ was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM @CHEMICAL$.	0
The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; @GENE$, however, under the same conditions, was inhibited by only 50% with 141 microM @CHEMICAL$.	2
Similarly, with the @GENE$-pY527 substrate, @CHEMICAL$ inhibition was also PTP dependent.	0
Similarly, with the src-pY527 substrate, @CHEMICAL$ inhibition was also @GENE$ dependent.	0
@CHEMICAL$ inhibited @GENE$ with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.	2
@CHEMICAL$ inhibited PTPmeg1 with an IC50 value of 23 microM, @GENE$ with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.	2
@CHEMICAL$ inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit @GENE$ at concentrations up to 1 mM.	0
The @CHEMICAL$ inhibition of these three @GENE$ and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.	2
@GENE$ inhibition by @CHEMICAL$ or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.	2
@GENE$ inhibition by hisphosphonates or @CHEMICAL$ was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.	2
@GENE$ inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent @CHEMICAL$, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.	0
@GENE$ inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent @CHEMICAL$, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.	0
@GENE$ inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a @CHEMICAL$ residue are required for full inhibition.	0
These observations show substrate- and enzyme-specific @GENE$ inhibition by alendronate and support the possibility that a certain PTP(s) may be the molecular target for @CHEMICAL$ action.	0
These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain @GENE$(s) may be the molecular target for @CHEMICAL$ action.	0
These observations show substrate- and enzyme-specific @GENE$ inhibition by @CHEMICAL$ and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.	2
These observations show substrate- and enzyme-specific PTP inhibition by @CHEMICAL$ and support the possibility that a certain @GENE$(s) may be the molecular target for alendronate action.	0
Ligand binding specificities of the eight types and subtypes of the @CHEM-GENE$ expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEM-GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (@CHEMICAL$) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @GENE$, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEM-GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEMICAL$ (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @GENE$, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @CHEM-GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (@CHEMICAL$) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEM-GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @CHEMICAL$ (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @GENE$, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @GENE$, the @CHEMICAL$ (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEM-GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEMICAL$ (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @GENE$, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @GENE$, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @CHEM-GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (@CHEMICAL$) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @CHEM-GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the @GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the @CHEMICAL$ receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @CHEM-GENE$, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the @GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the @GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse @CHEMICAL$ receptor, the prostaglandin D (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEM-GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the @GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEMICAL$ (DP) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and @GENE$ subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the @GENE$, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the @GENE$, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the @CHEM-GENE$, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the @GENE$, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the @GENE$, the thromboxane A (TP) receptor and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the @GENE$ and the EP1, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the @GENE$, EP2, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, @GENE$, EP3 and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
Eight types and subtypes of the mouse prostanoid receptor, the prostaglandin D (@CHEMICAL$) receptor, the prostaglandin F (FP) receptor, the prostaglandin I (IP) receptor, the thromboxane A (TP) receptor and the EP1, EP2, @GENE$ and EP4 subtypes of the prostaglandin E receptor, were stably expressed in Chinese hamster ovary cells.	0
The @CHEM-GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The @CHEMICAL$, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The @CHEMICAL$, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The @CHEMICAL$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The @CHEMICAL$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The @CHEMICAL$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, @CHEMICAL$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @CHEM-GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @CHEMICAL$ and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @CHEMICAL$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @CHEMICAL$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @CHEMICAL$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and @CHEMICAL$ receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and @CHEMICAL$ receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @CHEM-GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @CHEMICAL$ receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @CHEMICAL$ receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @CHEMICAL$ receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as @CHEMICAL$, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, @CHEMICAL$ and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and @CHEMICAL$ for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEMICAL$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEMICAL$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEMICAL$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEM-GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEMICAL$, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @CHEMICAL$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, @CHEMICAL$, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, @CHEMICAL$, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, @CHEMICAL$, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, @CHEMICAL$, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, @CHEMICAL$, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, @CHEMICAL$, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, @CHEMICAL$ and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, @CHEMICAL$ and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, @CHEMICAL$ and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, @CHEMICAL$ and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, @CHEMICAL$ and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, @CHEMICAL$ and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and @CHEMICAL$ for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and @CHEMICAL$ for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and @CHEMICAL$ for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and @CHEMICAL$ for IP, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and @CHEMICAL$ for @GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and @CHEMICAL$ for IP, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @CHEMICAL$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @CHEMICAL$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @CHEMICAL$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for @CHEMICAL$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @CHEM-GENE$, and S-145, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @CHEMICAL$, and S-145, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and @CHEMICAL$, I-BOP and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and @CHEMICAL$, I-BOP and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and @CHEMICAL$, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and @CHEMICAL$, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and @CHEMICAL$, I-BOP and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and @CHEMICAL$, I-BOP and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, @CHEMICAL$ and GR 32191 for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, @CHEMICAL$ and GR 32191 for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, @CHEMICAL$ and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, @CHEMICAL$ and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, @CHEMICAL$ and GR 32191 for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, @CHEMICAL$ and GR 32191 for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and @CHEMICAL$ for TP.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and @CHEMICAL$ for TP.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and @CHEMICAL$ for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and @CHEMICAL$ for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and @CHEMICAL$ for TP.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and @CHEMICAL$ for @GENE$.	0
The @GENE$, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @CHEMICAL$.	0
The DP, @GENE$ and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @CHEMICAL$.	0
The DP, IP and @GENE$ showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @CHEMICAL$.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for @GENE$, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @CHEMICAL$.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for @GENE$, and S-145, I-BOP and GR 32191 for @CHEMICAL$.	0
The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for @CHEM-GENE$.	0
The @CHEM-GENE$ bound PGF2 alpha and fluprostenol with Ki values of 3-4 nM.	0
The @GENE$ bound @CHEMICAL$ alpha and fluprostenol with Ki values of 3-4 nM.	0
The @GENE$ bound PGF2 alpha and @CHEMICAL$ with Ki values of 3-4 nM.	0
The @GENE$ receptor bound @CHEMICAL$, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.	0
The @GENE$ receptor bound 17-phenyl-PGE2, @CHEMICAL$ and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.	0
The @GENE$ receptor bound 17-phenyl-PGE2, sulprostone and @CHEMICAL$ in addition to PGE2 and PGE1, with Ki values of 14-36 nM.	0
The @GENE$ receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to @CHEMICAL$ and PGE1, with Ki values of 14-36 nM.	0
The @GENE$ receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and @CHEMICAL$, with Ki values of 14-36 nM.	0
@CHEMICAL$ and two putative @GENE$ antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor.	0
16,16-dimethyl-PGE2 and two putative @GENE$ antagonists, @CHEMICAL$ and SC-19220, did not show any significant binding to this receptor.	4
16,16-dimethyl-PGE2 and two putative @GENE$ antagonists, AH6809 and @CHEMICAL$, did not show any significant binding to this receptor.	4
@CHEMICAL$, a putative @GENE$ agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.	3
@CHEMICAL$, a putative EP3 agonist, and misoprostol, a putative @GENE$/EP3 agonist, also bound to this receptor with Ki values of 120 nM.	0
@CHEMICAL$, a putative EP3 agonist, and misoprostol, a putative EP2/@GENE$ agonist, also bound to this receptor with Ki values of 120 nM.	0
M&B-28767, a putative @GENE$ agonist, and @CHEMICAL$, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.	0
M&B-28767, a putative EP3 agonist, and @CHEMICAL$, a putative @GENE$/EP3 agonist, also bound to this receptor with Ki values of 120 nM.	3
M&B-28767, a putative EP3 agonist, and @CHEMICAL$, a putative EP2/@GENE$ agonist, also bound to this receptor with Ki values of 120 nM.	3
The two receptors were discriminated by @CHEMICAL$, AH-13205 and AH-6809 that bound to the @GENE$ receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by @CHEMICAL$, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the @GENE$ receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by @CHEMICAL$, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the @GENE$ but not to the EP2 receptor.	0
The two receptors were discriminated by @CHEMICAL$, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the @GENE$ receptor.	0
The two receptors were discriminated by butaprost, @CHEMICAL$ and AH-6809 that bound to the @GENE$ receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, @CHEMICAL$ and AH-6809 that bound to the EP2 receptor but not to the @GENE$ receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, @CHEMICAL$ and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the @GENE$ but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, @CHEMICAL$ and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the @GENE$ receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and @CHEMICAL$ that bound to the @GENE$ receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and @CHEMICAL$ that bound to the EP2 receptor but not to the @GENE$ receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and @CHEMICAL$ that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the @GENE$ but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and @CHEMICAL$ that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the @GENE$ receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the @GENE$ receptor but not to the EP4 receptor, and by @CHEMICAL$ that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the @GENE$ receptor, and by @CHEMICAL$ that bound to the EP4 but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by @CHEMICAL$ that bound to the @GENE$ but not to the EP2 receptor.	0
The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by @CHEMICAL$ that bound to the EP4 but not to the @GENE$ receptor.	0
The @GENE$ receptor showed the broadest binding profile, and bound @CHEMICAL$, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, @CHEMICAL$, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, @CHEMICAL$, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, @CHEMICAL$, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, @CHEMICAL$ and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and @CHEMICAL$, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to @CHEMICAL$ and PGE1, with Ki values of 0.6-3.7 nM.	0
The @GENE$ receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and @CHEMICAL$, with Ki values of 0.6-3.7 nM.	0
In addition, three @CHEM-GENE$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three @CHEMICAL$ ligands, iloprost, carbacyclin and isocarbacyclin, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three @CHEMICAL$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three @CHEMICAL$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, @CHEMICAL$, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, @CHEMICAL$, carbacyclin and isocarbacyclin, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, @CHEMICAL$, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, @CHEMICAL$, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, @CHEMICAL$ and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, @CHEMICAL$ and isocarbacyclin, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, @CHEMICAL$ and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, @CHEMICAL$ and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, carbacyclin and @CHEMICAL$, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and @CHEMICAL$, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and @CHEMICAL$, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and @CHEMICAL$, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, carbacyclin and isocarbacyclin, and one @CHEMICAL$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @CHEM-GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @CHEMICAL$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @CHEMICAL$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, @CHEMICAL$, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @GENE$ ligand, @CHEMICAL$, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, @CHEMICAL$, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, @CHEMICAL$, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @CHEMICAL$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @CHEMICAL$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @CHEM-GENE$ and TP receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @CHEMICAL$ and @GENE$, respectively.	0
In addition, three @GENE$ ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @CHEMICAL$ receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one @GENE$ ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @CHEMICAL$ receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the @GENE$ and @CHEMICAL$ receptors, respectively.	0
In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and @CHEM-GENE$, respectively.	0
8-Epi-PGF2 alpha showed only weak binding to the @CHEMICAL$, TP, FP, EP2 and @GENE$ receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @CHEM-GENE$, TP, FP, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @CHEMICAL$, @GENE$, FP, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @CHEMICAL$, TP, @GENE$, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @CHEMICAL$, TP, FP, @GENE$ and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, @CHEMICAL$, FP, EP2 and @GENE$ receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @GENE$, @CHEMICAL$, FP, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, @CHEM-GENE$, FP, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, @CHEMICAL$, @GENE$, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, @CHEMICAL$, FP, @GENE$ and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, TP, @CHEMICAL$, EP2 and @GENE$ receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the @GENE$, TP, @CHEMICAL$, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, @GENE$, @CHEMICAL$, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, TP, @CHEM-GENE$, EP2 and EP3 receptor at 10 microM concentration.	0
8-Epi-PGF2 alpha showed only weak binding to the IP, TP, @CHEMICAL$, @GENE$ and EP3 receptor at 10 microM concentration.	0
The structures of @CHEM-GENE$ from herpes simplex virus type 1 in complex with substrates and a substrate analogue.	0
@CHEM-GENE$ from Herpes simplex virus type 1 (TK) was crystallized in an N-terminally truncated but fully active form.	0
@CHEMICAL$ kinase from Herpes simplex virus type 1 (@GENE$) was crystallized in an N-terminally truncated but fully active form.	0
@GENE$ from Herpes simplex virus type 1 (TK) was crystallized in an @CHEMICAL$-terminally truncated but fully active form.	0
Thymidine kinase from Herpes simplex virus type 1 (@GENE$) was crystallized in an @CHEMICAL$-terminally truncated but fully active form.	0
The structures of @GENE$ complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (@CHEMICAL$), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or @CHEMICAL$ (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (@CHEMICAL$) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with @CHEMICAL$ at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the @CHEMICAL$-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the ATP-site and @CHEMICAL$ (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (@CHEMICAL$), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
The structures of @GENE$ complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), @CHEMICAL$ (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.	0
@CHEM-GENE$ catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride.	0
@GENE$ catalyzes the phosphorylation of @CHEMICAL$ resulting in an ester, and the phosphorylation of dTMP giving rise to an anhydride.	0
@GENE$ catalyzes the phosphorylation of dT resulting in an @CHEMICAL$, and the phosphorylation of dTMP giving rise to an anhydride.	0
@GENE$ catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of @CHEMICAL$ giving rise to an anhydride.	0
@GENE$ catalyzes the phosphorylation of dT resulting in an ester, and the phosphorylation of dTMP giving rise to an @CHEMICAL$.	0
The presented @CHEM-GENE$ structures indicate that there are only small differences between these two modes of action.	0
Cavity and water molecules reduce the substrate specificity to such an extent that @CHEM-GENE$ can phosphorylate various substrate analogues useful in pharmaceutical applications.	0
Cavity and water molecules reduce the substrate specificity to such an extent that @GENE$ can @CHEMICAL$ various substrate analogues useful in pharmaceutical applications.	0
@CHEM-GENE$ is structurally homologous to the well-known nucleoside monophosphate kinases but contains large additional peptide segments.	0
@CHEMICAL$ is structurally homologous to the well-known @GENE$ but contains large additional peptide segments.	0
@GENE$ is structurally homologous to the well-known @CHEMICAL$ kinases but contains large additional peptide segments.	0
TK is structurally homologous to the well-known @CHEM-GENE$ but contains large additional peptide segments.	0
Blockage of the @CHEM-GENE$ by the gastrointestinal prokinetic agent cisapride.	0
Blockage of the @GENE$ by the gastrointestinal prokinetic agent @CHEMICAL$.	2
The @GENE$ (HERG), which encodes the rapidly activating delayed rectifier @CHEMICAL$ current and is important in cardiac repolarization, may serve as a target for the action of cisapride.	0
The human ether-a-go-go-related gene (@GENE$), which encodes the rapidly activating delayed rectifier @CHEMICAL$ current and is important in cardiac repolarization, may serve as a target for the action of cisapride.	0
The @GENE$ (HERG), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of @CHEMICAL$.	0
The human ether-a-go-go-related gene (@GENE$), which encodes the rapidly activating delayed rectifier K+ current and is important in cardiac repolarization, may serve as a target for the action of @CHEMICAL$.	0
We tested the hypothesis that @CHEMICAL$ blocks @GENE$.	2
Under voltage-clamp conditions, @CHEMICAL$ block of @GENE$ is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).	2
Block of @GENE$ with @CHEMICAL$ after channel activation was voltage dependent.	2
At -20 mV, 10 nM @CHEMICAL$ reduced @GENE$ tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).	2
We conclude that @CHEMICAL$ is a potent blocker of @GENE$ channels expressed in HEK293 cells.	2
Analysis of @CHEM-GENE$ in the human spinal cord.	0
@CHEM-GENE$ in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies.	0
@CHEMICAL$ receptors in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with @GENE$ subunit-specific antibodies.	0
@GENE$ in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with @CHEMICAL$ receptor subunit-specific antibodies.	0
NMDA receptors in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with @CHEM-GENE$ subunit-specific antibodies.	0
@GENE$ in postmortem human spinal cord were analyzed using @CHEMICAL$ ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies.	0
NMDA receptors in postmortem human spinal cord were analyzed using @CHEMICAL$ ligand binding and immunoblotting with @GENE$ subunit-specific antibodies.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEM-GENE$ showed that NR1, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEMICAL$ receptors showed that @GENE$, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEMICAL$ receptors showed that NR1, @GENE$, NR2C, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEMICAL$ receptors showed that NR1, NR2A, @GENE$, and NR2D subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEMICAL$ receptors showed that NR1, NR2A, NR2C, and @GENE$ subunits could all be found in the human spinal cord of which NR1 was preferentially located to the dorsal half.	0
None of these parameters were affected by postmortem intervals up to 72 h. Immunoblotting of native @CHEMICAL$ receptors showed that NR1, NR2A, NR2C, and NR2D subunits could all be found in the human spinal cord of which @GENE$ was preferentially located to the dorsal half.	0
Immunoprecipitation of solubilized receptors revealed that @GENE$, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @CHEMICAL$ receptors are heteroligimeric receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, @GENE$, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @CHEMICAL$ receptors are heteroligimeric receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and @GENE$ subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @CHEMICAL$ receptors are heteroligimeric receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the @GENE$ subunit, indicating that native human spinal cord @CHEMICAL$ receptors are heteroligimeric receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @CHEM-GENE$ are heteroligimeric receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @CHEMICAL$ receptors are @GENE$ assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that @GENE$, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord NMDA receptors are @CHEMICAL$ receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, @GENE$, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord NMDA receptors are @CHEMICAL$ receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and @GENE$ subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord NMDA receptors are @CHEMICAL$ receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the @GENE$ subunit, indicating that native human spinal cord NMDA receptors are @CHEMICAL$ receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord @GENE$ are @CHEMICAL$ receptors assembled by at least three different receptor subunits.	0
Immunoprecipitation of solubilized receptors revealed that NR1, NR2C, and NR2D subunits coprecipitated with the NR2A subunit, indicating that native human spinal cord NMDA receptors are @CHEM-GENE$ assembled by at least three different receptor subunits.	0
These results provide a basis for the development of drugs selectively aimed at spinal cord @CHEM-GENE$ for the future treatment of spinal cord disorders.	0
@CHEM-GENE$ and sodium channel mechanisms in the rapid pressor response to cocaine.	0
@CHEMICAL$ transporter and @GENE$ mechanisms in the rapid pressor response to cocaine.	0
@GENE$ and @CHEMICAL$ channel mechanisms in the rapid pressor response to cocaine.	0
Monoamine transporter and @CHEM-GENE$ mechanisms in the rapid pressor response to cocaine.	0
@GENE$ and sodium channel mechanisms in the rapid pressor response to @CHEMICAL$.	0
Monoamine transporter and @GENE$ mechanisms in the rapid pressor response to @CHEMICAL$.	0
cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the @CHEM-GENE$ antagonist, SCH 23390.	0
cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the @GENE$ antagonist, @CHEMICAL$.	4
@CHEMICAL$ (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the @GENE$ antagonist, SCH 23390.	0
@CHEMICAL$ uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to @CHEMICAL$ (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (@CHEMICAL$, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, @CHEMICAL$, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, @CHEMICAL$, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, @CHEMICAL$, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, @CHEMICAL$, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, @CHEMICAL$, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and @CHEMICAL$) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @CHEM-GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	0
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (@CHEMICAL$, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	2
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, @CHEMICAL$, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	2
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, @CHEMICAL$, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	2
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, @CHEMICAL$, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	2
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, @CHEMICAL$, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.	2
Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse @GENE$ selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and @CHEMICAL$) either did not produce a rapid pressor response or produced only a small pressor response.	2
At nonconvulsant doses, the @CHEM-GENE$ blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.	0
At nonconvulsant doses, the @GENE$ blockers @CHEMICAL$, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, @CHEMICAL$, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, dibucaine, @CHEMICAL$, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, dibucaine, dyclonine, @CHEMICAL$, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, @CHEMICAL$, quinidine, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, @CHEMICAL$, and tetracaine produced a small pressor response or no increase in BP.	2
At nonconvulsant doses, the @GENE$ blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and @CHEMICAL$ produced a small pressor response or no increase in BP.	2
The present data suggest that the inhibition of @CHEM-GENE$ functions, either alone or in combination, does not mediate the rapid pressor response to cocaine.	0
The present data suggest that the inhibition of @CHEM-GENE$ functions, either alone or in combination, does not mediate the rapid pressor response to cocaine.	0
The present data suggest that the inhibition of @CHEM-GENE$ functions, either alone or in combination, does not mediate the rapid pressor response to cocaine.	0
The present data suggest that the inhibition of @GENE$ functions, either alone or in combination, does not mediate the rapid pressor response to @CHEMICAL$.	0
The @GENE$-blocking action of cocaine per se does not appear to be involved in the rapid pressor response to @CHEMICAL$.	0
The @CHEM-GENE$-blocking action of cocaine per se does not appear to be involved in the rapid pressor response to cocaine.	0
The @GENE$-blocking action of @CHEMICAL$ per se does not appear to be involved in the rapid pressor response to cocaine.	2
Identification of cDNAs encoding two human alpha class @CHEMICAL$ transferases (GSTA3 and GSTA4) and the heterologous expression of @GENE$.	0
Identification of cDNAs encoding two @CHEM-GENE$ (GSTA3 and GSTA4) and the heterologous expression of GSTA4-4.	0
Identification of cDNAs encoding two human alpha class @CHEMICAL$ transferases (@GENE$ and GSTA4) and the heterologous expression of GSTA4-4.	0
Identification of cDNAs encoding two human alpha class @CHEMICAL$ transferases (GSTA3 and @GENE$) and the heterologous expression of GSTA4-4.	0
The Expressed Sequence Tag database has been searched for examples of previously undescribed @CHEM-GENE$.	0
Characterization of binding sites of a new @CHEM-GENE$ antagonist, [3H]SR 142948A, in the rat brain.	0
Characterization of binding sites of a new @GENE$ antagonist, @CHEMICAL$, in the rat brain.	4
The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of @GENE$, @CHEMICAL$ (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.	4
The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of @GENE$, [3H]SR 142948A (@CHEMICAL$), in the rat brain.	4
The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of @CHEM-GENE$, [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.	0
@CHEMICAL$ binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and @GENE$.	0
[3H]SR 142948A binding was inhibited by @CHEMICAL$, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and @GENE$.	0
[3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, @CHEMICAL$ (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and @GENE$.	0
[3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (@CHEMICAL$) and @GENE$.	0
[3H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole -3-carbonyl]amino]-adamantane-2-carboxylic acid) and @CHEM-GENE$.	0
Saturation and competition studies in the presence or absence of the @CHEM-GENE$ antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @CHEMICAL$ H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @GENE$ (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @CHEMICAL$ H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @GENE$ antagonist, @CHEMICAL$, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	4
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, @CHEMICAL$, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @GENE$ (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, @CHEMICAL$, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @GENE$ antagonist, levocabastine, revealed that @CHEMICAL$ bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that @CHEMICAL$ bound with similar affinities to both the levocabastine-insensitive @GENE$ (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that @CHEMICAL$ bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @GENE$ antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the @CHEMICAL$-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the @CHEMICAL$-insensitive @GENE$ (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the @CHEMICAL$-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @GENE$ antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @CHEMICAL$ NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @CHEM-GENE$ (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @CHEMICAL$ NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the @GENE$ antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned @CHEMICAL$-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive @GENE$ (20% of the total binding population) and the recently cloned @CHEMICAL$-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned @CHEMICAL$-sensitive @GENE$ (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).	0
In conclusion, these findings indicate that @CHEMICAL$ is a new potent antagonist radioligand which recognizes with high affinity both @GENE$ and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.	4
In conclusion, these findings indicate that @CHEMICAL$ is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and @GENE$ and represents thus an excellent tool to study neurotensin receptors in the rat brain.	4
In conclusion, these findings indicate that @CHEMICAL$ is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study @GENE$ in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both @CHEM-GENE$ and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both @CHEMICAL$ NT1 and @GENE$ and represents thus an excellent tool to study neurotensin receptors in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both @CHEMICAL$ NT1 and NT2 receptors and represents thus an excellent tool to study @GENE$ in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both @GENE$ and NT2 receptors and represents thus an excellent tool to study @CHEMICAL$ receptors in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and @GENE$ and represents thus an excellent tool to study @CHEMICAL$ receptors in the rat brain.	0
In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study @CHEM-GENE$ in the rat brain.	0
The @CHEMICAL$ action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors @GENE$ and RAR gamma.	0
The @CHEMICAL$ action of adapalene are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and @GENE$.	0
The @CHEMICAL$ action of adapalene are mediated by the @GENE$ retinoic acid receptors RAR beta and RAR gamma.	0
The @CHEMICAL$ action of adapalene are mediated by the ligand-activated gene transcription factors @GENE$ RAR beta and RAR gamma.	0
The retinoid action of @CHEMICAL$ are mediated by the ligand-activated gene transcription factors retinoic acid receptors @GENE$ and RAR gamma.	0
The retinoid action of @CHEMICAL$ are mediated by the ligand-activated gene transcription factors retinoic acid receptors RAR beta and @GENE$.	0
The retinoid action of @CHEMICAL$ are mediated by the @GENE$ retinoic acid receptors RAR beta and RAR gamma.	0
The retinoid action of @CHEMICAL$ are mediated by the ligand-activated gene transcription factors @GENE$ RAR beta and RAR gamma.	0
The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors @CHEMICAL$ receptors @GENE$ and RAR gamma.	0
The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors @CHEMICAL$ receptors RAR beta and @GENE$.	0
The retinoid action of adapalene are mediated by the @GENE$ @CHEMICAL$ receptors RAR beta and RAR gamma.	0
The retinoid action of adapalene are mediated by the ligand-activated gene transcription factors @CHEM-GENE$ RAR beta and RAR gamma.	0
Isoform-specific inhibition of @CHEM-GENE$ by dihydropyridines is independent of isoform-specific gating properties.	0
Isoform-specific inhibition of @GENE$ by @CHEMICAL$ is independent of isoform-specific gating properties.	2
@CHEMICAL$ (DHPs) block @GENE$ more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.	2
Dihydropyridines (@CHEMICAL$) block @GENE$ more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.	2
Dihydropyridines (DHPs) block @CHEM-GENE$ more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.	0
@CHEMICAL$ (a DHP antagonist) blocks the @GENE$ more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.	2
Nisoldipine (a @CHEMICAL$ antagonist) blocks the @GENE$ more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.	2
We expressed cardiac or @GENE$ subunits in combination with beta2a and alpha2/delta subunits in human embryonic kidney cells, and used 2 mM @CHEMICAL$ as the permeant ion.	0
We thus conclude that the more potent @CHEMICAL$ inhibition of smooth muscle versus @GENE$ is not attributable to differences in channel inactivation or activation.	2
We thus conclude that the more potent nisoldipine inhibition of smooth muscle versus @CHEM-GENE$ is not attributable to differences in channel inactivation or activation.	0
Intrinsic, gating-independent @CHEM-GENE$ binding affinity differences must be invoked to explain the isoform-specific sensitivity of the DHP block.	0
Intrinsic, gating-independent @GENE$ binding affinity differences must be invoked to explain the isoform-specific sensitivity of the @CHEMICAL$ block.	0
@CHEM-GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@CHEMICAL$ reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs @CHEMICAL$ synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	5
Methylenetetrahydrofolate reductase deficiency impairs @CHEMICAL$ synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of @CHEMICAL$ (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	0
Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of @CHEMICAL$ (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both @CHEMICAL$- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	0
Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both @CHEMICAL$- and adenosyl cobalamin and deficiencies of @GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and @CHEMICAL$ and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	0
Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and @CHEMICAL$ and deficiencies of @GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @CHEMICAL$ synthase (CblE/G) are associated with defective methyl cobalamin synthesis.	0
Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @CHEM-GENE$ (CblE/G) are associated with defective methyl cobalamin synthesis.	0
@GENE$ deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective @CHEMICAL$ synthesis.	0
Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of @GENE$ (CblE/G) are associated with defective @CHEMICAL$ synthesis.	5
Increased @GENE$-mediated cationic @CHEMICAL$ transport functionally compensates in Cat1 knockout cell lines.	5
Increased Cat3-mediated cationic @CHEMICAL$ transport functionally compensates in @GENE$ knockout cell lines.	0
The majority of @CHEMICAL$ transport is mediated by @GENE$, although several other carriers have been kinetically defined.	5
@GENE$ cationic @CHEMICAL$ transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.	5
System y+ cationic @CHEMICAL$ transport is mediated by proteins encoded by a family of genes, @GENE$, Cat2, and Cat3.	5
System y+ cationic @CHEMICAL$ transport is mediated by proteins encoded by a family of genes, Cat1, @GENE$, and Cat3.	5
System y+ cationic @CHEMICAL$ transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and @GENE$.	5
High affinity @CHEMICAL$ transport was investigated in embryonic fibroblast cells derived from @GENE$ knockout mice that lack functional Cat1.	0
High affinity @CHEMICAL$ transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional @GENE$.	0
However, the apparent affinity for @CHEMICAL$ transport was 2.4 times lower in @GENE$(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport.	0
However, the apparent affinity for @CHEMICAL$ transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of @GENE$-mediated transport.	5
These results suggest that @GENE$ compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity @CHEMICAL$ transport.	5
These results suggest that Cat3 compensates for the loss of functional @GENE$ in cells derived from Cat1 knockout mice and mediates the majority of high affinity @CHEMICAL$ transport.	0
These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from @GENE$ knockout mice and mediates the majority of high affinity @CHEMICAL$ transport.	0
Effect of @CHEMICAL$, a new @GENE$ antagonist, on gastric emptying of a solid-liquid meal in humans.	4
We studied the role of endogenous @GENE$ in the emptying of a solid/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist @CHEMICAL$.	0
We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent @GENE$ antagonist @CHEMICAL$.	4
@CHEMICAL$ markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial @GENE$ levels (P<0.01) as compared to placebo.	2
@CHEMICAL$ markedly increased postprandial plasma @GENE$ release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.	1
The study demonstrates for the first time the marked gastrokinetic properties of the new @GENE$ antagonist @CHEMICAL$ in humans.	4
@GENE$ (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	0
Concanavalin A (@GENE$)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	0
Concanavalin A (Con A)-induced @GENE$, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	2
Concanavalin A (Con A)-induced IFN-gamma, @GENE$, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	2
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and @GENE$ mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	2
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective @GENE$ agonist @CHEMICAL$ and by the selective beta2AR agonist fenoterol.	3
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist @CHEMICAL$ and by the selective @GENE$ agonist fenoterol.	0
@GENE$ (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	0
Concanavalin A (@GENE$)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	0
Concanavalin A (Con A)-induced @GENE$, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	2
Concanavalin A (Con A)-induced IFN-gamma, @GENE$, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	2
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and @GENE$ mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	2
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective @GENE$ agonist isoproterenol and by the selective beta2AR agonist @CHEMICAL$.	0
Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective @GENE$ agonist @CHEMICAL$.	3
The observed inhibition on @GENE$, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist @CHEMICAL$ (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, @GENE$, and IL-3 mRNA was blocked by the selective beta2AR antagonist @CHEMICAL$ (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, GM-CSF, and @GENE$ mRNA was blocked by the selective beta2AR antagonist @CHEMICAL$ (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective @GENE$ antagonist @CHEMICAL$ (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.	4
The observed inhibition on @GENE$, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by @CHEMICAL$ (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, @GENE$, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by @CHEMICAL$ (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, GM-CSF, and @GENE$ mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by @CHEMICAL$ (10(-6) M), a nonselective antagonist.	1
The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective @GENE$ antagonist ICI 118,551 (10(-6) M) and by @CHEMICAL$ (10(-6) M), a nonselective antagonist.	4
The selective @GENE$ antagonist @CHEMICAL$ (0.3 x 10(-6) M) did not have any effect.	4
Secretion of @GENE$ protein in the presence of increasing concentrations of @CHEMICAL$ followed a similar pattern as observed for GM-CSF mRNA.	1
Secretion of GM-CSF protein in the presence of increasing concentrations of @CHEMICAL$ followed a similar pattern as observed for @GENE$ mRNA.	1
In addition, the @GENE$-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular @CHEMICAL$ (cAMP) levels.	0
In addition, the betaAR-mediated inhibition of @GENE$, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular @CHEMICAL$ (cAMP) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, @GENE$, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular @CHEMICAL$ (cAMP) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and @GENE$ mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular @CHEMICAL$ (cAMP) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and @GENE$ protein secretion were related to the accumulation of intracellular @CHEMICAL$ (cAMP) levels.	0
In addition, the @GENE$-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (@CHEMICAL$) levels.	0
In addition, the betaAR-mediated inhibition of @GENE$, GM-CSF, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (@CHEMICAL$) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, @GENE$, and IL-3 mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (@CHEMICAL$) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and @GENE$ mRNA accumulation and GM-CSF protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (@CHEMICAL$) levels.	0
In addition, the betaAR-mediated inhibition of IFN-gamma, GM-CSF, and IL-3 mRNA accumulation and @GENE$ protein secretion were related to the accumulation of intracellular cyclic adenosine monophosphate (@CHEMICAL$) levels.	0
Although @GENE$ mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist @CHEMICAL$ had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.	0
Although beta3AR mRNA was detectable in @GENE$-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist @CHEMICAL$ had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.	0
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of @GENE$ expression: the beta3AR agonist @CHEMICAL$ had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.	0
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the @GENE$ agonist @CHEMICAL$ had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.	3
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist @CHEMICAL$ had no effect on the accumulation of the studied @GENE$ mRNAs, and did not significantly affect cellular cAMP levels.	0
Although @GENE$ mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular @CHEMICAL$ levels.	0
Although beta3AR mRNA was detectable in @GENE$-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular @CHEMICAL$ levels.	0
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of @GENE$ expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular @CHEMICAL$ levels.	0
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the @GENE$ agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular @CHEMICAL$ levels.	0
Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied @GENE$ mRNAs, and did not significantly affect cellular @CHEMICAL$ levels.	0
@CHEM-GENE$ binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.	0
@GENE$ binding and uterotonic activity of @CHEMICAL$ and its metabolites following enzymatic degradation.	0
Metabolites of the analogue @CHEM-GENE$ (carbetocin) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.	0
Metabolites of the analogue 1-deamino-1-carba-2-tyrosine(O-methyl)-@GENE$ (@CHEMICAL$) following incubation with a rat kidney homogenate were isolated and their pharmacodynamic properties investigated.	0
Both @CHEMICAL$, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial @GENE$ of a similar magnitude as oxytocin.	0
Both @CHEMICAL$, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as @GENE$.	0
Both carbetocin, @CHEMICAL$ metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial @GENE$ of a similar magnitude as oxytocin.	0
Both carbetocin, @CHEMICAL$ metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as @GENE$.	0
Both carbetocin, carbetocin metabolite I and @CHEMICAL$ metabolite II displayed binding affinities to the myometrial @GENE$ of a similar magnitude as oxytocin.	0
Both carbetocin, carbetocin metabolite I and @CHEMICAL$ metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as @GENE$.	0
Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial @CHEM-GENE$ of a similar magnitude as oxytocin.	0
Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial @CHEMICAL$ receptor of a similar magnitude as @GENE$.	0
Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial @GENE$ of a similar magnitude as @CHEMICAL$.	0
Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as @CHEM-GENE$.	0
@CHEMICAL$ was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for @GENE$.	0
Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of @CHEMICAL$, as is the case for @GENE$.	0
Carbetocin was found to have agonistic properties on isolated myometrial strips and it was found to exert this effect through generation of inositol phosphates, as is the case for @CHEM-GENE$.	0
However, maximal contractile effect of @CHEMICAL$ was approximately 50% lower than that of @GENE$ (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM).	0
However, maximal contractile effect of carbetocin was approximately 50% lower than that of @CHEM-GENE$ (2.70 +/- 0.12 g compared to 5.22 +/- 0.26 g) and EC50 was approximately ten times higher (48.0 +/- 8.20 nM compared to 5.62 +/- 1.22 nM).	0
All three compounds displayed antagonistic properties against @CHEM-GENE$ in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).	0
All three compounds displayed antagonistic properties against @GENE$ in vitro, with @CHEMICAL$ being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).	2
All three compounds displayed antagonistic properties against @GENE$ in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and @CHEMICAL$ metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).	2
All three compounds displayed antagonistic properties against @GENE$ in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than @CHEMICAL$ metabolite I (pA2 = 7.81).	2
These results indicate that @CHEMICAL$ is a partial agonist/antagonist to the @GENE$ while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.	4
These results indicate that carbetocin is a partial agonist/antagonist to the @CHEM-GENE$ while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.	0
These results indicate that carbetocin is a partial agonist/antagonist to the @GENE$ while the two metabolites @CHEMICAL$ metabolite I and carbetocin metabolite II are pure antagonists.	4
These results indicate that carbetocin is a partial agonist/antagonist to the @GENE$ while the two metabolites carbetocin metabolite I and @CHEMICAL$ metabolite II are pure antagonists.	4
All three analogues bound to the myometrial @CHEM-GENE$, albeit with much lower affinities than to the oxytocin receptor.	0
All three analogues bound to the myometrial @CHEMICAL$ V1 receptor, albeit with much lower affinities than to the @GENE$.	0
All three analogues bound to the myometrial @GENE$, albeit with much lower affinities than to the @CHEMICAL$ receptor.	0
All three analogues bound to the myometrial vasopressin V1 receptor, albeit with much lower affinities than to the @CHEM-GENE$.	0
Only @CHEMICAL$ bound to the renal @GENE$ though the binding affinity was very low (61.3 +/- 14.6 nM).	0
Only carbetocin bound to the renal @CHEM-GENE$ though the binding affinity was very low (61.3 +/- 14.6 nM).	0
Crystallographic analysis of the @CHEM-GENE$ with bound catechol inhibitors at 2.0 A resolution.	0
Crystallographic analysis of the @GENE$ with bound @CHEMICAL$ inhibitors at 2.0 A resolution.	2
The @CHEM-GENE$ represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by catechol derivatives.	0
The @GENE$ represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by @CHEMICAL$ derivatives.	2
Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of @CHEM-GENE$ (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A.	0
Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human @CHEMICAL$ hydroxylase (@GENE$), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A.	0
Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of @GENE$ (hPheOH), cocrystallized with various potent and well-known @CHEMICAL$ inhibitors and refined at a resolution of 2.0 A.	2
Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (@GENE$), cocrystallized with various potent and well-known @CHEMICAL$ inhibitors and refined at a resolution of 2.0 A.	2
Crystallographic comparison with the structurally related @CHEM-GENE$ binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.	0
Crystallographic comparison with the structurally related @GENE$ binary complex with the oxidized cofactor @CHEMICAL$ revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.	0
Crystallographic comparison with the structurally related @GENE$ binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the @CHEMICAL$ and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4.	0
Crystallographic comparison with the structurally related @GENE$ binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the @CHEMICAL$ versus BH4.	2
All GCs including the antagonistic compound @CHEMICAL$ efficiently reduced @GENE$-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression.	2
All GCs including the antagonistic compound @CHEMICAL$ efficiently reduced NF-kappaB-mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the @GENE$ is sufficient for transrepression.	0
Cooperative binding of @CHEMICAL$ and MgADP in the @GENE$ is modulated by glibenclamide.	0
Cooperative binding of ATP and @CHEMICAL$ in the @GENE$ is modulated by glibenclamide.	0
Cooperative binding of ATP and MgADP in the @CHEM-GENE$ is modulated by glibenclamide.	0
Cooperative binding of ATP and MgADP in the @GENE$ is modulated by @CHEMICAL$.	0
The ATP-sensitive @CHEMICAL$ (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced @GENE$ secretion.	0
The @CHEM-GENE$ in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion.	0
The @CHEMICAL$-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose-induced @GENE$ secretion.	0
The @CHEM-GENE$ in pancreatic beta cells are critical in the regulation of glucose-induced insulin secretion.	0
The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of @CHEMICAL$-induced @GENE$ secretion.	1
The @GENE$ in pancreatic beta cells are critical in the regulation of @CHEMICAL$-induced insulin secretion.	0
Although electrophysiological studies provide clues to the complex control of @GENE$ by @CHEMICAL$, MgADP, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear.	0
Although electrophysiological studies provide clues to the complex control of KATP channels by @CHEMICAL$, MgADP, and pharmacological agents, the molecular mechanism of @GENE$ regulation remains unclear.	0
Although electrophysiological studies provide clues to the complex control of @GENE$ by ATP, @CHEMICAL$, and pharmacological agents, the molecular mechanism of KATP-channel regulation remains unclear.	0
Although electrophysiological studies provide clues to the complex control of KATP channels by ATP, @CHEMICAL$, and pharmacological agents, the molecular mechanism of @GENE$ regulation remains unclear.	0
The @GENE$ is a heterooligomeric complex of SUR1 subunits of the @CHEMICAL$-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of @GENE$ subunits of the @CHEMICAL$-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the @CHEMICAL$-binding-cassette superfamily with two @GENE$ (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the @CHEMICAL$-binding-cassette superfamily with two nucleotide-binding folds (@GENE$ and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the @CHEMICAL$-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and @GENE$) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the @CHEMICAL$-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and NBF2) and the pore-forming @GENE$ subunits.	0
The @GENE$ is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two @CHEMICAL$-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of @GENE$ subunits of the ATP-binding-cassette superfamily with two @CHEMICAL$-binding folds (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two @CHEM-GENE$ (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two @CHEMICAL$-binding folds (@GENE$ and NBF2) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two @CHEMICAL$-binding folds (NBF1 and @GENE$) and the pore-forming Kir6.2 subunits.	0
The KATP channel is a heterooligomeric complex of SUR1 subunits of the ATP-binding-cassette superfamily with two @CHEMICAL$-binding folds (NBF1 and NBF2) and the pore-forming @GENE$ subunits.	0
Here, we report that @CHEMICAL$ and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to @GENE$.	0
Here, we report that MgATP and @CHEMICAL$, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to @GENE$.	0
Here, we report that MgATP and MgADP, but not the @CHEMICAL$ salt of gamma-thio-ATP, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to @GENE$.	0
Here, we report that MgATP and MgADP, but not the Mg salt of @CHEMICAL$, stabilize the binding of prebound 8-azido-[alpha-32P]ATP to @GENE$.	0
Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound @CHEMICAL$ to @GENE$.	0
Mutation in the @GENE$ of NBF2 of SUR1 abolished this stabilizing effect of @CHEMICAL$.	0
Mutation in the Walker A and B motifs of @GENE$ of SUR1 abolished this stabilizing effect of @CHEMICAL$.	0
Mutation in the Walker A and B motifs of NBF2 of @GENE$ abolished this stabilizing effect of @CHEMICAL$.	0
These results suggest that @GENE$ binds @CHEMICAL$ strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds @CHEMICAL$ strongly at @GENE$ and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds @CHEMICAL$ strongly at NBF1 and that MgADP, either by direct binding to @GENE$ or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds @CHEMICAL$ strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at @GENE$, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds @CHEMICAL$ strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at @GENE$.	0
These results suggest that @GENE$ binds 8-azido-ATP strongly at NBF1 and that @CHEMICAL$, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at @GENE$ and that @CHEMICAL$, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that @CHEMICAL$, either by direct binding to @GENE$ or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that @CHEMICAL$, either by direct binding to NBF2 or by hydrolysis of bound MgATP at @GENE$, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that @CHEMICAL$, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at @GENE$.	0
These results suggest that @GENE$ binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound @CHEMICAL$ at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at @GENE$ and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound @CHEMICAL$ at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to @GENE$ or by hydrolysis of bound @CHEMICAL$ at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound @CHEMICAL$ at @GENE$, stabilizes prebound 8-azido-ATP binding at NBF1.	5
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound @CHEMICAL$ at NBF2, stabilizes prebound 8-azido-ATP binding at @GENE$.	0
These results suggest that @GENE$ binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound @CHEMICAL$ binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at @GENE$ and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound @CHEMICAL$ binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to @GENE$ or by hydrolysis of bound MgATP at NBF2, stabilizes prebound @CHEMICAL$ binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at @GENE$, stabilizes prebound @CHEMICAL$ binding at NBF1.	0
These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound @CHEMICAL$ binding at @GENE$.	0
The @CHEMICAL$ caused release of prebound 8-azido-[alpha-32P]ATP from @GENE$ in the presence of MgADP or MgATP in a concentration-dependent manner.	0
The sulfonylurea glibenclamide caused release of prebound @CHEMICAL$ from @GENE$ in the presence of MgADP or MgATP in a concentration-dependent manner.	0
The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from @GENE$ in the presence of @CHEMICAL$ or MgATP in a concentration-dependent manner.	0
The sulfonylurea glibenclamide caused release of prebound 8-azido-[alpha-32P]ATP from @GENE$ in the presence of MgADP or @CHEMICAL$ in a concentration-dependent manner.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two @GENE$ of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes @CHEMICAL$ to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of @GENE$ suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes @CHEMICAL$ to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at @GENE$, causes @CHEMICAL$ to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes @CHEMICAL$ to be released from @GENE$.	0
This direct biochemical evidence of cooperative interaction in @CHEMICAL$ binding of the two @GENE$ of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in @CHEMICAL$ binding of the two NBFs of @GENE$ suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in @CHEMICAL$ binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at @GENE$, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in @CHEMICAL$ binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from @GENE$.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two @GENE$ of SUR1 suggests that @CHEMICAL$ both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of @GENE$ suggests that @CHEMICAL$ both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that @CHEMICAL$ both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at @GENE$, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that @CHEMICAL$ both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from @GENE$.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two @GENE$ of SUR1 suggests that glibenclamide both blocks this cooperative binding of @CHEMICAL$ and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of @GENE$ suggests that glibenclamide both blocks this cooperative binding of @CHEMICAL$ and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of @CHEMICAL$ and MgADP and, in cooperation with the MgADP bound at @GENE$, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of @CHEMICAL$ and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from @GENE$.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two @GENE$ of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and @CHEMICAL$ and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of @GENE$ suggests that glibenclamide both blocks this cooperative binding of ATP and @CHEMICAL$ and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and @CHEMICAL$ and, in cooperation with the MgADP bound at @GENE$, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and @CHEMICAL$ and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from @GENE$.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two @GENE$ of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the @CHEMICAL$ bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of @GENE$ suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the @CHEMICAL$ bound at NBF2, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the @CHEMICAL$ bound at @GENE$, causes ATP to be released from NBF1.	0
This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the @CHEMICAL$ bound at NBF2, causes ATP to be released from @GENE$.	0
